<SEC-DOCUMENT>0001558370-25-007498.txt : 20250513
<SEC-HEADER>0001558370-25-007498.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513080919
ACCESSION NUMBER:		0001558370-25-007498
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MeiraGTx Holdings plc
		CENTRAL INDEX KEY:			0001735438
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981448305
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38520
		FILM NUMBER:		25937261

	BUSINESS ADDRESS:	
		STREET 1:		450 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-860-7985

	MAIL ADDRESS:	
		STREET 1:		450 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgtx-20250331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/13/2025 11:46:23 AM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 29208165-cc7d-43e3-9dc5-16cd13a5455d -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:mgtx="http://meiragtx.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>MeiraGTx Holdings plc_March 31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" sign="-" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_pLW7zRbgPkiZZTuqjAHLng">0.51</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" sign="-" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_L88EaDIR1022qZsEDwWwPQ">0.32</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_lbaBp-22o0eZqucwxghBGw">79032341</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_jfmsnVHfOUaPeVejw9xz8w">64065895</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityCentralIndexKey" id="Tc_HVGxmDvBkka3JUogfYTXQQ_2_1">0001735438</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:CurrentFiscalYearEndDate" id="Tc_Oalb8CgkVUqE77Zk2hVoDQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentFiscalYearFocus" id="Tc_puGQ3jeV30qOs6M38y1mhw_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentFiscalPeriodFocus" id="Tc_XfG5r6FecEePFo-j6RMLdQ_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:AmendmentFlag" id="Tc_y9CAMYgt8UGE8Czpqw3LQA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="0" name="us-gaap:CommonStockSharesIssued" id="Hidden_7Dm_VXGCCUuvwcHM8-AKPw">78397380</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" name="mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" id="Hidden_MlA4-b9GnE64Lz0dPLcYmQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_d94u8XNHz02l4qukD_X6Xg">79418438</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_FourthAnniversaryMember_vESYVjpkuUShuXlxTP4-vw" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_3IRehDe7iE-PuKwN7f8KxA">0.25</ix:nonFraction><ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg" name="mgtx:PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" id="Hidden_eNuWP8gC10unY9sqGjg8MQ">P6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KtvJ2z7CkE2LvZ68mPcahg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="Hidden_9vrz3CYLdkSqMQ_3AtrhKQ">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_2cEA7rky_EClnxjTOR8EiQ">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_N4ipPyW_6EecGrCOlZuzUQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" name="mgtx:OperatingLeaseNumberNewLeasesRecognized" id="Hidden_50G5iuwwS0COib-U_gl6RQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" name="mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" id="Hidden_rcbwIQOgN0KERK7K18fcyg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" name="mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" id="Hidden_UfokOTS--kuNnksgF_hYAA">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mgtx-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7PBWyW10bku3vczbnolVKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__pIlUQOGC0SWQ9sbcUlL7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ftpWq1xELEO_xiKl9XZu4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hEK3ws0ZrEaEwHAN5Wlu5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6ol14QM12kWnqbV_R0D-VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1se73GomfkuSyGy7U1wlaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XWbwq0m_K0WELesuemAQ5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ab2cnm6P6UGXoyJRBNe9KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dOQiYLrDx0es2KwdD-YnMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWFIJ4f8Mk6kiZm_hwhuVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Lkt8NZWQY0euvcA_dbiXxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cA5kA7WhY0mOZMiW4kBz8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KtvJ2z7CkE2LvZ68mPcahg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_FHMLfDF-0EKO7Asq-e8OTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uVSHbG4-lEuN03PZ2bf2fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:ThirdAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_SecondAnniversaryMember_4r0tTmCAu0SQFy7DaGc90A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:SecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_FourthAnniversaryMember_vESYVjpkuUShuXlxTP4-vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FourthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_Nbb73BCKL0iQXbnKJ4G6zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_qIzB0lDadUGRb33apH8qog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J7FckVRKbkG1Z9ZPt1KhVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g32i2heQxEy-pHMU_5YOow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember__19Q6cUiYEa7qmq_KO8jNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_US_isAzfTWGxEaw8ldhWLyHVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_GB_mLJbdBSl7Euj6MToEtRJ-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_EiRkplRRA0e4VFOvaZVcUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_cfMdJz0u7EKj-RrpFQyMpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_6w38CaNnUkWyGPBi3mG6OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vu8hoWsZ4UmhtEkvY_FXHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9UJzipOWs02UMP-44_Jc4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_E01NWWscaku_l4LSWzU0oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_psKKUO-LuUiwEGnyG3klfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PWqb2kP-wEuEFAiVAHEfUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vNTUyBj1R0iHgetCERxoKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtv4RBfxkuuH4RrzAnNHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yNUlMtvIhEu4s5tbktrKBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uKmiWTXiFUui62_GfPyv8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_w0975VuH_EaNXB4Ka939BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RF2S-NSeJU61RDz1CxpR0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_FinancingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_PerceptiveAdvisorsLlcMember_oAxyTHASgU6LiyqF1ZUF5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:PerceptiveAdvisorsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:VisiogeneLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A34VtYETjkq5z4-tujaPuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_42lCiz8CVUyY3EVhVz0_cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_O1KWw4ArDkiJPoDlyECyng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_9Zn4kfnKBEST_irxiQRuhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_1LCuyPsVy0exXA5eGmOHbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nPdsKTqjKEeHIAIo7QnFLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_oyaq6jivUkawB4YLvbDI0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b0HC4nScVUuIG_mYjEASwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_e_mz02J0OEe3fPVeHHSu4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember_uFjEWSkzu0eHvfAynbX9jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_EPMBHNhui0SPV5q0DQTs9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_gOdpVqSBHEGJvzck7tJOZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2025_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_KaXdu7E4UU23VU_CUmILww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Z5HMPaYik0ye7_ykI_APgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4qcy_d4u7k2Tb5wX8MN_yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_x0anTYpTGEKJId2AT2QSMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_WEvytmm6-0as4ezA8Dxq_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yqGmJ2-KHka0ENT6fES9GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_X4X9AYdDDEK7RWtpLuhYsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WpG7KMWBlUKStgi4QQoKBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_co_X9kDcaUaRbStYIRfBYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Yx2Gw2c3R0GT0T-W4aVOLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-FBDFJh7Y02IFx7FP5-LHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SDGzmNr-NEmKPaMrfqtjDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_bD1h8zBZy0a-rhyOQJBXYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_PIX3BS0nTUa5tETrcj8elg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_iZlT0i7a9E65CzOL8E1S9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_vpSCkZsxXEKNmuae513iJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_t4aotRLKJECS_tQUX6xOmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingFrameworkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-09</xbrli:startDate><xbrli:endDate>2025-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_3HrtmboMJUKcXvGtnUlX-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_BvXvmLHTZ0qgp_SP__HdmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_tiGUIO0qBk69Z-8zacyddg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:HologenTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-09</xbrli:startDate><xbrli:endDate>2025-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_bTo8MlYWIEagDkty02ovVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_vxfqy9OKIUWACknu_IhoYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MinimumMember_2b1HMRkaD06hhuC2_CUTZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_BgkV0HRRGEO9W9pctp9CrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_dEYHtikRfE2XPBZmM5ggNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_IGvtLNP2dUW4TTCCJvLt-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_e-G_0F-wWkOXxtBy8N16Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_H2Pm54Ton0yrKe8l8jzgVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_GkhjCPAPaECcrC8N78W-Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_x8bvSHQN80e1DIGnCPEO1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_zgUUktVOakyME70F8CQ1DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_anYll54pokiQcp14tL7FPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:HologenTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-09</xbrli:startDate><xbrli:endDate>2025-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_Di1tUbrdG0CEvFGNkpUsfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_28_2025_ft_AZCvNMkWsZ3SF2L-s5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001735438</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_be8e3b02_01b9_4735_9dba_aa532c3148f5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentType" id="Narr_WcNNC4Me9E-hX8wCVwbIog"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentQuarterlyReport" id="Narr_2f6HeZ3yEECo--yWLXYopA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:4pt;margin-top:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:9pt;font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentPeriodEndDate" id="Narr_0v56svkCmU2BSq_nFIuwxQ"><b style="font-size:9pt;font-weight:bold;">March 31, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:DocumentTransitionReport" id="Narr_oz94P-sn6U6wO6u7wdT4zg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:4pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityFileNumber" id="Narr_lSdIjpVycUqsUqE3jDU9PQ"><b style="font-size:9pt;font-weight:bold;">001-38520</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:1pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:22pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityRegistrantName" id="Narr_BffKW7k_VECDynfzx3StHA"><b style="font-weight:bold;">MeiraGTx Holdings plc</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_fea02b11_1f5e_4272_a725_a239c774f7aa"></a><a id="Tc_asAMFg0vB0CseoocOC_cSQ_2_0"></a><a id="Tc_5Kji3jcYTkSKf6CWe4zV7A_2_2"></a><a id="Tc_287sgnGMc0qqujnGJ-bO0A_4_0"></a><a id="Tc_FZGciB4zRkWr6dw1FjrWKA_5_0"></a><a id="Tc_sIK63QB2pEqIZuw0hTpV_w_6_0"></a><a id="Tc_U_RC4wfFpECkR3A1H4lc_w_6_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityIncorporationStateCountryCode" id="Tc_3BBKyXGokkSQYmENG-wHvA_1_0"><b style="font-size:8pt;font-weight:bold;">Cayman Islands</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityTaxIdentificationNumber" id="Tc_83VgfdpWT0ScvgUHLxAHRQ_1_2"><b style="font-size:8pt;font-weight:bold;">98-1448305</b></ix:nonNumeric></p></td></tr><tr style="height:20.4pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b><br/><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityAddressAddressLine1" id="Narr_u8sd_J5rOk2oy2LZw-51EA"><b style="font-size:8pt;font-weight:bold;">450 East 29</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:8pt;font-weight:bold;">&#160;Street</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityAddressAddressLine2" id="Narr_k9GVbcVFr0m8XX46F4FWSw"><b style="font-size:8pt;font-weight:bold;">14</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:8pt;font-weight:bold;">&#160;Floor</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityAddressCityOrTown" id="Narr_SFcjVRwNC0OL4GJT12qn1A"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityAddressStateOrProvince" id="Narr_Qzr5-qwDH0OFoInenPApdg"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityAddressPostalZipCode" id="Tc_hrc-GiLlH0CUubN-kXj5qA_5_2"><b style="font-size:8pt;font-weight:bold;">10016</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:CityAreaCode" id="Narr_Kzwz9S-i9k67R6QJlrtwZw"><b style="font-size:9pt;font-weight:bold;">646</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:LocalPhoneNumber" id="Narr_0ez9cT69xEa04xFU1riBXw"><b style="font-size:9pt;font-weight:bold;">860-7985</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Former name, former address, and former fiscal&#160;year, if changed since last report)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9724bf6a_a57b_4ea3_adec_c1fa80dc59b1"></a><a id="Tc_cEpgc0m7n0qsAv_IDC2JUw_1_0"></a><a id="Tc_vy9V2fShC0O6ncjhsGjHMA_1_2"></a><a id="Tc_jFUlhwqooU6ga1fO7q4vdQ_1_4"></a><a id="Tc_rFIbZ9JHvUevksRFRQfqCw_2_0"></a><a id="Tc_0PUB8QfFC0WdDr32wn3g7A_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:32.21%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:32.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading</b><br/><b style="font-weight:bold;">Symbol(s)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.48%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange</b><br/><b style="font-weight:bold;">on&#160;which&#160;registered</b></p></th></tr><tr><td style="vertical-align:top;width:32.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:Security12bTitle" id="Narr_0IeOKLwSPUmA62EoQZVMDg"><span style="font-size:8pt;">Ordinary Shares,</span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">$0.00003881 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:TradingSymbol" id="Tc_IzyzmBz7SEOSPPce8tgCFA_2_2"><span style="font-size:8pt;">MGTX</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:SecurityExchangeName" id="Narr_YsnqlJ1jmESuqoIq28MPQQ"><span style="font-size:8pt;">The Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Global Select Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityCurrentReportingStatus" id="Narr_tq8GPy42kESfO0zKiuh77g"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityInteractiveDataCurrent" id="Narr_r_KrA7Gv5UKSGlm9ZTpitA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;">Accelerated filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;</p></td></tr><tr style="height:7.65pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityFilerCategory" id="Narr_-SNTKV2UxUSgriD8GZqlog"><span style="font-size:8pt;">Non-accelerated&#160;filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;</span><span style="font-size:8pt;white-space:pre-wrap;">  &#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Small&#160;reporting&#160;company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntitySmallBusiness" id="Narr_EJiFI10_KUq4T9_dG_xf9A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging&#160;growth&#160;Company&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityEmergingGrowthCompany" id="Narr_rzNHy8yMdUiI6VMA0N2ddQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="dei:EntityShellCompany" id="Narr_4HEO0_Q7vkaoNBCBAUsAag"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">As of April 28, 2025, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_4_28_2025_ft_AZCvNMkWsZ3SF2L-s5Q" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_5B9-tYjP9067Eal4-mcZMw">80,365,359</ix:nonFraction> ordinary shares, $0.00003881 par value per share, outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e2cd8613_78ee_44a0_acec_740c8b4390d5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">This Quarterly Report on Form&#160;10-Q (the &#8220;Form&#160;10-Q&#8221;) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form&#160;10-Q that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expectations regarding meetings with global regulatory authorities and the FDA, product pipeline, anticipated product benefits, goals and strategic transactions or priorities, product candidate development and status and expectations relating to clinical trials, growth expectations or targets, pre-clinical and clinical data expectations and expectations related to financing arrangements and the intended use of proceeds thereunder, as well as statements that include the words &#8220;expect,&#8221; &#8220;will,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;anticipate&#8221; and similar statements of a future or forward-looking nature. These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under &#8220;Item&#160;1A. Risk Factors&#8221; in this Form&#160;10-Q.&#160;These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form&#160;10-Q. Any such forward-looking statements represent management&#8217;s estimates as of the date of this Form&#160;10-Q. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Form&#160;10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are providing the following summary of the principal risk factors contained in this Form 10-Q to enhance the readability and accessibility of our risk factor disclosures. We encourage you to carefully review in their entirety the full risk factors set forth in the section&#160;of this Form 10-Q captioned &#8220;Part II&#8212;Item 1A. Risk Factors&#8221;<i style="font-style:italic;"> </i>for additional information regarding the material factors that make an investment in our ordinary shares speculative or risky. These risks and uncertainties include, among others, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is no guarantee that we will receive in a timely fashion or at all the additional milestone payments contemplated under the Asset Purchase Agreement or the revenues associated with our manufacture of the commercial supply of the RPGR Product under the Supply Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our review of potential strategic transactions may not result in an executed or consummated transaction or other strategic alternative and may not result in anticipated benefits to us or our shareholders, and the process of reviewing strategic transactions or its conclusion could be disruptive and distracting to our business operations and management.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is difficult to predict the time and cost of product candidate development on our novel gene therapy platform. A limited number of gene therapies have been approved in the United States or in Europe.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome. Further, we may encounter substantial delays in our clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The affected populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and our contract manufacturers for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing facilities and the third-party manufacturing facilities which we rely on may not continue to meet regulatory requirements and have limited capacity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to regulation and other legal obligations relating to data privacy and protection. Compliance with these requirements is complex and costly. &#160;The actual or perceived failure to comply with such obligations could materially harm our business, results of operations, and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to increase or decrease the size of our organization, and we may experience difficulties in managing these organizational changes, which could disrupt our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preliminary Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unless the context otherwise requires, references in this Form&#160;10-Q to &#8220;Meira,&#8221; &#8220;MeiraGTx,&#8221; &#8220;we,&#8221; &#8220;us&#8221;, &#8220;our&#8221; or &#8220;the Company&#8221; refer to MeiraGTx Holdings plc and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have proprietary rights to trademarks, trade names and service marks appearing in this Form&#160;10-Q that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this Form&#160;10-Q without the <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and TM symbols, but any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this Form&#160;10-Q are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TOC"></a><a id="_3ea44335_4c3b_4464_b654_1ad27f548113"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.91%;"><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_819042"><b style="font-style:normal;font-weight:bold;">PART I.</b></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_819042"><b style="font-style:normal;font-weight:bold;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:7.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_806846"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_806846"><span style="font-style:normal;font-weight:normal;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_392522"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMPREHENSIVELOSS_182033"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SHAREHOLDERSEQUITY_36765"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statement of Shareholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SHAREHOLDERSDEFICITEQUITY_618444"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statement of Shareholders&#8217; Equity </span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_138361"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_891132"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_891132"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_341431"><b style="font-style:normal;font-weight:bold;">PART II.</b></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_341431"><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_709588"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_709588"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_220365"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_220365"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_54116"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_54116"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_51301"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_51301"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_145683"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_145683"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">103</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_373262"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_373262"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_71538"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_22b938d7_9d88_4827_b193_1adfd8b7738b"></a><a id="PARTIFINANCIALINFORMATION_819042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I&#8212;FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_806846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</b></p><a id="CONSOLIDATEDBALANCESHEETS_392522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_afde26c2_7664_4124_aa14_25eb60ef38da"></a><a id="Tc_eL-yZlePAUuNvlY_qgFjrg_1_2"></a><a id="Tc_7tK_PiuC1EWjOv28UK5evw_1_5"></a><a id="Tc_40Ka3p9h0Ueg9EZ44neODQ_2_2"></a><a id="Tc_MTSrdMZOHEmL6dJtyaaK8A_2_5"></a><a id="Tc_Xuv6oBcXIEuokbC_OyT81A_3_0"></a><a id="Tc_9F40BhhPNEWnMMQoxzK6Jg_4_0"></a><a id="Tc__rS27Awkl0uSeHhsZ5vtnw_5_0"></a><a id="Tc_w4zfyK9lSEeV9H23jRSLRQ_5_2"></a><a id="Tc_erRcgB0upEG1vtAC5VMsjg_5_5"></a><a id="Tc_j_PhLmrQq0maiLEWdDOPSw_6_0"></a><a id="Tc_uMG3WpRcWUCWMnRkt4thDQ_7_0"></a><a id="Tc_K1XXfLyxgUiC2zFWqlW8kA_8_0"></a><a id="Tc_LLom4K55T0GfYQkY-ntAsQ_9_0"></a><a id="Tc_unbFVvHmNkC4rslAvOSg5Q_10_0"></a><a id="Tc_WY2AFxkUt0OJ_rMJ4GWXaA_11_0"></a><a id="Tc_NoVtbuavVkWhbEeC2-NfRQ_12_0"></a><a id="Tc_sRKoDWYNq02GWCcmVp1Gzg_13_0"></a><a id="Tc_k96I7P3rxEW7M-l0uVO0Fw_14_0"></a><a id="Tc_ntd0ocDp_0OenfLYp2cbqg_15_0"></a><a id="Tc_uqP9nYbwQ0KEclt2PeOjIQ_16_0"></a><a id="Tc_Oc53FXKuPU2WmZ_m1Mnl-w_17_0"></a><a id="Tc_EFieweCipkGKRZfp8nvEEw_18_0"></a><a id="Tc_hcHqSdwshEqQiOVkeOI4mg_19_0"></a><a id="Tc_aeAIlWfZrUqmzKVSdVkfLw_20_0"></a><a id="Tc_m9YKMDj_6kKqOVYnJPXWaA_20_2"></a><a id="Tc_gPLpIar_mkG2t_sKvuONJw_20_5"></a><a id="Tc_nvq_KiGkpEqJcep14ZgiLQ_22_0"></a><a id="Tc_6Bp6IV8n2UiCv2k_YfS8TQ_23_0"></a><a id="Tc_HQM7VWC6g0GGCtk1OI3Kqg_24_0"></a><a id="Tc_2vnXu3RJIUiVwA-7fuH_Sw_24_2"></a><a id="Tc_E0nHkabpDk-f79lJXZsevw_24_5"></a><a id="Tc_CSz8Wjr6l0KHQEycFuQTRQ_25_0"></a><a id="Tc_wp_Ri2etvk-5X0P_goCSzg_26_0"></a><a id="Tc_CS_h1SwjXUmcys3VPTC4Bg_27_0"></a><a id="Tc_97mF8Mx7j0KCZY7ci1jYrQ_28_0"></a><a id="Tc_PEi_jr9jt02-xyUPDe-aWw_29_0"></a><a id="Tc_9sR3x12u6U-pSR4alXNLFg_30_0"></a><a id="Tc_h3WuNq3pJkmCgVAHB-55Ig_31_0"></a><a id="Tc_qGmyrUhQEk2W3ciUNOuzEA_32_0"></a><a id="Tc_YloCCGDov06owPjCGzXJCw_33_0"></a><a id="Tc_M5xxjgqxHUixnor7qYHu8Q_34_0"></a><a id="Tc_IgJuCV1u-kGuhQ4502oKbQ_35_0"></a><a id="Tc_PKoi8MSM0UKl4LT89OZEkw_36_0"></a><a id="Tc_zdNl5uG9LUmjH2FudJc9yA_37_0"></a><a id="Tc_Gc4ksEiSeU68jXFdEw0QmA_38_0"></a><a id="Tc_CYnQZYy2fE-b_iPQ0cJMxg_39_0"></a><a id="Tc_Sp55N__Ix0eogyf2wh_A3w_40_0"></a><a id="Tc_K20ZO368dEG25fnumsWIrA_41_0"></a><a id="Tc_7c83zdPJV0Kx678E7qQ1Lg_42_0"></a><a id="Tc_c5sLOyAur0yNERUuu4ugLg_42_2"></a><a id="Tc_2STtknWVOE-1_0JvXL0xIQ_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASSETS</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">CURRENT ASSETS:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_DGHk0Ve3z0eJi7zgrvwafQ_5_3">66,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_v9iEMyq4pUeBTPJd-dnyuw_5_6">103,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_lfGCLlLpzkCkC4Yp0ZUhgQ_6_3">734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_9vem8F0pqkufm2_Mdv0g5w_6_6">707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Contract assets - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_F5WACDj1KUy2cW_N207Yzg_7_3">270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_syHJnXZJvkydpucMJ9WGOw_7_6">950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_WSxDK9PvkUO24_O0TnWSfg_8_3">607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_qHO_C6__mku7xOJZ5GNe-Q_8_6">385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_EtJMzuMcOUOsjBZFyYJYnQ_9_3">6,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_sALEmssBzEGN8wczcu4aKA_9_6">6,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Tax incentive receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReceivable" scale="3" id="Tc_bA7ziC1iFUObJE7eTLTNbA_10_3">4,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReceivable" scale="3" id="Tc_ppYhGnBJ20iA_eFy1-Z3Rw_10_6">8,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_h9KUPjf6-ECvBT0Dcke8OA_11_3">606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_yrP233BObkGhpH_osUiBWw_11_6">2,018</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_HFmxRrGo_UqLpM52e-wpqA_12_3">79,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_tdIYRA7tvkuRaIeBJKvvXg_12_6">123,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Xq4LQfxNAEC2_7lfZAocvA_13_3">104,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Ws8Oi41NcEO-0LxlwcUQnw_13_6">102,878</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_t9o7vz1V3ki2ge0vYEfmcw_14_3">773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_R0q2y6zLLk-ix5zhMzH0yg_14_6">821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_3E0m-JcU5EeJHimS44unbg_15_3">2,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_yxKafGafw0myZfgqChVWIg_15_6">2,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Y_pa2F0k6Um05dZXsU26vQ_16_3">1,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_BJUNjBosf0WN_T7bna1KkA_16_6">1,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity method and other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="Tc_bXYSyF-ZfUSKoJeXoD8pWA_17_3">6,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="Tc_rZz6hd7n6Ue9d3Q_roc4Mw_17_6">6,749</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets - operating leases, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_MtaEBTpRJ0Waie_LdkcmGw_18_3">6,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_zUsQgZErXkKPO3XoUqDoVw_18_6">10,576</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets - finance leases, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_-mdBCgWL2kWdNv5XyQdSAw_19_3">22,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_aVTFJ4TL5Ems63_gcHfdIA_19_6">22,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_MA_KV8EIJE6Yjq_5HQH88A_20_3">224,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_h6xMP_O6OUiMfu9z4wibQg_20_6">269,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LIABILITIES AND SHAREHOLDERS' EQUITY</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">CURRENT LIABILITIES:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_bqRwzMwq5UmYx633Ivad4A_24_3">20,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_QIJOX-Z4EU6LyhzX8JD7vQ_24_6">23,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_t0bee3VDn02iq-vQL5tygA_25_3">23,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_cHu7kOk54USniWzmm-FqWg_25_6">27,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligations, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ZGBQx-PjO0KDLE7DZys9JA_26_3">3,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_FJucujbtKkKAjL3Vd1oDQQ_26_6">4,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue - related party, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_UgzyGIZ0xECeU2N3SsUPPg_27_3">4,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_tyB8TyjQkEafNdM1jqTtQw_27_6">4,827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_vEFbDZpvakax0_YckOobzQ_28_3">580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_rY-LcB2O00aQw8k3kR0qnA_28_6">903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Total Current Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Oxalusl93k28O9_4ukyR-w_29_3">52,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_BzHHiDZsKU2G3IFjTGVCSw_29_6">60,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_561ibGCl_0iAGUMCQeBRNQ_30_3">59,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_S-NqksMeHkWvC3j7xAlrIA_30_6">57,576</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_dyZFhyval0iTIc1dIWaKUg_31_3">4,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Q8lmyB-JUUSq9w5-vIvoOA_31_6">7,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Asset retirement obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_5Wci5LOoN0WBuPBqA0K3bQ_32_3">1,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_Z0epb4cZt0Wsm7ZWEr1hYQ_32_6">2,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_dPnVJCNYKEieK-ejsEw0JQ_33_3">73,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_M1CJ_bdd8EyafquOQfE9rQ_33_6">73,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_b1vp9jKbJU2rlnhgeH3zTQ_34_3">190,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_6SU7l7WexESaEv9_-2Om3A_34_6">201,924</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">COMMITMENTS AND CONTINGENCIES (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">SHAREHOLDERS' EQUITY:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Ordinary Shares, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="8" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TEIB7SWDOECaFLcxwTjQ7g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="8" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4HqPPDj15kmWyd6mGzKwkw">0.00003881</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_490whYY7zUCVqtKEpTVFLg"><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Jg0a-o5E2kmU5rlqP8RQDQ">1,288,327,750</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_aHr4mYtBO0yAKsqaBd_kog">79,418,438</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_kKhJPLO-gU2_-tJT_-odBg">78,397,380</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_7Dm_VXGCCUuvwcHM8-AKPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and</span><span style="font-size:8pt;"><br/></span><span style="-sec-ix-hidden:Hidden_d94u8XNHz02l4qukD_X6Xg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> at March 31, 2025 and December 31, 2024, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_5kW7ozro5U-eZ6m7mtffJA_37_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_AcuMfJ4L6UuOrHFOFadc0A_37_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital in excess of par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_2fOE9nTPKkOGFGzkzI-SHQ_38_3">780,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_jbwN-J4zF0O9y9YxrGz7iA_38_6">773,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_tE0RsX1Ng0-pu3OLDD99lQ_39_3">5,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_mn3EPQ9kKkOLAy_Ll6-7bw_39_6">3,719</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_irFeHfioW0eGIDI9oeA-OQ_40_3">742,003</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_7JLGOyb_aUm_VnAvTPeV-Q_40_6">702,022</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Total Shareholders' Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wJNoT0mySkKMG3aosI8_nA_41_3">33,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gb_1lruOGEWWf4IQ69qP7Q_41_6">67,827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Xs2ZymsVjkuLNgu_KGMTog_42_3">224,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_AEAjmc42cE2GhE6GPpIUGw_42_6">269,751</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c7dfaaec_ad88_4807_bc26_bf46bfb8d183"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</b></p><a id="COMPREHENSIVELOSS_182033"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_b27a3dd8_a9e9_4643_887c_37f9ab6dc018"></a><a id="Tc_5PWgaPD6I0KZ6wPqn9raMw_1_2"></a><a id="Tc_cVjtUvNsyEq61cVUU0nOdQ_2_2"></a><a id="Tc_3CGsnuqTGU2ThMGlG9hz8Q_2_5"></a><a id="Tc_Km38ZxWuvU6Yxopnfew5BA_4_0"></a><a id="Tc_yXNb7d8v10SZdRu9AAa5ag_4_2"></a><a id="Tc_mty9XxN4KUS9QpCwerAaUA_4_5"></a><a id="Tc_l7_PgC4NkkumJzN-mpgY1g_5_0"></a><a id="Tc_YfzyDfSxt0ut5gqGuLD0Fw_6_0"></a><a id="Tc_TUhtyetj_E2J2yQmBiMbMw_6_6"></a><a id="Tc_o9nUmjWtTk-UWMgLIQy85g_7_0"></a><a id="Tc_dQEpRv5QXU-_ejyOw_aFfA_8_0"></a><a id="Tc_De8xRJYhiUOXM_RKNZInSg_9_0"></a><a id="Tc_ISF3Oh0geUKojNPMw2lCAQ_10_0"></a><a id="Tc_T6jgV3plq0CXWERRxF94cQ_11_0"></a><a id="Tc_eDRzRpZPDkGQzrJxWuQ3Sw_12_0"></a><a id="Tc_Q-qKLzVqIEi-Cw2XjndsNw_13_0"></a><a id="Tc_EjuHm4YhS0W3eu2DvUQmgg_14_0"></a><a id="Tc_n-QyAuS_bUG8GN8Js4OpKA_15_0"></a><a id="Tc_-peKslVxKEy5OhLYjzyY3w_15_3"></a><a id="Tc_5h4qY1zJFU6ieOL7bxCxjA_16_0"></a><a id="Tc_iU1g0Z6ShUeYVcRMuf01xQ_17_0"></a><a id="Tc_PD96Hx0SBUKXhIYtQ3SZMg_18_0"></a><a id="Tc_FhqYzeL-1kaHLIC-OzSotw_19_0"></a><a id="Tc_GyafKC0ceUaThg2xCwRTgQ_19_2"></a><a id="Tc_hozB0uSzYk2V5u_wzSMxgw_19_5"></a><a id="Tc_YfMAwEKjJkmxKqdUbu3Z-A_21_0"></a><a id="Tc_Hiitq3_JGUyzLboGE-ZIzQ_21_2"></a><a id="Tc_xwQnJGmzQUqB5yEij7nGeA_21_5"></a><a id="Tc__m5GkJL70kOJ2tC31bU4GA_22_0"></a><a id="Tc_Y50phxuack-ujj7J4uhVIg_23_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month&#160;Periods&#160;Ended&#160;March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ServiceRevenueFromRelatedParties" scale="3" id="Tc_9fu8n-E5YkyUMPIwSszHuQ_4_3">1,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ServiceRevenueFromRelatedParties" scale="3" id="Tc_2c3siRUyxkaoKlgbLpTxzQ_4_6">697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_mBylX5t24kGMLRnWynDt5g_6_3">1,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_56BBYQibi0-cxSK4nLWA8A_7_3">9,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_-NhVF1sR3EeVKy1Rg31PDg_7_6">13,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_zbNAS4BCmU6esr7W3vQOGw_8_3">32,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_d8JDgV7-0EK5r8hYGPCEpQ_8_6">34,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_XUPCZucs7kGi1uLbyoCasA_9_3">43,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_4lQbP0tTMUS_3P6Io1bRxw_9_6">47,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_sFuY5i9Faki7t9JxU7adsw_10_3">41,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_EbrNs1pgHUm81YZVChYc-A_10_6">46,772</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-operating income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency gain (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_vLC2yoFhQUeLwg3JQYdlZg_12_3">3,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_akR1VwKXJ0aQ57izASQH4A_12_6">535</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_UQz4obyqtUizSHTwJr6jYw_13_3">971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_zbUS_qfL6kO6DVvMnOhG4g_13_6">1,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_3w3-rkVN-EmXjypJaYv8dg_14_3">3,043</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="Tc_WPqTPt0enkWvaLTk4RDI2Q_14_6">3,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on sale of nonfinancial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:GainLossOnSaleOfNonfinancialAssets" scale="3" id="Tc_auhXERiE_0SL98pL9ru9yw_15_6">29,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_82LzLfuehUyZ_hOtfCc07Q_16_3">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_288Pely5DUGCXaDyLRwOEg_16_6">20,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_AQ0_V-gfjk2jPSsYpam8Tw_18_3">1,347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_Ffb7v9SPDUC5l2hqXbWFYg_18_6">1,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_R46aa4DMpUeppGDWAtGETw_19_3">41,328</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_j4h6wxFIk0CxuHu1o68IKg_19_6">22,133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_EQvqrkqZkEWXeEl4TVSn8w_21_3">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_SylaL9m1-kunQjeFEGm4lA_21_6">20,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per ordinary share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pLW7zRbgPkiZZTuqjAHLng;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FWY7i72NX0Szqe7eJY2dRw_22_3">0.51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_L88EaDIR1022qZsEDwWwPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_HaCzygv0Gk6kIidTxa8w3w_22_6">0.32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average number of ordinary shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2Spm0Sp3ZEqUXWiLMyQRsg_23_3">79,032,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wvTwvifdvkqAnckJHTCaBQ_23_6">64,065,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4300e91f_3096_4e76_bb5a_7ed4656af530"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</b></p><a id="SHAREHOLDERSEQUITY_36765"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FOR THE PERIOD ENDED MARCH 31, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_434224a9_ed15_4531_bdef_13472227748a"></a><a id="Tc_GbWxBxCfTkC6BYYmo9t5Xw_1_10"></a><a id="Tc_Qo07Pv3lJUacupT3B_XW_g_1_16"></a><a id="Tc_7E9XCfP2NUyTGVvlSK7WOQ_2_2"></a><a id="Tc_dKLs4L4cVE2jeK7TcRFTYQ_2_7"></a><a id="Tc_JJONZinSSkinhHErE6Dglg_2_10"></a><a id="Tc_iICq8LISdEqEjWY73SQVaA_2_13"></a><a id="Tc_gQK7lc4MUESh34YBgXQxvQ_2_16"></a><a id="Tc_AldZn9gCJkiozTc2iF2vPQ_3_2"></a><a id="Tc_bi8k_4aDLUOMZ_0eEf_cLw_3_4"></a><a id="Tc_Ns5Fvy_cXkmw9FzDJuserw_3_7"></a><a id="Tc_VhMz2pEDwEGh_3tiR-HM6A_3_10"></a><a id="Tc_Fk0Qc4vjQkil7bshXlK4Kg_3_13"></a><a id="Tc_W0sMBmAUQ0KbMjWq--XjmQ_3_16"></a><a id="Tc_GFi0cCDPeUuC7cI9_asl2A_5_0"></a><a id="Tc_F-vkutki0k2IT1YZ9XQnYw_5_4"></a><a id="Tc_aoRserofOkiSAqpKp9-yLw_5_7"></a><a id="Tc_FihWvJdI8UelSeWPUxLeNw_5_10"></a><a id="Tc_Lgms9kLiuECF8eLBqzk-pQ_5_13"></a><a id="Tc_hY4P6lPfvEaYKhP7hdv0mg_5_16"></a><a id="Tc_sCEFqPyf9UOypM8EoB3D-A_6_0"></a><a id="Tc_mhaikpea9kixb9L53wAydg_6_5"></a><a id="Tc_giI7m-tAa0qtAfKeAsWdpg_6_11"></a><a id="Tc_rNH9DpNZoE6ZJ71RKj52Dw_6_14"></a><a id="Tc__XEVzob_dUKTdn8OT4RMKA_7_0"></a><a id="Tc_2eBQlXhzF0KjHzUAN5uUYA_7_5"></a><a id="Tc_hEQN8Gi6f0STa6MTF2q1Kw_7_11"></a><a id="Tc_Op28gdTAw0q9-hp48mTl_g_7_14"></a><a id="Tc_pycp0_zDAkGcRf6uLMpLTQ_8_0"></a><a id="Tc_ebOZ7dokj0q8vZDuJ3sAVA_8_2"></a><a id="Tc_NXtmoCg190Ob8xsNqHgYrg_8_5"></a><a id="Tc_n28mjL9lTU-F5aK1d42e4A_8_11"></a><a id="Tc_Yirxudng206s_bjyYEJ6MQ_8_14"></a><a id="Tc_GVhrRR13z0S3iXpsROSn1Q_9_0"></a><a id="Tc_x3E1v0zwjE6Tvrj2NKWCFg_9_2"></a><a id="Tc_DCXij-NwEkioZ6jWDcmo5Q_9_5"></a><a id="Tc_WQpiFUF3gk6GwtAAKAFYmg_9_8"></a><a id="Tc_i4VgLSLIDEe1qQdGLggHKw_9_14"></a><a id="Tc_nP2cM8p0FEeo5GciD8f6jQ_10_0"></a><a id="Tc_JMX99dr2GkKo4wrZatX7gA_10_2"></a><a id="Tc_IOmnuCx8wEuKVpi05vis9g_10_5"></a><a id="Tc_IVKHsgQ6B0SguuMRLqqXWg_10_8"></a><a id="Tc_DojTjADwtUiJDdYKmGakpQ_10_11"></a><a id="Tc_MmssZJcqykK1Q99ZBfkcww_11_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Ordinary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital in Excess</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Comprehensive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shareholders'</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">of Par Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_-n1rbm_MIEGVrivyx4FVbA_5_2">78,397,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Hv1FT0mvOku2m-K71L3UAg_5_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6ol14QM12kWnqbV_R0D-VA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jYCsg_bGQ0K8A2wyBrimeg_5_8">773,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1se73GomfkuSyGy7U1wlaA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_e_4qAZTt3kaZirrVafDKQA_5_11">3,719</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hEK3ws0ZrEaEwHAN5Wlu5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FAxZI3B130ahx89ekp57Xw_5_14">702,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_h5DpjM-icEGDge4N0h1FBA_5_17">67,827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation activity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_3JRWprCCAEqik4aOcnfIyg_6_2">457,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_RbSq38qn7Uu9dBAnmAmOlA_6_8">2,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_Rn6edlq5k0eXHW1yKfyozQ_6_17">2,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ordinary shares in at-the-market offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__kRb5igcL0qUmea32vefkQ_7_2">563,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_p5tivpStpkGP3aErWHitFg_7_8">4,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_7gXhnBf7jkeQ3Tbe8DMRWQ_7_17">4,482</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs in connection with ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_GHZXLw1PGUK7qSyK4SW4Xw_8_8">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_SmcLueiNSk60J7BIDQC30A_8_17">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J7FckVRKbkG1Z9ZPt1KhVg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_ZNYSsal95E6oU4Asz4HJXQ_9_11">1,347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_QCvnbwOUKUKJHfMHQjH6SQ_9_17">1,347</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the three-month period ended March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vu8hoWsZ4UmhtEkvY_FXHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gYnB54Cs-U6cElIi60nBig_10_14">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zbreMQmJKEqzrrR2Ts9xlg_10_17">39,981</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_sZFvxur7Y0SMix_0o1WCTw_11_2">79,418,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xILHP5bp006Zghar7XKhEQ_11_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__pIlUQOGC0SWQ9sbcUlL7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jU5SyUb0hUKMMLA5Y6SMtQ_11_8">780,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ftpWq1xELEO_xiKl9XZu4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3drCfpq6wUqo9i0wABmz9A_11_11">5,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7PBWyW10bku3vczbnolVKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8KzYydg4hEih5ovJfyjxLw_11_14">742,003</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_muaI9FB5ZU2IMsnp0qJzDg_11_17">33,099</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</b></p><a id="SHAREHOLDERSDEFICITEQUITY_618444"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FOR THE PERIOD ENDED MARCH 31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_2497e0a2_cc2c_4e89_a00c_22e036d37c56"></a><a id="Tc_NmYbBHs4FUmPuZ_Kj3vklA_1_10"></a><a id="Tc_gd8ESC4jf022DEHP5lxWvg_1_16"></a><a id="Tc_vMZ2DMBikEWW0VoOYhLjOA_2_2"></a><a id="Tc_5gkwNDyCvk6xaL2iOwaJXw_2_7"></a><a id="Tc_oRfhh7L0qU6iWxWG2qz14w_2_10"></a><a id="Tc_Jqdhr-1Mikuz-fL1Gb1cRg_2_13"></a><a id="Tc_9cuFiDlr_U-o4rNri1igGw_2_16"></a><a id="Tc_jsHvnZ08MEyGHPXkXELCyg_3_2"></a><a id="Tc_QEe2KIip6UGb0qMijQhaLQ_3_4"></a><a id="Tc_D3UZAtYLtESN3pJir82lFw_3_7"></a><a id="Tc_WFdbaxWrdEyTAwAw6cQ7mQ_3_10"></a><a id="Tc_nGluwgzwG02BxWtNTLVLlw_3_13"></a><a id="Tc_d4V94Zc4ika90yzkg5kTgg_3_16"></a><a id="Tc_dz1vDZmaFkODI5BDmK2fbQ_5_0"></a><a id="Tc_HKKDyuNCRUyselx26LsfaA_5_4"></a><a id="Tc_GTn5J3LH6UGvztL4DYHjDw_5_7"></a><a id="Tc_yBUYzpF-2k2aoWtOvMyDgA_5_10"></a><a id="Tc_lJerprTJBk2LSFSimoVSrQ_5_13"></a><a id="Tc_-xJXdG7B8keTt-TkvMAoog_5_16"></a><a id="Tc_XF3ozL0HYU-3htm8x9_B7Q_6_0"></a><a id="Tc_N6z3v0imAE6N0EPoyLFRcg_6_5"></a><a id="Tc_CDzYipBflUS5Zgr4basJww_6_11"></a><a id="Tc_aCj218JqJ0-vsCpk1bXScA_6_14"></a><a id="Tc_-YLIyxwfUkytzrhvvZe5jg_7_0"></a><a id="Tc_mBPxibOHME-LAkOieqJclg_7_5"></a><a id="Tc_TNCmMsYmq0GQwFnjMhEdqA_7_11"></a><a id="Tc_mN-t-TsekE-ZzR23tcAA_g_7_14"></a><a id="Tc_-qHGwKyv_0qZybZhx7O9-g_8_0"></a><a id="Tc_35gzT2OGBEGDaMRM9C_aCg_8_2"></a><a id="Tc_z6VkDs2nTEW6avWT7qlBug_8_5"></a><a id="Tc_FNiHPr30S0WSh7OclASPGg_8_11"></a><a id="Tc_kkIGP7ouA0C4AMuJ-vcFdA_8_14"></a><a id="Tc_Zsw6IPMvd0mh7Q14YJUDDw_9_0"></a><a id="Tc_KrsFPiD_eUmCKqQlcUJHtQ_9_2"></a><a id="Tc_EkEJGP4cFkOiqIn0Gep4Hg_9_5"></a><a id="Tc_3ovjSdZorEybKZX70RwSpQ_9_8"></a><a id="Tc_ikE6pcBSRkWL8RWtI5wi6w_9_14"></a><a id="Tc_AVledm-GI0SwJfv75v4PZw_10_0"></a><a id="Tc_E9j_LCbP-EqZVd8D1ru3kg_10_2"></a><a id="Tc_zR1HtEgYd0KUyOY8pAMzEQ_10_5"></a><a id="Tc_o7oQ8LXBi0Sd296PW7gYZQ_10_8"></a><a id="Tc_AeiRn5gDD0CwsGWNOdgMFQ_10_11"></a><a id="Tc_yl8ti8P0RESALdxRPS68YA_11_0"></a><a id="Tc_QsvX0Z1xA0eyhUrpbPIzEw_11_4"></a><a id="Tc_o9r2SxuMzU-fUitVeEsJbA_11_7"></a><a id="Tc_4HPmFRUwOEuV85WFMXgCBA_11_10"></a><a id="Tc_YjhiPsHMVUWRe8zsqYMxJA_11_13"></a><a id="Tc_yKKK1rVSYkOt2iz5Ei_oqA_11_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Ordinary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Capital in Excess</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Comprehensive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shareholders'</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">of Par Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_GQd4w7ZzhkGG0VndQsTSTA_5_2">63,601,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3i_0G3c6uE2z-V_0QCA2dA_5_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Lkt8NZWQY0euvcA_dbiXxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_muaev53R4USmI0zzjgle3g_5_8">693,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cA5kA7WhY0mOZMiW4kBz8Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IFElO7TxrkehPtqK11uoSA_5_11">1,435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWFIJ4f8Mk6kiZm_hwhuVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s-hZe0Ek10WFhzAZDk1C3g_5_14">554,231</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VesUA7aPvEOLXX31whFCYg_5_17">138,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation activity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="Tc_VSY65r114km08X84JlQKfQ_6_2">441,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_sn3ezNZnZ0qftpkLDtDd9Q_6_8">4,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_oZAyX7oNZEmw7vjEv8wdGQ_6_17">4,739</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ordinary shares in at-the-market offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_vIG1tY8UZUCr1ptpYyr21Q_7_2">256,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_-H5V2nPUGEuXBdKbo0urIA_7_8">1,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_FmQugme_5EuqMqpUToQ9jw_7_17">1,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs in connection with ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_tcmze-u5iEii3obSJjvYzg_8_8">635</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_rcW7db3JGkSQVySs-JMZMg_8_17">635</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g32i2heQxEy-pHMU_5YOow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_P_kTCojv4U265NK307I-pw_9_11">1,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_lH4VW9KI4k29FpucYidU5Q_9_17">1,691</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the three-month period ended March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9UJzipOWs02UMP-44_Jc4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_a2jrfB_rYk2Hx5MijUPs2g_10_14">20,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UeaDhyGOq0S1u1fJ3Yw4Tw_10_17">20,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Balance at March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_SkP6CrFWJkONSlh0kGOnCA_11_2">64,298,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3fl1qAGW50Sz5N1waqgucA_11_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ab2cnm6P6UGXoyJRBNe9KQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sn5cczSi-0S9lbezm5hiDA_11_8">699,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dOQiYLrDx0es2KwdD-YnMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KdGHPRn4Zkmw8IjMkCgvBg_11_11">3,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XWbwq0m_K0WELesuemAQ5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_OHAfzjdBXEOE7Ai6_nJYuA_11_14">574,673</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_e7qr1ZXE4Uei6AGbgRG2zQ_11_17">121,734</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_00e35123_b528_4bcf_bed3_6dbc4f38295a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</b></p><a id="STATEMENTSOFCASHFLOWS_138361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_2c280045_a05e_4931_a66b_c8202eb2570b"></a><a id="Tc_6_sRyQx5cUmIXEUL8ALb-g_1_2"></a><a id="Tc_1rwh_33VpE-oNjLMsJiS9Q_2_2"></a><a id="Tc_du9JVy4LIk2cxumAvqgTVQ_2_5"></a><a id="Tc_Cr2fN-vvHU65ywi16lKa1A_3_0"></a><a id="Tc_f4xMmmmm_UylwxR5LlGBtA_4_0"></a><a id="Tc_4kk7vIgBOkGBhJIZSbJq4Q_4_2"></a><a id="Tc_-c9Z8OiGj0W1pVtaVeIqLg_4_5"></a><a id="Tc_XSi9i2hkOEaOGzrtv20o5A_5_0"></a><a id="Tc_VK6j_1XAhka_zDb2nmSMng_6_0"></a><a id="Tc_o3Z-OBzeqUibJ9O3zyNpdg_7_0"></a><a id="Tc_NZ-FrFPuqEm-adFWM0Ouiw_8_0"></a><a id="Tc_n7lPGUFdfkeZDB5MVNEidA_9_0"></a><a id="Tc_IOYG-34w-E2yhxY8iBbSeQ_10_0"></a><a id="Tc_5U4Qz-VvNEm2SHbmwui5FA_10_6"></a><a id="Tc_dOU3-OjL00C6Fs55TWM-hg_11_0"></a><a id="Tc_JHEvrpsmmkyPRR3pNTmvYA_11_6"></a><a id="Tc_P2h6fE_yBEiGp27RigKISQ_12_0"></a><a id="Tc_dzPREjiJzU6Z1emHxBllvw_13_0"></a><a id="Tc_ha89qeWOQEeA8E29TlM1sQ_14_0"></a><a id="Tc_Npg2s8GyIU6Y8-ObnfPXtw_14_3"></a><a id="Tc_xnZAg1qDwEulGQjTcawfNQ_15_0"></a><a id="Tc_qenSD-gjakaaBJ3jof5Uxg_16_0"></a><a id="Tc_hhpjWE8CQkqFOfknw7Efcw_17_0"></a><a id="Tc_zExIfATWb023bJNs1ZTNXg_17_6"></a><a id="Tc__pLan5mX3EaiZH1ym9Fz3g_18_0"></a><a id="Tc_sMqCGzFO6EuUiWc43SYHHQ_18_6"></a><a id="Tc_uO4bvpf7MEuJ7zrsPNjRgA_19_0"></a><a id="Tc_bW1YTs-jT0qOLtRgb1IyuQ_20_0"></a><a id="Tc_WLwRwGnxoUqLJsUge5zIGA_20_6"></a><a id="Tc__kFX8n1_xUOoYachmiWtBA_21_0"></a><a id="Tc_zARnsIBdAUGk3nJQmcw8-g_22_0"></a><a id="Tc_9GNhyYmuUkGBqdpNSMRyXA_22_3"></a><a id="Tc_BGL9rDNFNUSHuF2VfzCKkQ_23_0"></a><a id="Tc_M-yUFvaiwkiG6GNUYb_PUg_24_0"></a><a id="Tc_GoYffMdOZkeT70rQHv-qOg_25_0"></a><a id="Tc_au_xmpDmZ0WLx-xBM4TXbg_26_0"></a><a id="Tc_rIL59PizB0Kvupqdu2dybQ_27_0"></a><a id="Tc_75dF-FkAak-vBBlO5xS59w_28_0"></a><a id="Tc_9ZbdZWqMeky8CIAcY-0j0w_30_0"></a><a id="Tc_qgfExEXhbUe9j-uzKg-p3Q_31_0"></a><a id="Tc_otTR-wqaHU2YbxnOsbFx4g_32_0"></a><a id="Tc_QOkwZR5Z_ES6crWb01a0Ng_32_3"></a><a id="Tc_0y9m2OYvhUOyz85jOdsC4Q_33_0"></a><a id="Tc_PpGsBlMeQk2YbGBXa4AvCQ_35_0"></a><a id="Tc_Pzy8m2uJhUeSSOVUoExO4g_36_0"></a><a id="Tc_jBcR61Up6k22KQUlQH-Yhg_36_6"></a><a id="Tc_dsACeLJGE0CBn3_Hn7z-3g_37_0"></a><a id="Tc_0a3LTBGdjkCAo7AC3zbQxw_38_0"></a><a id="Tc_ubcBFgbOvEuLpE2Lb4lyZQ_39_0"></a><a id="Tc_jJDiiTHo2U--X-BhMmHghg_40_0"></a><a id="Tc_Buzj_X00nU-zv9E1cG9qtg_42_0"></a><a id="Tc_XLeu-zXKYUm5TnfRJozLcw_43_0"></a><a id="Tc_ua5jSO4Zc0C62ReUWftAHg_44_0"></a><a id="Tc_P5fckVDRB0euHvRdCL_U-Q_45_0"></a><a id="Tc_DPgl8dHuPEGt5knl1FCObA_45_2"></a><a id="Tc_3EZ7eS4pR0anzhipRJyZkw_45_5"></a><a id="Tc_-tPnY_qN9Uun8mwQTzecEg_47_0"></a><a id="Tc_9ZLDlED3fE2nizUZrRYL4Q_48_0"></a><a id="Tc_iGKelsmpFkS-O-C3kqCBbw_48_2"></a><a id="Tc_urGnxtQK3Eezx5rj6kxU3g_48_5"></a><a id="Tc__0Mvt3e9ckywJo2o6fQAcQ_49_0"></a><a id="Tc_XrezXWqsZUWPk7JR3ta1Bw_49_2"></a><a id="Tc_5Gog8SytwEmEya-BrWYbjg_49_5"></a><a id="Tc_1giX1bWKZUaxa0bf2X9a1A_49_6"></a><a id="Tc_s8_xyoFg0UGQKJHy_10ysw_50_0"></a><a id="Tc_TP9C1ROji0iUYFJS9EcRjA_50_2"></a><a id="Tc_bP2wdzqUS0KtWbWEV6eK-g_50_5"></a><a id="Tc_QrmHDGqw-UyOLVHzr6tswA_50_6"></a><a id="Tc_0IHCBiLi0kC4ePQ1H7giqA_51_0"></a><a id="Tc_eaax9KdlykmMyJPY1QBQvw_52_0"></a><a id="Tc_n4x1LvPMEUK9CX_aR3MwGQ_52_2"></a><a id="Tc_f4yBqbSOsEyrzXrKazKsdw_52_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month Periods&#160;Ended March&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_X1tFxC-ZIk2YuxmfmVNRfQ_4_3">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_gxnFNQ_jKkS8KLa3qTEu1A_4_6">20,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7paOPzOZ1Eeit6gn4lBV9Q_6_3">4,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_k-3WOx_A6k2ZATbXyi1qmg_6_6">6,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency (gain) loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_LxYAPOttb0Orld-Q5W6kCw_7_3">3,687</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_Nq3dG_eGMEeOSpjW5rhtEg_7_6">535</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_VIdyEDsbTkCzy_rDc47RQA_8_3">3,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_lHFL4gLW_kiKZ4tXZsAcng_8_6">3,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net change in right-of-use assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_ZUd5njEFQ0uMVYOEU_W8Bg_9_3">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_Y9WZMuzy6U6lGurDheauTQ_9_6">36</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Gain on termination of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="Tc_4fps5os970yHPtq0dsn7tQ_10_3">1,365</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Gain on disposal of equipment, furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_b-cpzFLgxE25dhvYqZeqWA_11_3">122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of interest on asset retirement obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationAccretionExpense" scale="3" id="Tc_RtvR7BnnEk-0kfpiuUvrFQ_12_3">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationAccretionExpense" scale="3" id="Tc_wCXERUHvfkCtykifcc_8oQ_12_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_tnNRUyn-jEW5vv9hjfp6AA_13_3">274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_ZIIOZcKFn0uL5U177nF37A_13_6">273</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of nonfinancial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:GainLossOnSaleOfNonfinancialAssets" scale="3" id="Tc_U0G3zZAtKEuVJ_t4lVVxhA_14_6">29,018</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">(Increase) decrease in operating assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accounts receivable - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="Tc_ShT7rLGjukefxLaBIgLH1Q_16_3">49</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="Tc_sPEAqoePu0uo37ZGdU4SVQ_16_6">1,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Contract assets - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" sign="-" scale="3" id="Tc_0MhKhVvaWkOAJ7GzwveKUA_17_3">701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets" scale="3" id="Tc_-09413bmDk6t8EN1sHQiqw_18_3">203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_xB3iMCJpzUa6RjXbYgG-yw_19_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_zrRxcxYx8UaOCES4odl8hw_19_6">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Tax incentive receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="3" id="Tc_eboNgnyjlkCmekMdSMWC2g_20_3">4,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" sign="-" scale="3" id="Tc_26g3FP-Hd0iKj6dg3ywYOg_21_3">1,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" sign="-" scale="3" id="Tc_oVgLe_03jUqHzjYkeCRIGg_21_6">626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Other assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_h4zOY0ORXEGOfIjpc3fUJg_22_6">632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Increase (decrease) in operating liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_1LyxLMkw002UDKs0R76Uug_24_3">3,061</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_4T7JpL6HnEeCQmp_0ihHuQ_24_6">5,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_FhwEt4jthE-5skiNg7tCBg_25_3">3,585</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_iKZP8TRnjk6k0JrVsnZAlg_25_6">24,231</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" sign="-" scale="3" id="Tc_rJJxNTuxW06oU884O4sGGw_26_3">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="Tc_bdOz_aaJyEyk6t0Y7mIyWQ_26_6">37</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Deferred revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_CtaYU8ugD0KIwjUMDskURA_27_3">329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="Tc_ak9puPfNC0yRCsu9sQ7nEA_27_6">20,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_USOCObbf7Eukp-b7SX_12A_28_3">36,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_-YgAsaV0aEWSrzhIuDvKKA_28_6">36,741</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_jRyqNvctcEGV_1dUvJawEw_31_3">1,710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_jaEsyYdeXkKSXxE6uo_krA_31_6">1,678</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of nonfinancial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ProceedsFromGainOnSaleOfNonfinancialAssets" scale="3" id="Tc_Z5nUHJaqr0K_LYffmsTfUw_32_6">29,018</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash (used in) provided by investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_DMxYNm2lCUK414Iiz4Y7Cw_33_3">1,710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_f9ZZz9-WRUm50Gwn0HguhA_33_6">27,340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_SoqV97G8zUqRnPIL8RM33Q_36_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payments of withholdings on shares withheld for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_G04ly4qHKkWG57IT2TfnVQ_37_3">2,761</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_osqKSdWRekSRPA9zPc_0Pg_37_6">2,221</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from the issuance of ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_G65-3yipd0-zX_cX8Yg6bQ_38_3">4,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_GG8hos2LyU-WnO3smMl_dA_38_6">1,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Issuance costs in connection with ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_PYJ4kNFavkmjm-pIdCQgiw_39_3">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_J5wG5f78q025EyXxOTuGyw_39_6">635</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash provided by (used in) financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_od7-Jq7oqEqSWW1Con2Jzw_40_3">1,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_UNKM6aMjc0yTEVP2kunHPA_40_6">1,270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_oo5Ec_vzHUiq2rFJMs8l6w_42_3">36,825</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_aIQ3bIo9fkGWkuWPuMJt3A_42_6">10,671</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_TD8W6OPS7UCD3oNC3rgHKw_43_3">233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_CnKuEmbok0eyw8GaTTA5Aw_43_6">287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash, cash equivalents and restricted cash at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_EWPZbYyCe0Cz9MqXlA2YHg_44_3">105,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Fqx_FBVO9EKmApu50AOWXg_44_6">130,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash, cash equivalents and restricted cash at end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_o_3ivRHeDU6VNOsS6T8dRw_45_3">68,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_fNb0Oq_MOEmX8dMu1TrMHw_45_6">120,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash transactions:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Fixed asset acquisitions included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="3" id="Tc_L4gdjm3IiEODViUJ8mVPbw_48_3">615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="3" id="Tc_CWPakGf4PEmMcdYKCH4EqQ_48_6">1,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Change in estimate of asset retirement obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationRevisionOfEstimate" scale="3" id="Tc_43v8q7P5_0WquxMoguw0Kg_49_3">1,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Receivable from sale of fixed assets included in other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" scale="3" id="Tc_T-OebM7suUOmvrNcA0kLrA_50_3">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_gH7n9qXHlUiISSwWn23aDw_52_3">2,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_VyZffcsMTUarcd_Vz22djQ_52_6">2,953</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c53485d6_f358_4739_a929_1e443aaff288"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES</p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_G4MHzo5OmE-F0TwRlzZzQg" continuedAt="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">MeiraGTx Holdings plc and subsidiaries (the &#8220;Company&#8221; or &#8220;Meira Holdings&#8221;), an exempted company incorporated under the laws of the Cayman Islands, is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. MeiraGTx clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by the Company&#8217;s internal end-to-end manufacturing capabilities. The Company has two viral vector production facilities for good manufacturing practices (&#8220;GMP&#8221;), internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. In addition, the Company has developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness. The Company&#8217;s core capabilities in viral vector and capsid optimization allow increased potency, decreased dose and significantly reduced cost of goods for its genetic medicines. The Company has developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive expression of any transgene under the control of oral small molecules. The Company is focusing the riboswitch platform on <i style="font-style:italic;">in vivo </i>delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin via oral small molecules, as well as cell therapy for oncology and autoimmune diseases, and long-term intractable pain. &#160;The Company has developed unique comprehensive technology capabilities to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Hologen Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On March 9, 2025 (the &#8220;Signing Date&#8221;), the Company and its affiliates entered into a strategic collaboration with Hologen Limited, a non-cellular company limited by shares incorporated in Guernsey (&#8220;Hologen&#8221;), and its affiliates. &#160;Hologen is a leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. As part of the strategic collaboration, the Company and Hologen have entered into the Framework Agreements (as defined below), pursuant to which the Company and its affiliates will receive from Hologen an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingUpfrontPaymentReceived" scale="6" id="Narr_OQCRJETDKk2F1wKEssmRhQ">200</ix:nonFraction> million (the &#8220;Upfront Payment&#8221;) on the Closing Date (as defined below), and Hologen will provide additional funding of up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_tiGUIO0qBk69Z-8zacyddg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingToProvideAdditionalCapital" scale="6" id="Narr_Txetm6B5wUOilDBDiL7RCA">230</ix:nonFraction> million as further described below. As part of the strategic collaboration, the Company also received <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw" decimals="0" format="ixt:num-dot-decimal" name="mgtx:ClassSharesOfHologenReceivedInTransaction" scale="0" id="Narr_3OFYDwb3vkmcePakSmFSYw">250,000</ix:nonFraction> Class A shares of Hologen at a nominal price. Furthermore, the Company has the option to receive up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw" decimals="0" format="ixt:num-dot-decimal" name="mgtx:ContingentClassSharesReceivableOfHologenInTransaction" scale="0" id="Narr_pxsTI6UOOE2S5LbQTFg0tg">500,000</ix:nonFraction> Class A shares of Hologen at a nominal price if certain funding obligations as described herein are not met by Hologen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The closing of the transactions contemplated by the Framework Agreements (the &#8220;Closing Date&#8221;) is expected to occur in the second calendar quarter of 2025, subject to customary closing and funding conditions, including the receipt of the clearances and approvals applicable to the proposed transactions under the foreign direct investment laws of the United Kingdom and the satisfaction or waiver of certain other closing conditions. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont1" continuedAt="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"><i style="font-style:italic;">Neuro Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">On the Signing Date, the Company, MeiraGTx Neuro UK Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Neuro UK&#8221;), Hologen Neuro AI Limited, a non-cellular company limited by shares incorporated in Guernsey and an affiliate of Hologen (&#8220;Hologen Neuro&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Neuro Framework Agreement&#8221;), pursuant to which, on the Closing Date, the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Neuro US&#8221;), Hologen, Hologen Neuro and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England and an affiliate of Hologen (&#8220;Hologen Neuro UK&#8221;), shall enter into a Collaboration and License Agreement (the &#8220;Hologen Collaboration Agreement&#8221;) for the research, development, manufacture and commercialization of the Company&#8217;s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson&#8217;s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the &#8220;Clinical Programs&#8221;) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the &#8220;Delivery Device&#8221;), in each case, in accordance with the terms and conditions of the Hologen Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On the Closing Date, under the Hologen Collaboration Agreement, MeiraGTx Neuro US will receive the applicable portion of the Upfront Payment in consideration for granting to Hologen Neuro and Hologen Neuro UK, as of the Closing Date and subject to the license granted by Hologen Neuro and Hologen Neuro UK back to MeiraGTx Neuro UK, exclusive, worldwide, royalty-free, fully paid-up licenses to certain of the Company&#8217;s intellectual property rights for the research, development, manufacture and commercialization of the Clinical Programs and the Delivery Device. On the Closing Date, (a) MeiraGTx Neuro UK will receive Class A shares of Hologen Neuro representing a <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ" decimals="2" format="ixt:num-dot-decimal" name="mgtx:ClassShareOwnershipPercentageOfHologenNeuro" scale="-2" id="Narr_b04qpA2ry0Wu6UwOisL9ag">30</ix:nonFraction>% ownership of the issued share capital of Hologen Neuro, in consideration for the provision of services to Hologen Neuro and Hologen Neuro UK as specified in the Hologen Collaboration Agreement, including services relating to the development of the Clinical Programs and the Delivery Device and certain other transition services, and (b) Hologen Guernsey will receive Class B shares of Hologen Neuro representing a <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ" decimals="2" format="ixt:num-dot-decimal" name="mgtx:ClassBShareOwnershipPercentageOfHologenNeuro" scale="-2" id="Narr_xtcv5D6guE6c1WwXWlxvzg">70</ix:nonFraction>% ownership of the issued share capital of Hologen Neuro, in consideration for paying the applicable portion of the Upfront Payment to MeiraGTx Neuro US, as well as a commitment to provide additional capital of up to $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingToProvideAdditionalCapital" scale="6" id="Narr_1FcZxDFuJUu1dVQeCWT7pg">230</ix:nonFraction> million to fund the development of the Clinical Programs and the Delivery Device. Additionally, Hologen will license to Hologen Neuro its proprietary multi-modal generative foundation models (LMMs), or large medicine models, pursuant to a license agreement mutually agreeable to the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of the Closing Date, Hologen Neuro shall be governed by a board of directors comprised of three representatives designated by Hologen and two representatives designated by MeiraGTx Neuro UK, and certain material business decisions (as further enumerated in the Neuro Framework Agreement) will require the approval of at least <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ" decimals="2" format="ixt:num-dot-decimal" name="mgtx:PercentageApprovalOfDirectors" scale="-2" id="Narr_DdJYI8c1Mk63nC3ZXOWCwA">70</ix:nonFraction>% of the directors then in office. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Following the Closing Date and in accordance with the terms of the Hologen Collaboration Agreement, the parties shall negotiate in good faith and enter into clinical and commercial supply agreements, pursuant to which MeiraGTx Neuro UK (directly, or through affiliates or subcontractors) shall manufacture and supply AAV-GAD, AAV-BDNF and other potential locally delivered genetic medicines to the central nervous system. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont2" continuedAt="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"><i style="font-style:italic;">Manufacturing Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">On the Signing Date, MeiraGTx Manufacturing Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Manufacturing&#8221;), MeiraGTx Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Limited&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Manufacturing Framework Agreement&#8221; and, together with the Neuro Framework Agreement, the &#8220;Framework Agreements&#8221;), pursuant to which, on the Closing Date and in exchange for the applicable portion of the Upfront Payment, Hologen will acquire a minority interest in MeiraGTx Manufacturing, an entity that will comprise the Company&#8217;s flexible and scalable end-to-end genetic medicines manufacturing business, which is solely run by MeiraGTx Manufacturing and MeiraGTx Limited prior to the Closing Date. Hologen will also contribute a portion of the annual funding to MeiraGTx Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of the Closing Date, MeiraGTx Manufacturing shall be governed by a board of directors comprised of three representatives designated by MeiraGTx Limited and two representatives designated by Hologen, and certain material business decisions (as further enumerated in the Manufacturing Framework Agreement) will require the approval of at least <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww" decimals="2" format="ixt:num-dot-decimal" name="mgtx:PercentageApprovalOfDirectors" scale="-2" id="Narr_69lBMT1m_0yihB646OUlwQ">70</ix:nonFraction>% of the directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">For a period of twelve months following the Closing Date, Hologen has an exclusive, irrevocable option to purchase additional shares in MeiraGTx Manufacturing at a specified price, such that following exercise of such option, Hologen shall own <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww" decimals="2" format="ixt:num-dot-decimal" name="mgtx:PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" scale="-2" id="Narr_CZ0Ii0J8hEi4jDCY7i8o8A">40</ix:nonFraction>% of the issued share capital of MeiraGTx Manufacturing in the aggregate. &#160;In the event that Hologen does not exercise its option, MeiraGTx has an exclusive, irrevocable option to purchase all of the shares of MeiraGTx Manufacturing held by Hologen for the same price that Hologen paid for such shares. Such option shall be exercisable anytime beginning on the third anniversary of the Closing Date and ending <ix:nonNumeric contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww" format="ixt-sec:durwordsen" name="mgtx:RepurchaseOptionVestingPeriod" id="Narr_rdjoBw_luU6E0MNbka5h0w">three years</ix:nonNumeric> thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Asset Purchase and Related Agreements with Johnson &amp; Johnson Innovative Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On January&#160;30, 2019, the Company entered into a Collaboration, Option and License Agreement with Johnson &amp; Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.)<span style="color:#ff0000;"> </span>(the &#8220;Collaboration Agreement&#8221;), for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases (&#8220;IRD&#8221;). Under the terms of the Collaboration Agreement, the Company received funding for certain research, manufacturing, clinical development and commercialization costs, and had the potential to obtain additional milestone payments upon the achievement of such milestones and royalties on future net sales of products. On December 20, 2023, the Company entered into an Asset Purchase Agreement (&#8220;Asset Purchase Agreement&#8221;) with Johnson &amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) (&#8220;UCLB&#8221;), on the one hand, and MeiraGTx UK II Limited and MeiraGTx Limited, on the other hand (the &#8220;UCLB RPGR License Agreement&#8221;), relating to the research, development, manufacture and exploitation of botaretigene sparoparvovec, or bota-vec (formerly referred to as AAV-RPGR), for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene, or XLRP-RPGR (the &#8220;RPGR Product&#8221;), and other related assets as described in the Asset Purchase Agreement. In connection with entering into the Asset Purchase Agreement, the Company entered into a Termination Agreement with Johnson &amp; Johnson Innovative Medicine terminating the Collaboration Agreement. The Company and Johnson &amp; Johnson Innovative Medicine also entered into a Supply Agreement on December 20, 2023 (the &#8220;Supply Agreement&#8221;) pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp; Johnson Innovative Medicine. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont3" continuedAt="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Under the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine paid the Company a non-refundable upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:AssetPurchaseAgreementFundingReceived" scale="6" id="Narr_N-4mBqm950OdHh1AqknNlA">65.0</ix:nonFraction> million in December 2023. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine agreed to pay the Company future contingent consideration of up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_anYll54pokiQcp14tL7FPQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ContingentFundingAvailable" scale="6" id="Narr_DY0NXyd1F06WrR6VeJEDXw">350.0</ix:nonFraction> million, as follows: (i) a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_vxfqy9OKIUWACknu_IhoYg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForExtensionOfClinicalTrials" scale="6" id="Narr_ch6bBPNlMkCgvbO3BTLiAg">50.0</ix:nonFraction> million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForDevelopmentOfDrugSubstances" scale="6" id="Narr_VgvgJB2fokKJvsDtF0zNHw">10.0</ix:nonFraction> million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForDevelopmentOfDrugProducts" scale="6" id="Narr_ZeSmv9fJvUy9KXhmBMAMow">5.0</ix:nonFraction> million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates" scale="6" id="Narr_SFnqvSCFQkaDEw4oVtgBQg">175.0</ix:nonFraction> million upon the first commercial sale of an RPGR Product in the United States; (v) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" scale="6" id="Narr_kHAaktVoXkGlYyetfLB8Ow">75.0</ix:nonFraction> million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForTransferOfManufacturingTechnology" scale="6" id="Narr_ir5Vme10Hkqq9Fl_TW9K5A">25.0</ix:nonFraction> million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp; Johnson Innovative Medicine; and (vii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForRegulatoryApproval" scale="6" id="Narr_mkm77yadHUWNdKMeBNJXiQ">10.0</ix:nonFraction> million upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. During 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_bTo8MlYWIEagDkty02ovVw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingReceived" scale="6" id="Narr_ls_aP3Yw20OcTvkTlw5meQ">60.0</ix:nonFraction> million in milestone payments from Johnson &amp; Johnson Innovative Medicine. Johnson &amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Interim Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to&#160;Form&#160;10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary in order to make the condensed consolidated financial statements not misleading. Operating results for the three-month period ended March 31, 2025&#160;are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the&#160;year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal&#160;year ended December 31, 2024 (the &#8220;Form&#160;10-K&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing. The Company&#8217;s accumulated deficit at March 31, 2025 totaled $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_bSudVECu8EyKaUIIChKGEg">742.0</ix:nonFraction> million, and management expects to incur substantial losses in future periods. The success of the Company is subject to certain risks and uncertainties, including, among others: uncertainty of product development; competition in the Company&#8217;s field of use; uncertainty of capital availability; uncertainty in the Company&#8217;s ability to enter into agreements and consummate transactions with collaborative partners; expanding and protecting the Company&#8217;s intellectual property portfolio; dependence on third parties; and dependence on key personnel. For the three months ended March 31, 2025, the Company used $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_BqiP2NGvgUy506KJMOFcJw">36.8</ix:nonFraction> million in cash flows from operations and there are no assurances that the Company will generate positive cash flows in the future. Additionally, there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_G4MHzo5OmE-F0TwRlzZzQg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of March 31, 2025, the Company had cash, cash equivalents and restricted cash in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr__BrIPQL67UmA3ORvabN6Yw">68.6</ix:nonFraction> million, which consisted of depository and money market accounts held at large international banks. The Company estimates that its cash and cash equivalents on-hand, tax incentive receivable and accounts receivable &#8211; related party at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen Limited, will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these condensed consolidated financial statements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company&#8217;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;">The Company&#8217;s capital resources and operations to date have been funded primarily with the proceeds from the Collaboration Agreement, Asset Purchase Agreement and private and public equity offerings, as well as the proceeds from the debt financing described in Note 10. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Vw-M7JBipU2FH_yt_EXG0w" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. &#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies and Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Certain of the Company&#8217;s significant accounting policies are described below. All of the Company&#8217;s significant accounting policies are disclosed in the notes to the audited consolidated financial statements as of and for the&#160;year ended December 31, 2024 included in the Company&#8217;s Form&#160;10-K.&#160;</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_5_VDMn-fDUu-brzsj9jT7w" continuedAt="Tb_5_VDMn-fDUu-brzsj9jT7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx, LLC, a Delaware limited liability company (&#8220;Meira LLC&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#160;II&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (&#8220;Meira Ireland&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira Netherlands&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Belgium, a private company with limited liability incorporated under the laws of Belgium (&#8220;Meira Belgium&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">BRI-Alzan,&#160;Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Bio, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira B.V.&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neurosciences,&#160;Inc., a Delaware corporation; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Therapeutics, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#8221;);</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Ybzl4YrZGkacZKoHE48GZw_1_2"></a><a id="Tc_XgsJVrDP0kCT87StJxuWmQ_1_5"></a><a id="Tc_VTLhP59VdUe0_4p738d-XQ_2_2"></a><a id="Tc_tMESoIZlmU6jcFS7IBsVGQ_2_5"></a><a id="Tc_hM51v0mo0kepvs00BfmuuQ_3_0"></a><a id="Tc_Zw7K-SshVUSUQSZzVg62Ng_3_2"></a><a id="Tc_k4V68DQxq0iGD6nkxWgnJw_3_5"></a><a id="Tc_997HL8YTn0eYhY3hENJ3Nw_4_0"></a><a id="Tc_U4ruGDxGWkW1tI-21q9nqw_5_0"></a><a id="Tc_QXE2uFNyUE6Z8LTc28eSAw_5_2"></a><a id="Tc_VHd-3OQrnUOHW8JvVthhYQ_5_5"></a><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont1" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont2"><ix:continuation id="Tb_5_VDMn-fDUu-brzsj9jT7w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro I, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro II, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Manufacturing Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ocular UK Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Gene Regulation Limited, a limited company incorporated under the laws of England and Wales; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro UK Limited, a limited company incorporated under the laws of England and Wales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:UseOfEstimates" id="Tb_XX_znLPQ1USae9X92BC0Qg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: service revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_sLpY97Nld0C8RbAwhVvEcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Restricted cash represents a guarantee put in place as required by the terms of the research and innovation grant from IDA Ireland which offers financial assistance in establishing the Company&#8217;s operations in Shannon, Ireland. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company&#8217;s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_E3F7LzMTA0Sqc9urtEQTgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_y4Uf5pjZjkGXDrRKZtQQjw_3_3">66,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_K-aXQsJXSUuAmo9oHhiCrw_3_6">103,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_j32-YTKOwUKch3H9tDp7XQ_4_3">2,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_SY2BbjAU8kqEYfApKuTUiw_4_6">2,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5Fn74psgrEO_MeGhErSaQQ_5_3">68,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_lRspxIDA4UWU8h9sz6lxxg_5_6">105,668</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_Ydc-3ERsyE-XNayir99VLQ" continuedAt="Tb_Ydc-3ERsyE-XNayir99VLQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="RANGEA3M10"></a><a id="_1e968550_0c57_4ded_92e9_e7c7159a52a8"></a><a id="Tc_iZGixVeDEUKCwHIhDmC3xg_1_2"></a><a id="Tc_z4Ot772Y_0SyT2Mm0TqYQA_2_5"></a><a id="Tc_-_dYRlV4Qk6cXDAHeC7pFw_2_8"></a><a id="Tc_t798JxFWeEaumxWTLdmnWw_2_11"></a><a id="Tc_mXj99iSsWkWGJ4xotWgCRg_3_2"></a><a id="Tc_-_Nc7liRl0mVOpy4zlViqA_3_5"></a><a id="Tc_WW5Y6X8rTE6mF-FocrJOQg_3_8"></a><a id="Tc_-oyfs4IEhkan1qchhzx2gg_3_11"></a><a id="Tc_oM6M-xDLBkql8W2BgsaMtg_4_0"></a><a id="Tc_pqGblOzx9U2bpChCi80tHQ_4_2"></a><a id="Tc_-enqttY340GE_PY9ZnUXTw_4_5"></a><a id="Tc_SvkN7BePHkKR6kGMu3kujA_4_8"></a><a id="Tc_scKnC6kW40GS4k4hQFdwsw_4_11"></a><a id="Tc_dpvx9KJW6U-WW7HmRX0gnA_5_0"></a><a id="Tc_BAkaCtshoUeNEzsER2dwLw_5_2"></a><a id="Tc_YSKR8nQmbUCbAY4pJWiD0w_5_5"></a><a id="Tc_rMW_MMwf2kSpUiwXm9OfSA_5_8"></a><a id="Tc_IUbjrt-bkUmCCL9tGjsdbg_5_9"></a><a id="Tc_NfQn8phvlEOmLRutj_otrw_5_11"></a><a id="Tc_cAmBfUtWA02UjnDFt2OXYA_5_12"></a><a id="Tc_-EQIbJfA50SjbmSsSaL5xw_6_0"></a><a id="Tc_YmIL0esgkkK2GZYvSFu7Yg_6_2"></a><a id="Tc_5JwnGlbK4k29SVwZe5cNZg_6_5"></a><a id="Tc_KkvapkudzkOAOdiSf0wbFA_6_8"></a><a id="Tc_W_suUOcDkUu2zhRwca8wVw_6_9"></a><a id="Tc_bFSQ9O8gFUOdoqncUsQhEg_6_11"></a><a id="Tc_WXkiY4SOKkmhzmHbiIgzYQ_6_12"></a><a id="_4daebf7a_b855_4f0f_87b6_ff7114f635d5"></a><a id="Tc_ruyvMMRjoE6W5RkgQmrOhQ_1_2"></a><a id="Tc_O86EPpaspkuLUxvrEcmFyA_2_5"></a><a id="Tc__fb2ytJn-UO6hgvYCg1QEA_2_8"></a><a id="Tc_VwkcQoa4vkqxfkTWq8Fmww_2_11"></a><a id="Tc_07zd9jOf7k6HLVKhlalLxA_3_2"></a><a id="Tc_dQSxR-8ysUeaHWK3s6CPGA_3_5"></a><a id="Tc_HddvynklMUexFu3ZM4vkeg_3_8"></a><a id="Tc_QRNhTlMOw0GAgVvrGdsdmQ_3_11"></a><a id="Tc_wRvMBpSRPE-CDi9w-hicFQ_4_0"></a><a id="Tc_gvOT47vJD0u3hZAKTd5Jfg_4_2"></a><a id="Tc_8LRK92YrOUOU9ib3fCJ2ig_4_5"></a><a id="Tc_tWUg6a9na02Ko_8wlxKqig_4_8"></a><a id="Tc_0atighhFo063uuk-XbUucQ_4_11"></a><a id="Tc_PRTtWkRu6EKSogi2pgCO_Q_5_0"></a><a id="Tc_PzJf11_Qn0qs48AGeHpe6A_5_2"></a><a id="Tc_gLzOE82lWU6PVHKVac1cmA_5_5"></a><a id="Tc_5X3_JryqX0WSq0fSt8hF5g_5_8"></a><a id="Tc_HPj9_gNwgkunZeFSx3eRIw_5_9"></a><a id="Tc_E5ttZQtlDES1_QkW1jZQ5Q_5_11"></a><a id="Tc_Akovl9-ZOUaiiLybV97RbA_5_12"></a><a id="Tc_2AmtjG8zvUKYGiEEOM4Scg_6_0"></a><a id="Tc_50KPePGKUUePmJFniV7tAA_6_2"></a><a id="Tc_EQcg2tnGjUaagUzeMrA-Uw_6_5"></a><a id="Tc_j-ew98v3nEOIPc2MAzRqyw_6_8"></a><a id="Tc_e2ddVw8x0E-GceyL9NUImw_6_9"></a><a id="Tc_NfrCqFVoXUe5_C-bNowhvg_6_11"></a><a id="Tc_J36OevDWB0ednbB0pem15Q_6_12"></a><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont2" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont3"><ix:continuation id="Tb_Ydc-3ERsyE-XNayir99VLQ_cont1" continuedAt="Tb_Ydc-3ERsyE-XNayir99VLQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company&#8217;s own credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company follows ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;">The table below represents the values of the Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_NqR4a2kLv0Kxiu7pE94yLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vNTUyBj1R0iHgetCERxoKw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_8gCJ6jfi8EmoKlxQbIQLgw_5_3">57,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_psKKUO-LuUiwEGnyG3klfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_CUdVUd2zqEa_lucHl7B_qg_5_6">57,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtv4RBfxkuuH4RrzAnNHw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_4T9gfdYOSEyxNQQko2Smaw_6_3">2,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PWqb2kP-wEuEFAiVAHEfUw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_ZJrfegF2h0ehDHWbYqUy4A_6_6">2,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant&#160;Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_w0975VuH_EaNXB4Ka939BA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_dvvRs7L45Ey9d8bW-MQRJw_5_3">80,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yNUlMtvIhEu4s5tbktrKBw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_ZO2N6CrPD0yqKAZQLTThDQ_5_6">80,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RF2S-NSeJU61RDz1CxpR0w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_NJPVo4qUNkG9EpYcHSfsJQ_6_3">2,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uKmiWTXiFUui62_GfPyv8A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" id="Tc_VlSxBZGCy0mPrl2NTTO--Q_6_6">2,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.3pt;">At March 31, 2025, the Company's financial instruments included cash and cash equivalents, restricted cash, accounts receivable &#8211; related party, and accounts payable. The carrying amounts reported in the Company's condensed consolidated financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments. In addition, at March 31, 2025, the Company believes the carrying value of the Tranche 1 Notes (as defined in Note 10) approximates fair value as the interest rate is reflective of the rate the Company could obtain on debt with similar terms and conditions.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_bGA4sOg3U0uGEUxcWx3EPQ_1_2"></a><a id="Tc_vAFcWuYXU0GV3YFGKNR6xQ_2_2"></a><a id="Tc_Cr8Kv4eerEODqbyRJHp1Qg_2_5"></a><a id="Tc_wd6NvpOwiECSqoQx0FlSwQ_3_0"></a><a id="Tc_cNzm95PKE0ifBJwRt7OTBw_3_2"></a><a id="Tc_1ETN9trx7UG9nzEB8rZJ3g_3_5"></a><a id="Tc_HGRaczfCGkez_-X1n_mDfQ_4_0"></a><a id="Tc_McMlRfvFG0-KMQ7lKyHvAQ_4_6"></a><a id="Tc_FnRi8h1O40qC1sAVgEN0_g_5_0"></a><a id="Tc_m81A2xqqxUuHe8fytYK7_Q_6_0"></a><a id="Tc_NLsR90Cay0W8hHElr_Wymg_7_0"></a><a id="Tc_M8lDpiV3_U6w-Tmwwwww3w_7_2"></a><a id="Tc_nezSbgYDKket2hutMiVEBw_7_5"></a><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont3" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont4"><ix:continuation id="Tb_Ydc-3ERsyE-XNayir99VLQ_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:AssetRetirementObligationsPolicy" id="Tb_1VKP3VestES7UcWXIuJrZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Asset Retirement Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.3pt;">Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level&#160;3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported on the condensed consolidated balance sheets were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;">The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, for which the Company had an associated asset retirement obligation liability in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationLiabilitiesSettled" scale="6" id="Narr_BLrJcfW8-kqF25j_ogBnkA">1.7</ix:nonFraction> million and a corresponding leasehold improvement with a net book value of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="Narr_HvhmuDPhPkefa7dPLCTUyQ">0.3</ix:nonFraction> million as of March 31, 2025. The landlord no longer requires the Company to make any changes to the premises prior to the lease termination and the Company only expects to incur $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationCashPaidToSettle" scale="6" id="Narr_YL8zChNY5Um4QvXD3esRQA">0.1</ix:nonFraction> million related to decontamination costs. Therefore, a change in estimate of the asset retirement obligation was recorded resulting in a gain on termination of lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GainOnTerminationOfLeaseLiabilities" scale="6" id="Narr_jP-Ul5E1wk2p9Xsf64X9iw">1.3</ix:nonFraction> million which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.5pt;">The change in asset retirement obligations is as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock" id="Tb_leZNRZLpkUGvzPV9bIKsNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_GnpdCGTSP0edK4yoa6_tOg_3_3">2,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_ITXkbvWHaE2DvEhYpmUwHw_3_6">2,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in estimate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationRevisionOfEstimate" scale="3" id="Tc_w-eZEpStwk2pwxFrUv5d8g_4_3">1,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Amortization of interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AssetRetirementObligationsAmortizationOfInterest" scale="3" id="Tc_GiwxWILewE2LcCTvo9LH3A_5_3">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AssetRetirementObligationsAmortizationOfInterest" scale="3" id="Tc_3doRYfyDjE2pbLN5K3A6XA_5_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss" scale="3" id="Tc_w26D56GQIkyr1Dues9y7yw_6_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss" sign="-" scale="3" id="Tc_LkEBpgx2sUSwjshk-gO8kA_6_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_ZksA9XtAvUGvHOSWUuwXnA_7_3">1,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetRetirementObligation" scale="3" id="Tc_JRpkA4k5Qk6b0wxDOtuRpQ_7_6">2,440</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="mgtx:ScheduleOfIrelandGrantsPolicyTextBlock" id="Tb_7o5yMOnvCUKwUfsprEQhAw" continuedAt="Tb_7o5yMOnvCUKwUfsprEQhAw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 24.5pt;">IDA Ireland Grant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">In August 2021, Meira Ireland entered into an agreement pursuant to which it received a grant from IDA Ireland for financial assistance in establishing its operations in Shannon, Ireland. Under the terms of the grant, Meira Ireland is eligible to receive the lesser of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_x8bvSHQN80e1DIGnCPEO1g" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantAmountForJobCreation" scale="6" id="Narr_RYI9MT2u-kGj418f1Ufa1Q">1.0</ix:nonFraction> million or &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg" decimals="0" format="ixt:num-dot-decimal" name="mgtx:GrantAmountForJobCreation" scale="0" id="Narr_FCtwUcH5NUSA8yLeClIq4w">10,000</ix:nonFraction> for each job created (the &#8220;employment grant&#8221;) and the lesser of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_GkhjCPAPaECcrC8N78W-Ng" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantAmountForMachineryAndEquipment" scale="6" id="Narr_LENe9TK4WE2s7KLa8Sc88Q">1.2</ix:nonFraction> million or <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg" decimals="2" format="ixt:num-dot-decimal" name="mgtx:GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" scale="-2" id="Narr_RgcWAjZ-_0WUt6v1jFZO3A">4</ix:nonFraction>% of the actual expenditure on the provision of machinery and equipment (the &#8220;capital grant&#8221;). Meira Ireland may apply for a drawdown of the employment grant once a job has been created and the position has been held for a period of at least one month, and may apply for a drawdown of the capital grant once an eligible asset has been purchased and installed, conditioned on the creation of a cumulative number of jobs by the end of the immediately preceding year. An aggregate of <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_BvXvmLHTZ0qgp_SP__HdmA" decimals="0" format="ixt:num-dot-decimal" name="mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding" scale="0" id="Narr_p2Z1-w0T00aSYx-Zg4x-eQ">100</ix:nonFraction> jobs must be created to receive the maximum benefit under the capital grant. An application for a drawdown must be accompanied by an audit certification for compliance with the terms of the grant. The Company has a guarantee in place with a bank in favor of IDA Ireland, pursuant to which it restricts cash in the amount of claims made under the grant such that the Company maintains the funds to cover any portion of the grant income that may become repayable in the future. This amount is presented as restricted cash in the accompanying condensed consolidated balance sheet. All grant drawdowns were required to be completed by December 31, 2024, and the agreement terminates on the later of <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA" format="ixt-sec:durwordsen" name="mgtx:FinancialAssistanceDurationFromLastGrantPayment" id="Narr_oRabxM07Nka2p_-6Y3asVg">five years</ix:nonNumeric> from the date of the last payment from the grant or <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg" format="ixt-sec:durwordsen" name="mgtx:FinancialAssistanceDurationFromCompletionOfCapitalInvestment" id="Narr_pEw1W638GEiZznRhtXko8g">five years</ix:nonNumeric> from completion of the capital investment, which is expenditure of at least &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" scale="6" id="Narr_IuRIKwh54kaMm6LStOMKMg">30.0</ix:nonFraction> million on eligible machinery and equipment. &#160;</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont4" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont5"><ix:continuation id="Tb_7o5yMOnvCUKwUfsprEQhAw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">The Company recognizes grant income when there is reasonable assurance that the Company will comply with the conditions attached to the grant and that it will receive the grant. Grant income from the employment grant is recognized as a deduction from the amount of the related expense, and grant income from the capital grant is deducted from the carrying amount of the related asset and recognized in income over the asset&#8217;s useful life in the form of a reduced depreciation charge. The Company received its first drawdown under the grant in 2023, which was comprised of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_e-G_0F-wWkOXxtBy8N16Xg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantFundingReceived" scale="6" id="Narr_WaoCgGLskEy9E_UOQjV9yg">0.6</ix:nonFraction> million for the employment grant and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_H2Pm54Ton0yrKe8l8jzgVA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantFundingReceived" scale="6" id="Narr_St7NyfPQFUi1XJ-5lq0bbQ">0.4</ix:nonFraction> million for the capital grant. The Company received its second drawdown under the grant in 2024, which was comprised of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_dEYHtikRfE2XPBZmM5ggNQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantFundingReceived" scale="6" id="Narr_JNaMO0GVok2cL65G_lRZQA">0.5</ix:nonFraction> million for the employment grant and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_IGvtLNP2dUW4TTCCJvLt-Q" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GrantFundingReceived" scale="6" id="Narr_qlhDTXak9U-HzusUuOdc9A">0.5</ix:nonFraction> million for the capital grant. During the three-months ended March 31, 2025 and 2024, the Company recognized de minimis grant income as a reduction of research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">During the <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA" format="ixt-sec:durwordsen" name="mgtx:FinancialAssistanceDurationFromLastGrantPayment" id="Narr_sTyhfuprA0yYIa_465KGcA">five-year</ix:nonNumeric> period ending on the termination of the grant agreement, Meira Ireland must maintain compliance with the terms of the grant. If the total number of jobs is less than <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_3HrtmboMJUKcXvGtnUlX-g" decimals="0" format="ixt:num-dot-decimal" name="mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding" scale="0" id="Narr_lAjo3eswZEC05y78_TVzDA">100</ix:nonFraction> at the time of IDA Ireland&#8217;s annual review, the Company may have to repay a portion of the capital grant, and if a job for which the Company received employment grant funding remains vacant for a period in excess of <span style="-sec-ix-hidden:Hidden_eNuWP8gC10unY9sqGjg8MQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span> calendar months, the Company may have to repay the employment grant received for that job. As of March 31, 2025, the Company is in compliance with the terms of the grant.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_YU_kpPmmVkWdVuXvfQed8g" continuedAt="Tb_YU_kpPmmVkWdVuXvfQed8g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 24.45pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition the Company performs the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the contract(s)&#160;with a customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iv.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocate the transaction price to the performance obligations within the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">v.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognize revenue when (or as) the entity satisfies a performance obligation.</span></td></tr></table><div style="margin-top:9pt;"></div></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont5" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont6"><ix:continuation id="Tb_YU_kpPmmVkWdVuXvfQed8g_cont1" continuedAt="Tb_YU_kpPmmVkWdVuXvfQed8g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">If there are multiple performance obligations, the Company allocates the transaction price to each performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a performance obligation requires significant judgment.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont6" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont7"><ix:continuation id="Tb_YU_kpPmmVkWdVuXvfQed8g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company records amounts as contract assets when the right to consideration is deemed unconditional. Contract assets are reclassified as accounts receivable once billed. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s condensed consolidated balance sheet.&#160;Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party, current.&#160;Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company&#8217;s revenue arrangements include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Milestone Payments:&#160;At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and Development Services: Under the Asset Purchase Agreement, research and development services (PPQ services) are recorded as incurred under cost of service revenue &#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Customer Options: Customer options are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_TKh8Ydm4oUega_iYwgU22g" continuedAt="Tb_TKh8Ydm4oUega_iYwgU22g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company&#8217;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_LLM1FEavc0-qaVMqzqvbNA_1_2"></a><a id="Tc_p1KzKQFwpEKWLO_i8NC5Kw_1_4"></a><a id="Tc_7SUWNjddCkK8uNqZzcntOg_2_2"></a><a id="Tc_nzHw15TlsEWPH1mXSxX9EQ_2_4"></a><a id="Tc_4lPuS7PqiUWYVu2Ve8U_oA_3_0"></a><a id="Tc_OB_k4UkWQE-KDZur92Tw0w_4_0"></a><a id="Tc_Y1XcbON3cU6i4_FYzgaKmw_5_0"></a><a id="Tc_fqq1xExq5kG9vhCytAHGHQ_5_2"></a><a id="Tc_7_wIR2ozwEW1Hh3aW2VqsA_6_0"></a><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont7" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont8"><ix:continuation id="Tb_TKh8Ydm4oUega_iYwgU22g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expenses, as the case may be.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Xe13pORDik25N-OEuCsNCQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Net Loss per Ordinary Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company&#8217;s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary share equivalents had been issued at the beginning of the&#160;year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_HH-YxA6Wlk-0POn-s5mMMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b0HC4nScVUuIG_mYjEASwA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_7ErTSkNa5UitakL2HmPacQ_3_2">8,022,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_gOdpVqSBHEGJvzck7tJOZA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VGFMYAy2akOnIsW1GJGzEg_3_4">8,484,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_oyaq6jivUkawB4YLvbDI0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LBA_RZ9gCk-CcZikz8ekLQ_4_2">3,389,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_EPMBHNhui0SPV5q0DQTs9A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_DxJJfyKWvkCGJxrCAV1s1A_4_4">4,094,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember_uFjEWSkzu0eHvfAynbX9jQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ULy_LtBv2UyGfOWHR1JB2Q_5_4">185,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nPdsKTqjKEeHIAIo7QnFLA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_mfrhqn-w7UKrSUDjjdjPOw_6_2">700,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_e_mz02J0OEe3fPVeHHSu4w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_uU5yCWWSD0OgCR_X4BKkAw_6_4">700,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Rz4gzG6Ir0GLsnlB6_r9ig_7_2">12,112,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_4-vEQK7a9UyURM30SCmktg_7_4">13,464,394</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_HBbcCvar70SRR73-bgmXYw" continuedAt="Tb_HBbcCvar70SRR73-bgmXYw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable and operating segment, which is the development and manufacturing of genetic medicines, for purposes of reporting financial condition and results of operations. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM allocates resources and assesses performance of the Company&#8217;s single reportable segment by regularly reviewing the segment net loss that also is reported on the condensed consolidated statement of operations and comprehensive loss as net loss.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_77e957ce_5dcc_4875_9378_bce555b0c1ac"></a><a id="Tc_HbSvoDWrpEuU1lgcNPFIJQ_1_2"></a><a id="Tc_vofMv99g2EW_KDK7Eq9GNQ_2_2"></a><a id="Tc_JwJeTW8gKUSME6MF8cywsQ_2_5"></a><a id="Tc_aXdeUtCsAk-J1iBWnHDHkg_3_0"></a><a id="Tc__NGyljLxoUmSWmgorjFC7g_3_2"></a><a id="Tc_XMOZR_L7MUCe1QehJ6zllg_3_5"></a><a id="Tc_DAsW0TL7_kadQ8e2brQtIQ_4_0"></a><a id="Tc_gjxNyBZICEabqlUEWCKxEA_5_0"></a><a id="Tc_Yiqjvfxuok-qFb-yCGTZHA_5_6"></a><a id="Tc_unxqj6vDEEO5birKVyhDQw_6_0"></a><a id="Tc_3bqpNDZsYUepqdYLwHSfLw_7_0"></a><a id="Tc_AOJK_lfiOE6cp7Dul8Tbsg_8_0"></a><a id="Tc__bmciQZz1EqNjpbyBa52Bw_8_3"></a><a id="Tc_mOICbYlbJES9J70ZjhhmHw_9_0"></a><a id="Tc_UixjFM0zPUCzrnAGlPnTHQ_10_0"></a><a id="Tc_udoWmFrDLU6pSKH174HK1w_10_3"></a><a id="Tc_xlJ48MZ_8kKXg18i14IbNw_11_0"></a><a id="Tc_k9in1D8yV0y4DqTlGrwDoQ_12_0"></a><a id="Tc_oUHzDc6dHUqd6hOEKfZkcQ_13_0"></a><a id="Tc_1H4iFTOV1EqMVpXFiV-Hmw_14_0"></a><a id="Tc_A0fBwFwnFkyHIubr99OgvQ_15_0"></a><a id="Tc_trHXZW-kJ0OGSK1cMyv2UQ_16_0"></a><a id="Tc_ZHzSH95_RUmbKcopEVcEgQ_17_0"></a><a id="Tc_kbmBZRJQNUK0ZZqKqPX8SQ_18_0"></a><a id="Tc_B5AN1wxLlEeBuLWALs5n-A_19_0"></a><a id="Tc_b8il1_NuVESPvUOe_gw0qg_19_3"></a><a id="Tc_rEhGB0BTvUmgsCLm1Iy9qA_20_0"></a><a id="Tc_8do5g1k4Z0G5Dr2ieA0k_g_21_0"></a><a id="Tc_I2Y58GZtc0Knhv-15zmqzw_22_0"></a><a id="Tc_6kJT1obJVkyM50H1xQhYAw_23_0"></a><a id="Tc_svr5Nn4FukOgmZl5qTixyA_24_0"></a><a id="Tc_dSO5eEnlCEqvoUUOlgok4w_24_2"></a><a id="Tc_O2VgQNAl6UmwWgsYBk-blQ_25_0"></a><a id="Tc_qe-otbxsHEm8Vu_oGDZubw_25_3"></a><a id="Tc_WCtTsf9VMECX_rt6R1iiVw_25_6"></a><a id="Tc_36Rz-oYKtkaLcCp4n027gQ_26_0"></a><a id="Tc_8tR1XqCPdUyu7kOpmVd-6Q_26_2"></a><a id="Tc_eaPz7uvHIUCUhRGsRLDE9Q_26_5"></a><a id="Tc_3Xm2xlWUy0CwIoTX3sGrlA_1_2"></a><a id="Tc_iU-A8rct6ki2SwPE5zXGQA_1_5"></a><a id="Tc_OEH3TlbxxEyFwYQgwaggyQ_2_2"></a><a id="Tc_AzS5BnMPp0WZARN65isUsA_2_5"></a><a id="Tc_qE-omzQbhESY6l9WJ5KK9g_3_0"></a><a id="Tc_AtowfZfAX0iJ-3c8Tsk0Hw_3_2"></a><a id="Tc_bCd3tKXYWkSZrXSq6CgeDw_3_5"></a><a id="Tc_M1T5FWe0tUCtneG5efZQAQ_4_0"></a><a id="Tc_YO96THctdkikp3W0QpXDqQ_5_0"></a><a id="Tc_Wnt7Eem75k2-7cwQA4xXug_6_2"></a><a id="Tc_GOaPopAbnEanQff3Cr9yCQ_6_5"></a><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont8" continuedAt="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont9"><ix:continuation id="Tb_HBbcCvar70SRR73-bgmXYw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_521JCjE1nkGs5wMswWUdiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ServiceRevenueFromRelatedParties" scale="3" id="Tc_kYTOp3G0f0Kii9qk5H4y8g_3_3">1,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ServiceRevenueFromRelatedParties" scale="3" id="Tc_EIdUAxciF0-KVXbSXF5JnA_3_6">697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_pE-mEd9Wi0q7U0VLmbOLjQ_5_3">1,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:SegmentGeneralAndAdministrativeExpenses" scale="3" id="Tc_9Ff0hSVYb0m4xjzWQDP7ug_6_3">6,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:SegmentGeneralAndAdministrativeExpenses" scale="3" id="Tc_vEv2edeccUaFd0GIZP_irw_6_6">8,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Botaretigene sparoparvovec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct1" scale="3" id="Tc_Rma0QDPtyEaJzKCOelVsYg_8_6">3,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-hAQP1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct2" scale="3" id="Tc_Hb7Sa4cuv02xcgPZR3D0FA_9_3">4,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct2" scale="3" id="Tc_DLwECa4jvEKDkWKXl1sxQw_9_6">1,663</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-CNGB3 / AAV-CNGA3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct3" sign="-" scale="3" id="Tc_2QDDvhCWHUiGXOhc-ZOK3A_10_6">1,179</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-GAD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct4" scale="3" id="Tc_WGwt2O6iqEyrbGZ3V7VImA_11_3">1,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ClinicalProgramsDrugProduct4" scale="3" id="Tc_gKK6AvFb6kuMlE0D1Tz3Jg_11_6">2,170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Other ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentClinicalTrials" scale="3" id="Tc_4hvYHlYhr0Km_XzfLAvLRg_12_3">1,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentClinicalTrials" scale="3" id="Tc_MbAnGWEJy0OPwELgjgEhfg_12_6">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentManufacturing" scale="3" id="Tc_YwhupzaQd0-Y3GXr6aoIAw_13_3">17,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentManufacturing" scale="3" id="Tc_nheKqqxtqkODnOky5Pn2eg_13_6">18,360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Gene regulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchGeneRegulation" scale="3" id="Tc_lIiNpOkNlUm15Pq9u6Y-dA_15_3">2,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchGeneRegulation" scale="3" id="Tc_cthZb3V-OES_NmnU3GbfHw_15_6">2,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Neurodegenerative diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchNeurodegenerativeDiseases" scale="3" id="Tc_WtIkw29VukammzDmfIxSCg_16_3">426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchNeurodegenerativeDiseases" scale="3" id="Tc_YuG3R6PFZECcDFvbpjNvIg_16_6">391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Preclinical ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchPreclinicalOcularDiseases" scale="3" id="Tc_68rxqNVZ2EGQV618ruIVQQ_17_3">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:PreClinicalResearchPreclinicalOcularDiseases" scale="3" id="Tc_ggUOZuZjgkqTiEPXmdlTjg_17_6">327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentOther" sign="-" scale="3" id="Tc_5aiS11WMIUS0outivrMEOA_18_3">624</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ResearchAndDevelopmentOther" scale="3" id="Tc_3JN5x3Gj7UyhfuReZvnWHQ_18_6">541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Johnson &amp; Johnson Innovative Medicine reimbursement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:InnovativeMedicineReimbursement" scale="3" id="Tc_2UCEcuGfC0KRFGFnYzJTEA_19_6">652</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_jbG34-ztz0OcNhfIsRtnXw_20_3">4,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_HSn2TLr3vE-cCFAfK3oKfQ_20_6">6,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_prd9t_vTBkyoc4e8NF4Jiw_21_3">3,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_jZuzyye3Mku9kaPE_MQK-A_21_6">3,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Zcoa2pvKjkKILGQOKs68wA_22_3">43,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_erSWw4wIR0aNeW0hgJCMKg_22_6">47,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:OtherSegmentItemsIncomeStatement" scale="3" id="Tc_0Fxfl1bFLk2xCPP-B_r2hw_23_3">1,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:OtherSegmentItemsIncomeStatement" scale="3" id="Tc_i6gfrwEqk0OAvMD-5-l_Cg_23_6">26,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:SegmentNetIncomeLoss" sign="-" scale="3" id="Tc_ejDAqkC_pEOkgPn4hvk6PQ_24_3">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:SegmentNetIncomeLoss" sign="-" scale="3" id="Tc_Zzx7YIzSnUqWs7GCP3J41Q_24_6">20,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments or reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7XHUTbyg50iEI5XCHOOyLQ_26_3">39,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cZXJbspHXkuZu6LbslQOhw_26_6">20,442</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1 </sup>Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company&#8217;s service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following table summarizes long-lived assets by geographical area (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="Tb_tX92qTu830CiGL3JAGrcwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_US_isAzfTWGxEaw8ldhWLyHVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_Yc4Q88c7K0aMW39Xh856pQ_3_3">2,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_cfMdJz0u7EKj-RrpFQyMpw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_Z5k0DT2D0kq1l07NuYG_yg_3_6">7,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_GB_mLJbdBSl7Euj6MToEtRJ-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_4lJgaaCblkeec5HgBkA0Pw_4_3">28,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_6w38CaNnUkWyGPBi3mG6OQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_kmpQXSrAqkm-UxnOeB3KWQ_4_6">28,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">European Union</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember__19Q6cUiYEa7qmq_KO8jNg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_gjnp0fP550iYaS9kodB3Tg_5_3">103,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_EiRkplRRA0e4VFOvaZVcUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_bpW8IFxBzE-jNcWQoBFrFA_5_6">100,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_02X9cvP3H06wByIf2lsA-Q_6_3">134,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_ktebdGeL4EydGwhZ0gDCFA_6_6">136,473</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vw-M7JBipU2FH_yt_EXG0w_cont9"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_XA_iDe0yZUGbwtgPiWjLXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. This update includes a number of amendments to clarify or improve disclosure and presentation requirements of a variety of topics in order to allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the requirements and to align the requirements in the FASB accounting standard codification with the SEC&#8217;s regulations. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact of these amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement: Reporting Comprehensive Income: Expense Disaggregation Disclosures (Subtopic 220-40), which requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date, which revised the effective date of ASU No. 2024-03 for interim periods. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of ASU 2024-03 and ASU 2025-01 on its consolidated financial statements.</p></ix:nonNumeric></ix:continuation><a id="Tc_rS_4qymq70OnT8KEvJFTaA_1_4"></a><a id="Tc_IJHocfz2GkatlcVrl3iTKw_2_0"></a><a id="Tc_q--ZB2vhz0muevg-lrrjKg_2_2"></a><a id="Tc_IbJ6TTMc9keayMNo1zvffw_2_4"></a><a id="Tc_52oeSPHDHEi1d-xnB45GoQ_2_7"></a><a id="Tc_upVEjwnFuEetfEVANrTPBQ_2_10"></a><a id="Tc_VxRji-F4j0uPhD0XxiMPFg_3_0"></a><a id="Tc_Ul9wuNuLUkWbkRxs1rx3Hw_3_2"></a><a id="Tc_h9XQ9nRGnEacGJzZ20pfuA_3_5"></a><a id="Tc_kJYaw5sTvU2_smxXdYeevQ_3_7"></a><a id="Tc_6CjVXIIDqk6_htUVeb_plQ_3_10"></a><a id="Tc_4fz7opFpMUOIBmWf5Nr9Tg_4_0"></a><a id="Tc__V2wUkBgD06BpHuExyCovQ_4_2"></a><a id="Tc_-W8CJTZX2Emak9Y0VceFuA_4_5"></a><a id="Tc_kFBpEW24e0KkpawnFLaaOA_5_0"></a><a id="Tc_5wQQ1NgcsEWW3X3hLzdynQ_5_7"></a><a id="Tc_qYWxF9DrREm62umME6XJnQ_5_10"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="Tb_XPIaGlHVhEqUUCUr69KNBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. &#160;&#160;&#160;&#160;&#160;&#160;Equity Method and Other Investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;">The Company&#8217;s investments consist of the following (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:EquityMethodInvestmentsTextBlock" id="Tb_kkIIjNnfw0OPmOoWcMaPtA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Investee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost Basis</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Visiogene LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Method Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Tc_U_f8VEaI7EmqvRhqz9P0Gg_3_4">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="3" id="Tc_pKLgJlVVykSFt0jvzQAcHg_3_8">5,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="3" id="Tc_CZn9RcL5gkCe886i1QupYQ_3_11">5,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Tc_PdkfazkiZU-AQpu8wPamiw_4_4">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="3" id="Tc_VscANXUZPkyD8YlxJ4NpOA_4_8">1,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="3" id="Tc_qpOfDQ2WrUGf3Hda7dd0XA_4_11">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity method and other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="3" id="Tc_DexFtk274kyJLfdNj2HSUw_5_8">6,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="3" id="Tc_sGm7unlxtEGtKJV6rw29Bg_5_11">6,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_QAkkjWBtSUKi-FmRL6MTPA_1_2"></a><a id="Tc_d93TDZfERUyU003NoQqpAA_1_5"></a><a id="Tc_2TkFiSuyGUKkGD0nFWHsjQ_2_2"></a><a id="Tc_hbWePkCmR0SH1MtxKJPZxg_2_5"></a><a id="Tc_B7p5wbz5H0O_12RnVKvFDA_3_0"></a><a id="Tc_1Y3lOnz_NEOyJFToKPuMZw_3_2"></a><a id="Tc_l2XgXfJrUkaLM89OpspA4A_3_5"></a><a id="Tc_VMtU_oQVzkSOURynPqoQMQ_4_0"></a><a id="Tc_Fbel0et1WUSJuxHMkudNTQ_5_0"></a><a id="Tc_234K-Sp8QU2KU5mXqUvWvw_6_0"></a><a id="Tc_gTxfmA57yUW7QJYvGWNNJg_6_6"></a><a id="Tc_TseGaX2yEEiNTC6QBToyPA_7_0"></a><a id="Tc_VA40T6gHf0uAd7RKCRaMnQ_8_0"></a><a id="Tc_RICQn4NIM0KthDZ780WUBw_9_0"></a><a id="Tc_36Qr_WCKlEONBnXA6bLHOA_10_0"></a><a id="Tc_1YSjfr9w1EWyoHWEJYAG7A_11_0"></a><a id="Tc_VuSQZfjIpUWois3qE3jbeQ_12_0"></a><a id="Tc_MpdBbdYWs0-ELcFKMIvF0w_13_2"></a><a id="Tc_cRxHLHbiDUiSzJEvVuYjYg_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_uGPTaBQTmE6L2QB0ygkSGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. &#160;&#160;&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Accrued expenses for the periods presented are comprised of the following (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_0nZV98gEwkKiTsVHeYAQPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits" scale="3" id="Tc_Nib3vf5WT0KGTdNsRCUQ5A_3_3">8,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits" scale="3" id="Tc_LUb10D2gA0CDHOE2aSQqBw_3_6">11,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_fMlJSU5-Cky5uZeNFDgjMQ_4_3">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_yw5nHtcC_UieopD7TFbEhQ_4_6">6,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedResearchAndDevelopment" scale="3" id="Tc_lsN90yElB0y0Q4H5inS7Gw_5_3">2,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedResearchAndDevelopment" scale="3" id="Tc_Y3Jh-cN-4EG-CCsfYQ5Irg_5_6">2,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on Tranche 1 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositLiabilitiesAccruedInterest" scale="3" id="Tc_kZESISPkiE2p-B_5vTIIkw_6_3">2,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedClinicalTrialCosts" scale="3" id="Tc_n3g9qXMNE0GoXzWW1Ss5Jg_7_3">2,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedClinicalTrialCosts" scale="3" id="Tc_oh7JDozWlEOSl-OP7eIckA_7_6">3,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense" scale="3" id="Tc_1_TwVbwO5E-ZPkGhgPLXJA_8_3">2,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense" scale="3" id="Tc_1sbNYUNDO0C2R7I9JwfBcQ_8_6">1,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedConsultingExpenses" scale="3" id="Tc_zLtoG2FKwkKxYKD07lDGVQ_9_3">1,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedConsultingExpenses" scale="3" id="Tc_CHFRBxbkyUS14Y7_h-tRSA_9_6">1,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rent and facilities costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" scale="3" id="Tc_3hV_IzY1pkCPCiU-MSCCbg_10_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" scale="3" id="Tc__wFXk97qWk2TKHdpVe8hVw_10_6">257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets" scale="3" id="Tc_Tx2Xw6w6TkWCEM0voZJtyw_11_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets" scale="3" id="Tc_TglZXrq0pkGaq4Xmgtb-3Q_11_6">326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_orDQ0eWiVkuRU9azike_Uw_12_3">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_cP6SxnezAEOoEy4dP028dg_12_6">140</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_pvqa26R2YUG8pqvkC1KZKQ_13_3">23,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_oLyrqRQZpk-7AmqBPhqdqA_13_6">27,414</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_ot3Htxl0o0WQnv_Sl9CW8Q_1_9"></a><a id="Tc_CrsDeu8MIEeApuKWm90ZDw_2_5"></a><a id="Tc_8_9Shfcmc0W7jQF2ZX2SEg_2_9"></a><a id="Tc_nV5OfNIU-02G72wpK15JwA_3_5"></a><a id="Tc_L0TnJzC1hEat5eWzTNmWSQ_3_9"></a><a id="Tc_2VjRVfw8V06EzKqSP3RgXA_4_3"></a><a id="Tc_QNdpMhXdikOw7qNOxiDd1A_4_5"></a><a id="Tc_cSg0XQbk30aDqo2WZpFb4w_4_9"></a><a id="Tc_cwNJ1OKU2kOYQRv1YLnAAg_5_3"></a><a id="Tc_Dr8XCxOxL0uAkQrZrw5fzQ_5_5"></a><a id="Tc_venzSHiuHUqAzqjNYprgfg_5_9"></a><a id="Tc_CUnYVaqTHkGBBVz5IIrxbA_6_0"></a><a id="Tc_8as2VS595UKpi2eHPnB3rw_6_5"></a><a id="Tc_glk8mr-Jd06wuVVte2zfuQ_6_10"></a><a id="Tc_6XJcIiysrUK_3LBdsmKCgQ_7_0"></a><a id="Tc_T8TrNMiILkCVj4-kpVv0Sw_7_3"></a><a id="Tc_8O4xPSQFjkqWYrqlcMFlug_7_5"></a><a id="Tc_xtsA72SZYkWXlcJviqZbVg_7_6"></a><a id="Tc_ugx3KikRs0eGiZmEwpuISg_8_0"></a><a id="Tc_aMrs2g8_zEeQ8b8R8ypj_g_8_5"></a><a id="Tc_gKJpv15i_Eyu18WrZgP7sw_9_0"></a><a id="Tc_q7wFT-e_MUu9ZGU6jxtxCw_9_5"></a><a id="Tc_arxItvwm8Eydy83EDkgYiw_10_0"></a><a id="Tc_ywsTBHBj5UeCp_S7lLlTNg_10_5"></a><a id="Tc_PReqbKv5GUKuVpyxevACnw_10_10"></a><a id="Tc_xhflBYYAJ0i10-BlAdGvnQ_11_0"></a><a id="Tc_JTT-I72iQ0ip49U-zSfsAQ_11_5"></a><a id="Tc_ArkKoVGDNkWi9bk28VHQ-w_11_10"></a><a id="Tc_Bh2sw-48iUCWHjSHEJyuNA_12_0"></a><a id="Tc_LjfltR_BKU62IyV7kqrP5w_12_5"></a><a id="Tc_eI_WbUEjF0mqCa3xl9ObWQ_12_10"></a><a id="Tc_Mw8hr2dA1E-DKRODDOPARA_13_0"></a><a id="Tc_bG7VTo4QOEaplH0GdI9oeA_13_2"></a><a id="Tc_O-RtnUDRp0uNssthtPIn1g_14_0"></a><a id="Tc_DmrX0XxlZkqfuLsEUEKrOQ_14_2"></a><a id="Tc_HwijY8kQDkmC-KMdbwr75g_1_2"></a><a id="Tc_ZBi-6TUpHE6egk22csY_gA_2_2"></a><a id="Tc_2OfjfDX33E-yjHLr8Dvj0w_2_5"></a><a id="Tc_jUjWxDiNq0KacTAM1qkkQA_3_0"></a><a id="Tc_Ku4Q2ylWtE6yPQy9xdO2-w_3_2"></a><a id="Tc_ZMcDhV-bRkazalEvrmwv5g_3_5"></a><a id="Tc_KBdIt2hU1kO9EKdMow9H-g_4_0"></a><a id="Tc_4ACdRBVGd0ijofhb_HJwCw_5_0"></a><a id="Tc_8RBjoB4D4kK5rplNY4P68Q_5_2"></a><a id="Tc_vaO3K0bUwUu9K0ZHcVU9rA_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_0o70HcsBgUqHqVQw3gpFjA" continuedAt="Tb_0o70HcsBgUqHqVQw3gpFjA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. &#160;&#160;&#160;&#160;&#160;&#160;Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company&#8217;s 2018 Incentive Award Plan and 2016 Equity Incentive Plan (collectively, the &#8220;Plans&#8221;) were adopted by the Company&#8217;s board of directors and shareholders. Under the Plans, the Company has granted share options and restricted share units (&#8220;RSUs&#8221;) to selected officers, employees, non-employee members of the board of directors and non-employee consultants. The Company&#8217;s board of directors or a committee thereof administers the Plans. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="font-style:italic;font-weight:bold;">Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">A summary of the Company&#8217;s share option activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows (in thousands, except share and per share amounts):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_-BfwkaV8P0C0HVkWCbLniQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_VIKxg8ZCSU23QwJbWtdc-Q_6_3">8,232,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_f9OURpD5xkm25ZMAw1ARxg_6_6">12.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_XGD4QqVIo0CPSoNdkcbUmQ_6_9"> 5.35</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_iclkMx19pEKLbQloUu7bGg_8_3">638</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7pglixdkiEmrfxKlGS7BQA_8_6">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_fzeeogUVaE6xXWct1Cu2Aw_9_3">208,960</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_tQUzssHxL0yr0OugZZBkMA_9_6">16.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_aC_DDxt150SK3keME7awvA_10_3">8,022,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8hiI88OGn0CwHfVkvgwMtw_10_6">12.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_8NrJhSlC9EelrxZ3G0_rGQ_10_9"> 5.18</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_zbBNpC4vYUOL-3cTE1skcQ_11_3">6,956,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_is2xR0CoZUiVw2t0_a21ow_11_6">12.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_UpZEKqnLp0-SPiO14Eq-0g_11_9"> 4.79</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_-wqHwegYokmtZ1eSCJxh_A_12_3">8,022,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_jfqD49-y3kCe6Wm2VAXNhQ_12_6">12.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_hQTe_i9UPEW9vCgjpfGdeQ_12_9"> 5.18</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_ltsyvYeINEO9dQ3PAu4QSQ_13_3">2,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_Jq1TF9psRUmvIXWW2KA30Q_14_3">2,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.5pt;">Options granted under the Plans have a maximum contractual term of <span style="-sec-ix-hidden:Hidden_9vrz3CYLdkSqMQ_3AtrhKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten years</span></span>. Options granted generally vest <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_8LxrSFIxu0GJpgydg3W3VQ">25</ix:nonFraction>% on the first anniversary of the date of grant and the balance ratably over the next <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OcNay0HHIkW29F0CCsfiYA">36</ix:nonNumeric> months. Options granted to directors when they join the board generally vest in <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_Nbb73BCKL0iQXbnKJ4G6zQ" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_sguYsaBFyU6BpVy8qRYTOw">36</ix:nonNumeric> equal monthly installments following the date of grant, and annual options granted to directors generally vest on the earlier of the first anniversary of the date of grant or the day before the Company&#8217;s annual meeting of shareholders after the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">The Company recorded the following share-based compensation expense in connection with the options for the three-month periods ended March 31, 2025 and 2024 (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_mirp1fjS5ESmgV34SpiW4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_x0anTYpTGEKJId2AT2QSMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Hztbk7Am6E2_KTk6JjFlCQ_3_3">939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Yx2Gw2c3R0GT0T-W4aVOLw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_eabXruRwLEmRgQVgDYUUjA_3_6">1,635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_WEvytmm6-0as4ezA8Dxq_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_60QfTtMMckWPt99Q04bSow_4_3">597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-FBDFJh7Y02IFx7FP5-LHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bvNcPPn--EaYoAoR8H8ZWg_4_6">1,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iBggVZgkUE6oy4n7hR7u8Q_5_3">1,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4LjK6jhMvUC4mj6_ivFrsQ_5_6">2,688</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_rZnvjEPtg0ejg7uz8ZyjqQ_1_2"></a><a id="Tc_GK_cBoPsyUiXrdECv49Bng_1_4"></a><a id="Tc_0EdAzFAzhkOB_8Ft_ehW5Q_2_0"></a><a id="Tc_7ha26GsEdECAWsl_G4Hydg_2_2"></a><a id="Tc_g5QRQUHwTEWZHJz25veBzg_2_4"></a><a id="Tc_2oRT4SHSNE2eOH5RB1FgYA_3_0"></a><a id="Tc_HlD2Zp-QHkWBa_aZLX8KyQ_3_2"></a><a id="Tc_uTcIQejodEKHa-IyR-M0Og_4_0"></a><a id="Tc_npKG_PbygUqfYLUqw5mmKw_4_2"></a><a id="Tc_lMjTxnHoIkSU4S1A9BbEcA_5_0"></a><a id="Tc_HmtBrDcRnUWitNbnfzF-aQ_5_2"></a><a id="Tc_AdmCDgk_CkuW6bpU6JjGAA_5_4"></a><a id="Tc_1roELuAJEEWkyA_-cnCUSA_1_5"></a><a id="Tc_v5TDympL5kujv2k983LN9w_2_2"></a><a id="Tc_tMH_PYPYpUiVmIE8VGC9fw_2_5"></a><a id="Tc_th7_ewhybEe3HuScUsDxig_3_2"></a><a id="Tc_0nR2WPO98U6aFI9Rxqc_Yg_3_5"></a><a id="Tc_vOTF7jTOEEiVXSRssWRhHQ_4_2"></a><a id="Tc_hxZyAHlhO0q5amEyYOVt6A_4_5"></a><a id="Tc_-9975v5i5UiQotibQHzcqw_5_0"></a><a id="Tc_HQParIkYDUeWLMLo_lIGPw_5_5"></a><a id="Tc_sd8zSXVqFk6n6Typwr5Q1A_6_0"></a><a id="Tc_QqO5d4WNe0ekHzOfJnlZZw_6_3"></a><a id="Tc_0Ob_alOksEe_pMIcrnfUYA_6_5"></a><a id="Tc_NsCM3-GjXkKg1q_x296f5w_6_6"></a><a id="Tc_w1PmB9P4dEu6aOqD2kFpJw_7_0"></a><a id="Tc_BBfjMvHES0eVpzsPev_vjg_7_5"></a><a id="Tc_Fb0XF4AA1ES8j46ag6Z5ZQ_8_0"></a><a id="Tc_kHRtHi9FxEWnFPymm6zlNg_8_3"></a><a id="Tc_Rhccc76WMkivc4cMjXYUbQ_8_5"></a><a id="Tc__RJ26rS3aEuprNQvUnpZvw_8_6"></a><a id="Tc_NQblWM2EC0iQcQhb5n8Npw_9_0"></a><a id="Tc_29q_9O65rUet-E1VBTfXVg_9_5"></a><ix:continuation id="Tb_0o70HcsBgUqHqVQw3gpFjA_cont1" continuedAt="Tb_0o70HcsBgUqHqVQw3gpFjA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The total fair value of options vested during the three-month periods ended March 31, 2025 and 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_Rv6mdLH1c02VdI0fzltv4g"><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr__W054KAowUaUY3NY8c_p0Q">2.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_e6SPVjPil0utO5otAWop0g"><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_RU1fzFTFm06gwLSEtTlF1Q"><ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_WIaFmOdmXkilOahJhF8Hjg">4.3</ix:nonFraction></ix:nonFraction></ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_FfeT9ZoGkkGIrH2GmkXSSQ">no</ix:nonFraction> options granted during the three-month period ended March 31, 2025. The weighted-average grant date fair value of options granted during the three-month period ended March 31, 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_VQSAjad4dkuv0eHOVeGoWA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_HEHke4FjBkuQnHzXFuVAXw">3.91</ix:nonFraction></ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The grant date fair values of the share options granted were estimated using the Black-Scholes option valuation model with the following ranges of assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_AC7fyhbGJUOU7LIdLfSZUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_KBrumKJzqEOfVTGz0hwssQ">4.04</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_eaXywuTjskCh36TlWGd4fg">4.17</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_mnM_Z8CRBEmCgP-2TJYaRw_3_4">67</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_yUCSWS3kmUKiMqjKMCaTRw_4_4">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_FHMLfDF-0EKO7Asq-e8OTw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_v5FQwDxM4kev2SZTdyPEkg">3.6</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uVSHbG4-lEuN03PZ2bf2fw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_hCoZVt07DkOKxBz30WFRqA">6.1</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of March 31, 2025, the total compensation expense relating to unvested options granted that had not yet been recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A34VtYETjkq5z4-tujaPuw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_VPxK_yXYjUChiuXiYi-alg">6.8</ix:nonFraction> million, which is expected to be realized over a period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_BVL5anStYke9eQQClkMG7A">2.9</ix:nonNumeric> years. The Company will issue shares upon exercise of options from ordinary shares reserved under the Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Restricted Share Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">A summary of the Company&#8217;s RSU activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_mesChtZHe0ugmZQPMv-Bxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_vMMoBS5-k0i03anq6OZDVQ_5_3">4,252,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_mRJ7ibOoTEy5MfOdP9x5lA_5_6">8.91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc__3ZJ8bhkB0iO6HJa651FMA_7_3">862,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_gkPzOJbQW0m8JtUZjRbXHQ_7_6">13.70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_p8KAhXCYB0OsprM7e7zx2A_9_3">3,389,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_RU5m-mazbUWTFE068d7f7A_9_6">7.69</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 24.5pt;">RSUs granted generally vest <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_SecondAnniversaryMember_4r0tTmCAu0SQFy7DaGc90A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_H_tpjRDgQ0KVYgn6RrfTFQ">50</ix:nonFraction>% on the second anniversary of the date of grant and <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_nMDyq_90Akayh-1yVu4RFA">25</ix:nonFraction>% on the <span style="-sec-ix-hidden:Hidden_2cEA7rky_EClnxjTOR8EiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third</span></span> and <span style="-sec-ix-hidden:Hidden_3IRehDe7iE-PuKwN7f8KxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fourth</span></span> anniversaries of the date of grant. Annual RSUs granted to directors generally vest in a single installment on the earliest to occur of the first anniversary of the grant date or the day immediately prior to the date of the next annual meeting of the Company&#8217;s shareholders occurring after the date of grant. The RSUs granted to the directors in June 2021 will be paid on or within 30 days after the date a director ceases to serve on the board. For RSUs granted in June 2022 and future years, the directors may annually elect whether to defer the payment of their annual RSU awards under the Deferred Compensation Plan for Non-Employee Directors, which was adopted by the board on December 17, 2021.&#160;As of March 31, 2025, there were <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_PIX3BS0nTUa5tETrcj8elg" decimals="0" format="ixt:num-dot-decimal" name="mgtx:VestedSharesDeferred" scale="0" id="Narr_KvQm0dJUuUKXI5tGprx4Iw">272,500</ix:nonFraction> vested shares that have been deferred. The related share-based compensation expense, which is recognized ratably over the requisite service period, is included in general and administrative and research and development expenses, as applicable, in the condensed consolidated statements of operations and comprehensive loss.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_hSpXR9TrdEmoleMzo19IcQ_1_2"></a><a id="Tc_T-bjLqoYKEe-NbCVWqF1gw_2_2"></a><a id="Tc_cGmy373SG0GlyFyvkKvnKg_2_5"></a><a id="Tc_ZAE4UG3F5kWHTGjgkiWczA_3_0"></a><a id="Tc_oYJEHV4kTUSnMSuSkyd1bA_3_2"></a><a id="Tc_sn4LvQfnX0mQqqzJa_gB_w_3_5"></a><a id="Tc_Xf1K-4Mtp0SXzwonU5f7Xw_4_0"></a><a id="Tc_v2-JvF4dsEykLAFd9NoeRQ_5_0"></a><a id="Tc_eLy-pH0mw02-uIfbFnzsig_5_2"></a><a id="Tc_1ugOVIS9Ck2oBE0XKPERiw_5_5"></a><a id="Tc_tJNlu66I7EKdLXbQsenaYw_1_2"></a><a id="Tc_8VM_6obemka7pfQK-hlbAA_2_2"></a><a id="Tc_iKPeMarQ6kGdLdssjG87sw_2_5"></a><a id="Tc_KmS5dEAVjEy_ejklbYtgMg_3_0"></a><a id="Tc_Pl8ZYHf4UUeP05DkxIgnqQ_3_2"></a><a id="Tc_-78Tq2hL_UGNFBVYToPT3A_3_5"></a><a id="Tc__G9OYYna2kqMcSXV-8-v4g_4_0"></a><a id="Tc_s-rY4sYQx06cPu8x1dCK1A_5_0"></a><a id="Tc_e3iaoLoicUOslqFscyXHqQ_5_2"></a><a id="Tc_F-xEX-I700mq5ENbdkpwuQ_5_5"></a><ix:continuation id="Tb_0o70HcsBgUqHqVQw3gpFjA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 24.45pt;">The Company recorded the following share-based compensation expense in connection with the RSUs for the three-month periods ended March 31, 2025 and 2024 (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_Ywt901KUj0iFYAqzQSq2Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Z5HMPaYik0ye7_ykI_APgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YqFrze4n40WwUZIiAi-eWQ_3_3">1,107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WpG7KMWBlUKStgi4QQoKBg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-hqaYG6oJUeln4tjHtkCGw_3_6">1,240</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4qcy_d4u7k2Tb5wX8MN_yQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_B2BI2GM-tEGh__NqOzcyEg_4_3">2,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_co_X9kDcaUaRbStYIRfBYA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-P_Q8JGcbkWDsCypqkmFJg_4_6">3,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_N7a6Sd38Zk6P4XY-XFlZ8Q_5_3">3,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Fp3EO2WgDEiMO_pnKmaUSA_5_6">4,272</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">As of March 31, 2025, the total compensation expense relating to unvested RSUs granted that had not yet been recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_GWIIMCruSkKf457hyPPQcQ">18.5</ix:nonFraction> million, which is expected to be realized over a period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Exi1spgx00Oj4qf3NepllA">3.1</ix:nonNumeric> years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">To satisfy employee minimum statutory tax withholding requirements for restricted share units that vest, the Company withholds a portion of the vesting ordinary shares. During the three months ended March 31, 2025 and 2024, the Company withheld <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Narr_s-piOxIvsECvsyhYqkTM4g">405,459</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Narr_jmG07Be28kyc9Cy7YtuaMQ">348,652</ix:nonFraction> ordinary shares with a total value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="Narr_hEPZAsbvQUiciYj2HnxSug">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="Narr_qCi0JCjYmU61HF44DSPGmw">2.2</ix:nonFraction> million, respectively. These amounts are presented as a cash outflow from financing activities in the accompanying condensed consolidated statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">During the three-month periods ended March 31, 2025 and 2024, the Company recognized total share-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_OZsMEkWk0UifKyDntDHOvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yqGmJ2-KHka0ENT6fES9GA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tFLZW1n5mkS7W2uqirDiZQ_3_3">2,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SDGzmNr-NEmKPaMrfqtjDA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_siBb7dBulkmzukua-HQ7gQ_3_6">2,875</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_X4X9AYdDDEK7RWtpLuhYsw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_3LlZ9eL-zUScoeyll6U2Ig_4_3">2,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_bD1h8zBZy0a-rhyOQJBXYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6fDb8UtELkKuI1bR-Tu4jw_4_6">4,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zGyCl9tPnEecfY4LwuXQIA_5_3">4,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IrZealTF20665Z8Iwzx6dQ_5_6">6,960</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2.15pt;text-align:justify;text-indent:-2.15pt;margin:0pt 0pt 12pt 22.3pt;">The Company does not expect to realize any tax benefits from its share option activity or the recognition of share-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt-sec:numwordsen" name="mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" scale="6" id="Narr_Mv6eoO5bK0mcpBHLxe6MfQ">no</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_MlA4-b9GnE64Lz0dPLcYmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amounts</span></span> related to <span style="-sec-ix-hidden:Hidden_rcbwIQOgN0KERK7K18fcyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">excess</span></span> <span style="-sec-ix-hidden:Hidden_UfokOTS--kuNnksgF_hYAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax</span></span> benefits have been reported in cash flows from operations or cash flows from financing activities for the three-month periods ended March 31, 2025 and 2024.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_oZNcXbN2xkmp6yt0BGTINw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 7pt 0pt;">6. &#160;&#160;&#160;&#160;&#160;&#160;Ordinary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 5pt 24.5pt;"><span style="font-style:italic;">At-the-Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 0pt 24.5pt;"><span style="font-weight:normal;">In December 2023, the Company entered into an </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> sales agreement with BofA Securities, Inc., or BofA, pursuant to which the Company may sell from time to time, ordinary shares having an aggregate offering price of up to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_qIzB0lDadUGRb33apH8qog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_iuI4qYIsV0KlTLrCGYJQhw">100.0</ix:nonFraction></span><span style="font-weight:normal;"> million through BofA, acting as the Company&#8217;s agent. During the three-month period ended March 31, 2025, the Company raised gross proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="Narr_ph7L6Wj3zEC5IQiDDjU8Lg">4.5</ix:nonFraction></span><span style="font-weight:normal;"> million through the sale of </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_P4qL3SWvKEWIz7MUNdXiFw">563,379</ix:nonFraction></span><span style="font-weight:normal;"> ordinary shares pursuant to an &#8220;at-the-market&#8221; equity offering program. Under the </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> equity program which is currently effective and may remain available for the Company to use in the future, the Company may sell an additional </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_t4aotRLKJECS_tQUX6xOmw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:SaleOfStockConsiderationAvailableInFutureTransactions" scale="6" id="Narr_vZvRg-4kJUquoOa7EWZngQ">87.1</ix:nonFraction></span><span style="font-weight:normal;"> million of ordinary shares. Whether the Company chooses to affect future sales under the </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> equity offering program will depend on a number of factors, including, among others, market conditions and the trading price of the Company</span><span style="font-weight:normal;">&#8217;</span><span style="font-weight:normal;">s ordinary shares relative to other sources of capital.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_B3DoDpaanUGF05DucaEZTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">7. &#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr__Qb6nGALyEixG64kYCQkog">no</ix:nonFraction>t record a provision for income <span style="-sec-ix-hidden:Hidden_N4ipPyW_6EecGrCOlZuzUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">taxes</span></span> for the three-month periods ended March 31, 2025 and 2024, as the Company has generated losses for all periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;">The Company periodically evaluates the realizability of its deferred tax assets based on all available evidence, both positive and negative. The realization of deferred tax assets is dependent on the Company&#8217;s ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. The Company weighed both positive and negative evidence and determined that there is a continued need for a full valuation allowance on its deferred tax assets (after consideration of the reversal of the deferred tax liabilities for the ROU assets and fixed assets) in the United States, United Kingdom, Ireland and Netherlands as of March 31, 2025. Should the Company determine that it would be able to realize its remaining deferred tax assets in the foreseeable future, an adjustment to its remaining deferred tax assets would cause a material increase to income in the period such determination is made.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_VJeBzon4I02hUJAM71GKeQ" continuedAt="Tb_VJeBzon4I02hUJAM71GKeQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">8. &#160;&#160;&#160;&#160;&#160;&#160;Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">Asset Purchase and Related Agreements with Johnson &amp; Johnson Innovative Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On December 20, 2023, the Company entered into the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets as described in the Asset Purchase Agreement. Simultaneously, the Company and Johnson &amp; Johnson Innovative Medicine also entered into a Supply Agreement pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp; Johnson Innovative Medicine. Under the Supply Agreement, MeiraGTx UK II, together with its affiliates, will manufacture commercial supply of the RPGR Product for Johnson &amp; Johnson Innovative Medicine for an initial term of <ix:nonNumeric contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ" format="ixt-sec:durwordsen" name="mgtx:InitialAgreementPeriodDuration" id="Narr_uKsrH7GK6Ue_Nzy1r8dZwg">four years</ix:nonNumeric>, with Johnson &amp; Johnson Innovative Medicine having an option to extend the Supply Agreement for a fifth year upon written notification. Johnson &amp; Johnson Innovative Medicine may terminate the Supply Agreement for convenience upon <ix:nonNumeric contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ" format="ixt-sec:durday" name="mgtx:AgreementTerminationPeriodDaysWrittenNotice" id="Narr_L5NkWMJ7kk-jvZuraQafzA">90</ix:nonNumeric> days&#8217; written notice with payment of a termination fee. Under the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine paid the Company a non-refundable upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:AssetPurchaseAgreementFundingReceived" scale="6" id="Narr_MnXS91dZ_k2umuSXbVOt1A">65.0</ix:nonFraction> million in December 2023 and the Company is eligible to receive fees from commercial supply of the RPGR Product and in addition, milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_zgUUktVOakyME70F8CQ1DQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ContingentFundingAvailable" scale="6" id="Narr_i_UGg6_A5EGuVX4uUDWC1A">350.0</ix:nonFraction> million, as follows: (i) a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForExtensionOfClinicalTrials" scale="6" id="Narr_-WmQmm90jEWltg1T1Qzaow">50.0</ix:nonFraction> million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForDevelopmentOfDrugSubstances" scale="6" id="Narr_EoRQMsxZl0yrjoy6z-NgOQ">10.0</ix:nonFraction> million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForDevelopmentOfDrugProducts" scale="6" id="Narr_Wvj56FX0502sqOy3ck1D5Q">5.0</ix:nonFraction> million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates" scale="6" id="Narr_Jss4r0_0CE2zciJWgFRurw">175.0</ix:nonFraction> million upon the first commercial sale of an RPGR Product in the United States; (v) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" scale="6" id="Narr_vruLVQNgcUK_qno6DSnisA">75.0</ix:nonFraction> million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForTransferOfManufacturingTechnology" scale="6" id="Narr_NUDES4TwQUehwOIuz3jb_A">25.0</ix:nonFraction> million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp; Johnson Innovative Medicine; and (vii) $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForRegulatoryApproval" scale="6" id="Narr_OaEepgRAG0yfq26DrGU7QA">10.0</ix:nonFraction> million upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. To date, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingReceived" scale="6" id="Narr_C785JQJh20KkQp1hdkG4ag">60.0</ix:nonFraction> million in milestone payments from Johnson &amp; Johnson Innovative Medicine. Johnson &amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_VJeBzon4I02hUJAM71GKeQ_cont1" continuedAt="Tb_VJeBzon4I02hUJAM71GKeQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">Revenue Recognition under the Asset Purchase and Related Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">The agreements entered into in December 2023 were executed at the same time and were negotiated with a single commercial objective; therefore, the contracts were combined and accounted for as a single contract. These agreements were accounted for as a termination of the Collaboration Agreement and the creation of a new contract where the transaction price includes the remaining deferred revenue &#8211; related party from the terminated agreement of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:RelatedPartyDeferredRevenueReclassified" scale="6" id="Narr_hkWr_ueXvkKFc1SiW4nYeQ">30.6</ix:nonFraction> million, the fixed upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:AssetPurchaseAgreementFundingReceived" scale="6" id="Narr_2Ss00WLW0kKME1iUcBT41A">65.0</ix:nonFraction> million under the Asset Purchase Agreement, and an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:VariableConsiderationForServices" scale="6" id="Narr_ZsCbUFWNG0q495UppsAWkg">1.8</ix:nonFraction> million estimated variable consideration for transition services, offset by a credit of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:OffsettingCreditForTransitionServices" scale="6" id="Narr_jzNtFeu4XkyRXuI_l0GAtw">5.1</ix:nonFraction> million for pre-funded inventory, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ContractPriceOfLicenseAgreement" scale="6" id="Narr_6Rq4AXaiqUiidzFGyONHiQ">92.3</ix:nonFraction> million. The transaction price was allocated to four performance obligations on a relative SSP basis, subject to certain exceptions for discounts and variable consideration. As the SSPs are not directly observable for any of the distinct goods and services, the SSPs were estimated based on a valuation. The total transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ContractPriceOfLicenseAgreement" scale="6" id="Narr_DoDewNq6XUmVCgzR4JPNrw">92.3</ix:nonFraction> million was allocated to the performance obligations with respect to SSPs as follows: process performance qualification (&#8220;PPQ&#8221;) services in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:PerformanceObligationForProcessPerformanceQualificationServices" scale="6" id="Narr_jZYiumoSUEGoI8Jx-Fb-hQ">2.9</ix:nonFraction> million net of future billings, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:PerformanceObligationForCommercialSupplyOfRpgrProduct" scale="6" id="Narr_jQV4PZg1VEKVdEgLYFe1rQ">6.9</ix:nonFraction> million, manufacturing technology transfer in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:PerformanceObligationForManufacturingTechnologyTransfer" scale="6" id="Narr_-ApUfhII3EavoB0qqS-0CA">28.7</ix:nonFraction> million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#8217;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp; Johnson Innovative Medicine in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:PerformanceObligationForSaleOfNonfinancialAssets" scale="6" id="Narr_ISiJYv6uD0yjvbhjM_nCEw">53.8</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">Since the commencement of the Asset Purchase Agreement and related agreements, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingForExtensionOfClinicalTrials" scale="6" id="Narr_xsdZJIE8JU6DCLoZAlHWJA">50.0</ix:nonFraction> million milestone payment in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product. The milestone payment was allocated to the four performance obligations on the same basis noted above increasing the value of each performance obligation as follows: PPQ services in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices" scale="6" id="Narr_reZWHxXofkujABfngzGNbQ">1.6</ix:nonFraction> million, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" scale="6" id="Narr_BA_TSN2Bz0Ce7sa5zDvTYA">3.8</ix:nonFraction> million, manufacturing technology transfer in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingAllocatedToManufacturingTechnologyTransfer" scale="6" id="Narr_Hx80GjhXDU-EkCgf5s23pw">15.6</ix:nonFraction> million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#8217;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp; Johnson Innovative Medicine in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingAllocatedToSaleOfNonfinancialAssets" scale="6" id="Narr_c8HRW5HOI0ujnuvtyQcZSw">29.0</ix:nonFraction> million. Additionally, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices" scale="6" id="Narr_zPnI0PiXSESsqpu5Kp_lqg">10.0</ix:nonFraction> million milestone payment in connection with the completion of certain specified development services for the drug substance for the RPGR Product which was allocated to the PPQ services performance obligation. The Company also entered into additional agreements to provide additional services under the Asset Purchase Agreement and related agreements amounting to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_12_1_2023_To_12_31_2023_Di1tUbrdG0CEvFGNkpUsfQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:AssetPurchaseAgreementFundingReclassified" scale="6" id="Narr_Cir7Qst1ZEe92Kn6bypocQ">5.8</ix:nonFraction> million which was included in the transaction price and allocated to each of the respective performance obligations. Furthermore, the Company recorded certain changes in estimates related to the valuation of its performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">The transaction price allocated to PPQ services will be recognized over time using an inputs method measure of progress. The transaction price allocated to the material right for the commercial supply of RPGR Product will be recorded as deferred revenue until Johnson &amp; Johnson Innovative Medicine exercises its option to purchase supply and the Company transfers control of such supply to Johnson &amp; Johnson Innovative Medicine. The transaction price allocated to the in-substance renewal option (material right) will be recorded as deferred revenue until Johnson &amp; Johnson Innovative Medicine exercises the option and the Company transfers control of the underlying goods or services to Johnson &amp; Johnson Innovative Medicine. The Company will account for the exercise of the in-substance renewal option (material right) as a continuation of the existing contract (i.e., a change in the transaction price). The transaction price allocated to the technology transfer will be recognized over time using an inputs method measure of progress. The Company will recognize a gain for the difference between the carrying amount of the nonfinancial assets and the consideration allocated to that unit of account when control of the nonfinancial assets transfers in accordance with ASC 610-20, <i style="font-style:italic;">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During the three-month period ended March 31, 2024, the Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:GainLossOnSaleOfNonfinancialAssets" scale="6" id="Narr_hOs22tsQP0yyVWNMh-z3rw">29.0</ix:nonFraction> million related to the sale of nonfinancial assets which is included in other income in the condensed consolidated statements of operations and comprehensive loss. There was no gain on sale of nonfinancial assets recognized during the three-month period ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">As of March 31, 2025, the aggregate transaction price allocated to unsatisfied performance obligations was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:RevenueUnsatisfiedPerformanceObligationAmount" scale="6" id="Narr_aZSxOIkReUmxTEXTj-ngjw">63.9</ix:nonFraction> million which the Company expects to recognize over an estimated period of approximately <ix:nonNumeric contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw" format="ixt-sec:duryear" name="mgtx:RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" id="Narr_tfmR2elC2UyABcOpKxpa6Q">2.8</ix:nonNumeric> years.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_-53fhqJPdEqrQCEUCO9JZg_1_0"></a><a id="Tc_mS0fR0fxS0m18QrNRG2XVQ_1_2"></a><a id="Tc_aWycTdI9jkaeV1NBqjuJ6g_2_0"></a><a id="Tc_LuKnuUmw6kmoMQ30g-Ns9w_3_0"></a><a id="Tc_Sjw7Wz_0c0S5UBGGjLoJEw_4_0"></a><a id="Tc_Lpn-b21H80Co__h92WP7Xg_5_0"></a><a id="Tc_NwH-g00wkUO0r215WkKn2g_5_2"></a><ix:continuation id="Tb_VJeBzon4I02hUJAM71GKeQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;">A summary of the deferred revenue is as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" id="Tb_A7-wn_hMoUCx-SPe_xNc8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_O1KWw4ArDkiJPoDlyECyng" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_pVNqVVJBM0mM2LHga3yO_g_1_3">62,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other amounts collected or invoiced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" scale="3" id="Tc_Pssu7lCjJE6FjH_s6VZYBQ_2_3">323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue recognized as service revenue during the three-month period ended March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:DeferredRevenueRecognizedDuringPeriod" scale="3" id="Tc_0l21nKw-nUK7JfNCU7rTDg_3_3">741</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-3" format="ixt:num-dot-decimal" name="mgtx:ContractWithCustomerLiabilityEffectOfExchangeRate" sign="-" scale="3" id="Tc_8zKXdk7JZUabNUL-vboc8A_4_3">1,874</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_GVV6C-bI2UiH-uBNFaQbPA_5_3">63,859</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During each of the three-month periods ended March 31, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:DeferredRevenueRecognizedDuringPeriod" scale="6" id="Narr_nb2etssbOUSLrdAnrdUISA">0.7</ix:nonFraction> million of deferred revenue &#8211; related party as service revenue in connection with PPQ services under the Asset Purchase Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During the three-month period ended March 31, 2025, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:ServiceRevenueFromRelatedParties" scale="6" id="Narr_gxl5V4tHb0GOXLhq0yWLmw">1.9</ix:nonFraction> million of service revenue, inclusive of the $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:DeferredRevenueRecognizedDuringPeriod" scale="6" id="Narr_RROzXx3xg0ep0eVO5b148g">0.7</ix:nonFraction> million of deferred revenue &#8211; related party recognized as service revenue, based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements. There was no service revenue based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements recognized during the three-month period ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;">Debt Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"><span style="font-style:normal;font-weight:normal;">On August 2, 2022 the Company, as borrower, and Meira UK II and Meira Ireland, as guarantors (the &#8220;Subsidiary Guarantors&#8221;), entered into a senior secured financing arrangement (the &#8220;Financing Agreement&#8221;) by and among the Company, the Subsidiary Guarantors, the lenders and other parties from time to time party thereto and Perceptive Credit Holdings III, LP, as administrative agent and lender (&#8220;Perceptive&#8221;). On December 19, 2022, the Financing Agreement was converted to a notes purchase agreement and guaranty (the &#8220;Notes Purchase Agreement&#8221;) between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. Perceptive Advisors, LLC, an affiliate of Perceptive, is a greater than </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_12_19_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_FinancingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_PerceptiveAdvisorsLlcMember_oAxyTHASgU6LiyqF1ZUF5g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_uj53NcaznESDT8Bf7SjnLA">10</ix:nonFraction>%</span><span style="font-style:normal;font-weight:normal;"> holder of the ordinary shares of the Company. Additionally, Ellen Hukkelhoven, Ph.D., a director of the Company, is an employee of Perceptive Advisors, LLC. Refer to the discussion in Note 10 for further information related to the accounting for the debt financing.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_HnSuyt-TPE2aCHKmPtB_VA" continuedAt="Tb_HnSuyt-TPE2aCHKmPtB_VA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">9. &#160;&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Company has commitments under operating leases for laboratory, warehouse, clinical trial sites and office space. The Company also has finance leases for manufacturing space and office equipment. The Company&#8217;s leases have initial lease terms ranging from <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MinimumMember_2b1HMRkaD06hhuC2_CUTZw" format="ixt-sec:durwordsen" name="mgtx:LeaseMaturityTerm" id="Narr_a10bwcZAckm5H-2zjLzDTg">3 years</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_BgkV0HRRGEO9W9pctp9CrQ" format="ixt-sec:durwordsen" name="mgtx:LeaseMaturityTerm" id="Narr_WJM8Ig-teUGxfRAwbwvKkA">191 years</ix:nonNumeric>. Certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include fixed payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">Total rent expense under these leases was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_ROVQ7t55rUWVgxnkB3DDQQ">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_qdrWxX3Ys0GLx93_fs4w1g">1.4</ix:nonFraction> million for the three-month periods ended March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">There were <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="0" format="ixt-sec:numwordsen" name="mgtx:OperatingLeaseNumberNewLeasesRecognized" scale="0" id="Narr_ipF-PYhzHka3yo7sqJnHeQ">no</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_50G5iuwwS0COib-U_gl6RQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leases</span></span> recognized during the three-month periods ended March 31, 2025 and 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, resulting in a remeasurement of the ROU asset and lease liability reflected in the accompanying condensed consolidated balance sheets. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_r7CuhMyMqEqL3bzKXyDVHg_1_2"></a><a id="Tc_J7EFP7FPUUC56NCUcJO6LQ_2_2"></a><a id="Tc_gwAWfNOdx0O95f8K0VFu5g_2_5"></a><a id="Tc_zmxvJaowjkuLB2_Hqw3EEA_3_0"></a><a id="Tc_KDBrT4I2D0qEhkVLHGAkng_4_0"></a><a id="Tc_8sRmIIi6x0ud7K5HdC8NDg_4_2"></a><a id="Tc_6vSInuPaGEWBQN0cWnGVVA_4_5"></a><a id="Tc_KfYiywwF5UKGRFf_10JTJw_5_0"></a><a id="Tc_ZcOuOVdRbkONXpk2XYZkdQ_6_0"></a><a id="Tc_spSdjROon0GzMDdPhBamCA_7_0"></a><a id="Tc_Oal2IAbM60mWEfKrmbzRjA_8_0"></a><a id="Tc_sRR3qz2QS02_RpyBnRXahA_8_2"></a><a id="Tc_NCliyAPxpUOjhAMoYXHOdA_8_5"></a><a id="Tc_SuNk_llBykeRQfLiLQbeHg_1_2"></a><a id="Tc_ORf42t_moE-27uf9hKTg3w_1_6"></a><a id="Tc_yeq4o4RlGEGOGKvsZaUx6w_2_2"></a><a id="Tc_zIsaqJPLx0aamSXfIa3eKQ_2_6"></a><a id="Tc_iEMW1FXlBkW92nV74qoVqg_3_0"></a><a id="Tc_siyVFUWhokW1sXqPOqktyA_4_0"></a><a id="Tc_1aog-9L-aECpvPKQQJ_Ghw_4_2"></a><a id="Tc_BMTzHMvitUa096sPEC4v1w_4_6"></a><a id="Tc_b1vdHnnYzUGNyPnmdidpxw_5_0"></a><a id="Tc_tUV-bWbhMke54VUnrXncAQ_5_2"></a><a id="Tc_lrHGKCAgz0ODe9wv5MTIuA_5_6"></a><a id="Tc_P_vReA5d40aWAYcJLVAnQQ_6_0"></a><a id="Tc_No_fpvr83UKfSic2V5Ee3w_7_0"></a><a id="Tc_UiJb94Z4w0SbD4KGmvNpJg_7_2"></a><a id="Tc_tHHfwBj690mtBMNgTcoQAQ_7_6"></a><a id="Tc_bO2-t7cgCEewPZAFqdj2MQ_8_0"></a><a id="Tc_JDUthCAi70avog1dSA1LUA_9_0"></a><a id="Tc_N0K2oj0IpECbHhy1eYWSaA_9_4"></a><a id="Tc_uW8LNUuNlkmo3Pzobn61Pg_9_8"></a><a id="Tc_6RNzVCtBoU61eyplchWJrQ_10_0"></a><a id="Tc_kJqa5OxqTU-X_Tjtv2LGDA_10_4"></a><a id="Tc_oSiAu1N0iUCVkRQ0Ldxl9g_10_8"></a><a id="Tc_lHNncwiMkkOwwKSk0JzCgw_11_0"></a><a id="Tc_S9jHtXK7qkiEAMsw8wAd7w_12_0"></a><a id="Tc_Cm2dFUQg7EKXl-30MSRbnA_12_4"></a><a id="Tc_ZB_vlDcqhEyscNEJdPk1gg_12_8"></a><a id="Tc_FlKwcfUtIU-FUQ5F-OGoog_13_0"></a><a id="Tc_SDZGTf63kUSjZgR3GmGr_w_13_4"></a><a id="Tc_kQ9-hC-IA0O6zQcNR3bvQw_13_8"></a><a id="Tc_MfQuIgvZEUiyf20TVbSppA_1_1"></a><a id="Tc_qWIwZo0M0kqs0hOmrf3Ieg_2_1"></a><a id="Tc_Z4fgndK3pkSfyB_O36Y2kA_2_4"></a><a id="Tc_e5ic5y0ZiEy7Dv2Jslc7oA_3_0"></a><a id="Tc_A1Xps7bzME-dwbv9GY5GEw_4_0"></a><a id="Tc_UyYXgB8r4kqnd9ftBvl7Gg_4_1"></a><a id="Tc_aVpt07XPp0mc64vv_K2qFQ_4_4"></a><a id="Tc_9u6MNb-mjUqZ1Y_xz3FDig_1_2"></a><a id="Tc_DQp30rfbtk6ozM2XWh52HA_2_0"></a><a id="Tc_NgTz87sQYEqCWk8i6R88MQ_2_2"></a><a id="Tc_IQ5SY6sJnU-JpXxJIa91pQ_3_0"></a><a id="Tc_TYiru1oYzEaVl7_GwiRPvQ_4_0"></a><a id="Tc_hcYqTdFM402aQ_qUTM0iig_5_0"></a><a id="Tc_l5cqG9hWUECtBJm_Ftvp2g_6_0"></a><a id="Tc_hiHPrpV5P0uZe6l7e_5zKg_7_0"></a><a id="Tc_1nnb9R1BJU-JeKAY5V2utQ_7_2"></a><a id="Tc_q-dPqMRD70O4Vuyv6pxbxA_8_0"></a><a id="Tc_47ID_wKAHEKlPz56sRfdcg_9_0"></a><a id="Tc_mx3l8wXXik28zV-21wXf9Q_9_2"></a><ix:continuation id="Tb_HnSuyt-TPE2aCHKmPtB_VA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The components of lease cost for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_SmgeTDpX7EC_iLFW8EKEdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_2MaokFYeXEmnpLTFbAEzCQ_4_3">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_Ugi2TDH7ykWNH9Q6jZxh7A_4_6">281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_qqG9VpaLuUuUrqefgNWzkA_5_3">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_cUe_IWphCE2PepwKRxNcPg_5_6">281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_g1w0xKZLnUqCbnMnYtuQFA_6_3">1,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_EeyRbTVSb02IsIcvc0aNbA_6_6">1,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_3xNwkMKkMUuU5ZItnQA4sw_7_3">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_1rI6UswtVUmln-l4Ad7eeA_7_6">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_r52-YiVQGUGRsd1o8ep7eA_8_3">1,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_kUGAltui3U63hjDspDm_Ng_8_6">1,759</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Amounts reported in the condensed consolidated balance sheets for leases where the Company is the lessee as of March 31, 2025 and December 31, 2024 were as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="mgtx:ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" id="Tb_wfCdy4qqjkuGGkyk_A7r8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_zTu3nQyxP0Kh4qU5aipBXw_4_3">6,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_TZoVDxjGDUyksz25HAXtFg_4_7">10,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized lease obligations</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_LUPkbcs1g0SmYGBkTVWPCw_5_3">7,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_ziyT7bgUz0eu1HzRkyaozQ_5_7">11,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_I4_5TJHj-Uy8KUnPVlwROg_7_3">22,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_M2tyEG-MHUGWmUv1Hn23eQ_7_7">22,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_6X2oMZhhxkycAWikbrG9Xw_9_3"> 4.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_kLxqOEE3Q0KyUv9Aa_aREQ_9_7"> 3.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_jshRJ2gW80esx4GU5KtRkg_10_3"> 173.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_ghuMtxSwPUmEybUWC_svRg_10_7"> 173.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_XNHnjvilVE-wSva-RDpplA_12_3">11.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_G_db2jmwwEyWN48-NPlRmQ_12_7">8.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_D70NOYvHDE6d-4fJXgUKew_13_3">8.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_WpxHjPmdKU-LBYqSk410gA_13_7">8.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Other information related to leases for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock" id="Tb_Nrwzi9GMw0ueq7rpeKFh0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_YZuZnbYvV0-HjIn0wcrjnQ_4_2">1,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_fmUySMKoOEi3XGrpk5qvzA_4_5">1,419</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Future minimum lease payments under non-cancellable leases as of March 31, 2025 are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="mgtx:ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" id="Tb_HWQXmoWrj0m-qai260nsEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Ii-fG2z4kUusx_vwudBP6Q_2_3">2,690</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_YInWUH4VMUKCv6uTOcrkGA_3_3">2,451</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_JUIpnDMCpUCLJNJ7JKqVNw_4_3">1,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_fFvbjR5VAU67teGyrzc6Kg_5_3">1,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_trQqpOWJIkCpLnnZ8iHZ3w_6_3">576</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease payments</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_xS7dNE-T4UuyMb88OXnbLA_7_3">8,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_79hccJAURkKPSc9iFmpgaQ_8_3">1,233</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_dd8xzT7jHEK6VczIiJyzug_9_3">7,383</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_Z31UGyDw5k2l1dBPg3eIOg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10. &#160;&#160;&#160;Debt Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">On August 2, 2022 the Company, and the Subsidiary Guarantors, entered into the Financing Agreement with Perceptive. On December 19, 2022, the Financing Agreement was converted to a Notes Purchase Agreement between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. The Company and the Subsidiary Guarantors entered into a Consent and Amendment with Perceptive on August 10, 2023 (the &#8220;First Consent and Amendment), and the Company and the Subsidiary Guarantors entered into a second Consent and Amendment with Perceptive on December 20, 2023 (the &#8220;Second Consent and Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Notes Purchase Agreement provides for an initial $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_J1U8kk-mzUWPupZA_s7Apw">75.0</ix:nonFraction> million notes issuance (the &#8220;Tranche 1 Notes&#8221;). &#160;Pursuant to the First Consent and Amendment, <span style="background:#ffffff;">the Company was able to request in its sole discretion, and Perceptive agreed to subscribe to purchase upon such request, an additional </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="6" id="Narr_MZD5PIyNP0WzmiXGtMXqqg">25.0</ix:nonFraction></span><span style="background:#ffffff;"> million notes issuance (the &#8220;Tranche 2 Notes&#8221;) at any time before August 2, 2024 subject to the terms of the Notes Purchase Agreement.</span> Previously, the Company&#8217;s request for issuance of the Tranche 2 Notes was to be determined at Perceptive&#8217;s sole discretion. The Notes Purchase Agreement matures on August 2, 2026 and is interest-only during the term. The Company has the option to redeem outstanding principal notes at any time along with an applicable early redemption fee. Under each of the First Consent and Amendment and the Second Consent and Amendment, the Notes Purchase Agreement was amended to increase the applicable early redemption fee. Outstanding amounts under the Notes Purchase Agreement bear interest at a fluctuating rate per annum equal to <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_42lCiz8CVUyY3EVhVz0_cQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_dI0wO1rLw0i14xrLBRMeWg">10.00</ix:nonFraction>% plus the secured overnight financing rate administered by the Federal Reserve Bank of New York for a <ix:nonNumeric contextRef="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw" format="ixt-sec:durwordsen" name="mgtx:SecuredOvernightFinancingRateAdjustmentTerm" id="Narr_6Lmm1RyVwk6xqZoWxLq4CA">one-month</ix:nonNumeric> tenor, subject to a <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw" decimals="4" format="ixt:num-dot-decimal" name="mgtx:BasisSpreadOnVariableRateFloor" scale="-2" id="Narr_HiQoTHxlNEab0DRWRwKVoA">1.00</ix:nonFraction>% floor. The annual interest rate was <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="Narr_SOsfLvSesUGshbNz1uPr2Q">14.34</ix:nonFraction>% at March 31, 2025. As of March 31, 2025, the outstanding balance of the Tranche 1 Notes was $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecuredDebtCurrent" scale="6" id="Narr_0SjaYKWwoEqraWK-ADKyTQ">75.0</ix:nonFraction> million plus accrued interest of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" id="Narr_EghgzLLwSE-DqbsOA-M2pg">2.6</ix:nonFraction> million. During the three-month periods ended March 31, 2025 and 2024, the Company recorded interest expense of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_PgO4Y5NXYkGPZowyURAqFA">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_E01NWWscaku_l4LSWzU0oQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_Vrwpld5kJ0iODVz6Y4YjBg">2.9</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Company&#8217;s obligations under the Notes Purchase Agreement are secured by the Company&#8217;s London, UK and Shannon, Ireland manufacturing facilities, $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GuaranteedBenefitLiabilityNet" scale="6" id="Narr_3iqKpwwXvEKWuyxjW0eN5g">3.0</ix:nonFraction> million of the Company&#8217;s cash and the bank accounts of the Subsidiary Guarantors, and the issued and outstanding equity interests of the Subsidiary Guarantors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Notes Purchase Agreement imposes certain covenants and restrictions on the Company and the Subsidiary Guarantors, including restrictions pertaining to: (i) the incurrence of additional indebtedness, (ii) limitations on liens, (iii) limitations on certain investments, (iv) making distributions, dividends and other payments, (v) mergers, consolidations and acquisitions, (vi) dispositions of assets, (vii) the Company&#8217;s maintenance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA" decimals="-5" format="ixt:num-dot-decimal" name="mgtx:SecuredCashAndBankAccounts" scale="6" id="Narr_q2THR8Ad_kiOl-BHqQyZsw">3.0</ix:nonFraction> million in a U.S. bank account, (viii) transactions with affiliates, (ix) changes to governing documents, (x) changes to certain agreements and leases and (xi) changes in control; however, certain of these restrictions contain exceptions which allow the Company to license, sell and monetize assets in its AAV-hAQP1 program in development to treat radiation-induced xerostomia, its AAV-GAD program in development to treat Parkinson&#8217;s disease and its gene regulation platform technologies. As of March 31, 2025, the Company is in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">In connection with entering into the Financing Agreement, the Company granted warrants to Perceptive to purchase up to (i) <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_iZlT0i7a9E65CzOL8E1S9w" decimals="0" format="ixt:num-dot-decimal" name="mgtx:SharesIssuedInConnectionWithFinancingAgreement" scale="0" id="Narr_Hyr4ApHIXkGRayDR44AfhA">400,000</ix:nonFraction> ordinary shares of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_9Zn4kfnKBEST_irxiQRuhw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_rOk7x0wJ_ke_bNFmhl4-bA">15.00</ix:nonFraction> per share and (ii) <ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_vpSCkZsxXEKNmuae513iJA" decimals="0" format="ixt:num-dot-decimal" name="mgtx:SharesIssuedInConnectionWithFinancingAgreement" scale="0" id="Narr_Ij48q3sZ20SA_K6YkbbojA">300,000</ix:nonFraction> ordinary shares of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg" contextRef="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_1LCuyPsVy0exXA5eGmOHbQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CFYhuGBlLkCXLKGM0IOBVA">20.00</ix:nonFraction> per share. The warrants are exercisable immediately and expire on August 2, 2027. The Company recorded a debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockDiscountOnShares" scale="6" id="Narr_Oa7DWHttZkOjPzDFH1wFyg">2.3</ix:nonFraction> million for the allocated fair value of the warrants. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;">The Company also capitalized certain lender and legal costs associated with the Notes Purchase Agreement totaling $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_NQc4Urslpk6AmICEr-3fSA">2.1</ix:nonFraction> million, which were recorded as a discount to the loan. The aggregate discount of $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_-wKMV-_cxEaPlabeYS0Kew">4.4</ix:nonFraction> million is being amortized to interest expense over the term of the Notes Purchase Agreement. The Company amortized $<ix:nonFraction unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg" contextRef="Duration_1_1_2024_To_3_31_2025_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_KaXdu7E4UU23VU_CUmILww" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_b_KBjwubmkqFjsqm5kZj-g">0.3</ix:nonFraction> million of the discount to interest expense during each of the three-month periods ended March 31, 2025 and 2024.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" name="us-gaap:CommitmentsDisclosureTextBlock" id="Tb_PZfDWn1Z30yrkXYUuQt7Pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">11.    Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 22.3pt;">There were <ix:nonFraction unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw" contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg" decimals="0" format="ixt-sec:numwordsen" name="mgtx:NumberOfNewMaterialCommitments" scale="0" id="Narr_qOoPa7FtLE-7j_Ek6a3FUw">no</ix:nonFraction> new material commitments or contingencies entered into during the three-month period ended March 31, 2025.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d6a8eb67_1b9c_426d_a32f_d33fee8e9fa2"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of financial condition and operating results together with our financial statements and related notes appearing in this Quarterly Report on Form&#160;10-Q (&#8220;Form&#160;10-Q&#8221;) and those included in our Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2024 (the &#8220;Form&#160;10-K&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form&#160;10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth in the &#8220;Risk Factors&#8221; section of this Form&#160;10-Q, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. For convenience of presentation some of the numbers have been rounded in the text below. Unless the context requires otherwise, references in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to MeiraGTx Holdings plc and its subsidiaries.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson&#8217;s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities. We have two GMP viral vector production facilities, internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. In addition, we have developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness. Our core capabilities in viral vector and capsid optimization allow increased potency, decreased dose and significantly reduced cost of goods for our genetic medicines. We have developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive control of any transgene under the control of oral small molecules. We are focusing the riboswitch platform on <i style="font-style:italic;">in vivo</i> delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin via oral small molecules, as well as cell therapy for oncology and autoimmune diseases, and long-term intractable pain. We have developed unique comprehensive technology capabilities to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our discussion of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). Since our formation, we have devoted substantially all of our resources to developing our technology platform, establishing our viral vector manufacturing facilities and our GMP plasmid and DNA production facility and developing manufacturing processes, advancing the product candidates in our ophthalmology, salivary gland and neurodegenerative disease programs, building our intellectual property portfolio, organizing and staffing our Company, developing our business plan, raising capital, and providing general and administrative support for these operations. To date, we have financed our operations primarily with cash on hand, proceeds from the sales of our equity securities, debt financing and upfront and milestone payments in connection with the Collaboration, Option and License Agreement with Johnson &amp; Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.), dated as of January 30, 2019 (the &#8220;Collaboration Agreement&#8221;), which also provided us with research funding, and the Asset Purchase Agreement, dated as of December 20, 2023, we entered into with Johnson &amp; Johnson Innovative Medicine (the &#8220;Asset Purchase Agreement&#8221;) pursuant to which we sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) (&#8220;UCLB&#8221;), on the one hand, and MeiraGTx UK II Limited and MeiraGTx Limited, on the other hand (the &#8220;UCLB RPGR License Agreement&#8221;), relating to the research, development, manufacture and exploitation of botaretigene sparoparvovec, or bota-vec (formerly referred to as AAV-RPGR), for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene, or XLRP-RPGR (the &#8220;RPGR Product&#8221;), and other related assets as described in the Asset Purchase Agreement. Through March 31, 2025, we received gross proceeds of approximately $626.7&#160;million from sales of our equity securities, gross proceeds of approximately $75.0 million from issuance of debt, $130.0 million in upfront and milestone payments from the Collaboration Agreement with Johnson &amp; </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Johnson Innovative Medicine, and $125.0 million from the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine. As of March 31, 2025, we had cash, cash equivalents and restricted cash of $68.6&#160;million, as well as $0.7 million in receivables due from Johnson &amp; Johnson Innovative Medicine in connection with PPQ and transition services we provided to Johnson &amp; Johnson Innovative Medicine.</p><p style="font-family:'Liberation Serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We are a clinical stage company and have not generated any product revenues to date. We have ongoing clinical development programs and a broad pipeline of preclinical programs. Since inception, we have incurred significant operating losses. Our net losses for the three-month periods ended March 31, 2025 and 2024 were $40.0 million and $20.4 million, respectively. As of March 31, 2025, we had an accumulated deficit of $742.0&#160;million. We do not expect to generate revenue from sales of products unless and until we successfully initiate and complete clinical development and obtain regulatory approval for any product candidates, or satisfy our third party obligations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our total operating expenses for the three-month periods ended March 31, 2025 and 2024 were $43.5 million and $47.5 million, respectively. We expect to continue incurring costs associated with our clinical activities for AAV-hAQP1 for the treatment of radiation-induced xerostomia and xerostomia associated with Sjogren&#8217;s syndrome, AAV-GAD for the treatment of Parkinson&#8217;s disease, as well as costs associated with the delivery of services under the Asset Purchase Agreement and related agreements. We also incurred expenses during the three-month period ended March 31, 2025 and expect to continue to incur expenses related to research activities in additional therapeutic areas to expand our pipeline, developing our potentially transformative gene regulation technology, hiring additional personnel as needed in manufacturing, research, clinical operations, quality and other functional areas, and associated cash and share-based compensation expense, as well as the further development of internal manufacturing capabilities and capacity and other associated costs including the management of our intellectual property portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will require additional capital in the future, which we may raise through equity offerings (including our &#8220;at-the-market&#8221; equity offering program), debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential commercialization of our product candidates. Furthermore, we expect to continue incurring costs associated with being a public company. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on our cash, cash equivalents, accounts receivable &#8211; related party and tax incentive receivable at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen Limited as described below, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into 2027 and to repay our debt obligation of $75.0 million to Perceptive (due in August 2026). This estimate does not include the $285.0 million in milestones we are eligible to receive under the Asset Purchase Agreement upon first commercial sale of an RPGR Product in the United States and in at least one of the United Kingdom, France, Germany, Spain and Italy, for completion of the transfer of certain manufacturing technology to Johnson &amp; Johnson Innovative Medicne and upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union, or EU, for commercial manufacture of the RPGR Product. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources.&#8221; Because of the numerous risks and uncertainties associated with the development of our product candidates, any future product candidates, our platform and technology and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funds may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Any future debt financing or preferred equity or other financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Hologen Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 9, 2025 (the &#8220;Hologen Signing Date&#8221;), we and our affiliates entered into a strategic collaboration with Hologen Limited, a non-cellular company limited by shares incorporated in Guernsey (&#8220;Hologen&#8221;), and its affiliates.  Hologen is a leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. As part of the strategic collaboration, we and Hologen entered into the Framework Agreements (as defined below), pursuant to which we and our affiliates will receive from Hologen an upfront cash payment of $200 million (the &#8220;Upfront Payment&#8221;) on the Hologen Closing Date (as defined below), and Hologen will provide additional funding of up to an additional $230 million as further described below. As part of the strategic collaboration, we also received 250,000 Class A shares of Hologen at a nominal price. Furthermore, we have the option to receive up to an additional 500,000 Class A shares of Hologen at a nominal price if certain funding obligations as described herein are not met by Hologen.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The closing of the transactions contemplated by the Framework Agreements (the &#8220;Hologen Closing Date&#8221;) is expected to occur in the second calendar quarter of 2025, subject to customary closing and funding conditions, including the receipt of the clearances and approvals applicable to the proposed transactions under the foreign direct investment laws of the United Kingdom and the satisfaction or waiver of certain other closing conditions.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Neuro Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On the Hologen Signing Date, we, MeiraGTx Neuro UK Limited, a private company limited by shares incorporated in England and one of our wholly-owned subsidiaries (&#8220;MeiraGTx Neuro UK&#8221;), Hologen Neuro AI Limited, a non-cellular company limited by shares incorporated in Guernsey and an affiliate of Hologen (&#8220;Hologen Neuro&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Neuro Framework Agreement&#8221;), pursuant to which, on the Hologen Closing Date, we, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company and one of our wholly-owned subsidiaries (&#8220;MeiraGTx Neuro US&#8221;), Hologen, Hologen Neuro and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England and an affiliate of Hologen (&#8220;Hologen Neuro UK&#8221;), shall enter into a Collaboration and License Agreement (the &#8220;Hologen Collaboration Agreement&#8221;) for the research, development, manufacture and commercialization of our (i) AAV-GAD investigational gene therapy for the treatment of Parkinson&#8217;s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the &#8220;Clinical Programs&#8221;) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">animals (the &#8220;Delivery Device&#8221;), in each case, in accordance with the terms and conditions of the Hologen Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Hologen Closing Date, under the Hologen Collaboration Agreement, MeiraGTx Neuro US will receive the applicable portion of the Upfront Payment in consideration for granting to Hologen Neuro and Hologen Neuro UK, as of the Hologen Closing Date and subject to the license granted by Hologen Neuro and Hologen Neuro UK back to MeiraGTx Neuro UK, exclusive, worldwide, royalty-free, fully paid-up licenses to certain of our intellectual property rights for the research, development, manufacture and commercialization of the Clinical Programs and the Delivery Device. On the Hologen Closing Date, (a) MeiraGTx Neuro UK will receive Class A shares of Hologen Neuro representing a 30% ownership of the issued share capital of Hologen Neuro, in consideration for the provision of services to Hologen Neuro and Hologen Neuro UK as specified in the Hologen Collaboration Agreement, including services relating to the development of the Clinical Programs and the Delivery Device and certain other transition services, and (b) Hologen Guernsey will receive Class B shares of Hologen Neuro representing a 70% ownership of the issued share capital of Hologen Neuro, in consideration for paying the applicable portion of the Upfront Payment to MeiraGTx Neuro US, as well as a commitment to provide additional capital of up to $230 million to fund the development of the Clinical Programs and the Delivery Device. Additionally, Hologen will license to Hologen Neuro its proprietary multi-modal generative foundation models (LMMs), or large medicine models, pursuant to a license agreement mutually agreeable to the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the Hologen Closing Date, Hologen Neuro shall be governed by a board of directors comprised of three representatives designated by Hologen and two representatives designated by MeiraGTx Neuro UK, and certain material business decisions (as further enumerated in the Neuro Framework Agreement) will require the approval of at least 70% of the directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following the Hologen Closing Date and in accordance with the terms of the Hologen Collaboration Agreement, the parties shall negotiate in good faith and enter into clinical and commercial supply agreements, pursuant to which MeiraGTx Neuro UK (directly, or through affiliates or subcontractors) shall manufacture and supply AAV-GAD, AAV-BDNF and other potential locally delivered genetic medicines to the central nervous system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Manufacturing Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">On the Hologen Signing Date, MeiraGTx Manufacturing Limited, a private company limited by shares incorporated in England and one of our wholly-owned subsidiaries (&#8220;MeiraGTx Manufacturing&#8221;), MeiraGTx Limited, a private company limited by shares incorporated in England and one of our wholly-owned subsidiaries (&#8220;MeiraGTx Limited&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Manufacturing Framework Agreement&#8221; and, together with the Neuro Framework Agreement, the &#8220;Framework Agreements&#8221;), pursuant to which, on the Hologen Closing Date and in exchange for the applicable portion of the Upfront Payment, Hologen will acquire a minority interest in MeiraGTx Manufacturing, an entity that will comprise our flexible and scalable end-to-end genetic medicines manufacturing business. Hologen will also contribute a portion of the annual funding to MeiraGTx Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">As of the Hologen Closing Date, MeiraGTx Manufacturing shall be governed by a board of directors comprised of three representatives designated by MeiraGTx Limited and two representatives designated by Hologen, and certain material business decisions (as further enumerated in the Manufacturing Framework Agreement) will require the approval of at least 70% of the directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For a period of twelve months following the Hologen Closing Date, Hologen has an exclusive, irrevocable option to purchase additional shares in MeiraGTx Manufacturing at a specified price, such that following exercise of such option, Hologen shall own 40% of the issued share capital of MeiraGTx Manufacturing in the aggregate. &#160;In the event that Hologen does not exercise its option, we have an exclusive, irrevocable option to purchase all of the shares of MeiraGTx Manufacturing held by Hologen for the same price that Hologen paid for such shares. Such option shall be exercisable anytime beginning on the third anniversary of the Hologen Closing Date and ending three years thereafter.</p><a id="_Hlk142508151"></a><a id="_Hlk39665173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Development Highlights and Anticipated Milestones </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk184310282"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Strategic Collaboration with Hologen AI:</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will receive $200 million in upfront cash consideration at closing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and Hologen will form a joint venture, Hologen Neuro AI Ltd, with additional committed funding from Hologen of up to $230 million into the joint venture to finance the development of the AAV-GAD program in Parkinson&#8217;s disease to commercialization, as well as other locally-delivered therapies to the CNS.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The joint venture, Hologen Neuro AI Ltd, will use Hologen&#8217;s proprietary multi-modal generative foundation models (LMMs).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will hold a 30% ownership in the joint venture and lead all clinical development and manufacturing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Hologen Neuro AI Ltd will enter into both clinical and commercial manufacturing supply agreements with us for exclusive manufacturing of AAV-GAD and other locally-delivered genetic medicines targeting the CNS.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Hologen will own a minority stake in our manufacturing subsidiary and will contribute a portion of the annual funding and deploy Hologen&#8217;s world leading generative AI capabilities to further accelerate the optimization of our proprietary manufacturing capabilities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">AAV-GAD for the Treatment of Parkinson&#8217;s Disease</b>: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On May 8</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the treatment of Parkinson&#8217;s disease not adequately controlled with anti-Parkinsonian medications.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">This RMAT was awarded following the presentation to the FDA of positive data from 3 clinical studies demonstrating the benefit of AAV-GAD when administered in a one-time stereotactic infusion to the subthalamic nucleus in the brain.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">A Phase 1 dose escalating clinical study (n=12) was conducted, followed by a double-blind, sham-controlled Phase 2 study (n=45) and a second randomized, double-blind, sham-controlled dose ranging clinical bridging study (n=14).    </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data from the double-blind, sham-controlled Phase 2 studies show significant clinically meaningful benefit on the standard motor endpoint in Parkinson&#8217;s disease, Unified Parkinson&#8217;s Disease Rating Scale (UPDRS) Part 3, as well as other validated measures of Parkinson&#8217;s symptoms. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Through the use of Hologen&#8217;s AI technology to analyze the data from double-blind sham controlled studies, disease modifying changes in the circuitry of the brain of the Parkinson&#8217;s patients receiving AAV-GAD therapy have been demonstrated. In addition, potentially protective changes in the substantia nigra and regions of the brain involving cognition and mood have been shown following AAV-GAD treatment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to initiate a Phase 3 study of AAV-GAD in the second half of 2025 and will continue to work with the FDA to expedite the development of the program supported by our end-to-end in-house manufacturing capabilities. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RMAT Designation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The requirements for receiving an RMAT designation include that the drug candidate is an advanced regenerative medicine, in this case a gene therapy; that the therapy is targeting a serious condition, in this case, Parkinson&#8217;s disease; and that the applicant has presented clinical evidence demonstrating that the drug candidate has the potential to address an unmet need in the serious condition. The RMAT requirement for clinical data supporting a benefit in an unmet need is a high hurdle, with less than half of all RMAT designation applications granted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RMAT designation includes the benefits of Fast Track and Breakthrough Therapy designations with rolling review and potential Priority Review of a product&#8217;s BLA. RMAT designation also allows for increased interaction with the FDA and immediate multidisciplinary comprehensive discussions of the ongoing product development program, clinical trials and plans for expediting the manufacturing development strategy, both clinical and CMC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">AAV2-hAQP1 for the Treatment of Xerostomia:  </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In December 2024, we were granted RMAT designation by the FDA for AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following FDA interactions over the past three months, we have aligned with the agency on both the clinical and CMC requirements for the ongoing Phase 2 AQUAx2 randomized, double-blind, placebo-controlled study to support a potential BLA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Phase 2 AQUAx2 (</span><span style="color:#0563c1;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;">NCT05926765</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">) randomized, double-blind, placebo-controlled study continues to enroll and dose participants at multiple sites in the US, Canada and the U.K.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The low dose cohorts have completed enrollment. Screening and enrollment of the remaining high dose cohorts is ongoing with the target for completion of enrollment in the fourth quarter of 2025, and the potential for a BLA filing supported by this study at the end of 2026.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">AAV-AIPL1 for LCA4 Caused by Mutations in the AIPL1 Gene:  </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2025, we announced that data demonstrating the efficacy of rAAV8.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">hRKp.AIPL1 </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for the treatment of LCA4 were published in </span><i style="color:#0563c1;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;">The Lancet</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in a paper titled, &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;; we held a webcast to review the data, and a replay of the webcast can be accessed </span><span style="color:#0563c1;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;">here</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As disclosed in the paper, 4 out of 4 young children with the AIPL1-associated retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">.hRKp.AIPL1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> with improved visual acuity, functional vision, and protection against progressive retinal degeneration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the strong safety and substantial efficacy demonstrated in this first cohort of 4 children treated unilaterally, a further 7 children were treated bilaterally, and all showed substantial benefit from treatment with rAAV8.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">hRKp.AIPL1.</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Meaningful responses have been observed in 11 out of 11 LCA4 children treated to date with rAAV8.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">hRKp.AIPL1.</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following recent meetings with the MHRA, we are in the process of preparing the submission of Marketing Authorization Application (MAA) under exceptional circumstances for rAAV8.</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">hRKp.AIPL1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> based on the results from the 11 treated children, with no further clinical data required.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have had positive engagement with the FDA over the past few weeks and aligned with the agency on the requirements in the areas of clinical, non-clinical and CMC to move forward towards a potentially expedited approval in the US.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AAV-AIPL1 for the treatment of LCA4 has orphan drug designation in the US and orphan designation in the European Union, and the Offices of Orphan Products Development and Pediatric Therapeutics of the FDA have granted Rare Pediatric Disease Designation (RPDD) to AAV8-RK-AIPL1 for the treatment of LCA4 retinal dystrophy.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Botaretigene Sparoparvovec for the Treatment of X-linked Retinitis Pigmentosa (XLRP):</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data from the Phase 3 LUMEOS trial of botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa was presented by Dr. Michael Clark, the primary clinical lead on the study from Johnson &amp; Johnson, at the Foundation Fighting Blindness 2025 Retinal Therapeutics Innovation Summit on May 2</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The novel primary endpoint to assess the effect of bilaterial treatment with bota-vec on functional vision as measured by a Visual Mobility Assessment (VMA), or maze, was not met but was directionally supportive.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">However, all but one of the secondary endpoints, including measures from all three visual domains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</span><span style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Functional Vision, Retinal Function and Visual Function </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8211;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> showed benefit with 95% CI intervals not including 0.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These included: </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Functional Vision: PRO: LLQ Extreme lighting domain score, a patient reported measure; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Retinal Function: three measures of retinal sensitivity by static perimetry, 5-point 7-decibel responders in both the Central 30 degrees and also in the full field, as well as mean retinal sensitivity in the central 10 degrees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Visual Function: Low luminance visual acuity (LLVA, ETDRS). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition, 40% (22/55) of treated patients showed improvement in &#8805;2 endpoints each in different domains of vision compared to 0% in the control group.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Safety profile of bota-vec was as expected and manageable with no new safety signals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&gt;90% of treatment related inflammation adverse events were mild, &lt;10% moderate and none were severe.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">While the primary endpoint showed a directional trend rather than significance, Dr. Clark described these data as interesting and exciting and stated that the overall totality of the data shows a clinically meaningful improvement in the bota-vec treated population.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This randomized, controlled Phase 3 clinical study is the third clinical study using AAV-RPGR for treatment of XLRP to show benefit in retinal sensitivity and other measures of vision with different control arms. Phase 1 (n=13) versus untreated fellow eye, Phase 2 (n=36) unilateral treatment versus randomized untreated control eyes in untreated patients, and the Phase 3 study bilateral treatment versus untreated randomized controls (n=95). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">XLRP is a rare inherited retinal disease with early onset and progressive degeneration to complete blindness in the third decade of life.  There are no treatments for XLRP, and XLRP caused by mutations in the RPGR gene (the target of AAV-RPGR) is one of the most severe forms of Retinitis Pigmentosa (RP).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA has granted Fast Track and orphan drug designations to bota-vec and the regulatory authorities in the EU have granted Priority Medicines, or PRIME, advanced therapy medicinal product, or ATMP, and orphan drug designations to bota-vec. Johnson &amp; Johnson Innovative Medicine is the sponsor of this program. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are eligible to receive up to $285 million upon the first commercial sales of bota-vec in the US and EU and manufacturing tech transfer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We also entered into a commercial supply agreement with Johnson &amp; Johnson Innovative Medicine for bota-vec manufacturing, which we anticipate will generate additional revenue during the product launch. As part of this commercial supply agreement, we are currently engaged in finalizing the PPQ documentation to potentially support CMC sections of global regulatory filings.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Riboswitch Gene Regulation Technology Platform for </b><span style="font-style:italic;font-weight:bold;">in vivo</span><b style="font-weight:bold;"> Delivery:</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We continue to progress our riboswitch technology platform in multiple potential indications, with an initial focus on obesity and metabolic disease, neuropathic pain and CAR-T.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We continue to generate compelling preclinical data with metabolic peptides and hormones, including incretins, myokines and leptin, which suggests greater efficacy on weight loss as well as a positive impact on fat to muscle ratio with certain novel combinations of peptides.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical data mentioned above as well as new data on chronic pain therapies is informing the decision for our first INDs using our riboswitch small molecule platform.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are in dialogue with regulatory agencies and intend to initiate first-in-human studies using the riboswitch platform in 2025.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#15161c;font-weight:bold;background:#ffffff;">Manufacturing:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">United Kingdom (MeiraGTx UK II Ltd.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our UK manufacturing facility holds two authorizations issued by the MHRA:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#221f1f;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MIA(IMP) Licence (MIA(IMP) 45522)&#160;&#8211; Authorizing manufacturing, fill-finish, and QC testing&#160;of Investigational Medicinal Products (IMPs).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#221f1f;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Specials Licence (MS 45522)&#160;&#8211; Authorizing manufacturing, fill-finish, and QC testing&#160;of &#8216;Special&#8217; medicinal products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The UK facility was inspected in May 2024, and the licences were successfully renewed. The outcome of this inspection confirmed that the site was found to be in compliance with GMP requirements for Investigational Medicinal Products (IMPs)&#160;and was operating at the required compliance level to support an application for a commercial MIA licence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#15161c;font-weight:bold;background:#ffffff;">Ireland (MeiraGTx Ireland DAC)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;background:#ffffff;">Our Shannon facility holds two authorizations issued by Ireland&#8217;s Health Products Regulatory Authority (HPRA):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#15161c;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#15161c;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">MIA Licence (M1316) &#8211; Authorizing QC testing of commercial products (awarded June 2023).</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#15161c;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#15161c;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">MIA(IMP) Licence (IMP13221) &#8211; Authorizing QC testing of Investigational Medicinal Products (IMPs) (awarded September 2023/QC and 2025/MFG).</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;background:#ffffff;">The QC laboratory is actively undertaking release and stability testing on PPQ batches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#15161c;background:#ffffff;">The latest HPRA inspection in February 2025 was highly successful&#8212;both QC licenses were renewed, and viral vector manufacturing was added to the MIA(IMP) license. This means the Shannon site can manufacture material for use in clinical trials, a first-of-its-kind license for a gene therapy facility in Ireland.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Service Revenue &#8211; Related Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our service revenue consisted of the process performance qualification (&#8220;PPQ&#8221;) services performed in connection with the Asset Purchase Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our operating expenses since inception have consisted primarily of general and administrative costs and research and development costs. Since 2024, we have incurred expenses classified as cost of service revenue &#8211; related party performed in connection with the Asset Purchase Agreement and related agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Cost of Service Revenue &#8211; Related Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our cost of service revenue consisted of the PPQ services performed in connection with the Asset Purchase Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in our executive, finance, legal, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and office facility-related expenses, which include direct depreciation costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We have incurred, and expect to continue to incur, increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Research and Development Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits and travel of our research and development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with third-party vendors that conduct clinical and preclinical studies and manufacture the drug product for the clinical trials and preclinical activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with clinical and preclinical activities including costs related to facilities, supplies, rent, insurance, certain legal fees, share-based compensation, and depreciation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred with the development and operation of our manufacturing facilities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We expense research and development costs as incurred.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. We expect to continue incurring increasing research and development costs associated with our clinical activities for AAV-hAQP1 for the treatment of radiation-induced xerostomia and xerostomia associated with Sjogren&#8217;s syndrome, as well as for AAV-GAD for the treatment of Parkinson&#8217;s disease, although certain of these increases relating to AAV-GAD are expected to be offset by the funding provided by Hologen after the anticipated closing of the strategic collaboration we entered into with them. In addition, we expect to continue to incur expenses related to research activities in additional therapeutic areas to expand our pipeline and develop our potentially transformative gene regulation technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot determine with certainty the duration and costs of future clinical trials of our product candidates or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our existing product candidates or any other product candidate we may develop will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, expense and results of clinical trials of our existing product candidates, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in clinical trial design and patient enrollment rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the actual probability of success for our product candidates, including the safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and receipt of any marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or another U.S. or foreign regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Non-Operating Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other non-operating income (expense) includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Foreign Currency Gain (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our condensed consolidated financial statements are presented in U.S. dollars, which is our reporting currency. The financial position and results of operations of our subsidiaries are measured using the foreign subsidiaries&#8217; local currency as the functional currency, either the pound sterling or the euro. These entities&#8217; cash accounts holding U.S. dollars and intercompany payables and receivables are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the condensed consolidated statements of operations and comprehensive loss.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Interest Income</p><p style="font-family:'Liberation Serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Interest income is comprised on interest earned on our interest-bearing bank accounts.</span></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Interest Expense</p><p style="font-family:'Liberation Serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Interest expense consists of interest expense and amortization of the debt discount in connection with the debt financing described in Note 10 to our condensed consolidated financial statements.</span></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Gain on Sale of Nonfinancial Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The gain on sale of nonfinancial assets represents the value allocated to the nonfinancial assets sold and assigned to Johnson &amp; Johnson Innovative Medicine including the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets pursuant to the Asset Purchase Agreement, net of carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other comprehensive loss includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Foreign Currency Translation Loss </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue and expenses of subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the condensed consolidated balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of shareholders&#8217; equity and as other comprehensive loss on the condensed consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgements that affect the reporting amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgements, including those related to service revenue, share-based compensation and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities that are not readily apparent from our sources. Actual results may differ from these estimates under different assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s critical accounting policies, significant judgements and estimates are included in the Company&#8217;s Form&#160;10-K for the&#160;year ended December 31, 2024 and Note&#160;2 to our unaudited condensed consolidated financial statements included elsewhere in this Form&#160;10-Q.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of Three Months Ended March 31, 2025 and 2024</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,926</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,229</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,378</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,378</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,783)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,322</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,542)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,522</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,947)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,596)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46,772)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,176</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-operating income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign currency gain (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (535)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,222</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 971</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,097</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (126)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,043)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,250)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 207</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gain on sale of nonfinancial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,018)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,981)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20,442)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,539)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Service Revenue &#8211; Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Service revenue was $1.9 million for the three months ended March 31, 2025, compared to $0.7 million for the three months ended March 31, 2024. The increase of $1.2 million was due to increased progress of PPQ services under the Asset Purchase Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of Service Revenue &#8211; Related Party</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of service revenue was $1.4 million for the three months ended March 31, 2025, due to progress of PPQ services under the Asset Purchase Agreement and related agreements. There was no cost of service revenue for the three months ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $9.4&#160;million for the three months ended March 31, 2025, compared to $13.2&#160;million for the three months ended March 31, 2024. The decrease of $3.8&#160;million was primarily due to a decrease of $1.3 million in share-based compensation, a decrease of $1.3 million in legal and accounting fees, a $1.3 million gain due to the early termination of a lease agreement, a decrease of $0.4 million in consulting fees and a decrease of $0.2 million in other office related costs. These decreases were partially offset by an increase of $0.7 million in payroll and payroll related costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 9pt 36pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Research and development expenses for the three months ended March 31, 2025 and 2024 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended March 31,</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Botaretigene sparoparvovec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,957</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,957)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">AAV-hAQP1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,852</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,663</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,189</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">AAV-CNGB3 / AAV-CNGA3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,179)</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,179</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">AAV-GAD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,459</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,170</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (711)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 293</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,152</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,359</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,360</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,001)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Gene regulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,286</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,499</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (213)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Neurodegenerative diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 391</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Preclinical ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 327</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 298</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,493</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,165)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,974</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,194)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Johnson &amp; Johnson Innovative Medicine reimbursement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (652)</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 652</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,322</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,542)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk86411734"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Clinical program expenses represent the direct costs for each clinical trial plus the cost of the clinical trial material charged from the manufacturing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Manufacturing expenses represent the costs to manufacture clinical trial material, including payroll, facilities, manufacturing supplies, raw materials, quality control and quality assurance. Upon completion of the manufacture of a batch of clinical trial material, the standard cost of manufacturing the batch of clinical trial material is charged to the clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Preclinical program expenses represent the direct costs for each group of preclinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Other research and development expenses represent costs that are not allocated to a specific clinical or preclinical program, such as payroll and payroll related costs, share-based compensation, travel, rent and facilities costs, depreciation and other non-program specific expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Research and development expenses for the three months ended March 31, 2025 were $32.8 million, compared to $34.3 million for the three months ended March 31, 2024. The decrease of $1.5 million was primarily due to a decrease of $1.0 million in manufacturing costs primarily due to a reclassification of cost of service revenue due to progress of PPQ services provided under the Asset Purchase Agreement and related agreements and a decrease of $2.2 million in other research and development expenses. These decreases were partially offset by a reduction in reimbursements from Johnson &amp; Johnson Innovative Medicine of $0.7 million, an increase of $0.9 million in clinical trial expenses primarily due to an increase in costs associated with our AAV-hAQP1 program and our other ocular disease programs. The increase in clinical trial expenses was partially offset by a decrease in costs related to bota-vec as Johnson &amp; Johnson Innovative Medicine is now primarily funding the expenses related to this program as a result of the Asset Purchase Agreement. Additionally, expenses related to our preclinical programs increased $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Foreign Currency Gain (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Foreign currency gain was $3.7 million for the three months ended March 31, 2025 compared to a loss of $0.5 million for the three months ended March 31, 2024. The change of $4.2 million was primarily due to the weakening of the U.S. dollar against the pound sterling and euro as it relates to the valuation of our intercompany payables and receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Interest income was $1.0 million for the three months ended March 31, 2025 compared to $1.1 million for the three months ended March 31, 2024. The decrease of $0.1 million was due to lower interest rates and cash balances held in interest bearing accounts during 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Interest Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Interest expense was $3.0 million for the three months ended March 31, 2025 compared to $3.2 million for the three months ended March 31, 2024. &#160;The decrease of $0.2 million was primarily due to a lower interest rate in connection with the debt financing described in Note 10 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Gain on Sale of Nonfinancial Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The gain on sale of nonfinancial assets was $0 for the three months ended March 31, 2025 compared to $29.0 million for the three months ended March 31, 2024. This decrease was a result of the recognition of the $50.0 million milestone during the three months ended March 31, 2024, which was allocated to the nonfinancial assets sold and assigned to Johnson &amp; Johnson Innovative Medicine including the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets described in the Asset Purchase Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant operating losses. For the three months ended March 31, 2025, we used $36.8 million in cash flows from operations. We did not generate positive cash flows from operations during the period and there are no assurances that we will generate positive cash flows in the future. Additionally, there are no assurances that we will be successful in obtaining an adequate level of financing for the development and commercialization of our product candidates. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting preclinical studies and clinical trials for our product candidates, building out internal capacity to have products manufactured to support preclinical studies and clinical trials as well as to manufacture commercial products, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result of these incurred and expected expenses we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any approved products and have never generated any revenue from product sales. We have historically financed our operations primarily through cash on hand and proceeds from the sale of our equity securities, the issuance of debt and upfront and milestone payments from the Collaboration Agreement and Asset Purchase Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Based on our current cash, cash equivalents, accounts receivable &#8211; related party, and tax incentive receivable at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen, we estimate that we will be able to fund our operating expenses and capital expenditure requirements into 2027 and to repay our debt obligation of $75.0 million to Perceptive (due in August 2026). This estimate does not include the $285.0 million in milestones we are eligible to receive under the Asset Purchase Agreement upon first commercial sale of an RPGR </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Product in the United States and in at least one of the United Kingdom, France, Germany, Spain and Italy, for completion of the transfer of certain manufacturing technology to Johnson &amp; Johnson Innovative Medicine and upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of March 31, 2025, we had $68.6 million of cash, cash equivalents and restricted cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our sources and uses of cash, cash equivalents and restricted cash for the period presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the Three Months Ended&#160;March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,828)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,741)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,710)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,340</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,713</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,270)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,825)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,671)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2025, our cash used in operating activities of $36.8 million was primarily due to a net loss of $40.0 million as we incurred expenses associated with research activities on our clinical programs, manufacturing of our clinical trial materials, preclinical research programs and general and administrative expenses. The net loss included non-cash income and expense of $3.2&#160;million, which consisted primarily of $4.9&#160;million of share-based compensation, $3.1 million of depreciation and amortization, $0.3 million of non-cash interest and $0.1 million of net change in right-of-use-assets and liabilities offset by $3.7 million of a foreign currency gain, $1.4 million of a gain on termination of lease liabilities and a $0.1 million gain on disposal of equipment, furniture and fixtures. &#160;Additionally, operating assets, consisting of accounts receivable &#8211; related party, contract assets &#8211; related party, inventory, prepaid expenses, tax incentive receivable and other current assets, decreased by $6.9&#160;million and operating liabilities, consisting of accounts payable, accrued expenses, other current liabilities and deferred revenue &#8211; related party, decreased by $7.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2024, our cash used in operating activities of $36.7&#160;million was primarily due to a net loss of $20.4 million as we incurred expenses associated with research activities on our clinical programs, manufacturing of our clinical trial materials, preclinical research programs and general and administrative expenses. The net loss included non-cash income of $18.0&#160;million, which consisted primarily of $29.0 million of a gain on sale of nonfinancial assets, $7.0&#160;million of share-based compensation, $3.3 million of depreciation and amortization, $0.5 million of a foreign currency loss and $0.3 million of amortization of debt discount. &#160;Additionally, operating assets, consisting of accounts receivable &#8211; related party, prepaid expenses, other assets and other current assets, decreased by $0.2&#160;million and operating liabilities, consisting of accounts payable, accrued expenses, other current liabilities and deferred revenue &#8211; related party, increased by $1.5&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the three months ended March 31, 2025 of $1.7&#160;million consisted of purchases of property and equipment for our manufacturing, laboratory and process development facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities for the three months ended March 31, 2024 of $27.3&#160;million consisted of $29.0 million from proceeds from the sale of nonfinancial assets offset by $1.7 million of purchases of property and equipment for our manufacturing, laboratory and process development facilities.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $1.7&#160;million for the three months ended March 31, 2025, which consisted of $4.5 million net proceeds from an &#8220;at-the-market&#8221; offering of our ordinary shares, offset by the payment of $2.8 million to cover tax withholding obligations upon the vesting of restricted share unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities was $1.3&#160;million for the three months ended March 31, 2024, which consisted of the payment of $2.2 million to cover tax withholding obligations upon the vesting of restricted share unit awards offset by $1.0 million of proceeds from an &#8220;at-the-market&#8221; offering of our ordinary shares, net of one-time costs relating to the preparation and filing of the shelf registration statement, accounting and legal fees, and negotiation of the sales agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not entered into any off-balance sheet arrangements under applicable SEC rules&#160;and do not have any holdings in variable interest entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f857b2fd_38e3_4101_b508_4d126220fe9b"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following section updates &#8220;Item 7A. Quantitative and Qualitative Disclosures of Market Risk&#8221; in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and should be read in conjunction with that report as well as our condensed consolidated financial statements included in &#8220;Part 1, Item 1. Financial Statements&#8221; of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;"><span style="font-style:italic;">Foreign Currency Exchange Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently operate in the United States, the United Kingdom and the European Union. Our activities in these jurisdictions expose us to currency exchange rate fluctuations, primarily between the U.S. Dollar and the British pound sterling and euro. When the U.S. Dollar strengthens against these currencies, the U.S. Dollar value of non-U.S. Dollar based losses increases. To the extent that our international activities recorded in local currencies increase in the future, our exposure to fluctuations in currency exchange rates will correspondingly increase. As of March 31, 2025, we did not hold any foreign currency forward contracts. With respect to our foreign currency exposures as of March 31, 2025, we estimate a 10% unfavorable movement in foreign currency exchange rates would have the effect of creating an additional foreign currency loss of approximately $11.0 million within other non-operating income (expense) for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;"><span style="font-style:italic;">Interest Rate Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk as a result of changes in interest rates applicable to borrowings under our Notes Purchase Agreement. Borrowings under the Notes Purchase Agreement bear interest at a fluctuating rate per annum equal to 10.00% plus the secured overnight financing rate (&#8220;SOFR&#8221;) administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a 1.00% floor. See Note 10 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q. We may use interest rate cap derivatives, interest rate swaps or other interest rate hedging instruments to economically hedge and manage interest rate risk with respect to our variable floating rate debt. As of March 31, 2025, the annual interest rate was 14.34% and the outstanding balance of the term loan was $75.0 million. Assuming no change in the outstanding borrowings under the Notes Purchase Agreement, we estimate that a hypothetical 1% increase in the SOFR would increase our annual interest expense by approximately $0.8 million as of March 31, 2025.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c52203fa_4833_4181_a4f6_af3b3fa52610"></a><a id="Item4ControlsandProcedures_891132"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Limitations on Effectiveness of Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:24pt;background:#ffffff;margin:0pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:24pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:23.75pt;background:#ffffff;margin:0pt;">Our management, with the participation of our Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial officer), evaluated, as of the end of the period covered by this Form&#160;10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15I&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)). Based on that evaluation, our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) concluded that our disclosure controls and procedures were effective at the reasonable assurance level at the end of the period covered by this Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:24pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_716b35c7_3f12_456a_99cf_65a19780fd60"></a><a id="PARTIIOTHERINFORMATION_341431"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II&#8212;OTHER INFORMATION</p><a id="Item1LegalProceedings_709588"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are not subject to any material legal proceedings.</p><a id="Item1ARiskFactors_220365"></a><a id="_18b1915f_8a0a_4884_ab6e_cf1426c77fce"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM&#160;1A.</b></span>RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Investing in our ordinary shares involves a high degree of risk. You should consider carefully the risks described below, together with the other information included or incorporated by reference in this Form 10-Q. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our ordinary shares could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage company with limited operating history. We were formed and began operations in 2015. We have never been profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses since inception, including net losses of approximately $40.0 million and $20.4 million for the three months ended March 31, 2025, and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of approximately $742.0 million. Since our inception, we have devoted substantially all of our resources to developing our technology platform, establishing our viral vector manufacturing facilities and plasmid and DNA production facility, developing manufacturing processes, advancing the product candidates in our ophthalmology, salivary gland and neurodegenerative disease programs, research and development activities, including our riboswitch gene regulation platform technology, building our intellectual property portfolio, organizing and staffing our company, developing our business plans, raising capital, securing debt financing and providing general and administrative support for these operations. We have not yet demonstrated an ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approval, manufacture product at a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Given the length of time typically needed to develop a new drug from the time it enters Phase 1 clinical trials to when it is approved for treating patients, if ever, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing genetic medicine products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenses and additional operating losses for the foreseeable future as we seek to advance product candidates through preclinical and clinical development, expand our research, development and manufacturing activities, develop new product candidates, build and expand our intellectual product portfolio, complete clinical trials, seek regulatory approval and, if we receive regulatory approval, commercialize our products. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time, including the ongoing Phase 2 AQUAx2 clinical trial of AAV-hAQP1 for the treatment of patients with radiation-induced xerostomia. In addition, we expect to continue incurring increasing research and development costs associated with our clinical activities for AAV-GAD for the treatment of Parkinson&#8217;s disease and research, preclinical and clinical activities for our riboswitch platform, although certain of these increases are expected to be offset by the funding provided by Hologen after the anticipated closing of the strategic collaboration we entered into with them. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with gene therapy product development, we are unable to accurately predict the timing or amount of increased expenses or whether we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before we generate any revenue from product sales, each of our programs and product candidates will require additional preclinical and/or clinical development, potential regulatory approval in multiple jurisdictions, manufacturing, building of a commercial organization, substantial investment and significant marketing efforts. Our expenses could increase beyond expectations if we are required by the FDA, UK Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), European Medicines Agency (the &#8220;EMA,&#8221;), or other regulatory authorities to perform preclinical studies and clinical trials in addition to those that we currently anticipate. These risks are further described under &#8220;&#8212;Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212;Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses for the foreseeable future. These net losses have had, and will continue to have, an adverse effect on our shareholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. If we are unable to develop and commercialize one or more of our product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we are unable to achieve and then maintain profitability, the value of our equity securities will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is no guarantee that we will receive in a timely fashion or at all the additional milestone payments contemplated under the Asset Purchase Agreement or the revenues associated with our manufacture of the commercial supply of the RPGR Product under the Supply Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 20, 2023, we and MeiraGTx UK II Limited entered into and consummated the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine pursuant to which we sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets as described in the Asset Purchase Agreement. MeiraGTx UK II Limited and Johnson &amp; Johnson Innovative Medicine also entered into a Supply Agreement on December 20, 2023 (the &#8220;Supply Agreement&#8221;) pursuant to which MeiraGTx UK II Limited, together with its affiliates, will manufacture commercial supply of the RPGR Product for Johnson &amp; Johnson Innovative Medicine for an initial term of four years, with Johnson &amp; Johnson Innovative Medicine having an option to extend the Supply Agreement for a fifth year upon written notification to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine paid us a non-refundable upfront cash purchase price of $65.0 million in December 2023. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine agreed to pay us future contingent consideration of up to an aggregate of $350.0 million, as follows: (i) a milestone payment of $50.0 million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $10.0 million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $5.0 million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $175.0 million upon the first commercial sale of an RPGR Product in the United States; (v) $75.0 million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $25.0 million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from us to Johnson &amp; Johnson Innovative Medicine; and (vii) $10.0 million upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. To date, we received $60.0 million in milestone payments from Johnson &amp; Johnson Innovative Medicine. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In connection with the sale and assignment of the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product to Johnson &amp; Johnson Innovative Medicine, Johnson &amp; Johnson Innovative Medicine has control and broad discretion over all aspects of the development and commercialization of the RPGR Product and we will have little, if any, influence over how such activities will be conducted. Johnson &amp; Johnson Innovative Medicine will also be responsible for seeking regulatory approval and initiating the first commercial sale in the relevant jurisdictions of the RPGR Product, as well as obtaining regulatory approval of its manufacturing facilities in the relevant jurisdictions for the purposes of conducting commercial manufacture of the RPGR Product. These regulatory approvals and initiation of the first commercial sales in the relevant jurisdictions would entitle us to receive milestone payments up to an aggregate of $260.0 million.  Our receipt of these milestones is dependent on Johnson &amp; Johnson Innovative Medicine&#8217;s ability to successfully develop and commercialize the RPGR Product and obtain the necessary regulatory approvals for its manufacturing facilities. If these regulatory approvals or commercial sales do not occur in a timely fashion or at all, then such milestone payments, and any revenues we may receive from manufacturing commercial supply of the RPGR Product, may be delayed or we may not receive such payments. Additionally, certain of these milestone based payments are payable upon our achievement of the specified development services, completion of the transfer of certain manufacturing technology to Johnson &amp; Johnson Innovative Medicine and our ability to manufacture sufficient commercial supply of the RPGR Product in a timely fashion. In the event we are not successful in completing these activities in a timely fashion or at all, we will not receive the milestone payments associated with the relevant milestone under the Asset Purchase Agreement or receive revenue for commercial supply of the RPGR Product under the Supply Agreement. In each of these circumstances, our anticipated cash inflows from these activities would be reduced or eliminated, which would have an adverse effect on our revenue and financial position.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and commercialize our product candidates, as well as continue to expand our manufacturing and supply chain capabilities. This will require additional capital, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Our ability to raise additional capital when needed has been and may in the future be adversely affected by external factors beyond our control, including changes in the political climate, geopolitical actions, changes in market interest rates, potential reforms and changes to government regulations, the effect of healthcare reform legislation, including those that may limit pricing of pharmaceutical products and drugs, market prices and conditions, prospects for favorable or unfavorable clinical trial results, new product initiatives, the manufacturing and distribution of new products, product safety and efficacy issues, new collaborations and strategic alliances and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing has diverted and may in the future divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed significant amounts of cash since inception. As of March 31, 2025, our cash, cash equivalents and restricted cash were $68.6 million. In addition, we expect to receive $0.7 million from receivables from Johnson &amp; Johnson Innovative Medicine during the second quarter of 2025 in connection with transition services we provided to Johnson &amp; Johnson Innovative Medicine. Based on our cash, cash equivalents, accounts receivable &#8211; related party and tax incentive receivable at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into 2027 and to repay our debt obligation of $75.0 million to Perceptive (due in August 2026). This estimate does not include the $285.0 million in milestones we are eligible to receive under the Asset Purchase Agreement upon first commercial sale of an RPGR Product in the United States and in at least one of the United Kingdom, France, Germany, Spain and Italy, for completion of the transfer of certain manufacturing technology to Johnson &amp; Johnson Innovative Medicine and upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to spend more than expected or consume capital significantly faster than we currently anticipate, such as inflation or other factors that may significantly increase our business costs. Because the length of time and activities associated with successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of our clinical development for our radiation-induced xerostomia product candidate, AAV-hAQP1, and for our product candidate for the treatment of Parkinson&#8217;s disease, AAV-GAD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of our ongoing clinical development for our AAV-AIPL1 gene therapy product candidate, our CNGB3 achromatopsia gene therapy product candidate, AAV-CNGB3, for our CNGA3 achromatopsia gene therapy product candidate, AAV-CNGA3, and for our RPE65-associated retinal dystrophy product candidate, AAV-RPE65;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of our product candidate for the treatment of ALS, AAV-UPF1, for our product candidate for the treatment of xerostomia associated with Sjogren&#8217;s syndrome, AAV-hAQP1, and our product candidate for the treatment of neovascular age related macular degeneration, or wet AMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of our potentially transformative riboswitch gene regulation platform technology designed to precisely and specifically control gene therapy expression levels via dose-response to orally delivered small molecules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we receive the milestone payments under the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing our current research programs and our preclinical development of product candidates from our current research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking to identify, assess, acquire and/or develop additional research programs and additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the preclinical testing and clinical trials for any product candidates we identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the&#160;outcome, timing and cost of meeting regulatory requirements established by the FDA, MHRA, EMA and other regulatory authorities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of expanding and protecting our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of further developing and scaling our manufacturing facilities and processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of completion of commercial-scale manufacturing facilities and activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of making royalty, milestone or other payments under current and any future in-license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the&#160;extent to which we in-license or acquire rights to other products, product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions where we choose to commercialize our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the&#160;initiation, progress, timing and results of our commercialization of our product candidates, if approved for commercial sale.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Raising additional capital through the sale of equity or convertible debt securities will dilute your ownership interest, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. For example, in connection with entering into the Financing Agreement (as defined below), we issued warrants to Perceptive (as defined below), to purchase 400,000 ordinary shares at an exercise price of $15.00 per share and 300,000 ordinary shares at an exercise price of $20.00 per share. Additional debt financing or preferred equity financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 2, 2022, we, as borrower, and our wholly-owned subsidiaries MeiraGTx UK II Limited and MeiraGTx Ireland DAC, as guarantors (the &#8220;Subsidiary Guarantors&#8221;), entered into a senior secured financing arrangement (the &#8220;Financing Agreement&#8221;) by and among us, the Subsidiary Guarantors, the lenders and other parties from time to time party thereto and Perceptive Credit Holdings III, LP, as administrative agent and lender (&#8220;Perceptive&#8221;). On December 19, 2022, the Financing Agreement was converted to a notes purchase agreement and guaranty (as converted, the &#8220;Notes Purchase Agreement&#8221;) between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. We and the Subsidiary Guarantors entered into a Consent and Amendment with Perceptive on August 10, 2023 (the &#8220;First Consent and Amendment), and we and the Subsidiary Guarantors entered into a second Consent and Amendment with Perceptive on December 20, 2023 (the &#8220;Second Consent and Amendment&#8221;). The Notes Purchase Agreement provides for an initial $75.0 million notes issuance (the &#8220;Tranche 1 Notes&#8221;). Pursuant to the First Consent and Amendment, we were able to request in our sole discretion, and Perceptive agreed to subscribe to purchase upon such request, an additional $25.0 million notes issuance (the &#8220;Tranche 2 Notes&#8221;, together with the Tranche 1 Notes, the &#8220;Notes&#8221;) at any time before August 2, 2024, subject to the terms of the Notes Purchase Agreement. Previously, the Company&#8217;s request for issuance of the Tranche 2 Notes was to be determined at Perceptive&#8217;s sole discretion. Under each of the First Consent and Amendment and the Second Consent and Amendment, the Notes Purchase Agreement was also amended to increase the applicable early redemption fee. The Notes incur interest, subject to certain provisions therein, at a fluctuating rate per annum equal to 10.00% plus the secured overnight financing rate administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a 1.00% floor. The Notes Purchase Agreement matures on August 2, 2026 and is interest-only during the term. The Notes Purchase Agreement also contains various restrictions and covenants, including, among other things, covenants regarding the incurrence of additional indebtedness, limitations on liens, limitations on certain investments, limitations on making distributions, dividends and other payments, mergers, consolidations and acquisitions, dispositions of assets, maintenance of at least $3.0 million in a U.S. bank account, transactions with affiliates, changes to governing documents, changes to certain agreements and leases and changes in control. Our obligations under the Notes Purchase Agreement are secured by our London, UK and Shannon, Ireland manufacturing facilities, $3.0 million of our cash and the bank accounts of the Subsidiary Guarantors, and the issued and outstanding equity interests of the Subsidiary Guarantors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our cash and cash equivalents available under the Notes Purchase Agreement and under any future financings, together with any funds generated by our operations, will be sufficient to satisfy our debt payment obligations. Our inability to generate funds, obtain financing sufficient to satisfy our debt payment obligations or remain in compliance with the debt covenants may result in such obligations being accelerated by our lenders, which would likely have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The covenants may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry, or take future actions. Additionally, our ability to comply with these restrictive covenants may be impacted by events beyond our control, such as economic conditions or major central bank policy actions. Our Notes Purchase Agreement provides that our breach or failure to satisfy certain covenants constitutes an event of default. Upon the occurrence of an event of default, in addition to an increase in the rate of interest on the Notes of 3% per annum, Perceptive could elect to declare all amounts outstanding thereunder to be immediately due and payable, proceed against the assets we provided as collateral, and, if such debt were accelerated, we may not have sufficient cash on hand or be able to sell sufficient collateral to repay it, which would have an immediate adverse effect on our business and operating results. This could potentially cause us to cease operations and result in a complete loss of your investment in our ordinary shares<b style="font-weight:bold;">.</b></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our review of potential strategic transactions may not result in an executed or consummated transaction or other strategic alternative and may not result in anticipated benefits to us or our shareholders, and the process of reviewing strategic transactions or its conclusion could be disruptive and distracting to our business operations and management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have, and may continue to, opportunistically identify and evaluate strategic opportunities regarding our assets. For example, in March 2025 we entered into a strategic collaboration with Hologen that is subject to customary closing and funding conditions that must be satisfied or waived prior to completion of the transaction. It is possible that the transaction may not be completed or may not be completed as quickly as expected, which could have a material adverse effect on the price of our ordinary shares. In addition, any significant delay in consummating or a failure to consummate the transaction could have a material adverse effect on our future business or operating results. There can be no assurance that we will be successful in our efforts to pursue or advance such options, or identify similar opportunities, or that any potential transaction would be consummated or, if consummated, will provide the anticipated benefits to us or otherwise enhance shareholder value. Any such potential transaction would be dependent upon a number of factors beyond our control, including, without limitation, market conditions, industry trends, the interest of third parties in our assets and whether the terms of any strategic transaction would be acceptable to us. The process of reviewing potential strategic alternatives is time consuming and may be distracting and disruptive to our business operations and long-term planning, which may cause concern to our current or potential customers, employees, investors, strategic partners and other constituencies and may have a material impact on our business and operating results or result in increased volatility in our share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future success and ability to generate product revenue is substantially dependent on our ability to successfully develop, manufacture, obtain regulatory approval for and successfully commercialize our product candidates. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We have invested and expect to continue to invest a meaningful portion of our efforts and expenditures over the next few years in the development of AAV-hAQP1, AAV-GAD, AAV-AIPL1 and our riboswitch gene regulation technology platform, as well as potentially AAV-CNGB3, AAV-CNGA3, AAV-RPE65, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, manufacturing sufficient supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that our product candidates will be successful in clinical trials, receive regulatory approval or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market our product candidates from the FDA, MHRA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized by us or any of our collaborators, widely accepted in the marketplace or more effective than other commercially available alternatives. Additionally, the research, testing, manufacturing, labeling, approval, sale, marketing and distribution of gene therapy products are and will remain subject to extensive and evolving regulation by the FDA, MHRA and other regulatory authorities. We are not permitted to market our product candidates in the United States until they receive approval of a biologics license application, or BLA, from the FDA, we cannot market them in the UK or EU until we receive approval for an MA, from the MHRA or European Commission, respectively, and we cannot market them in other countries until we receive any other required regulatory approval in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because some of our product candidates are based on similar technology, if any of our product candidates show unexpected adverse events or a lack of efficacy in the indications we intend to treat, or if we experience other regulatory or developmental issues, our development plans and business could be significantly harmed. Further, competitors may be developing products with similar technology and may experience problems with their products that could identify problems that would potentially harm our business.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify additional product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory pathway for a potential product candidate may be too complex and difficult to navigate successfully or economically.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. If we are unable to identify additional suitable product candidates for clinical development, this would adversely impact our business strategy and our financial position and share price and could potentially cause us to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">It is difficult to predict the time and cost of product candidate development on our novel gene therapy platform. A limited number of gene therapies have been approved in the United States or in Europe.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 0pt;">We have concentrated a portion of our research and development efforts on our gene therapy platform, which uses both transduction and gene control technology. Our future success depends on the successful development of these novel therapeutic approaches. To date, a limited number of products that utilize gene transfer have been approved in the United States or Europe.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our gene therapy platform is based on a suite of viral vectors which we can deploy with gene therapy constructs, which relies on the ability of AAV to efficiently transmit a therapeutic gene to certain kinds of cells. The mechanism of action by which these vectors target particular tissues is still not completely understood. Therefore, it is difficult for us to determine that our vectors will be able to properly deliver gene transfer constructs to enough tissue cells to reach therapeutic levels. We cannot be certain that animal models will exist for some of the diseases we expect to pursue, that our viral vectors will be able to meet safety and efficacy levels needed to be therapeutic in humans or that they will not cause significant adverse events or toxicities. Furthermore, prior work conducted by a third party in non-human primates suggests that intravenous, or IV, delivery of certain AAV vectors at very high doses may result in severe toxicity. The indications that we target do not use IV administration for viral vector delivery and do not use doses as high as those tested in these publications, and to date we have not observed the severe toxicities described in these publications with the naturally occurring AAV vectors that we use. However, we cannot be certain that we will be able to avoid triggering toxicities in our future preclinical studies or clinical trials. Any such results could impact our ability to develop a product candidate. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our gene therapy platform, or any similar or competitive gene therapy platforms, will result in the identification, development, and regulatory approval of any product candidates, or that other gene therapy technologies will not be considered better or more attractive. There can be no assurance that any development problems we experience in the future related to our gene therapy platform or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. Any of these factors may prevent us from completing our preclinical studies or clinical trials or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;">In addition, because our gene regulation technology is still in the research stage, we have not yet been able to assess safety in humans, and there may be long-term effects from treatment that we cannot predict at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="white-space:pre-wrap;">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and may change. Within the broader genetic medicine field, a limited number of therapeutic products have received approval from the FDA or a marketing authorization, or MA, from the  MHRA and European Commission. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products, which could impact the timing and cost of any regulatory approval. For example, in the United States, the FDA has established the Office of Therapeutic Products&#160;within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials may also be subject to review and oversight by an institutional biosafety committee and/or an institutional review board, or IRB, which are local institutional committees or boards, as applicable, that review, approve and oversee basic and clinical research conducted at the institution participating in the clinical trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;">In the EU, the EMA&#8217;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety, and efficacy of advanced therapy medicinal products, or ATMPs. ATMPs include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for MA for a gene therapy medicinal candidate that is submitted to the EMA. In the EU, the development and evaluation of a gene therapy product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and MA for gene therapy products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any gene therapy product candidate we may develop, but that remains uncertain at this point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Post Brexit, marketing authorization applications, or MAAs, for ATMPs in the UK are regulated nationally and assessed in accordance with the general provisions in place for the licensing of medicines, taking the specific requirements for this group of medicines into account. Definitions for individual classes of ATMPs remain unchanged and classification of ATMPs are undertaken by the MHRA. Data, traceability, exemptions from licensing, packaging and post-authorization requirements remain in line with EU requirements transposed into UK law. However, if the EMA issues new guidance on ATMPs going forward, there is a risk of regulatory divergence with the MHRA and separate procedures and standards with which we may need to comply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, MHRA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, MHRA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel treatments for diseases or conditions in which there may be limited clinical experience with novel endpoints and methodologies, there is heightened risk that the FDA, MHRA, EMA or other regulatory bodies may not consider the clinical trial endpoints we pursue to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. The prospectively designed natural history studies with the same endpoints as our corresponding clinical trials may not be accepted by the FDA, MHRA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome. Further, we may encounter substantial delays in our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 0pt;">The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive, can take many years to complete and is subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. Even if our future clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted indications. Our future clinical trial results may not be successful.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 0pt;">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA, MHRA, EMA or other regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA, MHRA, EMA or other regulatory authorities for support of an MAA, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 12pt 0pt;">To date, we have not completed any clinical development programs required for the approval of any of our product candidates. Although we are currently conducting several clinical development programs, we may experience delays in conducting any clinical trials and we do not know whether our ongoing and future clinical trials will begin on time, need to be redesigned, be able to recruit and enroll patients on time or be completed on schedule, or at all. Events that may prevent successful or timely completion of clinical development include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to generate sufficient preclinical, toxicology, or other </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> data to support the initiation of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching consensus with the FDA, MHRA or other regulatory authorities as to the design or implementation of our clinical trials and obtaining regulatory allowance or approval to commence a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to reach an agreement on acceptable terms with clinical trial sites or prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit and train clinical trial investigators with the appropriate competencies and experience to conduct the clinical trials, administer our product candidates and oversee clinical trial staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining IRB or ethics committee approval or positive opinion at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to recruit&#160;suitable patients to participate in a clinical trial; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to develop and validate any companion diagnostic we may decide to use in connection with a clinical trial, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in sufficiently developing, designing and manufacturing equipment or medical devices used to administer our product candidates in our clinical trials, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients not completing a clinical trial or returning for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites, CROs, or other third parties deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures to conduct clinical trials in accordance with good clinical practice, or GCP, requirements, or other applicable regulatory guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having an insufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to manufacture sufficient quantities of our product candidates for use in clinical trials, or to manufacture such product candidates to acceptable quality standards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may not have funds to cover the costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or a widespread health emergency, or natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any future collaborators that conduct clinical trials may face any of the above issues, and they may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the product removed from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA, MHRA or other foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates will require extensive clinical testing before we are prepared to submit a BLA or MAA for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical development for our product candidates and submit a BLA or MAA for regulatory approval of any of our product candidates or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, MHRA, EMA or other regulatory authorities on our clinical development program, and the FDA, MHRA, EMA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues from our product candidates may be delayed. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. For example changes in the leadership of the FDA and other federal agencies under the current presidential administration or reductions in funding, operations, staffing and policies of the FDA and other federal agencies could impact our clinical development plans and timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU has evolved over recent years. As of January 2025, clinical trials (and related applications) in the EU are now fully subject to the provisions of the EU Clinical Trials Regulation, or CTR, which allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state and provides for a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our development plans.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">It is currently unclear to what extent the UK will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from pre-existing EU legislation (as implemented into UK law, through secondary legislation). The extent to which the regulation of clinical trials in the UK may mirror the (EU) CTR in the long term is not yet certain.  In December 2024, the UK government introduced a legislative proposal which, if implemented, could provide a more flexible regime to make it easier to conduct clinical trials in the UK, increase the transparency of clinical trials conducted in the UK and make clinical trials more patient centered. The legislation may not be approved or could be approved with amendment, and any adoption into UK law may not be until early 2026. Under the terms of the Protocol on Ireland and Northern Ireland, provisions of the (EU) CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products currently apply in Northern Ireland. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pandemics, epidemics or outbreaks of an infectious disease have impacted and may in the future materially and adversely impact our business, including our preclinical studies, clinical trials, manufacturing capabilities and regulatory approvals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have and may in the future experience disruptions from pandemics, epidemics or outbreaks of an infectious disease that could severely impact our business, preclinical studies, clinical trials and laboratory and manufacturing activities, including, for example, delays or difficulties in enrolling patients in our clinical trials, delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, diversion of healthcare resources away from the conduct of clinical trials, interruption of key clinical trial activities due to limitations on travel imposed or recommended by regulatory authorities or others, interruption or delays in the operations of the FDA, MHRA, EMA or other regulatory authorities, interruption of, or delays in, the manufacturing of our product candidates, interruptions in preclinical studies due to restricted or limited operations at our laboratory facilities, limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, and interruption or delays to our sourced discovery and clinical activities. For example, as a result of the COVID-19 pandemic, we restricted onsite activities and also experienced some delays in enrolling, treating and monitoring patients in our clinical trials, as well as limited disruptions to our supply chain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which any future outbreaks or any variants of COVID-19 or another pandemic may impact our business, preclinical studies, clinical trials and laboratory and manufacturing activities will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of any pandemic, the timing, distribution and effectiveness of vaccines, vaccination rates, travel restrictions and physical distancing requirements in the countries where we do business, business closures or business disruptions, and the effectiveness of actions taken in the countries where we do business to contain and treat any such disease, respond to the reduction in global economic activity and resume normal economic and operating conditions. If we or any of the third parties with whom we engage experience prolonged shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. Furthermore, the magnitude of the economic impact of any pandemic including sustained inflation, supply chain disruptions, and major central bank policy actions may result in significant disruption of global financial markets, which could materially affect our performance, financial condition, results of operations, and cash flows, as well as our ability to raise additional capital. Additionally, major central bank policy actions may have a negative impact on our payment obligations under the Notes Purchase Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The affected populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our knowledge and understanding of these diseases. The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included, or supporting the information, in our SEC filings and other materials should be viewed with caution. Further, the data and statistical information included, or supporting the information, in our SEC filings and other materials, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of such data involves risks and uncertainties and is subject to change based on various factors. Our estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of the diseases we seek to address. The number of patients with the diseases we are targeting in the United States, the UK, the EU and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or access, all of which would harm our results of operations and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact public perception of our current and future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential therapeutic products involve introducing genetic material into patients&#8217; cells. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene regulation are unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example, on November 28, 2023, the FDA announced that it was investigating reports of T-cell malignancies, including CAR- positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR-T cell immunotherapies, and in January 2024, the FDA required the manufacturers of certain CAR-T therapies to add boxed warnings to product labeling cautioning against the risk of T-cell malignancies. Although none of our current product candidates utilize the same technology as these CAR-T immunotherapies, our product candidates use a viral delivery system. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates or the halting of clinical trials, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene therapy and we cannot assure that it will not occur in any of our planned or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to maintain the benefits of certain regulatory designations that we have obtained for our product candidates, and may in the future seek and fail to obtain such designations for other of our current or potential future product candidates. Even if such designations are obtained, they may not lead to faster development or regulatory review or approval, and they do not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of drugs and biological products that meet certain criteria. For example, the FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. Specifically, investigational drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the application may be eligible for priority review. In addition, the Fast Track product may be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. Even if Fast Track designation is granted, it may be rescinded if the product no longer meets the qualifying criteria. In August 2018, AAV-CNGB3 was issued Fast Track designation by the FDA for the treatment of achromatopsia caused by CNGB3 mutations. In January 2021, AAV-CNGA3 was issued Fast Track designation by the FDA for the treatment of achromatopsia caused by CNGA3 mutations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similarly, the EMA has established the PRIME scheme to expedite the development and review of product candidates that show a potential to address to a significant extent an unmet medical need, based on early clinical data. In February 2018, AAV-CNGB3 in the treatment of achromatopsia associated with defects in CNGB3 was admitted to the PRIME scheme of the EMA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor may also seek a Regenerative Medicine Advanced Therapy, or <span style="background:#ffffff;">RMAT, designation&#160;</span>for its product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> Century Cures Act. A biological product is eligible for RMAT designation if it qualifies as an RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions, and is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the biological product has the potential to address unmet medical needs for such a disease or condition. In a February 2019 guidance, the FDA also stated that certain gene therapies that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review, provided the applicable criteria are met. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical trials, patient registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy. In December 2024, the FDA granted RMAT designation to AAV-hAQP1 for the treatment of grade 2 or 3 radiation-induced xerostomia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Such regulatory designations are within the discretion of the FDA, MHRA, EMA and other regulatory authorities. Accordingly, even if we believe one of our product candidates meets the criteria for such regulatory programs and we seek such designations, the FDA, MHRA, EMA or other applicable regulatory authority may disagree and instead determine not to make such designation for such product candidate. We cannot be sure that our evaluation of our product candidates as qualifying for such regulatory designations will meet the regulatory authority&#8217;s expectations. In any event, the receipt of such regulatory designations for a product candidate may not result in a faster development process, review, or approval compared to product candidates considered for approval under conventional regulatory </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">procedures and does not assure ultimate approval by the regulatory authorities. In addition, even if additional product candidates are granted such regulatory designations, the regulatory authority may later&#160;decide that such product candidates no longer meet the conditions for qualification or decide that the time period for review or approval will not be shortened, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have received orphan drug designation and orphan designation from the FDA and European Commission, respectively, for AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-AIPL1, AAV-RDH12 and orphan drug designation from the FDA for AAV-hAQP1 and AAV-BBS10, and we may seek orphan drug designation or orphan designation for additional product candidates in the future, but any orphan drug designations or orphan designations we have received or may receive in the future may not confer marketing exclusivity or other expected benefits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the European Commission grants orphan designation on the basis of the EMA&#8217;s Committee for Orphan Medicinal Products opinion. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment, of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for qualified clinical testing, and user-fee waivers. In addition, if a product receives the first FDA approval of that drug for the disease or condition for which it has orphan drug designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the rare disease or condition. Under the FDA&#8217;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved another drug with the same principal molecular structural features, in the case of a biologic, for the same indication, unless the drug is demonstrated to be clinically superior to the previously approved drug. In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized MA procedure. Moreover, upon grant of an MA and assuming the requirement for orphan designation are also met at the time the MA is granted, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication.<span style="font-size:11pt;"> </span>The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. This period may be reduced to six years if, at the end of the fifth year, the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the orphan designation threshold. In the EU, an MA for an orphan designated product will not be granted if a similar product has been approved in the EU for the same therapeutic indication, unless the applicant can establish that (i) its product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior; (ii) the MA holder for the orphan medicinal product grants its consent; or (iii) if the MA holder of the orphan medicinal product is unable to supply sufficient quantities of product. A similar medicine is a product containing a similar active substance or substances as those contained in an already authorized product. Similar active substance is defined as an identical active substance, or an active substance with the same principal molecular structural features (but not necessarily all of the same molecular features) and which acts via the same mechanism.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is no pre-MA orphan designation in the UK. The MHRA reviews applications from companies for orphan designation in parallel to the corresponding MAA. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in the UK, rather than the EU, must not be more than five in 10,000. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in the UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have obtained orphan drug designation from the FDA and orphan designation from the European Commission for AAV-CNGB3 for the treatment of achromatopsia caused by mutations in the <i style="font-style:italic;">CNGB3</i> gene, for AAV-CNGA3 for the treatment of achromatopsia due to autosomal-recessive <i style="font-style:italic;">CNGA3</i> gene mutations, for AAV-RPE65 for the treatment of Leber congenital amaurosis, for AAV-AIPL1 for the treatment of inherited&#160;retinal dystrophy due to defects in <i style="font-style:italic;">AIPL1</i> gene and for AAV-RDH12 for the treatment of retinol dehydrogenase 12 (RDH12) mutation-associated retinal dystrophy, and we obtained orphan drug designation from the FDA for AAV-hAQP1 for the treatment of grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy and for AAV-BBS10 for the treatment of Bardet-Biedel syndrome (BBS) due to <i style="font-style:italic;">BBS10</i> mutations. We may seek orphan drug designation and orphan designation for other current and future product candidates. Even with orphan drug designation and orphan designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, which could prevent us from marketing our product candidates if another company is able to obtain orphan drug exclusivity before we do. In addition, exclusive marketing rights in the United States and the EU may be unavailable if we seek approval for a disease or condition broader than the orphan drug-designated and orphan-designated disease or condition or may be lost in the United States or EU if the FDA or foreign authorities later determine that the request for designation was materially defective or if we are unable to assure sufficient quantities of the drug to meet the needs of patients with the rare disease or condition following approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">Further, even if we obtain orphan drug exclusivity, that exclusivity may not effectively protect our product candidates from competition because different biologics with different active principal molecular structural features can be approved for the same disease or condition. In addition, the FDA can subsequently approve products with the same principal molecular structural features, in the case of a biologic, for the same disease or condition if the FDA concludes that the later product is safer, more effective, makes a major contribution to patient care, or if the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Likewise, in the EU and UK, the European Commission or MHRA, respectively, can authorize a similar product for the same therapeutic indication, if it concludes that the later product is safer, more effective or clinically superior; if the MA holder for the initial orphan medicinal product grants its consent; or if such MA holder is unable to supply sufficient quantities of the product. Neither orphan drug designation nor orphan designation shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation and orphan designation for other existing and future product candidates, we may never receive such designations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA has granted rare pediatric disease designation to a number of our gene therapy product candidates, however, there is no guarantee that FDA approval of any of these gene therapy candidates will result in a priority review&#160;voucher.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease drugs and biologics intended to treat certain orphan diseases affecting fewer than 200,000 patients in the U.S., the serious or life-threatening manifestations of which primarily affect individuals aged 18 years of age or younger, or affects more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for such disease or condition will be recovered from sales in the U.S. of such drug. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may be eligible to receive a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor, and such priority review vouchers have recently sold for between $100 million to $158 million. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The FDA has granted us rare pediatric disease designation for AAV-AIPL1 for the treatment of Leber congenital amaurosis (LCA4) retinal dystrophy, AAV-BBS10 for the treatment of BBS due to <i style="font-style:italic;">BBS10</i> mutations, AAV-RDH12 for the treatment of Leber congenital amaurosis (LCA) and early-onset severe retinal dystrophy (EOSRD), AAV8-RK-RetGC for the treatment of patients with Leber congenital amaurosis due to <i style="font-style:italic;">GUCY2D</i> mutations (LCA1), AAV-RPE65 for the treatment of inherited retinal dystrophy due to biallelic <i style="font-style:italic;">RPE65</i> mutations, AAV-CNGB3 for the treatment of achromatopsia caused by mutations in the <i style="font-style:italic;">CNGB3</i> gene and AAV-CNGA3 for the treatment of achromatopsia caused by mutations in the <i style="font-style:italic;">CNGA3</i> gene. There is no guarantee that we will be able to obtain a priority review&#160;voucher, even if one or more of these gene therapy product candidates is approved by the FDA. Under the current statutory provisions, the FDA may not award a rare pediatric disease priority review&#160;voucher&#160;to sponsors of marketing applications unless the drug has received rare pediatric disease designation as of December 20, 2024 and is approved by the FDA no later than September 30, 2026. Even though we received rare pediatric disease designation by the current statutory deadline of December 20, 2024 for all of these gene therapy product candidates except AAV8-RK-RetGC, which received such designation in January 2025, we may not receive a&#160;voucher&#160;for such gene therapy product candidates if we do not obtain approval by September 2026. It is possible that Congress may retroactively extend the date by which a rare pediatric disease-designated drug may be designated as such to be eligible for a priority review voucher, or extend the date by which a rare pediatric disease-designated drug must obtain approval in order to receive a priority review&#160;voucher, but even if such legislation is enacted, we may not obtain approval by that date, and even if we do, we may not obtain a priority review&#160;voucher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and our contract manufacturers for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing facilities and the third-party manufacturing facilities which we rely on may not continue to meet regulatory requirements and have limited capacity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have relationships with a limited number of suppliers for the manufacturing of plasmid, a component of our viral vectors and product candidates. We also have GMP manufacturing facilities in London, United Kingdom and Shannon, Ireland, which we expect can supply our current clinical and preclinical programs, as well as our third party supply obligations, through regulatory approval and, should they be approved, provide sufficient capacity for their commercial production. However, if we experience slowdowns or problems with our facilities or are unable to establish or scale our internal manufacturing capabilities, we will need to continue to contract with manufacturers that can produce the preclinical, clinical and commercial supply of our products. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for components of our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA or MAA on a timely basis. Generally, our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must successfully complete a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or the product candidates that we manufacture for third parties. In addition, certain regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the product candidates that we manufacture for third parties or the associated quality systems for compliance with the regulations applicable, if and when approved, to the activities being conducted. If these facilities do not successfully complete a pre-approval plant inspection, FDA, MHRA or other regulatory approval of the product candidates will not be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business. If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA, MHRA or other regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be harmed. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA and/or MAA supplement which could result in further delay. Regulatory agencies may also require additional studies if a new manufacturer is relied upon for clinical or commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any contamination in our manufacturing process, shortages of raw materials or failure of our plasmid supplier to deliver necessary components, or other issues with the manufacturing process, could result in delays in our clinical development or marketing schedules.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. In addition, our manufacturing process is complex, and the manufacturing batch cycle period can be several weeks long. Each batch cycle may not yield planned quantities or meet the required standards. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates, failure of manufacturing equipment or systems or other issues with our manufacturing process, could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expanding our manufacturing capacity has and will continue to be costly and we may be unsuccessful in doing so in a timely manner, which could delay our current and future clinical development programs, or delay the commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition to our existing manufacturing facilities in London, United Kingdom and Shannon, Ireland, we may lease, operate, purchase, or construct additional facilities to supply our clinical and preclinical programs, as well as to meet our third party supply obligations, or conduct expanded manufacturing or other related activities in the future.  Expanding our manufacturing capacity to produce the preclinical, clinical and commercial supply of our products and their components, as well as our obligations under the Supply Agreement with Johnson &amp; Johnson Innovative Medicine if the RPGR Product is successfully commercialized, has required and will continue to require substantial additional expenditures, time, and various regulatory approvals and permits, as well as hiring, training and retraining employees and managerial personnel to staff our manufacturing and supply chain operations. Start-up costs can be large and may exceed our expectations, and scale-up entails significant risks related to process development and manufacturing yields. In addition, we may face difficulties or delays in developing or acquiring the necessary production equipment and technology to manufacture sufficient quantities of our product candidates for use in clinical trials and, should they be approved, to supply the commercial market at reasonable costs and in compliance with applicable regulatory requirements. We may not successfully expand, establish or sustain sufficient manufacturing capabilities or manufacture our products economically or in compliance with GMP and other regulatory requirements, and we and our collaborators may not be able to build or procure additional capacity in the required timeframe to meet the requirements of our clinical programs or to meet potential commercial demand for our product candidates. This could also delay or require us to discontinue one or more of our clinical development programs or could interfere with our efforts to successfully </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">commercialize our products. As a result, our business, prospects, operating results, and financial condition could be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. This may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to study sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial or side effects that may arise in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business&#160;interruptions resulting from geopolitical actions, including war and terrorism, or widespread health emergencies, or natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other clinical trials for product candidates that are in the same therapeutic areas as our product candidates or approved products for the same clinical indications (such as Luxturna marketed by Spark Therapeutics, Inc. for the treatment of RPE65-associated retinal disease) may reduce the number and type of patients available to us. Furthermore, although we have conducted and may in the future conduct natural history studies to better characterize the patient populations we seek to address, any natural history studies we may undertake could fail to provide us with patients for our clinical trials, because patients enrolled in the natural history studies may not be good candidates for our clinical trials or may choose to not enroll in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause serious adverse events or undesirable side effects or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or, result in significant negative consequences following marketing approval, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Serious adverse events or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, MHRA or other authorities. Results of our clinical trials could reveal a high and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death. A risk in any gene therapy product based on viral vectors is the risk of insertional mutagenesis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If unacceptable side effects or deaths arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, the DSMB, or other regulatory bodies could suspend or terminate our clinical trials or the FDA, MHRA or other regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Undesirable side effects or deaths in clinical trials with our product candidates may cause the FDA or comparable foreign regulatory authorities to place a clinical hold on the associated clinical trials, to require additional studies, or otherwise to delay or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients or similar risk management measures;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product could become less competitive;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Results from previous preclinical studies or clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Frequently, product candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for drugs and biologic products proceeding through clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval, which could negatively impact our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA, MHRA, competent authorities in the EU and other regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The time required to obtain approval by the FDA, MHRA, European Commission and other regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not expected before early 2026. The revisions may however have a significant impact on the pharmaceutical industry in the long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have not obtained regulatory approval for any product candidate and it is possible that none of our product candidates in clinical programs or any other product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States, the UK or the EU until we receive regulatory approval of a BLA from the FDA or of an MAA from the MHRA or European Commission, respectively. It is possible that the FDA may refuse to accept for substantive review any BLAs, or the MHRA or EMA any of our MAAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prior to obtaining approval to commercialize a product candidate in the United States, the UK, the EU or elsewhere, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, MHRA, EMA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses, or with respect to biologics in the United States, that such product candidates are safe, pure, and potent for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, MHRA, European Commission or other regulatory authorities. The FDA, MHRA or EMA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA, MHRA or EMA required studies, approval of any regulatory approval applications that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Of the large number of potential products in development, only a small percentage successfully complete the FDA, MHRA, or other foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.85pt;margin:0pt;"><span style="font-size:7.85pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain FDA, MHRA or European Commission approval for our product candidates in the United States, UK or EU, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States, the MHRA in the UK or the competent authorities in the EU does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approval of one or more of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, MHRA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with GMP and similar requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The FDA, MHRA and other regulatory authorities closely regulate the post-approval marketing and promotion of genetic therapy medicines to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, MHRA and other regulatory authorities impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the U.S. federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. Similar risks apply in foreign jurisdictions.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our manufacturing processes or third-party manufacturers, or failure to comply with regulatory requirements, may yield various results, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.35pt;margin:0pt;"><span style="font-size:9.35pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or holds on clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.8pt;margin:0pt;"><span style="font-size:11.8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA&#8217;s and foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may also disclose interim data from our clinical trials. Interim data from these trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. Adverse differences between interim data and topline, preliminary, or final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and our company in general. In addition, the information we choose to publicly disclose regarding a particular clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 9.95pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government or regulatory agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, approved or commercialized in a timely manner, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, disruptions caused by global health concerns, ability to hire and retain key personnel, including those with experience relating to novel gene therapy product candidates, acceptance of the payment of user fees, statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Disruptions at the FDA and other government or regulatory agencies such as the EMA, following its relocation to Amsterdam and related reorganization (including staff changes), may also slow the time necessary for new product candidates to be reviewed and/or approved, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.  In addition, the current presidential administration has threatened to lay off thousands of federal health workers, including at the FDA, which may delay review times for approval of our product candidates and impact our ability to correspond with the FDA regarding the development of our programs in a timely fashion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States, the UK, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a licensure framework for follow on biologic products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which was temporarily suspended from May 1, 2020 through March 31, 2022, and reduced payments to several types of Medicare providers.  In March 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In August 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new manufacturer discounting program (which began in 2025). The IRA permits the Secretary of the U.S. Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. For that and other reasons, it is currently unclear how the IRA will be effectuated. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for our product candidates. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of our product candidates, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the UK and EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the UK or the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the UK and the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in the UK and in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted in the EU. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product (i.e., oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030). The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In markets outside of the United States, the UK and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the UK the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.05pt;margin:0pt;"><span style="font-size:8.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.2pt;margin:0pt;"><span style="font-size:9.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse laws and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.55pt;text-indent:-16.55pt;margin:0pt 3.6pt 0pt 52.55pt;"><span style="display:inline-block;min-width:16.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 69pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;</span></td><td style="width:3.95pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.55pt;text-indent:-16.55pt;margin:0pt 3.6pt 0pt 52.55pt;"><span style="display:inline-block;min-width:16.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar healthcare laws and regulations in the UK, EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 2.95pt 0pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to regulation and other legal obligations relating to data privacy and protection. Compliance with these requirements is complex and costly. The actual or perceived failure to comply with such obligations could materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;">The global data protection landscape is continually evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, access to, confidentiality, disclosure, storage, processing, retention and security of personal information such as information that we may collect in connection with clinical trials in the U.S. and abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;"><span style="white-space:pre-wrap;">In the U.S., HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, healthcare clearinghouses and certain healthcare providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity, as well as their covered subcontractors. Most healthcare providers, including research institutions and other vendors from which we may obtain health-related information, are subject to privacy and security regulations promulgated under HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Further, we may also be subject to other state laws governing the privacy, processing and protection of personal information. For example, the California Consumer Privacy Act, or CCPA, requires covered businesses that process the personal information of California residents to, among other things: provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Similar laws have been passed in other states, and are continuing to be proposed at the state and the federal level, reflecting a trend toward more stringent privacy legislation in the United States. HIPAA, the CCPA and other domestic privacy and data protection laws and regulations may increase our compliance costs and potential liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;"><span style="white-space:pre-wrap;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, the General Data Protection Regulation, or GDPR, imposes stringent requirements for processing the personal data of individuals within the European Economic Area, or EEA, or in the context of our activities within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and, among other things, potential fines for noncompliance of up to &#8364;20 million or up to 4% of the total worldwide annual turnover of the relevant undertaking in the preceding financial year, whichever is higher, and other administrative penalties.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.25pt;margin:0pt;"><span style="font-size:9.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.7pt;margin:0pt;">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S. Case law from the Court of Justice of the European Union states that reliance on the standard contractual clauses &#8211; a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism &#8211; alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. The European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;) on July 10, 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the adequacy of the DPF as an approved GDPR transfer mechanism to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. If, owing to the restriction or perceived restriction of personal data transfers, we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;">Further, we are subject to the UK GDPR, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant undertaking&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF. UK privacy law has been, and continues to be, subject to scrutiny and proposed changes. This could affect the ease of data transfers between the EEA and the UK in the future. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although we work to comply with applicable laws, regulations and standards, as well as our contractual obligations and other legal obligations, relating to data privacy and security, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction and/or organization to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy data and security concerns, even if unfounded, could result in additional costs, claims by and liability to third parties, government investigations and enforcement actions, damage to our reputation, and other adverse affects on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.7pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.5pt;margin:0pt;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. Additionally, if environmental regulations are enacted that restrict our ability to use one or more of the materials or compounds necessary to manufacture our product candidates, and we are unable to find suitable alternatives or such alternatives require additional testing or will extend the manufacturing timeline, then we may be unable to manufacture our product candidates in a timely manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.8pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.8pt;margin:0pt 2.95pt 0pt 0pt;">We may be subject to environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production efforts or those of our third-party manufacturers may be interrupted or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Due to our international operations, we are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our operations are subject to anti-corruption laws, including the UK Bribery Act 2010, or Bribery Act; the U.S. Foreign Corrupt Practices Act, or FCPA; and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed by, or providing prohibited payments or anything else of value to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA, or local anti-corruption laws. In addition, we cannot predict the nature, scope, or effect of future regulatory requirements to which any of our international operations might be subject or the manner in which existing laws might be administered or interpreted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We also are subject to other laws and regulations governing any international operations, including regulations administered by the governments of the UK and the U.S., and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, or, collectively, the Trade Control laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA, and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement, and other sanctions and remedial measures and legal expenses. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws, or Trade Control laws by UK, U.S., or other authorities, even if it is ultimately determined that we did not violate such laws, could be costly and time-consuming, require significant personnel resources, and harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have established internal controls to detect and prevent violations of applicable anti-corruption laws and to remedy any weaknesses identified. There can be no assurance, however, that the policies and procedures will be followed at all times or effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents, or collaborators and, as a result, we could be subject to fines, penalties, or prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.8pt;margin:0pt;"><span style="font-size:10.8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.35pt;margin:0pt;"><span style="font-size:9.35pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The development and commercialization of new gene therapy products is highly competitive. Moreover, the gene regulation and manufacturing fields are characterized by rapidly changing technologies and a strong emphasis on intellectual property. We may face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs, including inherited retinal diseases and neurodegenerative diseases. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. Differences in the scientific approaches may create confusion or uncertainty among clinical trial investigators or patient populations, which could delay or hinder enrollment or initiation of our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our platform and products focus on the development of gene therapies and gene regulation technology. In 2017, the FDA approved the first gene treatment for RPE65-associated retinal disease, Luxturna, a commercially available product developed by Spark Therapeutics, Inc., which was purchased by Roche. There are a number of other companies developing ocular gene therapy products, including Applied Genetic Technologies Corporation, and 4D Molecular Therapeutics, Inc. There are a number of companies developing gene therapy products for neurodegenerative diseases, including Voyager Therapeutics, Inc., Brain Neurotherapy Bio, Inc., and Eli Lilly and Company. In addition to competition from other gene therapies, any products we may develop may also face competition from other types of therapies, such as small molecule, antibody, or protein therapies. Many of our current or potential competitors, either alone or with their collaboration partners, have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific, manufacturing and management personnel and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop, limiting demand or the price we are able to charge, or that could render any products that we may develop obsolete or non-competitive. Our competitors also may obtain FDA, MHRA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products, could reduce physician utilization of our products if approved. Assuming there is such coverage by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the UK, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 12.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of sales and marketing efforts;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.8pt;margin:0pt;"><span style="font-size:11.8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our product candidates for sale at competitive prices;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support, and publicity concerning our products or competing products and treatments;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of competitive products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA, MHRA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td><td style="width:3.95pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenues for a substantial period, the failure of these product candidates to find market acceptance would harm our business and could require us to seek additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 16.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target indications of our programs, even if they are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so or we may seek collaborative arrangements or external funding to commercialize our product candidates. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of such capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. Additionally, if any commercial launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may not have the resources in the foreseeable future to allocate to the sales and marketing of our product candidates in certain markets. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product and such collaborator&#8217;s ability to successfully market and sell the product. We may pursue collaborative arrangements regarding the sale and marketing of AAV-hAQP1, AAV-GAD, our IRD programs, our riboswitch gene regulation platform technology or other future gene therapy programs, if approved, for the United States and/or certain markets overseas; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unable to build our own sales force or negotiate or maintain a collaborative relationship for the commercialization of our product candidates, we may be forced to delay potential commercialization or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities internationally, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Some indications targeted by our ophthalmology programs are rare, but we anticipate realizing synergies in commercializing our IRD product candidates, should they be approved. Failure to realize synergies in our sales, marketing and distribution efforts may harm our commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we or our collaborators are unable to establish or maintain adequate sales, marketing and distribution capabilities, we will not be successful in commercializing our product candidates and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.8pt;margin:0pt;"><span style="font-size:8.8pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If any of our products are commercialized outside of the United States, the UK or the EU, a variety of risks associated with international operations could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any of our products are approved for commercialization, we have entered into, and intend to enter into, agreements with third parties to market them in certain jurisdictions outside the United States, the UK and the EU. We expect that we and our third-party collaborators will be subject to additional risks related to international pharmaceutical operations, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.35pt;margin:0pt;"><span style="font-size:9.35pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic commercialization in foreign countries;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tighter restrictions on data privacy and security and the collection and use of patient data;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced or loss of protection for intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign reimbursement, pricing and insurance regimes;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:29.7pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-size:6pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or widespread health emergencies, or natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.15pt;margin:0pt;"><span style="font-size:9.15pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater difficulty with enforcing our contracts;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential noncompliance with the FCPA, the Bribery Act and similar anti-bribery and anticorruption laws in other jurisdictions;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.5pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.55pt;text-indent:-16.55pt;margin:0pt 3.6pt 0pt 52.55pt;"><span style="display:inline-block;min-width:16.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>workforce uncertainty in countries where labor unrest is more common than in the United States and compliance with tax, employment, immigration and labor laws for employees living or traveling abroad.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:29.7pt;margin:0pt 2.95pt 0pt 3pt;"><span style="font-size:6pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:36pt;margin:0pt;">We have no prior experience in these areas and we may rely on other third parties to help us establish our international commercialization operations. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by individual countries in Europe with which we and our third-party collaborators will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.4pt;margin:0pt;"><span style="font-size:9.4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">which the reference product was first licensed by the FDA. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Jurisdictions outside the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2006. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If our GMP manufacturing facilities are unable to supply our product candidates for all of our current preclinical, clinical and potential commercial needs, including our third party supply obligations, we will be forced to seek out third-party manufacturers. We currently contract with third parties for the manufacture of plasmid used in producing product candidates. Relying on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We produce our product candidates in our GMP viral vector manufacturing facility in London, UK, completed in early 2018, and our second, large scale GMP viral vector manufacturing facility and our first GMP plasmid and DNA production facility came online in 2022 in Shannon, Ireland. However, if our current facilities are damaged, suffer any form of delay or regulatory challenges, we experience slowdowns or problems with our facilities or we are unable to scale our internal manufacturing capabilities to meet demand for our product candidates, we will need to contract with third-party manufacturers to produce our product candidates. We have also agreed to manufacture commercial supply of the RPGR Product for Johnson &amp; Johnson Innovative Medicine<span style="white-space:pre-wrap;">, if and when approved, under the Supply Agreement.  If we fail to meet our obligations under the Supply Agreement, we may not be able to find a third-party manufacturer suitable to us or </span>Johnson &amp; Johnson Innovative Medicine to perform such manufacturing obligations, which could negatively impact our receipt of revenues under the Supply Agreement. While we now have our own plasmid manufacturing capabilities in our Shannon, Ireland facilities, we also rely on third-party manufacturers from time to time for the manufacture of plasmid used in the production of some product candidates. We do not have a long-term supply agreement with any of the third-party manufacturers, and we purchase our required supply on a purchase order basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We and our third-party manufacturers may also encounter difficulties or delays in manufacturing of our product candidates or the plasmid used in the production of our product candidates. Geopolitical actions, natural disaster or a widespread health emergency could impact our supply chain. To the extent that we or our third-party manufacturers are located in geographies affected by these matters, it may result in the temporary closing of manufacturing facilities and may increase the costs associated with manufacturing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.8pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:52.55pt;margin-top:0pt;padding-left:16.55pt;text-indent:-16.55pt;"><span style="display:inline-block;min-width:16.45pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible breach of the manufacturing agreement by the third party, including failure to provide appropriate quantities in a timely manner;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting.</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We and our third-party manufacturers may not be able to comply with GMP regulations or similar regulatory requirements that might be required by the FDA, MHRA or EMA. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could adversely affect supplies of our candidates and harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any therapies that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under GMP or similar regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.7pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or any components required for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have in the past, and may in the future, collaborate with third parties for the development, manufacture and commercialization of our product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our product candidates successfully, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have entered into collaboration agreements with third parties for the development and commercialization of our product candidates, including the Collaboration Agreement with Johnson &amp; Johnson Innovative Medicine for the development and commercialization of AAV-CNGB3, AAV-CNGA3 and bota-vec, which Collaboration Agreement was terminated in December 2023 in connection with our entering into the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine. In addition, in October 2023 we provided Sanofi and its affiliates with a right of first negotiation for use of our riboswitch gene regulation technology for certain Immunology and Inflammation (I&amp;I), including modulation of IL-4 and IL-13, and Central Nervous System (CNS) targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for our Phase 2 xerostomia program, under the Investment Agreement. We also entered into a strategic collaboration with Hologen in March 2025 as described above that is expected to close in the second calendar quarter of 2025 subject to customary closing and funding conditions. We may seek additional collaborative relationships in the future. Failure to obtain a collaborative relationship for our product candidates may significantly impair their commercial potential. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, such as:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may not devote sufficient capital or resources towards our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may change the success criteria for a product candidate thereby delaying or ceasing development of such candidate;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaboration partner may terminate a strategic alliance;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a dispute may arise between us and a partner concerning the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a partner may use our products or technology in such a way as to make us subject to litigation with a third party.</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have relied, and we expect to continue to rely, on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if these third parties perform in an unsatisfactory manner, our business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect to rely on CROs, clinical trial sites, and other vendors to ensure our preclinical studies and clinical trials are conducted properly and on time. We may also engage third parties such as clinical data management organizations, medical institutions and clinical investigators to conduct or assist in our clinical trials or other preclinical and clinical research and development work. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our third-party service providers&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with applicable protocol, legal, quality, regulatory and scientific standards, including among </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">other things, GCP requirements for clinical trials and good laboratory practice requirements for certain preclinical studies. Our reliance on these third parties does not relieve us of our regulatory responsibilities. For example, we are conducting the Phase 2 AQUAx2 clinical trial of AAV-hAQP1 for the treatment of patients with radiation-induced xerostomia at multiple clinical trial sites in North America and the United Kingdom. If any locations terminate the clinical trial, we may be required to find another party to conduct any new trials. We may be unable to find a new party to conduct new trials of our product candidates or obtain clinical supply of our product candidates or AAV vectors for such trials. If we elect to internalize some or all activities related to the conduct of our preclinical studies or clinical trials that are currently performed by our third-party service providers, or if we are required to do so due to a service provider&#8217;s termination of our relationship, then we may be required to source additional technology and personnel in order to perform the relevant activities. We may be unsuccessful in our efforts to internalize some or all relevant activities, either on the desired timeline or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our third-party service providers are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time, attention, expertise and resources to our clinical and nonclinical programs. These third-party service providers may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If our third-party service providers do not successfully carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our preclinical studies or clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates could be harmed, our costs could increase, and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We depend on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We currently in-license certain intellectual property from research institutions, universities and other third parties. We may also enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations on us. If we fail to comply with our obligations to any of our current or future collaborators, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may rely on other third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us. It is possible that the licensors&#8217; infringement proceedings or defense activities may be less vigorous than if we conduct them ourselves. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 11.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 11.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product candidates. Our success depends in part on our ability to secure and maintain patent protection in the United States and other countries with respect to our current product candidates and any future product candidates we may develop. We seek to protect our proprietary position by filing or collaborating with our licensors to file patent applications in the United States and abroad related to our proprietary technologies, development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Moreover, the issuance, scope, validity, enforceability and commercial value of our patent rights are uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">It is also possible that we might fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our proprietary products and technology, including current product candidates, any future product candidates we may develop, and our gene regulation technology in the United States or in other countries, in whole or in part. Alternately, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. For example, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Even if patents do successfully issue and even if such patents cover our current product candidates, any future product candidates we may develop and our gene regulation technology, third parties may challenge their validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any of our product candidates or gene regulation technology. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate and our gene regulation technology under patent protection could be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our current or future product candidates or technology, it could dissuade companies </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our ability to commercialize future product candidates. Any such outcome could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The patent position of biotechnology and pharmaceutical companies is uncertain, involves complex legal and factual questions, and is characterized by the existence of large numbers of patents and frequent litigation based on allegations of patent or other intellectual property infringement or violation. In addition, the laws of jurisdictions outside the United States may not protect our rights to the same extent as the laws of the United States. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our product candidates, prohibit our use of proprietary technology or sale of products or put our patents and other proprietary rights at risk.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and <i style="font-style:italic;">inter partes</i> reviews, and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents, and the holders of any such patents may be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">able to prohibit our use of those compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we obtained a license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, defending such claims would cause us to incur substantial expenses and, if we are not successful in defending such claims, it could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. These damages potentially include increased damages (possibly treble damages) and attorneys&#8217; fees if we are found to have infringed such rights willfully. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. We might also be forced to redesign or modify our product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Competitors may infringe our patents or other intellectual property. If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, the UK, the EU and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, the UK, the EU and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could be filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the UK, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we fail to correctly identify or interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates in a manner that no longer infringes third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Obtaining and enforcing patents in the biotechnology and genetic medicine industries involve both technological complexity and legal complexity. In addition, the Leahy-Smith America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the U.S. patent system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents that may be important for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States, the UK or the EU. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States, the UK and the EU, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put at risk our or our licensors&#8217; patents of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts, or the efforts of our licensors or collaborators, to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 15.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">during product development and the FDA regulatory review process. In the UK and the EU, our product candidates may be eligible for term extensions based on similar legislation. In each of these jurisdictions, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be essentially shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction in revenue from applicable products could be substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others, including inventors or developers of our owned or in-licensed patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or our other collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors may fail to meet obligations to the U.S. government with respect to in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; and</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and confidential know-how are difficult to protect, and we have limited control over the protection of trade secrets and confidential know-how used by our licensors, collaborators and suppliers. Because we have relied in the past on third parties to manufacture our product candidates, because we may continue to do so in the future, and because we expect to collaborate with third parties on the development of our current product candidates and any future product candidates we develop, we may, at times, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Under such circumstances, trade secrets and confidential know-how can be difficult to maintain as confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may also be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Courts outside the United States are sometimes less willing to protect proprietary information, technology and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademark MeiraGTx is the subject of registrations and/or pending applications in the EU, UK and United States. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license or acquire additional intellectual property from third parties, and such intellectual property may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. For example, our programs may involve product candidates or equipment that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compositions and pre-existing pharmaceutical compositions. These pharmaceutical products may be covered by intellectual property rights held by others. We may be required by the FDA, MHRA, EMA or other foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies licensed to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may need to increase or decrease the size of our organization, and we may experience difficulties in managing those organizational changes, which could disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March 31, 2025, we had 372 employees. If we seek to expand our organization, we may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities or strategic opportunities related to our assets, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our potential ability to generate revenue could be reduced and we may not be able to implement our business strategy. Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited. Alternatively, if we seek to decrease the number of employees in our organization in the future in response to adverse business events, it may lead to additional unanticipated attrition. If our future staffing is inadequate because of additional unanticipated attrition or because we failed to retain the staffing level required to accomplish our business objectives, we may be delayed or unable to continue the development of our product candidates, which could impede our ability to generate revenues and achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of Alexandria Forbes, Ph.D., our President and Chief Executive Officer, Rich Giroux, our Chief Operating Officer and Chief Financial Officer and Stuart Naylor, Ph.D., our Chief Development Officer, as well as the other principal members of our management, scientific and clinical teams. Although we have formal employment agreements with certain of our executive officers, these agreements do not prevent them from terminating their employment with us at any time and, for certain of our executive officers, entitle them to receive severance payments in connection with their voluntary resignation of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, we rely on consultants and advisors, including scientific and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.95pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time, costs and diversion of management resources to defend the related litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates, if approved for commercial sale; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, clinical product and clinical trial liability, employment practices liability, property, transit, auto, workers&#8217; compensation, umbrella, cyber and directors&#8217; and officers&#8217; insurance. Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and restrictive, and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for our product candidates or manufacture commercial products for third parties, we intend to acquire insurance coverage to include, as necessary, the sale, manufacture and supply of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Operating as a public company may make it more difficult and more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. If we are unable to maintain existing insurance with adequate levels of coverage, any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Misconduct by our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) applicable laws and regulations of the FDA, MHRA, EMA and other regulatory or governmental authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy and security, fraud and abuse and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations may suffer in the event of system failures and our systems and those of our business partners and service providers may be vulnerable to cybersecurity risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our information technology, or IT, systems, including manufacturing systems, as well as those of our business partners and service providers, are vulnerable to damage from computer viruses, unauthorized access, hardware and software failures, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur, it could result in a material disruption of our product candidate development programs or manufacturing operations. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. A significant interruption to our manufacturing operations could delay the completion of clinical trials and increase the costs of those trials, or impede our ability to meet any third party supply obligations. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the ordinary course of our business, we, our business partners and our service providers collect, process and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees. The secure processing, maintenance and transmission of this information is critical to our operations. Increased cybersecurity threats pose a risk to this information, in addition to our and our business partners&#8217; and service providers&#8217; systems and networks. Cybersecurity threats including state-sponsored attacks, ransomware, phishing, insider threats, supply chain compromises, and vulnerabilities in cloud-based services, are increasing in frequency, sophistication, persistence and severity. Attackers, ranging from criminal organizations to nation-state actors, may target our systems for financial, competitive, or political motives. We may also face increased cybersecurity risks due to our reliance on internet technology and by allowing some of our employees to work remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Despite our security measures, our IT and infrastructure may be vulnerable to cyber-attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions that could have a negative impact, including loss or destruction of data, including confidential or critical business information. In addition, there can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully effective in protecting our systems and information. Although, to our knowledge, we have not experienced any such material security breach to date, we may experience cybersecurity incidents such as malware infections, ransomware, phishing attempts, thefts of personal, confidential, proprietary or other critical business information and other attempts at compromising our IT that are typical for a company of our size in our market. Any security breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, result in significant expenses in implementing future security measures and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and financial results, and delay clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The use or anticipated use of&#160;new and evolving technologies, such as artificial intelligence&#160;(&#8220;AI&#8221;), by us or third parties may increase or create new operational risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We have in the past and will in the future integrate new and evolving technologies, such as AI, into our business.  AI&#160;technologies offer numerous potential benefits, such as creating or increasing operational efficiencies, and we expect an increase in the use of&#160;AI&#160;and generative&#160;AI&#160;by us, third parties on our behalf, and other market actors, including our competitors. However, the deployment of such technologies also poses certain risks, including that the algorithms may be flawed, misused or otherwise function in an unexpected manner; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. In addition, use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations in certain jurisdictions. Governments have passed and may pass additional laws regulating generative AI. The introduction of AI technologies into our operations may potentially result in new or enhanced governmental or regulatory scrutiny, litigation, confidentiality or security risks or other complications. The regulatory landscape governing AI technologies is evolving rapidly, and changes in laws, regulations or enforcement practices may potentially impose new compliance requirements, restrict certain AI applications or increase regulatory obligations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the analyses that&#160;AI-based applications assist in producing are or are perceived to be deficient, inaccurate or biased, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Our competitors may also adopt&#160;AI&#160;or generative&#160;AI&#160;more quickly or more effectively than we do, which could cause </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">competitive harm. Furthermore, use of&#160;AI-based software may lead to the release of confidential information which may impact our ability to realize the benefits of our intellectual property.<span style="font-family:'Aptos';font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The rapid evolution of AI will require the application of significant resources to design, develop, test, oversee and maintain our products and services to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors or partners may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our ordinary shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our share price is likely to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your ordinary shares at or above your purchase price. The market price for our ordinary shares may be influenced by many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or expected changes in our growth rate relative to our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of our product candidates or those of our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments related to our existing or any future collaborations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of new product candidates that may address our markets and make our product candidates less attractive;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any potential strategic transactions related to our assets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or expected changes in estimates as to financial results, development timelines, recommendations by securities analysts or shifting investor perceptions;</span></td><td style="width:3.95pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:52.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Item 1A. Risk Factors&#8221; section and elsewhere in this Form 10-Q.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a security has been volatile, holders of that security have sometimes instituted securities class action litigation against the issuer. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If any of the holders of our ordinary shares were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities. Broad market and industry factors may negatively affect the market price of our ordinary shares, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause the price of our ordinary shares to decline rapidly and unexpectedly. If the market price of our ordinary shares does not exceed your purchase price, you may not realize any return on your investment in us and may lose some or all of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may raise additional capital pursuant to our shelf registration statement, including through our </span><b style="font-weight:bold;">&#8220;</b><span style="font-style:italic;font-weight:bold;">at-the-market&#8221; offering program, or through additional public or private placements, any of which could substantially dilute the investment of our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sales of a substantial number of our ordinary shares in the public market could dilute your ownership interest. Pursuant to an &#8220;at-the-market&#8221; sales agreement we entered into with BofA Securities, Inc., or BofA, in December 2023, we may sell from time to time, ordinary shares having an aggregate offering price of up to $100.0 million through BofA, acting as our agent. During the three month period ended March 31, 2025, the Company raised gross proceeds of $4.5 million through the sale of 563,379 ordinary shares pursuant to an &#8220;at-the-market&#8221; equity offering program.&#160; Whether we choose to affect future sales under the &#8220;at-the-market&#8221; equity offering program will depend on a number of factors, including, among others, market conditions and the trading price of our ordinary shares relative to other sources of capital. The issuance from time to time of ordinary shares through our &#8220;at-the-market&#8221; equity offering program or in any other equity offering, or the perception that such sales may occur, could have the effect of depressing the market price of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our executive officers, directors and principal shareholders, if they choose to act together, have the ability to significantly influence all matters submitted to shareholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March 31, 2025, our executive officers, directors and shareholders who owned more than 5% of our outstanding ordinary shares and their respective affiliates, in the aggregate, hold ordinary shares representing approximately 56.0% of our outstanding ordinary shares. In addition, in connection with entering into the Financing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement, we issued to an affiliate of Perceptive Advisors, LLC, our largest shareholder that employs a director serving on our board, warrants to purchase an aggregate of 700,000 of our ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result, if these shareholders choose to act together, they would be able to significantly influence all matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other shareholders may desire. Any of these actions could adversely affect the market price of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 11.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our ordinary shares less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting ordinary shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting ordinary shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404, and have certain other reduced disclosure obligations, including, among other things, not being required to provide selected financial data, supplemental financial information or risk factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may choose to take advantage of some, but not all, of the available exemptions for smaller reporting companies. We cannot predict whether investors will find our ordinary shares less attractive if we rely on these exemptions. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in our organizational documents and Cayman Islands law may discourage or prevent a change of control, even if an acquisition would be beneficial to our shareholders, which could depress the price of our ordinary shares and prevent attempts by our shareholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our memorandum and articles of association contain provisions that may discourage unsolicited takeover proposals that shareholders may consider to be in their best interests. Our board of directors is divided into three classes with staggered, three-year terms. Our board of directors has the ability to designate the terms of and issue preferred shares without shareholder approval. We are also subject to certain provisions under Cayman Islands law that could delay or prevent a change of control. Together these provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">There may be difficulties in enforcing foreign judgments against our management or us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain of our directors and management reside outside the United States. A significant portion of our assets and such persons&#8217; assets are located outside the United States. As a result, it may be difficult or impossible for investors to effect service of process upon us within the United States or other jurisdictions, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In particular, investors should be aware that there is uncertainty as to whether the courts of the Cayman Islands or any other applicable jurisdictions would recognize and enforce judgments of U.S. courts obtained against us or our directors or management predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States or entertain original actions brought in the Cayman Islands or any other applicable jurisdiction&#8217;s courts against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The rights of our shareholders differ from the rights typically offered to shareholders of a U.S. corporation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our corporate affairs and the rights of holders of ordinary shares are governed by Cayman Islands law, including the provisions of the Cayman Islands Companies Act (as amended), or the Companies Act, the common law of the Cayman Islands and by our memorandum and articles of association. We are also subject to the federal securities laws of the United States. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, the decisions of whose courts are of persuasive authority, but are not binding on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a different body of securities laws as compared to the United States, and certain states, such as Delaware, may have more fully developed and judicially interpreted bodies of corporate law. In addition, Cayman Islands companies may not have standing to initiate a shareholders derivative action in a Federal court of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a United States company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We expect to be treated as resident in the UK for tax purposes, but may be treated as a dual resident company for UK tax purposes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:29.15pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our board of directors conducts our affairs so that the central management and control of the company is exercised in the UK. As a result, we expect to be treated as resident in the UK for UK tax purposes. Accordingly, we expect to be subject to UK taxation on our income and gains, except where an exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">However, we may be treated as a dual resident company for UK tax purposes. As a result, our right to claim certain reliefs from UK tax may be restricted, and changes in law or practice in the UK could result in the imposition of further restrictions on our right to claim UK tax reliefs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 15.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors in our ordinary shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on the current and anticipated value of our assets, including goodwill, and the current and anticipated composition of our income, assets and operations, we do not believe we were a PFIC for the taxable year ended on December 31, 2024, and do not expect to be a PFIC for the current taxable year. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure you that the U.S. Internal Revenue Service, or the IRS, will not take a contrary position. Furthermore, a separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. Accordingly, we cannot assure you that we were not a PFIC for our taxable year ended on December 31, 2024 or that we will not be a PFIC for our current taxable year or any future taxable year. A non-U.S. company will be considered a PFIC for any taxable year if (i) at least 75% of its gross income is passive income (including interest income), or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income. The value of our assets generally is determined by reference to the market price of our ordinary shares, which may fluctuate considerably. In addition, the composition of our income and assets is affected by how, and how quickly, we spend any cash we raise. If we were to be classified as a PFIC for any taxable year during which a U.S. holder holds our ordinary shares, certain materially adverse U.S. federal income tax consequences could apply to such U.S. holder. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If a U.S. holder of our ordinary shares is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares, such U.S. holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any). If our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as controlled foreign corporations (regardless of whether we are treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations from starting with respect to your U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries is treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we will furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. holders of our ordinary shares should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or challenges to our tax position could adversely affect our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to complex tax laws that are subject to change or differing interpretations, including on a retroactive basis. Any such changes in tax laws, regulations and treaties, or the interpretation thereof, tax policy initiatives and reforms under consideration and the practices of tax authorities in jurisdictions in which we operate could adversely affect our tax position, including our effective tax rate or tax payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.95pt 0pt 3pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have significant U.S. federal and state net operating losses, or NOLs, and UK and Ireland carryforward tax losses which we may not be able to realize or which may be restricted under applicable law. We also benefit from certain tax incentive regimes, such as research and development tax credits. Any adverse change to these regimes, the application thereof or challenges to the tax position we have adopted under these rules could adversely affect our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2024, we had federal and state NOL carryforwards in the United States of $74.3 million and $19.3 million, respectively, and cumulative carryforward tax losses in the UK of $203.7 million, which we expect to be available to reduce future taxable income subject to any relevant restrictions (including those in the U.S. and UK that limit the percentage of taxable income that can be reduced by NOLs and carried forward losses). As of December 31, 2024, cumulative carryforward tax losses in Ireland were $78.3 million. U.S. federal NOLs generated after December 31, 2017 are not subject to expiration but such NOLs may only offset 80% of taxable income for taxable years beginning after December 31, 2020. U.S. federal NOLs generated prior to December 31, 2017 may only be carried forward for 20 years. As of December 31, 2024, we also had orphan drug and research and development credits in the U.S. in the amount of $22.5 million, both of which may be carried forward for 20 years and are expected to begin expiring in 2035 if not utilized. We also had research and development credits in the UK of $1.9 million, which may be carried forward indefinitely until utilized. The UK and Ireland carryforward tax losses will continue indefinitely, subject to relevant restrictions, under current jurisdictional tax law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The NOLs and carryforward tax losses are subject to review and possible adjustment by the applicable tax authorities. Additionally, carryforward tax losses, and research and development tax credits, may become subject to limitations in the event of certain cumulative changes in the ownership interest of significant shareholders, as determined under Sections 382 of the United States Internal Revenue Code, as well as the Corporation Tax Act 2010 Part 14 under the UK tax rules and the Taxes Consolidation Act 1997 (TCA 1997) under the Ireland tax rules. This could limit the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk192592964"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">amount of NOLs or carryforward tax losses that we can utilize annually to offset future taxable income or tax liabilities. We have conducted a review of changes in the ownership interest of significant shareholders and determined that as of August 2024, there were no limitations in the UK. However, for U.S. purposes, we determined that a change of ownership occurred in April 2016 and again in June 2018, but there was not a limit for utilizing these losses to offset the 2022 income. We have performed a 382 analysis through August 2024 and no additional change of ownership has occurred. Subsequent ownership changes and changes to the U.S. federal or state or UK tax rules in respect of the utilization of NOLs and carryforward tax losses may further affect the limitation in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may engage in acquisitions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have, and may in the future, enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our ordinary shares or other equity securities to the shareholders of the acquired company, which would reduce the percentage ownership of our existing shareholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Exchange rate fluctuations may adversely affect our results of operations and financial condition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 33.1pt 0pt 2.9pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Owing to the international scope of our operations, fluctuations in exchange rates may adversely affect us, particularly between the U.S. dollar on the one hand, and the pound sterling and euro on the other hand. As a result, our business and the market price of our securities may be affected by such fluctuations, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our management team has broad discretion as to the use of the net proceeds from public and private equity or debt financings and the investment of these proceeds may not yield a favorable return. We may invest the proceeds in ways with which our shareholders disagree. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We have broad discretion in the application of any net proceeds we have received in the past or may receive in the future pursuant to existing or future equity and debt financings, including under our &#8220;at-the-market&#8221; equity offering program. Shareholders may not agree with our decisions, and our use of the proceeds and our existing cash and cash equivalents may not improve our results of operation or enhance the value of our ordinary shares. Our ability to apply certain proceeds may be restricted.  For example, in August 2024, we conducted an equity financing by selling an aggregate of 12.75 million ordinary shares at a price of $4.00 per share for gross proceeds of $51.0 million. Our failure to apply any such funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the market price of our ordinary shares to decline. In addition, until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value. Additionally, our existing cash and cash equivalents are subject to general credit, liquidity, market and interest rate risks, which have been and may, in the future, be exacerbated by a U.S. and/or global financial crises. We may realize losses in the fair value of certain of our investments or a complete loss of these investments if the credit markets tighten, which would have an adverse effect on our results of operations, liquidity and financial condition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We incur substantial costs as a result of operating as a public company, and our management is required to devote substantial time to new and existing compliance initiatives and corporate governance practices. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33pt;margin:0pt 32.95pt 0pt 3pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a public company, and particularly since we no longer qualify as an emerging growth company and if we no longer qualify as a smaller reporting company or a non-accelerated filer in the future, we incur and will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, The Nasdaq Global Select listing requirements and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33pt;margin:0pt 3.8pt 0pt 3pt;"><span style="font-size:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we are a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404, we engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we, or our independent registered public accounting firm, if we no longer qualify as a non-accelerated filer, will not be able to conclude that our internal control over financial reporting is effective as required by Section 404. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. If we identify one or more material weaknesses or determine we have inadequate internal controls, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts cease to publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our ordinary shares, our share price and trading volume could decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The trading market for our ordinary shares relies in part on the research and reports that industry or securities analysts publish about us or our business. We do not control these analysts. Furthermore, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our share performance, or if any of our preclinical studies or clinical trials and operating results fail to meet the expectations of analysts, our share price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Expectations relating to environmental, social and governance factors may impose additional costs and expose us to new risks. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is an increasing focus from the SEC, foreign regulators, stock exchanges, certain investors and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance factors. The SEC has adopted rules regarding new climate-related disclosure, which have been stayed by the SEC pending the outcome of pending litigation challenging the new rules. Some investors may use these and other environmental, social and governance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and disclosures relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have varied and in some cases inconsistent standards. In addition, the criteria by which companies&#8217; corporate responsibility practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we elect not to or are unable to satisfy such new criteria or do not meet the criteria of a specific third-party provider, some investors may conclude that our policies with respect to corporate responsibility are insufficient. We may face </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. Furthermore, if our competitors&#8217; corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate or disclose certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals or be subject to litigation for such failures. If we fail to satisfy the expectations of investors and other stakeholders or our initiatives are not executed as planned, our reputation and financial results could be adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 32.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Under Cayman Islands law, we may only make distributions by way of dividend out of profits, or out of our share premium account (provided that immediately following the date that the dividend is proposed to be paid we are able to pay our debts as they fall due in the ordinary course of business). We have never declared or paid any cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the Notes Purchase Agreement prohibits us from paying dividends during its term and the terms of existing and future financing agreements may also preclude us from paying dividends.  As a result, capital appreciation, if any, of our ordinary shares would be your sole source of gain on an investment in our ordinary shares for the foreseeable future. See the &#8220;Dividend Policy&#8221; section of our Form 10-K for the year ended December 31, 2024 previously filed with the SEC for additional information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c82f9ed3_8d7a_433c_868f_562ee1249d8d"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c59cb195_dc27_4391_b096_89d8d3785f12"></a><a id="Item3DefaultsUponSeniorSecurities_54116"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Defaults Upon Senior Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_9f167e5d_a95c_4df8_857b_3b1770273fc1"></a><a id="Item4MineSafetyDisclosures_51301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_d62fe75a_7ac6_47bc_a88a_9e8ae56e3b95"></a><a id="Item5OtherInformation_145683"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Other Information.</p><a id="_Hlk47110732"></a><a id="_Hlk47110096"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">During the three months ended March 31, 2025,&#160;</span>none<span style="background:#ffffff;">&#160;of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act)&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_iNHiZvSbukW_9mu5iWfpBw">adopted</ix:nonNumeric><span style="background:#ffffff;">,&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="mgtx:Rule10b51ArrangementModifiedFlag" id="Narr_d8dOKR02gU-fSeNP4CKVnQ"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_6G_CVr8RdE-jC91-_9KU5w">modified</ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;">&#160;or&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="mgtx:NonRule10b51ArrangementModifiedFlag" id="Narr_g2QRJaX_8EqM5qJYhK1l9A"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_RsJiBHrls0mQNEMWPTTZlw">terminated</ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;">&#160;a &#8220;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_UHGwOc1iDUObWH1bnrKFfA"><span style="background:#ffffff;">Rule 10b5-1</span></ix:nonNumeric><span style="background:#ffffff;"> trading arrangement&#8221; and/or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2d506d82_a7a4_4ee6_bcad_6297a7aad60d"></a><a id="Item6Exhibits_373262"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;6. Exhibits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:40.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:5.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b><br/><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:11.53%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/Furnished</b><br/><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mgtx-20250331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated March 31, 2025, between MeiraGTx, LLC and ARE-East River Science Park, LLC.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mgtx-20250331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mgtx-20250331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mgtx-20250331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">**</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mgtx-20250331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">**</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.93%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Cover Page Interactive Data File (Formatted in Inline XBRL and contained in exhibit 101)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.45%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.63%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.53%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">**&#160;&#160;&#160;Furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">&#8224; &#160; &#160; Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8df93405_1c2b_4eee_9b35_0e7d603796fc"></a><a id="SIGNATURES_71538"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MeiraGTx Holdings plc (Registrant)</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2025</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Alexandria Forbes</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Alexandria Forbes</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">principal executive officer and authorized signatory</i>)</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Date: May 13, 2025</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Richard Giroux</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Richard Giroux</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer and Chief Operating Officer</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">principal financial officer and principal accounting officer</i>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mgtx-20250331xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/13/2025 11:46:21 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Execution Version</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THIS LEASE AGREEMENT is made as of this 31st day of March, 2025, between <b style="font-weight:bold;">ARE-EAST RIVER SCIENCE PARK, LLC</b>, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and <b style="font-weight:bold;">MEIRAGTX, LLC</b>, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BASIC LEASE PROVISIONS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Address:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">450 East 29<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Street, New York, New York, 10016.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Premises:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">That portion of the Project, containing approximately 14,235 rentable square feet (as determined by Landlord and accepted for all purposes by Tenant), located within Suites 400, 401, 402, and 403 in the approximately 309,035 rentable square foot East Tower (the &#8220;<b style="font-weight:bold;">Building</b>&#8221;) of The Alexandria Center for Life Science - New York City (collectively, together with the underlying land, related site improvements and the immediately adjacent West Tower, the &#8220;<b style="font-weight:bold;">Project</b>&#8221;), as shown on <b style="font-weight:bold;">Exhibit A-1</b> and<b style="font-weight:bold;"> Exhibit A-2</b>, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(b)</u> hereof.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Shared Lab Area:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">That portion of the Building on the fourth (4<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) floor, as shown on<b style="font-weight:bold;"> Exhibit N</b>.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Project</b>:</p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Alexandria Center for Life Science &#8211; New York City, including the Land, all buildings (including the Building) and other improvements located (or to be located) thereon and appurtenances thereto.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Base Rent:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">One Million Five Hundred Eighty Thousand Eighty-Five and 00/100 Dollars ($1,580,085.00) per annum, payable as One Hundred Thirty-One Thousand Six Hundred Seventy-Three and 75/100 ($131,673.75) per month, based on One Hundred Eleven and 00/100 Dollars ($111.00) per rentable square foot of the Premises per annum, payable in equal monthly installments in advance, subject to escalation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u> (&#8220;<b style="font-weight:bold;">Base Rent</b>&#8221;).</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Building&#8217;s Share:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The proportionate share of the Project attributed to the Building is forty-two and forty-seven hundredths percent (42.47%).</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Land:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">That certain real property more particularly described on <b style="font-weight:bold;">Exhibit B</b>.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tenant&#8217;s Share:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tenant&#8217;s Share (SLA):</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Target Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">On or prior to August 1, 2025.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rent Adjustment Percentage:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">Three percent (3.0%)</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Base Term:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and ending ninety-one (91) months from the first day of the first full calendar month of the Term (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u>) hereof.</p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Permitted Use:</b></p></td><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development laboratory, related office and other related uses consistent with the character of the Project and otherwise in compliance with the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> hereof.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Address for Rent Payment via Regular Mail:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Address for Rent Payment via Overnight Courier:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Wire/ACH Payment Information</b>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:96pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Bank Name:</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></font> [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:96pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Bank Address:</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></font> [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:96pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Account Name:</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></font> [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Account Number:</b> <font style="display:inline-block;width:16.57pt;"></font> [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wire</b><b style="font-weight:bold;"> ABA Number:</b> <font style="display:inline-block;width:6.85pt;"></font> [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ACH</b><b style="font-weight:bold;"> ABA Number:</b> <font style="display:inline-block;width:6.28pt;"></font> [***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tenant&#8217;s Notice Address:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Landlord&#8217;s Notice Address:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior to Tenant&#8217;s Occupancy</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upon Tenant&#8217;s Occupancy</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following Exhibits and Addenda are attached hereto and incorporated herein by this reference:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT A</b> &#8211; PREMISES DESCRIPTION</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT B</b> &#8211; DESCRIPTION OF PROJECT</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT C</b> &#8211; <font style="text-transform:uppercase;">LANDLORD&#8217;S WORK</font></p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT D</b> &#8211;- ACKNOWLEDGEMENT OF COMMENCEMENT DATE</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT E</b> &#8211; RULES AND REGULATIONS</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT F</b> &#8211; TENANT&#8217;S PERSONAL PROPERTY</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT G</b> &#8211; INTENTIONALLY OMITTED</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT H</b> &#8211; INTENTIONALLY OMITTED</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT I</b> &#8211; SHARED LAB SYSTEMS</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT J</b> &#8211; ADDITIONAL INSUREDS</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT K</b> &#8211; INTENTIONALLY OMITTED</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT L</b> &#8211; OPEN SPACE DESCRIPTION</p></td></tr><tr><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT M</b> &#8211; SUPERIOR INSTRUMENT EXCERPTS</p></td><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Segoe UI Symbol';">&#9746;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><font style="font-family:'Segoe UI Symbol';">&#160;</font><b style="font-weight:bold;">EXHIBIT N</b> &#8211; SHARED LAB AREA</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><b style="font-weight:bold;">Lease of Premises.</b> &#160;Upon and subject to all of the terms and conditions hereof, Landlord hereby leases the Premises to Tenant and Tenant hereby leases the Premises from Landlord. Tenant shall have a license, on a non-exclusive basis in common with other tenants and users of the Project, to use all of the Building&#8217;s public hallways, lobbies, fitness center, corridors and passages and the Building&#8217;s public stairways as &#8220;Common Areas&#8221; from time to time, in accordance with the Rules and Regulations applicable thereto and all Legal Requirements; but &#8220;Common Areas&#8221; shall not include any area within the Premises or any other leased or leasable area of the Project, and such access and use shall be subject to the terms of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Superior Instruments (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27</u>). Landlord reserves the right to modify, from time to time, the Project, the Building, the Open Space and the Common Areas, provided that such modifications do not materially adversely affect Tenant&#8217;s use of the Premises for the Permitted Use. No vault or cellar is leased hereunder, anything to the contrary indicated elsewhere in this Lease notwithstanding. As used herein, the term &#8220;<b style="font-weight:bold;">Open Space</b>&#8221; shall mean the portion of the Project that will be subject to a permanent and perpetual public use and access easement, of a location and size substantially as shown on <b style="font-weight:bold;">Exhibit L</b>, or otherwise in accordance with the Declaration (Corrective) dated December 29, 2006 by ARE &#8211; East River Science Park, LLC, recorded February 20, 2007 at CRFN 2007000094401, as the same may be modified from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><b style="font-weight:bold;">Delivery; Landlord&#8217;s Work; Acceptance of Premises; Commencement Date</b>. &#160;Landlord shall [***] deliver the Premises to Tenant on or before the Target Commencement Date, with Landlord&#8217;s Work, if any, Substantially Completed (as defined in the Work Letter) (&#8220;<b style="font-weight:bold;">Delivery</b>&#8221; or &#8220;<b style="font-weight:bold;">Deliver</b>&#8221;); provided that in no event shall Delivery occur prior to July 1, 2025. [***] &#8220;<b style="font-weight:bold;">Landlord&#8217;s Work</b>&#8221; shall mean the completion of the core and shell of the building, the items listed on Exhibit C attached hereto [***], and the items listed on, and governed by the terms and conditions of, the work letter attached hereto as Exhibit C-1 (the &#8220;<b style="font-weight:bold;">Work Letter</b>&#8221;) and completion of the Shared Lab Area and installation of the Shared Lab Systems (as hereinafter defined) in substantial conformance with the Exhibits to this Lease. Tenant shall be solely responsible for ensuring that the Shared Lab Area, the Building and tenant improvement designs and specifications are consistent with Tenant&#8217;s requirements. Tenant shall solely be responsible for all costs incurred by Landlord to alter the Building as a result of Tenant&#8217;s requested changes, if any, which changes shall be subject to approval by Landlord in its sole discretion. Landlord shall have no obligation to, and shall not, secure any permits, approvals or entitlements related to Tenant&#8217;s specific use of the Premises or Tenant&#8217;s business operations therein. Except as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u>, Landlord shall have no obligation to perform any work at the Project in connection with preparing the Premises for, or accommodating, Tenant&#8217;s occupancy. If Landlord fails to timely Deliver the Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Lease shall not be void or voidable, provided that [***]. Tenant expressly waives any right to rescind this Lease under Section 223-a of the New York Real Property Law or under any present or future statute of similar import then in force and further expressly waives the right to recover any damages, direct or indirect, which may result from Landlord&#8217;s failure to deliver possession of the Premises by the Target Commencement Date or to grant access to certain portions of the Premises prior to the Target Commencement Date as permitted hereunder. Tenant agrees that the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u> are intended to constitute &#8220;an express provision to the contrary&#8221; within the meaning of said Section 223-a.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The &#8220;<b style="font-weight:bold;">Commencement Date</b>&#8221; shall be the earliest of: (i) the date Landlord Delivers the Premises to Tenant; (ii) the date Landlord could have Delivered the Premises but for Tenant Delays (as defined in the Work Letter) and Force Majeure; and (iii) the date Tenant conducts any business in the Premises or any part thereof, provided that, notwithstanding the foregoing, in no event shall the Commencement Date occur prior to July 1, 2025. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement Date and the expiration date of the Term when such are established in the form of the &#8220;Acknowledgement of Commencement Date&#8221; attached to this Lease as <b style="font-weight:bold;">Exhibit D</b>; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, Tenant&#8217;s failure to execute and deliver such acknowledgment shall not affect Landlord&#8217;s rights hereunder. The &#8220;<b style="font-weight:bold;">Term</b>&#8221; of this Lease shall be the Base Term, as defined above in the Basic Lease Provisions and any Extension Terms which Tenant may elect pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 49</u> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Exhibit A-1 </b>depicts the Premises as of the date hereof. [***]. Other than Landlord&#8217;s Work [***], Landlord shall have no obligation for any defects in the Premises, to perform any work or make any installations in order to prepare the Premises for Tenant&#8217;s occupancy. Tenant&#8217;s taking possession of the Premises shall be conclusive evidence that Tenant accepts the Premises and that the Premises were in good condition at the time possession was taken. Any occupancy of the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, including the obligation to pay Rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the Premises, the Building or the Project, and/or the suitability of the Premises, the Building or the Project for the conduct of Tenant&#8217;s business, and Tenant waives any implied warranty that the Premises, the Building or the Project are suitable for the Permitted Use. No rights, easements or licenses are acquired by Tenant by implication or otherwise except as expressly set forth in this Lease. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior representations, inducements, promises, agreements, understandings and negotiations which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant&#8217;s representations, warranties, acknowledgments and agreements contained herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><b style="font-weight:bold;">Rent</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Base Rent</b>. &#160;The first month&#8217;s Base Rent shall be due and payable [***] delivery of an executed copy of this Lease to Landlord. Thereafter, Tenant shall pay to Landlord in advance, without demand, abatement, deduction or set-off, monthly installments of Base Rent on or before the first day of each calendar month during the Term hereof, in lawful money of the United States of America, at the office of Landlord for payment of Rent set forth above, or to such other person or at such other place as Landlord may from time to time designate in writing [***] subject to the Base Rent Abatement (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(b))</u>, if applicable. Payments of Base Rent for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent obligations. Tenant shall have no right at any time to abate, reduce, or set-off any Rent (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u>) due hereunder except for any abatement as may be expressly provided in this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Additional Rent. &#160;</b>In addition to Base Rent, Tenant agrees to pay to Landlord as additional rent (&#8220;<b style="font-weight:bold;">Additional Rent</b>&#8221;): [***]. Base Rent and Additional Rent are collectively referred to herein as &#8220;<b style="font-weight:bold;">Rent</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><b style="font-weight:bold;">Base Rent Adjustments</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Base Rent shall be increased on each annual anniversary of the first day of the first full month during the Term of this Lease (each an &#8220;<b style="font-weight:bold;">Adjustment Date</b>&#8221;) by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately before such Adjustment Date. Base Rent, as so adjusted, shall thereafter be due as provided herein. Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</u>, the foregoing annual adjustment in the Base Rent as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(a)</u> shall be based on the full and unabated amount of Base Rent payable for the first twelve (12) month period from and after the Commencement Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Notwithstanding anything to the contrary contained in this Lease, but provided Tenant is not in Default hereunder, Landlord hereby grants Tenant an abatement of the Base Rent payable during (i) the period beginning on the Commencement Date and ending four (4) months after the Commencement Date (the &#8220;<b style="font-weight:bold;">Initial Base Rent Abatement</b>&#8221;) and (ii) the period beginning on the first anniversary of the Commencement Date and ending three (3) months after the first anniversary of the Commencement Date (collectively, the &#8220;<b style="font-weight:bold;">Base Rent Abatement</b>&#8221;). For the avoidance of doubt, if the Commencement Date occurs on the first day of a month, the Initial Base Rent Abatement will be measured from that date. If the Commencement Date occurs on a day other than the first day of a month, the Initial Base Rent Abatement will be measured from the first day of the following month. [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><b style="font-weight:bold;">Operating Expense Payments</b>. &#160;Landlord shall deliver to Tenant a written estimate of Operating Expenses for each calendar year during the Term (the &#8220;<b style="font-weight:bold;">Annual Estimate</b>&#8221;), which may be revised by Landlord from time to time during such calendar year. During each month of the Term, on the same date that Base Rent is due, Tenant shall pay Landlord an amount equal to 1/12<sup style="font-size:7.5pt;vertical-align:top;">th</sup> of Tenant&#8217;s Share of the Annual Estimate. Payments for any fractional calendar month shall be prorated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The term &#8220;<b style="font-weight:bold;">Operating Expenses</b>&#8221; means, [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Within one hundred twenty (120) days after the end of each calendar year (or such longer period as may be reasonably required), Landlord shall furnish to Tenant a statement (an &#8220;<b style="font-weight:bold;">Annual Statement</b>&#8221;) showing in reasonable detail: (a) the total and Tenant&#8217;s Share of actual Operating Expenses for the previous calendar year, and (b) the total of Tenant&#8217;s payments in respect of Tenant&#8217;s Share of Operating Expenses for such year. If Tenant&#8217;s Share of actual Operating Expenses for such year exceeds Tenant&#8217;s payments of Tenant&#8217;s Share of Operating Expenses for such year, then the excess shall be due and payable by Tenant as Rent within thirty (30) days after delivery of such Annual Statement to Tenant. If Tenant&#8217;s payments of Operating Expenses for such year exceed Tenant&#8217;s Share of actual Operating Expenses for such year, then Landlord shall pay the excess to Tenant within 30 days after delivery of such Annual Statement, except that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Each Annual Statement shall be final and binding upon Tenant unless Tenant, within [***] after Tenant&#8217;s receipt thereof, shall contest any item therein by giving written notice to Landlord, specifying each item contested and the reason therefor. If, during such [***], Tenant reasonably and in good faith questions or contests the accuracy of Landlord&#8217;s statement of Tenant&#8217;s Share of Operating Expenses, Landlord will provide access to Landlord&#8217;s books and records relating to the operation of the Project and such information as Landlord reasonably determines to be responsive to Tenant&#8217;s questions (the &#8220;<b style="font-weight:bold;">Expense Information</b>&#8221;). If after Tenant&#8217;s review of such Expense Information, Landlord and Tenant cannot agree upon the amount of Tenant&#8217;s Share of Operating Expenses, then Tenant shall have the right to have an independent public accounting firm selected by Tenant from among the four (4) largest in the United States, working pursuant to a fee arrangement other than a contingent fee (at Tenant&#8217;s sole cost and expense) and approved by Landlord (which approval shall not be unreasonably withheld or delayed), audit and/or review the Expense Information for the year in question (the &#8220;<b style="font-weight:bold;">Independent Review</b>&#8221;). The results of any such Independent Review shall be binding on Landlord and Tenant. If the Independent Review shows that the payments actually made by Tenant with respect to Operating Expenses for the calendar year in question exceeded Tenant&#8217;s Share of Operating Expenses for such calendar year, Landlord shall at Landlord&#8217;s option either (i) credit the excess amount to the next succeeding installments of estimated Operating Expenses or (ii) pay the excess to Tenant within thirty (30) days after delivery of such statement, except that after the expiration or earlier termination of this Lease or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. If the Independent Review shows that Tenant&#8217;s payments with respect to Operating Expenses for such calendar year were less than Tenant&#8217;s Share of Operating Expenses for the calendar year, Tenant shall pay the deficiency to Landlord within thirty (30) days after delivery of such statement. If the Independent Review shows that Tenant has overpaid with respect to Operating Expenses by more than five percent (5%) then Landlord shall reimburse Tenant for the out of pocket accounting costs actually incurred by Tenant for the Independent Review Operating Expenses for the calendar years in which Tenant&#8217;s obligation to share therein begins and ends shall be prorated. Notwithstanding anything set forth herein to the contrary, if the Building is not at least ninety-five percent (95%) occupied on average during any year of the Term, Tenant&#8217;s Share of Operating Expenses for such year shall be computed as though the Building had been ninety-five percent (95%) occupied on average during such year. <b style="font-weight:bold;">&#8220;Tenant&#8217;s Share</b>&#8221; shall be the percentage set forth in the Basic Lease Provisions as Tenant&#8217;s Share as reasonably adjusted by Landlord. Landlord may equitably increase Tenant&#8217;s Share (or Tenant&#8217;s Share of Operating Expenses, as the case may be) for any item of expense or cost reimbursable by Tenant that relates to a repair, replacement, or service that benefits only the Premises or only a portion of the Project that includes the Premises or that varies with Tenant&#8217;s occupancy or use of the Premises. Base Rent, Additional Rent (including Tenant&#8217;s Share of Operating Expenses) and other amounts payable by Tenant to Landlord hereunder are collectively referred to herein as &#8220;<b style="font-weight:bold;">Rent</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><b style="font-weight:bold;">Intentionally Omitted</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-weight:bold;">Use</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant shall have twenty-four (24) hours per day, seven (7) days per week access to its Premises, the Building and the parking area, subject to restricted access due to Force Majeure, necessary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for repairs or emergency conditions, or arising due to Legal Requirements. Tenant shall use the Premises solely for the Permitted Use set forth in the Basic Lease Provisions, and in compliance with all present and future laws, orders, judgments, ordinances, regulations, codes, directives, permits, licenses, covenants and restrictions of all state, federal, municipal and local governments, departments, commissions and boards and any direction of any public officer pursuant to law, and all orders, rules and regulations of the New York Board of Fire Underwriters, Insurance Services Office, or any similar body, in each case, applicable to the Premises and the use and occupancy thereof, including, without limitation, the Americans With Disabilities Act, 42 U.S.C. &#167; 12101, et seq. (together with the regulations promulgated pursuant thereto, &#8220;<b style="font-weight:bold;">ADA</b>&#8221;) (collectively, &#8220;<b style="font-weight:bold;">Legal Requirements</b>&#8221; and each, a &#8220;<b style="font-weight:bold;">Legal Requirement</b>&#8221;). Tenant shall not occupy, use or operate the Premises, or allow the Premises or any part thereof to be occupied, used or operated for any unlawful purpose or in violation of any certificate of occupancy affecting the Building and/or the Project or for any use that may constitute a nuisance, public or private. Tenant shall not permit any part of the Premises to be used as a &#8220;place of public accommodation&#8221;, as defined in the ADA or any similar legal requirement. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit waste, overload the floor or structure of the Premises, subject the Premises to any use that would damage the Premises or obstruct or interfere with the rights of Landlord or other tenants or occupants of the Project, including, without limitation, conducting or giving notice of any auction, liquidation, or going out of business sale on the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Subject to the terms hereof, immediately following Tenant&#8217;s discovery of any violation or breach of any Legal Requirement in the Premises, or by Tenant in the Common Areas, or under this Lease or any Superior Instrument, Tenant shall take all reasonably necessary steps, legal and equitable, to effect or compel the cure of such violation or breach, including, if necessary, the payment of any associated taxes, fines, charges, assessments or fees, and the removal from the Premises of any subtenants or licensees using a portion of the Premises. Notwithstanding the foregoing, if any Tax, fee, charge or assessment is levied against Landlord or Landlord&#8217;s property that is attributable to Tenant&#8217;s failure to comply with any Legal Requirement, then Landlord shall have the right, but not the obligation, to pay such Tax, fee, charge or assessment. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant will not use or permit the Premises to be used for any purpose or in any manner that is prohibited under the Ground Lease (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27</u>) or that would void Tenant&#8217;s, Landlord&#8217;s or the Condominium Board&#8217;s insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant shall reimburse Landlord or the Condominium Board, as applicable, [***] following demand for any additional premium charged for any such insurance policy by reason of Tenant&#8217;s failure to comply with the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> or otherwise caused by Tenant&#8217;s particular manner of use and/or occupancy of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent odors, sounds or vibrations from the Premises from extending into Common Areas, or other space in the Project. Tenant shall not place any machinery or equipment weighing five hundred (500) pounds or more in or upon the Premises or transport or move such items through the Common Areas of the Project or in the Project elevators without the prior written consent of Landlord. Landlord reserves the right to prescribe the weight and position of all safes, files, paper and book storage facilities, business machines and other heavy equipment and installations located within the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Tenant shall not, without the prior written consent of Landlord, use the Premises in any manner which will require ventilation, air exchange, heating, gas, steam, electricity or water beyond the existing capacity of the Project as proportionately allocated to the Premises based upon Tenant&#8217;s Share as usually furnished for the Permitted Use, nor shall Tenant use the Premises in a manner that results in transmissions from the Premises at a frequency which interferes with any other tenant&#8217;s use of any portion of the Building or the Project other than the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Tenant shall not use the Premises or any part thereof, or permit the Premises or any part thereof to be used for the preparation, dispensing, consumption or sale of food or beverages in any manner whatsoever, whether for &#8220;on&#8221; or &#8220;off&#8221; premises consumption (other than the consumption of food by employees and invitees of Tenant).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Landlord shall, as an Operating Expense (to the extent such Legal Requirement is generally applicable to similar buildings in the area in which the Project is located) or at Tenant&#8217;s expense (to the extent such Legal Requirement is applicable solely by reason of Tenant&#8217;s, as compared to other tenants of the Project, particular use of the Premises) make any alterations or modifications to the Common Areas or the exterior of the Building that are required by Legal Requirements, including the ADA. Tenant, at its sole expense, shall make any alterations or modifications to the interior of the Premises that are required by Legal Requirements (including, without limitation, compliance of the Premises with the ADA). Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses incurred in investigating or resisting the same (including, without limitation, reasonable attorneys&#8217; fees, charges and disbursements and costs of suit) (collectively, &#8220;<b style="font-weight:bold;">Claims</b>&#8221;) arising out of or in connection with Legal Requirements, and Tenant shall indemnify, defend, hold and save Landlord harmless from and against any and all Claims arising out of or in connection with any failure of the Premises to comply with any Legal Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><b style="font-weight:bold;">Holding Over</b>. &#160;If, with Landlord&#8217;s express written consent, Tenant retains possession of the Premises after the expiration or earlier termination of the Term, (i) unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord at any time, or shall become a tenant at sufferance upon the terms described hereinbelow, (ii) all of the other terms and provisions of this Lease (including, without limitation, the adjustment of Base Rent pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u> hereof) shall remain in full force and effect (excluding any expansion or renewal option or other similar right or option) during such holdover period, (iii) Tenant shall continue to pay Base Rent in the amount payable upon the date of the expiration or earlier termination of this Lease or such other amount as Landlord may indicate, in Landlord&#8217;s sole and absolute discretion, in such written consent, and (iv) all other payments shall continue under the terms of this Lease. The parties recognize and agree that the damage to Landlord resulting from any failure by Tenant to timely surrender possession of the Premises as aforesaid will be extremely substantial, will exceed the amount of the monthly installments of the Base Rent and Rental theretofore payable hereunder, and will be impossible to accurately measure. Tenant therefore agrees that if Tenant remains in possession of the Premises after the expiration or earlier termination of the Term without the express written consent of Landlord, then, in addition to any other rights or remedies Landlord may have hereunder or at law, and without in any manner limiting Landlord&#8217;s right to demonstrate and collect any damages suffered by Landlord and arising from Tenant&#8217;s failure to surrender the Premises as provided herein, (A) Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly rental shall be [***], and (B) to the extent Tenant holds over for more than [***], then Tenant shall be responsible for all damages suffered by Landlord resulting from or occasioned by Tenant&#8217;s holding over, including consequential damages. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly provided, and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall not be construed as consent for Tenant to retain possession of the Premises. Acceptance by Landlord of Rent after the expiration of the Term or earlier termination of this Lease shall not result in a renewal or reinstatement of this Lease. The acceptance by Landlord of any such use and occupancy payment by Tenant pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall in no event preclude Landlord from commencing and prosecuting a holdover or summary eviction proceeding, and the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall be deemed to be an &#8220;agreement expressly providing otherwise&#8221; within the meaning of Section 232-c of the Real Property Law of the State of New York and any successor or similar law of like import. Nothing contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall (i) imply any right of Tenant to remain in the Premises after the expiration of the Term without the execution of a new lease, (ii) imply any obligation of Landlord to grant a new lease or (iii) be construed to limit any right or remedy that Landlord has against Tenant as a holdover tenant or trespasser and no acceptance by Landlord of payments from Tenant after the Expiration Date shall be deemed to be other than on account of the amount to be paid by Tenant in accordance with the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u>. The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall survive the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><b style="font-weight:bold;">Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Landlord shall pay, as part of Operating Expenses, all taxes, levies, fees, assessments and governmental charges of any kind, existing as of the Commencement Date or thereafter enacted (collectively referred to as &#8220;<b style="font-weight:bold;">Taxes</b>&#8221;), imposed by any federal, state, regional, municipal, local or other governmental authority or agency, including, without limitation, quasi-public agencies (collectively, &#8220;<b style="font-weight:bold;">Governmental Authority</b>&#8221;) during the Term, including, without limitation, all Taxes: (i) imposed on or measured by or based, in whole or in part, on rent payable to (or gross receipts received by) Landlord under this Lease and/or from the rental by Landlord of the Project or any portion thereof, or (ii) based on the square footage, assessed value or other measure or evaluation of any kind of the Premises or the Project, or (iii) assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Project, including parking, or (iv) assessed or imposed by, or at the direction of, or resulting from Legal Requirements, or interpretations thereof, promulgated by any Governmental Authority, or (v) imposed as a license or other fee, charge, tax, or assessment on Landlord&#8217;s business or occupation of leasing space in the Project, or (vi) any taxes or assessments levied after the date of this Lease in whole or in part for public benefits to the Project, including without limitation any Business Improvement District (&#8220;BID&#8221;) tax increment financing (&#8220;<b style="font-weight:bold;">TIF</b>&#8221;) or Commercial Rent Occupancy Tax (&#8220;<b style="font-weight:bold;">CROT</b>&#8221;) taxes and assessments payable by Landlord and any and all other governmental and quasi-governmental assessments without taking into account any discount that Landlord may receive by virtue of any early payment of Taxes. Landlord may contest by appropriate legal proceedings the amount, validity, or application of any Taxes or liens securing Taxes. Taxes shall include all payments in lieu of taxes (&#8220;PILOT&#8221;) and other impositions and costs for which Landlord is responsible under any Superior Lease (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27</u>) including without limitation under Articles 3 and 4 of the Ground Lease. Taxes shall not take into account any exemption which Landlord is entitled to under any governmental incentive program for investment and/or employment creation where Landlord is the induced party including without limitation the Industrial and Commercial Incentive Program (&#8220;<b style="font-weight:bold;">ICIP</b>&#8221;), the Industrial and Commercial Abatement Program (&#8220;<b style="font-weight:bold;">ICAP</b>&#8221;), or Ground Lease or any other governmental incentive program. Taxes shall not include any net income taxes, franchise, capital stock, gift, estate or inheritance taxes imposed on Landlord or the owner of any interest in the Project or any federal, state or local documentary taxes imposed against the Project or any portion thereof or interest therein, except to the extent the same, however denominated, are imposed in substitution for any Taxes payable hereunder as a result of any change in the manner of taxation of the ownership or operation of real estate in which case the same shall be deemed to be included within the definition of the term &#8220;Taxes.&#8221; If any such Tax is levied or assessed directly against Tenant, then Tenant shall be responsible for and shall pay the same at such times and in such manner as the taxing authority shall require. Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any personal property or trade fixtures placed by Tenant in the Premises, whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant&#8217;s personal property or trade fixtures are levied against Landlord or Landlord&#8217;s property, or if the assessed valuation of the Project is increased by a value attributable to improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real property so as to become a part thereof, higher than the base valuation on which Landlord from time-to-time allocates Taxes to all tenants in the Project, Landlord shall have the right, but not the obligation, to pay such Taxes. Landlord&#8217;s determination of any excess assessed valuation shall be binding and conclusive, absent manifest error. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord promptly upon demand. With respect to any tax year, all reasonable and customary expenses, including attorneys&#8217; fees and disbursements, experts&#8217; and other witnesses&#8217; fees, incurred in contesting the validity or amount of any Taxes or in obtaining a refund of Taxes shall be considered as part of the Taxes for such tax year. Special assessments, if any, shall be deemed paid in the maximum number of installments allowed by the Governmental Authority having jurisdiction thereover, notwithstanding that Landlord may elect to pay the same on a different schedule. If at any time the methods of taxation prevailing as of the date hereof shall be altered so that in lieu of or as an express substitute for the whole or any part of the Taxes, assessments, rents, rates, charges, levies or impositions now assessed, levied or imposed upon all or any part of the Project or any part thereof, there shall be assessed, levied or imposed (1) a tax, assessment, levy, imposition or charge based on the income or rents received therefrom, whether or not wholly or partially as a capital levy or otherwise, or (2) a tax, assessment, levy, imposition or charge measured by or based in whole or in part upon all or any part of the Project, or (3) a license fee measured by the rents, or (4) any other tax, assessment, levy, imposition, charge or license fee with respect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the Project, or any part thereof, however described or imposed, then all such taxes, assessments, levies, impositions, charges or license fees or the part thereof so measured or based shall be deemed to be Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant hereby covenants and agrees to (i) pay any and all CROT taxes and assessments payable by Landlord with respect to any rent due hereunder, (ii) pay any and all New York City and New York State transfer taxes, sales taxes and any and all other taxes payable by or on behalf of Tenant, as the same shall become due or payable, (iii) any and all taxes, fees, charges or assessments levied against Tenant, Owner or the Building as a result of Tenant&#8217;s failure to comply with any Legal Requirement, and (iv) file all tax returns required to be filed in connection with the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><b style="font-weight:bold;">Parking</b>. &#160;Subject to all matters of record, Force Majeure, a Taking (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 19</u> below), the terms and conditions of this Lease and the exercise by Landlord of its rights hereunder, Tenant shall have the right, in common with other tenants of the Project, [***] in accordance with the rentable area of the Premises and the rentable areas of the Project occupied by such other tenants, to park in those areas designated for non-reserved parking, subject in each case to Landlord&#8217;s rules and regulations and subject to the rights of ingress and egress of other tenants and their employees, agents and invitees to other areas of the Project, provided, however, that Landlord shall have the right, without notice in an emergency and otherwise for any reason upon not less than five (5) days&#8217; written notice, to relocate all or part of the non-reserved parking to other locations in the parking areas of the Project, and/or to suspend or terminate the right to use any or all the parking spaces. Landlord may allocate parking spaces among Tenant and other tenants in the Project pro rata as described above if Landlord determines that such parking facilities are becoming crowded. Landlord shall not be responsible for enforcing Tenant&#8217;s parking rights against any third parties, including other tenants of the Project<i style="font-style:italic;">. </i>If applicable, Tenant shall comply with the Project&#8217;s transportation plans to be created by Landlord under the guidelines set forth by the City of New York (the &#8220;<b style="font-weight:bold;">City</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-weight:bold;">Utilities; Services; Refuse and Trash.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">General</b>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Landlord shall provide [***]. Tenant shall be responsible to pay Landlord any taxes, interest or penalties due and payable to the extent caused by Tenant&#8217;s delay in making any payment due hereunder. Tenant acknowledges that Landlord is not the generator of Utilities and that Landlord&#8217;s obligation to deliver Utilities to the Premises pursuant to this Lease consequently is subject to the provision of electrical energy and water service to the Project, as applicable, by the respective utility company responsible for delivering same to the Project. Landlord shall have no liability for the availability, capacity, quality, continuity or character of service of Utilities, and no eviction or constructive eviction of Tenant, termination of this Lease or abatement of Rent shall arise due to, nor shall Landlord have any liability due to any loss, cost, claim, damage or expense arising from the availability, capacity, quality, continuity or character of service of Utilities or any interruption, deterioration or removal of any of the foregoing, except as caused by Landlord&#8217;s willful misconduct. [***]. Tenant acknowledges that the capacity of such utilities available to the Premises is part of the overall capacity of such utilities available to the Project for its use on a non-exclusive basis in common with all other tenants at the Project. Tenant agrees to limit use of water and sewer with respect to Common Areas to normal restroom use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Special Provisions Regarding Electricity</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>[***]. &#160;In the event that electrical service to the Premises is not separately metered, Landlord may, at Landlord&#8217;s option, install and maintain, at Landlord&#8217;s expense, submeters to measure Tenant&#8217;s consumption of electrical current, in which event Tenant shall reimburse Landlord for the quantities of electrical current shown on such submeters in the amount of [***], as Additional Rent. All meters and all additional panel boards, feeders, risers; wiring and other conductors and equipment which may be required to obtain electricity shall be installed by Landlord; and, the costs of such installation shall be borne by Landlord. Landlord, to the extent permitted by applicable Legal Requirements, shall not discontinue furnishing electricity to the Premises until such installations have been made and Tenant shall be able to obtain electricity directly from the utility company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>In the event that any tax shall be imposed upon Landlord&#8217;s receipts from the sale, use or resale of electrical energy or any other utility service to Tenant, the pro rata share allocable to such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">service received by Tenant shall be passed onto, included in the bill of, and paid by Tenant if and to the extent not prohibited by applicable Legal Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>Tenant shall enter into such modifications of this Lease as Landlord may from time to time reasonably request in connection with any requirement of the New York State Public Service Commission, or any successor thereto, or any requirement of law pertaining to the supplying of electrical service or the charges therefor under any provision of this Lease. If because of any such requirement, any provision of this Section cannot be given full effect, whether with respect to any past period or any future period, the parties shall enter into such modifications of this Lease setting forth substitute provisions, consistent with such requirements, which, to the maximum extent possible, achieve the intended purposes of the provisions of this Section which cannot be given full effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>Landlord&#8217;s sole obligation for either providing emergency generators or providing emergency back-up power to Tenant shall be: (i) to provide emergency generators with not less than the stated capacity of the emergency generators located in the Building as of the Commencement Date, [***] and (ii) to contract with a third party to maintain the emergency generator as per the manufacturer&#8217;s standard maintenance guidelines. Landlord shall have no obligation to provide Tenant with operational emergency generators or back-up power or to supervise, oversee or confirm that the third party maintaining the emergency generators is maintaining the generators as per the manufacturer&#8217;s standard guidelines or otherwise. During any period of replacement, repair or maintenance of the emergency generators when the emergency generators are not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant with an alternative back-up generator or generators or alternative sources of back-up power. Tenant expressly acknowledges and agrees that Landlord does not guaranty that such emergency generators will be operational at all times or that emergency power will be available to the Premises when needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Refuse and Trash</b>. &#160;Landlord shall provide refuse and trash collection and janitorial services at the Building for ordinary office refuse and rubbish and cleaning, and the cost of such services shall be included in Operating Expenses. To the extent that the refuse and trash and/or cleaning needs generated by Tenant exceeds the refuse and trash and/or cleaning needs customarily generated by other tenants of the Building, Tenant shall pay to Landlord the costs that Landlord reasonably incurs for such removal and/or cleaning, within [***] after rendition of bills therefor, as Additional Rent. In respect of refuse and trash other than ordinary office refuse and rubbish (such as bio/medical waste, &#8220;wet trash&#8221; and construction debris, and cleaning with respect thereto), Tenant shall contract directly with the third-party service provider (acceptable to Landlord in its sole discretion) for the provision of such services and, in such case, Tenant shall pay such service provider directly, prior to delinquency. In all cases, Tenant shall store and stage all its waste, refuse, trash and recyclables within its Premises or in such enclosure areas as may be designated by Landlord and shall keep the Premises in a neat and clean condition. Tenant shall not dispose of any refuse in the Common Areas, and if Tenant does so, Tenant shall be liable for Landlord&#8217;s reasonable charge for such removal. Tenant shall comply with all Legal Requirements, whether imposed on Landlord or Tenant, regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash in the Premises and cleaning the Premises. Upon request by Landlord, Tenant shall sort and separate into categories designated by Landlord and shall place in separate receptacles (as may be designated by Landlord) all waste products, garbage, refuse and trash in the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Loading Dock and Freight Elevator</b>. &#160;Landlord shall provide, on a non-exclusive, first-come, first-served basis, freight elevator service to the floor on which the Premises are located and access to a loading dock adjacent to such freight elevator for Tenant&#8217;s deliveries in and out of the Premises in connection with the Permitted Use. Tenant shall have the right to contract directly with the provider of the Building&#8217;s security services for freight elevator service outside of regular business hours to the floor on which the Premises are located and access to a loading dock adjacent to such freight elevator, provided that Landlord shall not be responsible, or have any liability, for the provision of such services or for the inability of Tenant to obtain such services for any reason, [***]. Tenant&#8217;s use of the freight elevator and the loading dock shall be subject to the Superior Instruments, the Rules and Regulations, Landlord&#8217;s security requirements for the Building and/or the Project, and the terms of this Lease. Landlord shall have the right to change the operation or manner of operation of any of the elevators in the Building and/or to discontinue temporarily the use of any one or more cars in any of the elevator banks provided that at all times there will</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be at least one passenger elevator serving the Premises at all times (subject to such passenger elevator not being in service due to repairs or alterations being made thereto).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Usage Data</b>. &#160;Tenant agrees to provide Landlord with access to Tenant&#8217;s water and/or energy usage data on a monthly basis, either by providing Tenant&#8217;s applicable utility login credentials to Landlord&#8217;s designated online portal, or by another delivery method reasonably agreed to by Landlord and Tenant. The costs and expenses incurred by Landlord in connection with receiving and analyzing such water and/or energy usage data (including, without limitation, as may be required pursuant to applicable Legal Requirements) shall be included as part of Operating Expenses. Notwithstanding anything to the contrary herein, Landlord may equitably increase Tenant&#8217;s Share (or Tenant&#8217;s Share of Operating Expenses, as the case may be) in the event that Tenant&#8217;s use of water, energy or other Utilities is disproportionate to that of other tenants at the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Energy Use Disclosure Requirements</b>. Tenant acknowledges and agrees that Landlord must comply with New York City Local Law 84 Disclosure regulations, and that Tenant shall be obligated to deliver in a timely manner all of the required disclosures (&#8220;<b style="font-weight:bold;">Energy Use Disclosure</b>&#8221;) concerning energy consumption data when requested by the Landlord. Tenant acknowledges and agrees that the data provided in the Energy Use Disclosure is historical and such data is not intended to be deemed a projection of the future energy consumption at the Building, which consumption may vary materially from the information set forth in the Energy Use Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">LEED and Fitwel</b>. Tenant acknowledges that Landlord may, but shall not be obligated to, seek to obtain Leadership in Energy and Environmental Design (LEED), WELL Building Standard, Fitwel, or other similar &#8220;green&#8221; certification with respect to the Building and/or the Premises, and Tenant agrees to reasonably cooperate with Landlord, and to provide such information and/or documentation as Landlord may reasonably request, in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><b style="font-weight:bold;">Alterations and Tenant&#8217;s Property</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Any alterations, additions, or improvements made to the Premises by or on behalf of Tenant, including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation, removal or realignment of furniture systems (other than removal of furniture systems owned or paid for by Landlord) not involving any modifications to the structure of the Building or connections (other than by ordinary plugs or jacks) to Building Systems (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u>) (&#8220;<b style="font-weight:bold;">Alterations</b>&#8221;) shall be subject to Landlord&#8217;s prior written consent, which may be given or withheld in Landlord&#8217;s sole discretion if any such Alteration affects the structure of the Building or Building Systems, or if Landlord deems that such proposed Alteration will adversely affect Landlord&#8217;s ability to re-lease the Premises, but which shall otherwise not be unreasonably withheld or delayed. Tenant may construct nonstructural Alterations in the Premises without Landlord&#8217;s prior approval if the aggregate cost of all such work [***] (a &#8220;<b style="font-weight:bold;">Notice-Only Alteration</b>&#8221;), provided Tenant notifies Landlord in writing of such intended Notice-Only Alteration, and such notice shall be accompanied by plans, specifications, work contracts and such other information concerning the nature and cost of the Notice-Only Alteration as may be reasonably requested by Landlord, which notice and accompanying materials shall be delivered to Landlord not less than [***] in advance of commencement of any proposed construction. If Landlord approves any Alterations, Landlord may impose such conditions on Tenant in connection with the commencement, performance and completion of such Alterations as Landlord may deem appropriate in Landlord&#8217;s reasonable discretion. Any request for approval shall be in writing, delivered [***] advance of any proposed construction, and accompanied by plans, specifications, bid proposals, work contracts and such other information concerning the nature and cost of the Alterations as may be reasonably requested by Landlord, including the identities and mailing addresses of all persons performing work or supplying materials. Landlord&#8217;s right to review plans and specifications and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such plans and specifications or construction comply with applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all Alterations to comply with any applicable insurance requirements and with Legal Requirements and shall implement at its sole cost and expense any alteration or modification required by Legal Requirements as a result of any Alterations. Tenant shall pay to Landlord, as Additional Rent, on demand [***] all charges incurred by Tenant or its</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">contractors or agents in connection with any Alteration to cover Landlord&#8217;s overhead and expenses for plan review, coordination, scheduling and supervision. Before Tenant begins any Alteration, Tenant shall post on and about the Premises notices of non-responsibility pursuant to applicable law. Tenant shall reimburse Landlord and the Condominium Board for, and indemnify and hold Landlord and the Condominium Board harmless from, any actual, out-of-pocket expense incurred by Landlord and/or the Condominium Board, as applicable, by reason of faulty work done by Tenant or its contractors, delays caused by such work, or inadequate cleanup.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In the event Tenant installs a security systems or additional locks, Tenant shall supply Landlord with the necessary card(s) or key(s) and security codes to permit entry in the event of an emergency endangering life or property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant shall furnish security or make other arrangements satisfactory to Landlord to assure payment for the completion of all Alterations work free and clear of liens, and shall provide (and cause each contractor or subcontractor to provide) certificates of insurance for workers&#8217; compensation and other coverage in amounts and from an insurance company satisfactory to Landlord protecting Landlord and the Condominium Board against liability for personal injury or property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord: (i) sworn statements setting forth the names of all contractors and subcontractors who did the work and final lien waivers from all such contractors and subcontractors; and (ii) &#8220;as built&#8221; plans for any such Alteration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Other than (i) the items, if any, listed on <b style="font-weight:bold;">Exhibit F</b> attached hereto, (ii) any items agreed by Landlord in writing to be included on <b style="font-weight:bold;">Exhibit F</b> in the future, and (iii) any trade fixtures, machinery, equipment and other personal property which may be removed without damage to the Premises, which damage shall be repaired (including capping or terminating utility hook-ups behind walls) by Tenant prior to the expiration or earlier termination of the Term (collectively, &#8220;<b style="font-weight:bold;">Tenant&#8217;s Property</b>&#8221;), all property of any kind paid for by or on behalf of Landlord, all Alterations, real property fixtures, built-in machinery and equipment, built-in casework and cabinets and other similar additions and improvements built into the Premises so as to become an integral part of the Premises such as fume hoods which penetrate the roof or plenum area, built-in cold rooms, built-in warm rooms, walk-in cold rooms, walk-in warm rooms, deionized water systems, glass washing equipment, autoclaves, chillers, built-in plumbing, electrical and mechanical equipment and systems, and any power generator and transfer switch (collectively, &#8220;<b style="font-weight:bold;">Installations</b>&#8221;) shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at any time during the Term and shall remain upon and be surrendered with the Premises as a part thereof in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 28</u> following the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>No Alteration shall (i)&#160;affect the exterior walls, fascia or fenestration of the Building or the demising walls of the Premises, (ii)&#160;affect any part of the Project other than the Premises or require any alterations, installations, improvements, additions or other physical changes to be performed in or made to any portion of the Project other than the Premises, (iii)&#160;adversely affect any service required to be furnished by Landlord to Tenant or to&#160;any other tenant or occupant of the Project, (iv)&#160;adversely affect the functioning of any Building System, and (v)&#160;affect or require an amendment to (other than to confirm completion of the Alteration) the Certificate of Occupancy for the Premises or for any other part of the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Tenant covenants and agrees that no security agreement, lien, lease, conditional sales agreement, chattel mortgage or other title retention or instrument of similar import (a &#8220;<b style="font-weight:bold;">Security Agreement</b>&#8221;) shall be placed upon any improvement made by Tenant which is affixed to the Premises. In the event that any of Tenant&#8217;s Property are purchased or acquired by Tenant subject to a Security Agreement, Tenant agrees that no Security Agreement or Uniform Commercial Code filing statement shall be permitted to be filed against the Premises, the Building or any other part of the Project If any such lien, based on a Security Agreement or Uniform Commercial Code filing statement, is filed against the Premises or any other part of the Project, Tenant shall, [***], cause such lien or notice to be removed or discharged at Tenant&#8217;s cost and expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Tenant shall use its commercially reasonable and diligent efforts to perform such Alterations and other work at such times and in such manner as shall minimize any interference, disruption or disturbance from such performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>Tenant shall not, at any time prior to or during the Term, directly or indirectly employ, or permit the employment of, any contractor, mechanic or laborer in the Premises, in connection with any Alteration, if such employment would interfere or cause any conflict with other contractors, mechanics or laborers engaged in the construction, maintenance or operation of the Project by Landlord, Tenant or others. In the event of any such interference or conflict, Tenant, upon demand of Landlord, shall cause all contractors, mechanics or laborers causing such interference or conflict to leave the Building immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>In the event that Tenant installs indoor plumbing with flush and flow fixtures in the Premises (&#8220;Plumbing Fixtures&#8221;), (i) installation of such Plumbing Fixtures shall be subject to this Section 12, and (ii) Tenant shall specify to Landlord in writing that such Plumbing Fixtures do not exceed those in the Building. Applicable Plumbing Fixtures may better the rates listed below, but shall not exceed the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Water Closets:<font style="display:inline-block;width:12.85pt;"></font>1.1 GPF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Urinals:</font></font>0.125 GPF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Metering Lavatories:<font style="display:inline-block;width:23.86pt;"></font>.35 GPM or 0.07 GPC (based on a twelve (12)-second cycle)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Kitchen and Break Room Sink Faucets:<font style="display:inline-block;width:21.42pt;"></font>1.5 GPM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Shower Fixtures:<font style="display:inline-block;width:3.39pt;"></font>1.5 GPM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font>In the event that Tenant installs toilets, urinals, private lavatory faucets and/or showerheads in accordance with this Section 11 that are eligible for labeling, such toilets, urinals, private lavatory faucets and/or showerheads must be WaterSense labeled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font>In the event that Tenant installs any of the appliances listed below in accordance with this Section 12, such appliances must meet the following criteria:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Residential Clothes Washers:<font style="display:inline-block;width:26.25pt;"></font>ENERGY STAR or performance equivalent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Commercial Clothes Washers:<font style="display:inline-block;width:21.81pt;"></font>ENERGY STAR or performance equivalent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Residential Dishwashers (standard and compact): ENERGY STAR or performance equivalent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Prerinse Spray Valves:<font style="display:inline-block;width:16.35pt;"></font>&#8804; 1.3 gpm (4.9 lpm)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Ice Machine: ENERGY STAR or performance equivalent and use either air-cooled or closed-loop cooling, such as chilled or condenser water system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><b style="font-weight:bold;">Landlord&#8217;s Repairs</b>. &#160;Landlord, as an Operating Expense, shall maintain all of the structural portions of the Premises and the Project and Building Systems (as defined below) in good repair, reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant&#8217;s agents, servants, employees, invitees and contractors (collectively, &#8220;<b style="font-weight:bold;">Tenant Parties</b>&#8221;) excluded. Losses and damages caused by Tenant or any Tenant Party shall be repaired by Landlord at Tenant&#8217;s sole cost and expense. Landlord reserves the right to stop Building Systems services when necessary (i) by reason of accident or emergency, or (ii) for planned repairs, alterations or improvements, which are, in the judgment of Landlord, desirable or necessary to be made, until said repairs, alterations or improvements shall have been completed. Landlord shall have no responsibility or liability for failure to supply Building Systems services during any such period of interruption; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that Landlord shall, except in case of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">emergency, make a commercially reasonable effort to give [***] advance notice, of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements. Tenant shall promptly give Landlord written notice of any repair required to be effected by Landlord pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u>, after which Landlord shall have a reasonable opportunity to effect such repair. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance unless such failure shall persist for an unreasonable time after Tenant&#8217;s written notice of the need for such repairs or maintenance. Tenant waives its rights under any state or local law to terminate this Lease or to make such repairs at Landlord&#8217;s expense and agrees that the parties&#8217; respective rights with respect to such matters shall be solely as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism, war, or similar cause of damage or destruction shall be controlled by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u>. As used herein, the term &#8220;<b style="font-weight:bold;">Building Systems</b>&#8221; shall mean, collectively, the HVAC, plumbing, fire sprinkler, elevators and all other building systems located outside of the Premises and serving the Premises and other portions of the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If at any time any windows of the Premises are temporarily closed or darkened due to any Legal Requirement or by reason of repairs, maintenance, alterations, or improvements to the Building, or any scaffolding or &#8220;sidewalk bridge&#8221; is erected in front of the Building due to any Legal Requirement or by reason of any repairs, maintenance, alterations to the Building or any property adjacent to the Building, Landlord shall not be liable for any damage Tenant may sustain thereby and Tenant shall not be entitled to any compensation therefor, nor abatement or diminution of Base Rent or any other amount due under this Lease, nor shall the same release Tenant from its obligations hereunder, in whole or in part, by reason of inconvenience or annoyance to Tenant, or injury to or interruption of Tenant&#8217;s business, or otherwise, nor impose any liability upon Landlord or its agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><b style="font-weight:bold;">Tenant&#8217;s Repairs</b>. &#160;Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13,</u> Section 18<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, and</u> Section 19 hereof and reasonable wear and tear, Tenant, at its expense, shall repair, replace and maintain in good condition all nonstructural portions of the Premises, including, without limitation, entries, doors, ceilings, interior windows, interior walls, and the interior side of demising walls. Such repair and replacement may include capital expenditures and repairs whose benefit may extend beyond the Term. Should Tenant fail to make any such repair or replacement or fail to maintain the Premises, Landlord shall give Tenant notice of such failure. If Tenant fails to commence cure of such failure within [***] of Landlord&#8217;s notice, and thereafter diligently prosecute such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant [***] after demand therefor; provided, however, that if such failure by Tenant creates or could create an emergency, Landlord may immediately commence cure of such failure and shall thereafter be entitled to recover the costs of such cure from Tenant. Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 17</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18</u>, Tenant shall bear the full uninsured cost of any repair or replacement to any part of the Project that results from damage caused by Tenant or any Tenant Party and any repair that benefits only the Premises. Tenant shall not clean nor require, permit, suffer or allow any window in the Premises to be cleaned from the outside in violation of Section 202 of New York State Labor Law or any other applicable law, or of the Rules of the Board of Standards and Appeals, or of any other Board or body having or asserting jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><b style="font-weight:bold;">Mechanic&#8217;s Liens</b>. &#160;Tenant shall discharge, by bond or otherwise, any mechanic&#8217;s lien filed against the Premises, the Building or any other part of, or against, the Project for work claimed to have been done for, or materials claimed to have been furnished to, Tenant (other than for Landlord&#8217;s Work) within [***], at Tenant&#8217;s sole cost and shall otherwise keep the Premises and the Project free from any liens arising out of work performed for, materials furnished to, or obligations incurred by Tenant. Should Tenant fail to discharge any lien described herein, Landlord shall have the right, but not the obligation, to pay such claim or post a bond or otherwise provide security to eliminate the lien as a claim against title to the Project and the cost thereof shall be promptly due from Tenant as Additional Rent. If Tenant shall lease or finance the acquisition of office equipment, furnishings, or other personal property of a removable nature utilized by Tenant in the operation of Tenant&#8217;s business, Tenant covenants that any Security Agreement, and any Uniform Commercial Code Financing Statement filed as a matter of public record by any lessor or creditor of Tenant, shall upon its face or by exhibit thereto indicate that such Security Agreement or Financing Statement is applicable only to removable personal property of Tenant located within the Premises. Tenant shall cause to be inserted in any such Security Agreement the following provision: &#8220;Notwithstanding anything to the contrary contained herein, this lease, chattel mortgage, conditional sales agreement, title retention agreement or security agreement shall not create or be filed as a lien against the land, building</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and improvements comprising the real property in which the goods, machinery, equipment, appliances or other personal property covered hereby are to be located or installed&#8221;; and, in no event shall the address of the Project be furnished on any such Financing Statement without qualifying language as to applicability of the lien only to removable personal property, located in an identified suite held by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</font></font><b style="font-weight:bold;">Indemnification</b>. &#160;Tenant shall indemnify, defend and hold harmless Landlord and the Condominium Board, the entities (if any) comprising Landlord, each affiliate or subsidiary of Landlord, and its and their partners, members, shareholders, officers, directors, employees and agents, Lessors (including, without limitation, the City and any administrator of the Ground Lease) and Mortgagees (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27</u>) (each individually and collectively the &#8220;<b style="font-weight:bold;">Landlord Indemnitees</b>&#8221;) from and against any and all Claims against the Landlord Indemnitees of whatever nature arising directly or indirectly from, or out of: (a)&#160;any negligence or willful misconduct by, [***] (b)&#160;any accident, injury, death or damage whatsoever caused to any Person or to the property of any Person occurring within or about the Premises, (c)&#160;any accident, injury, death or damage whatsoever caused to any Person or to the property of any Person occurring outside of the Premises but anywhere within or about the Land, the Building, or the Project, expressly including, for purposes of this indemnification, the Common Areas and the Open Space, where such accident, injury, death or damage is caused (or is claimed to have been caused) by or otherwise involves an act or omission, or the negligence or willful misconduct, [***] and (d) any accident, injury, death or damage whatsoever caused to any Person or to the property of any Person occurring within or about the Premises, where such accident, injury, death or damage is caused (or is claimed to have been caused) by or otherwise relates to (x) the use or occupancy by any Tenant Party of, or any other activity, work, conduct of business or thing done, permitted or suffered by any Tenant Party in or about any of, the Premises, the Building, the Land or the Project, expressly including for purposes of this indemnification the Common Areas and the Open Space, or (y) a breach or default by any Tenant Party in the performance of any of its or Tenant&#8217;s obligations hereunder, unless, in each case set forth in clauses (a) through (d), demonstrated to have been caused solely by the willful misconduct or negligence of Landlord. This indemnity, defense and hold harmless agreement shall include indemnification from and against any and all liability, fines, suits, demands, costs and expenses of any kind or nature (including reasonable attorneys&#8217; fees and disbursements) incurred in or in connection with any such claim or proceeding brought thereon, and the defense thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.</font></font><b style="font-weight:bold;">Insurance</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Landlord shall maintain all risk property and, if applicable, sprinkler damage insurance covering the full replacement cost of the Project or such lesser coverage amount as Landlord may elect <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> such coverage amount is not less than ninety percent (90%) of such full replacement cost. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than Two Million and 00/100 Dollars ($2,000,000.00) for bodily injury and property damage with respect to the Project. Landlord may, but is not obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental hazard and earthquake, loss or failure of building equipment, errors and omissions, rental loss during the period of repair or rebuilding, workers&#8217; compensation insurance and fidelity bonds for employees employed to perform services and insurance for any improvements installed by Tenant or which are in addition to the standard improvements customarily furnished by Landlord without regard to whether or not the same are made a part of the Project. All such insurance, including any deductible associated therewith, shall be included as part of the Operating Expenses. The Project may be included in a blanket policy (in which case the cost of such insurance allocable to the Project will be determined by Landlord and/or the Condominium Board based upon the insurer&#8217;s cost calculations). Tenant shall also reimburse Landlord for any increased premiums or additional insurance which Landlord reasonably deems necessary as a result of Tenant&#8217;s use of the Premises. Tenant (and, during the prosecution of any Alterations, its general contractor, contractors and/or subcontractors), at its sole cost and expense, shall maintain during the Term: all risk property insurance (including fire, extended coverage, vandalism, boiler and machinery (and artificially generated electrical current), water and sprinkler damage, and off-premises failure of power or other utility services) with eighteen (18) months of business interruption and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises by Tenant at Tenant&#8217;s expense (including, without limitation, builder&#8217;s risk coverage for all Alterations); workers&#8217;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation insurance with no less than the minimum limits required by law; employer&#8217;s liability insurance with such limits as required by law; comprehensive automobile liability insurance (including automotive liability, including pollution coverage, from loading and unloading) with combined bodily injury and property damage coverage limits, per occurrence, of at least One Million and 00/100 Dollars ($1,000,000.00) ; and commercial general liability insurance and umbrella liability, in each case, for minimum combined bodily injury and property damage coverage limits totaling Two Million and 00/100 Dollars ($2,000,000.00) per occurrence and Five Million and 00/100 Dollars ($5,000,000.00) in the aggregate. The commercial general liability insurance policy shall name (i) Landlord, (ii) its officers, members, shareholders, directors, employees, managers, agents, invitees, contractors, subcontractors, general contractor (or construction manager, as applicable), (iii) Alexandria Real Estate Equities, Inc., (iv) New York City Health and Hospitals Corporation (and any other Ground Landlord (as defined in Section 27) from time to time), (v) the City, (vi) [intentionally omitted], (vii) the New York City Economic Development Corporation (and any other Ground Lease (as defined in Section 27) administrator/agent from time to time), and (viii) the Condominium Board (collectively, &#8220;<b style="font-weight:bold;">Landlord Parties</b>&#8221;), as additional insureds, [***]; contain a hostile fire endorsement and a contractual liability endorsement; and provide primary coverage to Landlord and the Condominium Board (any policy issued to Landlord or the Condominium Board providing duplicate or similar coverage shall be deemed excess over Tenant&#8217;s policies). Copies of such policies (if requested by Landlord or the Condominium Board), or certificates of insurance showing the limits of coverage required hereunder and showing Landlord and the Condominium Board as an additional insured, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord and the Condominium Board by Tenant upon commencement of the Term and prior to or upon each renewal of said insurance. Tenant&#8217;s policy may be a &#8220;blanket policy&#8221; which specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy. Tenant shall, at least five (5) business days prior to the expiration of such policies, furnish Landlord and the Condominium Board with renewal certificates. In addition, upon receipt by Tenant of any notice of cancellation or any other notice from the insurance carrier which may adversely affect the coverage of the insureds under such policy of insurance, Tenant shall promptly deliver to Landlord and the Condominium Board and any other additional insured hereunder a copy of such notice. If at any time Tenant (or its general contractor, contractors and/or subcontractors) shall fail to procure or maintain all insurance required to be carried by Tenant pursuant to this Lease, Landlord or the Condominium Board may procure (but shall have no obligation to procure) such insurance on behalf of Tenant (and its general contractor, contractors and/or subcontractors) and the cost thereof shall be payable by Tenant upon demand. Such insurer(s) shall be selected by Tenant, subject to Landlord&#8217;s approval, not to be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In each instance where insurance is to name Landlord and the Condominium Board as an additional insured, Tenant shall upon written request of Landlord also designate and furnish certificates so evidencing Landlord and the Condominium Board as additional insured to: (i) any lender of Landlord or the Condominium Board holding a security interest in the Project or any portion thereof, (ii) the landlord under any lease wherein Landlord is tenant of the real property on which the Project is located, if the interest of Landlord is or shall become that of a tenant under a ground or other underlying lease rather than that of a fee owner, and/or (iii) any management company retained by Landlord or the Condominium Board to manage the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The property insurance obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all rights based upon an assignment from its insured, against Landlord or Tenant, and their respective officers, directors, employees, members, managers, shareholders, partners, agents, representatives, servants, guests, invitees, visitors and contractors (&#8220;<b style="font-weight:bold;">Related Parties</b>&#8221;), in connection with any loss or damage thereby insured against. The Condominium Board shall also be a Related Party of Landlord hereunder. Neither party nor its respective Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property insurance required to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord and its respective Related Parties shall not be liable for, and Tenant hereby waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises or the Project from any cause whatsoever. If the foregoing waivers shall contravene any law with respect to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other&#8217;s insurer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Landlord may require insurance policy limits to be raised to conform with requirements of Landlord&#8217;s lender or the Condominium Board and/or to bring coverage limits to levels then being generally required of new tenants within the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Tenant acknowledges that Landlord shall not carry insurance on, and shall not be responsible for damage to, Tenant&#8217;s Property or any Alterations, betterments or improvements made by Tenant to the Premises. Tenant agrees that Landlord shall not be required to maintain insurance coverage with respect to the portions of the Premises for which Tenant is required to maintain insurance in accordance with the terms of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.</font></font><b style="font-weight:bold;">Restoration</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If, at any time during the Term, the Project or the Premises are damaged or destroyed by a fire or other insured casualty, Landlord shall notify Tenant within [***] after discovery of such damage or destruction as to the amount of time Landlord reasonably estimates it will take to restore the Project or the Premises, as applicable (the &#8220;<b style="font-weight:bold;">Restoration Period</b>&#8221;). If the Restoration Period is estimated to exceed [***] from the date that Landlord obtains all required permits to perform the restoration (the &#8220;<b style="font-weight:bold;">Maximum Restoration Period</b>&#8221;), Landlord may, in such notice, elect to terminate this Lease as of the date that is [***] after the date of discovery of such damage or destruction; provided, however, that notwithstanding Landlord&#8217;s election to restore, Tenant may elect to terminate this Lease by written notice to Landlord delivered [***] of receipt of a notice from Landlord estimating a Restoration Period for the Premises longer than the Maximum Restoration Period. Unless Landlord or Tenant, as applicable, so elects to terminate this Lease, Landlord shall, subject to receipt of sufficient insurance proceeds (with any deductible to be treated as a current Operating Expense), promptly restore the Premises (excluding any improvements installed by Tenant or by Landlord and paid for by Tenant unless covered by the insurance Landlord maintains as an Operating Expense hereunder, in which case such improvements shall be included, to the extent of such insurance proceeds, in Landlord&#8217;s restoration), subject to delays arising from the collection of insurance proceeds, from Force Majeure events or as needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the Premises issued by any Governmental Authority having jurisdiction over the use, storage, handling, treatment, generation, release, disposal, removal or remediation of Hazardous Materials (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30</u>) in, on or about the Premises (collectively referred to herein as &#8220;<b style="font-weight:bold;">Hazardous Materials Clearances</b>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that if repair or restoration of the Premises is not substantially complete as of the end of the Maximum Restoration Period or, if longer, the Restoration Period, Landlord may, in its sole and absolute discretion, elect not to proceed with such repair and restoration, or Tenant may by written notice to Landlord delivered [***] of the expiration of the Maximum Restoration Period or, if longer, the Restoration Period, as each may be tolled on a day-for-day basis by Tenant Delays and Force Majeure delays, elect to terminate this Lease, in which event Landlord shall be relieved of its obligation to make such repairs or restoration and this Lease shall terminate as of the date of such election, but Landlord shall retain any Rent paid and the right to any Rent payable by Tenant prior to the date of such election by Landlord or Tenant. In the event of any such termination, neither Landlord nor Tenant shall have any further rights, duties or obligations under this Lease, except with respect to provisions which expressly survive termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant, at its expense, shall promptly perform, subject to delays arising from the collection of insurance proceeds, from Force Majeure (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 34</u>) events or from obtaining Hazardous Materials Clearances, all repairs or restoration not required to be done by Landlord and shall promptly re-enter the Premises and commence doing business in accordance with this Lease. Notwithstanding the foregoing, Landlord or, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 28</u>, Tenant may terminate this Lease if the Premises are damaged during the last year of the Term and Landlord reasonably estimates that it will take more than two (2) months to repair such damage, or [***] Rent shall be abated from the date all required Hazardous Material Clearances are obtained until the repair and restoration of the Premises is substantially completed, in the proportion which the area of the Premises, if any, which is not usable by Tenant bears to the total area of the Premises, unless Landlord provides Tenant with other space during the period of repair that is suitable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for the temporary conduct of Tenant&#8217;s business. Such abatement shall be the sole remedy of Tenant, and except as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u>, Tenant waives any right to terminate this Lease by reason of damage or casualty loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The provisions of this Lease, including this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u>, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, or any other portion of the Project, and any statute or regulation which is now or may hereafter be in effect shall have no application to this Lease or any damage or destruction to all or any part of the Premises or any other portion of the Project, the parties hereto expressly agreeing that this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u> sets forth their entire understanding and agreement with respect to such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant hereby expressly waives the provision of Section 227 of the Real Property Law and agrees that the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u> shall govern and control in lieu thereof, this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u> being an express agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Landlord and Tenant acknowledge that Condominium Board has the responsibility under the Condominium By-Laws for certain aspects of restoration. In the event that Condominium Board, not Landlord, is responsible, in part or in full, under the Condominium Declaration for a restoration under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u>, the fulfillment by the Condominium Board of such obligation of Landlord, in part or in full, shall be deemed to constitute satisfaction by Landlord to the same extent of the restoration obligations of Landlord hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.</font></font><b style="font-weight:bold;">Condemnation</b>. &#160;If the whole or any material part of the Premises, the Building or the Project is taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof (a &#8220;<b style="font-weight:bold;">Taking</b>&#8221; or &#8220;<b style="font-weight:bold;">Taken</b>&#8221;), and the Taking would in Landlord&#8217;s reasonable judgment, either prevent or materially interfere with Tenant&#8217;s use of the Premises or materially interfere with or impair Landlord&#8217;s ownership or operation of the Building or Project, then upon written notice by Landlord this Lease shall terminate and Rent shall be apportioned as of said date. If part of the Premises shall be Taken, and this Lease is not terminated as provided above, Landlord shall promptly restore the Premises and the Project as nearly as is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable square footage of the Building, the rentable square footage of the Premises, Tenant&#8217;s Share of Operating Expenses and the Rent payable hereunder during the unexpired Term shall be reduced to such extent as may be fair and reasonable under the circumstances. Upon any such Taking, Landlord shall be entitled to receive the entire price or award from any such Taking without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant&#8217;s interest, if any, in such award. Tenant shall have the right, to the extent that same shall not diminish Landlord&#8217;s award, to make a separate claim against the condemning authority (but not Landlord) for such compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant&#8217;s trade fixtures, if a separate award for such items is made to Tenant. Tenant hereby waives any and all rights it might otherwise have pursuant to any provision of state law to terminate this Lease upon a partial Taking of the Premises, the Building, or the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.</font></font><b style="font-weight:bold;">Events of Default</b>. &#160;Each of the following events shall be a default (&#8220;<b style="font-weight:bold;">Default</b>&#8221;) by Tenant under this Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Payment Defaults</b>. &#160;Tenant shall fail to pay any installment of Rent or any other payment hereunder when due, including, without limitation, any penalties or interest accrued thereon; provided, however, that Tenant shall have the right to notice of any failure to pay Rent and an opportunity to cure any such failure to pay Rent [***] before a Default shall occur (provided that if such a notice is given, Tenant shall not have a right to notice of any further failure to pay Rent before a Default shall occur until Tenant thereafter has paid all Rent in full and on time for twelve consecutive months) and Tenant agrees that such notice shall be in lieu of and not in addition to, or shall be deemed to be, any notice required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Insurance</b>. Any insurance required to be maintained by Tenant pursuant to this Lease shall be canceled or terminated or shall expire or shall be reduced or materially changed, or Landlord or the Condominium Board shall receive a notice of nonrenewal of any such insurance and Tenant shall fail</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to obtain replacement insurance at least twenty (20) days before the expiration, cancellation, termination, or reduction of, or material change in, the current coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Abandonment</b>. Tenant shall abandon the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Improper Transfer</b>. &#160;Tenant shall assign, sublease or otherwise transfer (including, without limitation, by operation of law) or attempt to transfer all or any portion of Tenant&#8217;s interest in this Lease or the Premises except as expressly permitted herein, or Tenant&#8217;s interest in this Lease shall be attached, executed upon, or otherwise judicially seized and such action is not released or dismissed within 90 days of the action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Liens</b>. &#160;Tenant shall fail to discharge or otherwise obtain the release of any lien placed upon the Premises, the Building, or any other part of the Project in violation of this Lease [***] any such lien against the Premises, the Building, or any other part of the Project .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Insolvency Events</b>. &#160;Tenant or any guarantor or surety of Tenant&#8217;s obligations hereunder shall: (A) make a general assignment for the benefit of creditors; (B) commence any case, proceeding or other action seeking to have an order for relief entered on its behalf as a debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, liquidation, dissolution or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or of any substantial part of its property (collectively a &#8220;<b style="font-weight:bold;">Proceeding for Relief</b>&#8221;); (C) become the subject of any Proceeding for Relief which is not dismissed within ninety (90) days of its filing or entry or (D) die or suffer a legal disability (if Tenant, guarantor, or surety is an individual) or be dissolved or otherwise fail to maintain its legal existence (if Tenant, guarantor or surety is a corporation, partnership or other entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Estoppel Certificate or Subordination Agreement.</b> &#160;Tenant fails to execute any document required from Tenant under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 23</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">27</u> [***] after a second notice requesting such document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><b style="font-weight:bold;">Other Defaults</b>. &#160;Tenant shall fail to observe, perform or comply with any provision of this Lease other than those specifically referred to in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 20</u>, and, except as otherwise expressly provided herein, such failure shall continue for a period of [***] after written notice thereof from Landlord to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any notice given under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 20(h)</u> hereof shall: (i) specify the alleged default, (ii) demand that Tenant cure such default, (iii) be in lieu of, and not in addition to, or shall be deemed to be, any notice required under any provision of applicable law, and (iv) not be deemed a forfeiture or a termination of this Lease unless Landlord elects otherwise in such notice; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that if the nature of Tenant&#8217;s default pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 20(h)</u> is such that it cannot be cured by the payment of money and reasonably requires more than [***] to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said [***] and thereafter diligently prosecutes the same to completion; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that such cure shall be completed no later than [***] from the date of Landlord&#8217;s notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21.</font></font><b style="font-weight:bold;">Landlord&#8217;s Remedies</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Payment By Landlord; Interest</b>. Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of Tenant hereunder, make such payment or perform such act. All sums so paid or incurred by Landlord, together with interest thereon (from the date such sums were paid or incurred, at the annual rate (the &#8220;<b style="font-weight:bold;">Default Rate</b>&#8221;) equal to the Prime Rate + four percent (4%) (but in no event less than twelve percent (12%) or more than the maximum rate permitted under applicable law)) shall be payable to Landlord on demand as Additional Rent. Nothing herein shall be construed to create or impose a duty on Landlord to mitigate any damages resulting from Tenant&#8217;s Default hereunder. As used herein, the term &#8220;<b style="font-weight:bold;">Prime Rate</b>&#8221; shall mean the highest prime rate (or base rate) reported in the Money Rates column or section of The Wall Street Journal (Eastern Edition) published from time to time, as the rate in effect for corporate loans at large U.S. money center commercial banks (whether or not such rate has</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">actually been charged by any such bank). If The Wall Street Journal ceases publication of the Prime Rate, the &#8220;Prime Rate&#8221; shall mean the prime rate (or base rate) announced by Citibank, N.A., New York, New York (whether or not such rate has actually been charged by such bank). If such bank discontinues the practice of announcing the Prime Rate, the &#8220;Prime Rate&#8221; shall mean the highest rate charged by such bank on short-term, unsecured loans to its most creditworthy large corporate borrowers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Late Payment Rent</b>. &#160;Late payment by Tenant to Landlord of Rent and other sums due will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are not limited to, processing and accounting charges and late charges which may be imposed on Landlord under any Mortgage covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within [***] after the date such payment is due, Tenant shall pay to Landlord [***]. The parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. In addition to the late charge, Rent not paid when due and remaining unpaid on [***] after it first became due shall bear interest at the Default Rate from the date it first became due until paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Remedies</b>. &#160;Upon and during the continuance of a Default, Landlord, at its option, without further notice or demand to Tenant, shall have in addition to all other rights and remedies provided in this Lease, at law or in equity, the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. No cure, in whole or in part, of such Default by Tenant after Landlord has taken any action (beyond giving Tenant notice of such Default) to pursue any remedy provided for herein (including retaining counsel to file an action or otherwise pursue any remedies) shall in any way affect Landlord&#8217;s right to pursue such remedy or any other remedy provided Landlord herein or under law or in equity, unless Landlord, in its sole discretion, elects to waive such Default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>This Lease and the Term and estate hereby granted are subject to the limitation that whenever a Default shall have happened and be continuing, Landlord shall have the right, at its election, then or thereafter while any such Default shall continue and notwithstanding the fact that Landlord may have some other remedy hereunder or at law or in equity, to give Tenant written notice of Landlord&#8217;s intention to terminate this Lease on a date specified in such notice, which date shall be not less than [***] after the giving of such notice, and upon the date so specified, this Lease and the estate hereby granted shall expire and terminate with the same force and effect as if the date specified in such notice were the date hereinbefore fixed for the expiration of this Lease, and all right of Tenant hereunder shall expire and terminate, and Tenant shall be liable as hereinafter in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 21(c)</u> provided. If any such notice is given, Landlord shall have, on such date so specified, the right of re-entry and possession of the Premises and the right to remove all persons and property therefrom and to store such property in a warehouse or elsewhere at the risk and expense, and for the account, of Tenant. Should Landlord elect to re-enter as herein provided or should Landlord take possession pursuant to legal proceedings or pursuant to any notice provided for by law, Landlord may from time to time re-let the Premises or any part thereof for such term or terms and at such rental or rentals and upon such terms and conditions as Landlord may deem advisable, with the right to make commercially reasonable alterations in and repairs to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>In the event of any termination of this Lease as in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 21</u> provided or as required or permitted by law or in equity, Tenant shall forthwith quit and surrender the Premises to Landlord, and Landlord may, without further notice, enter upon, re-enter, possess and repossess the same by summary proceedings, ejectment or otherwise, and again have, repossess and enjoy the same as if this Lease had not been made, and in any such event neither Tenant nor any person claiming through or under Tenant by virtue of any law or an order of any court shall be entitled to possession or to remain in possession of the Premises. Landlord, at its option, notwithstanding any other provision of this Lease, shall be entitled to recover from Tenant, as and for liquidated damages, the sum of;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(A)<font style="display:inline-block;width:22.12pt;"></font>all Base Rent, Additional Rent and other amounts payable by Tenant hereunder then due or accrued and unpaid: and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(B)<font style="display:inline-block;width:22.67pt;"></font>the amount equal to the aggregate of all unpaid Base Rent and Additional Rent which would have been payable if this Lease had not been terminated prior to the end of the Term then in effect, discounted to its then present value in accordance with accepted financial practice using a rate of 5% per annum, for loss of the bargain; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(C)<font style="display:inline-block;width:22.67pt;"></font>all other damages and expenses (including reasonable attorneys&#8217; fees and expenses), if any, which Landlord shall have sustained by reason of the breach of any provision of this Lease; less</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(D)<font style="display:inline-block;width:22.12pt;"></font>the net proceeds of any re-letting actually received by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>Nothing herein contained shall limit or prejudice the right of Landlord, in any bankruptcy or insolvency proceeding, to prove for and obtain as liquidated damages by reason of such termination an amount equal to the maximum allowed by any bankruptcy or insolvency proceedings, or to prove for and obtain as liquidated damages by reason of such termination, an amount equal to the maximum allowed by any statute or rule of law whether such amount shall be greater or less than the excess referred to above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>Nothing in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 21</u> shall be deemed to affect the right of either party to indemnifications pursuant to this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>If Landlord terminates this Lease upon the occurrence of a Default, Tenant will quit and surrender the Premises to Landlord or its agents, and Landlord may, without further notice, enter upon, re-enter and repossess the Premises by summary proceedings, ejectment or otherwise. The words &#8220;enter&#8221;, &#8220;re-enter&#8221;, and &#8220;re-entry&#8221; are not restricted to their technical legal meanings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</font></font>If either party shall be in default in the observance or performance of any provision of this Lease, and an action shall be brought for the enforcement thereof in which it shall be determined that such party was in default, the party in default shall pay to the other all fees, costs and other expenses which may become payable as a result thereof or in connection therewith, including reasonable attorneys&#8217; fees and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</font></font>If Tenant shall default in the keeping, observance or performance of any covenant, agreement, term, provision or condition herein contained, Landlord, without thereby waiving such default, may perform the same for the account and at the reasonable expense of Tenant (a) immediately or at any time thereafter and without notice in the case of emergency or in case such default will result in a violation of any legal or insurance requirements, or in the imposition of any lien against all or any portion of the Premises, and (b) in any other case if such default continues after any applicable cure period provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 20</u>. All reasonable costs and expenses incurred by Landlord and/or the Condominium Board in connection with any such performance by it for the account of Tenant and all reasonable costs and expenses, including attorneys&#8217; fees and disbursements incurred by Landlord and/or the Condominium Board in any action or proceeding (including any summary dispossess proceeding) brought by Landlord and/or the Condominium Board to enforce any obligation of Tenant under this Lease and/or the right of Landlord and/or the Condominium Board in or to the Premises, shall be paid by Tenant to Landlord within [***] after demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</font></font>Independent of the exercise of any other remedy of Landlord hereunder or under applicable law, Landlord may conduct an environmental test of the Premises as generally described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30(d)</u>, at Tenant&#8217;s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</font></font>Nothing contained in this Lease shall be construed as limiting or precluding the recovery by Landlord against Tenant of any sums or damages to which, in addition to the damages particularly provided above, Landlord may lawfully be entitled by reason of any default hereunder on the part of Tenant. Anything in this Lease to the contrary notwithstanding, during the continuation of any default by Tenant, Tenant shall not be entitled to exercise any rights or options, or to receive any funds or proceeds being held, under or pursuant to this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</font></font>Tenant waives and surrenders all right and privilege that Tenant might have under or by reason of any present or future law to redeem the Premises or to have a continuance of this Lease after Tenant is dispossessed or ejected therefrom by process of law or under the terms of this Lease or after any termination of this Lease. Tenant also waives the provisions of any law relating to notice and/or delay in levy of execution in case of any eviction or dispossession for nonpayment of rent, and the provisions of any successor or other law of like import.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</font></font>Except as otherwise provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 21</u>, no right or remedy herein conferred upon or reserved to Landlord is intended to be exclusive of any other right or remedy, and every right and remedy shall be cumulative and in addition to any other legal or equitable right or remedy given hereunder, or now or hereafter existing. No waiver of any provision of this Lease shall be deemed to have been made unless expressly so made in writing. Landlord shall be entitled, to the extent permitted by law, to seek injunctive relief in case of the violation, or attempted or threatened violation, of any provision of this Lease, or to seek a decree compelling observance or performance of any provision of this Lease, or to seek any other legal or equitable remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</font></font>Landlord may continue to collect Rent as the same becomes due without terminating this Lease and without waiving any other rights or remedies Landlord may have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</font></font>Anything contained herein to the contrary notwithstanding, if any termination of this Lease shall be stayed by order of any court having jurisdiction over any proceeding related to an insolvency event described herein, or by federal or state statute, then, following the expiration of any such stay, or if the trustee appointed in any such proceeding, Tenant or Tenant as debtor-in-possession shall fail to assume Tenant&#8217;s obligations under this Lease within the period prescribed therefor by law (or within ninety (90) days after entry of the order for relief if no such period is prescribed by law) or such other period as may be allowed by the court, or if said trustee, Tenant or Tenant as debtor-in-possession shall fail to provide adequate protection of Landlord&#8217;s right, title and interest in and to the Premises or adequate assurance of the complete and continuous future performance of Tenant&#8217;s obligations under this Lease, Landlord, to the extent permitted by law or by leave of the court having jurisdiction over such proceeding, shall have the right, at its election, to terminate this Lease on [***] notice to Tenant, Tenant as debtor-in-possession or said trustee and upon the expiration of said [***] period this Lease shall cease and expire as aforesaid and Tenant, Tenant as debtor-in-possession or said trustee shall promptly quit and surrender the Premises as aforesaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiv)</font></font>Except as expressly provided herein, none of Landlord or any Landlord Party shall be liable for consequential damages hereunder. [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.</font></font><b style="font-weight:bold;">Assignment and Subletting</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">General Prohibition</b>. &#160;Without Landlord&#8217;s prior written consent subject to and on the conditions described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 22</u>, Tenant shall not, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the Premises or any part thereof or mortgage, pledge, or hypothecate its leasehold interest or grant any concession or license within the Premises, and any attempt to do any of the foregoing shall be void and of no effect. If Tenant is a corporation, partnership or limited liability company, the shares or other ownership interests thereof which are not actively traded upon a stock exchange or in the over-the-counter market, a transfer or series of related or unrelated transfers whereby twenty-five percent (25%) or more of the issued and outstanding shares or other direct or indirect ownership interests of such corporation, partnership or limited liability company are, or voting control is, transferred</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(but excepting transfers upon deaths of individual owners) from a person or persons or entity or entities which were owners thereof at the time of execution of this Lease to persons or entities who were not owners of [***] the shares or other ownership interests of the corporation, partnership or limited liability company at the time of execution of this Lease, shall be deemed an assignment of this Lease requiring the consent of Landlord as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 22</u>. Notwithstanding the foregoing, any public offering of shares or other ownership interest in Tenant on a nationally recognized domestic U.S. stock exchange shall not be deemed an assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If this Lease is assigned to any person or entity pursuant to the provisions of 11 U.S.C. Section&#160;101 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">et seq.</u>, or any successor statute (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;), any and all monies or other consideration payable or otherwise to be delivered in connection with such assignment shall be paid or delivered to Landlord, shall be and remain the exclusive property of Landlord and shall not constitute property of Tenant or of the estate of Tenant within the meaning of the Bankruptcy Code. Any and all monies or other consideration constituting Landlord&#8217;s property under the preceding sentence not paid or delivered to Landlord shall be held in trust for the benefit of Landlord and shall be promptly paid to or turned over to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If Tenant desires to assign, hypothecate or otherwise transfer this Lease or to sublet the Premises other than pursuant to a Permitted Assignment (as defined below), then at least fifteen (15) business days, but not more than forty-five (45) business days, before the date Tenant desires the assignment or sublease to be effective (the &#8220;<b style="font-weight:bold;">Assignment Date</b>&#8221;), Tenant shall give Landlord a notice (the &#8220;<b style="font-weight:bold;">Assignment Notice</b>&#8221;) containing such information about the proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous Materials proposed to be used, stored, handled, treated, generated in or released or disposed of from the Premises, the Assignment Date, any relationship between Tenant and the proposed assignee or sublessee, and all material terms and conditions of the proposed assignment or sublease, including a copy of the proposed assignment or sublease in its final form, and such other information as Landlord may deem reasonably necessary or appropriate to its consideration as to whether to grant its consent (the &#8220;<b style="font-weight:bold;">Assignment Information</b>&#8221;). Notwithstanding the foregoing, in advance of providing the Assignment Notice, [***]. Landlord may, by giving written notice to Tenant within fifteen (15) business days after receipt of the Assignment Notice: (i) grant such consent, (ii) refuse such consent, in its sole and absolute discretion, if (A) the proposed assignment, hypothecation or other transfer or subletting concerns more than (together with all other then effective subleases) fifty percent (50%) of the Premises or (B) the proposed assignee or subtenant is a tenant of the Project or any other property owned (in whole or in part) or managed by Landlord or an subsidiary or affiliate of Landlord or any other Person that has, within the six (6) months prior, initiated negotiations with Landlord regarding, or toured (or made an appointment to tour) the Project with a view to, [***], (iii) refuse such consent, in its reasonable discretion, if the proposed subletting concerns (together with all other then effective subleases) fifty percent (50%) or less of the Premises (provided that Landlord shall further have the right to review and approve or disapprove the proposed form of sublease prior to the effective date of any such subletting), (iv) sublease such portion of the Premises from the Tenant on the terms described in the Assignment Notice, or (v) terminate this Lease with respect to the space described in the Assignment Notice as of the Assignment Date (an &#8220;<b style="font-weight:bold;">Assignment Termination</b>&#8221;). If Landlord delivers notice of its election to exercise an Assignment Termination, Tenant shall have the right to withdraw such Assignment Notice by written notice to Landlord of such election within five (5) business days after Landlord&#8217;s notice electing to exercise the Assignment Termination. If Tenant withdraws such Assignment Notice, this Lease shall continue in full force and effect. If Tenant does not withdraw such Assignment Notice, this Lease, and the term and estate herein granted, shall terminate as of the Assignment Date with respect to the space described in such Assignment Notice. No failure of Landlord to exercise any such option to terminate this Lease, or to deliver a timely notice in response to the Assignment Notice, shall be deemed to be Landlord&#8217;s consent to the proposed assignment, sublease or other transfer. [***]. Any Person to which this Lease is assigned pursuant to the provisions of the Bankruptcy Code shall be deemed without further act or deed to have assumed all of the obligations arising under this Lease on and after the date of such assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If Tenant assumes this Lease and proposes to assign the same pursuant to the provisions of the Bankruptcy Code to any Person who shall have made a <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">bona fide</u> offer to accept an assignment of this Lease on terms acceptable to Tenant, then notice of such proposed assignment shall be given to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Landlord by Tenant no later than [***] after receipt by Tenant, but in any event no later than [***] prior to the date that Tenant shall make application to a court of competent jurisdiction for authority and approval to enter into such assignment and assumption. Such notice shall set forth (i)&#160;the name and address of such Person, (ii)&#160;all of the terms and conditions of such offer, and (iii)&#160;adequate assurance of future performance by such Person under the Lease as set forth below, including, without limitation, the assurance referred to in Section&#160;365(b)(3) of the Bankruptcy Code. Landlord shall have the prior right and option, to be exercised by notice to Tenant given at any time prior to the effective date of such proposed assignment, to accept an assignment of this Lease upon the same terms and conditions and for the same consideration, if any, as the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">bona fide</u> offer made by such Person, less any brokerage commissions which would otherwise be payable by Tenant out of the consideration to be paid by such Person in connection with the assignment of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The term &#8220;adequate assurance of future performance&#8221; as used in this Lease shall mean that any proposed assignee shall, among other things, (i)&#160;deposit with Landlord on the assumption of this Lease a sum equal to [***] of the then Base Rent as security for the faithful performance and observance by such assignee of the terms and obligations of this Lease, (ii)&#160;furnish Landlord with financial statements of such assignee for the prior three (3) fiscal years, as finally determined after an audit and certified as correct by a certified public accountant, which financial statements shall show (A) net annual operating income of at least [***] the then annual Base Rent for each of such three (3) years and (B) a net worth of at least [***] the aggregate Base Rent payable during the remaining term of the Lease, (iii)&#160;grant to Landlord a security interest in such property of the proposed assignee as Landlord shall deem necessary to secure such assignee&#8217;s future performance under this Lease, and (iv)&#160;provide such other information or take such action as Landlord, in its reasonable judgment shall determine is necessary to provide adequate assurance of the performance by such assignee of its obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>If, at any time after the originally named Tenant herein may have assigned Tenant&#8217;s interest in this Lease, this Lease shall be disaffirmed or rejected in any insolvency proceeding of the types described herein, or in any similar proceeding, or in the event of termination of this Lease by reason of any such proceeding or by reason of lapse of time following notice of termination based upon any Default, each prior Tenant, including, without limitation, the originally named Tenant, upon request of Landlord given within thirty (30) days next following any such disaffirmance, rejection or termination (and actual notice thereof to Landlord in the event of a disaffirmance or rejection or in the event of termination other than by act of Landlord), shall (i)&#160;pay to Landlord all Fixed Rent and other items of Rental due and owing by the assignee to Landlord under this Lease to and including the date of such disaffirmance, rejection or termination, and (ii)&#160;as &#8220;tenant&#8221;, enter into a new lease with Landlord of the Premises for a term commencing on the effective date of such disaffirmance, rejection or termination and ending on the Expiration Date, unless sooner terminated as in such lease provided, at the same Fixed Rent and upon the then executory terms, covenants and conditions as are contained in this Lease, except that (A)&#160;Tenant&#8217;s rights under the new lease shall be subject to the possessory rights of the assignee under this Lease and the possessory rights of any person claiming through or under such assignee or by virtue of any statute or of any order of any court, (B)&#160;such new lease shall require that Tenant shall cure all defaults existing under this Lease with due diligence, and (C)&#160;such new lease shall require Tenant to pay all items of Rental reserved in this Lease which, had this Lease not been so disaffirmed, rejected or terminated, would have accrued after the date of such disaffirmance, rejection or termination with respect to any period prior thereto. If any such prior Tenant shall default in its obligation to enter into said new lease for a period of ten (10) days next following Landlord&#8217;s request therefor, then, in addition to all other rights and remedies by reason of such default, either at law or in equity, Landlord shall have the same rights and remedies against such Tenant as if such Tenant had entered into such new lease and such new lease had thereafter been terminated as of the commencement date thereof by reason of such Tenant&#8217;s default thereunder. Notwithstanding anything to the contrary contained herein, Landlord&#8217;s consent to an assignment of this Lease or a subletting of any portion of the Premises to any Affiliate of Tenant shall not be required for so long as the transferee remains an Affiliate of Tenant and assumes all of the obligations of Tenant under this Lease, provided that Landlord shall have the right to approve the form of any such sublease or assignment. In addition, Tenant shall have the right to assign this Lease, upon thirty (30) days prior written notice to Landlord but without obtaining Landlord&#8217;s prior written consent, to a corporation or other entity which is a successor-in-interest to Tenant, by way of merger, consolidation or corporate reorganization, or by the purchase of all or substantially all of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the assets or the ownership interests of Tenant provided that (i) such merger or consolidation, or such acquisition or assumption, as the case may be, is for a good business purpose and not principally for the purpose of transferring this Lease, and (ii) the net worth (as determined in accordance with generally accepted accounting principles (&#8220;<b style="font-weight:bold;">GAAP</b>&#8221;)) of the assignee is not less than the net worth (as determined in accordance with GAAP) of Tenant as of the date of Tenant&#8217;s most current quarterly or annual financial statements, and (iii) such assignee shall agree in writing to assume all of the terms, covenants and conditions of this Lease from and after the effective date of the assignment (each of the transactions described in this paragraph, a &#8220;<b style="font-weight:bold;">Permitted Assignment</b>&#8221;). For the purposes of this Lease, &#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; shall mean a person or entity which shall Control, be under the Control of, or be under common Control with, the person or entity in question, and &#8220;Control&#8221; and &#8220;control&#8221; shall mean the direct or indirect legal or beneficial ownership of more than fifty percent (50%) of the outstanding voting stock of a corporation, or of more than fifty percent (50%) of any other equity and voting interest if not a corporation, and the possession of power to direct or cause the direction of the management and policy of such corporation or other entity, whether through the ownership of voting securities, by statute or according to the provisions of a contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Additional Conditions</b>. As a condition to any such assignment or subletting, whether or not Landlord&#8217;s consent is required, Landlord may require:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>that any assignee or subtenant agree, in writing at the time of such assignment or subletting, that if Landlord gives such party notice that Tenant is in default under this Lease, such party shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments will be received by Landlord without any liability except to credit such payment against those due under this Lease, and any such third party shall agree to attorn to Landlord or its successors and assigns should this Lease be terminated for any reason; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, in no event shall Landlord or its successors or assigns be obligated to accept such attornment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>a list of Hazardous Materials, certified by the proposed assignee or sublessee to be true and correct, which the proposed assignee or sublessee intends to use, store, handle, treat, generate in, release or dispose of from the Premises, together with copies of all documents relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by the proposed assignee or subtenant in the Premises or on the Project, prior to the proposed assignment or subletting, including, without limitation: permits; approvals; reports and correspondence; storage and management plans; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute discretion); and all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks. Neither Tenant nor any such proposed assignee or subtenant is required, however, to provide Landlord with any portion(s) of such documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>that the originally named Tenant herein reaffirm its continuing primary liability under this Lease; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>that the assignee or subtenant remake the representations and warranties of Tenant hereunder as of the effective date of such assignment or subletting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><b style="font-weight:bold;">No Release of Tenant, Sharing of Excess Rents</b>. Notwithstanding any assignment or subletting, Tenant and any guarantor or surety of Tenant&#8217;s obligations under this Lease shall at all times remain fully and primarily responsible and liable for the payment of Rent and for compliance with all of Tenant&#8217;s other obligations under this Lease. If the Rent due and payable by a sublessee or assignee (or a combination of the rental payable under such sublease or assignment plus any bonus or other consideration therefor or incident thereto in any form) exceeds the sum of (i) the Rent payable under this Lease, (excluding however, any Rent payable under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 22</u>) and (ii) [***]. If Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for Tenant&#8217;s</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">obligations under this Lease, all rent from any such subletting, and Landlord as assignee and as attorney-in-fact for Tenant, or a receiver for Tenant appointed on Landlord&#8217;s application, may collect such rent and apply it toward Tenant&#8217;s obligations under this Lease; except that, until the occurrence of a Default, Tenant shall have the right to collect such rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><b style="font-weight:bold;">No Waiver</b>. &#160;The consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or any sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release Tenant or any assignee or sublessee of Tenant from full and primary liability under this Lease. The acceptance of Rent hereunder, or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment or other transfer of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font><b style="font-weight:bold;">Prior Conduct of Proposed Transferee. &#160;</b>Notwithstanding any other provision of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 22</u>, if (i) the proposed assignee or sublessee of Tenant has been required by any prior landlord, lender or Governmental Authority to take remedial action in connection with Hazardous Materials contaminating a property, where the contamination resulted from such party&#8217;s action or use of the property in question, (ii) the proposed assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority), or (iii) the risk that Landlord would be targeted as a responsible party in connection with the remediation of any pre-existing environmental condition in the vicinity of or underlying the Project would be materially increased or exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord shall have the absolute right to refuse to consent to any assignment or subletting to any such party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.</font></font><b style="font-weight:bold;">Estoppel Certificate. &#160;</b>Tenant shall, within fifteen (15) business days of written notice from Landlord, execute, acknowledge and deliver a statement in writing in any form reasonably requested by a proposed lender or purchaser, (i) certifying that this Lease is unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii) acknowledging, to Tenant&#8217;s knowledge, that there are not any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (iii) setting forth such further information with respect to the status of this Lease or the Premises as may be reasonably requested thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant&#8217;s failure to deliver such statement within such time shall, at the option of Landlord, be conclusive upon Tenant that the Lease is in full force and effect and without modification except as may be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.</font></font><b style="font-weight:bold;">Quiet Enjoyment</b>. &#160;So long as Tenant shall perform all of the covenants and agreements herein required to be performed by Tenant, Tenant shall, subject to the terms of this Lease and the Superior Instruments, at all times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25.</font></font><b style="font-weight:bold;">Prorations.</b> &#160;All prorations required or permitted to be made hereunder shall be made on the basis of a three hundred sixty (360) day year and thirty (30) day months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26.</font></font><b style="font-weight:bold;">Rules and Regulations</b>. &#160;Tenant shall, at all times during the Term and any extension thereof, comply with all reasonable rules and regulations at any time or from time to time established by Landlord covering use of the Premises and the Project (the &#8220;<b style="font-weight:bold;">Rules and Regulations</b>&#8221;). The current Rules and Regulations are attached hereto as <b style="font-weight:bold;">Exhibit E</b>. If there is any conflict between said Rules and Regulations and other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or obligation for the breach of any Rules or Regulations by other tenants in the Project and shall not enforce such Rules and Regulations in a discriminatory manner. Such rules and regulations may include, without limitation, rules and regulations relating to the use of the Project amenities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and/or rules and regulations which are intended to encourage social distancing, promote and protect health and physical well-being within the Building and the Project and/or intended to limit the spread of Infectious Conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.</font></font><b style="font-weight:bold;">Subordination</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The following capitalized terms, whenever used in this Lease, shall have the respective meanings ascribed to such terms as follows: (i) &#8220;<b style="font-weight:bold;">Superior Instruments</b>&#8221; shall mean each of the Ground Lease, the Condominium Declaration and any Superior Lease or Mortgage, the Operating Agreement (as defined in the Ground Lease) and all matters to which any of the foregoing are subordinate; (ii) &#8220;<b style="font-weight:bold;">Ground Lease</b>&#8221; shall mean that certain Agreement of Lease, dated as of December 29, 2006, between New York City Health and Hospitals Corporation, a New York not-for-profit corporation, as landlord, and Landlord, as tenant, entered into in respect of the Project and as the same may be further amended or otherwise modified; (iii) &#8220;<b style="font-weight:bold;">Ground Landlord</b>&#8221; shall mean the then landlord under the Ground Lease; (iv) intentionally omitted; (v) &#8220;<b style="font-weight:bold;">Superior Leases</b>&#8221; shall mean the leases to which this Lease is subject and subordinate; (vi) &#8220;<b style="font-weight:bold;">Superior Lessor</b>&#8221; shall mean the lessor under a Superior Lease; (vii) &#8220;<b style="font-weight:bold;">Superior Party</b>&#8221; shall mean each of the Ground Landlord, any Superior Lessor, the Condominium Board, any Mortgagee and the City of New York; (viii) &#8220;<b style="font-weight:bold;">Mortgage</b>&#8221; shall mean any mortgage, deed of trust, security assignment and other encumbrance now existing or hereafter created on or against the Project or the Premises, and all amendments, restatements, renewals, modifications, consolidations, refinancing, assignments and extensions thereof; (ix) &#8220;<b style="font-weight:bold;">Mortgagee</b>&#8221; shall mean the Holder or Holders (including the agent for any lending syndicate) of a Mortgage and shall be deemed to include the beneficiary under a deed of trust; and (x) the &#8220;<b style="font-weight:bold;">Condominium Declaration</b>&#8221; shall have the meaning set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On or about December 4, 2014, the Project was subjected to the provisions of Article 9-B of the New York Real Property Law, thereby creating The East River Science Park Condominium (the &#8220;<b style="font-weight:bold;">Condominium</b>&#8221;) in accordance with that certain Declaration Establishing a Plan for Condominium Ownership of the Premises known as 430-450 East 29th Street, New York, New York Pursuant to Article 9-B of the Real Property Law of the State of New York, as the same may be further amended or otherwise modified (the &#8220;<b style="font-weight:bold;">Condominium Declaration</b>&#8221;). The units of the Condominium are sometimes referred to herein individually as a &#8220;<b style="font-weight:bold;">Unit</b>&#8221; and collectively as &#8220;<b style="font-weight:bold;">Units</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>This Lease and Tenant&#8217;s interest and rights hereunder are hereby made and shall be subject and subordinate at all times to the Superior Instruments and to the lien of any Mortgage, without the necessity of any further instrument or act on the part of Tenant; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u> that so long as there is no Default hereunder, Tenant&#8217;s right to possession of the Premises shall not be disturbed by the Holder of any such Mortgage. Tenant agrees, at the election of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees [***], to execute, acknowledge and deliver such instruments, confirming such subordination, and such instruments of attornment as shall be requested by any such Holder, provided any such instruments contain appropriate non-disturbance provisions assuring Tenant&#8217;s quiet enjoyment of the Premises as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 24</u> hereof. Notwithstanding the foregoing, any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant&#8217;s consent, by notice in writing to Tenant, and thereupon this Lease shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery or recording and in that event such Holder shall have the same rights with respect to this Lease as though this Lease had been executed prior to the execution, delivery and recording of such Mortgage and had been assigned to such Holder. If (i) in connection with obtaining financing for the Project, or of any Superior Lease, or any modification to the Condominium Declaration, a banking, insurance or other Superior Party shall request reasonable modifications in this Lease as a condition to such financing or modification to the Condominium Declaration, and/or (ii) the provisions of any Superior Instruments require Tenant to deliver any instruments or acknowledgements, Tenant will not unreasonably withhold its consent thereto and/or unreasonably condition or delay the delivery thereof, as the case may be, provided that such modifications and/or instruments or acknowledgements, in either instance, do not (A) extend or shorten the Term, (B) reduce the usable area of the Premises, (C) increase the Base Rent or any Additional Rent (D) except to a de minimis extent, otherwise increase the obligations of Tenant or the rights of Landlord under this Lease or (E) except to a de minimis extent, otherwise decrease the obligations of Landlord or the rights of Tenant under this Lease. At Ground Landlord&#8217;s option, on the termination of the Ground Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pursuant to an event of default by Landlord as the tenant thereunder, the Tenant shall attorn to, or shall enter into a direct lease on terms identical to the Lease with, Ground Landlord for the balance of the unexpired term of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>By its execution and delivery of this Lease, Tenant expressly acknowledges and agrees that it shall comply, and cause its agents, employees, contractors, subcontractors, subtenants, operators, licensees, franchisees, concessionaires or other occupants of the Premises to comply, fully and faithfully at all times, to the extent applicable to the Premises, with all terms, covenants and conditions of the Superior Instruments of which Tenant has been given notice from time to time (including but not limited to those terms, covenants and conditions appearing in the excerpts of Superior Instruments attached as Exhibit M hereto) and which by their terms are applicable to a space lease of all or any portion of the Project (collectively, &#8220;<b style="font-weight:bold;">Tenant&#8217;s Superior Instrument Obligations</b>&#8221;), such acknowledgment and agreement being a material inducement to Landlord&#8217;s execution and delivery of this Lease and leasing of the Premises to Tenant. Tenant further acknowledges and agrees that, pursuant to the Ground Lease, any act or omission of Tenant or any of its agents, employees, contractors, subcontractors, subtenants, operators, licensees, franchisees, concessionaires or other occupants of the Premises that violates any provision of the Ground Lease may be deemed to be a violation of such provision by Landlord as the tenant under the Ground Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant acknowledges and agrees that, notwithstanding anything herein to the contrary, Landlord may modify or amend this Lease from time to time in order to avoid the occurrence of a default under the Superior Instruments, provided such modification or amendment does not (i) extend or shorten the Term, (ii) reduce the usable area of the Premises, (iii) increase the Base Rent or any Additional Rent (iv) except to a de minimis extent, otherwise increase the obligations of Tenant or the rights of Landlord under this Lease or (v) except to a de minimis extent, otherwise decrease the obligations of Landlord or the rights of Tenant under this Lease. Tenant shall promptly execute any such modification or amendment to this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Condominium Board shall be a third party beneficiary of all sections in this Lease in which it is mentioned. In the event that, under the Condominium Documents, any duty of Landlord hereunder is within the power of the Condominium Board, (i) if Landlord and Condominium Board are Affiliates, such duty hereunder shall be a duty to cause Condominium Board to take such action, and (ii) if Landlord and Condominium Board are not Affiliates, such duty hereunder shall be a duty to take commercially reasonable efforts to cause Condominium Board to take such action. To the extent that Condominium Board shall fulfill any of Landlord&#8217;s duties hereunder, the same shall constitute satisfaction by Landlord of such duties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.</font></font><b style="font-weight:bold;">Surrender</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Upon the expiration of the Term or earlier termination of Tenant&#8217;s right of possession, Tenant shall surrender the Premises to Landlord in the same condition as received, subject to any Alterations or Installations permitted by Landlord to remain in the Premises, free of Hazardous Materials brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises by any person other than a Landlord Party (collectively, &#8220;<b style="font-weight:bold;">Tenant HazMat Operations</b>&#8221;) and with all Hazardous Materials Clearances in place, and in broom clean condition, ordinary wear and tear and casualty loss and condemnation (which are covered by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 18</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">19</u>) excepted. At least three (3) months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required by any Governmental Authority) to be taken by Tenant in order to surrender the Premises (including any Installations permitted by Landlord to remain in the Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and otherwise released for unrestricted use and occupancy (the &#8220;<b style="font-weight:bold;">Surrender Plan</b>&#8221;). Such Surrender Plan shall be accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of any Tenant Party with respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises, and shall be subject to the review and approval of Landlord&#8217;s environmental consultant. In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily completed and Landlord shall have the right, subject to reimbursement at Tenant&#8217;s expense as set forth below, to cause Landlord&#8217;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of this Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of-pocket expense incurred by Landlord for Landlord&#8217;s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify satisfactory completion of the same, which cost [***]. Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord&#8217;s environmental consultant with respect to the surrender of the Premises to third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address any residual effect of Tenant HazMat Operations in, on or about the Premises, such failure shall be deemed a failure to vacate in accordance with this Lease, and Landlord shall retain all remedies available under this Lease, at law or equity including, without limitation, the right to collect rent on a holdover basis, and Landlord shall have the right to take such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Project are surrendered free from any residual impact from Tenant HazMat Operations, the cost of which actions shall be reimbursed by Tenant as Additional Rent, without regard to the limitation set forth in the first paragraph of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 28</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Prior to the expiration of the Term, Tenant shall immediately return to Landlord all keys and/or access cards to parking facilities, the Project, restrooms or all or any portion of the Premises furnished to or otherwise procured by Tenant. If any such access card or key is lost, Tenant shall pay to Landlord, at Landlord&#8217;s election, either the cost of replacing such lost access card or key or the cost of reprogramming the access security system in which such access card was used or changing the lock or locks opened by such lost key. Any Tenant&#8217;s Property, Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned and may be stored, removed, and disposed of by Landlord at Tenant&#8217;s expense, and Tenant waives all claims against Landlord for any damages resulting from Landlord&#8217;s retention and/or disposition of such property. All obligations of Tenant hereunder not fully performed as of the termination of the Term, including the obligations of Tenant under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30</u> hereof, shall survive the expiration or earlier termination of the Term, including, without limitation, indemnity obligations, payment obligations with respect to Rent and obligations concerning the condition and repair of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.</font></font><b style="font-weight:bold;">Waiver of Jury Trial; Consent to Jurisdiction; Prohibited Parties</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>TENANT AND LANDLORD WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT ARISING OUT OF THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Landlord and Tenant each hereby (i) irrevocably and unconditionally consents and submits to the jurisdiction of any Federal, state, county or municipal court sitting in the County and State of New York in respect to any action or proceeding concerning any matters arising out of or in any way relating to this Lease; (ii) irrevocably waives all objections as to venue and any and all rights it may have to seek a change of venue with respect to any such action or proceedings if the same is brought in the County of New York; (iii) agrees that this Lease and the rights and obligations of the parties shall be governed by and construed, and all actions, proceedings and all controversies and disputes arising under or of or relating to this Lease shall be resolved in accordance with the internal substantive laws of the State of New York applicable to agreements made and to be wholly performed within the State of New York, (iv) waives any defense to any action or proceeding granted by the laws of any other country or jurisdiction unless such defense is also allowed by the laws of the State of New York and (v) agrees that any final judgment rendered against it in any such action or proceeding shall be conclusive and may be enforced in any other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by suit on the judgment or in any other manner provided by law. Tenant hereby represents that it is subject to service of process in the State of New York and covenants that it will remain so subject for the term of this Lease. If for any reason Tenant should cease to be so subject to service of process in the State of New York, Tenant hereby designates and appoints Richard Giroux, Chief Operating Officer, MeiraGTx, LLC, 450 East 29<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Street, Suites 400-403, New York, NY 10016 as its agent upon whom may be served all process, pleadings, notices or other papers which may be served upon Tenant as a result of any of its obligations under this Lease, and if such agent shall cease to act or otherwise cease to be subject to service of process in the State of New York, Tenant designates and appoints the Secretary of State of New York as its agent for service; provided, however, that the serving of such process, pleadings, notices or other papers shall not constitute a condition to Tenant&#8217;s obligations hereunder. For the term of this Lease, Tenant&#8217;s agent designated herein shall accept and acknowledge in Tenant&#8217;s behalf service of any and all process in any such suit, action or proceeding brought in any such court. Tenant agrees and consents that any such service of process upon such agents and written notice of such service to the Tenant in the manner set forth herein shall be taken and held to be valid personal service upon Tenant whether or not Tenant shall then be doing, or at any time shall have done, business within the State of New York and that any such service of process shall be of the same force and validity as if service were made upon Tenant according to the laws governing the validity and requirements of such service in the State of New York, and waive all claim of error by reason of any such service. Such agents shall not have any power or authority to enter into any appearance or to file any pleadings in connection with any suit, action or other legal proceedings against Tenant or to conduct the defense of any such suit, action or any other legal proceeding except as expressly authorized by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant represents and warrants to Landlord that (i) it and each Affiliate or Principal directly or indirectly owning an interest in it is not a Prohibited Entity (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29(d)</u>), (ii) none of the funds or other assets of it constitute property of, or are beneficially owned, directly or indirectly, by, any Person (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29(d)</u>) on the List (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29(d)</u>), (iii) no Person on the List has any interest of any nature whatsoever in it (whether directly or indirectly), and (iv) none of its funds have been derived from any unlawful activity with the result that the investment in it is prohibited by law or that this Lease is in violation of law. Tenant covenants and agrees (I) to comply with all Legal Requirements relating to money laundering, anti-terrorism, trade embargos and economic sanctions, now or hereafter in effect, (II) to immediately notify the other in writing if any of the representations, warranties or covenants set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29(c)</u> are no longer true or have been breached or if it has a reasonable basis to believe that they may no longer be true or have been breached, (III) not to use funds from any Person on the List to make any payment due to Landlord under this Lease and (IV) at the request of the other, to provide such information as may be reasonably requested by Landlord to determine the other&#8217;s compliance with the terms hereof. Tenant hereby acknowledges and agrees that inclusion on the List of Tenant or any Affiliate or Principal of Tenant at any time during this Lease Term shall be a material default of this Lease. Tenant, and all beneficial owners of Tenant, are currently (i) in compliance with and shall at all times during the Term of this Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;<b style="font-weight:bold;">OFAC</b>&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;<b style="font-weight:bold;">OFAC Rules</b>&#8221;), (ii) not listed on, and shall not during the Term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (iii) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules. Notwithstanding anything to the contrary contained herein, Tenant shall not permit the Premises or any portion thereof to be used or occupied by any Person on the List (on a permanent, temporary or transient basis), and any such use or occupancy of the Premises by any such Person shall be a material default of this Lease. Notwithstanding anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29(c)</u>, (x) so long as Landlord or its ultimate parent is a company whose capital stock is traded on a recognized public exchange, Landlord makes no representations or warranties as to the persons or entities owning an interest in Landlord, and (y) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The following capitalized terms, whenever used in this Lease, shall have the respective meanings ascribed to such terms as follows: (i) &#8220;<b style="font-weight:bold;">Prohibited Entity</b>&#8221; shall mean (A) any Prohibited Person or (B) any Person that is identified on the List; (ii) &#8220;<b style="font-weight:bold;">Prohibited Person</b>&#8221; shall mean (A) any Person (1) that</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">is in default, after notice and beyond the expiration of any applicable cure period, of such Person&#8217;s obligations under any material written agreement with the City, the State of New York or any of their instrumentalities, or (2) that directly controls, is controlled by, or is under common control with a Person that is in default, after notice and beyond the expiration of any applicable cure period, of such Person&#8217;s obligations under any material written agreement with the City, the State of New York or any of their instrumentalities, unless, in each instance, such default or breach either (a) has been waived in writing by the City, the State of New York or any of their instrumentalities as the case may be, or (b) is being disputed in a court of law, administrative proceeding, arbitration or other forum, or (c) is cured within thirty (30) days after a determination and notice to Tenant from Landlord that such Person is a Prohibited Person as a result of such default; (B) any Person that is an Organized Crime Figure; (C) any government, or any Person that is directly or indirectly controlled (rather than only regulated) by a government, that is finally determined to be in violation of (including, but not limited to, any participant in an international boycott in violation of) the Export Administration Act of 1979, as amended, or any successor statute, or the regulations issued pursuant thereto, or any government that is, or any Person that, directly or indirectly, is controlled (rather than only regulated) by a government that is subject to the regulations or controls thereof; (D) any government, or any Person that, directly or indirectly, is controlled (rather than only regulated) by a government, the effects or the activities of which are regulated or controlled pursuant to regulations of the United States Treasury Department or executive orders of the President of the United States of America issued pursuant to the Trading with the Enemy Act of 1917, as amended; (E) any Person that is in default in the payment to the City of any real estate taxes, sewer rents or water charges totaling more than Ten Thousand and 00/100 Dollars ($10,000.00), unless such default is then being contested in good faith in accordance with applicable Legal Requirements or unless such default is cured within thirty (30) days after a determination and notice to Tenant from Landlord that such Person is a Prohibited Person as a result of such default; or (F) any Person (1) that has solely owned, at any time during the three (3) year period immediately preceding a determination of whether such Person is a Prohibited Person, any property which, while in the ownership of such Person, was acquired by the City by in rem tax foreclosure, other than a property in which the City has released or is in the process of releasing its interest pursuant to the Administrative Code of the City, or (2) that, directly or indirectly controls, is controlled by, or is under common control with a Person that has owned, at any time in the three (3) year period immediately preceding a determination of whether such Person is a Prohibited Person, any property which, while in the ownership of such Person, was acquired by the City by in rem tax foreclosure, other than a property in which the City has released or is in the process of releasing its interest to such Person pursuant to the Administrative Code of the City; (iii) &#8220;<b style="font-weight:bold;">Organized Crime Figure</b>&#8221; shall mean any Person (A) who has been convicted in a criminal proceeding for a felony or any crime involving moral turpitude or that is an organized crime figure or is reputed to have substantial business or other affiliations with an organized crime figure, or (B) who, directly or indirectly controls, is controlled by, or is under common control with, a Person who has been convicted in a criminal proceeding for a felony or any crime involving moral turpitude or that is an organized crime figure or is reputed to have substantial business or other affiliations with an organized crime figure; and, the determination as to whether any Person is an organized crime figure or is reputed to have substantial business or other affiliations with an organized crime figure shall be within the sole discretion of Landlord, which discretion shall be exercised in good faith, or as determined by the Ground Landlord in accordance with the terms of the Ground Lease; (iv) &#8220;<b style="font-weight:bold;">Person</b>&#8221; shall mean (A) an individual, corporation, limited liability company, partnership, joint venture, estate, trust, unincorporated association or other business entity, (B) any federal, state, county or municipal government (or any bureau, department, agency or instrumentality thereof), and (C) any fiduciary acting in such capacity on behalf of any of the foregoing; (v) &#8220;<b style="font-weight:bold;">List</b>&#8221; shall mean, collectively, as updated from time to time, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC pursuant to any authorizing statute, executive order or regulation; and (vi) &#8220;<b style="font-weight:bold;">Principal</b>&#8221; shall mean [***], in respect of Tenant, any Person that is a direct or indirect owner of an equity interest in Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30.</font></font><b style="font-weight:bold;">Environmental Requirements</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Prohibition/Compliance/Indemnity</b>. &#160;Tenant shall not cause or permit any Hazardous Materials (as hereinafter defined) to be brought upon, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises or the Project in violation of applicable Environmental</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Requirements (as hereinafter defined) by Tenant or any Tenant Party. If Tenant breaches the obligation stated in the preceding sentence, or if the presence of Hazardous Materials in the Premises during the Term or any holding over results in contamination of the Premises, the Project or any adjacent property, or if contamination of the Premises, the Project or any adjacent property by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises by anyone other than Landlord and Landlord&#8217;s employees, agents and contractors otherwise occurs during the Term or any holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors, employees, agents and contractors harmless from any and all actions (including, without limitation, remedial or enforcement actions of any kind, administrative or judicial proceedings, and orders or judgments arising out of or resulting therefrom), costs, claims, damages (including, without limitation, punitive damages and damages based upon diminution in value of the Premises or the Project, or the loss of, or restriction on, use of the Premises or any portion of the Project), expenses (including, without limitation, attorneys&#8217;, consultants&#8217; and experts&#8217; fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative or criminal penalties, injunctive or other relief (whether or not based upon personal injury, property damage, or contamination of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, &#8220;<b style="font-weight:bold;">Environmental Claims</b>&#8221;) which arise during or after the Term as a result of such contamination. This indemnification of Landlord by Tenant includes, without limitation, costs incurred in connection with any investigation of site conditions or any cleanup, treatment, remedial, removal, or restoration work required by any federal, state or local Governmental Authority because of Hazardous Materials present in the air, soil or ground water above, on, or under the Premises. Without limiting the foregoing, if the presence of any Hazardous Materials on the Premises, the Building, the Project or any adjacent property caused or permitted by Tenant or any Tenant Party results in any contamination of the Premises, the Building, the Project or any adjacent property, Tenant shall promptly take all actions at its sole expense and in accordance with applicable Environmental Requirements as are necessary to return the Premises, the Building, the Project or any adjacent property to the condition existing prior to the time of such contamination, provided that Landlord&#8217;s approval of such action shall first be obtained, which approval shall not unreasonably be withheld so long as such actions would not potentially have any material adverse long-term or short-term effect on the Premises, the Building or the Project. [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Business.</b> &#160;Landlord acknowledges that it is not the intent of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30</u> to prohibit Tenant from using the Premises for the Permitted Use. Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored according to all then applicable Environmental Requirements. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or from the Premises (&#8220;<b style="font-weight:bold;">Hazardous Materials List</b>&#8221;). Tenant shall deliver to Landlord an updated Hazardous Materials List at least once a year and shall also deliver an updated list before any new Hazardous Material is brought onto, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and correct copies of the following documents (the &#8220;<b style="font-weight:bold;">Haz Mat Documents</b>&#8221;) relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent with the receipt from or submission to a Governmental Authority: permits; approvals; reports and correspondence; storage and management plans, notice of violations of any Legal Requirements; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute discretion); all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks; and a Surrender Plan (to the extent surrender in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 28</u> cannot be accomplished in three (3) months). Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities. It is not the intent of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30(b)</u> to provide Landlord with information which</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">could be detrimental to Tenant&#8217;s business should such information become possessed by Tenant&#8217;s competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Tenant Representation and Warranty</b>. &#160;Tenant hereby represents and warrants to Landlord, as of the date hereof, that (i) neither Tenant nor any of its legal predecessors has been required by any prior landlord, lender or Governmental Authority at any time to take remedial action in connection with Hazardous Materials contaminating a property which contamination was permitted by Tenant or such predecessor or resulted from Tenant&#8217;s or such predecessor&#8217;s action or use of the property in question, and (ii) Tenant is not subject to any enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority). If Landlord determines that this representation and warranty was not true as of the date of this Lease, Landlord shall have the right to terminate this Lease in Landlord&#8217;s sole and absolute discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Testing</b>. &#160;Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant&#8217;s use. Tenant shall be required to pay the reasonable cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant&#8217;s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30</u>, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord&#8217;s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Underground Tanks</b>. &#160;If underground or other storage tanks storing Hazardous Materials located on the Premises or the Project are used by Tenant or are hereafter placed on the Premises or the Project by Tenant, Tenant shall install, use, monitor, operate, maintain, upgrade and manage such storage tanks, maintain appropriate records, obtain and maintain appropriate insurance, implement reporting procedures, properly close any underground storage tanks, and take or cause to be taken all other actions necessary or required under applicable state and federal Legal Requirements, as now exist or may hereafter be adopted or amended in connection with the installation, use, maintenance, management, operation, upgrading and closure of such storage tanks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Tenant&#8217;s Obligations</b>. &#160;Tenant&#8217;s obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 30</u> shall survive the expiration or earlier termination of this Lease. During any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to complete the removal from the Premises of any Hazardous Materials (including, without limitation, the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Surrender Plan), Tenant shall continue to pay the full Rent in accordance with this Lease attributable to any portion of the Premises not relet by Landlord in Landlord&#8217;s sole discretion, which Rent shall be prorated daily.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Definitions. </b> As used herein, the term &#8220;<b style="font-weight:bold;">Environmental Requirements</b>&#8221; means all applicable present and future statutes, regulations, ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to health, safety, or environmental conditions on, under, or about the Premises or the Project, or the environment, including without limitation, the following: the Comprehensive Environmental Response, Compensation and Liability Act; the Resource</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Conservation and Recovery Act; and all state and local counterparts thereto, and any regulations or policies promulgated or issued thereunder. As used herein, the term &#8220;<b style="font-weight:bold;">Hazardous Materials</b>&#8221; means and includes any substance, material, waste, pollutant, or contaminant listed or defined as hazardous or toxic, or regulated by reason of its impact or potential impact on humans, animals and/or the environment under any Environmental Requirements, asbestos and petroleum, including crude oil or any fraction thereof, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel (or mixtures of natural gas and such synthetic gas). As defined in Environmental Requirements, Tenant is and shall be deemed to be the &#8220;<b style="font-weight:bold;">operator</b>&#8221; of Tenant&#8217;s &#8220;<b style="font-weight:bold;">facility</b>&#8221; and the &#8220;<b style="font-weight:bold;">owner</b>&#8221; of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes, by-products, or residues generated, resulting, or produced therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>Tenant shall comply with (or cause to be complied with) all applicable federal, state and local laws concerning any Regulated Medical Waste that Tenant or any subtenant or occupant of the Premises produces, brings on, keeps, uses, stores, disposes or treats in or about the Premises or transported from the Premises. Tenant shall also comply with all applicable federal, state and local laws related to the health and safety of its employees. &#8220;<b style="font-weight:bold;">Regulated Medical Waste</b>&#8221; means any substance, gas, material or chemical, or any part thereof, which is defined as or included in the definition of &#8220;regulated medical waste&#8221; or words of similar import under any Environmental Requirement, including by not limited to Section 27-1502 of the New York Environmental Conservation Law, 42 U.S.C. Section 6901 et seq., the Medical Waste Tracking Act of 1988 and Track XIII of the New York State Public Health Law and the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.</font></font><b style="font-weight:bold;">Tenant&#8217;s Remedies/Limitation of Liability</b>. &#160;Landlord shall not be in default hereunder unless Landlord fails to perform any of its obligations hereunder within [***] after written notice from Tenant specifying such failure (unless such performance will, due to the nature of the obligation, require a period of time in excess of [***], then after such period of time as is reasonably necessary). Upon any default by Landlord, Tenant shall give notice by FedEx, or registered or certified mail to any Holder of a Mortgage covering the Premises and to any landlord of any lease of property in or on which the Premises are located and Tenant shall offer such Holder and/or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Project by power of sale or a judicial action if the same should prove necessary to effect a cure; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> Landlord shall have furnished to Tenant in writing the names and addresses of all such persons who are to receive such notices. All obligations of Landlord hereunder shall be construed as covenants, not conditions; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord&#8217;s obligations hereunder. All obligations of Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Premises and not thereafter. The term &#8220;<b style="font-weight:bold;">Landlord</b>&#8221; in this Lease shall mean only the owner for the time being of the Premises. Upon the transfer by such owner of its interest in the Premises, such owner shall thereupon be released and discharged from all obligations of Landlord thereafter accruing, but such obligations shall be binding during the Term upon each new owner for the duration of such owner&#8217;s ownership.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">32.</font></font><b style="font-weight:bold;">Inspection and Access</b>. &#160;Landlord and its agents, representatives, and contractors may enter the Premises at any reasonable time to inspect the Premises and to make such repairs as may be required or permitted pursuant to this Lease and for any other business purpose. Landlord and Landlord&#8217;s representatives may enter the Premises during business hours on not less than [***] advance written notice (except in the case of emergencies in which case no such notice shall be required and such entry may be at any time) for the purpose of effecting any such repairs, inspecting the Premises, showing the Premises to prospective purchasers and, during the last year of the Term, to prospective tenants or for any other business purpose. Landlord may erect a suitable sign on the Premises stating the Premises are available to let or that the Project is available for sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions on or about the Premises, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that no such easement, dedication, designation or restriction materially, adversely affects Tenant&#8217;s use or occupancy of the Premises for the Permitted Use. At Landlord&#8217;s request, Tenant shall execute such instruments as may be necessary for such easements, dedications or restrictions. Tenant shall at all times, except in the case of emergencies, have the right to escort Landlord or its agents, representatives, contractors or guests while</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the same are in the Premises, provided such escort does not materially and adversely affect Landlord&#8217;s access rights hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.</font></font><b style="font-weight:bold;">Security</b>. &#160;Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime may not in given instances prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant agrees that Landlord shall not be liable for, and Tenant waives any claim against Landlord with respect to, any loss by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any other breach of security with respect to the Premises. Tenant shall be solely responsible for the personal safety of Tenant&#8217;s officers, employees, agents, contractors, guests and invitees while any such person is in, on or about the Premises, the Building and/or the Project. Tenant shall at Tenant&#8217;s cost obtain insurance coverage to the extent Tenant desires protection against such criminal acts. All employees, contractors and/or agents of any provider of security services to the Premises engaged by Tenant shall be prohibited from carrying firearms (e.g. handguns, rifles, shotguns, etc.). Each individual employee or independent contractor of any such service provider shall have been registered with Landlord by facsimile or mail at least 48 hours in advance of such person arriving at the Project to perform service, which registration shall require such personal information and history, and photographs, as Landlord shall reasonably require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">34.</font></font><b style="font-weight:bold;">Force Majeure</b>. &#160;Landlord shall not be responsible or liable for delays in the performance of its obligations hereunder when caused by, related to, or arising out of acts of God, strikes, lockouts, or other labor disputes, vandalism, pandemics, riots, insurrections, embargoes, quarantines, weather, national, regional, or local disasters, calamities, or catastrophes, inability to obtain labor or materials (or reasonable substitutes therefor) at reasonable costs or failure of, or inability to obtain, utilities necessary for performance, governmental restrictions, orders, limitations, regulations, or controls, national emergencies, delay in issuance or revocation of permits, enemy or hostile governmental action, terrorism, insurrection, riots, civil disturbance or commotion, fire or other casualty, and other causes or events beyond the reasonable control of Landlord (&#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221;) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.</font></font><b style="font-weight:bold;">Brokers, Entire Agreement, Amendment</b>. &#160;Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;<b style="font-weight:bold;">Broker</b>&#8221;) in connection with this transaction and that no Broker brought about this transaction other than CBRE, Inc. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than the broker, if any named in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 35</u>, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">36.</font></font><b style="font-weight:bold;">Limitation on Landlord&#8217;s Liability.</b> &#160;NOTWITHSTANDING ANYTHING SET FORTH HEREIN OR IN ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT TO THE CONTRARY: (A) NEITHER LANDLORD NOR THE CONDOMINIUM BOARD SHALL BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT AND EACH SUCH OTHER PERSON ASSUME ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR CONSEQUENTIAL TO: TENANT&#8217;S PERSONAL PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES, AND/OR SCIENTIFIC, BUSINESS, ACCOUNTING AND OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY AND ALL INCOME DERIVED OR DERIVABLE THEREFROM; (B) THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD OR THE CONDOMINIUM BOARD FOR ANY ACT OR OCCURRENCE IN, ON OR ABOUT THE PREMISES OR ARISING IN ANY WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT MATTER HEREOF AND ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO LANDLORD&#8217;S INTEREST IN THE PROJECT OR ANY PROCEEDS FROM SALE OR CONDEMNATION THEREOF AND ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD&#8217;S INTEREST IN THE PROJECT OR IN CONNECTION WITH ANY SUCH LOSS; AND (C) IN NO EVENT SHALL ANY PERSONAL LIABILITY BE ASSERTED AGAINST ANY OF LANDLORD&#8217;S OR THE CONDOMINIUM BOARD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CONTRACTORS. UNDER NO CIRCUMSTANCES SHALL LANDLORD OR ANY OF LANDLORD&#8217;S OR THE CONDOMINIUM BOARD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT&#8217;S BUSINESS OR FOR ANY LOSS OF INCOME OR PROFIT THEREFROM. TENANT ACKNOWLEDGES AND AGREES THAT MEASURES AND/OR SERVICES IMPLEMENTED AT THE PROJECT, IF ANY, INTENDED TO ENCOURAGE SOCIAL DISTANCING, PROMOTE AND PROTECT HEALTH AND PHYSICAL WELL-BEING AND/OR INTENDED TO LIMIT THE SPREAD OF INFECTIOUS CONDITIONS, MAY NOT PREVENT THE SPREAD OF SUCH INFECTIOUS CONDITIONS. LANDLORD SHALL HAVE NO LIABILITY AND TENANT WAIVES ANY CLAIMS AGAINST LANDLORD WITH RESPECT TO ANY LOSS, DAMAGE OR INJURY IN CONNECTION WITH (X) THE IMPLEMENTATION, OR FAILURE OF LANDLORD OR ANY LANDLORD INDEMNIFIED PARTIES TO IMPLEMENT, ANY MEASURES AND/OR SERVICES AT THE PROJECT INTENDED TO ENCOURAGE SOCIAL DISTANCING, PROMOTE AND PROTECT HEALTH AND PHYSICAL WELL-BEING AND/OR INTENDED TO LIMIT THE SPREAD OF INFECTIOUS CONDITIONS, OR (Y) THE FAILURE OF ANY MEASURES AND/OR SERVICES IMPLEMENTED AT THE PROJECT, IF ANY, TO LIMIT THE SPREAD OF ANY INFECTIOUS CONDITIONS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">37.</font></font><b style="font-weight:bold;">Severability</b>. &#160;If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, then and in that event, it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention of the parties to this Lease that in lieu of each clause or provision of this Lease that is illegal, invalid or unenforceable, there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable clause or provision as shall be legal, valid and enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">38.</font></font><b style="font-weight:bold;">Signs; Exterior Appearance</b>. &#160;Tenant shall not, without the prior written consent of Landlord, which may be granted or withheld in Landlord&#8217;s sole discretion: (i) attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting or other projection to any outside wall of the Project, (ii) use any curtains, blinds, shades or screens other than Landlord&#8217;s standard window coverings, (iii) coat or otherwise sunscreen the interior or exterior of any windows, (iv) place any bottles, parcels, or other articles on the window sills, (v) place any equipment, furniture or other items of personal property on any exterior balcony, or (vi) paint, affix or exhibit on any part of the Premises or the Project any signs, notices, window or door lettering, placards, decorations, or advertising media of any type which can be viewed from the exterior of the Premises. Interior signs on doors and the directory tablet in the Building lobby and the fourth (4<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) floor elevator lobby (the &#8220;<b style="font-weight:bold;">Interior Signs</b>&#8221;) shall be inscribed, painted or affixed for Tenant by Landlord at the sole cost and expense of Tenant, and shall be of a size, color and type acceptable to Landlord, provided that Tenant is responsible for removing the Interior Signs at the end of the Term and that Tenant shall be responsible for restoring any damage in removing the Interior Signs. Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord&#8217;s standard lettering. The directory tablet shall be provided exclusively for the display of the name and location of tenants of the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.</font></font><b style="font-weight:bold;">Zoning Rights. &#160;</b>At all times, Landlord shall have the right, and Tenant shall not have the right, (i) to cause all or any part of the Premises and/or the zoning lot upon which the Building is located in whole or in part (hereinafter referred to solely for purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 39</u> as the &#8220;<b style="font-weight:bold;">Land</b>&#8221;) and/or the Building, to be combined with any other land, condominium units or other premises so as to constitute the combined premises into a single zoning &#8220;lot&#8221; or &#8220;development&#8221; or &#8220;enlargement&#8221; as those terms are now, or may hereafter be, defined in the Zoning Resolution of The City of New York (the &#8220;<b style="font-weight:bold;">Zoning Resolution</b>&#8221;), (ii) to cause any lot, development or enlargement at any time constituting or including all or any part of the Premises, the Land or the Building to be subdivided into two or more lots, developments or enlargements, (iii) to cause development rights (whether from the Land or other premises) to be transferred to any such lot, development or enlargement, (iv) to cause other combinations, subdivisions and transfers to be effected, whether similar or dissimilar to those now permitted by law or (v) to exploit, sell, convey, lease or otherwise transfer any so called &#8220;air rights,&#8221; &#8220;air space,&#8221; &#8220;zoning rights&#8221; or &#8220;development rights&#8221; above or appurtenant to the Land and/or the Building provided that and for so long as the foregoing actions described in clauses (i) through (v) do not (a) adversely affect Tenant or Tenant&#8217;s use and enjoyment of the Premises, (b) increase the Base Rent or any Additional Rent, (c) otherwise increase the obligations of Tenant or the rights of Landlord under this Lease or (d) otherwise decrease the obligations of Landlord or the rights of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tenant under this Lease. Tenant hereby acknowledges that it is not a &#8220;party in interest&#8221; as defined in the Zoning Resolution, and shall not and cannot become a &#8220;party in interest&#8221; under any circumstances by virtue of its leasehold interest hereunder. Tenant further acknowledges that neither Tenant nor the estate or interest of Tenant hereunder would be &#8220;adversely affected&#8221; (within the meaning of the Zoning Resolution) by any development of the Land or the Building or any such combined premises nor by the filing of any declaration combining all or a part of the Land and/or the Building with any other premises and that Tenant&#8217;s estate and interest hereunder are not and would not be superior to any such declaration. Notwithstanding the foregoing, in the event that Tenant is deemed to have any of the rights disclaimed above, or is deemed to be a party in interest, Tenant hereby transfers such rights and any rights as a party in interest to Landlord. In furtherance thereof, Tenant will within three (3) business days after written request by Landlord execute and deliver to Landlord a waiver of its right to join in a Declaration of Restrictions pursuant to Section 12-10 of the Zoning Resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">40.</font></font><b style="font-weight:bold;">Excavation.</b> &#160;In the event that an excavation, or any construction, should be undertaken in connection with the Building or other purposes upon land adjacent to the Building and/or the Project, or should be authorized to be made, Tenant shall, upon reasonable prior notice, if necessary, afford to the person or persons causing or authorized to cause such excavation or construction or other purpose, the right, for brief periods of time and in a manner so as to avoid any material interference with Tenant&#8217;s business, subject to such reasonable conditions as Tenant may reasonably impose, to enter upon the Premises for the purpose of doing such work as shall reasonably be necessary to protect or preserve the wall or walls of the Building, from injury or damage and to support them by proper foundations, pinning and/or underpinning, or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">41.</font></font><b style="font-weight:bold;">Employment Reporting and Requirements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>With regard to each annual period from July 1 through June 30 from and after the date of this Lease if requested by Landlord, Tenant shall complete with regard to itself and any of its subtenants, items 1-5, 15 and 16 of the Employment and Benefits Report (with the dates therein updated to reflect the applicable Fiscal Year) attached as Exhibit P to the Ground Lease, and Tenant shall sign such report and submit it to Landlord before July 15 immediately following such annual period; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant shall, in good faith, consider such proposals as the City and/or City-related entities may make with regard to any jobs Tenant may seek to fill in relation to its activities on or concerning the Premises, and shall provide the City and such entities with the opportunity to (A) refer candidates who are City residents having the requisite experience for the positions in question, and/or (B) create a program to train City residents for those jobs, and to report to Ground Landlord, upon Ground Landlord&#8217;s request, regarding the status of its consideration of such proposals (it being understood that Tenant shall not be required to hire any candidate which Tenant, in good faith, considers unqualified for the applicable position).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Both Landlord and Ground Landlord and their respective designees shall be beneficiaries of each such agreement by Tenant. Landlord hereby reserves the right, on behalf of itself and Ground Landlord, and their respective designees, as such third party beneficiaries, to seek specific performance by Tenant, at the expense of Tenant, of the aforesaid obligations contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 41</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.</font></font><b style="font-weight:bold;">Prohibited Distinctions.</b> &#160;Tenant covenants and agrees to be bound by the following covenants, which shall be binding for the benefit of Landlord and Ground Landlord and enforceable by Landlord and Ground Landlord against Tenant to the fullest extent permitted by law and equity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant (and any lessees of the Premises or any part thereof) shall comply with all applicable federal, state, and local laws in effect from time to time prohibiting discrimination or segregation by reason of age, race, creed, religion, sex, color, national origin, ancestry, sexual orientation or affectional preference, disability, or marital status (collectively, &#8220;<b style="font-weight:bold;">Prohibited Distinctions</b>&#8221;) in the lease or occupancy of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall not effect or execute any agreement, lease, conveyance, or other instrument whereby the lease or occupancy of the Premises, or any part thereof, is restricted upon the basis of any Prohibited Distinction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant (and any lessees of the Premises or any part thereof) shall include the covenants of (a) and (b) in any agreement, sublease, conveyance, or other instrument with respect to the lease or occupancy of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">43.</font></font><b style="font-weight:bold;">Application for Benefits. </b>Landlord hereby notifies Tenant that Landlord intends may avail itself of the ICIP and/or ICAP. In connection therewith, all of Tenant&#8217;s construction managers, contractors and subcontractors employed in connection with construction work at the Building shall be contractually required by Tenant to comply with the New York City Department of Small Business Services/Division of Labor Services (&#8220;<b style="font-weight:bold;">DLS</b>&#8221;) requirements applicable to construction projects benefiting from the ICIP, ICAP, and/or other such incentive programs. Such compliance, as of the date hereof, as to ICIP, includes the following: the submission and approval of a Construction Employment Report, attendance at a pre-construction conference with representatives of the DLS and adherence to the provisions of Article 22 of the ICIP Rules and Regulations, the provisions of New York City Charter Chapter 13-B and the provisions of Executive Order No. 50 (1980). Furthermore, at Landlord&#8217;s request, Tenant shall (A) report to Landlord the number of workers permanently engaged in employment in the Premises, the nature of each worker&#8217;s employment and, to the extent applicable, the New York City residency of each worker, (B) provide access to the Premises by employees and agents of the Department (as such term is defined in the ICIP Rules and Regulations) at all reasonable times upon reasonable advance notice, and (C) enforce the contractual obligations of Tenant&#8217;s construction managers, contractors and subcontractors to comply with the DLS requirements. In addition, upon request by Landlord Tenant shall provide, and shall cause any subtenant or other occupant of the Premises to provide, to Landlord and to any other entity specified by Landlord in writing, any information that Landlord needs in order to satisfy the reporting requirements set forth in the provisions of any governmental incentive, benefit or loan program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">44.</font></font><b style="font-weight:bold;">Release of Portion(s) of the Project. </b> Landlord, at any time and from time to time, shall have the right to subdivide, transfer title to, or enter into a ground lease or long-term net lease (a &#8220;<b style="font-weight:bold;">Partial Conveyance</b>&#8221;) of, or convert to a condominium form of ownership, any portion of the Project (including, for example, by transferring one or more of the Project&#8217;s buildings and/or another portion or portions of the Project) to another Person not in Control of, Controlled by or under common Control with, Landlord, which such Partial Conveyance may reduce the size of the Project. In the event of such a Partial Conveyance by Landlord, Landlord and Tenant agree to enter into an amendment of this Lease in form reasonably satisfactory to Landlord and Tenant to adjust the definitions of Real Property and Project, if necessary and in accordance with the conditions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 45</u>, to describe accurately the land and improvements constituting the remaining portion of the Land and Project after such Partial Conveyance; to adjust Tenant&#8217;s Share, if necessary to reflect the transfer of the portion of the Land and/or the Project included in such Partial Conveyance; and to make any other changes that may be necessary or appropriate so that Tenant continues to be responsible for its other obligations, including the payment of Rent, under this Lease and to enjoy its rights and privileges under this Lease, subject to and in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 45</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">45.</font></font><b style="font-weight:bold;">Shared Lab Area</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">General Provisions</b>. &#160;Notwithstanding anything to the contrary herein, Tenant shall have a license, on a non-exclusive basis in common with other tenants and users of the fourth (4th) floor of the Building, to use the Shared Lab Area for the Permitted Use, in accordance with the Rules and Regulations applicable thereto and all Legal Requirements, but such access and use shall be subject to the terms of the Superior Instruments (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27</u>). The Shared Lab Area contains certain equipment, furnishings, systems, and personal property, as more particularly described on <b style="font-weight:bold;">Exhibit [I]</b> (collectively, the &#8220;<b style="font-weight:bold;">Shared Lab Systems</b>&#8221;). The license granted hereby is personal to Tenant and shall not, except as provided in the next sentence, be assigned or otherwise pledged or transferred, directly or indirectly. In the case of a Permitted Assignment, Tenant shall have no further right to use the Shared Lab Area and the Shared Lab Systems in accordance with the terms and conditions of this Lease; provided, however, that</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the following shall have the non-exclusive license to use the Shared Lab Systems in accordance with the terms and conditions of this Lease: (i) a subtenant approved by Landlord in accordance with the provisions of this Lease that subleases fifty percent (50%) or more of the Premises, and (ii) an assignee permitted under a Permitted Assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Relocation/Modification of Shared Lab Area</b>. &#160;Landlord shall have the right at any time and from time to time in the exercise of its sole and absolute subjective discretion to reconfigure, relocate, or modify the Shared Lab Area and to revise, expand, suspend, terminate, or discontinue any of the Shared Lab Systems. Landlord shall provide reasonable notice to Tenant of the relocation, suspension, termination, or discontinuance of any Shared Lab Systems as long as Landlord has actual knowledge of any such relocation, suspension, termination, or discontinuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Interference</b>. Tenant shall use the Shared Lab Area and the Shared Lab Systems in a manner that will not unreasonably interfere with the rights of any tenants or occupants in the Building or users of the Shared Lab Area or the providers of the services associated with the Shared Lab Systems. Landlord assumes no responsibility for enforcing Tenant&#8217;s rights or for protecting the Shared Lab Area from any person or entity, including, but not limited to, other tenants or occupants of the Building or users of the Shared Lab Area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Limitations</b>. Landlord&#8217;s sole obligation for providing the Shared Lab Systems shall be: (A) to provide the Shared Lab Systems as is determined by Landlord in the exercise of its sole and absolute subjective discretion, and (B) to contract with one or more third parties to maintain the Shared Lab Systems that are deemed by Landlord in the exercise of its sole and absolute subjective discretion to need periodic maintenance in accordance with the manufacturer&#8217;s or supplier&#8217;s standard guidelines or otherwise. During any period of replacement, repair, or maintenance of the Shared Lab Systems when they are not operational (including, but not limited to, any delays thereto due to the inability to obtain parts or replacements), Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary, or back-up Shared Lab Systems. Tenant acknowledges and agrees that, because the Shared Lab Area and Shared Lab Systems are provided for the benefit of all tenants and users of the fourth (4th) floor of the Building, Landlord may reduce the Shared Lab Area and/or Shared Lab Systems and/or the resources therein from time to time in response to a lack of usage by such tenants or obsolescence or similar reasons and users and may increase, replace or otherwise modify the Shared Lab Area and/or Shared Lab Systems and/or resources therein from time to time in response to the needs of such tenants and users. Landlord shall have no liability for any such reduction, increase, replacement or modification of the Shared Lab Area and/or Shared Lab Systems, and none of the foregoing shall reduce the Base Rent payable by Tenant hereunder. Tenant acknowledges and agrees that increases, replacements and/or modifications of the Shared Lab Area and/or Shared Lab Systems may result in an increase in Operating Expenses (SLA), and Tenant agrees to pay Tenant&#8217;s Share (SLA) of any such increase in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 45(h)</u> below. The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">No Warranties</b>. &#160;Landlord makes no warranties of any kind, express or implied, with respect to the Shared Lab Area and Shared Lab Systems, and Landlord disclaims any such warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the Shared Lab Systems will be operational at all times, will be of sufficient capacity to accommodate Tenant&#8217;s use thereof, will be free of Hazardous Materials, or will function or perform adequately, and Landlord shall not be liable for any damages resulting from the failure of the Shared Lab Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Other Lease Provisions</b>. &#160;Although the Shared Lab Area does not form a part of the Premises, the provisions of this Lease (A) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (B) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance, indemnification, Hazardous Materials Clearance, and environmental requirements triggered by Tenant&#8217;s use of the Shared Lab Area), and (C) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the Shared Lab Area and the Shared Lab Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><b style="font-weight:bold;">Termination</b>. If Tenant Defaults in its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 45</u>, and, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 45(c)</u>, Landlord has elected to terminate the Lease, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant, to terminate immediately Tenant&#8217;s license to use the Shared Lab Area. The expiration or earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the Shared Lab Area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><b style="font-weight:bold;">Shared Lab Area Operating Expenses</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><b style="font-weight:bold;">Shared Lab Area Operating Expense Payments</b>. &#160;Landlord shall deliver to Tenant an Annual Estimate of Operating Expenses (SLA) for each calendar year during the Term, which may be revised by Landlord from time to time during such calendar year. During each month of the Term, on the same date that Base Rent is due, Tenant shall pay Landlord, as Additional Rent hereunder, an amount equal to 1/12th of Tenant&#8217;s Share (SLA) of the Annual Estimate of Operating Expenses (SLA). Payments for any fractional calendar month shall be prorated based on the number of days in the applicable month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>The term &#8220;<b style="font-weight:bold;">Operating Expenses (SLA)</b>&#8221; means [***] all costs and expenses of maintaining, repairing, replacing and operating the Shared Lab Area and the Shared Lab Systems incurred or accrued each calendar year by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>Each Annual Statement shall include (a) the total and Tenant&#8217;s Share (SLA) of actual Operating Expenses (SLA) for the previous calendar year and (b) the total of Tenant&#8217;s payments in respect of Tenant&#8217;s Share (SLA) of actual Operating Expenses (SLA) for such year. If Tenant&#8217;s Share (SLA) of actual Operating Expenses (SLA) for such year exceeds Tenant&#8217;s payments of Tenant&#8217;s Share (SLA) of Operating Expenses (SLA) for such year, then the excess shall be due and payable by Tenant as Rent within 30 days after delivery of such Annual Statement to Tenant. If Tenant&#8217;s payments of Operating Expenses (SLA) for such year exceed Tenant&#8217;s Share (SLA) of actual Operating Expenses (SLA) for such year, then Landlord shall pay the excess to Tenant within thirty (30) days after delivery of such Annual Statement, except that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. Operating Expenses (SLA) for the calendar years in which Tenant&#8217;s obligation to share therein begins and ends shall be prorated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">46.</font></font><b style="font-weight:bold;">Miscellaneous</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Notices</b>. &#160;All notices or other communications between the parties shall be in writing and shall be deemed duly given upon delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and Tenant may from time to time by written notice to the other designate another address for receipt of future notices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Joint and Several Liability</b>. &#160;If and when included within the term &#8220;<b style="font-weight:bold;">Tenant</b>,&#8221; as used in this instrument, there is more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Financial Information</b>. Tenant shall furnish Landlord with true and complete copies of (i) Tenant&#8217;s most recent audited annual financial statements [***] of the end of each of Tenant&#8217;s fiscal years during the Term, (ii) Tenant&#8217;s most recent unaudited quarterly financial statements [***] the end of each of Tenant&#8217;s first three fiscal quarters of each of Tenant&#8217;s fiscal years during the Term, (iii) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Recordation</b>. &#160;Neither this Lease nor a memorandum of lease shall be filed by or on behalf of Tenant in any public record. Landlord may prepare and file, and upon request by Landlord Tenant will execute, a memorandum of lease. Each such memorandum shall include such matters as may be required</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">by the Register of New York County or Section 291-c of the Real Property Law of the State of New York to be included therein so as to permit the same to be recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Interpretation</b>. &#160;The normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit or otherwise describe the scope or intent of this Lease, or any provision hereof, or in any way affect the interpretation of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Not Binding Until Executed</b>. &#160;The submission by Landlord to Tenant of this Lease shall have no binding force or effect, shall not constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until execution of this Lease by both parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">Limitations on Interest</b>. &#160;It is expressly the intent of Landlord and Tenant at all times to comply with applicable law governing the maximum rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so as to render usurious any interest called for under this Lease, or contracted for, charged, taken, reserved, or received with respect to this Lease, then it is Landlord&#8217;s and Tenant&#8217;s express intent that all excess amounts theretofore collected by Landlord be credited on the applicable obligation (or, if the obligation has been or would thereby be paid in full, refunded to Tenant), and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced, without the necessity of the execution of any new document, so as to comply with the applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><b style="font-weight:bold;">Time</b>. &#160;Time is of the essence as to the performance of Tenant&#8217;s obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><b style="font-weight:bold;">Incorporation by Reference</b>. &#160;All exhibits and addenda attached hereto are hereby incorporated into this Lease and made a part hereof. If there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font><b style="font-weight:bold;">Intentionally Omitted</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">47.</font></font><b style="font-weight:bold;">Right to Expand</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Expansion in the Building</b>. &#160;Tenant shall have the one-time right, but not the obligation, to expand the Premises (the &#8220;<b style="font-weight:bold;">Expansion Right</b>&#8221;) to include any Available Space in the Building upon the terms and conditions in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 48</u>. For avoidance of doubt, the term of this Lease with respect to any Available Space shall be co-terminus with the term of this Lease for the Premises. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 48</u>, &#8220;<b style="font-weight:bold;">Available Space</b>&#8221; shall mean [***]. If there is any Available Space in the Building, Landlord shall, at such time as Landlord shall elect so long as Tenant&#8217;s rights hereunder are preserved, deliver to Tenant written notice (the &#8220;<b style="font-weight:bold;">Expansion Notice</b>&#8221;) of such Available Space, [***]. Tenant shall have [***] following delivery of the Expansion Notice to deliver to Landlord written notification of Tenant&#8217;s exercise of the Expansion Right. Provided that no right to expand is exercised by any tenant with superior rights<b style="font-weight:bold;">,</b> Tenant shall be entitled to lease such Available Space upon the terms and conditions set forth in the Expansion Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Amended Lease</b>. &#160;If: (i) Tenant fails to timely deliver notice accepting the terms of an Expansion Notice, or (ii) after the expiration of a period of [***] from the date Tenant gives notice accepting Landlord&#8217;s offer to lease such Available Space, no lease amendment or lease agreement for the Available Space has been executed, and Landlord tenders to Tenant an amendment to this Lease setting forth the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">terms for the rental of the Available Space consistent with those set forth in the Expansion Notice and otherwise consistent with the terms of this Lease and Tenant fails to execute such Lease amendment within [***] following such tender, Tenant shall be deemed to have waived its right to lease such Available Space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Exceptions</b>. &#160;Notwithstanding the above, the Expansion Right shall not be in effect and may not be exercised by Tenant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>during any period of time that Tenant is in Default under any provision of the Lease; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>if Tenant has been in Default under any provision of this Lease [***], whether or not the Defaults are cured, during the [***] period prior to the date on which Tenant seeks to exercise the Expansion Right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Termination.</b> &#160;The Expansion Right shall terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Expansion Right, if, after such exercise, but prior to the commencement date of the lease of such Available Space, (i) Tenant fails to timely cure any default by Tenant under the Lease; or (ii) Tenant has Defaulted [***] during the period from the date of the exercise of the Expansion Right to the date of the commencement of the lease of the Available Space, whether or not such Defaults are cured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">Subordinate</b>. &#160;Tenant&#8217;s rights in connection with the Expansion Right are and shall be subject to and subordinate to lease renewal negotiations of the existing tenant in the Available Space as of the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><b style="font-weight:bold;">No Extensions</b>. &#160;The period of time within which any Expansion Rights may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Expansion Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">48.</font></font><b style="font-weight:bold;">Right to Extend Term. &#160;</b>Tenant shall have the right to extend the Term of the Lease upon the following terms and conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Extension Rights</b>. &#160;Tenant shall have one (1) right (an &#8220;<b style="font-weight:bold;">Extension Right</b>&#8221;) to extend the term of this Lease for five (5) years (an &#8220;<b style="font-weight:bold;">Extension Term</b>&#8221;) on the same terms and conditions as this Lease (other than Base Rent) by giving Landlord written notice of its election to exercise each Extension Right at [***] prior, and no earlier than [***] prior, to the expiration of the Base Term of the Lease or the expiration of any prior Extension Term. Upon the commencement of any Extension Term, Base Rent shall be payable [***] of the Market Rate (as defined below). Base Rent shall thereafter be adjusted on each annual anniversary of the commencement of such Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined. As used herein, &#8220;<b style="font-weight:bold;">Market Rate</b>&#8221; shall mean the then market rental rate as determined by Landlord and agreed to by Tenant, which shall take into consideration [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Rights Personal.</b> &#160;Extension Rights are personal to Tenant and are not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in the Premises except that they may be assigned in connection with any Permitted Assignment of this Lease .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Exceptions</b>. &#160;Notwithstanding anything set forth above to the contrary, Extension Rights shall not be in effect and Tenant may not exercise any of the Extension Rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>during any period of time that Tenant is in Default under any provision of this Lease; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>if Tenant has been in Default under any provision of this Lease [***], whether or not the Defaults are cured, during the [***] period immediately prior to the date that Tenant intends to exercise an Extension Right, whether or not the Defaults are cured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><b style="font-weight:bold;">No Extensions</b>. &#160;The period of time within which any Extension Rights may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Extension Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><b style="font-weight:bold;">Termination</b>. &#160;The Extension Rights shall terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of an Extension Right, if, after such exercise, but prior to the commencement date of an Extension Term, (i) Tenant fails to timely cure any default by Tenant under this Lease; or (ii) Tenant has Defaulted [***] during the period from the date of the exercise of an Extension Right to the date of the commencement of the Extension Term, whether or not such Defaults are cured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.</font></font><b style="font-weight:bold;">Landlord Consent.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If, pursuant to the terms of this Lease, any consent or approval by Landlord or Tenant is not to be unreasonably withheld or is subject to a specified standard, then in the event of a final determination that the consent or approval was unreasonably withheld or that such specified standard has been met (such that the consent or approval should have been granted), the consent or approval shall be deemed granted but the granting of the consent or approval shall be the only remedy to the party requesting or requiring the consent or approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If any matter which is the subject of a request for consent or approval hereunder by Tenant requires the consent or approval by any Superior Party under the Superior Instruments (including, by way of example, proposed Alterations), Tenant shall submit in writing such request (together with any plans, specifications or other materials or documents necessary or appropriate in connection therewith) to Landlord, and Landlord shall, provided Tenant is not then in monetary or material non-monetary default hereunder, in each instance, beyond the expiration of any applicable notice and/or cure period, promptly forward such request to such of the foregoing parties from whom consent is required and otherwise cooperate reasonably with Tenant in requesting and seeking to obtain such required consent; and, in any such case, Landlord shall in no event be deemed to have unreasonably withheld or delayed any such request for consent or approval if any of the foregoing parties shall fail to respond to such request (unless such failure is deemed to constitute consent under the applicable Superior Instrument) or shall deny same. If Landlord shall so determine that any such matter requires the consent or approval of any of the foregoing parties, Landlord shall use good faith reasonable efforts to obtain from such parties such consent or approval (but without any obligation to pay any fee to such party unless Tenant agrees to pay the same); provided that Tenant shall submit to Landlord, upon Landlord&#8217;s request therefor, all plans, specifications or other materials, information or documentation as may be reasonably required by such parties, under the Superior Instruments in connection with each such parties&#8217; respective consideration of such request. Tenant shall pay to Landlord, within thirty (30) days after demand therefor, as Additional Rent, all actual out-of-pocket fees, charges or other expenses Landlord may incur arising out of any such request for consent or approval. In no event shall Tenant communicate (other than through Landlord) with any Superior Party in respect of any Alterations or any other matter pertaining to this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50.</font></font><b style="font-weight:bold;">Hazardous Activities</b>. &#160;Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents and contractors, reserves the right to refuse to perform any repairs or services in any portion of the Premises which, pursuant to Tenant&#8217;s routine safety guidelines, practices or custom or prudent industry practices, require any form of protective clothing or equipment other than safety glasses. In any such case, Tenant shall contract with parties who are acceptable to Landlord, in Landlord&#8217;s reasonable discretion, for all such repairs and services, and Landlord shall, to the extent required, equitably adjust Tenant&#8217;s Share of Operating Expenses in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">51.</font></font><b style="font-weight:bold;">Internet Service. &#160;</b>It is currently anticipated that wireless internet service (&#8220;<b style="font-weight:bold;">Internet Service</b>&#8221;) will be available in the Common Areas and Open Space in the Project. In the event that Internet Service is so available, Tenant shall have the right, on a non-exclusive basis in common with other tenants and users of the Project, to use such Internet Service, subject to the further terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;52</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Tenant acknowledges that Landlord is not the generator of Internet Service and that the availability and quality of Internet Service consequently is subject to the provision of the same to the Project by the third party provider(s) responsible for delivering same to the Project. Landlord shall have no liability for the availability, capacity, quality, continuity or character of service of Internet Service, and no abatement of Rent or other penalty shall arise due to, nor shall Landlord have any liability due to any loss, cost, claim, damage or expense arising from the availability, capacity, quality, continuity or character of service of Internet Service or any interruption, deterioration or removal of Internet Service. Tenant acknowledges that the capacity of Internet Service available for use by Tenant (if any) is part of the overall capacity of Internet Service available to the Project for use on a non-exclusive basis in common with all other tenants at the Project. Tenant agrees to limit Tenant&#8217;s use of Internet Service to Tenant&#8217;s reasonable share of the then-existing capacity of Internet Service, and Tenant shall not use Internet Service in a manner that interferes with any other tenant&#8217;s or user&#8217;s use of such Internet Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>By accessing or using Internet Service, Tenant accepts and agrees to comply with all terms and conditions applicable thereto (including any modifications and/or additions thereto provided in connection with accessing or using Internet Service from time to time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant acknowledges and agrees that all information (including, without limitation, data files, written text, computer software, music, audio files or other sounds, photographs, graphics, videos or other images) which Tenant may have access to as a part of, or through Tenant&#8217;s use of, Internet Service (collectively, &#8220;<b style="font-weight:bold;">Content</b>&#8221;) is the sole responsibility of the person from whom such Content originated. Tenant acknowledges and agrees that by using Internet Service, Tenant may be exposed to Content that Tenant may find offensive, indecent or objectionable, and Tenant uses the Internet Service at its own risk. Landlord and any third party provider(s) responsible for delivering Internet Service to the Project reserve the right (but shall have no obligation) to pre-screen, review, flag, filter, modify, refuse or remove any or all Content from the Internet Service. Landlord does not control the Content posted via the Internet Service and, as such, does not guarantee the accuracy, integrity, or quality of such Content. Under no circumstances shall Landlord or any Superior Parties be liable in any way for any Content, including, without limitation, any errors or omissions in any Content, or for any loss or damage arising out of or in connection with Tenant&#8217;s use of the Internet Service (including, without limitation, damages for loss of use, lost profits or loss of data or information of any kind).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant is solely responsible for maintaining Tenant&#8217;s account for the use of Internet Service, and Tenant is fully responsible for all activities that occur under Tenant&#8217;s account and in connection with Tenant&#8217;s use of the Internet Service. Tenant agrees to notify Landlord and any third party provider(s) responsible for delivering Internet Service to the Project immediately of any unauthorized use of Tenant&#8217;s account or any other breaches of security of which Tenant becomes aware. Tenant is solely responsible for, and shall indemnify, defend, and hold harmless Landlord and the Superior Parties for, any Content created, uploaded, posted, emailed, transmitted, displayed or otherwise made available by Tenant via the Internet Service and for any and all consequences of Tenant&#8217;s use of the Internet Service (including, without limitation, any loss or damage suffered by Landlord or any Superior Parties arising therefrom or in connection therewith).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Tenant agrees not to use the Internet Service to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>upload, post, email, transmit or otherwise make available any Content that is unlawful, harmful, threatening, abusive, harassing, tortious, defamatory, vulgar, obscene, libelous, invasive of another&#8217;s privacy, hateful, or racially, ethnically or otherwise objectionable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>harm minors in any way;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>impersonate any person or entity or falsely state or otherwise misrepresent Tenant&#8217;s affiliation with a person or entity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>forge headers or otherwise manipulate identifiers in order to disguise the origin of any Content transmitted through the Internet Service;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>upload, post, email, transmit or otherwise make available any Content that Tenant does not have a right to make available under any law or under contractual or fiduciary relationships (such as inside information, proprietary and confidential information learned or disclosed as part of employment relationships or under nondisclosure agreements);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</font></font>upload, post, email, transmit or otherwise make available any Content that infringes any patent, trademark, trade secret, copyright or other proprietary or intellectual property rights of any party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</font></font>upload, post, email, transmit or otherwise make available any unsolicited or unauthorized advertising, promotional materials, &#8220;junk mail,&#8221; &#8220;spam,&#8221; &#8220;chain letters,&#8221; &#8220;pyramid schemes,&#8221; or any other form of solicitation, except in those areas (such as shopping) that are designated for such purpose;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</font></font>upload, post, email, transmit or otherwise make available any material that contains software viruses or any other computer code, files or programs designed to interrupt, destroy or limit the functionality of any computer software or hardware or telecommunications equipment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</font></font>disrupt the normal flow of dialogue, cause a screen to &#8220;scroll&#8221; faster than other users of the Internet Services are able to type, or otherwise act in a manner that negatively affects other users&#8217; ability to engage in real time exchanges;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</font></font>interfere with or disrupt the Internet Services or servers or networks connected to the Internet Services, or disobey any requirements, procedures, policies or regulations of networks connected to the Internet Services, including using any device, software or routine to bypass our robot exclusion headers;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</font></font>intentionally or unintentionally violate any applicable local, state, national or international law, including, but not limited to, regulations promulgated by the U.S. Securities and Exchange Commission, any rules of any national or other securities exchange, including, without limitation, the New York Stock Exchange, the American Stock Exchange or the NASDAQ, and any regulations having the force of law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</font></font>provide material support or resources (or to conceal or disguise the nature, location, source, or ownership of material support or resources) to any organization(s) designated by the United States government as a foreign terrorist organization pursuant to Section 219 of the Immigration and Nationality Act;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</font></font>&#8220;stalk&#8221; or otherwise harass another; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiv)</font></font>collect or store personal data about other users in connection with the prohibited conduct and activities set forth in clauses&#160;(i) through (xiii) above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Tenant acknowledges, consents to and agrees that Landlord and/or any third party provider(s) responsible for delivering Internet Service to the Project may access, preserve and disclose Tenant&#8217;s account information associated with the Internet Service if required to do so by applicable Legal Requirements or in a good faith belief that such access, preservation or disclosure is reasonably necessary to (i)&#160;comply with legal process, (ii)&#160;comply with the directives of law enforcement officials, (iii)&#160;enforce the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;52</u> and/or the terms and conditions applicable to the Internet Service from time to time, (iv)&#160;respond to claims that any Content violates the rights of third parties, (v)&#160;respond to Tenant&#8217;s requests for customer service, and/or (vi)&#160;protect the rights, property or personal safety of Landlord, the Superior Parties, any third party provider(s) responsible for delivering Internet Service to the Project, any users of Internet Service, any tenants or other occupants of the Project and the public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Tenant acknowledges and agrees that the Internet Service may include security components that permit digital materials to be protected, and that the use of these materials is subject to such usage rules as may be set by Landlord, any third party provider(s) responsible for delivering Internet Service to the Project, and/or any Content provider(s). Tenant shall not attempt to override or circumvent any of such usage rules, and any unauthorized reproduction, publication, further distribution or public exhibition of the materials provided on the Internet Service, in whole or in part, is strictly prohibited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[ Signatures on next page ]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">MeiraGTx, LLC</b>,</p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited liability company</p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard Giroux</p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Giroux, Chief Operating Officer</p></td></tr><tr><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARE-EAST RIVER SCIENCE PARK, LLC</b>,</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited liability company</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:51.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware limited partnership,</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">managing member</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARE-QRS CORP.,</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Maryland corporation,</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">general partner</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gary Dean</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:38.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gary Dean</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:38.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Vice President &#8211; Real Estate Legal</p></td></tr><tr><td style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT A-1 TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT A-2 TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT B TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT C TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT C-1 TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT D TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT E TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT F TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT G TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT H TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT I TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT J TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT K TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT L TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT M TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT N TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">[***]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>mgtx-20250331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/13/2025 11:46:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Alexandria Forbes, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt -0.04pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of MeiraGTx Holdings plc;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 6pt 31.5pt;">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 6pt 31.5pt;">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 6pt 31.5pt;">(c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 6pt 31.5pt;">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 6pt 31.5pt;">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt 0pt 0pt 31.5pt;">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ay</font></p></div></div></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2025</p></td><td colspan="2" style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Alexandria Forbes</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Alexandria Forbes</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">principal executive officer</i>)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>mgtx-20250331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/13/2025 11:46:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Richard Giroux, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of MeiraGTx Holdings plc;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2025</p></td><td colspan="2" style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Richard Giroux</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Richard Giroux</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer and Chief Operating Officer</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(principal financial officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>mgtx-20250331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/13/2025 11:46:20 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In connection with the Quarterly Report of MeiraGTx Holdings plc (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt 30.55pt;">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 30.55pt;">(2)&#160;&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Date: May 13, 2025</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Alexandria Forbes</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Alexandria Forbes</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(principal executive officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>mgtx-20250331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/13/2025 11:46:29 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In connection with the Quarterly Report of MeiraGTx Holdings plc (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 6pt 30.55pt;">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 30.55pt;">(2)&#160;&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Date: May 13, 2025</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Richard Giroux</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Richard Giroux</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer and Chief Operating Officer</b></p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(principal financial officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgtx-20250331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2025 11:46:40 AM-->
<!--Modified on: 5/13/2025 11:46:40 AM-->
<xsd:schema xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://meiragtx.com/20250331" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:mgtx="http://meiragtx.com/20250331" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>99940401 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" id="DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
        <link:definition>99940901 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails">
        <link:definition>99940904 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2" id="DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2">
        <link:definition>40907 - Disclosure - Lease Obligations - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Detail) -Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureDebtFinancingDetails" id="DisclosureDebtFinancingDetails">
        <link:definition>99941001 - Disclosure - Debt Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity" id="StatementCondensedConsolidatedStatementOfShareholdersEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>99930503 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>99930803 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" id="DisclosureOrganizationAndBasisOfPresentationDetails">
        <link:definition>99940101 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>99940202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails">
        <link:definition>99940204 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails">
        <link:definition>99940206 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" id="DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails">
        <link:definition>99940301 - Disclosure - Equity Method and Other Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" id="DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails">
        <link:definition>99940502 - Disclosure - Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" id="DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails">
        <link:definition>99940503 - Disclosure - Share-Based Compensation - Summary of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails">
        <link:definition>99940504 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>99940505 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureOrdinarySharesDetails" id="DisclosureOrdinarySharesDetails">
        <link:definition>99940601 - Disclosure - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>99940701 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" id="DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails">
        <link:definition>99940801 - Disclosure - Related Party Transactions - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails" id="DisclosureRelatedPartyTransactionsPerformanceObligationDetails">
        <link:definition>99940802 - Disclosure - Related Party Transactions - Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails" id="DisclosureRelatedPartyTransactionsFinancingAgreementDetails">
        <link:definition>99940803 - Disclosure - Related Party Transactions - Financing Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" id="DisclosureRelatedPartyTransactionsRevenueRecognitionDetails">
        <link:definition>99940804 - Disclosure - Related Party Transactions - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>99940905 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941101 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation" id="DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>995210101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments" id="DisclosureEquityMethodAndOtherInvestments">
        <link:definition>995210301 - Disclosure - Equity Method and Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210401 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>995210501 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureOrdinaryShares" id="DisclosureOrdinaryShares">
        <link:definition>995210601 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995210701 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995210801 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995210901 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureDebtFinancing" id="DisclosureDebtFinancing">
        <link:definition>995211001 - Disclosure - Debt Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables">
        <link:definition>99930203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables" id="DisclosureEquityMethodAndOtherInvestmentsTables">
        <link:definition>99930303 - Disclosure - Equity Method and Other Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930403 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99930903 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails">
        <link:definition>99940203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails">
        <link:definition>99940205 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" id="DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails">
        <link:definition>99940501 - Disclosure - Share-Based Compensation - Summary of Company's Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails" id="DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails">
        <link:definition>99940902 - Disclosure - Leases - Schedule of Consolidated Balance Sheets for Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails" id="DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails">
        <link:definition>99940903 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mgtx-20250331_cal.xml" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mgtx-20250331_def.xml" xlink:title="Definition Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mgtx-20250331_lab.xml" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mgtx-20250331_pre.xml" xlink:title="Presentation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element name="AccruedClinicalTrialCosts" id="mgtx_AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="AccruedConsultingExpenses" id="mgtx_AccruedConsultingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="AccruedLiabilitiesAccruedCompensationAndBenefits" id="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="AccruedResearchAndDevelopment" id="mgtx_AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="FirstAnniversaryMember" id="mgtx_FirstAnniversaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="JanssenPharmaceuticalsIncMember" id="mgtx_JanssenPharmaceuticalsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element name="RestrictedCashMember" id="mgtx_RestrictedCashMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <xsd:element id="mgtx_RightOfUseAsset" name="RightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mgtx_LeaseObligationsCurrent" name="LeaseObligationsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mgtx_LeaseObligationsNonCurrent" name="LeaseObligationsNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mgtx_LeaseMaturityTerm" name="LeaseMaturityTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mgtx_OperatingLeaseAbstract" name="OperatingLeaseAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_FinanceLeaseAbstract" name="FinanceLeaseAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" name="AccruedExpensesIncurredInConnectionWithFixedAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" name="AccruedLiabilitiesAccruedManufacturingCostsExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mgtx_ThirdAnniversaryMember" name="ThirdAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_FourthAnniversaryMember" name="FourthAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_SecondAnniversaryMember" name="SecondAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" name="JohnsonAndJohnsonInnovationJjdcIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" name="ContractWithCustomerLiabilityEffectOfExchangeRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" abstract="false" />
  <xsd:element id="mgtx_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mgtx_VisiogeneLlcMember" name="VisiogeneLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" id="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" id="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerceptiveCreditHoldingsMember" id="mgtx_PerceptiveCreditHoldingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermLoanMember" id="mgtx_TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BasisSpreadOnVariableRateFloor" id="mgtx_BasisSpreadOnVariableRateFloor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SecuredOvernightFinancingRateAdjustmentTerm" id="mgtx_SecuredOvernightFinancingRateAdjustmentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SecuredCashAndBankAccounts" id="mgtx_SecuredCashAndBankAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesIssuedInConnectionWithFinancingAgreement" id="mgtx_SharesIssuedInConnectionWithFinancingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExercisePriceScenarioMember" id="mgtx_ExercisePriceScenarioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceScenarioBMember" id="mgtx_ExercisePriceScenarioBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfNewMaterialCommitments" id="mgtx_NumberOfNewMaterialCommitments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PerceptiveAdvisorsLlcMember" id="mgtx_PerceptiveAdvisorsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancingAgreementMember" id="mgtx_FinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherEquityMethodInvestmentsMember" id="mgtx_OtherEquityMethodInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestoneFundingReceived" id="mgtx_MilestoneFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" id="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredRevenueRecognizedDuringPeriod" id="mgtx_DeferredRevenueRecognizedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ScheduleOfIrelandGrantsPolicyTextBlock" id="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainLossOnSaleOfNonfinancialAssets" id="mgtx_GainLossOnSaleOfNonfinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetPurchaseAgreementMember" id="mgtx_AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetPurchaseAgreementFundingReceived" id="mgtx_AssetPurchaseAgreementFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContingentFundingAvailable" id="mgtx_ContingentFundingAvailable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForDevelopmentOfDrugSubstances" id="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForDevelopmentOfDrugProducts" id="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForSaleOfDrugProductsInUnitedStates" id="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" id="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForTransferOfManufacturingTechnology" id="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForRegulatoryApproval" id="mgtx_MilestoneFundingForRegulatoryApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantsIdaIrelandMember" id="mgtx_GrantsIdaIrelandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantsIdaIrelandEmploymentMember" id="mgtx_GrantsIdaIrelandEmploymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantsIdaIrelandCapitalMember" id="mgtx_GrantsIdaIrelandCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantAmountForJobCreation" id="mgtx_GrantAmountForJobCreation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantAmountForMachineryAndEquipment" id="mgtx_GrantAmountForMachineryAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" id="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfNewJobsCreatedToReceiveGrantFunding" id="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FinancialAssistanceDurationFromLastGrantPayment" id="mgtx_FinancialAssistanceDurationFromLastGrantPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FinancialAssistanceDurationFromCompletionOfCapitalInvestment" id="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" id="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrantFundingReceived" id="mgtx_GrantFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" id="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AgreementTerminationPeriodDaysWrittenNotice" id="mgtx_AgreementTerminationPeriodDaysWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InitialAgreementPeriodDuration" id="mgtx_InitialAgreementPeriodDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RelatedPartyDeferredRevenueReclassified" id="mgtx_RelatedPartyDeferredRevenueReclassified" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetPurchaseAgreementFundingReclassified" id="mgtx_AssetPurchaseAgreementFundingReclassified" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="VariableConsiderationForServices" id="mgtx_VariableConsiderationForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContractPriceOfLicenseAgreement" id="mgtx_ContractPriceOfLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" id="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" id="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromGainOnSaleOfNonfinancialAssets" id="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingForExtensionOfClinicalTrials" id="mgtx_MilestoneFundingForExtensionOfClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OffsettingCreditForTransitionServices" id="mgtx_OffsettingCreditForTransitionServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerformanceObligationForProcessPerformanceQualificationServices" id="mgtx_PerformanceObligationForProcessPerformanceQualificationServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerformanceObligationForCommercialSupplyOfRpgrProduct" id="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerformanceObligationForManufacturingTechnologyTransfer" id="mgtx_PerformanceObligationForManufacturingTechnologyTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerformanceObligationForSaleOfNonfinancialAssets" id="mgtx_PerformanceObligationForSaleOfNonfinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ServiceRevenueFromRelatedParties" id="mgtx_ServiceRevenueFromRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetRetirementObligationsAmortizationOfInterest" id="mgtx_AssetRetirementObligationsAmortizationOfInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BankOfAmericaSecuritiesInc.Member" id="mgtx_BankOfAmericaSecuritiesInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockConsiderationAvailableInFutureTransactions" id="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingAllocatedToProcessPerformanceQualificationServices" id="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" id="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingAllocatedToManufacturingTechnologyTransfer" id="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingAllocatedToSaleOfNonfinancialAssets" id="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseNumberNewLeasesRecognized" id="mgtx_OperatingLeaseNumberNewLeasesRecognized" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AlexandriaForbesPhdMember" id="mgtx_AlexandriaForbesPhdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RichardGirouxMember" id="mgtx_RichardGirouxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AlexandraForbesStockTradingPlanMember" id="mgtx_AlexandraForbesStockTradingPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RichardGirouxStockTradingPlanMember" id="mgtx_RichardGirouxStockTradingPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" id="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueUnsatisfiedPerformanceObligationAmount" id="mgtx_RevenueUnsatisfiedPerformanceObligationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" id="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ResearchAndDevelopmentClinicalTrials" id="mgtx_ResearchAndDevelopmentClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentManufacturing" id="mgtx_ResearchAndDevelopmentManufacturing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentOther" id="mgtx_ResearchAndDevelopmentOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InnovativeMedicineReimbursement" id="mgtx_InnovativeMedicineReimbursement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherSegmentItemsIncomeStatement" id="mgtx_OtherSegmentItemsIncomeStatement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VestedSharesDeferred" id="mgtx_VestedSharesDeferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClinicalProgramsDrugProduct1" id="mgtx_ClinicalProgramsDrugProduct1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClinicalProgramsDrugProduct2" id="mgtx_ClinicalProgramsDrugProduct2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClinicalProgramsDrugProduct3" id="mgtx_ClinicalProgramsDrugProduct3" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClinicalProgramsDrugProduct4" id="mgtx_ClinicalProgramsDrugProduct4" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreClinicalResearchGeneRegulation" id="mgtx_PreClinicalResearchGeneRegulation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreClinicalResearchNeurodegenerativeDiseases" id="mgtx_PreClinicalResearchNeurodegenerativeDiseases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreClinicalResearchPreclinicalOcularDiseases" id="mgtx_PreClinicalResearchPreclinicalOcularDiseases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SegmentNetIncomeLoss" id="mgtx_SegmentNetIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SegmentGeneralAndAdministrativeExpenses" id="mgtx_SegmentGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingUpfrontPaymentReceived" id="mgtx_MilestoneFundingUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneFundingToProvideAdditionalCapital" id="mgtx_MilestoneFundingToProvideAdditionalCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="HologenTransactionAgreementMember" id="mgtx_HologenTransactionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HologenLimitedMember" id="mgtx_HologenLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassSharesOfHologenReceivedInTransaction" id="mgtx_ClassSharesOfHologenReceivedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentClassSharesReceivableOfHologenInTransaction" id="mgtx_ContingentClassSharesReceivableOfHologenInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassShareOwnershipPercentageOfHologenNeuro" id="mgtx_ClassShareOwnershipPercentageOfHologenNeuro" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassBShareOwnershipPercentageOfHologenNeuro" id="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageApprovalOfDirectors" id="mgtx_PercentageApprovalOfDirectors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" id="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" id="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ManufacturingFrameworkAgreementMember" id="mgtx_ManufacturingFrameworkAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RepurchaseOptionVestingPeriod" id="mgtx_RepurchaseOptionVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainOnTerminationOfLeaseLiabilities" id="mgtx_GainOnTerminationOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Rule10b51ArrangementModifiedFlag" id="mgtx_Rule10b51ArrangementModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonRule10b51ArrangementModifiedFlag" id="mgtx_NonRule10b51ArrangementModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgtx-20250331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2025 11:46:40 AM-->
<!--Modified on: 5/13/2025 11:46:40 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2" roleURI="http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureDebtFinancingDetails" roleURI="http://meiragtx.com/role/DisclosureDebtFinancingDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638827335966222771" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638827335966222771" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335966222771" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335966222771" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638827335966222771" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_AccountsReceivableNetCurrent_638827335966222771" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638827335966232780" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_InventoryNet_638827335966232780" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_PrepaidExpenseCurrent_638827335966232780" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_IncomeTaxReceivable_638827335966232780" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638827335966222771" xlink:to="us-gaap_OtherAssetsCurrent_638827335966232780" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638827335966232780" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638827335966232780" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638827335966232780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638827335966232780" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_638827335966242761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquityMethodInvestments_638827335966242761" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638827335966242761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638827335966242761" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638827335966242761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638827335966242761" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638827335966242761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638827335966242761" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638827335966242761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638827335966242761" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638827335966242761" xlink:to="us-gaap_LiabilitiesCurrent_638827335966252768" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638827335966252768" xlink:to="us-gaap_AccountsPayableCurrent_638827335966252768" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638827335966252768" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638827335966252768" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638827335966252768" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638827335966252768" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638827335966252768" xlink:to="us-gaap_DeferredIncomeCurrent_638827335966252768" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638827335966252768" xlink:to="us-gaap_OtherLiabilitiesCurrent_638827335966252768" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638827335966252768" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638827335966242761" xlink:to="us-gaap_DeferredIncomeNoncurrent_638827335966252768" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638827335966262761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638827335966242761" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638827335966262761" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation_638827335966262761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638827335966242761" xlink:to="us-gaap_AssetRetirementObligation_638827335966262761" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638827335966262761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638827335966242761" xlink:to="us-gaap_LongTermNotesPayable_638827335966262761" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638827335966262761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638827335966262761" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638827335966262761" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638827335966262761" xlink:to="us-gaap_CommonStockValue_638827335966262761" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638827335966272759" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638827335966262761" xlink:to="us-gaap_AdditionalPaidInCapital_638827335966272759" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638827335966272759" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638827335966262761" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638827335966272759" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638827335966272759" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638827335966262761" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638827335966272759" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335966272759" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335966272759" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638827335966282772" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638827335966282772" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335966282772" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638827335966282772" xlink:to="us-gaap_InvestmentIncomeInterest_638827335966282772" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638827335966282772" xlink:to="us-gaap_InterestExpense_638827335966282772" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638827335966282772" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335966282772" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638827335966282772" xlink:to="us-gaap_OperatingIncomeLoss_638827335966282772" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638827335966282772" xlink:to="us-gaap_OperatingExpenses_638827335966282772" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638827335966282772" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638827335966282772" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638827335966282772" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638827335966282772" xlink:to="us-gaap_SellingAndMarketingExpense_638827335966292763" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638827335966282772" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638827335966292763" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638827335966282772" xlink:to="mgtx_ServiceRevenueFromRelatedParties_638827335966292763" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_ProfitLoss_638827335966292763" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_ShareBasedCompensation_638827335966292763" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335966292763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335966292763" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638827335966302764" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638827335966302764" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638827335966302764" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_GainLossOnTerminationOfLease_638827335966302764" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_AssetRetirementObligationAccretionExpense_638827335966302764" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638827335966302764" order="9" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335966302764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335966302764" order="10" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_638827335966312760" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638827335966312760" order="12" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_638827335966312760" order="13" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638827335966312760" order="14" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638827335966312760" order="15" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_638827335966312760" order="16" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638827335966312760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638827335966312760" order="17" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638827335966322760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638827335966322760" order="18" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638827335966322760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638827335966322760" order="19" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638827335966322760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638827335966322760" order="20" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638827335966322760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335966292763" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638827335966322760" order="21" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335966322760" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335966322760" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335966322760" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638827335966332764" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335966322760" xlink:to="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_638827335966332764" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638827335966332764" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638827335966332764" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335966332764" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335966332764" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335966332764" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638827335966342763" order="4" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedClinicalTrialCosts_638827335966342763" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedResearchAndDevelopment" xlink:label="mgtx_AccruedResearchAndDevelopment_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedResearchAndDevelopment_638827335966342763" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638827335966342763" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_638827335966342763" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_638827335966342763" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_638827335966342763" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedConsultingExpenses_638827335966352766" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_638827335966352766" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_638827335966352766" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_638827335966352766" order="9" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638827335966352766" order="10" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638827335966352766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638827335966352766" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_VariableLeaseCost_638827335966352766" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638827335966362766" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638827335966362766" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_638827335966362766" order="3" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638827335966362766" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638827335966362766" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638827335966362766" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638827335966362766" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638827335966372765" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638827335966372765" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638827335966372765" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638827335966372765" order="5" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2" xlink:type="extended" xlink:title="40907 - Disclosure - Lease Obligations - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Detail) -Calc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638827335966372765" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638827335966372765" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638827335966372765" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638827335966372765" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://meiragtx.com/role/DisclosureDebtFinancingDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Debt Financing (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares_638827335966382780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_CommonStockDiscountOnShares_638827335966382780" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638827335966382780" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DeferredFinanceCostsNet_638827335966382780" order="2" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgtx-20250331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2025 11:46:40 AM-->
<!--Modified on: 5/13/2025 11:46:40 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementOfShareholdersEquity" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationTables" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationAdditionalInformationDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrdinarySharesDetails" roleURI="http://meiragtx.com/role/DisclosureOrdinarySharesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsPerformanceObligationDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsFinancingAgreementDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureDebtFinancingDetails" roleURI="http://meiragtx.com/role/DisclosureDebtFinancingDetails" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://meiragtx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="mgtx-20250331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureAccruedExpenses" roleURI="http://meiragtx.com/role/DisclosureAccruedExpenses" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensation" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureIncomeTaxes" roleURI="http://meiragtx.com/role/DisclosureIncomeTaxes" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://meiragtx.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureAccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureIncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/role/DisclosureCommitmentsAndContingencies" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseObligationsNonCurrent" xlink:label="mgtx_LeaseObligationsNonCurrent_1" xlink:title="mgtx_LeaseObligationsNonCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="mgtx_LeaseObligationsNonCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To mgtx_LeaseObligationsNonCurrent_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseObligationsCurrent" xlink:label="mgtx_LeaseObligationsCurrent" xlink:title="mgtx_LeaseObligationsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="mgtx_LeaseObligationsCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To mgtx_LeaseObligationsCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseObligationsNonCurrent" xlink:label="mgtx_LeaseObligationsNonCurrent_2" xlink:title="mgtx_LeaseObligationsNonCurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="mgtx_LeaseObligationsNonCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To mgtx_LeaseObligationsNonCurrent_2" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RightOfUseAsset" xlink:label="mgtx_RightOfUseAsset" xlink:title="mgtx_RightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract" xlink:to="mgtx_RightOfUseAsset" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract To mgtx_RightOfUseAsset" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To us-gaap_Liabilities" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_1" xlink:title="us-gaap_Liabilities_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_Liabilities_1" order="2" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_1" xlink:title="us-gaap_ExtinguishmentOfDebtAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_1" xlink:title="us-gaap_ExtinguishmentOfDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ExtinguishmentOfDebtAxis_1" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ExtinguishmentOfDebtAxis_1 To us-gaap_ExtinguishmentOfDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_1" xlink:title="us-gaap_ValuationTechniqueAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_1" xlink:title="us-gaap_ValuationTechniqueDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationTechniqueAxis_1" xlink:to="us-gaap_ValuationTechniqueDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationTechniqueAxis_1 To us-gaap_ValuationTechniqueDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis_1" xlink:title="us-gaap_TransactionTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_1" xlink:title="us-gaap_TransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TransactionTypeAxis_1" xlink:to="us-gaap_TransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TransactionTypeAxis_1 To us-gaap_TransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:title="us-gaap_RetirementPlanSponsorLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_1" xlink:title="us-gaap_RetirementPlanSponsorLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanSponsorLocationAxis_1 To us-gaap_RetirementPlanSponsorLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1 To us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgedStatusAxis" xlink:label="us-gaap_PledgedStatusAxis_1" xlink:title="us-gaap_PledgedStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgedStatusDomain" xlink:label="us-gaap_PledgedStatusDomain_1" xlink:title="us-gaap_PledgedStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PledgedStatusAxis_1" xlink:to="us-gaap_PledgedStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PledgedStatusAxis_1 To us-gaap_PledgedStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:title="us-gaap_GovernmentAssistanceTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_1" xlink:title="us-gaap_GovernmentAssistanceTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GovernmentAssistanceTypeAxis_1 To us-gaap_GovernmentAssistanceTypeDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AlexandriaForbesPhdMember" xlink:label="mgtx_AlexandriaForbesPhdMember" xlink:title="mgtx_AlexandriaForbesPhdMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="mgtx_AlexandriaForbesPhdMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To mgtx_AlexandriaForbesPhdMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RichardGirouxMember" xlink:label="mgtx_RichardGirouxMember" xlink:title="mgtx_RichardGirouxMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="mgtx_RichardGirouxMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To mgtx_RichardGirouxMember" order="2" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended" xlink:title="Trading Arrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember" xlink:title="ecd_AllTradingArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AlexandraForbesStockTradingPlanMember" xlink:label="mgtx_AlexandraForbesStockTradingPlanMember" xlink:title="mgtx_AlexandraForbesStockTradingPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="mgtx_AlexandraForbesStockTradingPlanMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllTradingArrangementsMember To mgtx_AlexandraForbesStockTradingPlanMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RichardGirouxStockTradingPlanMember" xlink:label="mgtx_RichardGirouxStockTradingPlanMember" xlink:title="mgtx_RichardGirouxStockTradingPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="mgtx_RichardGirouxStockTradingPlanMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllTradingArrangementsMember To mgtx_RichardGirouxStockTradingPlanMember" order="2" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Share-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization and Basis of Presentation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgtx_JanssenPharmaceuticalsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenLimitedMember" xlink:label="mgtx_HologenLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgtx_HologenLimitedMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenTransactionAgreementMember" xlink:label="mgtx_HologenTransactionAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_HologenTransactionAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ManufacturingFrameworkAgreementMember" xlink:label="mgtx_ManufacturingFrameworkAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_ManufacturingFrameworkAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReceived" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_AssetPurchaseAgreementFundingReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentFundingAvailable" xlink:label="mgtx_ContingentFundingAvailable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_ContingentFundingAvailable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingReceived" xlink:label="mgtx_MilestoneFundingReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForExtensionOfClinicalTrials" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForRegulatoryApproval" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingForRegulatoryApproval" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingUpfrontPaymentReceived" xlink:label="mgtx_MilestoneFundingUpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingUpfrontPaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingToProvideAdditionalCapital" xlink:label="mgtx_MilestoneFundingToProvideAdditionalCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_MilestoneFundingToProvideAdditionalCapital" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassSharesOfHologenReceivedInTransaction" xlink:label="mgtx_ClassSharesOfHologenReceivedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_ClassSharesOfHologenReceivedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentClassSharesReceivableOfHologenInTransaction" xlink:label="mgtx_ContingentClassSharesReceivableOfHologenInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_ContingentClassSharesReceivableOfHologenInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassShareOwnershipPercentageOfHologenNeuro" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_ClassShareOwnershipPercentageOfHologenNeuro" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PercentageApprovalOfDirectors" xlink:label="mgtx_PercentageApprovalOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_PercentageApprovalOfDirectors" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" xlink:label="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RepurchaseOptionVestingPeriod" xlink:label="mgtx_RepurchaseOptionVestingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mgtx_RepurchaseOptionVestingPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandMember" xlink:label="mgtx_GrantsIdaIrelandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mgtx_GrantsIdaIrelandMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandEmploymentMember" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mgtx_GrantsIdaIrelandMember" xlink:to="mgtx_GrantsIdaIrelandEmploymentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandCapitalMember" xlink:label="mgtx_GrantsIdaIrelandCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mgtx_GrantsIdaIrelandMember" xlink:to="mgtx_GrantsIdaIrelandCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForJobCreation" xlink:label="mgtx_GrantAmountForJobCreation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_GrantAmountForJobCreation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForMachineryAndEquipment" xlink:label="mgtx_GrantAmountForMachineryAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_GrantAmountForMachineryAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromLastGrantPayment" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_FinancialAssistanceDurationFromLastGrantPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantFundingReceived" xlink:label="mgtx_GrantFundingReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_GrantFundingReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="mgtx_RestrictedCashMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="us-gaap_StockAppreciationRightsSARSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockAppreciationRightsSARSMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" xlink:type="extended" xlink:title="99940206 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Equity Method and Other Investments - Summary of Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VisiogeneLlcMember" xlink:label="mgtx_VisiogeneLlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mgtx_VisiogeneLlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OtherEquityMethodInvestmentsMember" xlink:label="mgtx_OtherEquityMethodInvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mgtx_OtherEquityMethodInvestmentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Share-Based Compensation - Summary of Restricted Share Units (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940504 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940505 - Disclosure - Share-Based Compensation - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_FirstAnniversaryMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecondAnniversaryMember" xlink:label="mgtx_SecondAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_SecondAnniversaryMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ThirdAnniversaryMember" xlink:label="mgtx_ThirdAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_ThirdAnniversaryMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FourthAnniversaryMember" xlink:label="mgtx_FourthAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_FourthAnniversaryMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_DirectorMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VestedSharesDeferred" xlink:label="mgtx_VestedSharesDeferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_VestedSharesDeferred" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureOrdinarySharesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Ordinary Shares (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BankOfAmericaSecuritiesInc.Member" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgtx_BankOfAmericaSecuritiesInc.Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AtMarketOfferingMember" xlink:label="mgtx_AtMarketOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mgtx_AtMarketOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Related Party Transactions - Collaboration and License Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:to="mgtx_JanssenPharmaceuticalsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_ServiceRevenueFromRelatedParties" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_DeferredRevenueRecognizedDuringPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_InitialAgreementPeriodDuration" xlink:label="mgtx_InitialAgreementPeriodDuration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_InitialAgreementPeriodDuration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AgreementTerminationPeriodDaysWrittenNotice" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_AgreementTerminationPeriodDaysWrittenNotice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingReceived" xlink:label="mgtx_MilestoneFundingReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReceived" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_AssetPurchaseAgreementFundingReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentFundingAvailable" xlink:label="mgtx_ContingentFundingAvailable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_ContingentFundingAvailable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForExtensionOfClinicalTrials" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForRegulatoryApproval" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingForRegulatoryApproval" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RelatedPartyDeferredRevenueReclassified" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyDeferredRevenueReclassified" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VariableConsiderationForServices" xlink:label="mgtx_VariableConsiderationForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_VariableConsiderationForServices" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReclassified" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_AssetPurchaseAgreementFundingReclassified" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractPriceOfLicenseAgreement" xlink:label="mgtx_ContractPriceOfLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_ContractPriceOfLicenseAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OffsettingCreditForTransitionServices" xlink:label="mgtx_OffsettingCreditForTransitionServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_OffsettingCreditForTransitionServices" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForProcessPerformanceQualificationServices" xlink:label="mgtx_PerformanceObligationForProcessPerformanceQualificationServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PerformanceObligationForProcessPerformanceQualificationServices" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" xlink:label="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForManufacturingTechnologyTransfer" xlink:label="mgtx_PerformanceObligationForManufacturingTechnologyTransfer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PerformanceObligationForManufacturingTechnologyTransfer" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForSaleOfNonfinancialAssets" xlink:label="mgtx_PerformanceObligationForSaleOfNonfinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PerformanceObligationForSaleOfNonfinancialAssets" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" xlink:label="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" xlink:label="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" xlink:label="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" xlink:label="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Related Party Transactions - Performance Obligation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_JanssenPharmaceuticalsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationAmount" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Related Party Transactions - Financing Agreement (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveAdvisorsLlcMember" xlink:label="mgtx_PerceptiveAdvisorsLlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_PerceptiveAdvisorsLlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancingAgreementMember" xlink:label="mgtx_FinancingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mgtx_FinancingAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Related Party Transactions - Revenue Recognition (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:to="mgtx_JanssenPharmaceuticalsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_DeferredRevenueRecognizedDuringPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Leases - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseMaturityTerm" xlink:label="mgtx_LeaseMaturityTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mgtx_LeaseMaturityTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OperatingLeaseNumberNewLeasesRecognized" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mgtx_OperatingLeaseNumberNewLeasesRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://meiragtx.com/role/DisclosureDebtFinancingDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Debt Financing (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveCreditHoldingsMember" xlink:label="mgtx_PerceptiveCreditHoldingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mgtx_PerceptiveCreditHoldingsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_TermLoanMember" xlink:label="mgtx_TermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mgtx_TermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioMember" xlink:label="mgtx_ExercisePriceScenarioMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="mgtx_ExercisePriceScenarioMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioBMember" xlink:label="mgtx_ExercisePriceScenarioBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="mgtx_ExercisePriceScenarioBMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SecuredDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BasisSpreadOnVariableRateFloor" xlink:label="mgtx_BasisSpreadOnVariableRateFloor" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mgtx_BasisSpreadOnVariableRateFloor" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredOvernightFinancingRateAdjustmentTerm" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mgtx_SecuredOvernightFinancingRateAdjustmentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="us-gaap_LongtermDebtWeightedAverageInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongtermDebtWeightedAverageInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteedBenefitLiabilityNet" xlink:label="us-gaap_GuaranteedBenefitLiabilityNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_GuaranteedBenefitLiabilityNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredCashAndBankAccounts" xlink:label="mgtx_SecuredCashAndBankAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mgtx_SecuredCashAndBankAccounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SharesIssuedInConnectionWithFinancingAgreement" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mgtx_SharesIssuedInConnectionWithFinancingAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgtx-20250331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2025 11:46:40 AM-->
<!--Modified on: 5/13/2025 11:46:40 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity method and other investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - operating leases, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - finance leases, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease obligations, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred Income, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred revenue - related party, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred Income, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligation" xlink:to="us-gaap_AssetRetirementObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US">Asset retirement obligations at end of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US">Asset retirement obligations at beginning of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US">Asset retirement obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 79,418,438 and 78,397,380 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Equity Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Equity Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Shares issued to related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CONDENSED OPERATIONS AND COMPREHENSIVE LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ServiceRevenueFromRelatedParties" xlink:to="mgtx_ServiceRevenueFromRelatedParties_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ServiceRevenueFromRelatedParties_lbl" xml:lang="en-US">Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ServiceRevenueFromRelatedParties_lbl" xml:lang="en-US">Service revenue from related parties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ServiceRevenueFromRelatedParties_lbl" xml:lang="en-US">Service revenue - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Cost of service revenue - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other non-operating income (expense):</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency (gain) loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Amount of gain (loss) on the sale of non-financial assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Gain (loss) on sale of nonfinancial assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Gain on sale of nonfinancial assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Gain on sale of nonfinancial assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per ordinary share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per ordinary share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of ordinary shares outstanding, basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of ordinary shares outstanding, diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending Equity Balance (shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Equity Balance (shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation activity (shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in at-the-market offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in at-the-market offering (shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs in connection with ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Net change in right-of-use assets and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain on termination of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of equipment, furniture and fixtures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationAccretionExpense" xlink:to="us-gaap_AssetRetirementObligationAccretionExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_lbl" xml:lang="en-US">Asset Retirement Obligation, Accretion Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_lbl" xml:lang="en-US">Amortization of interest on asset retirement obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in operating assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Accounts receivable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Contract assets - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" xml:lang="en-US">Increase (Decrease) in Inventories and Other Operating Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in operating liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash flows from operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" xlink:to="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">The cash inflow from the gain recognized on the sale of nonfinancial assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Proceeds from gain on sale of nonfinancial assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Proceeds from sale of nonfinancial assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of share options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Payments of withholdings on shares withheld for income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Aggregate offering price authorized through at-market offerings</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs in connection with ordinary shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Offering costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash transactions:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xml:lang="en-US">Fixed asset acquisition included in accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:to="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" xml:lang="en-US">Asset Retirement Obligation, Revision of Estimate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" xml:lang="en-US">Change in estimate of asset retirement obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" xml:lang="en-US">Change in estimate</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" xlink:label="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" xlink:to="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_lbl" xml:lang="en-US">Receivable related to the sale of fixed assets that is included in the balance of other current assets at period-end.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_lbl" xml:lang="en-US">Non Cash Transaction Receivable From Sale of Fixed Assets Included in Other Current Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_lbl" xml:lang="en-US">Receivable from sale of fixed assets included in other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US">Equity Method and Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method and Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Financing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Financing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="us-gaap_AssetRetirementObligationsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationsPolicy" xlink:to="us-gaap_AssetRetirementObligationsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xml:lang="en-US">Asset Retirement Obligation [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xml:lang="en-US">Asset Retirement Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfIrelandGrantsPolicyTextBlock" xlink:label="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock" xlink:to="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for IDA Ireland Grants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_lbl" xml:lang="en-US">Schedule of Ireland Grants [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_lbl" xml:lang="en-US">IDA Ireland Grant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Ordinary Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of Change in Asset Retirement Obligation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of Change in Asset Retirement Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Securities Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of net loss for the segment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-lived Assets by Geographical Area</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of equity method and other investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Share Units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Inputs Used in Determining Fair Value of Share Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Share Unit (RSU) Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" xlink:label="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" xlink:to="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Leveraged Lease Investments [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Information Related to Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" xlink:label="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" xlink:to="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under Non-cancellable Leases [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under Non-cancellable Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_JanssenPharmaceuticalsIncMember" xlink:to="mgtx_JanssenPharmaceuticalsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_lbl" xml:lang="en-US">Janssen Pharmaceuticals Inc [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_lbl" xml:lang="en-US">Janssen Pharmaceuticals Inc</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenLimitedMember" xlink:label="mgtx_HologenLimitedMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_HologenLimitedMember" xlink:to="mgtx_HologenLimitedMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_HologenLimitedMember_lbl" xml:lang="en-US">Information pertaining to Hologen Limited.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_HologenLimitedMember_lbl" xml:lang="en-US">Hologen Limited [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_HologenLimitedMember_lbl" xml:lang="en-US">Hologen Limited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AssetPurchaseAgreementMember" xlink:to="mgtx_AssetPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset purchase agreement as defined by the Company.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenTransactionAgreementMember" xlink:label="mgtx_HologenTransactionAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_HologenTransactionAgreementMember" xlink:to="mgtx_HologenTransactionAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_HologenTransactionAgreementMember_lbl" xml:lang="en-US">Collaborative transaction with Hologen Limited.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_HologenTransactionAgreementMember_lbl" xml:lang="en-US">Hologen Transaction Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_HologenTransactionAgreementMember_lbl" xml:lang="en-US">Hologen Strategic Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ManufacturingFrameworkAgreementMember" xlink:label="mgtx_ManufacturingFrameworkAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ManufacturingFrameworkAgreementMember" xlink:to="mgtx_ManufacturingFrameworkAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ManufacturingFrameworkAgreementMember_lbl" xml:lang="en-US">Manufacturing Framework Agreement with Hologen Limited.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ManufacturingFrameworkAgreementMember_lbl" xml:lang="en-US">Manufacturing Framework Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ManufacturingFrameworkAgreementMember_lbl" xml:lang="en-US">Manufacturing Framework Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReceived" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AssetPurchaseAgreementFundingReceived" xlink:to="mgtx_AssetPurchaseAgreementFundingReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived_lbl" xml:lang="en-US">Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived_lbl" xml:lang="en-US">Asset Purchase Agreement Funding Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived_lbl" xml:lang="en-US">Non-refundable upfront cash funding</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentFundingAvailable" xlink:label="mgtx_ContingentFundingAvailable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ContingentFundingAvailable" xlink:to="mgtx_ContingentFundingAvailable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ContingentFundingAvailable_lbl" xml:lang="en-US">Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ContingentFundingAvailable_lbl" xml:lang="en-US">Contingent Funding Available</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingReceived" xlink:label="mgtx_MilestoneFundingReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingReceived" xlink:to="mgtx_MilestoneFundingReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingReceived_lbl" xml:lang="en-US">Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingReceived_lbl" xml:lang="en-US">Milestone Funding Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingReceived_lbl" xml:lang="en-US">Milestone funding</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:to="mgtx_MilestoneFundingForExtensionOfClinicalTrials_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials_lbl" xml:lang="en-US">Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials_lbl" xml:lang="en-US">Milestone Funding For Extension of Clinical Trials</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials_lbl" xml:lang="en-US">Milestone funding for extension of RPGR product clinical trials</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_lbl" xml:lang="en-US">Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_lbl" xml:lang="en-US">Milestone Funding For Development of Drug Substances</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_lbl" xml:lang="en-US">Milestone funding for development of drug substances</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_lbl" xml:lang="en-US">Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_lbl" xml:lang="en-US">Milestone Funding For Development of Drug Products</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_lbl" xml:lang="en-US">Milestone funding for development of drug products</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_lbl" xml:lang="en-US">Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_lbl" xml:lang="en-US">Milestone Funding For Sale of Drug Products in United States</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_lbl" xml:lang="en-US">Milestone funding for sale of drug products in the US</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_lbl" xml:lang="en-US">Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_lbl" xml:lang="en-US">Milestone Funding For Sale of Drug Products in The UK, France, Germany, Spain and Italy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_lbl" xml:lang="en-US">Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:to="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_lbl" xml:lang="en-US">Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_lbl" xml:lang="en-US">Milestone Funding For Transfer of Manufacturing Technology</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_lbl" xml:lang="en-US">Milestone funding for transfer of manufacturing technology</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForRegulatoryApproval" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingForRegulatoryApproval" xlink:to="mgtx_MilestoneFundingForRegulatoryApproval_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval_lbl" xml:lang="en-US">Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval_lbl" xml:lang="en-US">Milestone Funding For Regulatory Approval</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval_lbl" xml:lang="en-US">Milestone funding upon regulatory approval</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingUpfrontPaymentReceived" xlink:label="mgtx_MilestoneFundingUpfrontPaymentReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingUpfrontPaymentReceived" xlink:to="mgtx_MilestoneFundingUpfrontPaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingUpfrontPaymentReceived_lbl" xml:lang="en-US">Milestone funding received in collaboration with Hologen Limited.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingUpfrontPaymentReceived_lbl" xml:lang="en-US">Milestone funding upfront payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingToProvideAdditionalCapital" xlink:label="mgtx_MilestoneFundingToProvideAdditionalCapital" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingToProvideAdditionalCapital" xlink:to="mgtx_MilestoneFundingToProvideAdditionalCapital_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingToProvideAdditionalCapital_lbl" xml:lang="en-US">Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingToProvideAdditionalCapital_lbl" xml:lang="en-US">Milestone funding to provide additional capital</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassSharesOfHologenReceivedInTransaction" xlink:label="mgtx_ClassSharesOfHologenReceivedInTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClassSharesOfHologenReceivedInTransaction" xlink:to="mgtx_ClassSharesOfHologenReceivedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClassSharesOfHologenReceivedInTransaction_lbl" xml:lang="en-US">Stock issued during period in connection with strategic agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClassSharesOfHologenReceivedInTransaction_lbl" xml:lang="en-US">Class A shares of Hologen received in transaction</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentClassSharesReceivableOfHologenInTransaction" xlink:label="mgtx_ContingentClassSharesReceivableOfHologenInTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ContingentClassSharesReceivableOfHologenInTransaction" xlink:to="mgtx_ContingentClassSharesReceivableOfHologenInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ContingentClassSharesReceivableOfHologenInTransaction_lbl" xml:lang="en-US">Stock contingently issuable to company in connection with strategic agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ContingentClassSharesReceivableOfHologenInTransaction_lbl" xml:lang="en-US">Contingent class A shares receivable of Hologen in transaction</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassShareOwnershipPercentageOfHologenNeuro" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClassShareOwnershipPercentageOfHologenNeuro" xlink:to="mgtx_ClassShareOwnershipPercentageOfHologenNeuro_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClassShareOwnershipPercentageOfHologenNeuro_lbl" xml:lang="en-US">Percentage of ownership in company by share class.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClassShareOwnershipPercentageOfHologenNeuro_lbl" xml:lang="en-US">Class A share ownership percentage of Hologen Neuro</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" xlink:to="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro_lbl" xml:lang="en-US">Percentage of ownership in company by share class.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro_lbl" xml:lang="en-US">Class B share ownership percentage of Hologen Neuro</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PercentageApprovalOfDirectors" xlink:label="mgtx_PercentageApprovalOfDirectors" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PercentageApprovalOfDirectors" xlink:to="mgtx_PercentageApprovalOfDirectors_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PercentageApprovalOfDirectors_lbl" xml:lang="en-US">Percentage approval of directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PercentageApprovalOfDirectors_lbl" xml:lang="en-US">Percentage approval of directors</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" xlink:label="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" xlink:to="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares_lbl" xml:lang="en-US">Purchase option after twelve months, percentage of Company's outstanding common shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares_lbl" xml:lang="en-US">Purchase option after twelve months, percentage of Company's outstanding common shares</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RepurchaseOptionVestingPeriod" xlink:label="mgtx_RepurchaseOptionVestingPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RepurchaseOptionVestingPeriod" xlink:to="mgtx_RepurchaseOptionVestingPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RepurchaseOptionVestingPeriod_lbl" xml:lang="en-US">Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RepurchaseOptionVestingPeriod_lbl" xml:lang="en-US">Repurchase Option, Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RepurchaseOptionVestingPeriod_lbl" xml:lang="en-US">Vesting period, irrevocable option to purchase shares of MeiraGTx Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTable_lbl" xml:lang="en-US">Government Assistance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_lbl" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_lbl" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandMember" xlink:label="mgtx_GrantsIdaIrelandMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantsIdaIrelandMember" xlink:to="mgtx_GrantsIdaIrelandMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantsIdaIrelandMember_lbl" xml:lang="en-US">Represents information pertaining to IDA Ireland grants for financial assistance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantsIdaIrelandMember_lbl" xml:lang="en-US">Grants IDA Ireland [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GrantsIdaIrelandMember_lbl" xml:lang="en-US">IDA Ireland Financial Assistance Grants</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandEmploymentMember" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantsIdaIrelandEmploymentMember" xlink:to="mgtx_GrantsIdaIrelandEmploymentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember_lbl" xml:lang="en-US">Represents information pertaining to IDA Ireland grants for employment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember_lbl" xml:lang="en-US">Grants IDA Ireland Employment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember_lbl" xml:lang="en-US">IDA Ireland Employment Grants</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandCapitalMember" xlink:label="mgtx_GrantsIdaIrelandCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantsIdaIrelandCapitalMember" xlink:to="mgtx_GrantsIdaIrelandCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantsIdaIrelandCapitalMember_lbl" xml:lang="en-US">Represents information pertaining to IDA Ireland grants for capital expenditures.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantsIdaIrelandCapitalMember_lbl" xml:lang="en-US">Grants IDA Ireland Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GrantsIdaIrelandCapitalMember_lbl" xml:lang="en-US">IDA Ireland Capital Grants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceLineItems_lbl" xml:lang="en-US">Government Assistance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForJobCreation" xlink:label="mgtx_GrantAmountForJobCreation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantAmountForJobCreation" xlink:to="mgtx_GrantAmountForJobCreation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantAmountForJobCreation_lbl" xml:lang="en-US">Amount of financial assistance available for each new job created.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantAmountForJobCreation_lbl" xml:lang="en-US">Grant amount for job creation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GrantAmountForJobCreation_lbl" xml:lang="en-US">Grant funding for each new job created</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForMachineryAndEquipment" xlink:label="mgtx_GrantAmountForMachineryAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantAmountForMachineryAndEquipment" xlink:to="mgtx_GrantAmountForMachineryAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantAmountForMachineryAndEquipment_lbl" xml:lang="en-US">Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantAmountForMachineryAndEquipment_lbl" xml:lang="en-US">Grant amount for machinery and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" xlink:to="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_lbl" xml:lang="en-US">Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_lbl" xml:lang="en-US">Grants for machinery and equipment as a percentage of total cost to make</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_lbl" xml:lang="en-US">Grant amount for machinery and equipment (percent of actual expenditure)</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" xlink:to="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_lbl" xml:lang="en-US">Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_lbl" xml:lang="en-US">Number of new jobs created to receive Grant funding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_lbl" xml:lang="en-US">Aggregate number of new jobs required to receive Grant benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromLastGrantPayment" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FinancialAssistanceDurationFromLastGrantPayment" xlink:to="mgtx_FinancialAssistanceDurationFromLastGrantPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment_lbl" xml:lang="en-US">Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment_lbl" xml:lang="en-US">Financial Assistance Duration From Last Grant Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment_lbl" xml:lang="en-US">Termination period (from last grant payment)</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" xlink:to="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_lbl" xml:lang="en-US">Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_lbl" xml:lang="en-US">Financial Assistance Duration From Completion of Capital Investment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_lbl" xml:lang="en-US">Termination period (upon completion of capital investment)</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" xlink:to="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_lbl" xml:lang="en-US">Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_lbl" xml:lang="en-US">Expenditure requirement for grant funding on eligible machinery and equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_lbl" xml:lang="en-US">Expenditure requirement on eligible machinery and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantFundingReceived" xlink:label="mgtx_GrantFundingReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GrantFundingReceived" xlink:to="mgtx_GrantFundingReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GrantFundingReceived_lbl" xml:lang="en-US">Amount of funding received from IDA Ireland grants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GrantFundingReceived_lbl" xml:lang="en-US">Grant funding received</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" xlink:to="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_lbl" xml:lang="en-US">Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_lbl" xml:lang="en-US">Period of job vacancy before grant funding becomes repayable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_lbl" xml:lang="en-US">Vacant job duration prompting repayment of grant funding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair value measurements on recurring basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RestrictedCashMember" xlink:to="mgtx_RestrictedCashMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair value, net asset (liability)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationAbstract" xlink:label="us-gaap_AssetRetirementObligationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationAbstract_lbl" xml:lang="en-US">Asset Retirement Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetRetirementObligationsAmortizationOfInterest" xlink:label="mgtx_AssetRetirementObligationsAmortizationOfInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AssetRetirementObligationsAmortizationOfInterest" xlink:to="mgtx_AssetRetirementObligationsAmortizationOfInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AssetRetirementObligationsAmortizationOfInterest_lbl" xml:lang="en-US">Amortization of interest on asset retirement obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AssetRetirementObligationsAmortizationOfInterest_lbl" xml:lang="en-US">Asset Retirement Obligations, Amortization of Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AssetRetirementObligationsAmortizationOfInterest_lbl" xml:lang="en-US">Amortization of interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:to="us-gaap_AssetRetirementObligationLiabilitiesSettled_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled_lbl" xml:lang="en-US">Asset Retirement Obligation, Liabilities Settled</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled_lbl" xml:lang="en-US">ARO settled through early lease termination</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements associated with terminated lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationCashPaidToSettle" xlink:label="us-gaap_AssetRetirementObligationCashPaidToSettle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationCashPaidToSettle" xlink:to="us-gaap_AssetRetirementObligationCashPaidToSettle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationCashPaidToSettle_lbl" xml:lang="en-US">Asset Retirement Obligation, Cash Paid to Settle</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationCashPaidToSettle_lbl" xml:lang="en-US">Decontamination costs related to ARO</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainOnTerminationOfLeaseLiabilities" xlink:label="mgtx_GainOnTerminationOfLeaseLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_GainOnTerminationOfLeaseLiabilities" xlink:to="mgtx_GainOnTerminationOfLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_GainOnTerminationOfLeaseLiabilities_lbl" xml:lang="en-US">Amount of gain (loss) on termination of lease before expiration of lease term.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_GainOnTerminationOfLeaseLiabilities_lbl" xml:lang="en-US">Gain on termination of lease liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_GainOnTerminationOfLeaseLiabilities_lbl" xml:lang="en-US">Gain on termination of lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities excluded from EPS</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SegmentGeneralAndAdministrativeExpenses" xlink:label="mgtx_SegmentGeneralAndAdministrativeExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SegmentGeneralAndAdministrativeExpenses" xlink:to="mgtx_SegmentGeneralAndAdministrativeExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SegmentGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">The segment total of research and development expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SegmentGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Segment general and administrative expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SegmentGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct1" xlink:label="mgtx_ClinicalProgramsDrugProduct1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClinicalProgramsDrugProduct1" xlink:to="mgtx_ClinicalProgramsDrugProduct1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClinicalProgramsDrugProduct1_lbl" xml:lang="en-US">Amount of expense for clinical trials for Botaretigene Sparoparvovec drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClinicalProgramsDrugProduct1_lbl" xml:lang="en-US">Clinical Programs Drug Product 1</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClinicalProgramsDrugProduct1_lbl" xml:lang="en-US">Botaretigene Sparoparvovec</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct2" xlink:label="mgtx_ClinicalProgramsDrugProduct2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClinicalProgramsDrugProduct2" xlink:to="mgtx_ClinicalProgramsDrugProduct2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClinicalProgramsDrugProduct2_lbl" xml:lang="en-US">Amount of expense for clinical trials for AAV-hAQP1 drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClinicalProgramsDrugProduct2_lbl" xml:lang="en-US">Clinical Programs Drug Product 2</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClinicalProgramsDrugProduct2_lbl" xml:lang="en-US">AAV-hAQP1</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct3" xlink:label="mgtx_ClinicalProgramsDrugProduct3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClinicalProgramsDrugProduct3" xlink:to="mgtx_ClinicalProgramsDrugProduct3_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClinicalProgramsDrugProduct3_lbl" xml:lang="en-US">Amount of expense for clinical trials for AAV-CNGB3 / AAV-CNGA3 drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClinicalProgramsDrugProduct3_lbl" xml:lang="en-US">Clinical Programs Drug Product 3</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClinicalProgramsDrugProduct3_lbl" xml:lang="en-US">AAV-CNGB3 / AAV-CNGA3</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct4" xlink:label="mgtx_ClinicalProgramsDrugProduct4" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClinicalProgramsDrugProduct4" xlink:to="mgtx_ClinicalProgramsDrugProduct4_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClinicalProgramsDrugProduct4_lbl" xml:lang="en-US">Amount of expense for clinical trials for AAV-GAD drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClinicalProgramsDrugProduct4_lbl" xml:lang="en-US">Clinical Programs Drug Product 4</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClinicalProgramsDrugProduct4_lbl" xml:lang="en-US">AAV-GAD</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentClinicalTrials" xlink:label="mgtx_ResearchAndDevelopmentClinicalTrials" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ResearchAndDevelopmentClinicalTrials" xlink:to="mgtx_ResearchAndDevelopmentClinicalTrials_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ResearchAndDevelopmentClinicalTrials_lbl" xml:lang="en-US">Amount of expense for research and development pertaining to clinical trials for drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ResearchAndDevelopmentClinicalTrials_lbl" xml:lang="en-US">Research and development clinical trials</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ResearchAndDevelopmentClinicalTrials_lbl" xml:lang="en-US">Other ocular diseases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentManufacturing" xlink:label="mgtx_ResearchAndDevelopmentManufacturing" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ResearchAndDevelopmentManufacturing" xlink:to="mgtx_ResearchAndDevelopmentManufacturing_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US">Amount of expense for research and development pertaining to manufacturing of drug substances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US">Research and development Manufacturing</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ResearchAndDevelopmentManufacturing_lbl" xml:lang="en-US">Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchGeneRegulation" xlink:label="mgtx_PreClinicalResearchGeneRegulation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PreClinicalResearchGeneRegulation" xlink:to="mgtx_PreClinicalResearchGeneRegulation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PreClinicalResearchGeneRegulation_lbl" xml:lang="en-US">Amount of expense for pre-clinical research relating to gene regulation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PreClinicalResearchGeneRegulation_lbl" xml:lang="en-US">Pre-clinical research Gene Regulation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PreClinicalResearchGeneRegulation_lbl" xml:lang="en-US">Gene Regulation</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchNeurodegenerativeDiseases" xlink:label="mgtx_PreClinicalResearchNeurodegenerativeDiseases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PreClinicalResearchNeurodegenerativeDiseases" xlink:to="mgtx_PreClinicalResearchNeurodegenerativeDiseases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PreClinicalResearchNeurodegenerativeDiseases_lbl" xml:lang="en-US">Amount of expense for pre-clinical research relating to neurodegenerative diseases.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PreClinicalResearchNeurodegenerativeDiseases_lbl" xml:lang="en-US">Pre-clinical research Neurodegenerative Diseases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PreClinicalResearchNeurodegenerativeDiseases_lbl" xml:lang="en-US">Neurodegenerative diseases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchPreclinicalOcularDiseases" xlink:label="mgtx_PreClinicalResearchPreclinicalOcularDiseases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PreClinicalResearchPreclinicalOcularDiseases" xlink:to="mgtx_PreClinicalResearchPreclinicalOcularDiseases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PreClinicalResearchPreclinicalOcularDiseases_lbl" xml:lang="en-US">Amount of expense for pre-clinical research relating to preclinical ocular diseases.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PreClinicalResearchPreclinicalOcularDiseases_lbl" xml:lang="en-US">Pre-clinical research Preclinical Ocular Diseases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PreClinicalResearchPreclinicalOcularDiseases_lbl" xml:lang="en-US">Preclinical ocular diseases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentOther" xlink:label="mgtx_ResearchAndDevelopmentOther" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ResearchAndDevelopmentOther" xlink:to="mgtx_ResearchAndDevelopmentOther_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ResearchAndDevelopmentOther_lbl" xml:lang="en-US">Amount of expense for research and development classified as other.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ResearchAndDevelopmentOther_lbl" xml:lang="en-US">Research and development other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ResearchAndDevelopmentOther_lbl" xml:lang="en-US">Other research and development (1)</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_InnovativeMedicineReimbursement" xlink:label="mgtx_InnovativeMedicineReimbursement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_InnovativeMedicineReimbursement" xlink:to="mgtx_InnovativeMedicineReimbursement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_InnovativeMedicineReimbursement_lbl" xml:lang="en-US">Amount of expense for innovative medicine research reimbursed by Johnson &amp; Johnson.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_InnovativeMedicineReimbursement_lbl" xml:lang="en-US">Innovative Medicine Reimbursement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_InnovativeMedicineReimbursement_lbl" xml:lang="en-US">Johnson &amp; Johnson Innovative Medicine reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OtherSegmentItemsIncomeStatement" xlink:label="mgtx_OtherSegmentItemsIncomeStatement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OtherSegmentItemsIncomeStatement" xlink:to="mgtx_OtherSegmentItemsIncomeStatement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OtherSegmentItemsIncomeStatement_lbl" xml:lang="en-US">Other segment items of income (expense).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OtherSegmentItemsIncomeStatement_lbl" xml:lang="en-US">Other segment items income statement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OtherSegmentItemsIncomeStatement_lbl" xml:lang="en-US">Other segment items (2)</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SegmentNetIncomeLoss" xlink:label="mgtx_SegmentNetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SegmentNetIncomeLoss" xlink:to="mgtx_SegmentNetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SegmentNetIncomeLoss_lbl" xml:lang="en-US">The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SegmentNetIncomeLoss_lbl" xml:lang="en-US">Segment net income (loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SegmentNetIncomeLoss_lbl" xml:lang="en-US">Segment net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeanUnionMember" xlink:to="us-gaap_EuropeanUnionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US">European Union [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US">EUROPEAN UNION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VisiogeneLlcMember" xlink:label="mgtx_VisiogeneLlcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_VisiogeneLlcMember" xlink:to="mgtx_VisiogeneLlcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_VisiogeneLlcMember_lbl" xml:lang="en-US">Represents information pertaining to Visiogene LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_VisiogeneLlcMember_lbl" xml:lang="en-US">Visiogene LLC</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OtherEquityMethodInvestmentsMember" xlink:label="mgtx_OtherEquityMethodInvestmentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OtherEquityMethodInvestmentsMember" xlink:to="mgtx_OtherEquityMethodInvestmentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OtherEquityMethodInvestmentsMember_lbl" xml:lang="en-US">Represents information pertaining to equity method investments other than Visogene LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OtherEquityMethodInvestmentsMember_lbl" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity ownership in outstanding ordinary shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xml:lang="en-US">Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US">Accrued Liabilities Accrued Compensation And Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US">Accrued Liabilities Accrued Compensation And Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US">Compensation and benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedResearchAndDevelopment" xlink:label="mgtx_AccruedResearchAndDevelopment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedResearchAndDevelopment" xlink:to="mgtx_AccruedResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Deposit Liabilities, Accrued Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Interest on Tranche 1 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedClinicalTrialCosts" xlink:to="mgtx_AccruedClinicalTrialCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US">Accrued Clinical Trial Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US">Accrued Clinical Trial Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US">Clinical trial costs</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" xlink:to="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_lbl" xml:lang="en-US">Accrued Liabilities Accrued Manufacturing Costs Expense.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_lbl" xml:lang="en-US">Accrued Liabilities Accrued Manufacturing Costs Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_lbl" xml:lang="en-US">Manufacturing costs</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedConsultingExpenses" xlink:to="mgtx_AccruedConsultingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US">Accrued Consulting Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US">Accrued Consulting Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US">Consulting</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_lbl" xml:lang="en-US">Represents the carrying value of accrued expenses incurred in connection with rent and facility costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_lbl" xml:lang="en-US">Accrued Expenses Incurred In Connection With Rent and Facility Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_lbl" xml:lang="en-US">Rent and facilities costs</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_lbl" xml:lang="en-US">Represents the carrying value of accrued expenses incurred in connection with fixed assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_lbl" xml:lang="en-US">Accrued Expenses Incurred In Connection With Fixed Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_lbl" xml:lang="en-US">Fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share options granted during the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Options additional disclosures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average remaining contractual life of options, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average remaining contractual life of options, exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of options, Options vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, Options vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average remaining contractual life, Options vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of restricted share units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of restricted share units, Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of restricted share units, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of restricted share units, Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FirstAnniversaryMember" xlink:to="mgtx_FirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecondAnniversaryMember" xlink:label="mgtx_SecondAnniversaryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SecondAnniversaryMember" xlink:to="mgtx_SecondAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SecondAnniversaryMember_lbl" xml:lang="en-US">Second Anniversary member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SecondAnniversaryMember_lbl" xml:lang="en-US">Second Anniversary [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SecondAnniversaryMember_lbl" xml:lang="en-US">Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ThirdAnniversaryMember" xlink:label="mgtx_ThirdAnniversaryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ThirdAnniversaryMember" xlink:to="mgtx_ThirdAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third anniversary member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FourthAnniversaryMember" xlink:label="mgtx_FourthAnniversaryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FourthAnniversaryMember" xlink:to="mgtx_FourthAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FourthAnniversaryMember_lbl" xml:lang="en-US">Fourth Anniversary member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FourthAnniversaryMember_lbl" xml:lang="en-US">Fourth Anniversary [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FourthAnniversaryMember_lbl" xml:lang="en-US">Fourth Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Contractual term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of options, Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value of options granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unvested options compensation expense not yet recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Total compensation expense not yet recognized relating to unvested RSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period expected to realize unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VestedSharesDeferred" xlink:label="mgtx_VestedSharesDeferred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_VestedSharesDeferred" xlink:to="mgtx_VestedSharesDeferred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_VestedSharesDeferred_lbl" xml:lang="en-US">The number of shares that have fully vested and have been deferred.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_VestedSharesDeferred_lbl" xml:lang="en-US">Vested shares deferred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_VestedSharesDeferred_lbl" xml:lang="en-US">Shares vested and deferred</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Ordinary shares withheld for statutory tax requirements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Taxes withheld on issuance of share-based awards</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_lbl" xml:lang="en-US">Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_lbl" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities1</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_lbl" xml:lang="en-US">Excess tax benefits in cash flows from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_lbl" xml:lang="en-US">Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_lbl" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities1</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_lbl" xml:lang="en-US">Excess tax benefits in cash flows from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BankOfAmericaSecuritiesInc.Member" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_BankOfAmericaSecuritiesInc.Member" xlink:to="mgtx_BankOfAmericaSecuritiesInc.Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member_lbl" xml:lang="en-US">Information pertaining to BofA Securities, Inc.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member_lbl" xml:lang="en-US">Bank of America Securities, Inc. [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member_lbl" xml:lang="en-US">B of A Securities, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AtMarketOfferingMember" xlink:label="mgtx_AtMarketOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AtMarketOfferingMember" xlink:to="mgtx_AtMarketOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AtMarketOfferingMember_lbl" xml:lang="en-US">It represents the information pertaining to the ATM offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AtMarketOfferingMember_lbl" xml:lang="en-US">At-the-market Offering</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AtMarketOfferingMember_lbl" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Gross proceeds from sale of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Ordinary shares issued in transaction</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" xlink:to="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_lbl" xml:lang="en-US">Aggregate consideration available in future stock transactions after deduction of issuance costs in at-the-market offerings of equity securities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_lbl" xml:lang="en-US">Sale of Stock, Consideration Available in Future Transactions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_lbl" xml:lang="en-US">Value of ordinary shares available for future sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision recorded for income tax expense (benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:to="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_lbl" xml:lang="en-US">Pertaining to JJDC - the investment arm of Johnson &amp; Johnson and owner of Janssen.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_lbl" xml:lang="en-US">JJDC</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:to="mgtx_DeferredRevenueRecognizedDuringPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_lbl" xml:lang="en-US">Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_lbl" xml:lang="en-US">Deferred revenue recognized during period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_lbl" xml:lang="en-US">Deferred revenue recognized as service revenue during the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_lbl" xml:lang="en-US">Deferred revenue recognized as service revenue during the period</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_InitialAgreementPeriodDuration" xlink:label="mgtx_InitialAgreementPeriodDuration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_InitialAgreementPeriodDuration" xlink:to="mgtx_InitialAgreementPeriodDuration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_InitialAgreementPeriodDuration_lbl" xml:lang="en-US">Initial duration period of the asset purchase agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_InitialAgreementPeriodDuration_lbl" xml:lang="en-US">Initial Agreement Period Duration</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_InitialAgreementPeriodDuration_lbl" xml:lang="en-US">Initial agreement term</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AgreementTerminationPeriodDaysWrittenNotice" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AgreementTerminationPeriodDaysWrittenNotice" xlink:to="mgtx_AgreementTerminationPeriodDaysWrittenNotice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice_lbl" xml:lang="en-US">Days of written notice needed in order to terminate the asset purchase agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice_lbl" xml:lang="en-US">Agreement Termination Period Days Written Notice</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice_lbl" xml:lang="en-US">Written days-notice to terminate agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RelatedPartyDeferredRevenueReclassified" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyDeferredRevenueReclassified" xlink:to="mgtx_RelatedPartyDeferredRevenueReclassified_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified_lbl" xml:lang="en-US">Related-party deferred revenue reclassified under provisions of new license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified_lbl" xml:lang="en-US">Related-party deferred revenue reclassified</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified_lbl" xml:lang="en-US">Deferred revenue - related party included in contract price of license agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VariableConsiderationForServices" xlink:label="mgtx_VariableConsiderationForServices" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_VariableConsiderationForServices" xlink:to="mgtx_VariableConsiderationForServices_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_VariableConsiderationForServices_lbl" xml:lang="en-US">Variable consideration included in provisions of new license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_VariableConsiderationForServices_lbl" xml:lang="en-US">Variable consideration for services</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_VariableConsiderationForServices_lbl" xml:lang="en-US">Variable consideration for services included in contract price of license agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReclassified" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AssetPurchaseAgreementFundingReclassified" xlink:to="mgtx_AssetPurchaseAgreementFundingReclassified_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified_lbl" xml:lang="en-US">Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified_lbl" xml:lang="en-US">Asset purchase agreement funding reclassified</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified_lbl" xml:lang="en-US">Asset purchase agreement funding included in contract price of license agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractPriceOfLicenseAgreement" xlink:label="mgtx_ContractPriceOfLicenseAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ContractPriceOfLicenseAgreement" xlink:to="mgtx_ContractPriceOfLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ContractPriceOfLicenseAgreement_lbl" xml:lang="en-US">Total contract price of license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ContractPriceOfLicenseAgreement_lbl" xml:lang="en-US">Contract price of license agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OffsettingCreditForTransitionServices" xlink:label="mgtx_OffsettingCreditForTransitionServices" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OffsettingCreditForTransitionServices" xlink:to="mgtx_OffsettingCreditForTransitionServices_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OffsettingCreditForTransitionServices_lbl" xml:lang="en-US">Offsetting credit for transition services in determining contract price under license agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OffsettingCreditForTransitionServices_lbl" xml:lang="en-US">Offsetting credit for transition services</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForProcessPerformanceQualificationServices" xlink:label="mgtx_PerformanceObligationForProcessPerformanceQualificationServices" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerformanceObligationForProcessPerformanceQualificationServices" xlink:to="mgtx_PerformanceObligationForProcessPerformanceQualificationServices_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerformanceObligationForProcessPerformanceQualificationServices_lbl" xml:lang="en-US">License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerformanceObligationForProcessPerformanceQualificationServices_lbl" xml:lang="en-US">Performance obligation for process performance qualification services</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" xlink:label="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" xlink:to="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct_lbl" xml:lang="en-US">License agreement contract price allocated to performance obligation for commercial supply of RPGR product.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct_lbl" xml:lang="en-US">Performance obligation for commercial supply of RPGR product</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForManufacturingTechnologyTransfer" xlink:label="mgtx_PerformanceObligationForManufacturingTechnologyTransfer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerformanceObligationForManufacturingTechnologyTransfer" xlink:to="mgtx_PerformanceObligationForManufacturingTechnologyTransfer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerformanceObligationForManufacturingTechnologyTransfer_lbl" xml:lang="en-US">License agreement contract price allocated to performance obligation for manufacturing technology transfer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerformanceObligationForManufacturingTechnologyTransfer_lbl" xml:lang="en-US">Performance obligation for manufacturing technology transfer</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForSaleOfNonfinancialAssets" xlink:label="mgtx_PerformanceObligationForSaleOfNonfinancialAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerformanceObligationForSaleOfNonfinancialAssets" xlink:to="mgtx_PerformanceObligationForSaleOfNonfinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerformanceObligationForSaleOfNonfinancialAssets_lbl" xml:lang="en-US">License agreement contract price allocated to performance obligation for sale of nonfinancial assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerformanceObligationForSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Performance obligation for sale of nonfinancial assets</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" xlink:label="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" xlink:to="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices_lbl" xml:lang="en-US">Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices_lbl" xml:lang="en-US">Milestone funding allocated to process performance qualification services</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" xlink:label="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" xlink:to="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct_lbl" xml:lang="en-US">Milestone funding received and allocated to performance obligation for commercial supply of RPGR product.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct_lbl" xml:lang="en-US">Milestone funding allocated to commercial supply of RPGR product</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" xlink:label="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" xlink:to="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer_lbl" xml:lang="en-US">Milestone funding received and allocated to performance obligation for manufacturing technology transfer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer_lbl" xml:lang="en-US">Milestone funding allocated to manufacturing technology transfer</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" xlink:label="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" xlink:to="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Milestone funding received and allocated to performance obligation for sale of nonfinancial assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets_lbl" xml:lang="en-US">Milestone funding allocated to sale of nonfinancial assets</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationAmount" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RevenueUnsatisfiedPerformanceObligationAmount" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_lbl" xml:lang="en-US">Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_lbl" xml:lang="en-US">Revenue, unsatisfied performance obligation, amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_lbl" xml:lang="en-US">Deferred revenue, unsatisfied performance obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_lbl" xml:lang="en-US">Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_lbl" xml:lang="en-US">Revenue, unsatisfied performance obligation, expected recognition period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_lbl" xml:lang="en-US">Recognition period for deferred revenue, unsatisfied performance obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveAdvisorsLlcMember" xlink:label="mgtx_PerceptiveAdvisorsLlcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerceptiveAdvisorsLlcMember" xlink:to="mgtx_PerceptiveAdvisorsLlcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerceptiveAdvisorsLlcMember_lbl" xml:lang="en-US">Information pertaining to Perceptive Advisors, LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerceptiveAdvisorsLlcMember_lbl" xml:lang="en-US">Perceptive Advisors, LLC</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancingAgreementMember" xlink:label="mgtx_FinancingAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FinancingAgreementMember" xlink:to="mgtx_FinancingAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FinancingAgreementMember_lbl" xml:lang="en-US">Information pertaining to the financing agreement with Perceptive Advisors, LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FinancingAgreementMember_lbl" xml:lang="en-US">Secured Financing Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FinancingAgreementMember_lbl" xml:lang="en-US">Notes Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue at period-end</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" xlink:to="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_lbl" xml:lang="en-US">The amount of milestone payments collected or invoiced, categorized as other.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_lbl" xml:lang="en-US">Contract with Customer, Liability, Other Amounts Collected or Invoiced</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_lbl" xml:lang="en-US">Other amounts collected or invoiced</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" xlink:to="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_lbl" xml:lang="en-US">The effect of exchange rates on customer contract liability.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_lbl" xml:lang="en-US">Contract With Customer Liability Effect Of Exchange Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_lbl" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OperatingLeaseAbstract" xlink:label="mgtx_OperatingLeaseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OperatingLeaseAbstract" xlink:to="mgtx_OperatingLeaseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OperatingLeaseAbstract_lbl" xml:lang="en-US">Operating Lease [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OperatingLeaseAbstract_lbl" xml:lang="en-US">Operating Lease [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OperatingLeaseAbstract_lbl" xml:lang="en-US">Operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Capitalized lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinanceLeaseAbstract" xlink:label="mgtx_FinanceLeaseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FinanceLeaseAbstract" xlink:to="mgtx_FinanceLeaseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FinanceLeaseAbstract_lbl" xml:lang="en-US">Finance Lease [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FinanceLeaseAbstract_lbl" xml:lang="en-US">Finance Lease [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FinanceLeaseAbstract_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_WeightedAverageRemainingLeaseTermAbstract" xlink:label="mgtx_WeightedAverageRemainingLeaseTermAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="mgtx_WeightedAverageRemainingLeaseTermAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_WeightedAverageDiscountRateAbstract" xlink:label="mgtx_WeightedAverageDiscountRateAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_WeightedAverageDiscountRateAbstract" xlink:to="mgtx_WeightedAverageDiscountRateAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseMaturityTerm" xlink:label="mgtx_LeaseMaturityTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_LeaseMaturityTerm" xlink:to="mgtx_LeaseMaturityTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_LeaseMaturityTerm_lbl" xml:lang="en-US">Lease Maturity Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_LeaseMaturityTerm_lbl" xml:lang="en-US">Lease Maturity Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_LeaseMaturityTerm_lbl" xml:lang="en-US">Lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease rent expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OperatingLeaseNumberNewLeasesRecognized" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OperatingLeaseNumberNewLeasesRecognized" xlink:to="mgtx_OperatingLeaseNumberNewLeasesRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized_lbl" xml:lang="en-US">The number new leases recognized during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized_lbl" xml:lang="en-US">Operating Lease Number New Leases Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized_lbl" xml:lang="en-US">New leases recognized during period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveCreditHoldingsMember" xlink:label="mgtx_PerceptiveCreditHoldingsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PerceptiveCreditHoldingsMember" xlink:to="mgtx_PerceptiveCreditHoldingsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PerceptiveCreditHoldingsMember_lbl" xml:lang="en-US">Information pertaining to the financing agreement with Perceptive Credit Holdings..</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PerceptiveCreditHoldingsMember_lbl" xml:lang="en-US">Perceptive Credit Holdings</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_TermLoanMember" xlink:label="mgtx_TermLoanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_TermLoanMember" xlink:to="mgtx_TermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_TermLoanMember_lbl" xml:lang="en-US">Term loans granted under the Company's financing agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_TermLoanMember_lbl" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BaseRateMember_lbl" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US">SOFR</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioMember" xlink:label="mgtx_ExercisePriceScenarioMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ExercisePriceScenarioMember" xlink:to="mgtx_ExercisePriceScenarioMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ExercisePriceScenarioMember_lbl" xml:lang="en-US">Information related to warrants to buy common shares with various exercise prices.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ExercisePriceScenarioMember_lbl" xml:lang="en-US">Exercise Price - Scenario I</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioBMember" xlink:label="mgtx_ExercisePriceScenarioBMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ExercisePriceScenarioBMember" xlink:to="mgtx_ExercisePriceScenarioBMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ExercisePriceScenarioBMember_lbl" xml:lang="en-US">Information related to warrants to buy common shares with various exercise prices.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ExercisePriceScenarioBMember_lbl" xml:lang="en-US">Exercise Price - Scenario II</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Initial face amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Unused borrowing capacity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xml:lang="en-US">Secured Debt, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtCurrent_lbl" xml:lang="en-US">Term loan outstanding amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Stated interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BasisSpreadOnVariableRateFloor" xlink:label="mgtx_BasisSpreadOnVariableRateFloor" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_BasisSpreadOnVariableRateFloor" xlink:to="mgtx_BasisSpreadOnVariableRateFloor_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_BasisSpreadOnVariableRateFloor_lbl" xml:lang="en-US">Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_BasisSpreadOnVariableRateFloor_lbl" xml:lang="en-US">Basis Spread on Variable Rate Floor</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_BasisSpreadOnVariableRateFloor_lbl" xml:lang="en-US">Floor percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredOvernightFinancingRateAdjustmentTerm" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SecuredOvernightFinancingRateAdjustmentTerm" xlink:to="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_lbl" xml:lang="en-US">Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_lbl" xml:lang="en-US">Secured Overnight Financing Rate, Adjustment Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_lbl" xml:lang="en-US">SOFR adjustment term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="us-gaap_LongtermDebtWeightedAverageInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="us-gaap_LongtermDebtWeightedAverageInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Interest rate at period-end</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Increase in accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense on debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteedBenefitLiabilityNet" xlink:label="us-gaap_GuaranteedBenefitLiabilityNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteedBenefitLiabilityNet" xlink:to="us-gaap_GuaranteedBenefitLiabilityNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteedBenefitLiabilityNet_lbl" xml:lang="en-US">Guaranteed Benefit Liability, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GuaranteedBenefitLiabilityNet_lbl" xml:lang="en-US">Obligations secured by UK and Ireland subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredCashAndBankAccounts" xlink:label="mgtx_SecuredCashAndBankAccounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SecuredCashAndBankAccounts" xlink:to="mgtx_SecuredCashAndBankAccounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SecuredCashAndBankAccounts_lbl" xml:lang="en-US">Liquidity requirement for minimum amount of cash and bank accounts to be maintained and secured under the financing agreement with Perceptive Credit Holdings.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SecuredCashAndBankAccounts_lbl" xml:lang="en-US">Cash liquidity requirement</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SharesIssuedInConnectionWithFinancingAgreement" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SharesIssuedInConnectionWithFinancingAgreement" xlink:to="mgtx_SharesIssuedInConnectionWithFinancingAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement_lbl" xml:lang="en-US">Shares available for purchase in connection with the financing agreement with Perceptive Credit Holdings.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement_lbl" xml:lang="en-US">Shares Issued In Connection With Financing Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement_lbl" xml:lang="en-US">Shares available through warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDiscountOnShares" xlink:to="us-gaap_CommonStockDiscountOnShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xml:lang="en-US">Common Stock, Discount on Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xml:lang="en-US">Debt discount, allocated fair value of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt discount, capitalized issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NumberOfNewMaterialCommitments" xlink:label="mgtx_NumberOfNewMaterialCommitments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NumberOfNewMaterialCommitments" xlink:to="mgtx_NumberOfNewMaterialCommitments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NumberOfNewMaterialCommitments_lbl" xml:lang="en-US">Number of new material commitments entered into during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NumberOfNewMaterialCommitments_lbl" xml:lang="en-US">Number of new material commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_Rule10b51ArrangementModifiedFlag" xlink:label="mgtx_Rule10b51ArrangementModifiedFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_Rule10b51ArrangementModifiedFlag" xlink:to="mgtx_Rule10b51ArrangementModifiedFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Modified [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Modified [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_Rule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Modified</link:label>
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NonRule10b51ArrangementModifiedFlag" xlink:label="mgtx_NonRule10b51ArrangementModifiedFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NonRule10b51ArrangementModifiedFlag" xlink:to="mgtx_NonRule10b51ArrangementModifiedFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Non Rule 10b5-1 Arrangement Modified [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Non Rule 10b5-1 Arrangement Modified [Flag]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NonRule10b51ArrangementModifiedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Modified</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgtx-20250331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2025 11:46:40 AM-->
<!--Modified on: 5/13/2025 11:46:40 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://meiragtx.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementOfShareholdersEquity" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrganizationAndBasisOfPresentation" roleURI="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureEquityMethodAndOtherInvestments" roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureAccruedExpenses" roleURI="http://meiragtx.com/role/DisclosureAccruedExpenses" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensation" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrdinaryShares" roleURI="http://meiragtx.com/role/DisclosureOrdinaryShares" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureIncomeTaxes" roleURI="http://meiragtx.com/role/DisclosureIncomeTaxes" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeases" roleURI="http://meiragtx.com/role/DisclosureLeases" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureDebtFinancing" roleURI="http://meiragtx.com/role/DisclosureDebtFinancing" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://meiragtx.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureEquityMethodAndOtherInvestmentsTables" roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureAccruedExpensesTables" roleURI="http://meiragtx.com/role/DisclosureAccruedExpensesTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationTables" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesTables" roleURI="http://meiragtx.com/role/DisclosureLeasesTables" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" roleURI="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" roleURI="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureShareBasedCompensationAdditionalInformationDetails" roleURI="http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureOrdinarySharesDetails" roleURI="http://meiragtx.com/role/DisclosureOrdinarySharesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureIncomeTaxesDetails" roleURI="http://meiragtx.com/role/DisclosureIncomeTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsPerformanceObligationDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsFinancingAgreementDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" roleURI="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureDebtFinancingDetails" roleURI="http://meiragtx.com/role/DisclosureDebtFinancingDetails" />
  <link:roleRef xlink:type="simple" xlink:href="mgtx-20250331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://meiragtx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638827335967172798" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638827335967172798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638827335967172798" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638827335967172798" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638827335967172798" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638827335967172798" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638827335967172798" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638827335967172798" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638827335967172798" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638827335967172798" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638827335967182793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638827335967182793" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638827335967182793" order="8" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638827335967182793" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638827335967182793" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638827335967182793" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638827335967182793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638827335967182793" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638827335967192792" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638827335967192792" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638827335967192792" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638827335967192792" order="16" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638827335967192792" order="17" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638827335967192792" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638827335967192792" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638827335967192792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638827335967192792" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638827335967202789" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638827335967202789" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638827335967202789" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638827335967202789" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638827335967202789" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638827335967202789" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638827335967202789" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638827335967202789" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638827335967212777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638827335967212777" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638827335967212777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638827335967212777" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638827335967212777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638827335967212777" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638827335967212777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638827335967212777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638827335967212777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_AssetsCurrentAbstract_638827335967212777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335967222782" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_AccountsReceivableNetCurrent_638827335967222782" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638827335967222782" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_InventoryNet_638827335967222782" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_PrepaidExpenseCurrent_638827335967222782" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_IncomeTaxReceivable_638827335967222782" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_OtherAssetsCurrent_638827335967222782" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638827335967212777" xlink:to="us-gaap_AssetsCurrent_638827335967222782" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638827335967222782" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638827335967222782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638827335967222782" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_RestrictedCashNoncurrent_638827335967232777" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_OtherAssetsNoncurrent_638827335967232777" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_EquityMethodInvestments_638827335967232777" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638827335967232777" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638827335967232777" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638827335967212777" xlink:to="us-gaap_Assets_638827335967232777" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_AccountsPayableCurrent_638827335967242774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638827335967242774" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638827335967242774" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_DeferredIncomeCurrent_638827335967242774" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_OtherLiabilitiesCurrent_638827335967242774" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_LiabilitiesCurrent_638827335967242774" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_DeferredIncomeNoncurrent_638827335967242774" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638827335967242774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638827335967242774" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638827335967232777" xlink:to="us-gaap_AssetRetirementObligation_638827335967252774" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" xlink:to="us-gaap_LongTermNotesPayable_638827335967252774" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" xlink:to="us-gaap_Liabilities_638827335967252774" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" xlink:to="us-gaap_StockholdersEquityAbstract_638827335967252774" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638827335967252774" xlink:to="us-gaap_CommonStockValue_638827335967252774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638827335967252774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638827335967252774" xlink:to="us-gaap_AdditionalPaidInCapital_638827335967252774" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638827335967262779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638827335967252774" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638827335967262779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638827335967262779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638827335967252774" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638827335967262779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638827335967262779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638827335967252774" xlink:to="us-gaap_StockholdersEquity_638827335967262779" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638827335967262779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638827335967232777" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638827335967262779" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638827335967272779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638827335967272779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638827335967272779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638827335967272779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="mgtx_ServiceRevenueFromRelatedParties_638827335967272779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638827335967272779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638827335967272779" xlink:to="us-gaap_SellingAndMarketingExpense_638827335967272779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638827335967272779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638827335967272779" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638827335967272779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638827335967272779" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638827335967282783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638827335967272779" xlink:to="us-gaap_OperatingExpenses_638827335967282783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638827335967282783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335967282783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" xlink:to="us-gaap_InvestmentIncomeInterest_638827335967282783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" xlink:to="us-gaap_InterestExpense_638827335967282783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638827335967282783" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967282783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638827335967282783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638827335967282783" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638827335967292779" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638827335967292779" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335967292779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638827335967292779" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638827335967292779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638827335967292779" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638827335967292779" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638827335967292779" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638827335967292779" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638827335967292779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638827335967292779" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638827335967302775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638827335967302775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638827335967302775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638827335967302775" xlink:to="us-gaap_StatementEquityComponentsAxis_638827335967302775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638827335967302775" xlink:to="us-gaap_CommonStockMember_638827335967312786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638827335967302775" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638827335967312786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638827335967302775" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638827335967312786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638827335967302775" xlink:to="us-gaap_RetainedEarningsMember_638827335967312786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638827335967302775" xlink:to="us-gaap_EquityComponentDomain_638827335967312786" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638827335967302775" xlink:to="us-gaap_StatementLineItems_638827335967312786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_StockholdersEquity_638827335967312786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_SharesOutstanding_638827335967312786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638827335967312786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638827335967312786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638827335967312786" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638827335967312786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638827335967322786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638827335967322786" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638827335967322786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638827335967322786" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638827335967322786" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_NetIncomeLoss_638827335967322786" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638827335967322786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_StockholdersEquity_638827335967322786" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638827335967422787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638827335967312786" xlink:to="us-gaap_SharesOutstanding_638827335967422787" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_ProfitLoss_638827335967432817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_ShareBasedCompensation_638827335967432817" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638827335967432817" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638827335967432817" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638827335967432817" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_GainLossOnTerminationOfLease_638827335967432817" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638827335967432817" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_AssetRetirementObligationAccretionExpense_638827335967432817" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638827335967432817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638827335967432817" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967442779" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_638827335967442779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638827335967442779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets_638827335967442779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638827335967442779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638827335967442779" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_638827335967442779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_638827335967442779" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638827335967442779" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638827335967452777" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638827335967452777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638827335967452777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638827335967452777" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_638827335967452777" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638827335967452777" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638827335967432817" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335967452777" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638827335967452777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638827335967452777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638827335967452777" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638827335967462776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets" xlink:label="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638827335967452777" xlink:to="mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets_638827335967462776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638827335967452777" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638827335967462776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638827335967462776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638827335967462776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335967462776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335967462776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638827335967472780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638827335967472780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335967472780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638827335967462776" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638827335967472780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638827335967472780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638827335967472780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967472780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967472780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967472780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967472780" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388273359674727801" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388273359674727801" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638827335967482775" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638827335967482775" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_638827335967482775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638827335967482775" xlink:to="us-gaap_AssetRetirementObligationRevisionOfEstimate_638827335967482775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets" xlink:label="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638827335967482775" xlink:to="mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets_638827335967482775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638827335967482775" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638827335967482775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638827335967482775" xlink:to="us-gaap_InterestPaidNet_638827335967482775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation" xlink:type="extended" xlink:title="995210101 - Disclosure - Organization and Basis of Presentation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638827335967492784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638827335967492784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638827335967492784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638827335967492784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments" xlink:type="extended" xlink:title="995210301 - Disclosure - Equity Method and Other Investments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_638827335967502784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_638827335967502784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210401 - Disclosure - Accrued Expenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638827335967502784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638827335967502784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="995210501 - Disclosure - Share-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638827335967502784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638827335967502784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureOrdinaryShares" xlink:type="extended" xlink:title="995210601 - Disclosure - Ordinary Shares">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638827335967513126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638827335967513126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995210701 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638827335967513126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638827335967513126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995210801 - Disclosure - Related Party Transactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638827335967513126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638827335967513126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995210901 - Disclosure - Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638827335967513126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638827335967513126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureDebtFinancing" xlink:type="extended" xlink:title="995211001 - Disclosure - Debt Financing">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638827335967522783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtDisclosureTextBlock_638827335967522783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211101 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_638827335967522783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_638827335967522783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638827335967522783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638827335967522783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638827335967522783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638827335967522783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638827335967522783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638827335967522783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638827335967532782" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="us-gaap_AssetRetirementObligationsPolicy_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetRetirementObligationsPolicy_638827335967532782" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfIrelandGrantsPolicyTextBlock" xlink:label="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_ScheduleOfIrelandGrantsPolicyTextBlock_638827335967532782" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638827335967532782" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638827335967532782" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638827335967532782" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638827335967532782" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638827335967532782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638827335967532782" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638827335967542780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638827335967542780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_638827335967542780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638827335967542780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638827335967542780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_638827335967542780" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Equity Method and Other Investments (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_638827335967542780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_638827335967542780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Accrued Expenses (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Share-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967552780" xlink:to="us-gaap_AwardTypeAxis_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638827335967552780" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967552780" xlink:to="us-gaap_EmployeeStockOptionMember_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967552780" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638827335967552780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967552780" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638827335967552780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638827335967552780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638827335967562779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638827335967562779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967552780" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638827335967562779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Related Party Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_638827335967562779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Leases (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638827335967562779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock" xlink:label="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_638827335967562779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock_638827335967562779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock_638827335967572780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock" xlink:label="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock_638827335967572780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization and Basis of Presentation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" xlink:to="srt_RangeAxis_638827335967572780" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967572780" xlink:to="srt_RangeMember_638827335967572780" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967572780" xlink:to="srt_MaximumMember_638827335967572780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" xlink:to="srt_CounterpartyNameAxis_638827335967572780" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638827335967572780" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967572780" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967572780" xlink:to="mgtx_JanssenPharmaceuticalsIncMember_638827335967572780" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenLimitedMember" xlink:label="mgtx_HologenLimitedMember_638827335967572780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967572780" xlink:to="mgtx_HologenLimitedMember_638827335967572780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" xlink:to="us-gaap_TypeOfArrangementAxis_638827335967582783" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638827335967582783" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" xlink:to="us-gaap_CollaborativeArrangementMember_638827335967582783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" xlink:to="mgtx_AssetPurchaseAgreementMember_638827335967582783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_HologenTransactionAgreementMember" xlink:label="mgtx_HologenTransactionAgreementMember_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" xlink:to="mgtx_HologenTransactionAgreementMember_638827335967582783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ManufacturingFrameworkAgreementMember" xlink:label="mgtx_ManufacturingFrameworkAgreementMember_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967582783" xlink:to="mgtx_ManufacturingFrameworkAgreementMember_638827335967582783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638827335967572780" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638827335967582783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335967582783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638827335967582783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967592783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReceived" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_AssetPurchaseAgreementFundingReceived_638827335967592783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentFundingAvailable" xlink:label="mgtx_ContingentFundingAvailable_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_ContingentFundingAvailable_638827335967592783" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingReceived" xlink:label="mgtx_MilestoneFundingReceived_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingReceived_638827335967592783" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForExtensionOfClinicalTrials_638827335967592783" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_638827335967592783" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_638827335967592783" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_638827335967592783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_638827335967592783" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_638827335967602778" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_638827335967602778" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForRegulatoryApproval" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingForRegulatoryApproval_638827335967602778" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingUpfrontPaymentReceived" xlink:label="mgtx_MilestoneFundingUpfrontPaymentReceived_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingUpfrontPaymentReceived_638827335967602778" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingToProvideAdditionalCapital" xlink:label="mgtx_MilestoneFundingToProvideAdditionalCapital_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_MilestoneFundingToProvideAdditionalCapital_638827335967602778" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassSharesOfHologenReceivedInTransaction" xlink:label="mgtx_ClassSharesOfHologenReceivedInTransaction_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_ClassSharesOfHologenReceivedInTransaction_638827335967602778" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentClassSharesReceivableOfHologenInTransaction" xlink:label="mgtx_ContingentClassSharesReceivableOfHologenInTransaction_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_ContingentClassSharesReceivableOfHologenInTransaction_638827335967602778" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassShareOwnershipPercentageOfHologenNeuro_638827335967602778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_ClassShareOwnershipPercentageOfHologenNeuro_638827335967602778" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClassBShareOwnershipPercentageOfHologenNeuro" xlink:label="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro_638827335967612781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_ClassBShareOwnershipPercentageOfHologenNeuro_638827335967612781" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PercentageApprovalOfDirectors" xlink:label="mgtx_PercentageApprovalOfDirectors_638827335967612781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_PercentageApprovalOfDirectors_638827335967612781" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares" xlink:label="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares_638827335967612781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares_638827335967612781" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RepurchaseOptionVestingPeriod" xlink:label="mgtx_RepurchaseOptionVestingPeriod_638827335967612781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638827335967582783" xlink:to="mgtx_RepurchaseOptionVestingPeriod_638827335967612781" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_GovernmentAssistanceTable_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638827335967622783" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_638827335967622783" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandMember" xlink:label="mgtx_GrantsIdaIrelandMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_638827335967622783" xlink:to="mgtx_GrantsIdaIrelandMember_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandEmploymentMember" xlink:label="mgtx_GrantsIdaIrelandEmploymentMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_GrantsIdaIrelandMember_638827335967622783" xlink:to="mgtx_GrantsIdaIrelandEmploymentMember_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsIdaIrelandCapitalMember" xlink:label="mgtx_GrantsIdaIrelandCapitalMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_GrantsIdaIrelandMember_638827335967622783" xlink:to="mgtx_GrantsIdaIrelandCapitalMember_638827335967622783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638827335967622783" xlink:to="srt_RangeAxis_638827335967622783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967622783" xlink:to="srt_RangeMember_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967622783" xlink:to="srt_MaximumMember_638827335967622783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967622783" xlink:to="srt_MinimumMember_638827335967622783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems_638827335967622783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638827335967622783" xlink:to="us-gaap_GovernmentAssistanceLineItems_638827335967622783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForJobCreation" xlink:label="mgtx_GrantAmountForJobCreation_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_GrantAmountForJobCreation_638827335967632780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantAmountForMachineryAndEquipment" xlink:label="mgtx_GrantAmountForMachineryAndEquipment_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_GrantAmountForMachineryAndEquipment_638827335967632780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake" xlink:label="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake_638827335967632780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding" xlink:label="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding_638827335967632780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromLastGrantPayment" xlink:label="mgtx_FinancialAssistanceDurationFromLastGrantPayment_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_FinancialAssistanceDurationFromLastGrantPayment_638827335967632780" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment" xlink:label="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment_638827335967632780" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment" xlink:label="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment_638827335967632780" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GrantFundingReceived" xlink:label="mgtx_GrantFundingReceived_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_GrantFundingReceived_638827335967632780" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable" xlink:label="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_638827335967632780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638827335967622783" xlink:to="mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable_638827335967632780" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638827335967642778" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638827335967642778" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638827335967642778" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638827335967642778" xlink:to="us-gaap_FairValueInputsLevel1Member_638827335967642778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638827335967642778" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638827335967642778" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638827335967642778" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638827335967642778" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638827335967642778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" xlink:to="us-gaap_FairValueByAssetClassAxis_638827335967642778" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_638827335967642778" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638827335967642778" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember_638827335967642778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638827335967642778" xlink:to="mgtx_RestrictedCashMember_638827335967642778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638827335967642778" xlink:to="us-gaap_CashAndCashEquivalentsMember_638827335967652780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638827335967642778" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" xlink:to="us-gaap_FairValueNetAssetLiability_638827335967652780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638827335967652780" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" xlink:to="us-gaap_RestrictedCashNoncurrent_638827335967652780" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967652780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638827335967652780" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638827335967652780" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationAbstract" xlink:label="us-gaap_AssetRetirementObligationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligation_638827335967662781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationRevisionOfEstimate_638827335967662781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetRetirementObligationsAmortizationOfInterest" xlink:label="mgtx_AssetRetirementObligationsAmortizationOfInterest_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="mgtx_AssetRetirementObligationsAmortizationOfInterest_638827335967662781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_638827335967662781" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation_6388273359676627811" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligation_6388273359676627811" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationLiabilitiesSettled" xlink:label="us-gaap_AssetRetirementObligationLiabilitiesSettled_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationLiabilitiesSettled_638827335967662781" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross_638827335967662781" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationCashPaidToSettle" xlink:label="us-gaap_AssetRetirementObligationCashPaidToSettle_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationCashPaidToSettle_638827335967662781" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainOnTerminationOfLeaseLiabilities" xlink:label="mgtx_GainOnTerminationOfLeaseLiabilities_638827335967662781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="mgtx_GainOnTerminationOfLeaseLiabilities_638827335967662781" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638827335967672797" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638827335967672797" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638827335967672797" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638827335967672797" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" xlink:to="us-gaap_EmployeeStockOptionMember_638827335967672797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638827335967672797" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="us-gaap_StockAppreciationRightsSARSMember_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" xlink:to="us-gaap_StockAppreciationRightsSARSMember_638827335967672797" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638827335967672797" xlink:to="us-gaap_WarrantMember_638827335967672797" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638827335967672797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638827335967672797" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638827335967672797" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638827335967672797" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638827335967682799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ServiceRevenueFromRelatedParties_638827335967682799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_SellingAndMarketingExpense_638827335967682799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SegmentGeneralAndAdministrativeExpenses" xlink:label="mgtx_SegmentGeneralAndAdministrativeExpenses_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_SegmentGeneralAndAdministrativeExpenses_638827335967682799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct1" xlink:label="mgtx_ClinicalProgramsDrugProduct1_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ClinicalProgramsDrugProduct1_638827335967682799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct2" xlink:label="mgtx_ClinicalProgramsDrugProduct2_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ClinicalProgramsDrugProduct2_638827335967682799" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct3" xlink:label="mgtx_ClinicalProgramsDrugProduct3_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ClinicalProgramsDrugProduct3_638827335967682799" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ClinicalProgramsDrugProduct4" xlink:label="mgtx_ClinicalProgramsDrugProduct4_638827335967682799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ClinicalProgramsDrugProduct4_638827335967682799" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentClinicalTrials" xlink:label="mgtx_ResearchAndDevelopmentClinicalTrials_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ResearchAndDevelopmentClinicalTrials_638827335967692788" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentManufacturing" xlink:label="mgtx_ResearchAndDevelopmentManufacturing_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ResearchAndDevelopmentManufacturing_638827335967692788" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchGeneRegulation" xlink:label="mgtx_PreClinicalResearchGeneRegulation_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_PreClinicalResearchGeneRegulation_638827335967692788" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchNeurodegenerativeDiseases" xlink:label="mgtx_PreClinicalResearchNeurodegenerativeDiseases_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_PreClinicalResearchNeurodegenerativeDiseases_638827335967692788" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PreClinicalResearchPreclinicalOcularDiseases" xlink:label="mgtx_PreClinicalResearchPreclinicalOcularDiseases_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_PreClinicalResearchPreclinicalOcularDiseases_638827335967692788" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ResearchAndDevelopmentOther" xlink:label="mgtx_ResearchAndDevelopmentOther_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_ResearchAndDevelopmentOther_638827335967692788" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_InnovativeMedicineReimbursement" xlink:label="mgtx_InnovativeMedicineReimbursement_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_InnovativeMedicineReimbursement_638827335967692788" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ShareBasedCompensation_638827335967692788" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638827335967692788" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638827335967692788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_OperatingExpenses_638827335967692788" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OtherSegmentItemsIncomeStatement" xlink:label="mgtx_OtherSegmentItemsIncomeStatement_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_OtherSegmentItemsIncomeStatement_638827335967702783" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SegmentNetIncomeLoss" xlink:label="mgtx_SegmentNetIncomeLoss_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="mgtx_SegmentNetIncomeLoss_638827335967702783" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_NetIncomeLoss_638827335967702783" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails" xlink:type="extended" xlink:title="99940206 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638827335967702783" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638827335967702783" xlink:to="srt_StatementGeographicalAxis_638827335967702783" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638827335967702783" xlink:to="srt_SegmentGeographicalDomain_638827335967702783" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US_638827335967702783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638827335967702783" xlink:to="country_US_638827335967702783" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638827335967702783" xlink:to="country_GB_638827335967712779" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638827335967702783" xlink:to="us-gaap_EuropeanUnionMember_638827335967712779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638827335967702783" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638827335967712779" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638827335967712779" xlink:to="us-gaap_NoncurrentAssets_638827335967712779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Equity Method and Other Investments - Summary of Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638827335967712779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638827335967712779" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967712779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967712779" xlink:to="srt_EquityMethodInvesteeNameDomain_638827335967712779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VisiogeneLlcMember" xlink:label="mgtx_VisiogeneLlcMember_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638827335967712779" xlink:to="mgtx_VisiogeneLlcMember_638827335967712779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OtherEquityMethodInvestmentsMember" xlink:label="mgtx_OtherEquityMethodInvestmentsMember_638827335967712779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638827335967712779" xlink:to="mgtx_OtherEquityMethodInvestmentsMember_638827335967712779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638827335967712779" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638827335967722783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638827335967722783" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_638827335967722783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638827335967722783" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_638827335967722783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638827335967722783" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_638827335967722783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_638827335967722783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638827335967722783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638827335967722783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedResearchAndDevelopment" xlink:label="mgtx_AccruedResearchAndDevelopment_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedResearchAndDevelopment_638827335967732803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_638827335967732803" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedClinicalTrialCosts_638827335967732803" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense" xlink:label="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense_638827335967732803" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedConsultingExpenses_638827335967732803" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts_638827335967732803" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets" xlink:label="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets_638827335967732803" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638827335967732803" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638827335967732803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638827335967732803" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Share-Based Compensation - Summary of Company's Share Option Activity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638827335967742795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638827335967742795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638827335967742795" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638827335967742795" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388273359677427951" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388273359677427951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638827335967742795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638827335967742795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638827335967742795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638827335967752786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638827335967742795" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638827335967752786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638827335967752786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638827335967752786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638827335967752786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638827335967752786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638827335967752786" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638827335967752786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638827335967752786" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638827335967762778" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638827335967762778" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638827335967752786" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638827335967762778" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967762778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967762778" xlink:to="us-gaap_AwardTypeAxis_638827335967762778" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638827335967762778" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967762778" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638827335967762778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967762778" xlink:to="us-gaap_EmployeeStockOptionMember_638827335967762778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967762778" xlink:to="srt_RangeAxis_638827335967772784" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967772784" xlink:to="srt_RangeMember_638827335967772784" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967772784" xlink:to="srt_MinimumMember_638827335967772784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967772784" xlink:to="srt_MaximumMember_638827335967772784" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967762778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638827335967772784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638827335967772784" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638827335967772784" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638827335967772784" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638827335967772784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967772784" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638827335967772784" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Share-Based Compensation - Summary of Restricted Share Units (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967782778" xlink:to="us-gaap_AwardTypeAxis_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967782778" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967782778" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638827335967782778" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638827335967782778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638827335967782778" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638827335967792786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967782778" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638827335967792786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638827335967792786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638827335967792786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638827335967792786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638827335967792786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6388273359677927861" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638827335967792786" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6388273359677927861" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940504 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638827335967792786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638827335967792786" xlink:to="us-gaap_IncomeStatementLocationAxis_638827335967792786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638827335967792786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638827335967792786" xlink:to="us-gaap_IncomeStatementLocationDomain_638827335967792786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638827335967792786" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638827335967802781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638827335967792786" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638827335967802781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638827335967792786" xlink:to="us-gaap_AwardTypeAxis_638827335967802781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638827335967802781" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967802781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967802781" xlink:to="us-gaap_EmployeeStockOptionMember_638827335967802781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967802781" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638827335967802781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638827335967792786" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638827335967802781" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638827335967802781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638827335967802781" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638827335967802781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="99940505 - Disclosure - Share-Based Compensation - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" xlink:to="us-gaap_VestingAxis_638827335967812784" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638827335967812784" xlink:to="us-gaap_VestingDomain_638827335967812784" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638827335967812784" xlink:to="mgtx_FirstAnniversaryMember_638827335967812784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecondAnniversaryMember" xlink:label="mgtx_SecondAnniversaryMember_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638827335967812784" xlink:to="mgtx_SecondAnniversaryMember_638827335967812784" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ThirdAnniversaryMember" xlink:label="mgtx_ThirdAnniversaryMember_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638827335967812784" xlink:to="mgtx_ThirdAnniversaryMember_638827335967812784" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FourthAnniversaryMember" xlink:label="mgtx_FourthAnniversaryMember_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638827335967812784" xlink:to="mgtx_FourthAnniversaryMember_638827335967812784" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" xlink:to="us-gaap_GranteeStatusAxis_638827335967812784" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638827335967812784" xlink:to="us-gaap_GranteeStatusDomain_638827335967812784" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638827335967812784" xlink:to="srt_DirectorMember_638827335967812784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638827335967812784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" xlink:to="us-gaap_AwardTypeAxis_638827335967812784" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638827335967812784" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967822781" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967822781" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638827335967822781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638827335967822781" xlink:to="us-gaap_EmployeeStockOptionMember_638827335967822781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" xlink:to="srt_RangeAxis_638827335967822781" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967822781" xlink:to="srt_RangeMember_638827335967822781" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967822781" xlink:to="srt_MaximumMember_638827335967822781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638827335967812784" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638827335967822781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638827335967822781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638827335967832792" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638827335967832792" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638827335967832792" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638827335967832792" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638827335967832792" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638827335967832792" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638827335967832792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638827335967832792" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638827335967842788" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VestedSharesDeferred" xlink:label="mgtx_VestedSharesDeferred_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="mgtx_VestedSharesDeferred_638827335967842788" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638827335967842788" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638827335967842788" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1_638827335967842788" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1" xlink:label="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_638827335967842788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638827335967822781" xlink:to="mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1_638827335967842788" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureOrdinarySharesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Ordinary Shares (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638827335967852785" xlink:to="srt_CounterpartyNameAxis_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638827335967852785" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BankOfAmericaSecuritiesInc.Member" xlink:label="mgtx_BankOfAmericaSecuritiesInc.Member_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638827335967852785" xlink:to="mgtx_BankOfAmericaSecuritiesInc.Member_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638827335967852785" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638827335967852785" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638827335967852785" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AtMarketOfferingMember" xlink:label="mgtx_AtMarketOfferingMember_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638827335967852785" xlink:to="mgtx_AtMarketOfferingMember_638827335967852785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967852785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638827335967852785" xlink:to="srt_RangeAxis_638827335967852785" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967852785" xlink:to="srt_RangeMember_638827335967862786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967862786" xlink:to="srt_MaximumMember_638827335967862786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638827335967852785" xlink:to="us-gaap_ClassOfStockLineItems_638827335967862786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638827335967862786" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638827335967862786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638827335967862786" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638827335967862786" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638827335967862786" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638827335967862786" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SaleOfStockConsiderationAvailableInFutureTransactions" xlink:label="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638827335967862786" xlink:to="mgtx_SaleOfStockConsiderationAvailableInFutureTransactions_638827335967862786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Income Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638827335967862786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638827335967862786" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Related Party Transactions - Collaboration and License Agreements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637242787203974975" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637242787203974975" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967872784" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967872784" xlink:to="us-gaap_RelatedPartyDomain_638827335967872784" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638827335967872784" xlink:to="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967872784" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967872784" xlink:to="mgtx_JanssenPharmaceuticalsIncMember_638827335967872784" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" xlink:to="us-gaap_TypeOfArrangementAxis_638827335967872784" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638827335967872784" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967872784" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967872784" xlink:to="mgtx_AssetPurchaseAgreementMember_638827335967872784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335967872784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" xlink:to="srt_RangeAxis_638827335967872784" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335967872784" xlink:to="srt_RangeMember_638827335967882787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335967882787" xlink:to="srt_MaximumMember_638827335967882787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967872784" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="us-gaap_CommonStockSharesIssued_638827335967882787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638827335967882787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_6388273359678827871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="us-gaap_CommonStockSharesIssued_6388273359678827871" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ServiceRevenueFromRelatedParties" xlink:label="mgtx_ServiceRevenueFromRelatedParties_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_ServiceRevenueFromRelatedParties_638827335967882787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_DeferredRevenueRecognizedDuringPeriod_638827335967882787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_InitialAgreementPeriodDuration" xlink:label="mgtx_InitialAgreementPeriodDuration_638827335967882787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_InitialAgreementPeriodDuration_638827335967882787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AgreementTerminationPeriodDaysWrittenNotice" xlink:label="mgtx_AgreementTerminationPeriodDaysWrittenNotice_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_AgreementTerminationPeriodDaysWrittenNotice_638827335967892791" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingReceived" xlink:label="mgtx_MilestoneFundingReceived_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingReceived_638827335967892791" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReceived" xlink:label="mgtx_AssetPurchaseAgreementFundingReceived_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_AssetPurchaseAgreementFundingReceived_638827335967892791" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContingentFundingAvailable" xlink:label="mgtx_ContingentFundingAvailable_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_ContingentFundingAvailable_638827335967892791" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForExtensionOfClinicalTrials" xlink:label="mgtx_MilestoneFundingForExtensionOfClinicalTrials_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForExtensionOfClinicalTrials_638827335967892791" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugSubstances" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugSubstances_638827335967892791" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForDevelopmentOfDrugProducts" xlink:label="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForDevelopmentOfDrugProducts_638827335967892791" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_638827335967892791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates_638827335967892791" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly" xlink:label="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly_638827335967902781" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForTransferOfManufacturingTechnology" xlink:label="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForTransferOfManufacturingTechnology_638827335967902781" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingForRegulatoryApproval" xlink:label="mgtx_MilestoneFundingForRegulatoryApproval_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingForRegulatoryApproval_638827335967902781" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RelatedPartyDeferredRevenueReclassified" xlink:label="mgtx_RelatedPartyDeferredRevenueReclassified_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_RelatedPartyDeferredRevenueReclassified_638827335967902781" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_VariableConsiderationForServices" xlink:label="mgtx_VariableConsiderationForServices_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_VariableConsiderationForServices_638827335967902781" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementFundingReclassified" xlink:label="mgtx_AssetPurchaseAgreementFundingReclassified_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_AssetPurchaseAgreementFundingReclassified_638827335967902781" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractPriceOfLicenseAgreement" xlink:label="mgtx_ContractPriceOfLicenseAgreement_638827335967902781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_ContractPriceOfLicenseAgreement_638827335967902781" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OffsettingCreditForTransitionServices" xlink:label="mgtx_OffsettingCreditForTransitionServices_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_OffsettingCreditForTransitionServices_638827335967912787" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForProcessPerformanceQualificationServices" xlink:label="mgtx_PerformanceObligationForProcessPerformanceQualificationServices_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_PerformanceObligationForProcessPerformanceQualificationServices_638827335967912787" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct" xlink:label="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct_638827335967912787" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForManufacturingTechnologyTransfer" xlink:label="mgtx_PerformanceObligationForManufacturingTechnologyTransfer_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_PerformanceObligationForManufacturingTechnologyTransfer_638827335967912787" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerformanceObligationForSaleOfNonfinancialAssets" xlink:label="mgtx_PerformanceObligationForSaleOfNonfinancialAssets_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_PerformanceObligationForSaleOfNonfinancialAssets_638827335967912787" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices" xlink:label="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices_638827335967912787" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct" xlink:label="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct_638827335967912787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct_638827335967912787" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer" xlink:label="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer_638827335967922780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer_638827335967922780" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets" xlink:label="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets_638827335967922780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets_638827335967922780" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_GainLossOnSaleOfNonfinancialAssets" xlink:label="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967922780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967882787" xlink:to="mgtx_GainLossOnSaleOfNonfinancialAssets_638827335967922780" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Related Party Transactions - Performance Obligation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637179011865846951" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967922780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637179011865846951" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967922780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967922780" xlink:to="us-gaap_TypeOfArrangementAxis_638827335967932787" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638827335967932787" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967932787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967932787" xlink:to="mgtx_AssetPurchaseAgreementMember_638827335967932787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967922780" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967932787" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967932787" xlink:to="us-gaap_RelatedPartyDomain_638827335967932787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638827335967932787" xlink:to="mgtx_JanssenPharmaceuticalsIncMember_638827335967932787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967922780" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638827335967932787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationAmount" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967932787" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationAmount_638827335967932787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod" xlink:label="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_638827335967932787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967932787" xlink:to="mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod_638827335967932787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Related Party Transactions - Financing Agreement (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637242789318985947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637242789318985947" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967942788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967942788" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967942788" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967942788" xlink:to="us-gaap_RelatedPartyDomain_638827335967942788" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveAdvisorsLlcMember" xlink:label="mgtx_PerceptiveAdvisorsLlcMember_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638827335967942788" xlink:to="mgtx_PerceptiveAdvisorsLlcMember_638827335967942788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967942788" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967942788" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638827335967942788" xlink:to="srt_EquityMethodInvesteeNameDomain_638827335967942788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinancingAgreementMember" xlink:label="mgtx_FinancingAgreementMember_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638827335967942788" xlink:to="mgtx_FinancingAgreementMember_638827335967942788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967942788" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638827335967942788" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_638827335967942788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967942788" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_638827335967942788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967942788" xlink:to="us-gaap_CommonStockSharesIssued_638827335967952788" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967942788" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638827335967952788" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Related Party Transactions - Revenue Recognition (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967952788" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967952788" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967952788" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638827335967952788" xlink:to="us-gaap_RelatedPartyDomain_638827335967952788" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JohnsonAndJohnsonInnovationJjdcIncMember" xlink:label="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638827335967952788" xlink:to="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967952788" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_JanssenPharmaceuticalsIncMember" xlink:label="mgtx_JanssenPharmaceuticalsIncMember_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_JohnsonAndJohnsonInnovationJjdcIncMember_638827335967952788" xlink:to="mgtx_JanssenPharmaceuticalsIncMember_638827335967952788" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638827335967952788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967952788" xlink:to="us-gaap_TypeOfArrangementAxis_638827335967952788" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638827335967952788" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967962794" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_AssetPurchaseAgreementMember" xlink:label="mgtx_AssetPurchaseAgreementMember_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638827335967962794" xlink:to="mgtx_AssetPurchaseAgreementMember_638827335967962794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638827335967952788" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" xlink:to="us-gaap_ContractWithCustomerLiability_638827335967962794" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced" xlink:label="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" xlink:to="mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced_638827335967962794" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_DeferredRevenueRecognizedDuringPeriod" xlink:label="mgtx_DeferredRevenueRecognizedDuringPeriod_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" xlink:to="mgtx_DeferredRevenueRecognizedDuringPeriod_638827335967962794" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate" xlink:label="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_638827335967962794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638827335967962794" xlink:to="mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate_638827335967962794" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638827335968032808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638827335968032808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638827335968032808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost_638827335968032808" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638827335968032808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost_638827335968032808" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638827335968032808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost_638827335968032808" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638827335968032808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost_638827335968032808" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Leases - Schedule of Consolidated Balance Sheets for Leases (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OperatingLeaseAbstract" xlink:label="mgtx_OperatingLeaseAbstract_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_OperatingLeaseAbstract_638827335968042803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OperatingLeaseAbstract_638827335968042803" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638827335968042803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OperatingLeaseAbstract_638827335968042803" xlink:to="us-gaap_OperatingLeaseLiability_638827335968042803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_FinanceLeaseAbstract" xlink:label="mgtx_FinanceLeaseAbstract_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_FinanceLeaseAbstract_638827335968042803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_FinanceLeaseAbstract_638827335968042803" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638827335968042803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_WeightedAverageRemainingLeaseTermAbstract" xlink:label="mgtx_WeightedAverageRemainingLeaseTermAbstract_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_WeightedAverageRemainingLeaseTermAbstract_638827335968042803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_WeightedAverageRemainingLeaseTermAbstract_638827335968042803" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638827335968042803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_WeightedAverageRemainingLeaseTermAbstract_638827335968042803" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638827335968042803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_WeightedAverageDiscountRateAbstract" xlink:label="mgtx_WeightedAverageDiscountRateAbstract_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_WeightedAverageDiscountRateAbstract_638827335968042803" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_WeightedAverageDiscountRateAbstract_638827335968042803" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638827335968042803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638827335968042803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_WeightedAverageDiscountRateAbstract_638827335968042803" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638827335968042803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638827335968052788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_638827335968052788" xlink:to="us-gaap_OperatingLeasePayments_638827335968052788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637187731858204625" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637187731858204625" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638827335968052788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638827335968052788" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638827335968052788" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638827335968052788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638827335968052788" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638827335968062787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638827335968062787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638827335968062787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638827335968052788" xlink:to="us-gaap_OperatingLeaseLiability_638827335968062787" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Leases - Additional Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638827335968062787" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638827335968062787" xlink:to="srt_RangeAxis_638827335968062787" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638827335968062787" xlink:to="srt_RangeMember_638827335968062787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638827335968062787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335968062787" xlink:to="srt_MinimumMember_638827335968062787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638827335968062787" xlink:to="srt_MaximumMember_638827335968072796" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638827335968062787" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_LeaseMaturityTerm" xlink:label="mgtx_LeaseMaturityTerm_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" xlink:to="mgtx_LeaseMaturityTerm_638827335968072796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" xlink:to="us-gaap_OperatingLeaseExpense_638827335968072796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_OperatingLeaseNumberNewLeasesRecognized" xlink:label="mgtx_OperatingLeaseNumberNewLeasesRecognized_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" xlink:to="mgtx_OperatingLeaseNumberNewLeasesRecognized_638827335968072796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638827335968072796" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638827335968072796" xlink:to="us-gaap_OperatingLeaseLiability_638827335968072796" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureDebtFinancingDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Debt Financing (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638827335968072796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_LineOfCreditFacilityTable_638827335968072796" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="us-gaap_LineOfCreditFacilityAxis_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_638827335968082790" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_PerceptiveCreditHoldingsMember" xlink:label="mgtx_PerceptiveCreditHoldingsMember_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638827335968082790" xlink:to="mgtx_PerceptiveCreditHoldingsMember_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="us-gaap_DebtInstrumentAxis_638827335968082790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638827335968082790" xlink:to="us-gaap_DebtInstrumentNameDomain_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638827335968082790" xlink:to="us-gaap_SecuredDebtMember_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="us-gaap_CreditFacilityAxis_638827335968082790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638827335968082790" xlink:to="us-gaap_CreditFacilityDomain_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_TermLoanMember" xlink:label="mgtx_TermLoanMember_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638827335968082790" xlink:to="mgtx_TermLoanMember_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="us-gaap_VariableRateAxis_638827335968082790" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638827335968082790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638827335968082790" xlink:to="us-gaap_VariableRateDomain_638827335968082790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638827335968082790" xlink:to="us-gaap_BaseRateMember_638827335968093161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638827335968082790" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638827335968093161" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="srt_StatementScenarioAxis_638827335968093161" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638827335968093161" xlink:to="srt_ScenarioUnspecifiedDomain_638827335968093161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioMember" xlink:label="mgtx_ExercisePriceScenarioMember_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638827335968093161" xlink:to="mgtx_ExercisePriceScenarioMember_638827335968093161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_ExercisePriceScenarioBMember" xlink:label="mgtx_ExercisePriceScenarioBMember_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638827335968093161" xlink:to="mgtx_ExercisePriceScenarioBMember_638827335968093161" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638827335968072796" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638827335968093161" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DebtInstrumentFaceAmount_638827335968093161" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638827335968102790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="us-gaap_SecuredDebtCurrent_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_SecuredDebtCurrent_638827335968102790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638827335968102790" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_BasisSpreadOnVariableRateFloor" xlink:label="mgtx_BasisSpreadOnVariableRateFloor_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="mgtx_BasisSpreadOnVariableRateFloor_638827335968102790" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredOvernightFinancingRateAdjustmentTerm" xlink:label="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="mgtx_SecuredOvernightFinancingRateAdjustmentTerm_638827335968102790" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:label="us-gaap_LongtermDebtWeightedAverageInterestRate_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_LongtermDebtWeightedAverageInterestRate_638827335968102790" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_638827335968102790" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638827335968102790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_InterestExpenseDebt_638827335968102790" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteedBenefitLiabilityNet" xlink:label="us-gaap_GuaranteedBenefitLiabilityNet_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_GuaranteedBenefitLiabilityNet_638827335968112784" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SecuredCashAndBankAccounts" xlink:label="mgtx_SecuredCashAndBankAccounts_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="mgtx_SecuredCashAndBankAccounts_638827335968112784" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_SharesIssuedInConnectionWithFinancingAgreement" xlink:label="mgtx_SharesIssuedInConnectionWithFinancingAgreement_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="mgtx_SharesIssuedInConnectionWithFinancingAgreement_638827335968112784" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638827335968112784" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_CommonStockSharesIssued_638827335968112784" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638827335968112784" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares_638827335968112784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_CommonStockDiscountOnShares_638827335968112784" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638827335968122784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DeferredFinanceCostsNet_638827335968122784" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638827335968122784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638827335968093161" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638827335968122784" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NumberOfNewMaterialCommitments" xlink:label="mgtx_NumberOfNewMaterialCommitments_638827335968122784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="mgtx_NumberOfNewMaterialCommitments_638827335968122784" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_Rule10b51ArrangementModifiedFlag" xlink:label="mgtx_Rule10b51ArrangementModifiedFlag_638827335968132794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="mgtx_Rule10b51ArrangementModifiedFlag_638827335968132794" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="mgtx-20250331.xsd#mgtx_NonRule10b51ArrangementModifiedFlag" xlink:label="mgtx_NonRule10b51ArrangementModifiedFlag_638827335968132794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="mgtx_NonRule10b51ArrangementModifiedFlag_638827335968132794" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MeiraGTx Holdings plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">450 East 29th&#160;Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th&#160;Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">860-7985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares,$0.00003881 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,365,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001735438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,523<span></span>
</td>
<td class="nump">$ 103,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - related party</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets - related party</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,928<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Tax incentive receivable</a></td>
<td class="nump">4,221<span></span>
</td>
<td class="nump">8,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">79,889<span></span>
</td>
<td class="nump">123,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">104,408<span></span>
</td>
<td class="nump">102,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method and other investments</a></td>
<td class="nump">6,749<span></span>
</td>
<td class="nump">6,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases, net</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="nump">10,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets - finance leases, net</a></td>
<td class="nump">22,728<span></span>
</td>
<td class="nump">22,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">224,014<span></span>
</td>
<td class="nump">269,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,290<span></span>
</td>
<td class="nump">23,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">23,964<span></span>
</td>
<td class="nump">27,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease obligations, current</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred revenue - related party, current</a></td>
<td class="nump">4,241<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">52,372<span></span>
</td>
<td class="nump">60,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred revenue - related party</a></td>
<td class="nump">59,618<span></span>
</td>
<td class="nump">57,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations</a></td>
<td class="nump">4,086<span></span>
</td>
<td class="nump">7,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligations</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net</a></td>
<td class="nump">73,495<span></span>
</td>
<td class="nump">73,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">190,915<span></span>
</td>
<td class="nump">201,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 79,418,438 and 78,397,380 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital in excess of par value</a></td>
<td class="nump">780,165<span></span>
</td>
<td class="nump">773,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(5,066)<span></span>
</td>
<td class="num">(3,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(742,003)<span></span>
</td>
<td class="num">(702,022)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">33,099<span></span>
</td>
<td class="nump">67,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 224,014<span></span>
</td>
<td class="nump">$ 269,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481999/410-20-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00003881<span></span>
</td>
<td class="nump">$ 0.00003881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,288,327,750<span></span>
</td>
<td class="nump">1,288,327,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">79,418,438<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">79,418,438<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF CONDENSED OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ServiceRevenueFromRelatedParties', window );">Service revenue - related party</a></td>
<td class="nump">$ 1,926<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Cost of service revenue - related party</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,364<span></span>
</td>
<td class="nump">13,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">32,780<span></span>
</td>
<td class="nump">34,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">43,522<span></span>
</td>
<td class="nump">47,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,596)<span></span>
</td>
<td class="num">(46,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">3,687<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,043)<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GainLossOnSaleOfNonfinancialAssets', window );">Gain on sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,981)<span></span>
</td>
<td class="num">(20,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="num">(1,347)<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(41,328)<span></span>
</td>
<td class="num">(22,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (39,981)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares outstanding, basic</a></td>
<td class="nump">79,032,341<span></span>
</td>
<td class="nump">64,065,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares outstanding, diluted</a></td>
<td class="nump">79,032,341<span></span>
</td>
<td class="nump">64,065,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GainLossOnSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on the sale of non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GainLossOnSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ServiceRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ServiceRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Equity Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 693,841<span></span>
</td>
<td class="num">$ (1,435)<span></span>
</td>
<td class="num">$ (554,231)<span></span>
</td>
<td class="nump">$ 138,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Equity Balance (shares) at Dec. 31, 2023</a></td>
<td class="nump">63,601,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share based compensation activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation activity (shares)</a></td>
<td class="nump">441,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares in at-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares in at-the-market offering (shares)</a></td>
<td class="nump">256,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs in connection with ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,442)<span></span>
</td>
<td class="num">(20,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Equity Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">699,531<span></span>
</td>
<td class="num">(3,126)<span></span>
</td>
<td class="num">(574,673)<span></span>
</td>
<td class="nump">121,734<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Equity Balance (shares) at Mar. 31, 2024</a></td>
<td class="nump">64,298,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Equity Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">693,841<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
<td class="num">(554,231)<span></span>
</td>
<td class="nump">138,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Equity Balance (shares) at Dec. 31, 2023</a></td>
<td class="nump">63,601,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Equity Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">773,565<span></span>
</td>
<td class="num">(3,719)<span></span>
</td>
<td class="num">(702,022)<span></span>
</td>
<td class="nump">67,827<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Equity Balance (shares) at Dec. 31, 2024</a></td>
<td class="nump">78,397,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share based compensation activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation activity (shares)</a></td>
<td class="nump">457,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares in at-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares in at-the-market offering (shares)</a></td>
<td class="nump">563,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs in connection with ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,981)<span></span>
</td>
<td class="num">(39,981)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Equity Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 780,165<span></span>
</td>
<td class="num">$ (5,066)<span></span>
</td>
<td class="num">$ (742,003)<span></span>
</td>
<td class="nump">$ 33,099<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Equity Balance (shares) at Mar. 31, 2025</a></td>
<td class="nump">79,418,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,981)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gain) loss</a></td>
<td class="num">(3,687)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">3,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Net change in right-of-use assets and liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of lease liabilities</a></td>
<td class="num">(1,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment, furniture and fixtures</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAccretionExpense', window );">Amortization of interest on asset retirement obligations</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GainLossOnSaleOfNonfinancialAssets', window );">Gain on sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable - related party</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(1,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contract assets - related party</a></td>
<td class="nump">701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets', window );">Inventory</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Tax incentive receivable</a></td>
<td class="nump">4,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,061)<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(3,585)<span></span>
</td>
<td class="num">(24,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue - related party</a></td>
<td class="num">(329)<span></span>
</td>
<td class="nump">20,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(36,828)<span></span>
</td>
<td class="num">(36,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="num">(1,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets', window );">Proceeds from sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="nump">27,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholdings on shares withheld for income taxes</a></td>
<td class="num">(2,761)<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">4,482<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs in connection with ordinary shares</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="num">(1,270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(36,825)<span></span>
</td>
<td class="num">(10,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">105,668<span></span>
</td>
<td class="nump">130,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">68,610<span></span>
</td>
<td class="nump">120,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Fixed asset acquisition included in accounts payable and accrued expenses</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationRevisionOfEstimate', window );">Change in estimate of asset retirement obligations</a></td>
<td class="nump">1,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets', window );">Receivable from sale of fixed assets included in other current assets</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 2,863<span></span>
</td>
<td class="nump">$ 2,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GainLossOnSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on the sale of non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GainLossOnSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable related to the sale of fixed assets that is included in the balance of other current assets at period-end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the gain recognized on the sale of nonfinancial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481879/410-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationRevisionOfEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationRevisionOfEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in inventory, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">MeiraGTx Holdings plc and subsidiaries (the &#8220;Company&#8221; or &#8220;Meira Holdings&#8221;), an exempted company incorporated under the laws of the Cayman Islands, is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. MeiraGTx clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by the Company&#8217;s internal end-to-end manufacturing capabilities. The Company has two viral vector production facilities for good manufacturing practices (&#8220;GMP&#8221;), internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. In addition, the Company has developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness. The Company&#8217;s core capabilities in viral vector and capsid optimization allow increased potency, decreased dose and significantly reduced cost of goods for its genetic medicines. The Company has developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive expression of any transgene under the control of oral small molecules. The Company is focusing the riboswitch platform on <i style="font-style:italic;">in vivo </i>delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin via oral small molecules, as well as cell therapy for oncology and autoimmune diseases, and long-term intractable pain. &#160;The Company has developed unique comprehensive technology capabilities to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Hologen Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On March 9, 2025 (the &#8220;Signing Date&#8221;), the Company and its affiliates entered into a strategic collaboration with Hologen Limited, a non-cellular company limited by shares incorporated in Guernsey (&#8220;Hologen&#8221;), and its affiliates. &#160;Hologen is a leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. As part of the strategic collaboration, the Company and Hologen have entered into the Framework Agreements (as defined below), pursuant to which the Company and its affiliates will receive from Hologen an upfront cash payment of $200 million (the &#8220;Upfront Payment&#8221;) on the Closing Date (as defined below), and Hologen will provide additional funding of up to an additional $230 million as further described below. As part of the strategic collaboration, the Company also received 250,000 Class A shares of Hologen at a nominal price. Furthermore, the Company has the option to receive up to an additional 500,000 Class A shares of Hologen at a nominal price if certain funding obligations as described herein are not met by Hologen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The closing of the transactions contemplated by the Framework Agreements (the &#8220;Closing Date&#8221;) is expected to occur in the second calendar quarter of 2025, subject to customary closing and funding conditions, including the receipt of the clearances and approvals applicable to the proposed transactions under the foreign direct investment laws of the United Kingdom and the satisfaction or waiver of certain other closing conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"><i style="font-style:italic;">Neuro Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">On the Signing Date, the Company, MeiraGTx Neuro UK Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Neuro UK&#8221;), Hologen Neuro AI Limited, a non-cellular company limited by shares incorporated in Guernsey and an affiliate of Hologen (&#8220;Hologen Neuro&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Neuro Framework Agreement&#8221;), pursuant to which, on the Closing Date, the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Neuro US&#8221;), Hologen, Hologen Neuro and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England and an affiliate of Hologen (&#8220;Hologen Neuro UK&#8221;), shall enter into a Collaboration and License Agreement (the &#8220;Hologen Collaboration Agreement&#8221;) for the research, development, manufacture and commercialization of the Company&#8217;s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson&#8217;s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the &#8220;Clinical Programs&#8221;) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the &#8220;Delivery Device&#8221;), in each case, in accordance with the terms and conditions of the Hologen Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On the Closing Date, under the Hologen Collaboration Agreement, MeiraGTx Neuro US will receive the applicable portion of the Upfront Payment in consideration for granting to Hologen Neuro and Hologen Neuro UK, as of the Closing Date and subject to the license granted by Hologen Neuro and Hologen Neuro UK back to MeiraGTx Neuro UK, exclusive, worldwide, royalty-free, fully paid-up licenses to certain of the Company&#8217;s intellectual property rights for the research, development, manufacture and commercialization of the Clinical Programs and the Delivery Device. On the Closing Date, (a) MeiraGTx Neuro UK will receive Class A shares of Hologen Neuro representing a 30% ownership of the issued share capital of Hologen Neuro, in consideration for the provision of services to Hologen Neuro and Hologen Neuro UK as specified in the Hologen Collaboration Agreement, including services relating to the development of the Clinical Programs and the Delivery Device and certain other transition services, and (b) Hologen Guernsey will receive Class B shares of Hologen Neuro representing a 70% ownership of the issued share capital of Hologen Neuro, in consideration for paying the applicable portion of the Upfront Payment to MeiraGTx Neuro US, as well as a commitment to provide additional capital of up to $230 million to fund the development of the Clinical Programs and the Delivery Device. Additionally, Hologen will license to Hologen Neuro its proprietary multi-modal generative foundation models (LMMs), or large medicine models, pursuant to a license agreement mutually agreeable to the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of the Closing Date, Hologen Neuro shall be governed by a board of directors comprised of three representatives designated by Hologen and two representatives designated by MeiraGTx Neuro UK, and certain material business decisions (as further enumerated in the Neuro Framework Agreement) will require the approval of at least 70% of the directors then in office. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Following the Closing Date and in accordance with the terms of the Hologen Collaboration Agreement, the parties shall negotiate in good faith and enter into clinical and commercial supply agreements, pursuant to which MeiraGTx Neuro UK (directly, or through affiliates or subcontractors) shall manufacture and supply AAV-GAD, AAV-BDNF and other potential locally delivered genetic medicines to the central nervous system. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"><i style="font-style:italic;">Manufacturing Framework Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">On the Signing Date, MeiraGTx Manufacturing Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Manufacturing&#8221;), MeiraGTx Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#8220;MeiraGTx Limited&#8221;), and Hologen, entered into that certain Framework Agreement (the &#8220;Manufacturing Framework Agreement&#8221; and, together with the Neuro Framework Agreement, the &#8220;Framework Agreements&#8221;), pursuant to which, on the Closing Date and in exchange for the applicable portion of the Upfront Payment, Hologen will acquire a minority interest in MeiraGTx Manufacturing, an entity that will comprise the Company&#8217;s flexible and scalable end-to-end genetic medicines manufacturing business, which is solely run by MeiraGTx Manufacturing and MeiraGTx Limited prior to the Closing Date. Hologen will also contribute a portion of the annual funding to MeiraGTx Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of the Closing Date, MeiraGTx Manufacturing shall be governed by a board of directors comprised of three representatives designated by MeiraGTx Limited and two representatives designated by Hologen, and certain material business decisions (as further enumerated in the Manufacturing Framework Agreement) will require the approval of at least 70% of the directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">For a period of twelve months following the Closing Date, Hologen has an exclusive, irrevocable option to purchase additional shares in MeiraGTx Manufacturing at a specified price, such that following exercise of such option, Hologen shall own 40% of the issued share capital of MeiraGTx Manufacturing in the aggregate. &#160;In the event that Hologen does not exercise its option, MeiraGTx has an exclusive, irrevocable option to purchase all of the shares of MeiraGTx Manufacturing held by Hologen for the same price that Hologen paid for such shares. Such option shall be exercisable anytime beginning on the third anniversary of the Closing Date and ending three years thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Asset Purchase and Related Agreements with Johnson &amp; Johnson Innovative Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On January&#160;30, 2019, the Company entered into a Collaboration, Option and License Agreement with Johnson &amp; Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.)<span style="color:#ff0000;"> </span>(the &#8220;Collaboration Agreement&#8221;), for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases (&#8220;IRD&#8221;). Under the terms of the Collaboration Agreement, the Company received funding for certain research, manufacturing, clinical development and commercialization costs, and had the potential to obtain additional milestone payments upon the achievement of such milestones and royalties on future net sales of products. On December 20, 2023, the Company entered into an Asset Purchase Agreement (&#8220;Asset Purchase Agreement&#8221;) with Johnson &amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) (&#8220;UCLB&#8221;), on the one hand, and MeiraGTx UK II Limited and MeiraGTx Limited, on the other hand (the &#8220;UCLB RPGR License Agreement&#8221;), relating to the research, development, manufacture and exploitation of botaretigene sparoparvovec, or bota-vec (formerly referred to as AAV-RPGR), for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene, or XLRP-RPGR (the &#8220;RPGR Product&#8221;), and other related assets as described in the Asset Purchase Agreement. In connection with entering into the Asset Purchase Agreement, the Company entered into a Termination Agreement with Johnson &amp; Johnson Innovative Medicine terminating the Collaboration Agreement. The Company and Johnson &amp; Johnson Innovative Medicine also entered into a Supply Agreement on December 20, 2023 (the &#8220;Supply Agreement&#8221;) pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp; Johnson Innovative Medicine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Under the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine paid the Company a non-refundable upfront cash payment of $65.0 million in December 2023. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine agreed to pay the Company future contingent consideration of up to an aggregate of $350.0 million, as follows: (i) a milestone payment of $50.0 million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $10.0 million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $5.0 million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $175.0 million upon the first commercial sale of an RPGR Product in the United States; (v) $75.0 million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $25.0 million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp; Johnson Innovative Medicine; and (vii) $10.0 million upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. During 2024, the Company received $60.0 million in milestone payments from Johnson &amp; Johnson Innovative Medicine. Johnson &amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Interim Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to&#160;Form&#160;10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary in order to make the condensed consolidated financial statements not misleading. Operating results for the three-month period ended March 31, 2025&#160;are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the&#160;year ended December 31, 2024 included in the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal&#160;year ended December 31, 2024 (the &#8220;Form&#160;10-K&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing. The Company&#8217;s accumulated deficit at March 31, 2025 totaled $742.0 million, and management expects to incur substantial losses in future periods. The success of the Company is subject to certain risks and uncertainties, including, among others: uncertainty of product development; competition in the Company&#8217;s field of use; uncertainty of capital availability; uncertainty in the Company&#8217;s ability to enter into agreements and consummate transactions with collaborative partners; expanding and protecting the Company&#8217;s intellectual property portfolio; dependence on third parties; and dependence on key personnel. For the three months ended March 31, 2025, the Company used $36.8 million in cash flows from operations and there are no assurances that the Company will generate positive cash flows in the future. Additionally, there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of March 31, 2025, the Company had cash, cash equivalents and restricted cash in the amount of $68.6 million, which consisted of depository and money market accounts held at large international banks. The Company estimates that its cash and cash equivalents on-hand, tax incentive receivable and accounts receivable &#8211; related party at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen Limited, will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these condensed consolidated financial statements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company&#8217;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;">The Company&#8217;s capital resources and operations to date have been funded primarily with the proceeds from the Collaboration Agreement, Asset Purchase Agreement and private and public equity offerings, as well as the proceeds from the debt financing described in Note 10. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. &#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies and Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Certain of the Company&#8217;s significant accounting policies are described below. All of the Company&#8217;s significant accounting policies are disclosed in the notes to the audited consolidated financial statements as of and for the&#160;year ended December 31, 2024 included in the Company&#8217;s Form&#160;10-K.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx, LLC, a Delaware limited liability company (&#8220;Meira LLC&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#160;II&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (&#8220;Meira Ireland&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira Netherlands&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Belgium, a private company with limited liability incorporated under the laws of Belgium (&#8220;Meira Belgium&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">BRI-Alzan,&#160;Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Bio, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira B.V.&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neurosciences,&#160;Inc., a Delaware corporation; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Therapeutics, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro I, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro II, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Manufacturing Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ocular UK Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Gene Regulation Limited, a limited company incorporated under the laws of England and Wales; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro UK Limited, a limited company incorporated under the laws of England and Wales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: service revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Restricted cash represents a guarantee put in place as required by the terms of the research and innovation grant from IDA Ireland which offers financial assistance in establishing the Company&#8217;s operations in Shannon, Ireland. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company&#8217;s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,659</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,009</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,668</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company&#8217;s own credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company follows ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;">The table below represents the values of the Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant&#160;Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.3pt;">At March 31, 2025, the Company's financial instruments included cash and cash equivalents, restricted cash, accounts receivable &#8211; related party, and accounts payable. The carrying amounts reported in the Company's condensed consolidated financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments. In addition, at March 31, 2025, the Company believes the carrying value of the Tranche 1 Notes (as defined in Note 10) approximates fair value as the interest rate is reflective of the rate the Company could obtain on debt with similar terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Asset Retirement Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.3pt;">Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level&#160;3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported on the condensed consolidated balance sheets were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;">The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, for which the Company had an associated asset retirement obligation liability in the amount of $1.7 million and a corresponding leasehold improvement with a net book value of $0.3 million as of March 31, 2025. The landlord no longer requires the Company to make any changes to the premises prior to the lease termination and the Company only expects to incur $0.1 million related to decontamination costs. Therefore, a change in estimate of the asset retirement obligation was recorded resulting in a gain on termination of lease liabilities of $1.3 million which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.5pt;">The change in asset retirement obligations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,401</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in estimate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Amortization of interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,440</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 24.5pt;">IDA Ireland Grant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">In August 2021, Meira Ireland entered into an agreement pursuant to which it received a grant from IDA Ireland for financial assistance in establishing its operations in Shannon, Ireland. Under the terms of the grant, Meira Ireland is eligible to receive the lesser of &#8364;1.0 million or &#8364;10,000 for each job created (the &#8220;employment grant&#8221;) and the lesser of &#8364;1.2 million or 4% of the actual expenditure on the provision of machinery and equipment (the &#8220;capital grant&#8221;). Meira Ireland may apply for a drawdown of the employment grant once a job has been created and the position has been held for a period of at least one month, and may apply for a drawdown of the capital grant once an eligible asset has been purchased and installed, conditioned on the creation of a cumulative number of jobs by the end of the immediately preceding year. An aggregate of 100 jobs must be created to receive the maximum benefit under the capital grant. An application for a drawdown must be accompanied by an audit certification for compliance with the terms of the grant. The Company has a guarantee in place with a bank in favor of IDA Ireland, pursuant to which it restricts cash in the amount of claims made under the grant such that the Company maintains the funds to cover any portion of the grant income that may become repayable in the future. This amount is presented as restricted cash in the accompanying condensed consolidated balance sheet. All grant drawdowns were required to be completed by December 31, 2024, and the agreement terminates on the later of five years from the date of the last payment from the grant or five years from completion of the capital investment, which is expenditure of at least &#8364;30.0 million on eligible machinery and equipment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">The Company recognizes grant income when there is reasonable assurance that the Company will comply with the conditions attached to the grant and that it will receive the grant. Grant income from the employment grant is recognized as a deduction from the amount of the related expense, and grant income from the capital grant is deducted from the carrying amount of the related asset and recognized in income over the asset&#8217;s useful life in the form of a reduced depreciation charge. The Company received its first drawdown under the grant in 2023, which was comprised of $0.6 million for the employment grant and $0.4 million for the capital grant. The Company received its second drawdown under the grant in 2024, which was comprised of $0.5 million for the employment grant and $0.5 million for the capital grant. During the three-months ended March 31, 2025 and 2024, the Company recognized de minimis grant income as a reduction of research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">During the five-year period ending on the termination of the grant agreement, Meira Ireland must maintain compliance with the terms of the grant. If the total number of jobs is less than 100 at the time of IDA Ireland&#8217;s annual review, the Company may have to repay a portion of the capital grant, and if a job for which the Company received employment grant funding remains vacant for a period in excess of <span style="-sec-ix-hidden:Hidden_eNuWP8gC10unY9sqGjg8MQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span> calendar months, the Company may have to repay the employment grant received for that job. As of March 31, 2025, the Company is in compliance with the terms of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 24.45pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition the Company performs the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the contract(s)&#160;with a customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iv.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocate the transaction price to the performance obligations within the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">v.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognize revenue when (or as) the entity satisfies a performance obligation.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">If there are multiple performance obligations, the Company allocates the transaction price to each performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a performance obligation requires significant judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company records amounts as contract assets when the right to consideration is deemed unconditional. Contract assets are reclassified as accounts receivable once billed. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s condensed consolidated balance sheet.&#160;Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party, current.&#160;Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company&#8217;s revenue arrangements include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Milestone Payments:&#160;At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and Development Services: Under the Asset Purchase Agreement, research and development services (PPQ services) are recorded as incurred under cost of service revenue &#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Customer Options: Customer options are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company&#8217;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expenses, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Net Loss per Ordinary Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company&#8217;s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary share equivalents had been issued at the beginning of the&#160;year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,484,644</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,389,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,094,750</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,112,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,464,394</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable and operating segment, which is the development and manufacturing of genetic medicines, for purposes of reporting financial condition and results of operations. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM allocates resources and assesses performance of the Company&#8217;s single reportable segment by regularly reviewing the segment net loss that also is reported on the condensed consolidated statement of operations and comprehensive loss as net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 697</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,864</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Botaretigene sparoparvovec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,957</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-hAQP1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,663</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-CNGB3 / AAV-CNGA3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,179)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-GAD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,170</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Other ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,360</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Gene regulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,499</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Neurodegenerative diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Preclinical ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 541</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Johnson &amp; Johnson Innovative Medicine reimbursement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (652)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,275</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,469</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,330</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments or reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1 </sup>Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company&#8217;s service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following table summarizes long-lived assets by geographical area (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,209</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,419</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">European Union</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,845</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 134,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 136,473</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. This update includes a number of amendments to clarify or improve disclosure and presentation requirements of a variety of topics in order to allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the requirements and to align the requirements in the FASB accounting standard codification with the SEC&#8217;s regulations. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact of these amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement: Reporting Comprehensive Income: Expense Disaggregation Disclosures (Subtopic 220-40), which requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date, which revised the effective date of ASU No. 2024-03 for interim periods. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of ASU 2024-03 and ASU 2025-01 on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method and Other Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method and Other Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. &#160;&#160;&#160;&#160;&#160;&#160;Equity Method and Other Investments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;">The Company&#8217;s investments consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Investee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost Basis</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Visiogene LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Method Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,165</p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity method and other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. &#160;&#160;&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Accrued expenses for the periods presented are comprised of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,197</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,326</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,234</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on Tranche 1 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,864</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,540</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,530</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rent and facilities costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,414</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. &#160;&#160;&#160;&#160;&#160;&#160;Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company&#8217;s 2018 Incentive Award Plan and 2016 Equity Incentive Plan (collectively, the &#8220;Plans&#8221;) were adopted by the Company&#8217;s board of directors and shareholders. Under the Plans, the Company has granted share options and restricted share units (&#8220;RSUs&#8221;) to selected officers, employees, non-employee members of the board of directors and non-employee consultants. The Company&#8217;s board of directors or a committee thereof administers the Plans. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="font-style:italic;font-weight:bold;">Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">A summary of the Company&#8217;s share option activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,232,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (638)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (208,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,956,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.5pt;">Options granted under the Plans have a maximum contractual term of <span style="-sec-ix-hidden:Hidden_9vrz3CYLdkSqMQ_3AtrhKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten years</span></span>. Options granted generally vest 25% on the first anniversary of the date of grant and the balance ratably over the next 36 months. Options granted to directors when they join the board generally vest in 36 equal monthly installments following the date of grant, and annual options granted to directors generally vest on the earlier of the first anniversary of the date of grant or the day before the Company&#8217;s annual meeting of shareholders after the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">The Company recorded the following share-based compensation expense in connection with the options for the three-month periods ended March 31, 2025 and 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,635</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,688</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The total fair value of options vested during the three-month periods ended March 31, 2025 and 2024 was $2.0 million and $4.3 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">There were no options granted during the three-month period ended March 31, 2025. The weighted-average grant date fair value of options granted during the three-month period ended March 31, 2024 was $3.91 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The grant date fair values of the share options granted were estimated using the Black-Scholes option valuation model with the following ranges of assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.04 - 4.17%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">67%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.6 - 6.1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">As of March 31, 2025, the total compensation expense relating to unvested options granted that had not yet been recognized was $6.8 million, which is expected to be realized over a period of 2.9 years. The Company will issue shares upon exercise of options from ordinary shares reserved under the Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Restricted Share Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">A summary of the Company&#8217;s RSU activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,252,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.91</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (862,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.70</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,389,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.69</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 24.5pt;">RSUs granted generally vest 50% on the second anniversary of the date of grant and 25% on the <span style="-sec-ix-hidden:Hidden_2cEA7rky_EClnxjTOR8EiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third</span></span> and <span style="-sec-ix-hidden:Hidden_3IRehDe7iE-PuKwN7f8KxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fourth</span></span> anniversaries of the date of grant. Annual RSUs granted to directors generally vest in a single installment on the earliest to occur of the first anniversary of the grant date or the day immediately prior to the date of the next annual meeting of the Company&#8217;s shareholders occurring after the date of grant. The RSUs granted to the directors in June 2021 will be paid on or within 30 days after the date a director ceases to serve on the board. For RSUs granted in June 2022 and future years, the directors may annually elect whether to defer the payment of their annual RSU awards under the Deferred Compensation Plan for Non-Employee Directors, which was adopted by the board on December 17, 2021.&#160;As of March 31, 2025, there were 272,500 vested shares that have been deferred. The related share-based compensation expense, which is recognized ratably over the requisite service period, is included in general and administrative and research and development expenses, as applicable, in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 24.45pt;">The Company recorded the following share-based compensation expense in connection with the RSUs for the three-month periods ended March 31, 2025 and 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,240</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,032</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,272</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">As of March 31, 2025, the total compensation expense relating to unvested RSUs granted that had not yet been recognized was $18.5 million, which is expected to be realized over a period of 3.1 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">To satisfy employee minimum statutory tax withholding requirements for restricted share units that vest, the Company withholds a portion of the vesting ordinary shares. During the three months ended March 31, 2025 and 2024, the Company withheld 405,459 and 348,652 ordinary shares with a total value of approximately $2.8 million and $2.2 million, respectively. These amounts are presented as a cash outflow from financing activities in the accompanying condensed consolidated statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">During the three-month periods ended March 31, 2025 and 2024, the Company recognized total share-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,875</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,085</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2.15pt;text-align:justify;text-indent:-2.15pt;margin:0pt 0pt 12pt 22.3pt;">The Company does not expect to realize any tax benefits from its share option activity or the recognition of share-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, no <span style="-sec-ix-hidden:Hidden_MlA4-b9GnE64Lz0dPLcYmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amounts</span></span> related to <span style="-sec-ix-hidden:Hidden_rcbwIQOgN0KERK7K18fcyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">excess</span></span> <span style="-sec-ix-hidden:Hidden_UfokOTS--kuNnksgF_hYAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax</span></span> benefits have been reported in cash flows from operations or cash flows from financing activities for the three-month periods ended March 31, 2025 and 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Ordinary Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 7pt 0pt;">6. &#160;&#160;&#160;&#160;&#160;&#160;Ordinary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 5pt 24.5pt;"><span style="font-style:italic;">At-the-Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 0pt 24.5pt;"><span style="font-weight:normal;">In December 2023, the Company entered into an </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> sales agreement with BofA Securities, Inc., or BofA, pursuant to which the Company may sell from time to time, ordinary shares having an aggregate offering price of up to </span><span style="font-weight:normal;">$100.0</span><span style="font-weight:normal;"> million through BofA, acting as the Company&#8217;s agent. During the three-month period ended March 31, 2025, the Company raised gross proceeds of </span><span style="font-weight:normal;">$4.5</span><span style="font-weight:normal;"> million through the sale of </span><span style="font-weight:normal;">563,379</span><span style="font-weight:normal;"> ordinary shares pursuant to an &#8220;at-the-market&#8221; equity offering program. Under the </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> equity program which is currently effective and may remain available for the Company to use in the future, the Company may sell an additional </span><span style="font-weight:normal;">$87.1</span><span style="font-weight:normal;"> million of ordinary shares. Whether the Company chooses to affect future sales under the </span><span style="font-weight:normal;">&#8220;</span><span style="font-weight:normal;">at-the-market</span><span style="font-weight:normal;">&#8221;</span><span style="font-weight:normal;"> equity offering program will depend on a number of factors, including, among others, market conditions and the trading price of the Company</span><span style="font-weight:normal;">&#8217;</span><span style="font-weight:normal;">s ordinary shares relative to other sources of capital.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">7. &#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company did not record a provision for income <span style="-sec-ix-hidden:Hidden_N4ipPyW_6EecGrCOlZuzUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">taxes</span></span> for the three-month periods ended March 31, 2025 and 2024, as the Company has generated losses for all periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;">The Company periodically evaluates the realizability of its deferred tax assets based on all available evidence, both positive and negative. The realization of deferred tax assets is dependent on the Company&#8217;s ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. The Company weighed both positive and negative evidence and determined that there is a continued need for a full valuation allowance on its deferred tax assets (after consideration of the reversal of the deferred tax liabilities for the ROU assets and fixed assets) in the United States, United Kingdom, Ireland and Netherlands as of March 31, 2025. Should the Company determine that it would be able to realize its remaining deferred tax assets in the foreseeable future, an adjustment to its remaining deferred tax assets would cause a material increase to income in the period such determination is made.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">8. &#160;&#160;&#160;&#160;&#160;&#160;Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">Asset Purchase and Related Agreements with Johnson &amp; Johnson Innovative Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">On December 20, 2023, the Company entered into the Asset Purchase Agreement with Johnson &amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp; Johnson Innovative Medicine, and Johnson &amp; Johnson Innovative Medicine purchased and assumed, the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets as described in the Asset Purchase Agreement. Simultaneously, the Company and Johnson &amp; Johnson Innovative Medicine also entered into a Supply Agreement pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp; Johnson Innovative Medicine. Under the Supply Agreement, MeiraGTx UK II, together with its affiliates, will manufacture commercial supply of the RPGR Product for Johnson &amp; Johnson Innovative Medicine for an initial term of four years, with Johnson &amp; Johnson Innovative Medicine having an option to extend the Supply Agreement for a fifth year upon written notification. Johnson &amp; Johnson Innovative Medicine may terminate the Supply Agreement for convenience upon 90 days&#8217; written notice with payment of a termination fee. Under the Asset Purchase Agreement, Johnson &amp; Johnson Innovative Medicine paid the Company a non-refundable upfront fee of $65.0 million in December 2023 and the Company is eligible to receive fees from commercial supply of the RPGR Product and in addition, milestones of up to $350.0 million, as follows: (i) a milestone payment of $50.0 million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $10.0 million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $5.0 million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $175.0 million upon the first commercial sale of an RPGR Product in the United States; (v) $75.0 million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $25.0 million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp; Johnson Innovative Medicine; and (vii) $10.0 million upon regulatory approval of a Johnson &amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. To date, the Company received $60.0 million in milestone payments from Johnson &amp; Johnson Innovative Medicine. Johnson &amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 24.45pt;">Revenue Recognition under the Asset Purchase and Related Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">The agreements entered into in December 2023 were executed at the same time and were negotiated with a single commercial objective; therefore, the contracts were combined and accounted for as a single contract. These agreements were accounted for as a termination of the Collaboration Agreement and the creation of a new contract where the transaction price includes the remaining deferred revenue &#8211; related party from the terminated agreement of $30.6 million, the fixed upfront payment of $65.0 million under the Asset Purchase Agreement, and an aggregate of $1.8 million estimated variable consideration for transition services, offset by a credit of $5.1 million for pre-funded inventory, totaling $92.3 million. The transaction price was allocated to four performance obligations on a relative SSP basis, subject to certain exceptions for discounts and variable consideration. As the SSPs are not directly observable for any of the distinct goods and services, the SSPs were estimated based on a valuation. The total transaction price of $92.3 million was allocated to the performance obligations with respect to SSPs as follows: process performance qualification (&#8220;PPQ&#8221;) services in the amount of $2.9 million net of future billings, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $6.9 million, manufacturing technology transfer in the amount of $28.7 million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#8217;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp; Johnson Innovative Medicine in the amount of $53.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">Since the commencement of the Asset Purchase Agreement and related agreements, the Company received a $50.0 million milestone payment in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product. The milestone payment was allocated to the four performance obligations on the same basis noted above increasing the value of each performance obligation as follows: PPQ services in the amount of $1.6 million, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $3.8 million, manufacturing technology transfer in the amount of $15.6 million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#8217;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp; Johnson Innovative Medicine in the amount of $29.0 million. Additionally, the Company received a $10.0 million milestone payment in connection with the completion of certain specified development services for the drug substance for the RPGR Product which was allocated to the PPQ services performance obligation. The Company also entered into additional agreements to provide additional services under the Asset Purchase Agreement and related agreements amounting to an aggregate of $5.8 million which was included in the transaction price and allocated to each of the respective performance obligations. Furthermore, the Company recorded certain changes in estimates related to the valuation of its performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">The transaction price allocated to PPQ services will be recognized over time using an inputs method measure of progress. The transaction price allocated to the material right for the commercial supply of RPGR Product will be recorded as deferred revenue until Johnson &amp; Johnson Innovative Medicine exercises its option to purchase supply and the Company transfers control of such supply to Johnson &amp; Johnson Innovative Medicine. The transaction price allocated to the in-substance renewal option (material right) will be recorded as deferred revenue until Johnson &amp; Johnson Innovative Medicine exercises the option and the Company transfers control of the underlying goods or services to Johnson &amp; Johnson Innovative Medicine. The Company will account for the exercise of the in-substance renewal option (material right) as a continuation of the existing contract (i.e., a change in the transaction price). The transaction price allocated to the technology transfer will be recognized over time using an inputs method measure of progress. The Company will recognize a gain for the difference between the carrying amount of the nonfinancial assets and the consideration allocated to that unit of account when control of the nonfinancial assets transfers in accordance with ASC 610-20, <i style="font-style:italic;">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During the three-month period ended March 31, 2024, the Company recognized a gain of $29.0 million related to the sale of nonfinancial assets which is included in other income in the condensed consolidated statements of operations and comprehensive loss. There was no gain on sale of nonfinancial assets recognized during the three-month period ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">As of March 31, 2025, the aggregate transaction price allocated to unsatisfied performance obligations was $63.9 million which the Company expects to recognize over an estimated period of approximately 2.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;">A summary of the deferred revenue is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,403</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other amounts collected or invoiced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue recognized as service revenue during the three-month period ended March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (741)</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,874</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,859</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During each of the three-month periods ended March 31, 2025 and 2024, the Company recognized $0.7 million of deferred revenue &#8211; related party as service revenue in connection with PPQ services under the Asset Purchase Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;">During the three-month period ended March 31, 2025, the Company recognized $1.9 million of service revenue, inclusive of the $0.7 million of deferred revenue &#8211; related party recognized as service revenue, based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements. There was no service revenue based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements recognized during the three-month period ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;">Debt Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"><span style="font-style:normal;font-weight:normal;">On August 2, 2022 the Company, as borrower, and Meira UK II and Meira Ireland, as guarantors (the &#8220;Subsidiary Guarantors&#8221;), entered into a senior secured financing arrangement (the &#8220;Financing Agreement&#8221;) by and among the Company, the Subsidiary Guarantors, the lenders and other parties from time to time party thereto and Perceptive Credit Holdings III, LP, as administrative agent and lender (&#8220;Perceptive&#8221;). On December 19, 2022, the Financing Agreement was converted to a notes purchase agreement and guaranty (the &#8220;Notes Purchase Agreement&#8221;) between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. Perceptive Advisors, LLC, an affiliate of Perceptive, is a greater than </span><span style="font-style:normal;font-weight:normal;">10%</span><span style="font-style:normal;font-weight:normal;"> holder of the ordinary shares of the Company. Additionally, Ellen Hukkelhoven, Ph.D., a director of the Company, is an employee of Perceptive Advisors, LLC. Refer to the discussion in Note 10 for further information related to the accounting for the debt financing.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">9. &#160;&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Company has commitments under operating leases for laboratory, warehouse, clinical trial sites and office space. The Company also has finance leases for manufacturing space and office equipment. The Company&#8217;s leases have initial lease terms ranging from 3 years to 191 years. Certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include fixed payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">Total rent expense under these leases was $1.3 million and $1.4 million for the three-month periods ended March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">There were no <span style="-sec-ix-hidden:Hidden_50G5iuwwS0COib-U_gl6RQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leases</span></span> recognized during the three-month periods ended March 31, 2025 and 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, resulting in a remeasurement of the ROU asset and lease liability reflected in the accompanying condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The components of lease cost for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,759</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Amounts reported in the condensed consolidated balance sheets for leases where the Company is the lessee as of March 31, 2025 and December 31, 2024 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized lease obligations</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Other information related to leases for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">Future minimum lease payments under non-cancellable leases as of March 31, 2025 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,690</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,451</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,547</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,352</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 576</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease payments</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,616</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,233)</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,383</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Financing<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Financing</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">10. &#160;&#160;&#160;Debt Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">On August 2, 2022 the Company, and the Subsidiary Guarantors, entered into the Financing Agreement with Perceptive. On December 19, 2022, the Financing Agreement was converted to a Notes Purchase Agreement between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. The Company and the Subsidiary Guarantors entered into a Consent and Amendment with Perceptive on August 10, 2023 (the &#8220;First Consent and Amendment), and the Company and the Subsidiary Guarantors entered into a second Consent and Amendment with Perceptive on December 20, 2023 (the &#8220;Second Consent and Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Notes Purchase Agreement provides for an initial $75.0 million notes issuance (the &#8220;Tranche 1 Notes&#8221;). &#160;Pursuant to the First Consent and Amendment, <span style="background:#ffffff;">the Company was able to request in its sole discretion, and Perceptive agreed to subscribe to purchase upon such request, an additional </span><span style="background:#ffffff;">$25.0</span><span style="background:#ffffff;"> million notes issuance (the &#8220;Tranche 2 Notes&#8221;) at any time before August 2, 2024 subject to the terms of the Notes Purchase Agreement.</span> Previously, the Company&#8217;s request for issuance of the Tranche 2 Notes was to be determined at Perceptive&#8217;s sole discretion. The Notes Purchase Agreement matures on August 2, 2026 and is interest-only during the term. The Company has the option to redeem outstanding principal notes at any time along with an applicable early redemption fee. Under each of the First Consent and Amendment and the Second Consent and Amendment, the Notes Purchase Agreement was amended to increase the applicable early redemption fee. Outstanding amounts under the Notes Purchase Agreement bear interest at a fluctuating rate per annum equal to 10.00% plus the secured overnight financing rate administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a 1.00% floor. The annual interest rate was 14.34% at March 31, 2025. As of March 31, 2025, the outstanding balance of the Tranche 1 Notes was $75.0 million plus accrued interest of $2.6 million. During the three-month periods ended March 31, 2025 and 2024, the Company recorded interest expense of $2.7 million and $2.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Company&#8217;s obligations under the Notes Purchase Agreement are secured by the Company&#8217;s London, UK and Shannon, Ireland manufacturing facilities, $3.0 million of the Company&#8217;s cash and the bank accounts of the Subsidiary Guarantors, and the issued and outstanding equity interests of the Subsidiary Guarantors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">The Notes Purchase Agreement imposes certain covenants and restrictions on the Company and the Subsidiary Guarantors, including restrictions pertaining to: (i) the incurrence of additional indebtedness, (ii) limitations on liens, (iii) limitations on certain investments, (iv) making distributions, dividends and other payments, (v) mergers, consolidations and acquisitions, (vi) dispositions of assets, (vii) the Company&#8217;s maintenance of at least $3.0 million in a U.S. bank account, (viii) transactions with affiliates, (ix) changes to governing documents, (x) changes to certain agreements and leases and (xi) changes in control; however, certain of these restrictions contain exceptions which allow the Company to license, sell and monetize assets in its AAV-hAQP1 program in development to treat radiation-induced xerostomia, its AAV-GAD program in development to treat Parkinson&#8217;s disease and its gene regulation platform technologies. As of March 31, 2025, the Company is in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">In connection with entering into the Financing Agreement, the Company granted warrants to Perceptive to purchase up to (i) 400,000 ordinary shares of the Company at an exercise price of $15.00 per share and (ii) 300,000 ordinary shares of the Company at an exercise price of $20.00 per share. The warrants are exercisable immediately and expire on August 2, 2027. The Company recorded a debt discount of $2.3 million for the allocated fair value of the warrants. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;">The Company also capitalized certain lender and legal costs associated with the Notes Purchase Agreement totaling $2.1 million, which were recorded as a discount to the loan. The aggregate discount of $4.4 million is being amortized to interest expense over the term of the Notes Purchase Agreement. The Company amortized $0.3 million of the discount to interest expense during each of the three-month periods ended March 31, 2025 and 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">11.    Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 22.3pt;">There were no new material commitments or contingencies entered into during the three-month period ended March 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (39,981)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_Rule10b51ArrangementModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_NonRule10b51ArrangementModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NonRule10b51ArrangementModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b5-1 Arrangement Modified [Flag]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NonRule10b51ArrangementModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_Rule10b51ArrangementModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b5-1 Arrangement Modified [Flag]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_Rule10b51ArrangementModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx, LLC, a Delaware limited liability company (&#8220;Meira LLC&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#160;II&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (&#8220;Meira Ireland&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira Netherlands&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Belgium, a private company with limited liability incorporated under the laws of Belgium (&#8220;Meira Belgium&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">BRI-Alzan,&#160;Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Bio, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#8220;Meira B.V.&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neurosciences,&#160;Inc., a Delaware corporation; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Therapeutics, Inc., a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (&#8220;Meira UK&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro I, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro II, LLC, a Delaware limited liability company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Manufacturing Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Ocular UK Limited, a limited company incorporated under the laws of England and Wales;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Gene Regulation Limited, a limited company incorporated under the laws of England and Wales; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;">MeiraGTx Neuro UK Limited, a limited company incorporated under the laws of England and Wales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: service revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Restricted cash represents a guarantee put in place as required by the terms of the research and innovation grant from IDA Ireland which offers financial assistance in establishing the Company&#8217;s operations in Shannon, Ireland. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company&#8217;s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,659</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,009</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,668</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company&#8217;s own credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company follows ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;">The table below represents the values of the Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant&#160;Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.3pt;">At March 31, 2025, the Company's financial instruments included cash and cash equivalents, restricted cash, accounts receivable &#8211; related party, and accounts payable. The carrying amounts reported in the Company's condensed consolidated financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments. In addition, at March 31, 2025, the Company believes the carrying value of the Tranche 1 Notes (as defined in Note 10) approximates fair value as the interest rate is reflective of the rate the Company could obtain on debt with similar terms and conditions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Asset Retirement Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Asset Retirement Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.3pt;">Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level&#160;3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported on the condensed consolidated balance sheets were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;">The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;">During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, for which the Company had an associated asset retirement obligation liability in the amount of $1.7 million and a corresponding leasehold improvement with a net book value of $0.3 million as of March 31, 2025. The landlord no longer requires the Company to make any changes to the premises prior to the lease termination and the Company only expects to incur $0.1 million related to decontamination costs. Therefore, a change in estimate of the asset retirement obligation was recorded resulting in a gain on termination of lease liabilities of $1.3 million which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.5pt;">The change in asset retirement obligations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,401</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in estimate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Amortization of interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,440</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ScheduleOfIrelandGrantsPolicyTextBlock', window );">IDA Ireland Grant</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 24.5pt;">IDA Ireland Grant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">In August 2021, Meira Ireland entered into an agreement pursuant to which it received a grant from IDA Ireland for financial assistance in establishing its operations in Shannon, Ireland. Under the terms of the grant, Meira Ireland is eligible to receive the lesser of &#8364;1.0 million or &#8364;10,000 for each job created (the &#8220;employment grant&#8221;) and the lesser of &#8364;1.2 million or 4% of the actual expenditure on the provision of machinery and equipment (the &#8220;capital grant&#8221;). Meira Ireland may apply for a drawdown of the employment grant once a job has been created and the position has been held for a period of at least one month, and may apply for a drawdown of the capital grant once an eligible asset has been purchased and installed, conditioned on the creation of a cumulative number of jobs by the end of the immediately preceding year. An aggregate of 100 jobs must be created to receive the maximum benefit under the capital grant. An application for a drawdown must be accompanied by an audit certification for compliance with the terms of the grant. The Company has a guarantee in place with a bank in favor of IDA Ireland, pursuant to which it restricts cash in the amount of claims made under the grant such that the Company maintains the funds to cover any portion of the grant income that may become repayable in the future. This amount is presented as restricted cash in the accompanying condensed consolidated balance sheet. All grant drawdowns were required to be completed by December 31, 2024, and the agreement terminates on the later of five years from the date of the last payment from the grant or five years from completion of the capital investment, which is expenditure of at least &#8364;30.0 million on eligible machinery and equipment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;">The Company recognizes grant income when there is reasonable assurance that the Company will comply with the conditions attached to the grant and that it will receive the grant. Grant income from the employment grant is recognized as a deduction from the amount of the related expense, and grant income from the capital grant is deducted from the carrying amount of the related asset and recognized in income over the asset&#8217;s useful life in the form of a reduced depreciation charge. The Company received its first drawdown under the grant in 2023, which was comprised of $0.6 million for the employment grant and $0.4 million for the capital grant. The Company received its second drawdown under the grant in 2024, which was comprised of $0.5 million for the employment grant and $0.5 million for the capital grant. During the three-months ended March 31, 2025 and 2024, the Company recognized de minimis grant income as a reduction of research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">During the five-year period ending on the termination of the grant agreement, Meira Ireland must maintain compliance with the terms of the grant. If the total number of jobs is less than 100 at the time of IDA Ireland&#8217;s annual review, the Company may have to repay a portion of the capital grant, and if a job for which the Company received employment grant funding remains vacant for a period in excess of <span style="-sec-ix-hidden:Hidden_eNuWP8gC10unY9sqGjg8MQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span> calendar months, the Company may have to repay the employment grant received for that job. As of March 31, 2025, the Company is in compliance with the terms of the grant.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 24.45pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;">At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition the Company performs the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the contract(s)&#160;with a customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">iv.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocate the transaction price to the performance obligations within the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">v.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognize revenue when (or as) the entity satisfies a performance obligation.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;">At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements typically consist of a license to the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;">If there are multiple performance obligations, the Company allocates the transaction price to each performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a performance obligation requires significant judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company records amounts as contract assets when the right to consideration is deemed unconditional. Contract assets are reclassified as accounts receivable once billed. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s condensed consolidated balance sheet.&#160;Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party, current.&#160;Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">The Company&#8217;s revenue arrangements include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Milestone Payments:&#160;At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and Development Services: Under the Asset Purchase Agreement, research and development services (PPQ services) are recorded as incurred under cost of service revenue &#8211; related party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Customer Options: Customer options are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company&#8217;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expenses, as the case may be.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Ordinary Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Net Loss per Ordinary Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company&#8217;s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary share equivalents had been issued at the beginning of the&#160;year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,484,644</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,389,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,094,750</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,112,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,464,394</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable and operating segment, which is the development and manufacturing of genetic medicines, for purposes of reporting financial condition and results of operations. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the chief executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM allocates resources and assesses performance of the Company&#8217;s single reportable segment by regularly reviewing the segment net loss that also is reported on the condensed consolidated statement of operations and comprehensive loss as net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The following table sets forth information about the Company&#8217;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 697</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,864</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Botaretigene sparoparvovec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,957</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-hAQP1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,663</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-CNGB3 / AAV-CNGA3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,179)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-GAD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,170</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Other ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,360</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Gene regulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,499</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Neurodegenerative diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Preclinical ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 541</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Johnson &amp; Johnson Innovative Medicine reimbursement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (652)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,275</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,469</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,330</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments or reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1 </sup>Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">The Company&#8217;s service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;">The following table summarizes long-lived assets by geographical area (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,209</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,419</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">European Union</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,845</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 134,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 136,473</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. This update includes a number of amendments to clarify or improve disclosure and presentation requirements of a variety of topics in order to allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not previously subject to the requirements and to align the requirements in the FASB accounting standard codification with the SEC&#8217;s regulations. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact of these amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement: Reporting Comprehensive Income: Expense Disaggregation Disclosures (Subtopic 220-40), which requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date, which revised the effective date of ASU No. 2024-03 for interim periods. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of ASU 2024-03 and ASU 2025-01 on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ScheduleOfIrelandGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for IDA Ireland Grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ScheduleOfIrelandGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/410-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,659</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,009</p></td></tr><tr><td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,668</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level 3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair&#160;Value&#160;Measurement&#160;Using:</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant&#160;Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Significant</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Observable&#160;Inputs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Unobservable</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Level&#160;3)</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock', window );">Schedule of Change in Asset Retirement Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,401</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in estimate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Amortization of interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,440</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,484,644</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,389,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,094,750</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,112,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,464,394</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of net loss for the segment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 697</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Cost of service revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,864</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Clinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Botaretigene sparoparvovec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,957</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-hAQP1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,663</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-CNGB3 / AAV-CNGA3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,179)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">AAV-GAD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,170</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Other ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,360</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Preclinical programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Gene regulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,499</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Neurodegenerative diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Preclinical ocular diseases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Other research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 541</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Johnson &amp; Johnson Innovative Medicine reimbursement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (652)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,275</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,469</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,330</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments or reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,442)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1 </sup>Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets by Geographical Area</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,209</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,419</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">European Union</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,845</p></td></tr><tr><td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 134,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 136,473</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method and Other Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity method and other investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Investee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Investment Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost Basis</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Visiogene LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Method Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,165</p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity Investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total equity method and other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,665</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,197</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,326</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,234</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on Tranche 1 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,864</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,540</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,530</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rent and facilities costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,414</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,232,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (638)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (208,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,956,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,022,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aggregate intrinsic value of options exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Inputs Used in Determining Fair Value of Share Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.04 - 4.17%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">67%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3.6 - 6.1</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Share Unit (RSU) Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,252,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.91</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (862,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.70</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,389,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.69</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,875</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,085</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,960</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,635</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,688</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,240</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,032</p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,272</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Deferred Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,403</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other amounts collected or invoiced</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue recognized as service revenue during the three-month period ended March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (741)</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effects of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,874</p></td></tr><tr><td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue at March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,859</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total finance lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,759</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock', window );">Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized lease obligations</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock', window );">Schedule of Other Information Related to Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three-Month Periods Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock', window );">Schedule of Future Minimum Payments Under Non-cancellable Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,690</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,451</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,547</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,352</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 576</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total undiscounted lease payments</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,616</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,233)</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,383</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of the investment in leveraged leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481161/840-30-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479711/842-50-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,828<span></span>
</td>
<td class="nump">$ 36,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,649<span></span>
</td>
<td class="nump">68,610<span></span>
</td>
<td class="nump">$ 120,265<span></span>
</td>
<td class="nump">105,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals Inc | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AssetPurchaseAgreementFundingReceived', window );">Non-refundable upfront cash funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingReceived', window );">Milestone funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForExtensionOfClinicalTrials', window );">Milestone funding for extension of RPGR product clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForDevelopmentOfDrugSubstances', window );">Milestone funding for development of drug substances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForDevelopmentOfDrugProducts', window );">Milestone funding for development of drug products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates', window );">Milestone funding for sale of drug products in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly', window );">Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForTransferOfManufacturingTechnology', window );">Milestone funding for transfer of manufacturing technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForRegulatoryApproval', window );">Milestone funding upon regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_HologenLimitedMember', window );">Hologen Limited | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClassSharesOfHologenReceivedInTransaction', window );">Class A shares of Hologen received in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContingentClassSharesReceivableOfHologenInTransaction', window );">Contingent class A shares receivable of Hologen in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_HologenLimitedMember', window );">Hologen Limited | Hologen Strategic Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingUpfrontPaymentReceived', window );">Milestone funding upfront payment received</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingToProvideAdditionalCapital', window );">Milestone funding to provide additional capital</a></td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClassShareOwnershipPercentageOfHologenNeuro', window );">Class A share ownership percentage of Hologen Neuro</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClassBShareOwnershipPercentageOfHologenNeuro', window );">Class B share ownership percentage of Hologen Neuro</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PercentageApprovalOfDirectors', window );">Percentage approval of directors</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_HologenLimitedMember', window );">Hologen Limited | Manufacturing Framework Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PercentageApprovalOfDirectors', window );">Percentage approval of directors</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares', window );">Purchase option after twelve months, percentage of Company's outstanding common shares</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_RepurchaseOptionVestingPeriod', window );">Vesting period, irrevocable option to purchase shares of MeiraGTx Manufacturing</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Janssen Pharmaceuticals Inc | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContingentFundingAvailable', window );">Contingent Funding Available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Hologen Limited | Hologen Strategic Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingToProvideAdditionalCapital', window );">Milestone funding to provide additional capital</a></td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AssetPurchaseAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AssetPurchaseAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassBShareOwnershipPercentageOfHologenNeuro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership in company by share class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassBShareOwnershipPercentageOfHologenNeuro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassShareOwnershipPercentageOfHologenNeuro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership in company by share class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassShareOwnershipPercentageOfHologenNeuro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassSharesOfHologenReceivedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period in connection with strategic agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassSharesOfHologenReceivedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContingentClassSharesReceivableOfHologenInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock contingently issuable to company in connection with strategic agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContingentClassSharesReceivableOfHologenInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContingentFundingAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContingentFundingAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForDevelopmentOfDrugProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForDevelopmentOfDrugProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForDevelopmentOfDrugSubstances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForDevelopmentOfDrugSubstances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForExtensionOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForExtensionOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForTransferOfManufacturingTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForTransferOfManufacturingTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingToProvideAdditionalCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingToProvideAdditionalCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received in collaboration with Hologen Limited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PercentageApprovalOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage approval of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PercentageApprovalOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase option after twelve months, percentage of Company's outstanding common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RepurchaseOptionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RepurchaseOptionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgtx_HologenLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgtx_HologenLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_HologenTransactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_HologenTransactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_ManufacturingFrameworkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_ManufacturingFrameworkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandMember', window );">IDA Ireland Financial Assistance Grants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment', window );">Termination period (upon completion of capital investment)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandMember', window );">IDA Ireland Financial Assistance Grants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_FinancialAssistanceDurationFromLastGrantPayment', window );">Termination period (from last grant payment)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandEmploymentMember', window );">IDA Ireland Employment Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantFundingReceived', window );">Grant funding received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandEmploymentMember', window );">IDA Ireland Employment Grants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantAmountForJobCreation', window );">Grant funding for each new job created</a></td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandEmploymentMember', window );">IDA Ireland Employment Grants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantAmountForJobCreation', window );">Grant funding for each new job created</a></td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding', window );">Aggregate number of new jobs required to receive Grant benefits</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable', window );">Vacant job duration prompting repayment of grant funding</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandCapitalMember', window );">IDA Ireland Capital Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantFundingReceived', window );">Grant funding received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandCapitalMember', window );">IDA Ireland Capital Grants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantAmountForMachineryAndEquipment', window );">Grant amount for machinery and equipment</a></td>
<td class="nump">&#8364; 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandCapitalMember', window );">IDA Ireland Capital Grants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake', window );">Grant amount for machinery and equipment (percent of actual expenditure)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding', window );">Aggregate number of new jobs required to receive Grant benefits</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment', window );">Expenditure requirement on eligible machinery and equipment</a></td>
<td class="nump">&#8364; 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_FinancialAssistanceDurationFromLastGrantPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_FinancialAssistanceDurationFromLastGrantPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GrantAmountForJobCreation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial assistance available for each new job created.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GrantAmountForJobCreation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GrantAmountForMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GrantAmountForMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GrantFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funding received from IDA Ireland grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GrantFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandEmploymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandEmploymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mgtx_GrantsIdaIrelandCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,523<span></span>
</td>
<td class="nump">$ 103,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows</a></td>
<td class="nump">68,610<span></span>
</td>
<td class="nump">105,668<span></span>
</td>
<td class="nump">$ 120,265<span></span>
</td>
<td class="nump">$ 130,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements on recurring basis | Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements on recurring basis | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">57,020<span></span>
</td>
<td class="nump">80,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair value measurements on recurring basis | Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair value measurements on recurring basis | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">$ 57,020<span></span>
</td>
<td class="nump">$ 80,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=mgtx_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=mgtx_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAbstract', window );"><strong>Asset Retirement Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligations at beginning of period</a></td>
<td class="nump">$ 2,821<span></span>
</td>
<td class="nump">$ 2,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationRevisionOfEstimate', window );">Change in estimate</a></td>
<td class="nump">1,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AssetRetirementObligationsAmortizationOfInterest', window );">Amortization of interest</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligations at end of period</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationLiabilitiesSettled', window );">ARO settled through early lease termination</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements associated with terminated lease</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationCashPaidToSettle', window );">Decontamination costs related to ARO</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GainOnTerminationOfLeaseLiabilities', window );">Gain on termination of lease</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AssetRetirementObligationsAmortizationOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of interest on asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AssetRetirementObligationsAmortizationOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GainOnTerminationOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GainOnTerminationOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481999/410-20-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationCashPaidToSettle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid during the period to settle an asset retirement obligation. Amounts paid to settle an asset retirement obligation are generally included in the operating section of the Statement of Cash Flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481879/410-20-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationCashPaidToSettle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationLiabilitiesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations settled, or otherwise disposed of, during the period. This may include asset retirement obligations transferred to third parties associated with the sale of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationLiabilitiesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationRevisionOfEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationRevisionOfEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from EPS</a></td>
<td class="nump">12,112,739<span></span>
</td>
<td class="nump">13,464,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from EPS</a></td>
<td class="nump">8,022,989<span></span>
</td>
<td class="nump">8,484,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from EPS</a></td>
<td class="nump">3,389,750<span></span>
</td>
<td class="nump">4,094,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from EPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from EPS</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ServiceRevenueFromRelatedParties', window );">Service revenue - related party</a></td>
<td class="nump">$ 1,926<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Cost of service revenue - related party</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SegmentGeneralAndAdministrativeExpenses', window );">General and administrative</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClinicalProgramsDrugProduct1', window );">Botaretigene Sparoparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClinicalProgramsDrugProduct2', window );">AAV-hAQP1</a></td>
<td class="nump">4,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClinicalProgramsDrugProduct3', window );">AAV-CNGB3 / AAV-CNGA3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ClinicalProgramsDrugProduct4', window );">AAV-GAD</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ResearchAndDevelopmentClinicalTrials', window );">Other ocular diseases</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ResearchAndDevelopmentManufacturing', window );">Manufacturing</a></td>
<td class="nump">17,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PreClinicalResearchGeneRegulation', window );">Gene Regulation</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PreClinicalResearchNeurodegenerativeDiseases', window );">Neurodegenerative diseases</a></td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PreClinicalResearchPreclinicalOcularDiseases', window );">Preclinical ocular diseases</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ResearchAndDevelopmentOther', window );">Other research and development (1)</a></td>
<td class="num">(624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_InnovativeMedicineReimbursement', window );">Johnson &amp; Johnson Innovative Medicine reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">3,275<span></span>
</td>
<td class="nump">3,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">43,522<span></span>
</td>
<td class="nump">47,469<span></span>
</td>
<td class="nump">47,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_OtherSegmentItemsIncomeStatement', window );">Other segment items (2)</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SegmentNetIncomeLoss', window );">Segment net loss</a></td>
<td class="num">(39,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (39,981)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
<td class="num">$ (20,442)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClinicalProgramsDrugProduct1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for clinical trials for Botaretigene Sparoparvovec drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClinicalProgramsDrugProduct1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClinicalProgramsDrugProduct2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for clinical trials for AAV-hAQP1 drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClinicalProgramsDrugProduct2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClinicalProgramsDrugProduct3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for clinical trials for AAV-CNGB3 / AAV-CNGA3 drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClinicalProgramsDrugProduct3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClinicalProgramsDrugProduct4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for clinical trials for AAV-GAD drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClinicalProgramsDrugProduct4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_InnovativeMedicineReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for innovative medicine research reimbursed by Johnson &amp; Johnson.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_InnovativeMedicineReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_OtherSegmentItemsIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other segment items of income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_OtherSegmentItemsIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PreClinicalResearchGeneRegulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for pre-clinical research relating to gene regulation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PreClinicalResearchGeneRegulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PreClinicalResearchNeurodegenerativeDiseases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for pre-clinical research relating to neurodegenerative diseases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PreClinicalResearchNeurodegenerativeDiseases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PreClinicalResearchPreclinicalOcularDiseases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for pre-clinical research relating to preclinical ocular diseases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PreClinicalResearchPreclinicalOcularDiseases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ResearchAndDevelopmentClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development pertaining to clinical trials for drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ResearchAndDevelopmentClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ResearchAndDevelopmentManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development pertaining to manufacturing of drug substances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ResearchAndDevelopmentManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ResearchAndDevelopmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ResearchAndDevelopmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SegmentGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The segment total of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SegmentGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SegmentNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SegmentNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ServiceRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ServiceRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">$ 134,257<span></span>
</td>
<td class="nump">$ 136,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">2,515<span></span>
</td>
<td class="nump">7,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">UNITED KINGDOM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">28,255<span></span>
</td>
<td class="nump">28,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">EUROPEAN UNION</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">$ 103,487<span></span>
</td>
<td class="nump">$ 100,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method and Other Investments - Summary of Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Carrying Value</a></td>
<td class="nump">$ 6,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Cost Basis</a></td>
<td class="nump">$ 6,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_VisiogeneLlcMember', window );">Visiogene LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Carrying Value</a></td>
<td class="nump">$ 5,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Cost Basis</a></td>
<td class="nump">$ 5,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_OtherEquityMethodInvestmentsMember', window );">Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Carrying Value</a></td>
<td class="nump">$ 1,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Cost Basis</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_VisiogeneLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_VisiogeneLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_OtherEquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_OtherEquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits', window );">Compensation and benefits</a></td>
<td class="nump">$ 8,129<span></span>
</td>
<td class="nump">$ 11,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">4,163<span></span>
</td>
<td class="nump">6,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Interest on Tranche 1 Notes</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedClinicalTrialCosts', window );">Clinical trial costs</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">3,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense', window );">Manufacturing costs</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedConsultingExpenses', window );">Consulting</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts', window );">Rent and facilities costs</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets', window );">Fixed assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 23,964<span></span>
</td>
<td class="nump">$ 27,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedConsultingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Consulting Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedConsultingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value of accrued expenses incurred in connection with fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value of accrued expenses incurred in connection with rent and facility costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities Accrued Compensation And Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities Accrued Manufacturing Costs Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Company's Share Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Beginning balance</a></td>
<td class="nump">8,232,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(208,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending balance</a></td>
<td class="nump">8,022,989<span></span>
</td>
<td class="nump">8,232,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Beginning balance</a></td>
<td class="nump">$ 12.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Exercised</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Forfeited</a></td>
<td class="nump">16.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Ending balance</a></td>
<td class="nump">$ 12.48<span></span>
</td>
<td class="nump">$ 12.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable</a></td>
<td class="nump">6,956,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, Options exercisable</a></td>
<td class="nump">$ 12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life of options, outstanding</a></td>
<td class="text">5 years 2 months 4 days<span></span>
</td>
<td class="text">5 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life of options, exercisable</a></td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, Options vested and expected to vest</a></td>
<td class="nump">8,022,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Options vested and expected to vest</a></td>
<td class="nump">$ 12.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, Options vested and expected to vest</a></td>
<td class="text">5 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 2,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Share Units (Details) - Restricted Share Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of restricted share units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted share units, Beginning balance | shares</a></td>
<td class="nump">4,252,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted share units, Vested | shares</a></td>
<td class="num">(862,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted share units, Ending balance | shares</a></td>
<td class="nump">3,389,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Beginning balance | $ / shares</a></td>
<td class="nump">$ 8.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Ending balance | $ / shares</a></td>
<td class="nump">$ 7.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 4,887<span></span>
</td>
<td class="nump">$ 6,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">4,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 2,244<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options, Vested</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1', window );">Excess tax benefits in cash flows from operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1', window );">Excess tax benefits in cash flows from financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation expense not yet recognized relating to unvested RSUs</a></td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period expected to realize unrecognized compensation expense</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Ordinary shares withheld for statutory tax requirements</a></td>
<td class="nump">405,459<span></span>
</td>
<td class="nump">348,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld on issuance of share-based awards</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options, Vested</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unvested options compensation expense not yet recognized</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period expected to realize unrecognized compensation expense</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Contractual term</a></td>
<td class="text">P10Y<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=srt_DirectorMember', window );">Directors | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_VestedSharesDeferred', window );">Shares vested and deferred</a></td>
<td class="nump">272,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_FirstAnniversaryMember', window );">First Anniversary | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_FirstAnniversaryMember', window );">First Anniversary | Directors | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_SecondAnniversaryMember', window );">Second Anniversary | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_ThirdAnniversaryMember', window );">Third Anniversary | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_FourthAnniversaryMember', window );">Fourth Anniversary | Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_VestedSharesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have fully vested and have been deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_VestedSharesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_SecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_SecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_FourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_FourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate offering price authorized through at-market offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,482<span></span>
</td>
<td class="nump">$ 1,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_BankOfAmericaSecuritiesInc.Member', window );">B of A Securities, Inc. | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds from sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Ordinary shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgtx_BankOfAmericaSecuritiesInc.Member', window );">B of A Securities, Inc. | Public Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate offering price authorized through at-market offerings</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SaleOfStockConsiderationAvailableInFutureTransactions', window );">Value of ordinary shares available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SaleOfStockConsiderationAvailableInFutureTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration available in future stock transactions after deduction of issuance costs in at-the-market offerings of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SaleOfStockConsiderationAvailableInFutureTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgtx_BankOfAmericaSecuritiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgtx_BankOfAmericaSecuritiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgtx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgtx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision recorded for income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Collaboration and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,418,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,418,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ServiceRevenueFromRelatedParties', window );">Service revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,926<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AssetPurchaseAgreementFundingReclassified', window );">Asset purchase agreement funding included in contract price of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_GainLossOnSaleOfNonfinancialAssets', window );">Gain on sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals Inc | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ServiceRevenueFromRelatedParties', window );">Service revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_DeferredRevenueRecognizedDuringPeriod', window );">Deferred revenue recognized as service revenue during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_InitialAgreementPeriodDuration', window );">Initial agreement term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AgreementTerminationPeriodDaysWrittenNotice', window );">Written days-notice to terminate agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingReceived', window );">Milestone funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_AssetPurchaseAgreementFundingReceived', window );">Non-refundable upfront cash funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForExtensionOfClinicalTrials', window );">Milestone funding for extension of RPGR product clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForDevelopmentOfDrugSubstances', window );">Milestone funding for development of drug substances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForDevelopmentOfDrugProducts', window );">Milestone funding for development of drug products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates', window );">Milestone funding for sale of drug products in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly', window );">Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForTransferOfManufacturingTechnology', window );">Milestone funding for transfer of manufacturing technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingForRegulatoryApproval', window );">Milestone funding upon regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_RelatedPartyDeferredRevenueReclassified', window );">Deferred revenue - related party included in contract price of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_VariableConsiderationForServices', window );">Variable consideration for services included in contract price of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContractPriceOfLicenseAgreement', window );">Contract price of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_OffsettingCreditForTransitionServices', window );">Offsetting credit for transition services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PerformanceObligationForProcessPerformanceQualificationServices', window );">Performance obligation for process performance qualification services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct', window );">Performance obligation for commercial supply of RPGR product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PerformanceObligationForManufacturingTechnologyTransfer', window );">Performance obligation for manufacturing technology transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_PerformanceObligationForSaleOfNonfinancialAssets', window );">Performance obligation for sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices', window );">Milestone funding allocated to process performance qualification services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct', window );">Milestone funding allocated to commercial supply of RPGR product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer', window );">Milestone funding allocated to manufacturing technology transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets', window );">Milestone funding allocated to sale of nonfinancial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals Inc | Asset Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContingentFundingAvailable', window );">Contingent Funding Available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AgreementTerminationPeriodDaysWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Days of written notice needed in order to terminate the asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AgreementTerminationPeriodDaysWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AssetPurchaseAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AssetPurchaseAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AssetPurchaseAgreementFundingReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AssetPurchaseAgreementFundingReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContingentFundingAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContingentFundingAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContractPriceOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total contract price of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContractPriceOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_DeferredRevenueRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_DeferredRevenueRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_GainLossOnSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on the sale of non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_GainLossOnSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_InitialAgreementPeriodDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial duration period of the asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_InitialAgreementPeriodDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received and allocated to performance obligation for commercial supply of RPGR product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received and allocated to performance obligation for manufacturing technology transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received and allocated to performance obligation for sale of nonfinancial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForDevelopmentOfDrugProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForDevelopmentOfDrugProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForDevelopmentOfDrugSubstances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForDevelopmentOfDrugSubstances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForExtensionOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForExtensionOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingForTransferOfManufacturingTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingForTransferOfManufacturingTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_MilestoneFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_MilestoneFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_OffsettingCreditForTransitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offsetting credit for transition services in determining contract price under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_OffsettingCreditForTransitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement contract price allocated to performance obligation for commercial supply of RPGR product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PerformanceObligationForManufacturingTechnologyTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement contract price allocated to performance obligation for manufacturing technology transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PerformanceObligationForManufacturingTechnologyTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PerformanceObligationForProcessPerformanceQualificationServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PerformanceObligationForProcessPerformanceQualificationServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PerformanceObligationForSaleOfNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement contract price allocated to performance obligation for sale of nonfinancial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PerformanceObligationForSaleOfNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RelatedPartyDeferredRevenueReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related-party deferred revenue reclassified under provisions of new license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RelatedPartyDeferredRevenueReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ServiceRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ServiceRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_VariableConsiderationForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable consideration included in provisions of new license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_VariableConsiderationForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Performance Obligation (Details) - Asset Purchase Agreement - Janssen Pharmaceuticals Inc<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_RevenueUnsatisfiedPerformanceObligationAmount', window );">Deferred revenue, unsatisfied performance obligations</a></td>
<td class="nump">$ 63.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod', window );">Recognition period for deferred revenue, unsatisfied performance obligations</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RevenueUnsatisfiedPerformanceObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RevenueUnsatisfiedPerformanceObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Financing Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">79,418,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_PerceptiveAdvisorsLlcMember', window );">Perceptive Advisors, LLC | Notes Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership in outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_PerceptiveAdvisorsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_PerceptiveAdvisorsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mgtx_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Revenue Recognition (Details) - Janssen Pharmaceuticals Inc - Asset Purchase Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue at period-end</a></td>
<td class="nump">$ 63,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced', window );">Other amounts collected or invoiced</a></td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_DeferredRevenueRecognizedDuringPeriod', window );">Deferred revenue recognized as service revenue during the period</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate', window );">Effects of exchange rate changes</a></td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rates on customer contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments collected or invoiced, categorized as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_DeferredRevenueRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_DeferredRevenueRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">$ 1,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Consolidated Balance Sheets for Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_OperatingLeaseAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 6,348<span></span>
</td>
<td class="nump">$ 10,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Capitalized lease obligations</a></td>
<td class="nump">7,383<span></span>
</td>
<td class="nump">11,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_FinanceLeaseAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 22,728<span></span>
</td>
<td class="nump">$ 22,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">173 years 8 months 12 days<span></span>
</td>
<td class="text">173 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_FinanceLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_FinanceLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_OperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_OperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">8,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(1,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 7,383<span></span>
</td>
<td class="nump">$ 11,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease rent expenses</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_OperatingLeaseNumberNewLeasesRecognized', window );">New leases recognized during period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 7,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_LeaseMaturityTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_LeaseMaturityTerm', window );">Lease term</a></td>
<td class="text">191 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_LeaseMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Maturity Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_LeaseMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_OperatingLeaseNumberNewLeasesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number new leases recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_OperatingLeaseNumberNewLeasesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Financing (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,418,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,418,438<span></span>
</td>
<td class="nump">78,397,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Debt discount, allocated fair value of warrants</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt discount, capitalized issuance costs</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt | Exercise Price - Scenario I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SharesIssuedInConnectionWithFinancingAgreement', window );">Shares available through warrants</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt | Exercise Price - Scenario II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SharesIssuedInConnectionWithFinancingAgreement', window );">Shares available through warrants</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial face amount</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Unused borrowing capacity</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Term loan outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Interest rate at period-end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Increase in accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteedBenefitLiabilityNet', window );">Obligations secured by UK and Ireland subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SecuredCashAndBankAccounts', window );">Cash liquidity requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt | Term Loan | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember', window );">Perceptive Credit Holdings | Secured Debt | Term Loan | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_BasisSpreadOnVariableRateFloor', window );">Floor percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_SecuredOvernightFinancingRateAdjustmentTerm', window );">SOFR adjustment term</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_BasisSpreadOnVariableRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_BasisSpreadOnVariableRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SecuredCashAndBankAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity requirement for minimum amount of cash and bank accounts to be maintained and secured under the financing agreement with Perceptive Credit Holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SecuredCashAndBankAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SecuredOvernightFinancingRateAdjustmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SecuredOvernightFinancingRateAdjustmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_SharesIssuedInConnectionWithFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares available for purchase in connection with the financing agreement with Perceptive Credit Holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_SharesIssuedInConnectionWithFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteedBenefitLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the amount of expected guaranteed benefits in excess of the projected account balances for minimum guaranteed benefit contracts, as of the balance sheet date, net of reinsurance recoverables, for all guaranteed benefit types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480109/944-80-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteedBenefitLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=mgtx_ExercisePriceScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=mgtx_ExercisePriceScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=mgtx_ExercisePriceScenarioBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=mgtx_ExercisePriceScenarioBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mgtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mgtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgtx_NumberOfNewMaterialCommitments', window );">Number of new material commitments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NumberOfNewMaterialCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new material commitments entered into during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NumberOfNewMaterialCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "=!K5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "=!K5J L<0X\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=ZZ:1D249<+B!-(2$P"<8L2
M;XO6_%%BU.[M:<O6@> !.,;^Y?-GR:V.0H>$SRE$3&0Q7PVN\UGHN&9[HB@
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( "=!K5I4D5XI"P8   0@   8
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M;_EA0H[T%V9Q4?Z/7@^V5@^%VT)DR6$P*$BB=/^7O1T6HC$ VQT#R&$ ^>P
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M'X YE;-E 32! F1B!<*J;2@'#0 ^B0;> 4R+5> 38H<95S!C)\Q'H2&9HK%
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MUB(O;I>,)DP: _@^%T*_/I@!JL/.T2]02P,$%     @ )T&M6KHC4'2 !@
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MK:P$2:="UKJ1V,EZ-S(S:?-&8JCJWN!6Z6.UU(?IWV!1\)YNX*@C&ET,H%T
M4#0?"JW+;=LPP.J.P9B=&E);+T#17% T#Q3-QV)?1;F?MQT"K&X1G-S/CVM1
MOC&9PBI&^Q4H:F7+HH;9%QH2NRFUL--?Q21FEL;C$]Y^1$/3LLFI1:Q5Z5@M
MTX>W\^&LB<+<LJEC45M8OD"%.2B:!XKF0Z%U66W%.5:K\U=UH=68HQ<R4= 2
M3+5^F8 *<E T?V@&76Y:38[5HOS7FM%8E*:Z89F6TR\U4 D.BN:!HOE0:-W_
M=K::GJ@U/5A#6CW.V/(CHEK6=;NWJ[B@8WJ@:/[0#+I\M6J?J-4^?%^:B%+;
M,"D52E(=V-B2!$7S0-%\*+0NQ4<G$-0M"I#>M'J,T>4HMCRF6*A&T.8$*)H_
M,($N4VW/@:A[#F,:U&JHT82 GH4@LIX%U:W>VS[HH/[@H%U2VKX&4?<U1FA?
M-=)H3D"[&Z!H'A';-%/J.+9P5&C0KLM*VY$@ZH[$B[K4AI0D8U#52DPL6\."
MJI7830W-['>I96:63C2MWZ66A48UY\1Q#]*V ,AK6@"GFM3RK$F$OJ-C6Z=V
M/WF0_XMW0=$\4#0?"NW ZNSH;&EYUIA3\A E.8K9FL-K[RR>^^QP?/=P4Z2[
MZKCIU[0HTFUUN6'!BF6E ?]]G:;%\TUY@K4Y1#W_'U!+ P04    "  G0:U:
MK6_.9, (  "#*0  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+5:85/C
M.!+]*ZK<UA54P<26;"?A@"HF,+M4[0 U86\_"ULANG6LK*0$N%]_+=N)$EL6
M@<M\ =MIM5^KI7Y/DL]?A/Q+S1C3Z'6>%^JB-]-Z<=;OJW3&YE1]$0M6P"]3
M(>=4PZU\[JN%9#0K&\WS/@Z"I#^GO.A=GI?/'N3EN5CJG!?L02*UG,^I?/O*
M<O%RT0M[ZP<_^/-,FP?]R_,%?683IO]8/$BXZV^\9'S."L5%@22;7O2NPK-Q
M-#0-2HM_<_:BMJZ1">5)B+_,S6UVT0L,(I:S5!L7%/ZMV)CEN?$$./ZNG?8V
M[S0-MZ_7WK^5P4,P3U2QL<C_Y)F>7?2&/92Q*5WF^H=X^8W5 <7&7RIR5?Y%
M+Y7M (S3I=)B7C<&!'->5/_I:]T16PW C[L!KAO@9H.HHP&I&Y RT I9&=8U
MU?3R7(H7)(TU>#,79=^4K2$:7I@T3K2$7SFTTY?C^[OKF[O)S36"J\G][[?7
M5X]P,WF$?]]O[AXGZ/X;&E]-?D/??K__<X).T1^3:W3TRS'Z!?$"/<[$4M$B
M4^=]#6B,SWY:O_EK]6;<\6:"OHM"SQ2Z*3*6[;;O0Q2;4/ ZE*_8Z_ [E5\0
M"4\0#G#LP#/>OWGD@4,V/4M*?Z2K9ZF:H2E,$X6F4LP1S#Q)-2^>JZ'+-6?J
MS-5ME=O([=9,ZS.UH"F[Z,&\54RN6._RG_\(D^!?KI@/Y&RG!Z)-#T0^[Y=W
M4(5RH9QCHVJ9E"U-J5E=GI+1:!B>]U?;\!UF.(@BO#'; 19O@,7>U%QE_X&9
M!<5(*Z0%5*-4%"G/&2IJQ.:IN4Y-#I>*96:L[YW ^) )/)"SG7Y*-OV4>!,X
MF5')3DV5S% JYD =BI;%E[V::^8*OO(8;V4L&@X'C;2VC9)1$KB3.MB '7C!
M0E6'FEU T922%>D;.GH&%CON'(&#%H93DK20MJUB$KN!#C= AUZ@UPQ2E?*J
M)Z%V(CH74O/_E@]<2(<M#"1HS12'$1YT(!UMD([>G<#IC!;/S(Q_:1CQ5$Q/
M84(@JA2#V6/@YYP^\;R<#B[THQ:P01-[VP12X88>!I;8 B_X7ZF9LP723 )O
M5KTMIBAG,)S?PUR[WD$4DB1NX/8C^.3D#+>H.]PKPHRKA5 T-^&QOY=\82K;
M"9HN9<'U4K(R2U/^:J[=X8:.<#%N1NM%\]EHL8T6>Z.]VIHE)E)>0&:9TJ8'
MRM$(=5QSR4SP2#SE_+DT=0>,VP6(-,-MVT3#CD%I-4'H)=Q6$!E[TB9_J5@6
MVHF4M%#@0=2$ZC(B'5@M>X=^^EX/+QA9S& M1#&%B01,"4.MFO].Q%ZO'Z6_
MVMO.T,2C(.S*A)4 H5\#'-T6J32UX!B24%TU2+Z,T$GPX4$9_E#>=CO"<GSH
M)_FKM!Q\RL@@QE?T";)]"C<YU4#["RKUF[,/VAQ^&HV: ]-A!,"[AJ:E^M#/
M]6-8.4A086L:V@=OF\D'09.(_*_];"JL, C]RN"V6$'Q$M(=0)OA00NWJI;W
M#9^-P J&T*\8'B1;4)ZM!:*[0#@403.*MDE,.O0AMHH ^Q7!(WV%*9Y"%_,5
MVQKN+I"XK0"B8=P<+_X7?K*WL14 V"\ [O6,R5KP:D])QFU^#Q,R; ;3MDIP
MAPS#EK:QG[8KC!6V$[.H<@+T^OAH0<4N=N]8,F)+W=B_GE_S!3I:\\7Q+F%L
M:4HG:^"#+NP/Y6VW-ZPXP'YQL&&-!7WKG$,.[B9!TII$;;,X''40/+8$C[V\
M:1#*)?.7HMK%+L)XV-3Y+C,<81)V8+3<B_W<NSN!WUF48!>9-AG7840&'3 M
MW6(_W5ZS*0.(&=1,(*CE7OH N];7N 6W;86#J&O=BBV38C^3WNVS>>.$[6!9
MD@QQJU@Z[091UY"P#(I'']HVY* )U#Z[3MC+S!\N+P?RMKMU:JF:^*GZ82G3
MF2FVL.Y82),\_7:"%CDU/ >KV<TRU[F!ZEJ]#\*@D4*G63+H*#S$LC+QL_*#
M%"EC69V_#ZZ>_+X_O/O;IG3/XHE84B=^4M],KZ-Z?AV;+*UX!C=/;\XQZPRV
M3=3.1+7-8'D;=>A!LK5!_[$=^CH_>^S0'W:+_F<P.;%,3OQ,?O/*9,JKJ:;,
MAB_4RLZ-$]+FZN9FA/]UGPW'TC[QT_X#?:LV]B&<%ZYG,Y%GD%)5[F28\%3U
MF.49F@II%@1BSI"FKQUCU,7]@Y:(<9IAW$$'Q"H$XE<(N\6$*[6$(5KF2DB(
MB\JW.BHG=L=F?#1L[NLYK,)XV"'\B14-Q"\:;M=84Z$@'<#!J2B*^O36I&"O
M"!PJ(FP%X#!*NG;IB=409$\-L5W:;,%S50MG"&VE #6NN6YW6$&@@ZX:9^4$
M>7\+?WM_RP1T4H5E.'0%[%34^_AF,U7RU*@Z\[LS%N=._1 W!;/++@R20<=T
MB*PNB/RZX&8ZA1%4;G2_UB<3(.M8?4I13O+_+\+((0HP:6;+886''3([LL(A
M\@N'\=[($=7HB3WSHC#C#WH#UA$(1!(7F3,HQ_H_B).D*6I==K!@V]K6VXW,
MZH7(KQ<^%AF#Q^_'Y%CD#Y.6=G"8A3C 24=UB*QXB/SB8;)<+/+RL 'TG-G!
MSX4R9RV5U#LM8]&2%HJ6%<\M)**#"HE#>=OMD:W3?K^0^,9?(8G540Q-(<V*
ME[4>&#9?9M4RC#:V#:KSSSU6ZE%;>"1AL^PXC,(X[E"[D944D5]2C#='H$;5
MSDV]@2Q_],PI:BN$,!XDS1!^QF% 9.5&Y)<;/^P9P,[J96ISJW82*O;<@HP<
M(J-%&WYPGPW>*I9H\-DIG:Z7"A!S]>T<I-D]I0]TA%#WR,\XD(BL!(K\$JA<
M(94;^I54KDY<G6%7CI(=1FR=J;JL1G'S.*B_]3G;G,GG\BL_A<K*47T.MGE:
M?4GX-3P;EQ_<-9Y?A6=7Y7=U?>NF^CSQ.Y7 G@KE; HN@R\#&)BR^N*ONM%B
M47XT]R2T%O/R<L9HQJ0Q@-^G0NCUC7G!YKO+R_\!4$L#!!0    ( "=!K5K2
M5,BO#14  "Q$   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULS5QK<]M&
MEOTK*(TW:U=1U,NO1+:K9#OV:&(G&LN>W:]-H$EV!*"1;H 2]]?ON;<?:("D
M'A.G:CXDEDCT[=OW<>ZKH5?7VES9I91M=E.5M7V]MVS;YJ># YLO927L5#>R
MQC=S;2K1XE>S.+"-D:+@155Y<'QX^/R@$JK>>_.*/[LP;U[IKBU5+2],9KNJ
M$F;]5I;Z^O7>T5[XX(M:+%OZX.#-JT8LY*5LOS47!K\=1"J%JF1ME:XS(^>O
M]\Z.?GK[E)[G!_ZEY+5-?L[H)#.MK^B7\^+UWB$Q)$N9MT1!X)^5?"?+D@B!
MC3\\S;VX)2U,?P[4/_#9<9:9L/*=+O]'%>WR]=[+O:R0<]&5[1=]_7?IS_.,
MZ.6ZM/S_[-H]>_+C7I9WMM657PP.*E6[?\6-ET.RX.7AC@7'?L$Q\^TV8B[?
MBU:\>67T=6;H:5"C'_BHO!K,J9J4<MD:?*NPKGWSFUF(6OV?<"*JB^RML,IF
M>IY=&&EEW?(WKPY:[$4K#G)/]ZVC>[R#[DGV6=?MTF8_UX4LANL/P&-D]#@P
M^O;X5H*?A9EF)T>3[/CP^-DM]$[BP4^8WLEW/[BC^W0[77*BGVPC<OEZKR%"
M9B7WWOSPMZ/GAZ>W</TT<OWT-NI_@NO;Z1Y-L_N1SKXN9?9.5XVHU]EGJ8SX
M^/4F^[LN"U4O;-:4.:^UW<RJ0@FCI,T>MUCSP]]>'A\?GOJE_-O1::9-^()I
M14+^^R<34,ODC:R:5A99[O=5=:Y-HXV@#SL8F,EHBU)<,[_T\SNQKK#TW)9@
MQTXRG$1D*VE:E8NR)!*M7#"!299#&O3QOFV!0]E"UA*/994L5 XYV;COM6J7
M(#,S6A19HQI)8J0=2Q#RJP.QK#$:&U2T=YV7'1TKNQ#F2M56U_]MLT)9"3B9
M9$9 4"3;?54778XCW4BCR?.58&&>G5]\.MH7UNI<\9$-^*NQ1;&VK='-<CWM
M5;&Q?]99F;7"+"0M+35]5X!S"&--O-L* LD*;24+;_/TK<Y:X'V;S32.K^JE
M-(I($6N5-I+$4\$R<ET7BLYAG:"LQ!82^JD06VHIBRD;C^WR7%H[[XB-%:)"
M XQO@]YZ]H-XH3G;-= V[3E;.^WV5G3TXM2R-@U)1-;%?JOW);$FZFX.T.\,
M23X7C9BI$OQ).QT8\5+@B-<Z6T& )4PD;V&4$!Y4P08/&GY=AAB8+;0>TVX,
MQ9:<+-T;\\?/%[T%1^::4MA*%0/BH(B'8>80&D(3_0NS5?7^4I/>_MD)[+T&
MLS4T76;+;L9K8&M\FC5KP2#(L2F1)N>JY4?.?WT/61G=+9:L(6E@/27+LH3!
MG,/)"Z>O22I3EH=7#"F9N&W@QK"@]?C<,'M*"YRZP0+;^%K)TAG''YYY81M(
MU?)G"2>&%\ 4!OJ(.LW9M!*U02I#)3$]T0!H,MVTJHK@52+5(*\S)!7(6[>R
MSM<3'"M\1.;N@$HM:C6'Q=4M4,%(YX YW(^= <IV:E?@?\,U-@TI%5QK1&U=
MV@1GX]788-&5CLLHO<Z2V&;2-OH*[K%&V.1MC)II"]'FRZR5^;+6I5X0<*W@
M+M@@VDB[A&_RF1VKI$R$GER11=!!]PW11AX%+N0-125.J7 ^8IO99.9Z),V]
MN>$130)W&%%IY%)=.3ZWHFUS=PI:G/ =SZAKI[V5)HC7V"[[2ON*W '&;W6&
M (\5/[H /X@9EZ0C$$>"(WNW2FV6-$D:$O,YC 6/V8R$9%A,P"\!AR&P7T"L
MR)A*,:/@04)@TPTL?8(-<40060TXSN&0T):)^%^Z[PF%[%(8-LDD$N&$'SNX
MNI7KB 2>=!K/QJQ.X_X<I((?!5,RI(4*2:;:KW0!99"NC+.ILW.('FIS9\'7
MLF00AY67^TB'X8@14/&08/N(GP0[9IX:'*A"VM*U[FG3+5)\GF9GB.["1*#>
M(=!-O83#+0697ZH5>O(#0I2DQ#T[6Q@I:2O *'O2'*Q!UE0W0&Y-9VP'+Z5P
M=+U4Y!2W&\"U*@EC<DF"FAM=14X L%V#3T L%Q96BES!AZ!'*&:09I<ER3.U
MP6]^P85[-NB3#)OY*+4-)KJ5_502S!E@=:4*&4$8,I]#DT0$?'0-G5/4Z=>/
MCD]ZWK#%O#/8VF KF\/GPF;_IJ9*JX.TBNSXV>'D$))XAXAEL[-@[2 89=BR
MDU2<AR ^Y'*:?7 ,44ZP&5+H=T)I$EC<:>LYGQT^?/-,S;,<V1VJT%Z,LU(M
MA,,7UD@0$WB4> Y40:3-*#V!1WOB#MMRKT\OPC;%*@)')*2E2!*2[6:<YKV)
M@43C@;\#CQ',0 ABT'G>&4(1UIJD? H&6B*9 08AF"(#8C @@)Q0BOT[EM)"
M5R=2@ Y\D[D%.?1Y69J*,E*3%IHD]Y("!Z5$AM:+AFP4AD$_E4"%62DS[[:4
M%&@*I /)] $$.(-ZN$:2:XA'"EJV92=+D_1O-</I+^"G@'_2IGQT*,W.'5&J
M$*X%):NT**A8L^&'P_8'G&:_RL[H;>J@$$/$TV RL-))GT,[(M]^20,"S&Q%
MSGW_6/!SO2A9CO0?, O.M][7UX0*L3Q:QWK%DWV<ED,I+WT$"5[@OD$(^(YA
MR_';PVCJ=:.0YO8?!C;_U62,\W#8H+IMJDD=9:<"^YTV0L%D&PS?I=R-C\XG
MV:=/[TB*[R6LE. A2 ZR\.EVG@2</ZW4RPVECK6;AHVH[^]JF ]1]L ,0;PL
MG:)#DO5ND%H1^4_ 9AC6#ET'XL-U&QJ/62WU(2A+G*29R22I2N2HQ@@5P5 ?
ML<1XK)YD9V?_VO]X]MY#E \8/LNB148TZ\@ U\$A5XC%?*072WHB^O;]KQ_^
M#:JAR- H",C@0%,;P*K#9 =\7-"T5$-Q.8_"Q1?TT._V^IW0'4LHET?RN$+=
M@$+#(HR-@I3/#"]\[R!J@/9^K""NM!J$$BCT(K "4UT(D_,YQR3JQFQT&L3P
M^+X,[G/!'1QRI8<PBX@#IIHE"8?:RK.\:T4MZ4G$"]M)2H"YEG,Z=Y  P_"5
M'MAI)L3'LH/%6$=7513@4B&\#QR_Y^.E=7PF!?+.G%5,"40.ORHH8+HR@G6)
M_"=4NK$=XLWO#G.?AA U1+$^J-ZQ?A/C+H=),-%(0CFU5!+G&&6X=,"<BL9"
M^HVX^X%PWW+ZH.]$*H)8T3?DT@S9MPA#_L+FXI&"=W#P=?<&V4SD5T1A"[K+
M&Z0Z5/-.,JZ$KG&226;T6I3M>G\.H4V0(I'S-$(5^\A$/0OL,3'3V(X<U-,I
M:;+0N4X;RC3XJJ$1@/U^<#5VQY@AC6QTA^4\%D^VY#0#D]B=8[OGC6Q<\Y>3
MRNSD\+\R"G;&+E43V&3?*QP)ZL>H5I0;E";;[<GGDBL5.A+4,.=6VKT,C.R+
MFDOP>A?:[N4F?1(<=S.2NC+.KHG&EL[DO;7AE#K(5#E+9C"(6[J$Z?'L2>0W
M)F%;-/3VOAIZ\;TUA.(XE OWQXXM'GDY['&RU:LV/+VE&D[X=%7BH/[%[U3?
M_&EEH5J.6Y;KR;!&#YBT88O4:ACT1;>W9S9[,X\_??YL$4L@V)):\GT/QCTP
M3&Y%Y$#$_*GJ"'. 6OS1H"9#@<C=[;.MH#M.+5W^-@/B:LBC=I KLID6IJ#U
MKG33QHT_C*)JC\EBV][J^*#6YP!B!-PL\VM]Q]-;L#OUH K/&<IU9M1BE):6
MYXP7KE$4VB"R[BH9<UPZ_<Y2XDEPL3\Z'#+8-A>[G*>TU(2SK7,F)\E>&OB-
MFYD::3-W/32U7H./;(2Y6_.$^R4&DU2]7F^U7.B6DW9LP#.)N>#I%+9,<O+8
MZQOUWMT4H#<KNZW!MAD['CLQD*,P>+OI0M)T\XD9M8\%B^N)YW<<]#P#/OM.
M,N:_),N=9I\'DXM[]P>B"(;K_P/Z @.&^B0U?O\?P*)GX;NW".[499@N8S_X
M#K9C>XJ^MQ,7G*/Y7;:U]![:@P@(@%QT*>J%C#G/O4/I*"*)W$&6H+L@VE"!
MR.-%%)FTSW;K<$-TN%*[=H)F4@'5M^:W\U+>*.(N5$[,:C)=W73 X6PP@/7$
M8PE-<74I:<;6U0/4'VJ3]AL;$!DPR4UOR'<ZD@XUL1E\U*PCZ8^%*^JZ2QKM
M:9HR8&-W#-W!]E\83#>D<;^H&OWL^\32.WWN.\=40\H#K]K)"7GCBG(DOE(T
MWQEQ>V]9ND%Z4@0J8^1*.Y_K!Q'P8[BF'62>$11W&BG-'_JZ@R<0U)#GH91H
M$P;E#05<RZTU_M[MW//I# ?0FCWM!;,K7]_!CE>16$ 7"_:*<_>)7'%Z32R%
M_0J-D]'4(W)&N6S@*F[P</&599PWQ4IE![]+NB"0I(D!%"V,RH]S!CQ3?>YN
M/9 $'?EI=MF+LW<_?RKAH&O=*E"<R86J.:9[A&Z7RI ;U91,V#22C:%;>IQ@
M-UVCF&=3-5+,X4<$$E8"J:,,L.*+='.A9 S$<><?>DFMPNP'436G\;?SNH:#
M<*WP.10"R$/^ 7$16R>'- T_^G$X31M-MM\-AWJ_-;<T7Q_(RF.:W4L#T+ZJ
MR41A%& -AZZSB\&X&#!_7N?3)]FWV*P:R2:)L???GQ4_F%+R@,-( G#6\<XY
M[O-GT[Y8A(.\1SE=S<#;\>'QR;CH&]1<FZVIK3T].AW$PS>BOMN!.1_G1BK.
M,CCYO./4F8(;+))..2S5!S/C  0LB9-GA[THN AW\&1_XOXW91(ET@?-\NX%
MF*[RG8':WZ2-B93(EPH8DQ;>*#=:->ABR9O6W^&U;5?T7>\+%M-)]NG;YY]_
MN^PKE98#5'CJR\7'+U3$4Z?XU+6@'QVEK'4-7SVKFE*&74.TZQ$Z[1#$GD_8
M@J\Z4%K;<HFV<V?:^MGWWSFTP7?MNZ(3O]C8F'O;RMAV4-:)4KI[/0,RP43]
MO/6RI5H-M(GTGZ<<0[MVER$W)[L32AAJBI$?X4H\CKML2$[D4^<(;FMBAN1[
M?(> XS!^/AP(#Y//Y+H4276D8-IT*'FZ')(Z&]SHWCY[ZOIXJQV6Z2]\::#Y
M(!VZ_P;[[@J['-\Z]/<2UW$N,12]4S(S]W-'#6IH#E_YKEZBV;0R]R12#4^S
M]VX_ .?382"*UT4>/1^!Q0:D6"?D>Q]Z^@#0I%M3[O:*N^5&<6'NAT:^W4]]
MB9XG4>F.6.(D8R8A"^;3I3;UA@22"<RW=Y_>NN\V8NOTEOO2U !BD87;"K24
MHPEJ(E5PPC!7-:R378TTYX3&=Z9FDG(@9/O"17U:1X&9=.]N)(-\YQK R)Y
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MV=9?'*OI-#S(Z8PK&_MGGV1(IE!_4Y9/=:\IG(M4XDH^F!^^Q*:LOS@Z10G
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M0@%CFT6AYVH9S5%P#:*K-/V7QM-FD>8&Q@.X<) L+^%6F=./I%KJ$NXM\LS
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MXJ QDTE=7,G4OT+:1*HVMG1&<>K/^A[(SH 6&L<](8Q:M%X7V,(\O%"VSNX
M4SA,["VHFE0,Y(<(U<DPE.*!1.B1EG4"=K$-4]]V"FVX=$U02X.9EH)VI$5G
M]P $+^[1<Y /\P#D)8#$6^01Q#LAK@V.$ H#8;FW(6@.P2TI+5Z=C=48JOM>
M5IS:=:]Y5@K#,F* ,F6L.^>K2V!*5^/@&$WTC]0"D\U)6$AS M[!J3,[DW-L
MZ3F7Z@3_?E6E8&ZO/-/E[/EB@@E@0#\;DUP+*>\ T5^L56NGV69!BV.E"^-9
MJ"5'8!9@DXDE0O00R*W5E'<FYVKF:,X>NFAM!ZX3GIRVGFP(\EXH#?H\RZ?
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M7FP2L!,LOR4I6;"U@?@TW2+% BF2X1C@[#@A0N4N@+@4-=HOH?'E)K2&&AG
MXBHT'JD!@ZX*-5U !\B'D8(JSM!4[TR7U)1RU2[2\GYB'/J,015LO0QYJ43A
MNXCIU39$!1_@9.A8[3U:-Z(KUN8R)X+E(#'>G.E?.<3OH6R;SL&4+JKEHRZC
ML2V$#CH7;%1]>#EDC4YCC4Q:2^@Y121'!#R4:,W^+X2TQH1N ^PK-0<M%.P.
MGHOHG4Y!)J"^?<^U*.8"73Y\RGM[<EC>E[T$SI[ISS5OW=A2Y](\C^+,(1+
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M1)'!EABD@K("LH)2AUQR@(A4C,/&HLB, 1+ 2@E8P!.H&IDV*$%G&+#4"F(
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M14L*\EOT.#XTQ=BZ;2+)XW(D-I<M $6NS#+KX\[_QG3CR\"Z=!OS_:&*&=$
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M10\YWO,S7_VA-'-^;7EL2OB?_YPI"=_0 ?P^,= X?" &\3WV\W\#4$L#!!0
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MZ#R1Z4F%18NATNW>E\0/IYU5,/7K^DH/*^JR(,/-3EYM;_:":=191>&$W&>
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MK)8#2J%J,EY9(QSM+V?;U>LW9WP^'OA5T<&/?@OV9&?M)UY\*"YG&1M$FO+
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M6G".&\S.!]BOI-;W#P?A1YV.05>AN =@Z9^R:LXX_T6O8(-RF(:&UA4@Q\C
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MFR$L2>_?P]/AZ\4VO;0_'$^?/J"V1-=!NO<0S18O7\R$2Y\3TB+8)K["[VQ
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M:-(;FV,@NQ>CZVC1N%MZ*[2Y\UVS,H\L2+O S!="Z$/';N"?[>P/4$L#!!0
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M599"F#%9+$U2&,!*71:(2-E=M,&KS&T&,'"-8C1-@'8*G-O6BTUC&*20"'-
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M,M:]\S4E,.7N<7 ,K89'&E':]B0LI+DPPL.I"S>3]ZKI.9_WK:U:U3G8^JO
M=(;=;LRV 0SHY&/&;R%E-R#ZR[7J[#3;+&AQK'1I PMUY C, FPR=42([@GY
MU)J2\.39G7J:DQ!R=SMPG?#DK/-D2Y /0FG1X5H^!N9L'Y@G3P:S^V0+S'8$
MX6A/!($&9=BJ/F[#_<*C>1K<UB:U9=9MJA,0@_5X7])A>TK<!.78$<HQ9\TH
M#@N(N&PYJ!&'.QG;ME5)1SOM]&3]>\._N)2K9:)@GAWK!Z@( "T.$5'@:ZF6
M^O7L!=8V%]/>:77?W"_4>U1+3S;*#BVTMK)L$(F4E:_$5.R/UW@2[U BJF9$
M*/C(I*[O,LH)-BQ(]!\^25ES8O6G/?[6>!0.=(X>J6:DXE0\?8CT.726[_-'
M:?"VPLB0#YB#9;\E1ET;=+UAC5(JVPJ?,@+E:4LEQ>O2U#MR2?U57_"0Q$4U
M492!8OP8OT&L>R)U]>=9$YP(FF2K7/W*HM14>1ML#9+ _1,V"2F<9* L&59'
MX<LQ-[M*\X)*M#C\ X8UYI^0//&4@Z(<H5!="/R0>L>BZTJ'3!R? Z98FECS
MHG4?GR NS']DIS"A@*.L,:8$$\ ]4$0H$<E'D9(<MTU13+<JP><[3GY!,Z-5
M?XPF>DFU\6R7H6U @3=DB2V&QG98<]J_S2W^10'C"F?<00KVQUWMC%,>R.JN
M6$N2/L%T0?K2VSF8ZPP3IP@06 ##8O%U[JJCXRU%J8-,PEL$6)@WHG4E'UO"
M6"\8[L33G<3!<"FX]\_[,2$E6"O=J&N-T=ZB3UJZJ_CQST;5>+)-2EQ:2T]M
MYQ08'X"A9>FP?0-(Z=FE"D%JKMWYS/B6JY%B"1. BNT],>DEQP!VO\A>XW)"
M[OVFR2$AT;QA#+N9?(H,=E=JWJG"2V8YQD("+%+?=7G>+\9Z;G)89<;Q9T%@
M00M@/J0)+-\['9V&@Q,5UO*!]/K.Q*_[NJPX.4&.SYY!!VR1L%A.IJ+GZ80'
M39K[I(3DN:T[1Q7)X![ID$K5:7P*1C+JUA%D5!39U9119-XY!:S^.(S)=AH>
M<.E,#3L<<Y);8!EIIG@B(5]QD'UU.SENME([^R+1QXZC'AK,=& /G;/OL':9
MZ/;3 ]*JS9GX)KS:9(.X6)=8'YZZ.TZ 8LW"52-TGO&9D8&)(S()D]/QKN-
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MFTH99W!9IP!BK%\=MH$)XL660&S%(5Q-P%J0[7-4"KX2N/@!><[A$B(@V:R
M P171,'A[YI?DW0GL_?'/2L)(C2;?3Q>S_ZX<GKSOA4'[H!"0HBU>M?%FQ?G
M'IINVC-O[Y,AVCL1A%N]\\7L<N ,/TAZH^!_D=U43#RM<BQ01B748$0.4?"#
M/H7$ YBR:HE3!0$6 -7;%UG>P-%.;'FA#==YDOZ\Z31H '4KD.!._;65TXW#
M@5$_22#25X)G9&5P9W"V4P6^VR?B)<X=(;ZEQM#M*]%SH\8(^D7".+V&?Z9K
M05Z:TJ>/I</0]?O9/? =]!M?PV48M("+\FG;>\D8OZX%?$TRFE*C,EHL*B'K
M\FIOK(4!E*PF_QSKQSQ]^RYT%!E6/H"^<Q'9.G$2ZCQ3@NYHO=&X?+<JZ;N7
M'?<5X5EN%#1/"+P7U_KL>%;@]IW0CR !)8T9FAR!J"*%1(,>ZPSX @0F*,/G
MS>8V\VPKFT,O@1SM],UVZ-K@7J#56?9G)57]#,@U'E+.4IIKB6IF]C729OS-
M'EP<;,]O)43N2").VD2<[)V(7W&V.LX!?MGF,63Q%1Q7NWRY-JXS$P0/I>7Q
M,QXJ'6^3[7>^BGV X@B$FNM'IZZ:72OH@.0 198+%ZIF]>]@T0S*SY92;+E!
MT.WZ3H*>06@J"69ZUX _Z*<V?\"W'*BSXH%@#36 Y\,YT9V1T/(C;\C8T\Z+
M>$'$RKS[2V2>8NO'\7:T_6EA5K^H;Y?7OTN <N%2(U%.EK#5?AP%$R3JM_ZZ
MHWAIWM<77"E>F.::X(P(O0#FEYRK34<?T/[@<O8W4$L#!!0    ( "=!K5I.
M)#\YF@(  -H&   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;,55;4_;
M,!#^*Z? T"9539JTY:V-1!G3D$!4P-AG-[DV%HX=;(?2?[]SDH9V*M6V+_L2
M^^R[YY[SV4]&2Z6?389HX2T7THR]S-KBS/=-DF'.3%<5*&EGKG3.+)EZX9M"
M(TNKH%SX81 ,_9QQZ<6C:FVJXY$JK> 2IQI,F>=,KR8HU'+L];SUPCU?9-8M
M^/&H8 M\0/NCF&JR_!8EY3E*PY4$C?.Q=]$[F_2=?^7PQ'%I-N;@*IDI]>R,
MZW3L!8X0"DRL0V TO.(E"N& B,9+@^FU*5W@YGR-_JVJG6J9,8.72OSDJ<W&
MWHD'*<Y9*>R]6G['IIZ!PTN4,-47EK5OGYR3TEB5-\'$(.>R'ME;<PX; 2?!
M!P%A$Q!6O.M$%<NOS+)XI-42M/,F-#>I2JVBB1R7KBD/5M,NIS@;7[V4W*[@
M%FVF4F RA3N;H89K^8K&TNE; Y\?V4R@^3+R+65T<7[2H$]J]/ #] ANE;29
M@2N98KH=[Q/3EFZXICL)]P+>,MV%J->!, @'>_"BMORHPHO^O?Q=5=>@_=V@
M[AV=F8(E./;HH1C4K^C%1P>]87"^AW*_I=S?AQX_T+M,2X&@YH U_?R=OJKH
M\_WT]R<X.C@)@^@<_O=(O4ZRMME-2Q W>@./JP+A;BE1FXP7,$6=T#*)"5PR
MK5=<+N")B9),92Q,F.$&GC@)R@(EPLW-99ML^R)LI%@[$(-/K7$(@TXOBK;M
MX:"Y/+]A[@ +NJ<;:.NQUQGVACM6!T$ C\HR\2?]_NMC/H1AY[A_NF4/J9;&
MWG5C_0V]R5$O*E4UD*A2VEIZVM56N"]JO7IWKU6?FKS@TH# .84&W>.!![I6
MTMJPJJC4:Z8L:6$US>CG@]HYT/Y<*;LV7(+V=Q;_ E!+ P04    "  G0:U:
M-YR6Y/P"  !0!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RE55%/
MVS 0_BM60&B3(I(X:=I"6XD6T'A@JX!MSVYR:2P2N[,=VOW[G9.2!EHJI+TD
MOO/==]_=V>?16JIGG0,8LBD+H<=.;LSJPO-TDD/)]+E<@<"=3*J2&135TM,K
M!2RMG<K"H[X?>R7CPIF,:MU<34:R,@47,%=$5V7)U-\I%'(]=@+G5?' E[FQ
M"F\R6K$E/(+YN9HKE+P6)>4E",VE( JRL7,57$PC:U\;_.*PUITUL9DLI'RV
MPETZ=GQ+" I(C$5@^'N!&12%!4(:?[:83AO2.G;7K^BW=>Z8RX)IF,GB-T]-
M/G8&#DDA8U5A'N3Z&VSSZ5F\1!:Z_I)U8TN'#DDJ;62Y=48&)1?-GVVV=>@X
M#/P/'.C6@=:\FT URVMFV&2DY)HH:XUH=E&G6GLC.2YL4QZ-PEV.?F9RE22J
M@I3<;+#-&C3Y\L06!>BO(\\@O#7RDBW4M(&B'T"%Y%X*DVMR(U)(W_I[2*OE
M1E^Y3>E1P'NFSDD8N(3ZM'<$+VQS#6N\\).Y'DJQ08@.(]@;<J%7+(&Q@U=
M@WH!9W)V$L3^Y1%^4<LO.H8^><0;EU8%$)F1SW ]CG9V,J!^>$G^]X]=2/*Z
M#=>00+D 50OOS6R/ND)$9K*TW%ES^T1*%B @XT:W9J=DX 9TV)&#P V&?3)7
M,@-M+SXK2 :@]\)%;A"'>]K8#6E,'K S-6D;-(47G#PKG"-F1\\=]/H=B881
MN1,&L*6&(-DGQ03V@@3DNS0'@E,WIO[!@@7TDLRP$SQ!XD9Q_"92FT,0$0WV
MM*$[B".LN*@R'%>5XF+YSI^Z@1^U4N#V(A\++30.(6N\V["%Z)B%/I8%2V!+
M@MB\X(9C9F_!ASL7B@6ZY1L\@4QKZ-KLHML0/TR.!^)]'D&OPS':+]4IH:$[
MC*.NHN]&0:LX=)N\SI0K02WK66Y3J(1I!EZK;9^+JV9*[LR;MP;/])(+30K(
MT-4_[_<<HIKYW0A&KNJ9N9 &)W"]S/') V4-<#^3>#"V@@W0/J*3?U!+ P04
M    "  G0:U:5/RFU&D%  #$%@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6S56%ESVS80_BL8)<W8,S3%^TALS=C.T<PTK<='\M#I R2N)(Y)0@4@
M*?KW78 415H2+3M)T[Z(PK'?'M@+.%TR?B^F ))\S;-"G/6F4LY>]_MB-(6<
M"I/-H,"5,>,YE3CDD[Z8<:"))LJSOF-903^G:=$;G.JY*SXX97.9I05<<2+F
M>4[YZ@(RMCSKV;WUQ'4ZF4HUT1^<SN@$;D#>S:XXCOHU2I+F4(B4%83#^*QW
M;K^^L%U%H'=\3F$I&O^)4F7(V+T:?$S.>I:2"#(8205!\;. 2\@RA81R_%V!
M]FJ>BK#Y?XW^7BN/R@RI@$N6?4D3.3WK13V2P)C.,WG-EK]"I9"O\$8L$_J7
M+,N]8=PCH[F0+*^(48(\+<HO_5H9HD$067L(G(K T7*7C+24;ZFD@U/.EH2K
MW8BF_FA5-34*EQ;J5&XDQ]44Z>3@9DHYG%R@7@FY9#D>MJ#:7$>W=)B!.#[M
M2V2C-O='%>1%">GL@73))U;(J2#OB@22-GT?Q:ME=-8R7CB=@)\H-XEK&\2Q
M'+\#SZUU=C6>^U2=SSFGQ030Z209KDASWQ5=Z>GS)>4)^?,WA"0?)>3BKUT&
M*OE[N_FK0'LM9G0$9SV,) %\ ;W!JQ=V8+WIT,ZKM?.ZT <W&+C)/ /"QJ4&
MY(]9J9T*@%2N=@G<#?GJ1>18[AOR7_]^T3$(R<DS=IXO@&,:>C+/?737H')B
M6DP>1?A]G@^!J^-:S[S["GR4BFW02PPLCHEL3K-'8<M3%_7XBJ>C;<1;X#DY
M6@'EXGA#.I="TB)1TE-)WL((M(A5#'KUQLAP7,?PH[">>4ELQ_0W8]]T?:+A
MR0<,+C1Y2P3;>=,@?3CS\+NVRP;C*'"CXP:";X;N7G),XV-(FR(<.59DQ('5
MA+ #TXWW6[5M&DQ-HVF=FQIVL1S'B*.X;1<OVL+S33NJ[+,^,"BU5.FW@T5@
MQ'Y@!+;39A%M=GAF&#^ 7H!0ZJ/\R&6&A1$'DNGI#E;?I-7Y9,)A0B60%'TW
MQ7(^(@N:S75^8I5<K&E5H5;VB/*2.(;C;#.LH_$0;BT#/\;-"O<Z0T>R]NMD
M[1^<K#\6,S0#N5/^G188=1)CLTPA[VG*R>>U'LVL+G9E\VZ>S\VNVC0Z_*]3
M<7\RYJ"M#%QY#U<V/T&?LSS]L<-?,%PK%UNP# MLAK4'UX+F2H(5*0%TQU4*
M68*K5F-1ZMR$IJC2TPEQS4 AF':'Z8/:],'!IK]&%3 ]*J:E<>^*5)*CZYN[
MX\ZRV<WAWR]SVZ5D?WFJ-5Y/Z?Q,WJJ#?+A[8Y1-/6GXY,'UPC,<'P/8MQHA
M%IFQ_83:\+E,80\E/(H"+$16.Y.[9FCMR/J/,SDLR[N&&\5&V-(F-(.XPSG#
MVCG#IS5QN]I5%2B%@%V.V8W^O1WR=HJYX$1W_>0*>,J2JOEO6&Y'%L'65R^K
M<I3  F^(,]UCM]*O%[3&4>B3#U"@4V>:CB8J1:(O4W6[VW Q(L_>DM,S+*R/
MMTPBL=!6'6JKCII6W7#SC*C5V02J5>@XW*@^W*C3_._R6<96F#UO)!O=5XE\
MUREVPCSS&A'70L8_^9(4_P#M;&MS[[5^:(0] O^_";'8;;5S1N >%&!UIQ>'
M6W.V8?GNX6%F&[[;#O(@BKK.N/&V87<>PLZROK-CZ@9ZKC,Z&T&=GQQLE0#?
M6<'-BXO=^>3Q[='6#?^_B3;;L*W69=EP/.LI\8;=D^=MS;J&Y3J'1QPV+K[=
M&&-;%CJ[SKG?>%C,@4_T\ZE V'DARS?&>K9^HCTO'R8WV\OW733<!.]C)(,Q
MDEIFB)<47CZ9E@/)9OJ9<LBD9+G^.P6: %<;<'W,F%P/%(/ZX7KP#U!+ P04
M    "  G0:U::*=[V:0"   L!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6R556U/VS 0_BNG,"&0.I(F*7301J+ M'U JPK;/KO));&([<QV6MBO
MWSEILVZ43OO0^NWN>9Z[WETG:Z6?3(EHX5E4TDR]TMKZTO=-6J)@YDS5*.DE
M5UHP2T==^*;6R++6251^& 3GOF!<>LFDO9OK9*(:6W&)<PVF$8+IEQE6:CWU
MAM[V8L&+TKH+/YG4K, 'M%_KN::3WZ-D7* T7$G0F$^]Z^'E+';VK<$WCFNS
MLP<7R5*I)W?XG$V]P G""E/K$!@M*[S!JG) )./'!M/K*9WC[GZ+_K&-G6)9
M,H,WJOK.,UM.O;$'&>:LJ>Q"K3_A)IZ1PTM59=IO6'>V,3&FC;%*;)SI++CL
M5O:\R<..PSAXPR'<.(2M[HZH57G++$LF6JU!.VM"<YLVU-:;Q''I?I0'J^F5
MDY]-%E@QBQG,F;8O\*B9-*S-EX&31[:LT)Q.?$M$SMQ/-Z"S#C1\ S2">R5M
M:>!.9IC]Z>^3P%YEN%4Y"P\"WC-]!M%P &$0C@[@17W448L7_7?4^X+ML.+]
M6*YK+DW-4IQZU!8&]0J]Y/AH>!Y<'5 :]TKC0^C) W5AUE0(*H=;S%%KDKW
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M%[4#_X2#@-R(0F>*?"Q22/?MAPBF0>1O$5WXG0YOJ!R0P.L1W_5''?Z")L+
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MZ(P)_0;U^IQS^?) )]CLDWOU/U!+ P04    "  G0:U:M-[*G>@%  "]*
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M[1R3PHJ&^MD#BX9T)3)2P -#?)7GF/VZA8QN1I9K/3]X)/.%4 _L:+C$<YB
M^+I\8/+.KE&F)(>"$UH@!K.1=>->)VY?.6B+;P0V?.<:J:X\4?I=W7R:CBQ'
M1009I$)!8/FWAC%DF4*2<?RH0*VZ3>6X>_V,_D%W7G;F"7,8T^Q/,A6+D36P
MT!1F>)6)1[KY"%6' H67THSK7[2I;!T+I2LN:%XYRPAR4I3_^&=%Q(Z#VWO!
MP:L<O&,=_,K!/]:A5SGTCG4(*@?==;OLNR8NQ@)'0T8WB"EKB:8N-/O:6_)%
M"C50)H+)MT3ZB6A2#A!$9VA"Y@69D107 MVD*5T5@A1S]$ SDA+@"!=3] @I
M[+UFM)#7*<C1(SAZCVXX!U%:WQ'\1#(BE/<]8+YB,$58H ^8,/0-9RM 9S$(
M3#)^+CV_3F)T]NX<O4.D0%\6=,4E"!_:0O9316NG59]NRSYY+_3I'K-+Y+L7
MR'.\H,5]W.T>0UJ[]UK<X^-;;W-/CF_=;[K;4MM:8*\6V--X_@MX6ZXO_E,:
M.7&EP"O&E+#*ZC,M6/W@%G/"T5]WL@'T24#._VZ3IHRFUQZ-2GO7?(E3&%DR
MKW%@:["BWW]S0^>/-J%,@L4FP1)#8 U)_5I2OPL]&F.^T/*DZ@)^K,@:9VKV
MM>E10H4:2JT:ZR@, S6RUKM$'UJYCA\&5TVSN#.N4RDT!-:@L%=3V.ND\!&X
M8"054)+81EP)$.Q0XCF#_AYO;4;./FN=H9S*FB&P!FM!S5K0R=H7*G"F";LX
M&'MZ0+(FK2J/BP6@E!93N;=03VG!Y7HRQ<J$"_FGE@VU^FC[F=RWM([BX(#G
M<!"ZSIX:AU:N$X3A8$^/X'"PRV0;!DVSI,7,=\+>5MT&AV'-8=C)H<[':[WV
MY67>+1=.O>]Z3K5/.M7^@W:&Z?B%8=K9VJGYUB18;!(L,036D*Q?2]9_4TMH
MWZ2D)L%BDV")(;"&I(-:TL&1L_ "%;(<PTI6=)95DOXZ;]-E<,R*T&9TL")T
M!G<JCX; &CQ>U3Q>F<MF>M^2=&]7.IL[=>R;!(M-@B6&P!J:N<ZVYG/>5$*K
MPC&DJE&TV"A:8@JM*>Q.,>^:3VL5YF[*"OJ.M[^Y:C$;.%?^GEG<'>')?!I"
M:_*YK9W=SCHNNH,U9,B5N<OTMJV[X9.GA-%"V2A:8@JM*>&V5G;]MY7K3-;(
M8Z-HL5&TQ!1:4]AM!>]VE_"ORW5'5?6M5@>;N.[X3F;S_RCLW6UE[W:7]J_,
M=,=LZ;I;/GE&F$2+C:(EIM":&FZ_++CAVTIU1K\]&$6+C:(EIM":PFZ_/[B=
MM? K4UW_X/M5Z[;NT*QU6V>T]#>%5O)I[QQ_J=/->\SFI. H@YF$=R[[<EJR
M\L"PO!%TJ4_$GJ@0-->7"\!38,I OI]1*IYOU"%;?6P;_0M02P,$%     @
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M,J=O E16@)ZOI33'C770?&7,O@%02P,$%     @ )T&M6MI5'@G+ P  #A(
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MI7A1'JZ IB",@;Z_X%P]GY@$^^\QT_\ 4$L#!!0    ( "=!K5J=<$++4 ,
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M<@DD!JX'J-_GC,G=C9Z@.M&>_ ]02P,$%     @ )T&M6K"?;Y0_ P  # L
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MN^\3Z4U><NHR!"[(-#H>T[VM?>OE!U95=;LS5Y::I_JSH'85M=M ZPNE[,/
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M?X1G1E9MMYIHL;&M;BDT-DX[S/!7!:01P.\K(?1^8APT/S_Q;U!+ P04
M"  G0:U:OP\I>;$$  !*'0  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6S%65UOXC@4_2M6=K2:D3I-XGP0NH!$:7=WI*FV*M/=A]4^N,1 U"3.VJ:T
MJ_GQZS@A(2&X@#SBI4W"O<?WGGNP#O%@3>@S6V+,P6L2IVQH+#G/KDR3S98X
M0>R29#@5G\P)31 7MW1ALHQB%,JD)#:A9?EF@J+4& WDLWLZ&I 5CZ,4WU/
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MI?IR0DE$N2H WX\8DR\?5 .K-T'[_P%02P,$%     @ )T&M6HW9'L'% P
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M<VAE971S+W-H965T-#(N>&ULK51-;]LP#/TK@C<,*;!5CIUD0V8;:)(-ZZ%
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M%GQ[*Y_M$\FJYM8S]TQ*5C0/-Y0L*=<'J/=7C,GG)SK![H9*B[\ 4$L#!!0
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M$].AR7TN;-AOC:)93CBSN,&2&4QAQ91Y@,^*"<U<1#2<P UN4-1(_T3F@KM
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M.N#^>,=^Z;63EA4SN%#B)R]L-0L^!E!@R5IA[]3V*_9Z3AQ?KH3QO[#M:Z,
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M-[G9B[HVM9K2<&&G\<XH>LI)9Y(/2#70< 9W]()D58X@UW!=F4HAW'#!BZJ
MN@_<LD>:/J/A7F2HX*,49TLF4IH MB)9:_3Z"@WCN7Y#EO=W5_#ZU1MX!5S
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M'>CY6DKSU+ GE^ZDFGP'4$L#!!0    ( "=!K5HN&5_"I0,  !X1   9
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MEG_]N[B]I[4NFT,^Z_[)3SX!4$L! A0#%     @ )T&M6D;'34B5    S0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  G0:U:@+'$./(    K @  $0              @ '#    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  G0:U:F5R<(Q &  "<)P  $P
M    @ 'D 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "=!K5I4
MD5XI"P8   0@   8              " @24(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  G0:U:<'H(6 ,'  #0'   &
M    @(%F#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M)T&M6OD_I5>) @  / <  !@              ("!GQ4  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "=!K5K-&J]T. 4  /@4   8
M          " @5X8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  G0:U:NB-0=( &  !0+0  &               @(','0  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )T&M6JUOSF3 "   @RD
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M965T,3 N>&UL4$L! A0#%     @ )T&M6FU)TXKR"   5A\  !D
M     ("!V6X  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "=!K5HXJT][W08  -\1   9              "
M@;*3  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ )T&M
M6EOMREPO @  /P4  !D              ("!QIH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  G0:U:]Q0(;&P"  #(!@  &0
M        @($LG0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( "=!K5HS(XY18 (  ,('   9              " @<^?  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ )T&M6@2/'?$3)@  $X<
M !D              ("!9J(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  G0:U:OCI&02H'  !\&0  &0              @(&PR
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "=!K5I.)#\Y
MF@(  -H&   9              " @1'0  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ )T&M6C><EN3\ @  4 <  !D
M ("!XM(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  G
M0:U:5/RFU&D%  #$%@  &0              @($5U@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "=!K5IHIWO9I (  "P&   9
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M970R.2YX;6Q02P$"% ,4    "  G0:U:")<DN\4#  !Q#   &0
M    @(&C]P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M "=!K5K:51X)RP,   X2   9              " @9_[  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ )T&M6D.'$#6C!0  FQD  !D
M             ("!H?\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  G0:U:G7!"RU #  "<#0  &0              @(%[!0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "=!K5K_%"_0[@(
M &\*   9              " @0() 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ )T&M6HS@^F5J P  =PL  !D              ("!
M)PP! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  G0:U:
M&$\/GY8$  #=%@  &0              @('(#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( "=!K5JPGV^4/P,   P+   9
M      " @944 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ )T&M6A,Y-2'E @  " D  !D              ("!"Q@! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  G0:U:OP\I>;$$  !*'0
M&0              @($G&P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( "=!K5J1*.'/F@8  !4J   9              " @0\@ 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ )T&M6HW9'L'%
M P  *1$  !D              ("!X"8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  G0:U:BO\?P44"  "4!0  &0
M@('<*@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "=!
MK5H43&\5!@D  %Q)   9              " @5@M 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ )T&M6LYT%N)T @  =@4  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( "=!K5J&'FA_CP(   8&   9
M  " @?I& 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M)T&M6ING%Z(S P  M0H  !D              ("!P$D! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  G0:U:+AE?PJ4#   >$0  &0
M            @($J30$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( "=!K5J/R@R I@<  -E"   9              " @091 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ )T&M6E60"Y;L 0
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M2P$"% ,4    "  G0:U:?'[I&]0!  #&'P  &@              @ $+9 $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  G0:U:*F32
MILH!  ";'P  $P              @ $79@$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     /0 ] *(0   2: $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Equity Method and Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments</Role>
      <ShortName>Equity Method and Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureOrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Debt Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureDebtFinancing</Role>
      <ShortName>Debt Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Equity Method and Other Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables</Role>
      <ShortName>Equity Method and Other Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureLeases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940204 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940205 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940206 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Equity Method and Other Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails</Role>
      <ShortName>Equity Method and Other Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Share-Based Compensation - Summary of Company's Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Company's Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940503 - Disclosure - Share-Based Compensation - Summary of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940504 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940505 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureOrdinarySharesDetails</Role>
      <ShortName>Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureOrdinaryShares</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Related Party Transactions - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Related Party Transactions - Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Related Party Transactions - Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails</Role>
      <ShortName>Related Party Transactions - Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Related Party Transactions - Financing Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails</Role>
      <ShortName>Related Party Transactions - Financing Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Related Party Transactions - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails</Role>
      <ShortName>Related Party Transactions - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Leases - Schedule of Consolidated Balance Sheets for Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails</Role>
      <ShortName>Leases - Schedule of Consolidated Balance Sheets for Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Schedule of Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Debt Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureDebtFinancingDetails</Role>
      <ShortName>Debt Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureDebtFinancing</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mgtx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://meiragtx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mgtx-20250331.xsd</File>
    <File>mgtx-20250331_cal.xml</File>
    <File>mgtx-20250331_def.xml</File>
    <File>mgtx-20250331_lab.xml</File>
    <File>mgtx-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="mgtx-20250331x10q.htm">mgtx-20250331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="452">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mgtx-20250331x10q.htm": {
   "nsprefix": "mgtx",
   "nsuri": "http://meiragtx.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "mgtx-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mgtx-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgtx-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mgtx-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgtx-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mgtx-20250331x10q.htm"
     ]
    }
   },
   "keyStandard": 246,
   "keyCustom": 91,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 23,
   "hidden": {
    "total": 20,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 10,
    "http://meiragtx.com/20250331": 5
   },
   "contextCount": 129,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 598,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 452,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://meiragtx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "8",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "8",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "mgtx:ServiceRevenueFromRelatedParties",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation",
     "longName": "995210101 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments",
     "longName": "995210301 - Disclosure - Equity Method and Other Investments",
     "shortName": "Equity Method and Other Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://meiragtx.com/role/DisclosureAccruedExpenses",
     "longName": "995210401 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensation",
     "longName": "995210501 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://meiragtx.com/role/DisclosureOrdinaryShares",
     "longName": "995210601 - Disclosure - Ordinary Shares",
     "shortName": "Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://meiragtx.com/role/DisclosureIncomeTaxes",
     "longName": "995210701 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995210801 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://meiragtx.com/role/DisclosureLeases",
     "longName": "995210901 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://meiragtx.com/role/DisclosureDebtFinancing",
     "longName": "995211001 - Disclosure - Debt Financing",
     "shortName": "Debt Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://meiragtx.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211101 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables",
     "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables",
     "longName": "99930303 - Disclosure - Equity Method and Other Investments (Tables)",
     "shortName": "Equity Method and Other Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://meiragtx.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930403 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationTables",
     "longName": "99930503 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables",
     "longName": "99930803 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://meiragtx.com/role/DisclosureLeasesTables",
     "longName": "99930903 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
     "longName": "99940101 - Disclosure - Organization and Basis of Presentation (Details)",
     "shortName": "Organization and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA",
      "name": "mgtx:AssetPurchaseAgreementFundingReceived",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - IDA Ireland Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg",
      "name": "mgtx:FinancialAssistanceDurationFromCompletionOfCapitalInvestment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "mgtx:ScheduleOfIrelandGrantsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg",
      "name": "mgtx:FinancialAssistanceDurationFromCompletionOfCapitalInvestment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "mgtx:ScheduleOfIrelandGrantsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtv4RBfxkuuH4RrzAnNHw",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails",
     "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Asset Retirement Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ",
      "name": "us-gaap:AssetRetirementObligation",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg",
      "name": "us-gaap:AssetRetirementObligation",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock",
       "us-gaap:AssetRetirementObligationsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails",
     "longName": "99940204 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Anti-dilutive Securities Excluded from EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
     "longName": "99940205 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Net Loss for the Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "mgtx:ServiceRevenueFromRelatedParties",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "mgtx:SegmentGeneralAndAdministrativeExpenses",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails",
     "longName": "99940206 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Non-Current Assets by Geographical Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails",
     "longName": "99940301 - Disclosure - Equity Method and Other Investments - Summary of Investments (Details)",
     "shortName": "Equity Method and Other Investments - Summary of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:EquityMethodInvestmentQuotedMarketValue",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:EquityMethodInvestmentQuotedMarketValue",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "longName": "99940401 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails",
     "longName": "99940501 - Disclosure - Share-Based Compensation - Summary of Company's Share Option Activity (Details)",
     "shortName": "Share-Based Compensation - Summary of Company's Share Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
     "longName": "99940502 - Disclosure - Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)",
     "shortName": "Share-Based Compensation - Schedule of Grant Date Fair Values of the Share Options Granted Black-Scholes Valuation Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
     "longName": "99940503 - Disclosure - Share-Based Compensation - Summary of Restricted Share Units (Details)",
     "shortName": "Share-Based Compensation - Summary of Restricted Share Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
     "longName": "99940504 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "longName": "99940505 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
     "longName": "99940601 - Disclosure - Ordinary Shares (Details)",
     "shortName": "Ordinary Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://meiragtx.com/role/DisclosureIncomeTaxesDetails",
     "longName": "99940701 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
     "longName": "99940801 - Disclosure - Related Party Transactions - Collaboration and License Agreements (Details)",
     "shortName": "Related Party Transactions - Collaboration and License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2023_To_12_31_2023_Di1tUbrdG0CEvFGNkpUsfQ",
      "name": "mgtx:AssetPurchaseAgreementFundingReclassified",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
     "longName": "99940802 - Disclosure - Related Party Transactions - Performance Obligation (Details)",
     "shortName": "Related Party Transactions - Performance Obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw",
      "name": "mgtx:RevenueUnsatisfiedPerformanceObligationAmount",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw",
      "name": "mgtx:RevenueUnsatisfiedPerformanceObligationAmount",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
     "longName": "99940803 - Disclosure - Related Party Transactions - Financing Agreement (Details)",
     "shortName": "Related Party Transactions - Financing Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_19_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_FinancingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_PerceptiveAdvisorsLlcMember_oAxyTHASgU6LiyqF1ZUF5g",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails",
     "longName": "99940804 - Disclosure - Related Party Transactions - Revenue Recognition (Details)",
     "shortName": "Related Party Transactions - Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails",
     "longName": "99940901 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)",
     "shortName": "Leases - Schedule of Components of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails",
     "longName": "99940902 - Disclosure - Leases - Schedule of Consolidated Balance Sheets for Leases (Details)",
     "shortName": "Leases - Schedule of Consolidated Balance Sheets for Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mgtx:ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails",
     "longName": "99940903 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails",
     "longName": "99940904 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mgtx:ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mgtx:ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "99940905 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://meiragtx.com/role/DisclosureDebtFinancingDetails",
     "longName": "99941001 - Disclosure - Debt Financing (Details)",
     "shortName": "Debt Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2025_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_KaXdu7E4UU23VU_CUmILww",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941101 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "mgtx:NumberOfNewMaterialCommitments",
      "unitRef": "Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg",
      "name": "mgtx:NumberOfNewMaterialCommitments",
      "unitRef": "Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgtx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r52",
      "r838"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r655"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable - related party",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "mgtx_AccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Costs",
        "label": "Accrued Clinical Trial Costs",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AccruedConsultingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedConsultingExpenses",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Consulting Expenses",
        "label": "Accrued Consulting Expenses",
        "terseLabel": "Consulting"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AccruedExpensesIncurredInConnectionWithFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedExpensesIncurredInConnectionWithFixedAssets",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value of accrued expenses incurred in connection with fixed assets.",
        "label": "Accrued Expenses Incurred In Connection With Fixed Assets",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value of accrued expenses incurred in connection with rent and facility costs.",
        "label": "Accrued Expenses Incurred In Connection With Rent and Facility Costs",
        "terseLabel": "Rent and facilities costs"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedLiabilitiesAccruedCompensationAndBenefits",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities Accrued Compensation And Benefits",
        "label": "Accrued Liabilities Accrued Compensation And Benefits",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AccruedLiabilitiesAccruedManufacturingCostsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedLiabilitiesAccruedManufacturingCostsExpense",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities Accrued Manufacturing Costs Expense.",
        "label": "Accrued Liabilities Accrued Manufacturing Costs Expense",
        "terseLabel": "Manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "mgtx_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r62",
      "r117",
      "r488",
      "r508",
      "r509"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r15",
      "r373",
      "r376",
      "r434",
      "r504",
      "r505",
      "r774",
      "r775",
      "r776",
      "r783",
      "r784",
      "r785",
      "r787"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Capital in excess of par value",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r655",
      "r904"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r783",
      "r784",
      "r785",
      "r787",
      "r847",
      "r905"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "terseLabel": "Taxes withheld on issuance of share-based awards",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs in connection with ordinary shares",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r695",
      "r705",
      "r737"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r698",
      "r708",
      "r740"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "mgtx_AgreementTerminationPeriodDaysWrittenNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AgreementTerminationPeriodDaysWrittenNotice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Days of written notice needed in order to terminate the asset purchase agreement.",
        "label": "Agreement Termination Period Days Written Notice",
        "terseLabel": "Written days-notice to terminate agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r733",
      "r741",
      "r745",
      "r753"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r337"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r66",
      "r265",
      "r857"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from EPS",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Fixed asset acquisition included in accounts payable and accrued expenses",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ]
    },
    "mgtx_AssetPurchaseAgreementFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AssetPurchaseAgreementFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Asset Purchase Agreement Funding Received",
        "terseLabel": "Non-refundable upfront cash funding"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AssetPurchaseAgreementFundingReclassified": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AssetPurchaseAgreementFundingReclassified",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement.",
        "label": "Asset purchase agreement funding reclassified",
        "terseLabel": "Asset purchase agreement funding included in contract price of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement as defined by the Company.",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetRetirementObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligation",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation",
        "periodEndLabel": "Asset retirement obligations at end of period",
        "periodStartLabel": "Asset retirement obligations at beginning of period",
        "terseLabel": "Asset retirement obligations",
        "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r223"
     ]
    },
    "us-gaap_AssetRetirementObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetRetirementObligationAccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationAccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation, Accretion Expense",
        "terseLabel": "Amortization of interest on asset retirement obligations",
        "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r225"
     ]
    },
    "us-gaap_AssetRetirementObligationCashPaidToSettle": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationCashPaidToSettle",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation, Cash Paid to Settle",
        "terseLabel": "Decontamination costs related to ARO",
        "documentation": "Amount of cash paid during the period to settle an asset retirement obligation. Amounts paid to settle an asset retirement obligation are generally included in the operating section of the Statement of Cash Flows."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r222"
     ]
    },
    "us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes",
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_AssetRetirementObligationLiabilitiesSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationLiabilitiesSettled",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation, Liabilities Settled",
        "terseLabel": "ARO settled through early lease termination",
        "documentation": "Amount of asset retirement obligations settled, or otherwise disposed of, during the period. This may include asset retirement obligations transferred to third parties associated with the sale of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AssetRetirementObligationRevisionOfEstimate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationRevisionOfEstimate",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation, Revision of Estimate",
        "terseLabel": "Change in estimate of asset retirement obligations",
        "verboseLabel": "Change in estimate",
        "documentation": "Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "mgtx_AssetRetirementObligationsAmortizationOfInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AssetRetirementObligationsAmortizationOfInterest",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of interest on asset retirement obligation.",
        "label": "Asset Retirement Obligations, Amortization of Interest",
        "terseLabel": "Amortization of interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetRetirementObligationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationsPolicy",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Retirement Obligation [Policy Text Block]",
        "terseLabel": "Asset Retirement Obligations",
        "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r95",
      "r113",
      "r143",
      "r175",
      "r178",
      "r192",
      "r193",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r366",
      "r370",
      "r398",
      "r485",
      "r548",
      "r627",
      "r628",
      "r655",
      "r676",
      "r806",
      "r807",
      "r863"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121",
      "r143",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r366",
      "r370",
      "r398",
      "r655",
      "r806",
      "r807",
      "r863"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the information pertaining to the ATM offering.",
        "label": "At-the-market Offering",
        "terseLabel": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "mgtx_BankOfAmericaSecuritiesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "BankOfAmericaSecuritiesInc.Member",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to BofA Securities, Inc.",
        "label": "Bank of America Securities, Inc. [Member]",
        "terseLabel": "B of A Securities, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_BasisSpreadOnVariableRateFloor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "BasisSpreadOnVariableRateFloor",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Basis Spread on Variable Rate Floor",
        "terseLabel": "Floor percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r71",
      "r72"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r111",
      "r614"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r87"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows",
        "verboseLabel": "Cash, cash equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r68",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r68"
     ]
    },
    "mgtx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in measurement of lease liabilities [Abstract]",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClassBShareOwnershipPercentageOfHologenNeuro": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClassBShareOwnershipPercentageOfHologenNeuro",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership in company by share class.",
        "label": "Class B share ownership percentage of Hologen Neuro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r177",
      "r271",
      "r272",
      "r273",
      "r275",
      "r278",
      "r283",
      "r285",
      "r512",
      "r513",
      "r514",
      "r515",
      "r636",
      "r763",
      "r780"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "mgtx_ClassShareOwnershipPercentageOfHologenNeuro": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClassShareOwnershipPercentageOfHologenNeuro",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership in company by share class.",
        "label": "Class A share ownership percentage of Hologen Neuro"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClassSharesOfHologenReceivedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClassSharesOfHologenReceivedInTransaction",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period in connection with strategic agreement.",
        "label": "Class A shares of Hologen received in transaction"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClinicalProgramsDrugProduct1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClinicalProgramsDrugProduct1",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for clinical trials for Botaretigene Sparoparvovec drug substances.",
        "label": "Clinical Programs Drug Product 1",
        "terseLabel": "Botaretigene Sparoparvovec"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClinicalProgramsDrugProduct2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClinicalProgramsDrugProduct2",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for clinical trials for AAV-hAQP1 drug substances.",
        "label": "Clinical Programs Drug Product 2",
        "terseLabel": "AAV-hAQP1"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClinicalProgramsDrugProduct3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClinicalProgramsDrugProduct3",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for clinical trials for AAV-CNGB3 / AAV-CNGA3 drug substances.",
        "label": "Clinical Programs Drug Product 3",
        "terseLabel": "AAV-CNGB3 / AAV-CNGA3"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ClinicalProgramsDrugProduct4": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ClinicalProgramsDrugProduct4",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for clinical trials for AAV-GAD drug substances.",
        "label": "Clinical Programs Drug Product 4",
        "terseLabel": "AAV-GAD"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockDiscountOnShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDiscountOnShares",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails": {
       "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Discount on Shares",
        "terseLabel": "Debt discount, allocated fair value of warrants",
        "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r783",
      "r784",
      "r787",
      "r847",
      "r902",
      "r905"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Shares issued to related party",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r536",
      "r554",
      "r905",
      "r906"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 79,418,438 and 78,397,380 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r487",
      "r655"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r123",
      "r125",
      "r129",
      "r480",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r620"
     ]
    },
    "mgtx_ContingentClassSharesReceivableOfHologenInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ContingentClassSharesReceivableOfHologenInTransaction",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock contingently issuable to company in connection with strategic agreement.",
        "label": "Contingent class A shares receivable of Hologen in transaction"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ContingentFundingAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ContingentFundingAvailable",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Contingent Funding Available"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ContractPriceOfLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ContractPriceOfLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contract price of license agreement.",
        "label": "Contract price of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets - related party",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r290",
      "r291"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue at period-end",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r291"
     ]
    },
    "mgtx_ContractWithCustomerLiabilityEffectOfExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ContractWithCustomerLiabilityEffectOfExchangeRate",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of exchange rates on customer contract liability.",
        "label": "Contract With Customer Liability Effect Of Exchange Rate",
        "negatedLabel": "Effects of exchange rate changes"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments collected or invoiced, categorized as other.",
        "label": "Contract with Customer, Liability, Other Amounts Collected or Invoiced",
        "terseLabel": "Other amounts collected or invoiced"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r247",
      "r273",
      "r440",
      "r447",
      "r484",
      "r617",
      "r619"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r804"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r804",
      "r805"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Financing",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r141",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r232",
      "r233",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r259",
      "r266",
      "r267",
      "r268",
      "r412"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r46",
      "r47",
      "r89",
      "r91",
      "r147",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r653",
      "r781",
      "r799",
      "r800",
      "r801",
      "r856",
      "r858"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Initial face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r412",
      "r413",
      "r632",
      "r633",
      "r653"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Increase in accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r245"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r147",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r653",
      "r781",
      "r799",
      "r800",
      "r801",
      "r856",
      "r858"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Unamortized debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r855",
      "r856",
      "r858"
     ]
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Unused borrowing capacity",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r232"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails": {
       "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt discount, capitalized issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r855",
      "r856",
      "r858"
     ]
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Current",
        "terseLabel": "Deferred revenue - related party, current",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Deferred revenue - related party",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Revenue Recognition",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_DeferredRevenueRecognizedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "DeferredRevenueRecognizedDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Deferred revenue recognized during period",
        "negatedLabel": "Deferred revenue recognized as service revenue during the period",
        "terseLabel": "Deferred revenue recognized as service revenue during the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositLiabilitiesAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Liabilities, Accrued Interest",
        "terseLabel": "Interest on Tranche 1 Notes",
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r175",
      "r181",
      "r193",
      "r627",
      "r628"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Directors"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r903"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r305",
      "r333",
      "r334",
      "r336",
      "r642"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per ordinary share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r163",
      "r166",
      "r169",
      "r170",
      "r171",
      "r174",
      "r360",
      "r363",
      "r380",
      "r381",
      "r481",
      "r498",
      "r622"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per ordinary share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r166",
      "r169",
      "r170",
      "r171",
      "r174",
      "r360",
      "r363",
      "r380",
      "r381",
      "r481",
      "r498",
      "r622"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Ordinary Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r173"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period expected to realize unrecognized compensation expense",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation expense not yet recognized relating to unvested RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unvested options compensation expense not yet recognized",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r107",
      "r126",
      "r127",
      "r128",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r176",
      "r206",
      "r207",
      "r211",
      "r287",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r414",
      "r416",
      "r434",
      "r495",
      "r504",
      "r505",
      "r506",
      "r522",
      "r579"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r356",
      "r765",
      "r766",
      "r767",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Cost Basis",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity ownership in outstanding ordinary shares",
        "verboseLabel": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Carrying Value",
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Equity method and other investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r184",
      "r193",
      "r198",
      "r771",
      "r795"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method and Other Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method and Other Investments",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r202",
      "r205",
      "r767"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of equity method and other investments",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r695",
      "r705",
      "r737"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "us-gaap_EuropeanUnionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EuropeanUnionMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "European Union [Member]",
        "terseLabel": "EUROPEAN UNION",
        "documentation": "Economic and political union of member states, located primarily in Europe."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "mgtx_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities1",
        "terseLabel": "Excess tax benefits in cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities1",
        "terseLabel": "Excess tax benefits in cash flows from operations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "mgtx_ExercisePriceScenarioBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ExercisePriceScenarioBMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to warrants to buy common shares with various exercise prices.",
        "label": "Exercise Price - Scenario II"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ExercisePriceScenarioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ExercisePriceScenarioMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to warrants to buy common shares with various exercise prices.",
        "label": "Exercise Price - Scenario I"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.",
        "label": "Expenditure requirement for grant funding on eligible machinery and equipment",
        "terseLabel": "Expenditure requirement on eligible machinery and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r395",
      "r646"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r395",
      "r646"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r647"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r393",
      "r396",
      "r647"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r647"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r394",
      "r395",
      "r397",
      "r442",
      "r443",
      "r444",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r646",
      "r649"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r387",
      "r646",
      "r851",
      "r853"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r293",
      "r298",
      "r384",
      "r395",
      "r442",
      "r638",
      "r639",
      "r640",
      "r646"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r387",
      "r646",
      "r851",
      "r853"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r394",
      "r395",
      "r397",
      "r442",
      "r443",
      "r444",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r646",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value measurements on recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Fair value, net asset (liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r849"
     ]
    },
    "mgtx_FinanceLeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FinanceLeaseAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease [Abstract]",
        "label": "Finance Lease [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right-of-use asset",
        "verboseLabel": "Right-of-use assets - finance leases, net",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_VariableLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r424",
      "r654"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r654"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r654"
     ]
    },
    "mgtx_FinancialAssistanceDurationFromCompletionOfCapitalInvestment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FinancialAssistanceDurationFromCompletionOfCapitalInvestment",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Financial Assistance Duration From Completion of Capital Investment",
        "terseLabel": "Termination period (upon completion of capital investment)"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_FinancialAssistanceDurationFromLastGrantPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FinancialAssistanceDurationFromLastGrantPayment",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Financial Assistance Duration From Last Grant Payment",
        "terseLabel": "Termination period (from last grant payment)"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_FinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FinancingAgreementMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the financing agreement with Perceptive Advisors, LLC.",
        "label": "Secured Financing Agreement",
        "terseLabel": "Notes Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_FirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FirstAnniversaryMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Anniversary [Member]",
        "label": "First Anniversary [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Foreign currency (gain) loss",
        "terseLabel": "Foreign currency translation gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r576"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r741"
     ]
    },
    "mgtx_FourthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "FourthAnniversaryMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth Anniversary member",
        "label": "Fourth Anniversary [Member]",
        "terseLabel": "Fourth Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GainLossOnSaleOfNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GainLossOnSaleOfNonfinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on the sale of non-financial assets.",
        "label": "Gain (loss) on sale of nonfinancial assets",
        "negatedLabel": "Gain on sale of nonfinancial assets",
        "terseLabel": "Gain on sale of nonfinancial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on disposal of equipment, furniture and fixtures",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain on termination of lease liabilities",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "mgtx_GainOnTerminationOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GainOnTerminationOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain on termination of lease liabilities",
        "terseLabel": "Gain on termination of lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r558"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_GovernmentAssistanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_GovernmentAssistanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Table]",
        "documentation": "Disclosure of information about government assistance."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "mgtx_GrantAmountForJobCreation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantAmountForJobCreation",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial assistance available for each new job created.",
        "label": "Grant amount for job creation",
        "terseLabel": "Grant funding for each new job created"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GrantAmountForMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantAmountForMachineryAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.",
        "label": "Grant amount for machinery and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GrantFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funding received from IDA Ireland grants.",
        "label": "Grant funding received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "mgtx_GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.",
        "label": "Grants for machinery and equipment as a percentage of total cost to make",
        "terseLabel": "Grant amount for machinery and equipment (percent of actual expenditure)"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GrantsIdaIrelandCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantsIdaIrelandCapitalMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to IDA Ireland grants for capital expenditures.",
        "label": "Grants IDA Ireland Capital [Member]",
        "terseLabel": "IDA Ireland Capital Grants"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GrantsIdaIrelandEmploymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantsIdaIrelandEmploymentMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to IDA Ireland grants for employment.",
        "label": "Grants IDA Ireland Employment [Member]",
        "terseLabel": "IDA Ireland Employment Grants"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_GrantsIdaIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "GrantsIdaIrelandMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to IDA Ireland grants for financial assistance.",
        "label": "Grants IDA Ireland [Member]",
        "terseLabel": "IDA Ireland Financial Assistance Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteedBenefitLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteedBenefitLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guaranteed Benefit Liability, Net",
        "terseLabel": "Obligations secured by UK and Ireland subsidiaries",
        "documentation": "Sum of the amount of expected guaranteed benefits in excess of the projected account balances for minimum guaranteed benefit contracts, as of the balance sheet date, net of reinsurance recoverables, for all guaranteed benefit types."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "mgtx_HologenLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "HologenLimitedMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Hologen Limited.",
        "label": "Hologen Limited [Member]",
        "terseLabel": "Hologen Limited"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_HologenTransactionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "HologenTransactionAgreementMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative transaction with Hologen Limited.",
        "label": "Hologen Transaction Agreement [Member]",
        "terseLabel": "Hologen Strategic Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONDENSED OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r218",
      "r227",
      "r389",
      "r393",
      "r396",
      "r501",
      "r503",
      "r563",
      "r610",
      "r648",
      "r874"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r227",
      "r389",
      "r393",
      "r396",
      "r501",
      "r503",
      "r563",
      "r610",
      "r648",
      "r874"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r353",
      "r354",
      "r355",
      "r517",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision recorded for income tax expense (benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r105",
      "r160",
      "r161",
      "r175",
      "r182",
      "r193",
      "r342",
      "r343",
      "r352",
      "r499",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Receivable",
        "terseLabel": "Tax incentive receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Accounts receivable - related party",
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Contract assets - related party",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue - related party",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventoriesAndOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventoriesAndOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories and Other Operating Assets",
        "negatedLabel": "Inventory",
        "documentation": "Amount of increase (decrease) in inventory, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in operating assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Net change in right-of-use assets and liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in operating liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets, net",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Tax incentive receivable",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r733",
      "r741",
      "r745",
      "r753"
     ]
    },
    "mgtx_InitialAgreementPeriodDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "InitialAgreementPeriodDuration",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial duration period of the asset purchase agreement.",
        "label": "Initial Agreement Period Duration",
        "terseLabel": "Initial agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_InnovativeMedicineReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "InnovativeMedicineReimbursement",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for innovative medicine research reimbursed by Johnson &amp; Johnson.",
        "label": "Innovative Medicine Reimbursement",
        "negatedLabel": "Johnson &amp; Johnson Innovative Medicine reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r757"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r757"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r757"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r797",
      "r798"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Operating and Nonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r178",
      "r180",
      "r183",
      "r193",
      "r411",
      "r627",
      "r628"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense on debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r263",
      "r269",
      "r634",
      "r635"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r137",
      "r138"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r615",
      "r655"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r179",
      "r193",
      "r627",
      "r777"
     ]
    },
    "mgtx_JanssenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "JanssenPharmaceuticalsIncMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals Inc [Member]",
        "label": "Janssen Pharmaceuticals Inc"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_JohnsonAndJohnsonInnovationJjdcIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "JohnsonAndJohnsonInnovationJjdcIncMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to JJDC - the investment arm of Johnson &amp; Johnson and owner of Janssen.",
        "label": "JJDC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r654"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "mgtx_LeaseMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "LeaseMaturityTerm",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Maturity Term",
        "label": "Lease Maturity Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetRetirementObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements associated with terminated lease",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r433"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r433"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r46",
      "r47",
      "r48",
      "r51",
      "r52",
      "r53",
      "r54",
      "r143",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r367",
      "r370",
      "r371",
      "r398",
      "r535",
      "r623",
      "r676",
      "r806",
      "r863",
      "r864"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r92",
      "r490",
      "r655",
      "r782",
      "r796",
      "r854"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r110",
      "r143",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r367",
      "r370",
      "r371",
      "r398",
      "r655",
      "r806",
      "r863",
      "r864"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r50",
      "r781",
      "r804",
      "r805"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r50",
      "r781",
      "r804"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r781",
      "r804"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r50",
      "r233",
      "r781",
      "r804"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Long-lived Assets by Geographical Area",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, net",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Interest rate at period-end",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ManufacturingFrameworkAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ManufacturingFrameworkAgreementMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Framework Agreement with Hologen Limited.",
        "label": "Manufacturing Framework Agreement [Member]",
        "terseLabel": "Manufacturing Framework Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r300",
      "r338",
      "r387",
      "r448",
      "r500",
      "r502",
      "r510",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r594",
      "r608",
      "r609",
      "r630",
      "r636",
      "r641",
      "r649",
      "r650",
      "r651",
      "r652",
      "r664",
      "r808",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received and allocated to performance obligation for commercial supply of RPGR product.",
        "label": "Milestone funding allocated to commercial supply of RPGR product"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingAllocatedToManufacturingTechnologyTransfer",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received and allocated to performance obligation for manufacturing technology transfer.",
        "label": "Milestone funding allocated to manufacturing technology transfer"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingAllocatedToProcessPerformanceQualificationServices",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services.",
        "label": "Milestone funding allocated to process performance qualification services"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingAllocatedToSaleOfNonfinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received and allocated to performance obligation for sale of nonfinancial assets.",
        "label": "Milestone funding allocated to sale of nonfinancial assets"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForDevelopmentOfDrugProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForDevelopmentOfDrugProducts",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Development of Drug Products",
        "terseLabel": "Milestone funding for development of drug products"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForDevelopmentOfDrugSubstances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForDevelopmentOfDrugSubstances",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Development of Drug Substances",
        "terseLabel": "Milestone funding for development of drug substances"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForExtensionOfClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForExtensionOfClinicalTrials",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Extension of Clinical Trials",
        "terseLabel": "Milestone funding for extension of RPGR product clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForRegulatoryApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForRegulatoryApproval",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Regulatory Approval",
        "terseLabel": "Milestone funding upon regulatory approval"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Sale of Drug Products in The UK, France, Germany, Spain and Italy",
        "terseLabel": "Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForSaleOfDrugProductsInUnitedStates",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Sale of Drug Products in United States",
        "terseLabel": "Milestone funding for sale of drug products in the US"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingForTransferOfManufacturingTechnology": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingForTransferOfManufacturingTechnology",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding For Transfer of Manufacturing Technology",
        "terseLabel": "Milestone funding for transfer of manufacturing technology"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.",
        "label": "Milestone Funding Received",
        "terseLabel": "Milestone funding"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingToProvideAdditionalCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingToProvideAdditionalCapital",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device",
        "label": "Milestone funding to provide additional capital"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_MilestoneFundingUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "MilestoneFundingUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone funding received in collaboration with Hologen Limited.",
        "label": "Milestone funding upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r300",
      "r338",
      "r387",
      "r448",
      "r500",
      "r502",
      "r510",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r594",
      "r608",
      "r609",
      "r630",
      "r636",
      "r641",
      "r649",
      "r650",
      "r651",
      "r664",
      "r808",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash flows from operations",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for the period",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70",
      "r93",
      "r108",
      "r122",
      "r124",
      "r128",
      "r143",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r167",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r360",
      "r363",
      "r381",
      "r398",
      "r494",
      "r556",
      "r577",
      "r578",
      "r674",
      "r806"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r164",
      "r168",
      "r171",
      "r363"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable related to the sale of fixed assets that is included in the balance of other current assets at period-end.",
        "label": "Non Cash Transaction Receivable From Sale of Fixed Assets Included in Other Current Assets",
        "terseLabel": "Receivable from sale of fixed assets included in other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r699",
      "r709",
      "r733",
      "r741"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "mgtx_NonRule10b51ArrangementModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "NonRule10b51ArrangementModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Rule 10b5-1 Arrangement Modified [Flag]",
        "label": "Non Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "terseLabel": "Non-current assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "mgtx_NumberOfNewJobsCreatedToReceiveGrantFunding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "NumberOfNewJobsCreatedToReceiveGrantFunding",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.",
        "label": "Number of new jobs created to receive Grant funding",
        "terseLabel": "Aggregate number of new jobs required to receive Grant benefits"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_NumberOfNewMaterialCommitments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "NumberOfNewMaterialCommitments",
     "presentation": [
      "http://meiragtx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new material commitments entered into during the period.",
        "label": "Number of new material commitments"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_OffsettingCreditForTransitionServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "OffsettingCreditForTransitionServices",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offsetting credit for transition services in determining contract price under license agreement.",
        "label": "Offsetting credit for transition services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r624",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ]
    },
    "mgtx_OperatingLeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "OperatingLeaseAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease [Abstract]",
        "label": "Operating Lease [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating lease rent expenses",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeaseObligationsScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails",
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Capitalized lease obligations",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease obligations, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "mgtx_OperatingLeaseNumberNewLeasesRecognized": {
     "xbrltype": "integerItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "OperatingLeaseNumberNewLeasesRecognized",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number new leases recognized during the period.",
        "label": "Operating Lease Number New Leases Recognized",
        "terseLabel": "New leases recognized during period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfOtherInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r428"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating leases, net",
        "verboseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r654"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r655"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "verboseLabel": "Foreign currency translation loss",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r495"
     ]
    },
    "mgtx_OtherEquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "OtherEquityMethodInvestmentsMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equity method investments other than Visogene LLC.",
        "label": "Other Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r655"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other non-operating income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "mgtx_OtherSegmentItemsIncomeStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "OtherSegmentItemsIncomeStatement",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other segment items of income (expense).",
        "label": "Other segment items income statement",
        "terseLabel": "Other segment items (2)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r697",
      "r707",
      "r739"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r700",
      "r710",
      "r742"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r700",
      "r710",
      "r742"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Issuance costs in connection with ordinary shares",
        "terseLabel": "Offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments of withholdings on shares withheld for income taxes",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "mgtx_PercentageApprovalOfDirectors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PercentageApprovalOfDirectors",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage approval of directors.",
        "label": "Percentage approval of directors"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerceptiveAdvisorsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerceptiveAdvisorsLlcMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Perceptive Advisors, LLC.",
        "label": "Perceptive Advisors, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerceptiveCreditHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerceptiveCreditHoldingsMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the financing agreement with Perceptive Credit Holdings..",
        "label": "Perceptive Credit Holdings"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerformanceObligationForCommercialSupplyOfRpgrProduct",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement contract price allocated to performance obligation for commercial supply of RPGR product.",
        "label": "Performance obligation for commercial supply of RPGR product"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerformanceObligationForManufacturingTechnologyTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerformanceObligationForManufacturingTechnologyTransfer",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement contract price allocated to performance obligation for manufacturing technology transfer.",
        "label": "Performance obligation for manufacturing technology transfer"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerformanceObligationForProcessPerformanceQualificationServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerformanceObligationForProcessPerformanceQualificationServices",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services.",
        "label": "Performance obligation for process performance qualification services"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PerformanceObligationForSaleOfNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PerformanceObligationForSaleOfNonfinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement contract price allocated to performance obligation for sale of nonfinancial assets.",
        "label": "Performance obligation for sale of nonfinancial assets"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Period of job vacancy before grant funding becomes repayable",
        "terseLabel": "Vacant job duration prompting repayment of grant funding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "mgtx_PreClinicalResearchGeneRegulation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PreClinicalResearchGeneRegulation",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for pre-clinical research relating to gene regulation.",
        "label": "Pre-clinical research Gene Regulation",
        "terseLabel": "Gene Regulation"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PreClinicalResearchNeurodegenerativeDiseases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PreClinicalResearchNeurodegenerativeDiseases",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for pre-clinical research relating to neurodegenerative diseases.",
        "label": "Pre-clinical research Neurodegenerative Diseases",
        "terseLabel": "Neurodegenerative diseases"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_PreClinicalResearchPreclinicalOcularDiseases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PreClinicalResearchPreclinicalOcularDiseases",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for pre-clinical research relating to preclinical ocular diseases.",
        "label": "Pre-clinical research Preclinical Ocular Diseases",
        "terseLabel": "Preclinical ocular diseases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r208",
      "r209",
      "r616"
     ]
    },
    "mgtx_ProceedsFromGainOnSaleOfNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ProceedsFromGainOnSaleOfNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the gain recognized on the sale of nonfinancial assets.",
        "label": "Proceeds from gain on sale of nonfinancial assets",
        "terseLabel": "Proceeds from sale of nonfinancial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares",
        "verboseLabel": "Aggregate offering price authorized through at-market offerings",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of share options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r122",
      "r124",
      "r135",
      "r143",
      "r151",
      "r157",
      "r160",
      "r161",
      "r204",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r360",
      "r363",
      "r365",
      "r368",
      "r369",
      "r381",
      "r398",
      "r482",
      "r493",
      "r521",
      "r556",
      "r577",
      "r578",
      "r644",
      "r645",
      "r675",
      "r776",
      "r806"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r432",
      "r483",
      "r492",
      "r655"
     ]
    },
    "mgtx_PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase option after twelve months, percentage of Company's outstanding common shares.",
        "label": "Purchase option after twelve months, percentage of Company's outstanding common shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r292",
      "r300",
      "r328",
      "r329",
      "r330",
      "r338",
      "r387",
      "r445",
      "r446",
      "r448",
      "r500",
      "r502",
      "r510",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r594",
      "r608",
      "r609",
      "r630",
      "r636",
      "r641",
      "r649",
      "r650",
      "r651",
      "r652",
      "r664",
      "r668",
      "r803",
      "r808",
      "r851",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsIdaIrelandGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r292",
      "r300",
      "r328",
      "r329",
      "r330",
      "r338",
      "r387",
      "r445",
      "r446",
      "r448",
      "r500",
      "r502",
      "r510",
      "r527",
      "r528",
      "r587",
      "r589",
      "r591",
      "r592",
      "r594",
      "r608",
      "r609",
      "r630",
      "r636",
      "r641",
      "r649",
      "r650",
      "r651",
      "r652",
      "r664",
      "r668",
      "r803",
      "r808",
      "r851",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "mgtx_RelatedPartyDeferredRevenueReclassified": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "RelatedPartyDeferredRevenueReclassified",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related-party deferred revenue reclassified under provisions of new license agreement.",
        "label": "Related-party deferred revenue reclassified",
        "terseLabel": "Deferred revenue - related party included in contract price of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r299",
      "r438",
      "r439",
      "r486",
      "r491",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r553",
      "r555",
      "r586"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r559",
      "r560",
      "r563"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r299",
      "r438",
      "r439",
      "r486",
      "r491",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r553",
      "r555",
      "r586",
      "r862"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r439",
      "r441",
      "r518",
      "r519",
      "r520",
      "r561",
      "r562",
      "r563",
      "r583",
      "r585"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails",
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r247",
      "r273",
      "r440",
      "r447",
      "r484",
      "r618",
      "r619"
     ]
    },
    "mgtx_RepurchaseOptionVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "RepurchaseOptionVestingPeriod",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Repurchase Option, Vesting Period",
        "terseLabel": "Vesting period, irrevocable option to purchase shares of MeiraGTx Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ResearchAndDevelopmentClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ResearchAndDevelopmentClinicalTrials",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development pertaining to clinical trials for drug substances.",
        "label": "Research and development clinical trials",
        "terseLabel": "Other ocular diseases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r610",
      "r627",
      "r871"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "mgtx_ResearchAndDevelopmentManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ResearchAndDevelopmentManufacturing",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development pertaining to manufacturing of drug substances.",
        "label": "Research and development Manufacturing",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ResearchAndDevelopmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ResearchAndDevelopmentOther",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for research and development classified as other.",
        "label": "Research and development other",
        "terseLabel": "Other research and development (1)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r693",
      "r703",
      "r735"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r694",
      "r704",
      "r736"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r701",
      "r711",
      "r743"
     ]
    },
    "mgtx_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash [Member]",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r772",
      "r779"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r82",
      "r489",
      "r507",
      "r509",
      "r516",
      "r537",
      "r655"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r206",
      "r207",
      "r211",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r372",
      "r374",
      "r375",
      "r377",
      "r379",
      "r414",
      "r416",
      "r504",
      "r506",
      "r522",
      "r905"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r612",
      "r621"
     ]
    },
    "mgtx_RevenueUnsatisfiedPerformanceObligationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "RevenueUnsatisfiedPerformanceObligationAmount",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, unsatisfied performance obligation, amount",
        "terseLabel": "Deferred revenue, unsatisfied performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, unsatisfied performance obligation, expected recognition period",
        "terseLabel": "Recognition period for deferred revenue, unsatisfied performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "mgtx_Rule10b51ArrangementModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "Rule10b51ArrangementModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rule 10b5-1 Arrangement Modified [Flag]",
        "label": "Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_SaleOfStockConsiderationAvailableInFutureTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SaleOfStockConsiderationAvailableInFutureTransactions",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate consideration available in future stock transactions after deduction of issuance costs in at-the-market offerings of equity securities.",
        "label": "Sale of Stock, Consideration Available in Future Transactions",
        "terseLabel": "Value of ordinary shares available for future sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds from sale of ordinary shares",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Ordinary shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r301",
      "r764",
      "r786"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases [Table Text Block]",
        "terseLabel": "Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Securities Excluded from Computation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Change in Asset Retirement Obligation [Table Text Block]",
        "terseLabel": "Schedule of Change in Asset Retirement Obligations",
        "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Leveraged Lease Investments [Table Text Block]",
        "terseLabel": "Schedule of Other Information Related to Leases",
        "documentation": "Tabular disclosure of the components of the investment in leveraged leases."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r861"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r356",
      "r765",
      "r766",
      "r767",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r200",
      "r201",
      "r203",
      "r204",
      "r398"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r143",
      "r200",
      "r201",
      "r203",
      "r204",
      "r398"
     ]
    },
    "mgtx_ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Payments Under Non-cancellable Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments Under Non-cancellable Leases"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ScheduleOfIrelandGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ScheduleOfIrelandGrantsPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for IDA Ireland Grants.",
        "label": "Schedule of Ireland Grants [Policy Text Block]",
        "terseLabel": "IDA Ireland Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsFinancingAgreementDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r559",
      "r560",
      "r563"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r87",
      "r872"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of net loss for the segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Share Unit (RSU) Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Inputs Used in Determining Fair Value of Share Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r78",
      "r80",
      "r81",
      "r82",
      "r114",
      "r115",
      "r116",
      "r177",
      "r271",
      "r272",
      "r273",
      "r275",
      "r278",
      "r283",
      "r285",
      "r512",
      "r513",
      "r514",
      "r515",
      "r636",
      "r763",
      "r780"
     ]
    },
    "mgtx_SecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SecondAnniversaryMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Anniversary member",
        "label": "Second Anniversary [Member]",
        "terseLabel": "Second Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_SecuredCashAndBankAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SecuredCashAndBankAccounts",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity requirement for minimum amount of cash and bank accounts to be maintained and secured under the financing agreement with Perceptive Credit Holdings.",
        "label": "Cash liquidity requirement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt, Current",
        "terseLabel": "Term loan outstanding amount",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r89"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_SecuredOvernightFinancingRateAdjustmentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SecuredOvernightFinancingRateAdjustmentTerm",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Secured Overnight Financing Rate, Adjustment Term",
        "terseLabel": "SOFR adjustment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "mgtx_SegmentGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SegmentGeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The segment total of research and development expenses.",
        "label": "Segment general and administrative expenses",
        "terseLabel": "General and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r524",
      "r525",
      "r526",
      "r588",
      "r590",
      "r593",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r613",
      "r637",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r810",
      "r873",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "mgtx_SegmentNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SegmentNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Segment net income (loss)",
        "terseLabel": "Segment net loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r625",
      "r626",
      "r629"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Cost of service revenue - related party",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ServiceRevenueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ServiceRevenueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Service revenue from related parties",
        "terseLabel": "Service revenue - related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNetLossForSegmentDetails",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of restricted share units, Ending balance",
        "periodStartLabel": "Number of restricted share units, Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of restricted share units",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value, Ending balance",
        "periodStartLabel": "Weighted-average grant date fair value, Beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of restricted share units, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Options additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "positiveLabel": "Share options granted during the period",
        "terseLabel": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, Ending balance",
        "periodStartLabel": "Number of options, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, Ending balance",
        "periodStartLabel": "Weighted-average exercise price, Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, Options vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, Options vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "verboseLabel": "Contractual term",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfRestrictedShareUnitsDetails",
      "http://meiragtx.com/role/DisclosureShareBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfShareOptionsGrantedBlackScholesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life of options, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life of options, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life, Options vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options, Vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "mgtx_SharesIssuedInConnectionWithFinancingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "SharesIssuedInConnectionWithFinancingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for purchase in connection with the financing agreement with Perceptive Credit Holdings.",
        "label": "Shares Issued In Connection With Financing Agreement",
        "terseLabel": "Shares available through warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Equity Balance (shares)",
        "periodStartLabel": "Beginning Equity Balance (shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Ordinary shares withheld for statutory tax requirements",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r654"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r140"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r59",
      "r60",
      "r107",
      "r126",
      "r127",
      "r128",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r176",
      "r206",
      "r207",
      "r211",
      "r287",
      "r349",
      "r350",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r414",
      "r416",
      "r434",
      "r495",
      "r504",
      "r505",
      "r506",
      "r522",
      "r579"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r524",
      "r525",
      "r526",
      "r588",
      "r590",
      "r593",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r613",
      "r637",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r810",
      "r873",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r176",
      "r416",
      "r449",
      "r511",
      "r523",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r579",
      "r669"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r301",
      "r764",
      "r768",
      "r786"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r176",
      "r197",
      "r416",
      "r449",
      "r511",
      "r523",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r579",
      "r669"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r696",
      "r706",
      "r738"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of ordinary shares in at-the-market offering (shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r512",
      "r579",
      "r596"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share based compensation activity (shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationSummaryOfCompanySShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r314"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of ordinary shares in at-the-market offering",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r522",
      "r579",
      "r596",
      "r675"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share based compensation activity",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r55",
      "r56",
      "r82"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Equity Balance",
        "periodStartLabel": "Beginning Equity Balance",
        "totalLabel": "Total Shareholders' Equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r74",
      "r538",
      "r554",
      "r580",
      "r581",
      "r655",
      "r676",
      "r782",
      "r796",
      "r854",
      "r905"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Ordinary Shares",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r142",
      "r270",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r287",
      "r378",
      "r582",
      "r584",
      "r597"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "mgtx_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans granted under the Company's financing agreement.",
        "label": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_ThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "ThirdAnniversaryMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third anniversary member",
        "label": "Third Anniversary [Member]",
        "terseLabel": "Third Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://meiragtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsPerformanceObligationDetails",
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsNonCurrentAssetsByGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r101",
      "r102",
      "r103",
      "r104"
     ]
    },
    "mgtx_VariableConsiderationForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "VariableConsiderationForServices",
     "crdr": "debit",
     "presentation": [
      "http://meiragtx.com/role/DisclosureRelatedPartyTransactionsCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration included in provisions of new license agreement.",
        "label": "Variable consideration for services",
        "terseLabel": "Variable consideration for services included in contract price of license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "totalLabel": "Total finance lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r654"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureDebtFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "mgtx_VestedSharesDeferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "VestedSharesDeferred",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that have fully vested and have been deferred.",
        "label": "Vested shares deferred",
        "terseLabel": "Shares vested and deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://meiragtx.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "mgtx_VisiogeneLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "VisiogeneLlcMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureEquityMethodAndOtherInvestmentsSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Visiogene LLC.",
        "label": "Visiogene LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://meiragtx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAntiDilutiveSecuritiesExcludedFromEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "mgtx_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate [Abstract]",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of ordinary shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r171"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://meiragtx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of ordinary shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r171"
     ]
    },
    "mgtx_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://meiragtx.com/20250331",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://meiragtx.com/role/DisclosureLeasesScheduleOfConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.4-07)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481161/840-30-50-5"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479808/944-20-55-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/410-20/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481999/410-20-25-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481879/410-20-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481879/410-20-45-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479711/842-50-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001558370-25-007498-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-007498-xbrl.zip
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M!W?,5G2]E33:#;UY+23.\>'F#&C]B![(=D77[N^*>QX3=]+C5E+Z6EC-$WJ
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M?@J6Q:)ULPH:,E(X>!U5Z9-JHQZ,5L)@$$[@L---S.\X2Y]H,($>C-3%CSW
MZ!6$"=YO'\X&PF,*^N#MF5\MU(/1"AY2P?$[$+>H/K^B3\$-A'6<6=RK -O
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MF%1#P$K0/U+&]UT4,7C;^N/_ 5!+ P04    "  G0:U:*1+*.?,.  #MTP
M%0   &UG='@M,C R-3 S,S%?8V%L+GAM;.5=6W/J.!)^GZK]#][LR\X#X99[
MS3E3A,!,J@BD@,S,/DTY1@3M&(N1[83LK]^6;(.-D2T;B&6H.I4#N"7WUU];
MEY;4_NGGY=S4WA&U,;&^G=7/:V<:L@PRP=;;MS/7F59NSG[^_H\??OIGI?+'
M_;"G38CASI'E: 9%NH,FV@=V9MJ8+!:ZI3TA2K%I:O<43]Z0IM5KY_ /_FB5
MRG=>Q[UN0QEB:;RRQGD]N-#VJR/6G799K3>KC5KC4JO7[RZN[BYJ6NLI$'P"
MW:8X5=+$UE]W[,\KW%$#D);][6SF.(N[:O7CX^-\^4K-<T+?H'2M60T$SSS)
MNZ6-(](?S4"V7OWCJ3<R9FBN5[!E.[IEK$NQ:K:5J]_>WE;Y51"U\9W-R_>(
MH3O<[*EZ:4()]JT2B%783Y5ZH]*LGR_M2:!73*T4\' 5)\BO8'__0=,\0U-B
MHB&::ASCG?.Y0-_.;#Q?F*Q2_MN,HNFWL_F;LZPPOFI-3\5_C1R@G3E4FU@3
M9(%WP >;F'C"W.%>-]F=1C.$'/M,8[=Y&3ZN=)LC3'6H\MP@\RJ[6,U47?7P
M %97[<%TL$"4$VZW+!":+RB:00'\CGK$W@.Z+/?Z8NAMW9YU3?*Q9Y2A:O<"
MZ ';ADELEZ*685 733K+!5/ 9@_\Q#718+IQX0$Y.C:E8.U0^9[!]9 >N2WS
M#V)Y)N77VL1V<B'+5O.!875=!WY]PA:>NW-^\5G_Y)[S GY%^\1JL]; -/57
MTR^\%]"[W/<0)AF\FOC-:PSVH&1;-XU&#@,=1(L]F^L!O3I=;,$M8?B3RQ>V
MUQ!24Z=&H*G_<56U#76'>MI&L^I+5&UW/N>FJV!H^\Y2,0:U;?3=4*,!=G--
MKZ[ZN8=_L_:0MB'Q'GSW;\)TVE<?'(:"E@Z"$I/5K]AA-[J]O60#KUI-JVBK
MNN%S>]!_Z/1'G0?V:33H/3ZTQO#EOM5K]=L=;?1KIS,>\4%* ,<D1N2&)AN!
M$;K=>-QP4]U^Y=9S[<J;KB^8%2^JR'3LX!?F2Q?<COX/?[9L.P0-7!>9,)3>
MN%@M2J^V2RG8+U$]7^;/J^;-3>.ZV;R\O;IJ-!K7U_4-Q4/^T:)1#."[P3U\
M-\[GY5-*YG'S^7<B630G%)H4F..<::X-RI %NY=NGFD?"+_-''ZE %K8((8-
MTN"_SM\N?M=-UOZUG+9.Z2>T(K_IIHL$=$F559;&)++B!.?'JBCQ,-HC+D 8
M(@,!'.CA^LA)>3P3BAP)S9DA^NPV%&,7^CR'ZH;S.W9F;==VR!Q1;H]4DB5*
M1@W1;%S?U,K(=5ZD/N5-Q2A_M-Y!8T(_07T!MV&1(R$Q%9+/UH5B;#U3M-!Q
M,-E.?B2WRAX)?_+8?"(O%2/RT8*I!QKKRW67(7SZ8I)'0J(L,I_"*\4H'#@S
MO^5/F9_$!8^$0$E@/G_7BO'W3,D"4>?S&>;V#@S2V0!]P:;IXIXPJ8BRG&YO
M/S,"473 ^F@YNO6&H>7PL(+ZG:5ANFPI\!=")A_8-(7M:GK14G&:&Y"B(],A
MLAV*#0?QZ7.?6$9B*RL2+Q6'F4 H.D9E;8GS^82<&9FP<;;M\."X@#:!=!3P
M1>/Z2I' P#;6LF!0=#P:ZLI3G[2MLJ4B3!Z!JF-/;ZG<>N/K2T.FRF#Z8GLM
MOXBVI#+EHB\S$D6'H-ZJ&\I 8D*)4E&8%8=/X(UB!/:P_HI-[&#$]JR,'&+\
M-2,FJ&I[?8* Q?1BQ6))5UM!9Y/E(NR&:8@4784)J9T<>H@+1F%> LP;A8C;
M2D(B;4FP%&4O6"UZUC]9S$MN]2PJK#:+24J*%\\D$*I+*-L")_U4"N6/C-8,
M(!6-+T5'F@&6SY1X;V*A8^(X!U)%@TT/:(I Z8FW)I',[U;98Z)5'J"B(2@^
MOY=NC@72Q\1H%HB*1JBB3ID:I!*)J\VJY/@W$[AR=:WIT<>T<E$C7"DV-95D
M.!]*13M7'M89(@=3O@UZO:L^:4/O-OFCH#8;.D5[V!ZQWL:(SOO$0<',312#
MV")Z%$1* U.T1Y4.5\8%U>9/.OPG"4RF!UU03"A4P,4*V;H[GQ.+ TK<?+\A
MIB"1DJ3$V93")A-"*IK+UF2"/;6>=0R#O+:^P(XNVL@BD(ZBOVY<7]Z6EMDL
M$,OPL+8,PYTSTZ,)GYE%#CM[@WIVY+F/G,%TK"_%8<0LM1R50^P!NLQ@N6A'
M&;+3F!::='1JP63 #N&&.2 VL'@W5%K!8W*'G&AEQM9Q#_BINFF='GP_Z/G3
M+%D2PC0E'DYMR!Y.'8WAOZ=.?SS2!EUM\-P9ML:/(*"U^DSRZ7G8^16*/?[6
MT7J#41&G5[<\_BEM9V*)HB*6@E:L2RCXH^7%[(S/,=4M6S?X8VE-^#?_(9W\
MU_6VGJ6 /\S-%&Q0)/PB%B7]&KN481@* -;X!:X4D8DBA4_7FXJK[@'I<!2-
MIHK=\Q?H&1F:>S0%&7&CD*$&!7E.)RY.]JZ(%=V-L-Z![%GDT7(0A5\$O(O$
MCX3D3/ 4?;@#G?WCCD(B(U)'PU\ZJM297"47;_&L.^R7/X/&86"-=)8/J$^L
MJ9<]1S>WIE&1+%5RPG9!J>@BQVH1+G48M$6RY'1F1:;H&L=*_2 _71J!@9R"
M],E2D4!B(KK4\4R^9G1G#G]!%JAOPCRK-9EC"]L. _..DKO#E%(J\YO(4IS=
M/$@5';N.D G5O0&4)YW^A4+&$"U-"@M$8=\VKJ^:924X(TA%1[%#9".P%LN'
M]8#>D4GX@?-D>A/+'!'#V7$>9JN/8,@[0O0=&V@(JEDNZ@+D(>+1]6>=;CDO
M)%5&9?:R#7IS(95^2 M>;@BE*Y9>6;C(M[+0;HU^U;J]P>^%+"$ SHTT?='#
M^/!H1G\(23XCBMG1;Y9?WD8/R/M_E7T!/LQTZPT-P2"=Z109PBQJ7ZQ$,4%E
MIO<S)>\8_.?^\\5F^UA7CU[+@*%+TB%$^0H4;&&*\;*-"/<NYE-TW APIMA)
MF*"O!13TBATYB9.<@E91$D<SG2+^L@VV:@.]4M(>X>W"IT!N!N2*S@0*7*PZ
M3I?8U1P'"J#OX<S/@B(#<WO"9Q/YZ^VM.8&1]?^2V@>9HA%;-&M@BXNC<XW<
M=E T)K\Y_ G9)GI41KA*)EG^%)QC-V,H&O+?7(.*Y#I<)3H418VE"I^";^Q@
MB=2D644M)*P@L6,[V.(V]5_RD^H/\2*GY062^%,S;17$O?#4'<M3P3O%Y$BT
M=/E3\(K=C*%H+J_PB&@P92]%8J](8JEIG@$F=N<BST@K=Q(>D<L(OB?<?LDB
MQI?LVSDR>G<Q01!EJJG6%<1'O?'WMR2N;^6O*&JH.ABJ\&3$7S"IR&65P'V4
MVXX2QR=\)8RTWPAK.$V'R6:.P%/$84YE/"5X[XQW2)V?-UG;+>D5?'FJ.DW?
MR6F7P(F4BX'&$49??B/M,-%BI^D<$C8('$$<^%3&$;ASKSM5^;9CL^!I.H.4
M%0)W$$<YU7('/[-;QLXD7O2$72+=#H%3*!?A%"!:IPW+XQ>;I4_8-:1,$7B'
M<C%0\<PL.8-7:KFH&1HGXA$R1@A\0;5@YU8T&_F:LWC#1M&3=0@9.P0^L>>P
MYX%'%'D<0U#^-+TCBS&"C5OBV*DJ+A*DHO5WOTN[QD:YTW0)&2,$KJ#:;DV!
M>;SS]CMLY-Y2@8+.H>Q&;EGS*;HU%,92_.#)F+0,,!A%PC>5BC9Z2U<0-4M3
MX74[64[C3K*C-0YT(EBP0 NZ&0A-;':"BJTY9ENHE2]]S,3OPQ2*-@T"&WEO
MDMNAP]E2@8(>HFR'(VL^17/3AY\5GG]RP!6S.TM$#6RO3SC&#Q0EEU/0AW9D
M<$OWDLL(BAX_"OI*?V_"F(SU)5N 9@E)P3A=0C,=4,I;W4GXS3YMD]I=%11M
M#3\<C[;MLO>=#J:A).42+<O6<B?A(;F,H&H?X[O[8,I5#_"TB2U<BDDJ$H5^
MH?")MMU;"&G\J<>55JW 01(JL-VN)K%=BOP@<)  9&3,T,1EH^^-"P\L9[4I
MFU;A]J)V4:MK%6U](_CB5ZD%=;*L"_[]-#*-7_ZW?],?"TBPL+>79.YQQNG?
MHPV2&&@?4Y@8;7LJDX45?!Y3C;V:*V9#=9BA6S([VW/C)#"TO< QL)0!F:*3
M>!\(2U" ;)NKU$6238&@4%F)W0'=ER9_BH/Q?WG2+7>J&XY+H8?G;<;V+8DY
M:RDKK_N$>YA#V%F)#D_!H.FY1Q::XL1.4KJ.XR0Y"]C#G*).&? 0RW;-A+2H
MR<)1'.PUHU>E(TT25>I1Y@.P$RCTZ.TUF_#S$!;B^3Q8E*2+EV@B7@C)7LLQ
M\+DKW-1SRP40/41\C:ZK&]YKU5-F)GFJ.P7JI7$K>C#Y 2V(C9UX-Y/R9H?4
M<F4E?S> ASETO)\W0&4-DB07*CN_.="E'SK^HC @SY 1BOZQ(2&QO) FO\::
MH<PQP-MX#-"[T4;D;WTW]HV+:.R&A48 5[ %SARZ7L#S]YM.,=O&G:9E3$[!
MIRR&(?Q4R0%0=)'66U'P=!\R10;3%QOQ<9U$4CC)TE&#7*G J!QI<;)W0:RH
M"T13E"4\J7%!!8E-?%0E$93AE<>C&7@;RR&5QEI<L&RL22+(]_[A+QZV=%T'
M?GW"%IZ['IY@9?8%QBCL/%R;M2^FN6J<LB]LWM8NI 8UGBZ:KXP_J@G4T;@^
M&BA4"6D45%3LL =:6R1(K!BH_R \.B%?O("G6E:Y/O __D#F.WHBEC,3[7K(
M6YV2+40VUL,-R%[-4(8WS<H"_@_2:1>_[_JH!-6<J-LDPB_#6"(34.+2?;@+
M5'/*[B*"GV\0HZZ[C.&>^VA>>#U1BUV#Q2Y/Q6'$^&66M$OE,1]D'_[R04[9
M6P3H9=;&BYDBK5/>[F.RU :-&E(3)C9;NMXZ6])"*N6<.!G"B=./6L734=UG
ML8S3IVRO+I#*S5_Z=B,+RM+/;>#9\],DLV5L T1;<_8MCS.+ZCHR_]B?#?)-
M=0[<N[#4V:MC$UE#:?5:?'V05:BM:BPT$L94>;1LA[J,X!=+]U8@T"3(%2[<
MR)!:KH '.W08*=!C8/%S:Z+P5D*)J(/"IYO"4UQ(LQ5^.K-"5'2-*4C,XB^?
M\2U#?6$^9X'TL7":!=[.K[7U?V=_7J%E__Y_4$L#!!0    ( "=!K5H#_@(U
M7#8  &E; P 5    ;6=T>"TR,#(U,#,S,5]D968N>&UL[7UK<]LXENCWK=K_
MH,W]</=^<&PGG=E)UV2VY%=:4[;ED9WNW4]=- E)[%"$&B1E:W[]!4!*(D4\
M^0 @1U6[TXYX )PW@(.#@[_]]^LB&JP 2D(8?WEW_O[LW0#$/@S">/;E799.
M3_[Z[K___N__]K?_.#GYGXO)[2" ?K8 <3KP$?!2$ Q>PG0^>(++I1</[@!"
M810-+E 8S,!@<'[V'O\?_I_!R<G?:1\77H+;P'A ._OP_GSSX;+H#L8_#SZ=
MGG\\_7#VX=/@_/SGG_[R\T]G@^'=!O .XS8-I9!1&'__F?S/,QYQ@(F,DR_O
MYFFZ_/GT].7EY?WK,XK>0S3#K<\^GFX W^60/[\F807ZY>,&]OST?^YN'_TY
M6'@G89RD7NSO6I%N6.W./W_^?$J_;D'Q\$&ZA2UC\^DT_XA!D_#GA YU"WTO
MI1*2DC#@0I!_G6S 3LA/)^<?3CZ>OW]-@@U>-0HD?,)?0P'\ED-__[?!()<)
M@A&8@.F LN/G=+T$7]XEX6(9D4[I;W,$IE_>+6;IZPD1[=G'',7_\YAB#2&Z
M=PGC ,18D? ?"8S"@&C.]NMX^CCW$)C#*,!J??UG%J;K=P,R[+?):(OK H3(
MPT.\]^'BE'P\;=7]:1<$7H6)'\$D0X .06WE$BZ6&!DJ_2?O.0*)"BVJ/76,
M]AC-O#C\%QUB& =XV# 93Q\02##CZ*]7(/7"2),&C6Z[ED.V6'AHC64>SF+L
M=GPO3H>^#[,XQ0[R 2N''X($XS0!/JA\0C#&?_I499)1X(T0B+PX^(IP#XV8
MT#,J;C)NF"0@)6"WH?<<1F&*&]T!CXP0#-,;+T2_>E$&;#)4%T5'&8U_NPJC
M+ U7X!'X&:)T7+_Z41: X ;!Q?4RL<IF+03=9/(]C"\SA @$59J+]5< 9\A;
MSG&/T1"O@&QR6 .[CMF;3Z)W()W# *,Y3N< C>(52%**V):^TF^-&-5F'",3
M/%E7!ED$QM/<.>,EQ]:!),7"8[PDD D% ,%%Y/G?<3.,4D+ :#=XB0RB9JID
M#BTS#-V(=((%BD*?+.0(X+<X;*A#;<8QK$/L[]>OY,^&4V8G(QIAPS (0O)?
M+QK%4X@6S5>?3?KO?%V-]^-8OR@JS?26TT7'B$[PRA+K_H.'TO43=@6)YU.W
M< FCR'N&:+.$OPU]HA+#&0*@N3]O/YHA\A\ HCJ"I]KQ<Q3.FBMCLQ$,D7F#
M-2SV\<)BR^E.:11T;XC "5B!.,.??8A76IT+4=!]QP3>X@T*7A)VYB-5^NN8
MA"OPG&XUHA'2[!X8:.YW2F-<"?#?S^#J%/A!WC&6)(F:#A&6Z"SW,^,X6E<I
M(CTDK"XPE3^1/PBY/U%2*_W5NJLRK3'2HS@(5V&0>5$[9#G]<+'TD+]!M/BS
MC"L))()DX;T'&8)+\A^*PRE(P/2T@#]]"0. 3O"<AN +0.P1]ZG9#U)&"&W[
M(P.>%/_ A)W_]>3\_.1#KG;[8RGP6[BD2+TX\!#9A%QF20H7P]<PN8(++\3F
M,O6R*$TTUC_JG4F5INN@[(47D2GI<0[PAA+[.PPW!RG93[:/R(KZ-KNY(#]Z
M\?JQM!$:8H^^PIO-/O88*L.Y&0#9 %J);^P&=Y,YC:+[W0[=,6/P<"@#0;'_
MTR2MUMB(37=AJ)VC.HKQV.#)>]7E8:6AH35R-TOASM'% EJ$:1%*)O,(L0(0
MZWLC84<-D*XLLJ9>\DP7)EER,O.\9;'2PE,X^85TF>S67  $BSKNM2[RQ0V&
M/;U^3;&.AMC6K^-L ?+]\6V8I EO;=9D354ZPB:'S)\HKEZ$9V7&2F_;*HS3
MTR!<;%=CM$'/2.'Q"#]@?!+D"R4]%!G-S2%,UW>-\2U:]XTN'>9D 1;/9-&L
MA6NU:<^(SG$7R,^>P<F61WKH,CLH(8T5),QW]+?XGQ7$ 3'*  0;U$E_?:^)
MNT.GKT5K+QCVN(YT&%_&XJX/;$7K-7/ZUONPO"55'V,I+8[Z&%AUC<,<NS)*
MP]6(B(HT3,D N^:#4OM!'O@8W-&)(Z%Y9QML(^A7.HY(4AU$C9=CY)?=:JSX
MX?=2&LCF./TY21$6W6:@R'L&T9=WZ@T*BE4:G%HE^![&OB[-_#9\LEEM]"FO
M;Q?(+[_36/;N$*64%[%'C 3Z]_,]0A3@*T3LK&N(JN3@9<>F[RF""UV^0B5<
ML@2/!)=Y0'_3MECP:"_@*HS8$?:S$N*#)SA00!BB * O[_!?2Q1"A%<67]Z=
M63&)8BK&*[ UF7RQ#RUF1X;IQL&.8(ZUM.UNSY":=V?7NZC[%'5/8L!_:#B/
M2Z;<Q* =N@QE1[$=W):/D'J&+8:=.86^9XL/FK/%!SNBKV+@K/RK:!9*\-&!
MF2'/%A9[,C;0OA?? ^I,HR?A;)Z.I]\20(=@J3$'I*RY-9"VRLIA"N2-9U0U
MJ\AMM;*&E#M+E)(QR>=3^3QJ<.G*'-VMQ2H3Q4+V'PY,]K5M# >FY\F(,ZH+
M$Q '-9&\_W;*B)_HQ%4ZRBX11E@^?_Y\=C8X&>QZQO_8=#[ O0_R[@>D_TW@
M93N">;7>A<8C+R%YZ2GTOQ/<.$K.A>>JO+"%!4,NHW%5G.DP2:T#<FED@[:U
M;A5>0QD2+8V]?EPG,W@!UF7#9V.[F^LM:,9C]IR$04@2OCV:F2^S!1X\WQ9$
M+6Q0O,/BWEO@/TL1<Z%MR!OR>:#4M+7M*,@&ZB)EWI;X5)1M20U[J[;UA/L>
M3TMYO@*[8L)R]8D+;6.G6LICSL. WNZ7\FG4767UM+^5U>N%RYD&_;0U.YGH
M8"OLC-L?AYRR[34@PZHA7F1)&(,D&?I_9F&22Y=OBAQHKLH)X!VAE?R) !#.
M;M)V6O376K8U,KE0H"9&Q@V+2T+9M)10MVI,UZ_DD!\C-\^KG)#;,0)KXH%S
MU4G4P!%RB8L4&I.XD1;IU69MS4A!&E ''^-&Q">@;$5RQ*V:T ."2X#2]4/D
MT:-34F]@23"]6!,L!=:DT)*K78IM7>*'U- 46NKSHUN3TQ,9U,;/N DJ$52V
M1D5"K)HD+X7N8EW^(K!,]0ZX"JG7A64F"<VR#JA$='=&UT@:4(:5<5/3(:-L
M<6STNS>P!*4EO<'_VND,_L?O$[(G9-A,Y5M-,VI?36++#%+L?>5CW#ZHP&,-
M9(YB3"'WT"*ZQD#'>B0;_)GA:>5Z5<PMDC@V UH8Q>; NT&K.'3-@]>AM]M
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M_9)Q'*W?580%7E.R:0OV""^U>=?-A2V"3J[Q?K!3=/R/WX=15!J.^=2D#*S
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MQ)!($PMMM9W[/IN4-/_/=1#1#TI9I;"8>J-AOJDS$D D?5%RHM*5'')6_($
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MHY;D;XO=4O6)Q)A W>>,"9\S'GJRO>K>[SAJ+66R4.7&CP=77\GHK6]=PA
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MQ--R-=MU)6]#H>BXBHV6BG! LI>915;PCLPO\G2R"+,=.GZPR38[<]Q@/&;
M/UZP.U:86'GCS NMSQ)4?AF(E,<@<P?T]BZ)MY1M2N\8G]D\\B%MNX5C;?7V
M4(^"&7:;16E&WVIXI"#<Q) DD!4H,\*1>/Z\1'-ARSE(IFTI$ZUDBC0R'2A<
MSQB[ 0NGA $S22Y>%^$.'I1\BF/_)0C5$9P-*F9 ;R]:,\(WXR&%_+:,2?8
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M3JW:CNRU+X_E!'CG $&BK"8P$^4$9OS^J3LU!8;+S)A:PPXF7I)M*>N6ETX
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M5XFW2<^3W>J.=^K./LADT\,CN08;(4I_H /&<P)FKC1GA;G2\^+\BYP0R9+
M"T6?N%/F%^"J.]@->=AZ2<S^[SE^I@OBLW%(NGL2/8/0_$(/\0L44N 00"(Y
MEJ88XP$\0 ]QU-_HP&;_0T>!?G#1['_H8O8_.&GV/PPV^_G\IY/U_"]W'X[
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M5D.YC%@X6F;)EDG=)BS>/\\^>\DO-+M=+IECC5;J"$4%B126Z!DO8Q$Y&%X
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M;XT*P .JM\FQ]V#>%=U^6+-5!2J3FW1;!HC8OEW)=J-)>PL*IQ6[@HWV&0<
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M\/@2#YR6DHK[)KPG<!_+S4DX;; -'L>Q4T8..;0<1WAF*_]V1,;)QMPOW#.
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M7]S-/M]\A(4)S$ *%5%7Z]1S%.,NN.&>ZDD9A8(=!(]A!'QRN5<]CR8,CJM
M[P,I"+;F![+H^OFSW771!5SJ8ACRVF.O !?5A9>(Z.N3+:)PBU+@ >ZH!W7U
M%&>*@+MR$^893@-8RSBXL=+D'DZ1K9F% .ZI<H*U^][HEW[D</"$/>#!"A>Y
M'[ L4I?E/PO\;=7'0&BZZ-%4A,2%CXZ=*"_&,DUSSXM3;(FLI79TP R\X_'X
MK>!LSGXKXRC\?(MD+BZ^9H<=3P]0V."HPLFGH<RI<=W@&:QQU.O.!<^**R)(
M _Y62CH[L@A>M9H6,A(;,<IA7I8STHG]A?3;*'\/\;/:F^AYK\F?>']-N7I
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M4$[^W(5[8<I"2'J:E@,Y,06!\\/UJB\^1*J: Y;&U"H]6O9CD]@&@T>6O,?
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MAE/K9C8#Q--FMX/0$O*B)U4-6";K*K0P&_K(\HL)G,R*1$_\5NPEH%Q!3T9
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MDP;@2#KY!@9%O+7<\'?+2\ #L)!>@+;RE -\FQ!W_3)#CR%#J]-,>SRUH]7
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M76QYZS8 I#1;8NSG@Z.SL_,](&7Q,0>H1B$N^0&*N0D'.9F5;H-?@+WPD=L
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MBHB$B$R]F^G7'&T;U29XW1BEQISCI[F7ZVV1;,3C'U;HI,*,)DD<Q9;OP//
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M3%KTR^/5WZW+/2N'=NN&M8)37^='16Q4ZD@Z,"1O;,+C*$J6J6'UV8V^WX8
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M/+VU%H;2AR;&[HA,MFL\/<V:DQU.%3TG.&U6JSQ0FC:WR^<'_2:XX/CVLWP
MLUR&3/<;^'X#_UR5TWYN]SZWV\I3^3'ZL&?G6\:=,G)-]B/0P WWI&$T1&*Q
M;"A[CURM@AMN(@J!\,VU"2@;>W@8\"_DY6T'<]_]$U*")P4FC\\W5V)?6BIF
M*H,>JN:=MK'$[GRX& )X>HKQ3G*?$4CQRZ74T!(VW0EY%V"BO!H:3*@.MM0Z
M6D)%5%S< J?0K*W(GR'[(>L68]^Y!F_ "U:(HDS-8+FWLFJ66'%^ %FAP>E
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MWPE"6WA^Z2()RMC*LF#3HO%2V-YD=<_P^V)5TTKZ/9JGZ PQ,!ISP?.IZ&)
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MK<,/0D(9*S(0ZM6$8/9$ YB"'HA6"LE4MENWQ9>4&0J47K.C[AUA*EWMW[O
MG4.4J=-'PC8PL04*_B^:EU#3!49@W#_*.78P2 EJH)]*R)TL.R9CU09W1\A
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M7J1V(,*NOL'+YKQIDZDZ2'>U_KU3X+"AR0X)I:MM455UJZU/[R[#<V4;&NS
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MJ.[<I ?P.07D<C16I\W_I%QO9$\TB8ZB ID05=5U0B.7YLA6D$/3THDV<!O
MCC=]F@PZNK!69L;U;*ZY1A>H0]Y.%"%&968(&?ZJ=7'3H0$D@$-0%.WT@<MB
MF<2?L&?((X1I2U!?[NGH&/RBJHO5$ZWM^4S$S4&C$3L/NU/ZRW'*_TFOS;L-
MV0TV:K\B',*'<'OX)!J/VQDJ4&3BD>#A(D=]E'1ZD,69^4!L*OD..BZ>XA"W
M#63I./62T"YDB99MKK&U-8JD2C.6[O/53I&<9Q6[%PX?UL,<!+6 ^3Y^CNZ8
M/ <ULH/UF79[VRBD=^J+U_\MZ!<8$OM]>!]!'Z)^H%@69!8LA0U=0WNI.B,
MW%=G1 9M:.C6F#$@$J(E.F5IMJ3"JH_UL$?%7GBK6#+HUKBP5>>L2350(_Y$
M/X;_)FBX3[LMK)YBHI#8$-6Z^!+QX Q]R?# _.M*G+Q&:$1GE['7.-D0L@87
M3HV#]6PUI0ZB+[6A8NVM3NES\E4X>;LX[ XCOYL_(3.(A J?!X0H29 _#71G
M$\:I@7:QO=\2<)$#>WXP!Y"MX3N,Q5X!43R LY_=H\T;=@:W.#32+M$U](G5
M6_S\ +=Q@$<F@XZBX6@N3O)"FA!-_GUH?/AGZN]%LS<;'![?HB':MMW&!\:Z
M:*EH:]*'HML!FG!5DG4]Y.%"$OQKPJO>#BV>:J-^50+;H:7)(?0Z.%E#J/,%
MANE!/^YG*D]Z)OOQLVYL+V8I8E >GQ6W+8S>47'PX^N^3;G]Y^?##R'W:A1/
M<-"'I=O7G!;]*O^.)R?_Q1G^)S#6Y<CQ=B3&8USQAIL/*_U8]B!]L*M?K*@-
M,MB,N/N.-7LB4"W4L@VZ/JU7NX:2B*1>1JK^5H2FL*E;KNV3'W$ [MM6W@KD
MK&=\0*L0EX!"OD3B\Z;!8E";!?QO7QA]BZ,(YQ-&SC)7D;FQ"/ZZ%H>;2;.P
M)=Y;BGB?I^ KZZ@[_(XG%K--10/FNB>0?U*2&8H4LO416XL*<DJ8=J+ON]WB
M+59Y7Z&@R$/05W1N7;;XBLZ/5W2NN>EXE"LN.?GKK/YY-EW>==LY.Z;CNW,^
MQX]ONF]NKH\=90ID.$?5!!?95A=#3^%!N\-==\_/"^E99):7ZTHFU,AS9(&6
MY;WQ\_=MKR?<5W*!"/EZ,90=)_81V?=5$?,W?>U;0;-,YXB'&QV W.N65SK[
M(F8X3@9D0M-QF,LV'>\X'(USY].>VT=T []+G:&73Q3X:OA:0H,SU9'#&U(-
M.Z(T49,4447.=%1W%#4VW0NJ30*5/U7DHT>+F#_%S0#\AK?[/'[+FPYXXH"*
MV0.JNEA[XD^XHCBPX13;/R%LL!4A; '3DV8 FN6NF&+3?)$4RN%Q7]0+L7B,
MJYN<^+Z+E-Z*I7TPSGCQ<%_H0B+H\#D[)G0,UQR.HG%#0U$).N)<FW:_*W!D
MPL52$H>'H51!MZACJ&Q>8>_>)]^;I<+-/L6I9.BU:):GL\[ST)C<;6R6FCT(
MR#J^L4>!YN(=@4ZF0EJ0FU#D3*'8$5B!CCC8ZU@"]Q(?%_+]IOG"5)-T+F &
MRW>$VXV).]A)4=$' U1-69?Z3EIOT;:P5(/B;0V8P5@T8+5>2U$R%.9%E0T,
MI)?\Y.YWA+QG0L%[)AA=(&M!A]]0>+KYPL[4[XDW<GSO"7WU[@?BRN&_W;O
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M<J"4 -QKI#]1"^+_PDT//?G7UB)LK>9P.^/ ^>J-2@7N^7- 2W(D1#%". *
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M.Y5&=S8$;$-/P,J!9;D6-;YI[+11^OSB\\M!?HEOIDUB[0/EJ&DFA-L]1FO
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MQ(=!+5<KM#E4JADJ)^P]35.^Z\1G<9_%O:F;G,;CPV&KE])B3S2I< )(SJC
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MIPC]$E7"5%WS]6F*(M(IB"6QWN5-W9R/3/_A73J= G*R,(%HK4QG>\(<%Q1
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MW)8O0KF_(E>+#&#6&W]_R>5;;BJ<>E$ C/T@'=\O ]M47"8AOAB_,/V'W^;
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MJE:8S#*TA>$?%0R(UR)%80!7!SAP!!UDN\GF_$*O8DL-V9GB=E%R<X)*$+"
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M&,AHB1$.:F_M9^CL+;NE,%V+(3T+IR+&!+;5F'!A+@OL%F9OMS#\.=MI(SQ
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M]FAD_Z1)B,CY0HG<-YW(?7^1G%?RD\H/4/"Q_*1\?3-HS$DGIU1I@BY;.WK
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MA@>XNJ!J,<?F(-/A>\*Y@]T3!BUCK=E&TZ$<9RDT+C]2R4IQNO"A+4RGZKM
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MLS=/IE; !HC$YC?%AA.PP0!HT$/M4FZI46;Q)V/X:=QIV)9IL4O%)7I#F5U
M")>QTEW\7(E?Y"<5)7U?+MWFE+R>+W[[)[U'QG9E97:P$U? XACV:4R/7Q;$
M.F>?DP5-I2!C.5PCZ\"?>,W Y2\,CCN\Y;[FY4*@JNXU*#=GN&/6$X1<\ 5[
M'1O,!-KP^Q.!.;N8OU0.V/#'0L<3"N^(Y:OB_8K7%B@;^!CT!74AN$%H310#
MCTH-(SZFWW#>M!0),TN>@X?T:63%)QXQDT@_9=N G\M@+ 2DHTWF ?FXQLHS
M;=RDFM7'Y89\KY\L!ZK=RU;BM?IP*F8F\>6W?YCYLB:B86[>.J U6X2&A%[S
M[/ACW"+:.D5HNBP-#- F[#*+[^X*]5HN] G6Z@G_5YS-?[E_G6L:G+XTEU3C
M9O@AG8W@4%\ ZP##,RV1BN/=^D0A>&UMXYY\*7B5D3'#CFK,EVV-\!U9D1C@
M@DPU/,= Y\#\@ B:T Q<.P>GY5R3CG\$PEX\ CD:T0@DHJ:R>%80OVEO*>C1
M_HJFW45,OLI#!VEGJ_32@QYR 9 XFH7KF)^WR\Y4CH6>6PX7".#O#=P[-'/O
MDSJ.%+W0SPU[;VVSH!/J80 \N6:$F.'%(Q.196:]&#I>T!K25_E,H9F397;N
MT9N"/><*6)0F"KS2V2FJUMWG6>Z7E;/AYF+-@4V#^^#@TK9G=&]XO:=)2\3*
ML'Y4>L#.%"XBM8^E81>#@NX+:G#"['K K6!](:?O1RD /YQ'=DRO]O79@S.J
MO&@N=%7N*T$K8U3&'_#9$NTC@:/ DJ&!"D3(.*ICR*K7AP0L;1#<7NE*<.#]
MA*8J"=]!M(.?7EGR\0]WJ^&K$T\>.8,@VTQHL"@0?NA="N?G 5]W.[KFC$!]
MU0FM=O(# \#;A':SVMY>HC>)S;*L9Y8[DM5<U17+51)#W1)1]*FR -5DZ/"_
MA;X@$DUQX=<Q^,.G!@W"FBW38@*3)JYPKCX]%= P-S$0X*FC8$#P3&&NC/%;
MW139*MA8,]OB%T^YP1CZ@VJWB<S.09^P)I8@=\$_;J[:33J3P%[2#YI,#(,A
M1;;YS@1X;\+ G5<^CUUR1@&_P,S2B.2!LE I9E8O)\RNG^\]T+J@74$=!]7I
M2P7:<@9Q7,D=1=@!Z*F7R2F-G6W,O<-3F^ZT]1#=%X3*V?B%J\&> $[!YQGO
MA&=7\6$_ U .??;BOE;2-!\E3:.DZ=^<-$V]*&F:?J^DZ9,91L_DWGV2O,"P
MPC!%0(G2"Y3 @5A6B'ST[O!2B21#:4YA5 +^2/&_]L<EN!.VX8.!!_;\$ 7=
M3V<[-R,3)'[1C%O)5;\RDU96*VV>7:G5XN^6LX:_BM>V[H69JL?2LY.'62$3
M;\AGDT3Q8:K5U>*W?[*9XSVEK$K@R$VF-DM2 Q6AV]>!0J]T(?/!>BE@[:OQ
MHW>& ZL%&)/[4Y(+IK)1XQV M')BBY^045\!XFHO(XO:K:IFTG-]JK2D>2)M
M7>5.F[]=E^UAVW#F+2Y$A>9Y0[FW?!NOWZSEQ&D\VS?:V6MR42G?++_]D\K$
M][ OK;AG60;S)[VR*FZ[ZF]+ZE#@^(_52(O5Z&%=:%R>]_K%TE2S!^<3_?;5
M8,I.=:.RLA 35=<:(Z?6O8O)5C.4M-(D.SQIUM7:M#1>#!NID^Z54J381$\H
MIDV7*2380K,,Z/L%;N019WYP+MNR=YFX2=5/2KCJU2J-CA<QLFBFV'G*[PC\
M8C=[/YFF.*PC+82!RE[DH3$J&_:X8P\Q%261<!:Z'B_&%R?)D3Z]O%B89>LT
M_E@_ ^V0V,M"-$*'50@J<;C#"0EY24M_M-"]RN:P @4(-9VY[>:0B$7>GD7X
M?H<SR!WIS!:%T<6BMRY<WDQF)[5B30<&V6O[O!)_S'TQ@S#N6$3,\=K,T1$1
M'<_/%><: QFC[;S">:1SJCTL.J73UE0L5Y9I_=H:G[3@'$KDGN82BI:@&*85
MN!L@,F\:[,I \(A;O1SUC,T(&"'B@_?A@^DI!;>K@FN"50Z(^%[4Y'-+5->A
M?#$]*XI3ZUJ_F5;5VS6Q1E<G^0;HCC=@"[<V3-=<X/8@.-Z1P&9_)/#Y'PET
M!=3'HFM 3HK.FU=G)7HQ;$2,QBA0D-!U0?]#>4<Q,M<SDHB?31\>"J?JH-LO
M7&80A/>E!P]+A[ I^ ^B8-FKKP4!GC8;Y@FR2/!$0D!POZO\DDS<+W:Y?A$9
M-Z_/;&TG*[5V:AQ#N6LVG>5R:U$^Z_7K\F6-G-0O;I36L\Q>-^^U#A:G/I_^
M,9.H#+(TR(.\)\_:Q?P)ZC%VW%'>J=B(N )J$+[B=^U]:M*?BN%#^-7EL5!F
M[T.XWQWU 6_MU:<#7/D4Z/!;<^6PJ^=KZFW_O"*.RU-K'4_JB^OE:W'EWMBB
M:@[$9NIVF8PWI.YBVE67F1D!1LP^Y<*'U$U0I?2"W-KS0X3868+AD;.6.QBD
M'G&$+ XHA/E?;T[B#(EILFJ!(9&PG0K,DV5)M.VLH(?QM"?S?E!%8&_=7>]5
M0)CQVB^5; ?DES7LE?P->T=NPU[3;=C+NFT,L5!C;A"02):*A]^A$*"*8DWC
M8'B;8;O,0:-(RAR+;AA2 L4RD"0R]UT ""HRV+LB+?03O0YCQ6+3JW0J:KS4
M@> 9S,8P*?BUUQN(W\49VPJ[W0PTF1$>5:>_=>+IHFU-\-X-X^S@3$)F'+XT
M&A.U-:\NP7O*48DF*%,?'IQ;*=0I!6#M0G_9F\MT/MZ/>EY+"J;(O?;*H2.<
MT,LBSN]/BQVW9N:@A(=V_E9F;]TL^A!E:/,F/K(\Z\7&]\0;2]%XGS5>2.F&
M:A7-M R;0X9;.JO2!.-GQOZ5B,=:C,FP,:1*G$^1A]INJS;V:2=V<TQ9R<"C
M"O-2\(*U(.NT^)MA4;&J;?;BX(Q&NFXQ<>1W=FB]MKLD;HB3IS>+%O+0>JRY
MHG'#'2@LCGUU.B_9>__$11F)SP'E:0*+5BCC*UC^'LT>VV#W+KQG?P@:P79@
M6,6&=U@,F2F3F3@E+YX/!>Q73-Z<Z5AHS&D.#=X(IX>M^C#S:#UTC-Y#<:ZG
M$'B/S-M<I1*LSQ6CGM,+P)FI0GN RE3Y+%SCSWD%/8QGXIH5P'/4?/Y>-AZ6
M83O%[$[RDM< \_?22B43FYZ)MJRP]J7/WP9SHMM8TT]HFT1^I-S;VF8JPAOZ
MB0$=^!]^)F"].$((A:T)AG#SL7PU:8=/7(6^>9VRR.X=M@G>1T3+)2!EER[5
M1@K:=L]XH;_F*CC602KJ*P7$&HAQ4 UZ_;5R> $%)6!-+">#15N1CA2+7T'A
MR6K6WM&@%H*FTWI6&@YB4A'ZBR-LSX'M7MV1CX E.0.;,'61-H-"7>C4M= ;
MM&@9;K0B#51. [<O:(/#HR X"K:W=!-G[!K%T<N@A9WPA(1WCV1_'S-VH]+7
M%S30HHJ)%BJF;LBH<&39,YL5:6('+$FQ,-X65$B@&H'#WL!U=-K3.!E@@R3R
MH_OD939>NFTO;V\KQ=K5ZG=RL$Z7\39AA*R(!M[^,8O><LMLM=_HQL' H2[<
ML&/+UY62G:^L+\7>^7EI<EFM(+Y>.KD_P<[:^?(SCFMD:MB"5K(-)_S$X6=,
MDUT8Y#49[&@P \V'-^_UTQ[#7HL3I\Q?,:=,<8+>99\Q7G2!)[&IJ(X').I3
M\Z?ON;6OHM[/T[_H44\L!B*Y0Y>.: M=K!DQR:_-09T[;"*K9:!QD.!#.T9U
M(-(M/8 *[MW#X24TICW#F\O!=BOTQ)'\?8DHQA%"(/[R]P6EP@E'C.0KY'T.
M'BZ>&B,XP?1?L%MS/!-0XU '&*^6<3PE%@\,/C %(PS&,#%1KQ[CL>-9!\XM
MU3"[(!C/L<UWB.5L5&BTKM*S676@QJ;5LCRZ3"_B)YWKWPGQ.?)9)U9)-"<<
M?% ^6?=,;.?EFE!%5Y_NE].3!Z69K%<7X]XZ$\]>7M0:I](%%L)DC_/[JR6P
M#&_$.A%CB,4[(1S[PR"\+9-WKG!SRT\-JHHYCB#>B\'RR@7Q#\]YG,GX9L'8
MR]XS#/0D1P.67KUA[ S*'TX$G(6*0HP"Z)X!7@KV.3><.&3BQJES_)7*M@M1
MV794MOTWEVT?0B%V %)EWY&'UPY1HQXQO8J&[P([P'%+  %W#(5ZOO1[YV8\
MC5>_13WCFYNO>#;B_RK>2MON(O&+HB8'/_ ]&7I0#DZ,\V;K*IOKS8JI1GLA
M#NM9;(29S1]G]]BS['80#[ P;!JP:9 ;::X,K5U= [,&*#REWIK$<@3TFC_F
M[RER+@V#:4[GDJ&H3<W@[2ATC&:BY1Q\> !12M(C:I/D.N@H!B8EKM# Q9NH
M"]ZV;R$Z.$GN5'R?4\LN\<N]G4;34MMN3QA,%9R'$B&RZ66)T8J7E#D=:*,Q
MXLOZBWM'.T*J*(0%NB4$#*([@4X$[>! LS-.302-D !#;J*<.-.3>=DVHDI0
MGYC-S7Q1C.L-@%'_.'S1=GV=GM_7.=1@!C,LF9\GHNDIPY &Q_X*>G,H)II)
M_'[7$0>.H@:;X<9YF=H#]TKVBAQHB($AFX6[_'X3%^,&WHO](01T);<]25\'
M Y=/CKP1\8_ 1(X"*77O6BC2;K/?IG>9G+X;;\\ZUX5'X#A2J_D5J1L\<(\+
MF:<I'N./A5(]>;Q%='?+'0\83BC=-IP6HCY"P.930?7R"GAAB*$#S5CL=X\*
MVHD/L/.2._-Z&0(A_;<]!!&DZI7Z["-ZR]8,8/.'OULF0\OG8 2N]]:!HFC0
M.@D YOL$SW2,69N$T$8WAJ@$L92<?7.@@+?G%WR]><1/(,>SEQ63X<Y18?&*
M!_R]KP*Z&4;PM#;X9HK7\94!N].1_0.!,F;C.*2ET0IZSBA<@_-,29CCY3']
M*[A@SX"H>9E?'[1&.IYZ\!*433@XX+ RN_"J$U67IM\<J_-Z&:OE+DZ4>2]Y
M>C986X/*336^W+XF&/Z<T^02^$F<PR0LPR:O9JL^ZZAAGDC2.?OV_]\.AJ 8
MBI!OF_R)7&>C.*8,FBN!KPU=TU'7'ERBM+2_6U0@[NS+K+O+-8A/*PR!^Y?'
M0M&#BOJM\10332TOM^/6#;PPQ62RDM,=J;+?2BL%,S_'/L/IC<6SY"X71J+<
MMMX6RLS@NES38J-RSXX-C4?SOG#?S84(9?AS;R^4?V(1!C;@D"3HCTH-G'2W
MQ0>ASHP#K(9>!%HQ3*O@:<%P@84-7& 0G)\?NB-9^%\F37<C# W903]VT) #
MV,=> 9G3'MT/A=Q'-*"/;=D0LKB7='X-8#3C[YQT\<&M*HB^\QJ$VU@\MH.E
MX(7GA[L'YQ@V@/F7BY3 /EA=GOU=/W<WG)&">\ _/=P-J-.8",X1K.63X^OC
M,#QSZJYL\_P3.X+_]@V_L3.^;PYW=TZ(.E;LV>OM"1]P8R_XIP>W#R?M\UA1
M?12U(P>&5#H.Z$%GK7!&'\RD/>(I.L,9_$13?D<!Q'>]&<>]5 G9AFYBF!1;
M6CZ#UUXS=O0;\^U2I$AZO\'\;"P6; __!D>^GZ,V@&*W__Z,>>9$/$HT1XGF
MKY-H%ED\01K<#A_5]*UQ5YV*TMVE?E9)YZMW2XQB?&,;X#YY,S8OKHUR,SXM
M=?.YCG6QLONS%CR9V7SRNGLU:68*UW*/Q ?I>2Z5EV,WK4%R>TRK5NGHYW?J
MK)>]ETX[N?,3\[J*3VZ-.:EE$HOX3(]/R7QAQN,GHYEMMP:I07SSR;ME[C+6
M,2?7O4ZOU;E[O!YGD_4Q/+GU]FGZ.ILOMU8/<:5:SFK357^L72SAR:VW%PJY
MLZO\;5>+D]O);6I2J5^DZLM!>OOMO;1A5\NK:G_:3UCGL63BH: ]+ >9[2=;
M-Y6D?5I?]RK9N_Q55TKF2:>(3V[-\_I,CJ4:+4/K-<[Z^8O%M369W+;@26>>
M.\H&]@=F7Q#&3>XN3=@;9SJL4Y!U*#I_@6=_>"<Y7\/G7L3.ME]?+HHD-"1;
M%8U7-L .;YE5A$?VKB^]ZF+QGP>W8+?EZ2NN]#4OEVPL(>XM(6 A^:T7_-E"
M,16F/7Y.%!DV!'Z UGT\]<LUB@XG+(])*%J2Y.SX4%2]=&^@F-R!-N=WP[R0
M/?LIYJ6\U#U!2FI.=RS)GY7XH,QMSR2-4<4IKG*303<W@T?MJME*]#HB*=P4
MDB>E>&M\J.F='FN$Y"[CD%BIYMWU<& T:?.]-0(_T'Y9"(]%H2%H <&<M:+'
M>(V7] G-=K(;#I:AJ[SW @S$BPB<PAFO:LY%\Y_SLA(L+L+3W?;E2MF-5?]=
MHY<6@_E6.X/MHI>UUX'$[;TM4TQY]D[%9(4CYN;5*58XX6P1EH*(HQ$6([E+
M\A<)N?<:W;J@0!6-6_:$-1Q8J<&#\?C00L>3A9HUL#^ZI-#5>9<2?7OF;)5O
MDWVSH7=U)ZPH$-8%\^98B 2C9;C5[BPMG5V&]'?AH]7X[)8/^PDKT>(O0(KP
MC8('P9>D6[*F=VM$@=:<T$LZ3LT(;1<@FCJK-O'8@,?Q;)5]X+Q1MRT$:S W
M;R=1&C+FI/<'6+TLZT4&+V%7:2@AX1-W%F%OQM5XQ*:S9Q=4V>UH>H'&N;$J
M*[R*Q^TZ",OA946ZZ0TJNX 3^YEX1_;48?#@:]F+? 1$JADTF'CD5?3XV8+?
MFH:-U' C.75]][@8P@!J:Q@"NV[ANVE;$_\PR"&^G5M.*)%E0@6#+8J+]<N$
M\LA/4+I1?G'T6,.YA>+VF!-Q-INWPCAD'\P4UF'#>D:B8@@+4;4)NUJM^;06
M;>V 95/ 5J!$$2($F$GE\ H<8<GM+$F##.8NH-*0]DN;W0O,(W\JW+G4XO3G
MX->MO"(KWK6&=@R+#463G]FPK;R;D4K[\1RQ=="N& 8'2AW"@> 4A04WP'^/
M'Z_K^RXL[ZA%/@Z-;;YU10BK$'^J@GSC>U8ZXAH)YM7\MI"KJW*\E&\/B\O)
M]:(B':R1X"U.P&4=DHW0WKB>X)X,P#G"V 9M!N3'WCQ46\Y5$44GB+Y@338Z
M0P787N'H/B!08QR,*;GS<M%--+,R?EH^:0H!$58X&AK"4YEX65HQ)[ON0_KJ
M5N'Q#IRY&@H2?PD[T7Q=-EE#97;##Y<*0J%KB(85T-XHE* Z>''+[JK_L(L>
M!KW"O[LD:X<>Y>8^Z 9"++=ZC-YU=GL3L[.0$\I[PXX1?0>/LPAV^>\[_9UN
MFYA4^_'S/<K!.M*$R#8B/3XE\-M58I74:>[JL=8MQCL/4L$VK$JK.WXKF??E
M /SQ[Y_Q;7_3^^4+O$W&@$ZFA:9%8K3F=VZ2G\X__)/"Q 2?$$;=)1;6#X3J
M1=O2@W%Z^DD@MKX=6O<R47D61K<,9U[\?0FV9DMV/E\0@R*B<<W#<EI\D$SZ
M.)']EW^[^.N<K?-%_7WCXT4"Y$IGTYR_8TL#V(:EE; ;Y)/I')Y@"^0+Q"%(
M@VUMY@O>)BIQ',]XB9QP/DD\GT_\B<5_6_(SJ#!1+!*# 21,$.'N\54GCW/Y
MB"Z'1Y?$<2$BRP&2I7"<342$.3S"1'KL,.D2Z;'#)$OV.)^."/-FA/FW9:#)
M_&KF\3MOPG.7_:8J^XU+WUY]%\ _PP__W[?DM]_=D<1Q9J]U\1%;0H$&7/1%
MWQVQST#]PZ5U(G^<RQP:K;? -C?)'>FU0^'L3ZC7>$"+G_V)^4J@X4C!J2 ^
MK"W#^&7$#6^G^3X=-Z3_5 UZI?,__TN2"!F-WG.13B9HWRI+NW(9KR8('[ '
M^Q:\"R/A%=9+/=\#6^Y_O\:Z6 CL8YF9)BG\2TUM+E7X> "UU(L!U+837D6K
M)!H&WL2_QHR^"Y26^N:4S*_3O5%F?G]W/ZW>E(WVY9W5:MUC:7_JVS_9[%$F
MF=H"2XND.9+F8"#H[Y1F7^>G\FV_7IRT>]GINM"0)&UZ5\_?MCY G"]CXDW+
MO+CI].SB3"_H9Q.E9* X9_%J7NHHFRGLD>?#],]>:(5L5)]\&B/\L-Q0IK$^
MV,A^6EN_HD5R. [%%S1/@I4Y=1U[ QB@TD)4V'TJ&;OM7C:6O4MIDCHK6.5Y
M[J8U2*-%DCR*YW-O9Y!$(OY%19R;*9&(OZ7-\@(9[]PF3X;WQ5Y^^E"Y'17G
MEW:WI^ UX2R5\?CK&RF''SWITG+,EZ-^/U6A&2S0_*K.VT>IS^U="&J9%&@9
M6;>Q,/,05.K;AG ^?.D'H&'?.,;SYR#YGA;.G&JY]-P<&Y7&H$:JDXK1$5L(
MEX"QG_Q1-K'=^"E2'Y'Z>+.8T8<O_0#4QUL'E5Y3?ZAM<[XZ+Q?3O7XO/RF8
MCUEUM1J#_J#!ILQ1-KO=DFK#COLWO;/P-!;6&U\A.145@X;4:D0T;78MCMT.
MVP4O?"M+L52E;:XKL9NZN%:,0N'ZJK4-%A/^W)O""^^^5?)<Q19"C"_0 BN1
MB*#)(FBRW;SZ.:')VL5ZM5),U1)!W*Q!@A2R^4PF/HA+F=P@+1-Y4$B2PH#D
MI%PB4Q S23&_B9^EW%65U34I5WJ7I>79^:0\*Z5 H8=@G#VF&U8NE[P=Q#OK
M;K(VBW<?;EO%,#RRV$"^;:O7Z=8T*]V4BV>DE)N?+N')K;=;N4+^8G7:)Q71
MGJWZW2MYIO7QR41B\]'9S7VAH'3,_K1?O4BO=*L_+K5#H<MB@[J44Y6V&I]=
M-^;K]*-ZK3P4PZ#+^OW,;?8F;W0KV=EI[%27C(M&"\?<FFA,7X_,]'EE,A6U
MQ(,TF3RNDF-\<GNB>BU;BZW*5R?3!S7?3YZ,3;%FC</PT.8/U:':>%P5>LGA
MO#0I*?FX=89AS^TE$>W!LFY3Z7BU,FC>%NZTWDT7@R=;2^HLIO7<"6F>32_;
MV6FU9J>F]GT1GMQ:DBE=:J7LM ]C=M+3]*1U*B]-''-[2?)\L2I<7O2SO5B_
MGSN;M6_B8ZT8!MQV4IR*)<N<Z#U2KSR:E7927EZ% K?==B[;>:TU&_9*P^)M
M>G[15\KQI0^XS7W2J/4'M=IRE)QVYCUE>3,K-$8=?/O6DLY[PWO#B@VGO5FI
M=%6PJO>F/$3KI+#Y9'W4TO+SR4*M-&97;=NZ'^B6@6_?7KQ4G)V,>E:_&$_V
M[K7RJ95LW-SBZQ/;9*JTSH<7HV(FWKD?SCIF1[S*K):#[/8^W<[.K^+$'$^G
ME\GJW>VB<VKG;L?PY-:8F8NE5E6'E^EILM"Y7MZ1C%2_PR>W]NERNA#G4UM^
MG#:*#5GIC.++X6D1GMS:I_[ M'L-J3SMV<G'27LIB?GE-<YS:Y^&IYU6H9$?
MG_8:LOZ@23VS-:G@V[?WJ7\S56[3G<;E=#9YG)T-E?/QXVT+'PVN"1232(:C
MG#@8@K(:I$?QT2"?&V8'HU$ND4B/LJF,O,T#]GI1J[7O]4JVGVE/QZV9T9BT
MPM14(Y^M-.>B"3MQU5LMC(HT.UV'JJG!:)A<6Q=:K-?(3L:+V](XT:H4P]34
M]7(JM70QO9@^K$;3;O\A?SI;AJNI>.Y1+MPW1KEI]NSJ^G*BBNK5JABFIN16
M9]6.Y==FCXAG_<N4F2TUJZ%JZDR6%VMMJM9Z9'5JI^YJ,!$2JJ9:[?JDJ]8:
MRWBU.+Y>&%79E&>M4#6U;"]J)_-.NUF)E<I*81F;*-)I*TQ-C1>-;CJWN"C'
M[=3DKGC9E3,7HW&8FLI?M2\+R5NCT6OT"LHP-2I=))5QF)JR^KUQ5BQH8CQY
MJ0_R2W5U^4"?W%I2',[!\61RJL>S*=N>QFZ&/5MJA:JI9KMK]:=M.UNY[.AC
M)3D?EQJ#5IB::CY>C!*)04N+/YCI?+%*SN8D6PQ34^.KQT8EGU3[O6SS^NSR
M6I02TJP8IJ8R-ZG!A;%^N(GW.P_Q4<?*3TXSXS U==:\+PS&]>5X:FMWY+2S
M2I'V^3),354REG77LM1RI0.SG?83]W>M3"M4316G^D(MQ.X:/5%1KM;#ZT*N
M/0Q74\GBS+JOYA\7O<O;JE*I-&KICC0.4U.9^&63-*N7O1YISBY.->4Z9Q6+
M86JJTI+&24NKWO=$<=Q[)#6C&.LMP]34?8PL"_E%2JLTSIM2LE9\;#^LEV%J
MBB1E^7J97\4KL:I$UE>%>N]\%JJFZB.C]'!ZK=_T2&90B@WK^G*R"%=3%ZEL
M@RS*_9,XD;7A27Q.9HE,0$V]'#$T^2+$T-2WG>_8[SJ^P-%,OIH-_\>H)>AH
M"]33%GRN]D$AG)UZ #B**<ADI&"#&;<M'.+\4'RHI6ZK,@.^0NP;A"Z< _%,
MD3DBB"]%@79T0YB+"O^68NTA+!,^$0"KQQ]0=U%=^Q'Y7$ ^UNZ-=5O'+IPT
M*\2Z8LZ\G63-]3AZ&I^PAH^K.(^9CAAF\@)^#-ZK;IO.J*PI%$*H.5-VI\91
M3KQ- 7N.+QS]'%OE"".8@-*U;5"VL'FSK;--BL*"6^H L&R__HB"46T,;,Z)
MA(A/#I()@A#A3 .0:U9PVK#ASJ (-\=7X?0<<K#L7*063==B<V+0Z!I"I]!.
MC<$VCEMH,4M-D P"[Z=/OR9*Y:LVZ&2(-:90[)2$KCZ';<PGXT?"?Y00GYM+
M^4[!I:Q69DW*X#,09.4?BBN&@]-A:0_7^1Q&87L+)-N$U.)-!UWB! A).T:B
M$%( +)>>1[SO+ NR(JH9[>) .P^ZTW$@A?A4:7#'SQ/X7A<$B$+V^+Z<*, .
MAC19TR7@9UP[:W/;XG!VWC/ Q;H!$WXD;!+L*43=1!8U"&]2;WJ20AEW9?'N
MMPRPB/_*P7]C@AU<. 56TX<(7,9:+[*1F)@="Q41AO$][=<-BAD $$+\,H[^
M$Y@AFPKK9H<83%3_<4PF8!S8,/8DFZW7U]4'P\;E<M<\--;F5T,$,JYA3/?U
M\.*?+X6S^;.8E%L1DO0^PO@8E3R<1$P5U[IM_1PI*R*'":,O,./$_%AD*UBG
MX%0DX'?_]G_Q1XO8R+_0Z<'T]UVAV4J@_-__*F1SA5^;J9V-+,M68.X5[(A]
M4;TKY C>8O"GT/ S/943#CHH/-BZQ5K(2KSOL$11Z9A0L#[2"FI*BH#(E0Y#
M%4-QH,B7] @1)OR<=\YE8&11HA"/H@M%MGG<>K'SK;1&Q,(1"[LLG/P)YQKR
MK0,'"YJ3*>\G^/?(@[?U*7ZBT$%DT*&2A8T0#>RUS?_B8. 'PY?QB"T/E2U3
M/X6>IF_I5N!"9@@@EU%7"!2BA;Z- <:Q8]:#_A./^(/<V I7K-2*HV"E].Q'
M6]EGT1_O9M7PU!75<V[:[+WJ];;[GS-!HKU^_3"7N 74[G$/#6Y\_X_YI/7K
M";L+B,D@>/FY(PL4KMAS;#0&-6D;U%($^U+Y$!A&-X=.H6U-[B7(#:WMS.T$
MI^;G-:H.VP&4S.U,>_VAG1:3TZM%_'*EV+EYI9!>7Q4CB,;#@FA,%HX+?RE$
MXX&!,R6/"[F($ = B,1Q_B\%^SLT0B2/$W\ICMR!40)TTU^*LWAPA(A'A#@$
M0H!NBNRF@Z!$I)L.AA"1;CH(0D2ZZ5 H$>FF R$$^'3)B!"'0 CPZ?Y2".JW
MH<0+K]4_&>][OU7G7[#J-XVL'?227>3-1.)WH3>SN>/XQT)OYN?[D3=YH1)+
M;-%D!/NGKV2)?= S<5J_#2IQ&-SO#%N"&0X-!88Y(^J"X*QQ2%$S8Z$[^#6$
M);^Y06^*W[<_E!N1^\D8Z]O#[GZ^37O*K/\@&7D%D.8,/2D^]B3H> 6)$:T^
M#ZV$!E:<1!3;0['4>YRMOR-=D1GUZ<RH=_$Y?I_5T\?QM[6\GL'JM;?J8?/&
M^NG 27L(YXZOIIS5YD9TC>@:T?5@K0Y_]>B?FAT?',<*K*M,3,E0:#%T9#2\
MDM%PV''*5VL0]7<KI<PG"$E_I[<MA,2/3T/O%X?9(@YX#@<D(PYX.\/D4W!
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M_*7,AK9ALCFQWN$X69B&J6L:45DSSZ, 2?%458&'&8E@%X:!9IL&&6.U#39
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M1-,(>B#*?Q#1/S?XYX9L=T0!L= 4__^.A;K1LQ##:C,WQ&*(+ Z^*X.C[#E
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MX21"%=/36=Y@[A'J8J?LJ%\PW0"(S%*].^-OU&;QV5[<\F)E%\&S,JA]F'J
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MKX[X<<N- BS<$>:JS1P=Y#WW28$[_2!QU"QWOPBN6U1-W;=X5\7H=$WHV(Q
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M$R?G33=&X4DU4Z3R7,:2EV!R!;S29F!ZQW*5:W@+'^'-T5O(&[C+8>P#:2\
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MLZTQ/Q>$I&"Q\4(Y,;IF^'H8K)YYBSX/\$H]8L_=F3_\UR,"YE$!F2</>/.
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M+Q6/-Q5WW)-VYKF$SHO*_>M/Q9.8+T]&O6LG9T+)P[@<#UBB[;6]<9CM3L&
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MOXB*FU$\*]L)8">R\U9M28UFZ0DGPJ&$YP"#;R@#SGEM-'D-?VA[)1I]I!K
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MA>=,#Q_ECJ&_WAZBVKH8PW\3"-HDADCNVI&<6Q?0@WC-JD&K 1:F2M0R1:^
MC$!L^I>O?#"#[WQ 6X)<&/$G,48TVX1/S+]^\_:'8Q3+O71SQ/9]+N#?[(:3
MUW$,,P,;+9"G7[IU D<QKY?H?[QPO\3CW+IBH^7.,RL7'C/35;,]Y<"ZO=PO
M<5[W2\!V17\FQ/'+C''!9O_)A  OXH=>7G!NA$A$$C\4?OW,*,%%DGL!Y2Z$
MN,BF'T:(BVPZ+"7>6X?\FMUZ[%5_#_C[PR[2P^!+?!2#+Y:*1$_; /,:!M_?
MKX#NW9&H0I5$%1I.5"&_CBIL5:7_'C#?Y0P<9Y%ONO;C ("3J0@7_]+,3ILJ
M^H<A\WX3\\ W?5RH_"XJQP\AJ$Y:E_XWP2$/3#Y_C\+[$U7:)T^#P;&Q[H-4
MSE.#_AS;^M_=PH.%\6W1F-;CT?)H+%N<VKTKCMN+VN>U\[M/E51!FY#J&Y)9
MJ#AIA>V1R+G,J&)N?2KS-)7C@O\E;JH-_E$>LTLIU5N.2[U,8[A1RQF.O:N8
MTTEQ.(4Z._D-Y^U>W4[,JXE_G!:,E117XVQWWGDJR1DY+'4QHQC[XY]H*,JF
MCM/8@]KQU.?L(E\N\N5WY$O<+U]^#PSTT/*EJQ=3Y6KW6NF4V]90CC>;6OEZ
M> KY$AY-^<=B4KOM2(H:MYYOK'&VB+4B" X2XN*'! <Y@0-9?+% \&OZBB>3
MB6>#$7*:37#$Z;F#@GQWV\TYSB!:,QN'>5.ZQJ?"LB?&[=28N^LGY@_I:JVW
M;)Y"NEYSUR6N6 U;^>*HUZM-ZRMAF<?:+;#>.)"N\>-9;]_]1%[$TD4LG8O)
M]S:Q)&B]AZMQ3N [?*O?MAY+K<'UXTF<RG"CUTS?%H7^N)LSLTM].IX4;E$L
M)1$Q@HUQ!S?Z3NU3W6D66($O%7)>0G*'=YE/#@'QB3[UR==Z/A+X4S$Z/TM>
MUE)\LBW&8";)1OSA,?Q04)[2SF4]L5 LL>^6C$L0[B)1+A+E/&RZJUOC^FZZ
MNBIWN.ZPSL7RO?MRYB1AMX(>R]=A$KF\7*WW=+4\X3MMY]J=>(A+O6J!'1?K
MYK=%P*D@=]SF'MK;\V)3.6,1>S"PF8>6P*E#[)ZW'32C+9P V@HM,JIF,4O)
MHAW1OH9F;(#_UX&/Q>?B2843[SH'+A9 F[9K!Y\&#QN*3-DD)OEVDT]-LQXE
M6+"[E>N1Z(^V\::\HY7T=;H7NZ52-6O8[7%Y$$^D1LM&HRDT__@GFH[L IHP
MP)H*_(>O-1TY07  (?K($,""2%;2G\X[W5O(6>?5CN6C%T*9_!)M P$C/HU6
MM/ZLH!G.1_A<U$>6_$*.FOIPP;+UY_AT$*M)NJ)DP(**1+?%&$6ZB#!G)$ON
M- :7;@Z6C.0B7Z"O/[$G!!? MC1CR5C\@O3_(0P)RA""9& XF '8"FAXI*7>
M*!$+#KH"[GC(#VWB#64BVVD&D2,.^LF, OPP8"C(*F*M4)R&" .<1Z27VW/(
MD)[#5YH- UXK*6^&:_K&EXF8#5Y&GK[C%]TU73<Z&OWG(A!YPPSK<GU1FIGY
M[,Q<CAZGX[MJ? B*GDV$XHE=6+OW(&7]QM9_JF%UHJU_GA39U+7$I<=+X2J[
M3#U:-E\%51"+IT/)Q*Z5M7V<:#,O[]@+,P0NQ /(Z[JA+6#F!+SHT*K^M#[U
M^S1_1D1I2N1;BX+ W&GO)9A?=X_RC:>,V9\U.[(@/SYS-^JB;<-9X2+I%U4W
M.2_')L+GNB&G)<(T*[.WV>?'22<9O2G$X[EVHSA!J*!(P(GQ["<X+F@WR3,X
M$P06"(QI?@)N+>@WU'0ZPO$0 QI!=QB!-T>,9EO8D,(,#&W"#.#DJ0+![,)A
MP("03!>1AQ<$JISPZ]?@>?"(DN%Q[%.;$:S?BMA6SN\!!-C4T3YWP]H;W/:C
M%+Q[)]\&=(0$I7 )YF%1"YJ5^&12["GA<3$G#LKQ&7O=OL^<%_) _<FLYL?=
M,=N1!^5E3K5R-_59YEC( [_KF%^@!;Y?B]PK(.@G[^;]J4@#YTV7G]O<>^9T
M^;F]ON=-F)\+2W#>=+D(LC.ERT60'94PYUY^?PYW\WSMZPQ_ L)!P([]5,"#
MRX&Y-,I__&1\772$"P\<D >^/G;"[IJ_-Y3".8C],^A\/M(5A>?;"/V1ZU(/
MG$(^5#_S<EJ<W'+A\LV89_.UN^0@W[XJGJ2UQ2I4GKI1-3$9MU-=SI[*1DY^
M<O 2N! ;3W[34NV+$+D(D1-58A]*B+1SQ=6D9H1K^4FYP5>-P=1ZSIU$B)CR
M=3\E7MO*>+*RQS8?OFFFADT*BL"%TJG=*M*O[&1^*XR$,Y*#9].;?,SKZK](
M!_(7L;7>UDC\$'^XRCR*N5R^G&IU+;UBCQ[-^2D$9:RB/%U)E?"JTQ8T::DH
MR0Y7\O -TO$C-L9=1,IYB90+^L$YR)[?,-'>)GOZN>@HO;I^6K)\V!@MZ\W;
MZX?'D\B>Y"#73W>L?&5<MDO1?BM\9\>?YQ3$(!YBTX<WTL[,L_D)F 9G(6>^
M0$/R9_N])U_Z64G=-U8M?[Z,7!676>7*:JAY21@\QBMS^Z%9RE#@@G@HG?ZN
MZ*$7L7$1&^<O-K:,M9N98&2FX>5L7%_E>T_#>BUE:"=!)R@93Q*OW!4X-IE,
M/*5+\]4B*38I.D$R=)5\%13T5.@$ZP=3;R^L.LRD-KH=N$@TH;_:+!1V'@OL
M.^8B,6KE^7I^1 VFA* #M$,=^].=YG0&O\;FXSY8\0/L*"8=5?@?M,U8(_WR
M;F/5DM'<F]:]5FWL]'FUAZ@O";QM2AN=2()M&+ <9<F,>)B>9+D-0^J0= =)
MM&UH1+J^!K9"^RCIN#PV#?&J  L8\K)J6F3*[N7R9$4\C&"9$28C"*0Y<Z@L
M0^>GT!.[_?=P.K%.T914]V!.AM;B5WXA2*9YQR^N*:D*0*C@ UIWMS'CM<-%
M _OUJK.DI-43_3([$?3KF\I"2E8'S3_^4;7==KV-\X+S#,N+,#T>OV[(OWI5
M)1,/]Z^*:CX9KZQ8L5$1'B?-P+/VT=-"_\2!]EY,[K0/>J>5_(LB=%!XAC>L
MQA#Z\U*S/JRQY7RKG"I'TP-A.3S%:B1"^:W%O&$%G8$VKM^UP^&Q75/'YK#0
M&SUF,J=8 9S'K>E[\F;$SR07" 6A"H ^>"VRUX5)!9*OE1 DT/:W@0V@'[Y
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M"3RU;5!1O)#59VBI 2T$\'F-T@R<"U4 SQ!5!D-EL^-FJAB:AC\(Q*S[)K>
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MQT_TO[V_2JJJS:APJTJ@8>!DGI-Q6-](2X=>2TWC%UM;DME,\KYY%UY)]YI
M+MK&:YJP/%HB]>;!0^2G[YH+68WW2A >(MV'3K9RS;0:Q193D052.+A>L?]^
M):HQ:&MXR(_L@M$EU<88%.I='!\4JJ(!B_J5#7E#P]!$6[#H[&F8QRT0<_4*
MJC%3 .U+BY+V$03T@SRQ%3#H)<TVL=30O\'OVR"PU+6M*@6F;>LZ*/[U=NRG
M**D&(&3<W@^3#K2]#42OOGF*_G3%]LQ"\!28,,6[!=,I,Z42[(0VI#%4PK2H
MNWBPD$"I$ZU,8HG^68)6 FTBH+IR)AM MO?-EQHMH,JP9!7&1?7VYHN8.%!8
M_I(!]Z\U1D&PCKI>^K]9Q]QOX1%PMAHC'EP(0;))B7Q &@YOAZ@/?+#SOK ]
M<J'+A-[..[^_-B<C:=&OSO/)5*(DU56ED;X)ON<IJ,ZT1/?(&Y6BY;G;X?/X
M[+)IW*2*Y61'ZM56RZB1%I_FX/$---N@%S%M6PNA]XJM=6V)4X<,# T$DIQX
M\<ZA<&Q3>0!OP1DPM@X_FANR!;_!"F@9+'.RCL@[9H&9)=<@DEY^L8!W7ZDR
M,:G)>W\Z=XG\<H.SO*'NUM:EPUW\TNQ2*M6 2(+D8[-*HC;N5F]3XW'X>?8$
M^];D!ZO,'_]<L3NW?\$+3<<UVR Z$(0PGDYO<B W\3!^$W<@;8BTEX1\Z#U:
MCI<WG04>IJ*&#6E@JR*Q[FU]8&C(.Q*)B7YZR=.Y<MBX&KLO55+56*=;T_*%
M^KTZB8X_4NU$F2[P504@ D@6M\XDN#I>?6A?1<6GWIBS)W;[H7]?MZ+ >,E$
M0+63ET.4MVH/O>26RP=X42 8D;+G()(I(!<XU<QOTW\XK+S.=(=P I)I:2I-
M4]%ZNY.4T;TE+7UN/+<:=CICZ[[.CY?5?(HMI+/-:.XC]UL1GLL23W.XYC,O
MTQU<5]?K%(?)7B:1+]KW#W&[D^MFD=%BB:"ZNO7%2>O;<WXQ?\I_H9_O\H!?
MU)WHFK%S(S$7CYJ3&M^]9KE.*=8:Q&_BE?F'25QU=]JA<$$S\FB8F.1.H*P"
MEB9,_PZ#+L&E#.'NI#F97+'/^:YB#:-WT>:*U[ Z:1_-26N$IJH2)211:O1N
MII$,3I!+<?R(FKI^KT=RYP?>L"TNO4A:@RBY&%/I5//U-B,X<V<L$C'RXFT^
MX?,WL!OPVT5C'45C!;"6#_NL/L@9]A#+>BR,MP8S5UYK-:OFXDEAE\:SMDRN
MPK5A'6^RW<M<Q&C%]CU%<OE&D P+"[/PAC:PG:4-&%7&I%?!KH.R(DP-E)8S
MMY=YY\(\IV0>AQ+!K-.=/2>2A0<VP7+FM+Z,">-H+@&LL]?H.1#GZ#[?/HAO
M9A>V^3RVH55[?GXIJ32#0O,I@=QS:YIQ@^VQV3RW$N3;[K#0L@UL$4B]SC\D
M^R$;IK5A 3M%U[RZ:?X&97B 12X<<FH.&<.^@^PO@G<-WDX;W& UHXHEBU>6
MP26=AEVY;]:&0J?<FZI:,M=691.,WR,P#&\QBL2;F,SUJ@NW<X)T]B'&F7^(
M(2L@WA99 _+817M](I.110ZP^K_JQ8CAFSM)&*F:H@V#N:K6R>7;\;MYLR.-
MYO62O8H]]WO 5=Q[U9A3EDJFX%=K$_]D&,N;#=%=6V80R:]OZ#?25;=9W?[F
MR-+?9#S@P@L;?B(;MJ2A#0O3C&4&[_">X2\"^*[.YR5]V,H4V>5@RB5S1K&3
M:F;>9'@;WAOH->$S6@S!OYTSPJ:D2'AY]!9WPG_1*A7@6PE<Q2W91Y4GX:J\
M;6BZ!*(3OG)JLGRBU9^D"0A)19@[C<%[@'<N'"8QMDL<XC/B$'LCFME4.G';
MO!UQ;'G<U*,C<5R,\\,__DF^%G/8B2LYH<IW) S?'CG'HB/,@.*]X%@JY+8#
M$6;2EKQ"86C6<W(O"R=%.'V)5+7 /&FQL;H;.EWW9^S)-P>7NWS-DOK8I:3^
M4E+_K4KJ_<@L^^N^W'JN=U1_<8>M]]JHDGIW451+FDDP;:;E0]RR7\I4!I=,
MG;8&:@.[ TM4^74MUT:1RT[F;(XEJ-)"$FQ2E&,Y7=@(1H&(%+A8\H@J#36,
M=<-#)"+.,R;"?6U4DFC]9]IR^C<M;<4R2VJG(,51YYET,/A-GY3!DN(D02 M
MFD[5J^D?FOZ*5-V:&XLBPP3\TI]P]GK;%(4'84D_7)<3N#E#+-9TG^=AG7/O
MO<R<%.AZ[HEC4M'..=IZY]54[]2)&@Y/D5QY]&^O[HDTHJZ]$Z_F0?2ABUPR
MU<?R.OQKR#FD<DX_''X%:_,PCAIHV8W&75B.]# ;EPM"M"UWX^JCU/SCGQ@;
MV;VY:)U!I!$4K)QVBQ$^)6_XH\G\\8($KFVR;+?29<?E:CXJ=X3KN_CK!0DO
M*@M?60NM@M\ \+F0_SCDO^<-&6VVC4YX#*8Z&9% RC^9V7ZGT*T5V6G\*M'1
M=3/3A2G\$XVD7R8\>$?RA$COF?/.K=8+DF;!#:96A9N3"6&_-W)*'XN60 6)
M\D4>'(\AZF2SL5XD2[;:C7D2HNSEBN=5S2I(=OQAO&P]V*6>PA8S%I80!( A
M>%R!1-<-*8QE:,3R @6#02<LTT43%>R$"Z&/0NBL8[HUT$:K#YR(@_?.0!(G
M6]-XYH&7IQU9%E>%XK)>NY%!KU]QD=B+-*:=8+MFX1S-4!?;F3238:6N+AED
M!:1YJP^FO8NSB;@.'A1"N]W ICL9I(-I$UL:!W"CX8A0JM.?D?BW; HT)(.*
M)5CZ1$ =T5K:=@.>0S->L^"7!@R-)6]]%$>\/_;C=H;)(-=4>/]0P^XY4M/N
M22YO0.H[>!)PW2^X;EISMHG<AK&[61>!=T[G(*?EI'EMFGSH3.ZSPU4K?MNH
M85YY[SG897BGT2V0WXGKB#%'A[<I7_I*[ @\',+$^0:8VB RW9IRYD\'QJ71
M:#I0*W^M*QV<C#4-5E[8ZVCLU5B3I^Z1%Y1J@Y+/]W733[S]FO;I4;8G6KN3
M+VJE].TB7.B'1R"&N<@NC)C'?031?.#V /?Q4W5(\&^<9DP2\L)&3AU[F53+
M13(,+ #>*?XE[2SA=9;1BPP8DBK-,>1!6R8N?'=:OLMZU*1=(_5!2Q\:#B6#
MN:UY'V\\#:/W^?*]F!]6'@M2U&@B\O#+W!9Z.2/MI:\OG'!:3GBA@,&M< @N
M$\[HG<&H5(KE^9EVS4ZG[3";Q4*&=&3W$AY?:;@30'2K8> I!R0=+VRE[8T[
M<H<\3'[I*WA @(4@Y ,BO,#@DBW%Z0"523#7]&JS\&\%$](@9E%Y@MZTEGX0
M_L">!L*AI W57\V\KS'T/<43ES-PXC- :\9J/G8DDPI6NZ6V?/LX2]HY=OD\
MZX^>JSTUFT<'-[8G[A%ASBC?T991-7M*'?[P<_6+W=UX$+QF9"^S\$)=!7_T
MRHH7;H<\-PZVRODJNWHHS-BD>I^^F>8'2V'P8=3*W^[P6)CBTVTIG[[M)'/9
MBO:446ZZMYG7.CQV6WC.H^>#>LN[LPOTL5X++'B)/!)20,\?^;BOS207H<35
M2>BM$PU&"I>"A]SPTL#W.HG/=3DIWDGQ[@^[TW['Z3*DI^[-XD$;C.WGS/5
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M+TL)" \&-,%O=+Q^N#/\G#I8WMW6E3C9@?D^#LD[#HP#]^"<EX*A37RKDE^
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MK(=__P8G,".0"10ED:"]&" @D'M-,,\D<WV')A%8VZAT>05D!'-CC\>2,M)
MYX>8QBB2(U I])8AS=@:@C*RRD@37=&6TA:;;QZ("--"6\C%5< ;CVS3=!!A
M40Z OT2@3 84$0H^IO0) &5P<$?(5>TN^ FJ5D^R1S;"O3L-Q$?N7:N 121)
M=8KGH XK$L@V<[=5[49MVTLK?-?(<WSVICQI6-<]'&S[XMW@Y]QK>H_2V+9C
M/02YMC2>>A4!81Y-LG^_]/]T^<?UQ ,];]>2\2/HC(C6FDQDBUJ;5(5H+JE
M3?*F Z7GW#-+;GJ;P_G!_D<0W5O(WZ9L.=I( V$/YC*)FP< Y.&;*7]*_K=L
MHN22'_M'DT#N$)B_C1$]S%-GH!$_<[',%?J9H_[0O"&G!"V,C[,]*H 66DI$
M^.)?57C;Q)ZX7EH_>E-MC?D<FQR-["S7RW;NGH(!!K"U!>RQ#;>,<$B5QST
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M_(VDDU6;I\L__4(_NC1?=:2OZ%, $6W@H1VY>^8>21S[&%6?+Y;%<7'?VIU
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MB>8<"#='G<G<AT>99B.*%1-#@Y_@%R),2-%T(JXPRP>.$H:H0.3@BQ%*VA9
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M<";3^)K@$*D+.,0%'.+[@$/P1)#VQ"2?EOK)5"_:OQ)Z<2XI]O@8-^B)L=A
MDM+2U8#G_J ;07]1LJ0)5^558&!/[]NFB;4 JIA1>65IRJ8V*#@_^B2=SGGL
M@/.C<08NPJSGZ:4.U_.E76O.C)'Z3AP5-$36A1,@S[0DTU9H_8@#=J2IQTX#
M^N_@C25W#X!OQ?^5 ]B=A#4$^/91LQESI-D*UHKPM""$WI/L5%?X=X/W[<;
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M*2*&&$&150+.:&(O+JG*@<<8S $)*%9(80T!P2!5-4S?T$ CZ;(NP0\)^Z+
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M4"]:^KBLFJNQ.05?3IB+JRST6%ETQ0LQ$-&$MBQ?IN%AI4O%LH#+ !.S077
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M9"TKW*(KQ-&#^1^IAJ!VCG;.(E'3]A**5^8,HEW[QGA@7CUD+N#G2:U=TIA
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MCUK/<^MY;CW/]]9!=Q $U5*0D:_F<<$JV6<@*.%]A)]/"N\M<="/5&T@V>=
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M- V!A 1L#@\K4(Q-,278_NLXQ"CGM4CA!_)'=,BB*/"1\_/?U&,X?'8=X]I
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M==/^ (E'[!PJ"C@*?O@.7@0=*B"5ZO3#S][%^?L+[T,<$I\Q?BG6P/'!3&X
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M;1/ @SFEM[VPC4CD??_P:/,NZJ=!V0_0C^F;)_98P-(] RS]20>(AZY!OPN
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M%OAR_#L55UD9.ZU5")?=] W>N)VP'@SGI_%X[V?N%N9=3@3LT] "SM^92Z$
M51&,FU0@NAK44IC:]^[)CF=X2J)TP/\E\'8PFP'?)PEZ^?;4RRO8?;X\9.LQ
M!+\&WI?43:U$KH,\IM]IWRCZW#:MZW]S'"3PXNAO/_PQ/AX<C7KCZ(_^L>C_
M<=#=[_XQ&NP?_W$0=7N'<(/&XF3T ZL,_(LS(.'^;Q7BOY<D@6$_X,]$_O4F
M+A .OLKECQZ=0G%^$MRBX]GSI(MES=334X6I#$?8S^,CL0GO(BZ^;!61U<4T
M+60[DVI&/4@4:\.%>D?#.RR2H6O5"A4W5"V8TK2BCD;4YP->IQJE_<-TB(&Q
MX)$Y*(E22KP1H9B.X+IHBP_?7TP(?WB$;N8@DDU9_JQ2IPM<@(VGZ%U6BQ/R
M"MZGSUNL.?YY $/";&A[NAWOG?[=I?Z=$03<$PXV+,>NHO.&Y6^T3]RRG+9'
MO"5=$-.#1:ZQJ/(V-,1]^U6&<Y!^MHW]V\#S34L4]OF)1MQSOP'A7'62JB%Y
M=[Q/")YM]"@>KQ#>GU4>%U$<LB8COH)A@JVP2/%1VR74=M%4QDF%C7ADYQGC
M31Z)\D:(U'2^?2,[W\H9_8P=45"#;^Y^V_'^-6GX-2@=(KV"3]/"[J%;J$T*
M=9,5^U?8-%<Y6O;L+]@Y+3M&*0\F>M@SV94>#4S3TTDV1I(->:S]P^9ZN;RP
MV ,OL:;CM'$R#;DX_D$[C($W; MB[21QE\8-E[VAX'W ^T#31 &=S/5+J&]1
M,YBW:DXVX0Y\\T4O.GR &JD.S&'#'!D446VX<-(+OU.KH+Y.S2_7W40"X#Y_
M 6UD'%QG.2D44]"H2=N.TZ:AW;43"R8%A0X(5-Z0E%I<?:D;D^FF2<V! G2,
M(Z;^5YI2@GJWK7@C*\>@!_G%D62,JUW&5EY([_G+]2W)1]=L[\ 1=;?6"SRA
M'>6"U%&&&%+$/<-(Y .[^N+5VETRQ11.QU_9&MBHO]A@ .X0Z2)*.T;BQD:M
M16,/I9_KC^.Y+WN<6@Q;>00E1JW4!0="XJY]J)&#@C)%SRVW!T/W$]R/68),
M%^TC[!V%ABE8G2D>N&4(TQ@OI()P^>G=A50 7NK0(5D(TI'P3D046KP ;IG#
M_?DY2+]0XU4XPO_-\B]$R@%9AT3&'O"^+/>]HAK]*2\_W%V:W3C)LKSC70KQ
MB'UML9T$]H>H"N$>*_9^\&!M,?>_*/S:U\5-,"M,[S/WRXF(KOAB@VBI>#JP
M%N#G:3:5_<'P&59!@="#J_KKB01O&OBD-IE@OZQ3QQ#D,C;-/:A(975?@IZ.
M[D&G?_ 7+4%!M8<]Y+9XRO!3_4D$[!J\E /E3@,H?'-13?%':6;EL2R,>!=J
M;^A[%7B3^0QWG+( O>Y?%N0@4JQDZ/HK:NI16[]*'QK-ZUQ[W_*'-4F>IQS!
MZ+41C#:"\7PB&-(O$PY 5O7'P1\'QWWTRQQW_P@.QH=_!./^"#X>] Z[^PM^
MF0/<ISQ+$%_J'#VB$>J:?QR?=+O]WO8=,@<=3TV0>+.9XA9UO@_Q5#:QIORE
MMZ0HP[&D@O7?)3/>I%/ W%28UAHJ(')!IRAK3/_G>A?.4FRSC5V E;&(QAU+
M5^I_J!U#;,6H)<[T$GTIQ663<.J*CBUU6&J!6;3T=REJG26P3S"A;MBYPW.1
M_6"E=1YAH5.J0E.P^PGV) T*,$@H,5$U6^;\G$DLKE72'(Z6BTC-P,M(\T*=
MIN.=&;O&UP]?<4[3K6OVIMC=$=A6PCV*!8;YI6%K.D&KWEFDL8$!&*L2+=F;
M2^]:7*A^E*2*HU8]]_ZLHBMEQEF'@B\; =F-XY(3%L  HZ:0RZ:J&(B,1\0Y
MQRDVZJ]Z$-+<<MK^^KSAK3P=CL(85^HC,(7;]KG/(OVVK?[$J2V2'GVKHVN0
MRP:N5F_Q4[AC8^_M5S"EB+ ^C<=Q"+?XQ2P'Q1,>QE:KZLN,OWS)-UK_VOA;
M&WYMC!KU:U]= >0&K)J2OR(U(49NNT7A1&6D27N'Q0H:/;[EY;"8]WJ,SGL1
M8&H/3(X=4Q<FV-/M!WO=P9F)_'0'$7SP0KSDCXS&?ZE[%QLWZ9!=+MV3_@$M
M+IBRP^,%_D":H_;#RBQ]"3:TZ@5,+$5H0O2_\:#N=4BX<=+PU"Z^-;;U!OFE
M/A./66@SAT\PL4H]L=[A;]XY_WTSNU/C##I3?>TEG_,^82C?$ U'24!H;3E(
M!N1%-*;M<YJ]Y8!.C(: *S"4G:L5W'KW7XQ?+MS^\<+MMV_Q2R\RZ?W_YM!2
M<QHJ72;RT:K<=U / KHPR [1S91;%V;N)?$7M.?)JU?[@7^W=3].+'J!!._1
MO./I>"+ZK2>B]40\.T_$4?=PU!^$1W_TQ]W>'P>#P^"/DY-P_,?A(.B>'!WO
MCZ-#UQ-Q/KSX?';VZ?,O;R_.?GWWZ>+C\//9IU__Z!]T#_K=;7DA<%+,M,_.
MJ#"C]YIFZ%E3M/)BT&G1_8!96>><68;^W3^.]D\&Q\?;=Z1T.Q[-S;,FMSL9
MB3($A1%4.R22SK70DOENL_KLK;T?8G#M'=C>65[\@:ZPPX%#9']TCT?=D^Y@
M_,=QL(]>LN.#/X+1H?@C''</>H?AT=$X%-LZ*8?#8"EI$LQ?Q6F"O<9'219^
M<;;3R*ZCWJP!0WX#6<P-K$U"TI]]?OM1$M6PPXCTQ-@NSB[_X;T;GG[^=''Y
M8*I"O#K6JM)"I4Y72]/$VI0LN<9@I3>!)8$6AU$62B+%!"[O?[-*I2)1WBKJ
M:B'\<ERAUD2F"#R'VE\1YO$(S0N19#=@2F97@B)@VEI6 ;$Q[B-9S#H2E^44
MZ\YG&;FTT$3)L1),H%G3$)P[&\LD1/8NZ2POGDL6@A7)JMRH*F*T8WU+?<-8
MH?1L<127K5R.NJ,'D_)0*6W" UWCIJ3$;XJU%;(K_,A5-JE\$G3$0EBJ)SG1
M9+9(G(?5%(-=H4H8D0%E,!C9-==T-ORNB*HX1<?[1/N'=7&E]!]BF@4G49JD
M'4QC(Y>$\"A9@!\SWT="3+UXJKD(!CF#I,CDO&N[IA?>N($*46EQ#^$6Q)LT
MPW;$&ES!K5:UK+@@LKR0)8S Q]&C9"S!<ZE#T';^*C!N#4=GRD2]TV"&-UKW
MNGCPQ:Q.X6A8H<H5UB7/Y#0?QV&0EBKCJ8CY-H=B9DIO#;4J4J6$(QJ'[*\X
MK4S2E$ZBS+"@67"X6R8X<<1\[J4"K35V==,=F*)K&>N*@9C'L 2FELX#)9W<
M2;P'IGP;N,.5H,IEY&S$-!.,J@B[]A;8();3478"&>W(2V4\8 3J0&JS,5AQ
M;[\[H(<YD9MV9H1Y<FHK)'2!Y"(8^V9%8R3L1U0JV<*NF['UP:M2\<4#]R6_
MIV0 \]1B>I0+8H)EUDYQ_1W*:?#'7'HADR5 04_F*[+6)D%$.5T@0:857U?T
M:X1QV3#/HX.>G>EP2<ME!X)>\HW<GTA<9U2/48U0#I12<B2)8OXJ'$()(;)$
M4H692A%.4C!WK^8>:$$E'KJ/"1!P$G$Q44]=QYAP<RU0W:MA!9@R2W8O)D$Q
MC9ELWOPZQ*..*DXLED\2#(2>@SN8K..D,HOH6F8'<2T'#8/QJ"CF-&NE=<PF
M<+V3*:W!QS*,^!H%W57"3 #)IH)?"T8D($\GJ'R4I&'P#PQ: E6*FRI2DQMI
MTQCM:CS*"KA,\",<&DM)\%AQI6HGK=WU0?+%B?XQ^H$2C&%5K&=SZ2OZ?D#C
MB#/T+<&5B_^C@H-P(..Q^K&\R7[]+)5LQ?=C#FL>@ "#[T+F\3[G8.$G!!Y@
M%2*Q7_@ZIOFM@&XHJAGE7\M[@GDN1BY[=E7'G' 3IQQ_*P63/K-'I,*B"O&@
M6=7#]20"^'0"3$WL81([,-U9#&2-*H&#0H%E92-BN:SFT/3Q[ESC @TU&9*A
M%!YXQ53DG*[%PY/SCLI*9+X8*(*Y! &@>P*3S!1BQD@ B8WI1ZBAX+"RWH<D
M@YZ(2:1-!:X/"1%'-\LUE*QG)$$=.MY[C(P0N2>4&TQ**-8WE?.9S.!*082S
MG)=G3U@A-UZ45U>F')M^%,O2FL([IQRG;GTG<90;S$V.*1#*NR@UA%)EH6(
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MJ9E,QPSP<@)K4&438^4 ,#LB+SLJ]!3S7%"%M7^IYD9!@Y(U4!0VR^T $3-
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M,S)Y\U;@C8U@2KD*D"[>6O[:U%V1YES2/3'(?1;F)*D#43#?*[.]""ODC4Z
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M$5:\S=?%0>J*%9_* Q5><W'G_$3"<#?=+N<B[9B#N;%=8NRMJW48PF)CLL>
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M(QH#_-'[=$\;LY^DN$QJ#Y'BL,HRZF):<?Z63-!QVT8LL*N2\' PFC(SP4D
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M.?9A-F(*F[RPY+&MII:4)[?" Q$>YO;@L727?0MB:2\K#@E@J=GDR;LWP3J
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M]P_?GSW\UC00U;OY):SH&#B!I*L'=W!4:"LN.X@29.<\[#.8(:R)3X1[W*H
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M8Q,<!%%V(46OCR,^*^4ZDQUFVC$_,S]O;2FCVV34&$%@EYMBU6UC'M@Q>,@
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M>Y-K[TEBA*5$8W1,W#MC#6URZ=\)]Z!VYUWP#U*HA8%0H[U5XBJ*+E#'?,O
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MM'+'GA@F7S)CS1B1360'[E?AN\&BP#H6XHPH"AW<=0&[AJIL:="?,4#S#S-
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MNA-Z_KG\E7NL$*5H<C4Z"CSK 64<DQ145192OQ1$X52ATWWC[ 4J85T?N5+
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M#_XO7VIX7B3SDF"&CRPP\N8]H&U^"R?T6=T4,,6C=F]%B6Z/?-PX)4Y O@0
M$2Y:H'Z/9,E+*PO@[&--1QH4;HN#8J"D\[GE50JKJ[%SQ>, ;(8/MQZ&]*:A
MPA5*E29H';J !" V!H>)X##.&!$D;CR =DG=6JD4Y1 NLK Y8'0XBB[@CDT-
M.KY?989(W"@:/&@2%$ H^8-\4>O'G( *6D;#>:H3"%SM4DSR]_"7<G?9!?>)
M/HT!^E+6EHZHJRL*I[^[ZL+UR H' _SAQ<68&M D=[H(^@/A4&O[3:C7=I]+
M_!XT:%<XAV4E5!%5<54?2BF,(M_,M%G4!.';881?9_P%$19&5G&Y@#X%/:L=
M10WTPG?2P[ZUW 1G(>PUS\$V]-C9D_K9]PQEKQC0Q\-5P*"\/M@$N+:0AA#!
MN;<NF["@JZZ047]Y_SO9M?TVYW';\RW&>A7T)34%[]QNTF0EU^*E0K\H#;?I
MN_?X=(0ERRMY\5?W66-B@YC?E]_]LEBBDJ$Q X4LJ.\+0,[4)1"@%<;]MRZ\
M/#7D__8W-N21:!%10TJ7']<F* B]VZZZ<L7D>$C [ODX$MQ,F04S/?T"8-LR
M+/H<;@.=>J/WH2^Y'4^5A_T\J":]4^1*!OB/MP><BQHEB-*E+%OA-0>C:NHN
M6VI\'JZ6KWP:BIZ64OPY64:T 2:C4'R88,D)[$F^;6/9*HZ:3 9[\I:PM]%4
M/E_\:U-N"Z4/R9<V7NRV6*0]1(G@1X[*!7DL:!V8#,IJX6$"4:T]%0(?!5_H
M.&88X\>9.,-BXDP0"I-_&^?0580C6FP$=D_J15:.=T IJ$AR(.M;P(Z)/46J
M4\+;PPT7'D)_"1J)%%BT[01,F3)-.2HL9[X!D>@=2'Z^R]!+8&BR)LQA.)=A
M->L=]!S9FXH- &,+03RM+-A!.S\@3OJ3MBG4Y4^OJ"%IIN,JG$!Q]T"Z#OS:
M Z-"C7"1 $'UN=K#11YZ$8=8/7$91&(;37#Y>Z^RR$RC:"V]+R/I\P68_O'!
M##"= :8SP/2$(O\5'A"9<;_8#7I7SH\9..+Y4#4!Q\=:Z1<T /&E!KDZ.>_(
M9R)64BL"@=42+8.D+L)=,.)A[8)50YA$M5AZ024V/+*%&+_>9&#6;F)@V\%6
M%Z-Q4(SAG#AZR9Z).WJ@P6'A>VJ@1+-'XT6K8B>5M%.52,30;2NARXG=H3G_
M!FFC;ZL^4FR+!GU'0X<4;J12THA8 ?=H3O'FOF5B'E*Q6GC>=W?"J)2GJ;<3
M '!*^T=6DWBT?'*C%-YI$?TT#$"!Z0:4Y5P%3[ZC]/7RG=+55=<WY43](P=,
MB][H%$>NJ\P[-,Q@I8=2-(97#WJ>Z(13>5 +]! Q?F3)FH2O![&E0 $#Y6E%
MF2;TD+##\SIUV]?@MPGF(O;C?/&RWA6ZC;1CJN[\!F'[N)=V?8:(_AC"& 8_
M528QVNJRSIN5'3X$,'=,Q4(U?0<$? _B&3-;--:%=$&RQ*SV6+Y:'>@Y5U@R
M+\4J>K8J(-S.7BU6T2I4&%4VJS-X[Q##8\UMD]4O<WL\2<(U6H:6C7%OZ3VB
MA*(]&_B*E8E37KYNG\._=LHVX2FHXVP%T>E.4T<XL,MR)?(=*85KQ]I&/&Z]
M4Y,H2RWM0A-1&-&JQJ5\0O5XV8SM^YAW&.^45YLRTJ':':<"<3?UN^\.IF^Q
MM_Z;<LQ_AUK8"93462=4X1I(4F<1=D++4-^@]I1@-98,XAGPJ8)G$$DO4LK<
MD5+]A7(?QF#I1;CDN5]$'%!X:0QL<0/$TMA?W7#TZVO?FF+B,526S.K#W<]<
MA%DC!59=A7E5LCB]4O<3;4 DZA./#T(RSK]V U)F$6CEM!U&;T(W&RE'+=>+
M,L@QHD>J:<F^(',I\Q7/R2HG=M0[39)^H$Y+'R3EWG&6G#;J1JQ+BLU)V-T7
MKS*OA9@>D"$GZBQ$4A?;TUR1,LSQB!G#\+A8*10+CW)LV4,&:CU,\4*1&Z=W
M@1!_0ZO$&.6>N10:(H"#CJ1X,?'8)W79\"-S8M-V9 ]"_6 Q1+L8;J9NP9'K
M3EV1L2KMWZ%FYE)\KKS^*;.PK+'<A,,?EJ[>H10K#<LY?HRVKPT\;Y#2]1WO
MQ*:00>\H$4LB2VI7EU7GO1JFSZ0HFC$\X&O!)I-PI!JH'FF0#%Z=N+]K/Z&G
M/Q&]=T'E]ZZNOA>/]N<PB4VGW8=JG.0@T>ZR,HX*HE0WOE0ZS)SAL=!E4HQO
M_LO?+;&!7?-\5<4B!8/10541CT^+=&OZ(.]]I]X&VJ3"D>?>P:BJVQ( IWA#
MQ+,<1(>Z4,!9E<M2;/,;1UUUOOBG_B'ZR#R =% 1],"6?FPAX7"C1C<&REMC
M:YA8MSM-TO1)62G'0X4#1&(H-,D9[MA"D^C^%<Q3EE/?*//.>AL&LA&L7! P
M+UVM=CR)$:"^)W?W'8*5U!1!7G,K5!RN*Z)*W7ZKO3$PH3-7KF$;Z,Y[>%M0
M(S(89D5K-U(XJ0'XZ%BZ$-<AVM5*_F<$IN/4*U.J01?%\4_AFFL/9_9KQ]U%
M C*JD]Y>$?W>;H8?J\7WX5HF$7WXI6+S7L2><?^LZ;,O'CWZYA%$0K++KV)M
M^T7;!@W-:$(DF%]=9,S]@=W^/BA(SM0^>O P/.4/7T"/ :30B\<]_8GUH7NU
M@LX)QT -V/!E118!]L J1?,U.7S%):.B"23FOOJ5X@\VQ$MNL1U^DY&5$[O8
M<5\X+;&X5YX7Y]2DA^?+"+5KIA%1*D YE8D7VPHVZZM,RY9/?>L;-EC0S8BM
MGI$O7V(N7SZX/U@J&/<@X$+&M^:;,=X%' 4>J")":F+KL$^B/XRR@+R&>-UP
MS6A_/)F&%*!K:.W"0I9LO24#..AMR[<K_OYS7<*J5=Q_;D+D8BLYU%10RAI?
MY4;'@XF$28-P&(<= OKJ(GQ2(PN89"AML!J/R)=-W;9VMZ)RA[5<T.[2Y7 -
ME4'-DV@H?D4FQZ_)? >2'EG<2$BV"7X.0-71BA=0P#I&!<.;^7WMLJ3"BF"E
MX?()MTCTYJ@L3XE4&V;C)&:@(*RX$R@"A]5)>.:E4D.IR^'F!I5Y-2$3%!^+
MM1W!7"3I2;X2+/KMT4H]U(R[KK==1;?F9YP#?3CG0.<<Z)P#/6'G>+5O[6!5
MC\?X\4"'CY"[+9B[L646DKIQMQ4H2DSUWBO.K\ZC^QI\VYH+&((:QQ?N^X*$
MODX31;7+7S,-M?+8U]6T%?Z^N%T??7O^,(UU+1[%.K(OAW:D%[N!R+U%)=D'
M"D&P#] "> F648,PCG$&)FYOZ@-%-](C^86SKP7?=#](?'F4G)/M=G5T62CR
MR4JM8[3,35%NJ35G$ 7K!)"D*-CV*W^'^=88DO[H3:E',[TF13'($Z.)GGM2
M^S/(%R@=Q_R-D=534,\?KX6UUKFFHWO;QM8G6OY09R?,?ZQ!N>U/+-9A.E4!
MH[AVKA^RG;5/$GQS_N"N.0+YZ@<]2TD^X_S15[^6)O=''Y^/46VVN,=ZH$0(
MCE%_7*,/XE7.=/QIEG2M$"1NBDA.1B7QG5ZR.C/8@B?SUI$HQ'8$;>U<]02Z
M8^('N'"*DRG>4$Z$"7T)V7]@U?L^M^O;\T=W%"S^YB>DH]]22I)6+A]>2#)M
MQA7W^+*I\]7VZ&5EW>2=E A>PN7?*LOU(-MO?W&I406JT]^XZZS$;SEV88OE
MLUW)NAB!O1TGK9&0*H7"V U<P)_!]18Y0.[V)K8FRL0N"G9KL67HT J77'D)
M4H4[)4\HRR@ >T)'O!\ZR5M8#7ZI]>F\FE\UT-0EDJ)^?T;.],-D2E_+C+YZ
MQ'_LS2KLQ7Z;'_]45J07+K?U\C4YO$8>\(?^>RA4,60;<)P"-/D!GO B>#]G
M?R^7KQ%(($NFHY9.)%IAKS=A-2GH-H+JY*8F)+M&>4BFU.N*N**D?3I4,1>-
MM&1G</<@8H\2S"=2M-+KB0-[[ +!-MAUE;IVKET#_O;_V'O7YKB-)&OXKW3,
M$^^&)P*D+<EW;6P$+<D>[8Y&6LM>?T8WJDF,T$ /+J1Z?OU;>:VL M"D+,DF
M17R8L4AV X5"559>3I[SA@>-Z-(UX2F"N@%T;OT5X&N0"JX.HGA'/V6(HN=?
M;_C?&8M)7=!G_?4!<X;"C5CUQK+ 5=X6C&P >9>AK4E&R94\,X@%=6TK-.\6
MP"2"2UAN(?"9@\HA_@>3+G03K"  HHM<-L*+GJ.+N\TWN+BA<<;MT.FAZDMF
M5/JT\8 5_?*"N+6O+IJ*90/1H\L82#O#]CV!8](>ATE6A=/5&:\)71*'5='X
M50&.6NT(JD> 2%*JA(52N>)<XS+&D:QB)31TYOU7+\L&JS(E5DAIQN2*,&EE
MCXR=_#D_>X\Y@_(QK=+7WWV\('FA6[E_="LC$[WQ]H/VY:;%GGIO2;P/! 1&
M><EJ@O09;Z.I2*RN*ONT<0V?/OPC7N,)70/Y[]%Z3)MZ!@?I ,(]]5;Q75C5
M#S_BK]OUE5L3(8O?VC[Z7/7YCJ-I.%W.<\B%1'R!T:GB?PB'"J S7,W'2(OB
M7%PJ7COYHR/;?00_G\G\4<WC(-I#<1"*/7XX4^"A@2LX5/CE,!S*XV4,0AT-
M",POQN](.YKSU<#*MPAZ0V/+]IHEA;$5>>*N-.*,?AF=LYQ+E&^%:\*E+INR
M +"4P$):TBW#U^CCZ@K<;<; 0#L!K*+#-9,W(>AL,BV86>G\+I ."AJX62 E
MILUL@P(#%)!D"[6,@Q6/^HZ/.BZ!5 62%?-32.]\:*G/6S3ID@UQ.VDBEY-C
M.3EN>G(P;N(Y<$4B!OH5M$8P5 5E5#:8D99?,;7+@^^^^YI@%<]?G:E@%G8_
M@'L5P&AZ0LFQ(##@)'Z8/E/FH@1F?&+KSDT2;$_I;ZC!TVTN@,$) 4(2HT?*
M*VM7NVVIC5UXM;E[@J4HMP>\*1M',>9@UN#?PYYP:&2BMSDAA<3PU@<+:4VL
M,(46H/](Z6.MPQM &8F]\S&$D<+X4;J,#6?P^SL?B3.L<LIBSX1W^>WSTQ=3
MNYC:NV5J?WSZY.R&F1(JP@#^LM7*TJ[L4*>B)%%18;/B#C[NH\/(N@*$#>SU
M99LLV^3.;1,\CUX!%\]&'!(F!S)1YTTVD!"Y"/BPH?8B2E8QZM81E=M$'^Q0
M5]A:8G88T6@[$M=E=AEF!0I:];]OS]U-J-G#!6JV0,T6J-ER\"T'WWL>?!H9
M0YEZ1^V$5K]TJ+=YV2)6QO74@6;1!U*&UCX4*M<B(>"H"R7\2.>6(;3&KD49
MP]UV'^]]Q?;5Q:$#+NIZ]4JX?5\/@ BHT9&B%C#H9) VDZ1K/%/%+>;>E&+I
MB(.30Q$..N9B$J9),"); IE$>Y=R]$B14"N@3R[*JFA=K92[XVR5)&XP7Z)Y
M!O=VX_8BXMPPBP@K"5::N#;IZ+(&=AX*O-J@7*[\)3*="0O)EJ>#NIHA.2YO
MH%M]5KAMR=PC(JY9-!M"K6"O G5.[P%ITK?TT[XIRIQ^H +*1=DV^S;'K_TU
MTP$!TECOM<(/H(F \7P6_I!W7=DQ J8&I&K\T2PTBM!?<0+SBL8"]_*SZ9^
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M&S7(D8B)J9BOYCD2Q.^;CGHR<=@1,[9E#)2.3@K(]!''WI$/UM CLH.6!@7
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M?;*5%8%'IQ3[VC$1C?S= *SU\0D1FZ*KB;L30D:[!*4T9 4'< G63:^I%E8
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M]>SW6/ 5\6K[W:5%8BV98WV")X27OS ]04+YAJ<]-Q&_^Z&?A5SVAK2!PKZ
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M%C*_%L=Q**<X.VNWIN2#IZP7$_-T)(@RO0,@\0V]OU"T9T@A5 HK<%, HX-
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MVSW%^__F!"3//9[ ^+]M<[\&A@T)8G$C]&BQ (^(72L)IY[JWRD"+*8E1M-
M!*SP,_'*U%%W$BX:]W;C7+C0R0@[633X_093!$;SZX@R%1(_L3KHU@?#S!A\
M,X+(H YB6P-$R)9:K5&VL:POF^I2NAJCIY<-]&X[T.9'$NR0WV_0[.V(DPER
MDH&'JH)W"IF#\A*>*V@DP%:Y+(L!^<S-(:&M&G32^""R0#:PI$^N;_G=@8V>
M +"JL@)KAAFI4FIC [(N!UMS?P%.$S)E=O MT&^8N&#O\AT)!>L!U+*$43FI
MLT.\C=:&6=DC2TY8Y4,-VDZL7X.?RHM+& M,W\Y[;CVOP1NS(ML&7^RCI9#
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M OM-U^O671)H7]^C?Q<75SG) \L+)9P.O5)$9J.4=-E(P-,W*\;UM%0A1B.
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M]XDK,<(ORM;'-=(4(#]EH>(].NF6C;)LE$]BH^ 2GT"7&'(.B8/@4V5OXZ
M-O8;YV+PPXWB(08",MPN PQ"WY;K05IYJ.:T#=MSV57+KOIT=E6<B?8; YB'
M2R5I@6T5.#2L$H?L(=@CTJ1#B6Q"=]DN9DM7-*^'OFRE92O=T:T$VR14B"S
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MX:K.79&T$F>%PI9LL ]CU,3]#@A !(;[-V^KGPG_Q?1((P@Z(J>EKOL/[WM
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M045CY6#@#.&8E=W0IYB$^Y(53$.@E]-5$MF^AD+/9@='LO)S95:.K00&7P8
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M^J"P$,P,FQ)06!_46'+J8_/IOS _V]II[XE92-B.#XV2& ->N-R'N)N<*&,
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M7>]W*WE@$X$^"WK%&NE\X:(=SB7/$Y]&@5#.'F5^E8<\$Z6[N)6=CB]F?0O
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MD!DD%TQ,8YD[.3:2(8+R[2E((D1.02HQAFCL!.@&YIP9G!ML&T"!+NC>YH9
M_)%43E , SEAP=#+\EF&=@78JICI0@.<^*&P$P0\8ELF3A%)*;:@1KS"^;4T
MF6"QGFEY!M."[%W' /::]$R[EVF(<QU(;C4M9NSDN/UQ[ *2S6Y41\M)R&CK
M"BY8'/MEEB<40_)2?4[N';Q+-9]D45'M?6#?# (*D-$Q?932>.3T-%+SE/P0
M(_(D=NCFKH[EKE19)#5UJ@>#U68CF%Y& KQ7!7+=ZM:+,"E1:.71U?1(R^-^
MX@#]%;V:W(QJ@K*.PG7:?S>G!O$NAC'TGND'.=^CC_F>(>SULL*Y?2N%4:<
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M2,I"C<ND.2#- ;E7!R1,4VWDC!BME NO4<XEK\[1=K=4KE*B@'0S5%P#9>0
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M\",QWM'LYD9:,BR-KH)5?L=V"%"215K1H]'V^O4Q*=4$.-.+N:LZR5PA_F9
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M,C6:Q2$N716<@QH+)+@B-@XBI\*71]XT\?[U>J*!>PH8H6?,!Z;_9#]TZ9N
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MSNNHDRJ8LYAM!P3.NH2Q0:1CNC>G\YXOFVK#,?JW(Z[,,=U%'*'D=B$\>M4
MH;W6Q\Q[%1?S:N<S%38X_,M\%5'4&X$9(=JO'1/ U;S (G_'0%H:H$%+-_D^
MV$#Y);OK(.M3LHDD/H]A,T18L_@R0/\()=->[7F]X&F9@_P_(0R \76>"S2J
M&1H5-*8J:7DB7VG#H9/DK9>9$_+UV?Q:"[D!N3@JA10 JD\02WWL4X5M'XY8
MP[@Q D8\U%Z'JV&QQME'X4([23N .%^%H<!LG_;\"L6#!+!XDY8T.ACKZ&W
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M+DDX*]0S^8<[6!@(BPD(VXBDV9=0+5&'^P?[^X.*5E@6FF6U.\_U_X^,NE<
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MES=''SZ^?WEZMM\=] _XP]O997=WD$=RG4%3U>=V9+>H)*^X8_I[527I$B0
M&4*N_BKC7$%&MC $"5<Q6M,/S^-BGL.C)F$11&6R"$9A6>C; V^=7,WT102O
M&:J@T /4'^B[(M:O&:I)F(SA$H('(9,V?V$.-W.9ZA_A\[3Y,\ER/=GH-F_J
MY4USEVR],?[EUPK:LD8=H^X$59R$LT(]DW^X0X6M8\T%1W-$9]\[SV >^H<9
M_^(=P.7SMWQ?71W%IK#:0?M@_^Y=H2MD^JXVZ+KATEZ[L[=YB[#*)O>FIL4,
MYOOW1[U'5V_VX3>9IS>)WU6<A[]\^!S\JI6K?E41S))1\/B]435/;IQ^:01W
MPP7WEA=ATT7\BT,[&RCOWL1>:,?R6?![N BZ_58 _%*-<-[\A!Y^ZVW[>?'L
M9CG4O7;G0)P_LQ:SST&1)7$4B%OY#3>R+I+XM'@:'"7J<YA&>1P&K[)\J(J-
M/DL;+YG-\?P>Q_-.RR&\HPPQDXT[QS\-O;>XKO>C?]0<\.%F7Y@;+]_-(=^.
M0^Y7P] YW^2C?#R)U3AX^5F-2BR 8@K0YD W![HYT!MZH!__%-?D,>*Y_L5(
M?SPSS+[*'.N,F7VA=M'&=C$Z',ZS?/'3T_@?38BG.?#-@5\VT^_'?+;@R#:!
MK'MY!+<WD/4^'DW"/ I^B?.L_+Q59ZVY'A_$V?PV]O"]#615#WCC]#:'O#GD
M&^GT7B.*]2I.0^WY:L?WK>/NTF=O9RH/YWK0382K.>S-8=_PPW[M"-?8''DW
MPF4_#T>CK$SQW&=R[I<C7=+N<M?;Y7SQ^K*X(3*T(<.XIST"@]OL$7 +4;D\
MWRM%]?\&5GF?#G*UM> BBZ/ZS@+;]33,HH7^K\E\FOSC?P%02P,$%     @
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MF_0W6BJN<_UV^>\A<G=SPSR["8(>.+==XJ@OG+UO]L/.ALU[(]#1)<G= &E
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MX"8S@HZL2S+)H@<KWF1U9WGV9G,; G:HHFQ.G4(&-MDMA[#OR^",O/&,/F'
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MKLPBZOHA2ZR^M157$AU8CR$T2ZH>#A=5=^LM).+"*P+Q#5:-A8F;?DS,Q,M
MDR>^:=DY+H'&B)3+B@AG,):&T"8%1'$B1N&4Q?>QI'WV:+/W77!W3&X7E/D
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M7&F3-:0KXS;/J--MNF>$=$7746M15J[FUCB[,TESM8)R(23V]**_E PL.LL
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MW[.J@)-3../1)C*L)IC1N8=_9M1_?,;^EWUNTT\F17O)$+R261P=;25&W&S
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M(0;WNNV:X KXJ6+"-.+QI$P#.=:1"&7C(GCERF:CSMH)SCWA("A>'06ZVS1
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M,[UNO,)U/"5\G3WU4<*$4AM&WN:3M_GDSYA/'M"=H2LL"IFS3KXL*/RF]1B
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M7<%5+ 8%*A,DK6E$K6@;%^HVEC%Q.Q>T23,0>(K7581L[ZK;384>@+ (D3'
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MN70Z&L&!L&Z=5.P'U>9;%^!NCY,9;S\+BJ"JKTN37VCH>(1,$J-N@9\@./;
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M\M^R (\TET_!@:,BR(+K9S%I(.8[E^8E0@*)@VO]UV'.$-2.1L8R]1,Q--7
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MCVC#A&))AOUJ$1I3"A&YQ11S;)ZC)"^QY$:$YYS^5Y7M8FVM*VU1X5U5)GL
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M3P4)-L^DS)T\7^UTP],U7#(IQ>1(&EM7']R0KTERI6CH%+<DX;Z>8+3CO?&
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M7S(5"B .!V5%HQ%2Q.3/O_[KGV!!_+-PK<4THEI7[V^RP=,XM<=Q1!;QP!K
MRQ=1:K^Q H":@?=YM\)* O:$LN;;#!CWZ0D"@Y%:(->[%78"B3F!L0N+4] <
M3J>??A-ESC!^[PIN:\1)@F5"J2&)URJ9N>5<J-0AD<)+CL9]DX?37T75S07!
M\#QX5'*/8 .BH%:?+JE&J8WD#-S+@2HZIO=L%2FWB9P%MS!1IN;%E\$928Q
MK 1?Y)8W[LB\RVNZ(]"H5ERSH0G>,IN:[0 9#4F\,!\$(<%H-^";@1?^XF"X
M'E&5/;)<F=MV5#?LZ2].#=A$DBI;6WD9909*-QQ+(' EU>Z(!R] =/N8%6S1
M2D$SL_0R<RNS;V1."M0 UC0:-S$/]3 '+72S:L5T8Y@:KV8MV2LK<($K4<>!
MC'$X$K+*,!9",?)XBJIO.-ER8'H?FE-IT0SIY-"KE%]A0V(:PB^W]3GS@;*U
MWOQ79M%M7BB8U_T3Q)5K#1%KZL:90Z;ZA4P._LUXQVYWE.Z;^+]@6F&48,+=
MQ(=DTWP=%RY\:'@M\>>T9]W'4-*.>>2+A%BXB*],5R.[5)6D:.1Y@L,>,F@T
MY<(YF*V8<)&(^YI*%K3\GOF<82Z%V*/CJ&WK-#Y^H3WPLV75($H(9RUHB+5K
ME'/A4 <W%"?,]ITRUS?\VEDEMP!_ 7804;(;,6"[D$IP9^KMI*=)-3#QD@"2
M(=OD-E[GJ;-@5)U1:'N=6*#% YW)WJ'EXR:UP*00I6=*#$?-L2\3Z9P9XH8
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M--DHV1L?:[_%K?/C4,-<TJ&FO*YR>F@[&]T'^0M*?>[$5V'N.C [F.J"W!/
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M58$6F2[9W!-"RO>@B7W?C<9C6H!3+IE*34H8KZ>"# M04OPP WX8I(G<QOO
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ML.3%'CRC1_.,OMW',YJ4)&_'B<,1BKWT^C^8<P,@UC5E9BQZ"EO78EXQ,#A
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M:BH,2__87LF(/#?+Q["YHPYQ2GAPO8\)RGONF";M6HC&PZ#4O, TY(VT\:@
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M3D!\T'96_O&LX[)TXH9\VZ<FP.U@-S-@FE[2->8-^A8H3OHE?K@J)"5KENU
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MP@E9[?=(LE224"R&<V1720ZO>;?,]_S[U-SA^!!P>;,!?#>"V>T"$8K',?3
M4P5<[=@L?,WFO10K!MA',X;SUPD<G @TST@8)F"9H,9$FZ07;;K]V(&D0AJ>
M+TC@CQ-0AU*.-,NIIK"84ZS5.S,OGV]DHCS5"BX<7:<(-KI:9KD:XT\LZ^,H
M >++:"0?R'#-;;!Q)&S'_0UUS0]/7;+^<NV WZ8RK,BD.^8$&@>61GR26Q2+
M'9)95PC0W< ;6*=-C!CGHH."<X_KZL:"R-Q9GX\O+Z2<N)*&F0Z&WP?(GO>F
MF:]Q%RPS6&*(O*BE15,^7+GRP15!'##".NQ,W8!ZBDF@T0_@,:%X6A!7JV'%
M3@ &)<F[QR0)%AI4FJ0B<#7\&R3D=95-%0BZ?*C!6:")TPC:4E'=U+6B.!W)
M>UJ?%2_+(KTF\Q06E-#[T:A6/ ,5]E?.L& 'U:>W-<\/^2:0V^YZ1Y$NHGFZ
M0&N\MNFW>>2A+""4!7R0G-9JTYX+7DR9F 9[S4D<FLI#(G"B,DU#A4N91^V(
M^U07"8U=6K22&&HR 3Y23K2V]?0@1;=XM]>-JP6C>XI0LXHFPS2T]")=5AFU
M1.#ZL>>)92T) IHYE>II91J4.31H?">KT&M_P<8\NZRS<,O;N^7F)6_1-!.+
MVP;U.,Q=5X<VOE]#.. P^=Q$$$QM)-5C(UCBN +#JD"G-^-4SRQ=:NFD4TAS
M6#WN!J6XEZA(N6]&TDH3IE/EIPY0ARS81<7RR8S"S*K. ',E[)RK(=W7V^4N
M,&-%WZ0F9S.(21\&HMTBT>[2H5A,, :4\!A"K$S#,"T\"YL'BBOY$6,U14(I
MH^6**;HNUW"HC7S],J%T#%(P_BVASDGN^C?HE!B="A2R30K9+HE4"RQ;&Z6"
M5^=%^]3X&JXT9<<2V^5RZ2=QVFXD!_??:G$5T:L-SJ7\02_5O/F[T0P;F+($
M>S!T\X] =7"$XTB/9B!@ZC][P453NBYK%VDHF'94V)A3L0^6/5H!JF?Y<@E[
M.93L:H%]<(3QAYO'R!LW\/ <TD"T6R7:[5*M[1REFT1-"A2E;78[NDX+2GEZ
M1&.3X*-\G,1USALH>PHTIX4:./]J"[<PD*++(B>1QS5(7%^ZX!"'2=1QXW\C
MS8[? 1]];'XN$5'8-CI1WLRV602"VZ*)_[:)C ;N5[7DJ^./19,LOZ%L']!1
M/JT2K/[#L*F*.,V,5&"$V*C(L\Q(HHG2I>F'8<KRZI6;1CV#I=BBN=62YV[6
M](W],:UZL44R55SG@.XA*%GMOLMT%[HX28LIAO"I"P49 ^MX0"#"(D'E!]K:
M'FTU2<M6]DDU.UG8EMC:U""=/.)JPI]N\N)*F[0)2Y_.;\;R['R8K*3?C/J6
MR PG!3U*QF"<X\^D%_EE13*MLGH6R[U>6->A<0$+8QM)P;TCXTR3&@%2+Q4F
ME2K\[9"P0*D2%)P0\; #,6Z1&%MA*K+X23%Q6!Y4C?>KZS3/3 S+*3V$S2K0
MP!2YBB-&BF''E/M5S"_ A?5*1+!N!WU@THQ$2[%'<6@V8O*AY*PBTMDOO8L>
MT!BEA%,IEQJ(I**.%2XIX0QE466)]2;<94FE6OT8(^PV5K#@&O F_@-L$%V4
M<,OV]?S'_ASN9 32W?^CP> _ZU^\[/\<VSR\N]V9NC8P,0)I-L$C"R2_39)O
MTKP4/]16H:Z6V'#+TD^#*$*Y>Y 7@APQ2IB$O,@=T%954%'02.B$O\C*^@84
M,P9$\#YO?<VA:4?(BZE:I'_1L[ JPW$U#!\LB&,ND.5T-,4"?(;3ICI)1(N
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M;\^LX[T:G7;$44Y7LDB,DN*S-A'9CHC).)4NA<NDFSRC&FMH'.[UQHWY5)'
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M.LV&MKZ_60B_9=WU/X7]/U!+ P04    "  G0:U:B6?]=;X(  "?-0  &
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M,S%D,BYH=&U02P$"% ,4    "  G0:U:=X*6UEX%  "+&0  &
M    @ &3L 4 ;6=T>"TR,#(U,#,S,7AE>#,R9#$N:'1M4$L! A0#%     @
M)T&M6A_9)Q-:!0  DQD  !@              ( !)[8% &UG='@M,C R-3 S
C,S%X97@S,F0R+FAT;5!+!08     "P + .P"  "WNP4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>mgtx-20250331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgtx="http://meiragtx.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgtx-20250331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7PBWyW10bku3vczbnolVKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__pIlUQOGC0SWQ9sbcUlL7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ftpWq1xELEO_xiKl9XZu4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hEK3ws0ZrEaEwHAN5Wlu5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6ol14QM12kWnqbV_R0D-VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1se73GomfkuSyGy7U1wlaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XWbwq0m_K0WELesuemAQ5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ab2cnm6P6UGXoyJRBNe9KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dOQiYLrDx0es2KwdD-YnMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWFIJ4f8Mk6kiZm_hwhuVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Lkt8NZWQY0euvcA_dbiXxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cA5kA7WhY0mOZMiW4kBz8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KtvJ2z7CkE2LvZ68mPcahg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_FHMLfDF-0EKO7Asq-e8OTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uVSHbG4-lEuN03PZ2bf2fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_SecondAnniversaryMember_4r0tTmCAu0SQFy7DaGc90A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_FourthAnniversaryMember_vESYVjpkuUShuXlxTP4-vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_Nbb73BCKL0iQXbnKJ4G6zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_qIzB0lDadUGRb33apH8qog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J7FckVRKbkG1Z9ZPt1KhVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g32i2heQxEy-pHMU_5YOow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember__19Q6cUiYEa7qmq_KO8jNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_US_isAzfTWGxEaw8ldhWLyHVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_GB_mLJbdBSl7Euj6MToEtRJ-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_EiRkplRRA0e4VFOvaZVcUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_cfMdJz0u7EKj-RrpFQyMpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_6w38CaNnUkWyGPBi3mG6OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vu8hoWsZ4UmhtEkvY_FXHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9UJzipOWs02UMP-44_Jc4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_E01NWWscaku_l4LSWzU0oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_psKKUO-LuUiwEGnyG3klfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PWqb2kP-wEuEFAiVAHEfUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vNTUyBj1R0iHgetCERxoKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtv4RBfxkuuH4RrzAnNHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yNUlMtvIhEu4s5tbktrKBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uKmiWTXiFUui62_GfPyv8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_w0975VuH_EaNXB4Ka939BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RF2S-NSeJU61RDz1CxpR0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_FinancingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_PerceptiveAdvisorsLlcMember_oAxyTHASgU6LiyqF1ZUF5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:PerceptiveAdvisorsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:VisiogeneLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mgtx:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A34VtYETjkq5z4-tujaPuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_42lCiz8CVUyY3EVhVz0_cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_O1KWw4ArDkiJPoDlyECyng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_9Zn4kfnKBEST_irxiQRuhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_1LCuyPsVy0exXA5eGmOHbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nPdsKTqjKEeHIAIo7QnFLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_oyaq6jivUkawB4YLvbDI0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b0HC4nScVUuIG_mYjEASwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_e_mz02J0OEe3fPVeHHSu4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember_uFjEWSkzu0eHvfAynbX9jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_EPMBHNhui0SPV5q0DQTs9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_gOdpVqSBHEGJvzck7tJOZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2025_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_KaXdu7E4UU23VU_CUmILww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Z5HMPaYik0ye7_ykI_APgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4qcy_d4u7k2Tb5wX8MN_yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_x0anTYpTGEKJId2AT2QSMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_WEvytmm6-0as4ezA8Dxq_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yqGmJ2-KHka0ENT6fES9GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_X4X9AYdDDEK7RWtpLuhYsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WpG7KMWBlUKStgi4QQoKBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_co_X9kDcaUaRbStYIRfBYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Yx2Gw2c3R0GT0T-W4aVOLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-FBDFJh7Y02IFx7FP5-LHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SDGzmNr-NEmKPaMrfqtjDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_bD1h8zBZy0a-rhyOQJBXYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_PIX3BS0nTUa5tETrcj8elg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_iZlT0i7a9E65CzOL8E1S9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_vpSCkZsxXEKNmuae513iJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">mgtx:ExercisePriceScenarioBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_t4aotRLKJECS_tQUX6xOmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:BankOfAmericaSecuritiesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgtx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingFrameworkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-09</startDate>
            <endDate>2025-03-09</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_3HrtmboMJUKcXvGtnUlX-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_BvXvmLHTZ0qgp_SP__HdmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_tiGUIO0qBk69Z-8zacyddg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:HologenTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-09</startDate>
            <endDate>2025-03-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_bTo8MlYWIEagDkty02ovVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_vxfqy9OKIUWACknu_IhoYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MinimumMember_2b1HMRkaD06hhuC2_CUTZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_BgkV0HRRGEO9W9pctp9CrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_dEYHtikRfE2XPBZmM5ggNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_IGvtLNP2dUW4TTCCJvLt-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_e-G_0F-wWkOXxtBy8N16Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_H2Pm54Ton0yrKe8l8jzgVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_GkhjCPAPaECcrC8N78W-Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_x8bvSHQN80e1DIGnCPEO1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandEmploymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mgtx:GrantsIdaIrelandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_zgUUktVOakyME70F8CQ1DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_anYll54pokiQcp14tL7FPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-09</instant>
        </period>
    </context>
    <context id="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:HologenLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:HologenTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-09</startDate>
            <endDate>2025-03-09</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mgtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mgtx:PerceptiveCreditHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_Di1tUbrdG0CEvFGNkpUsfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_28_2025_ft_AZCvNMkWsZ3SF2L-s5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <instant>2025-04-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="2"
      id="Hidden_pLW7zRbgPkiZZTuqjAHLng"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="2"
      id="Hidden_L88EaDIR1022qZsEDwWwPQ"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Hidden_lbaBp-22o0eZqucwxghBGw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">79032341</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Hidden_jfmsnVHfOUaPeVejw9xz8w"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">64065895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_HVGxmDvBkka3JUogfYTXQQ_2_1">0001735438</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_Oalb8CgkVUqE77Zk2hVoDQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_puGQ3jeV30qOs6M38y1mhw_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_XfG5r6FecEePFo-j6RMLdQ_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_y9CAMYgt8UGE8Czpqw3LQA_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="0"
      id="Hidden_7Dm_VXGCCUuvwcHM8-AKPw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">78397380</us-gaap:CommonStockSharesIssued>
    <mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Hidden_MlA4-b9GnE64Lz0dPLcYmQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Hidden_d94u8XNHz02l4qukD_X6Xg"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">79418438</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_FourthAnniversaryMember_vESYVjpkuUShuXlxTP4-vw"
      decimals="2"
      id="Hidden_3IRehDe7iE-PuKwN7f8KxA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mgtx:PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg"
      id="Hidden_eNuWP8gC10unY9sqGjg8MQ">P6M</mgtx:PeriodOfJobVacancyBeforeGrantFundingBecomesRepayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KtvJ2z7CkE2LvZ68mPcahg"
      id="Hidden_9vrz3CYLdkSqMQ_3AtrhKQ">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A"
      decimals="2"
      id="Hidden_2cEA7rky_EClnxjTOR8EiQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Hidden_N4ipPyW_6EecGrCOlZuzUQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</us-gaap:IncomeTaxExpenseBenefit>
    <mgtx:OperatingLeaseNumberNewLeasesRecognized
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Hidden_50G5iuwwS0COib-U_gl6RQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0</mgtx:OperatingLeaseNumberNewLeasesRecognized>
    <mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Hidden_rcbwIQOgN0KERK7K18fcyg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1>
    <mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Hidden_UfokOTS--kuNnksgF_hYAA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</mgtx:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities1>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_WcNNC4Me9E-hX8wCVwbIog">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_2f6HeZ3yEECo--yWLXYopA">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_0v56svkCmU2BSq_nFIuwxQ">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_oz94P-sn6U6wO6u7wdT4zg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_lSdIjpVycUqsUqE3jDU9PQ">001-38520</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_BffKW7k_VECDynfzx3StHA">MeiraGTx Holdings plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_3BBKyXGokkSQYmENG-wHvA_1_0">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_83VgfdpWT0ScvgUHLxAHRQ_1_2">98-1448305</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_u8sd_J5rOk2oy2LZw-51EA">450 East 29th&#160;Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_k9GVbcVFr0m8XX46F4FWSw">14th&#160;Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_SFcjVRwNC0OL4GJT12qn1A">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_Qzr5-qwDH0OFoInenPApdg">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_hrc-GiLlH0CUubN-kXj5qA_5_2">10016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_Kzwz9S-i9k67R6QJlrtwZw">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_0ez9cT69xEa04xFU1riBXw">860-7985</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_0IeOKLwSPUmA62EoQZVMDg">Ordinary Shares,$0.00003881 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_IzyzmBz7SEOSPPce8tgCFA_2_2">MGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_YsnqlJ1jmESuqoIq28MPQQ">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_tq8GPy42kESfO0zKiuh77g">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_r_KrA7Gv5UKSGlm9ZTpitA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_-SNTKV2UxUSgriD8GZqlog">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_EJiFI10_KUq4T9_dG_xf9A">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_rzNHy8yMdUiI6VMA0N2ddQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_4HEO0_Q7vkaoNBCBAUsAag">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_4_28_2025_ft_AZCvNMkWsZ3SF2L-s5Q"
      decimals="0"
      id="Narr_5B9-tYjP9067Eal4-mcZMw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">80365359</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_DGHk0Ve3z0eJi7zgrvwafQ_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">66523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_v9iEMyq4pUeBTPJd-dnyuw_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">103659000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_lfGCLlLpzkCkC4Yp0ZUhgQ_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">734000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_9vem8F0pqkufm2_Mdv0g5w_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">707000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_F5WACDj1KUy2cW_N207Yzg_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">270000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_syHJnXZJvkydpucMJ9WGOw_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">950000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_WSxDK9PvkUO24_O0TnWSfg_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">607000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_qHO_C6__mku7xOJZ5GNe-Q_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">385000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_EtJMzuMcOUOsjBZFyYJYnQ_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6928000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_sALEmssBzEGN8wczcu4aKA_9_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6828000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxReceivable
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_bA7ziC1iFUObJE7eTLTNbA_10_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4221000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_ppYhGnBJ20iA_eFy1-Z3Rw_10_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">8971000</us-gaap:IncomeTaxReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_h9KUPjf6-ECvBT0Dcke8OA_11_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">606000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_yrP233BObkGhpH_osUiBWw_11_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2018000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_HFmxRrGo_UqLpM52e-wpqA_12_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">79889000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_tdIYRA7tvkuRaIeBJKvvXg_12_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">123518000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Xq4LQfxNAEC2_7lfZAocvA_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">104408000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_Ws8Oi41NcEO-0LxlwcUQnw_13_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">102878000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_t9o7vz1V3ki2ge0vYEfmcw_14_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">773000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_R0q2y6zLLk-ix5zhMzH0yg_14_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">821000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_3E0m-JcU5EeJHimS44unbg_15_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2087000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_yxKafGafw0myZfgqChVWIg_15_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2009000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Y_pa2F0k6Um05dZXsU26vQ_16_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1032000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_BJUNjBosf0WN_T7bna1KkA_16_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_bXYSyF-ZfUSKoJeXoD8pWA_17_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6749000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_rZz6hd7n6Ue9d3Q_roc4Mw_17_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6749000</us-gaap:EquityMethodInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_MtaEBTpRJ0Waie_LdkcmGw_18_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6348000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_zUsQgZErXkKPO3XoUqDoVw_18_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10576000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_-mdBCgWL2kWdNv5XyQdSAw_19_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">22728000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_aVTFJ4TL5Ems63_gcHfdIA_19_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">22198000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_MA_KV8EIJE6Yjq_5HQH88A_20_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">224014000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_h6xMP_O6OUiMfu9z4wibQg_20_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">269751000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_bqRwzMwq5UmYx633Ivad4A_24_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">20290000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_QIJOX-Z4EU6LyhzX8JD7vQ_24_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">23586000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_t0bee3VDn02iq-vQL5tygA_25_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">23964000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_cHu7kOk54USniWzmm-FqWg_25_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">27414000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_ZGBQx-PjO0KDLE7DZys9JA_26_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3297000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_FJucujbtKkKAjL3Vd1oDQQ_26_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4053000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_UgzyGIZ0xECeU2N3SsUPPg_27_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4241000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_tyB8TyjQkEafNdM1jqTtQw_27_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4827000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_vEFbDZpvakax0_YckOobzQ_28_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">580000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_rY-LcB2O00aQw8k3kR0qnA_28_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">903000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Oxalusl93k28O9_4ukyR-w_29_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">52372000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_BzHHiDZsKU2G3IFjTGVCSw_29_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">60783000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_561ibGCl_0iAGUMCQeBRNQ_30_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">59618000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_S-NqksMeHkWvC3j7xAlrIA_30_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">57576000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_dyZFhyval0iTIc1dIWaKUg_31_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_Q8lmyB-JUUSq9w5-vIvoOA_31_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">7523000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_5Wci5LOoN0WBuPBqA0K3bQ_32_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1344000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_Z0epb4cZt0Wsm7ZWEr1hYQ_32_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2821000</us-gaap:AssetRetirementObligation>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_dPnVJCNYKEieK-ejsEw0JQ_33_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">73495000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_M1CJ_bdd8EyafquOQfE9rQ_33_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">73221000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_b1vp9jKbJU2rlnhgeH3zTQ_34_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">190915000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_6SU7l7WexESaEv9_-2Om3A_34_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">201924000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="8"
      id="Narr_TEIB7SWDOECaFLcxwTjQ7g"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">0.00003881</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="8"
      id="Narr_4HqPPDj15kmWyd6mGzKwkw"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">0.00003881</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Narr_490whYY7zUCVqtKEpTVFLg"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">1288327750</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="0"
      id="Narr_Jg0a-o5E2kmU5rlqP8RQDQ"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">1288327750</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Narr_aHr4mYtBO0yAKsqaBd_kog"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">79418438</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="0"
      id="Narr_kKhJPLO-gU2_-tJT_-odBg"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">78397380</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_5kW7ozro5U-eZ6m7mtffJA_37_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_AcuMfJ4L6UuOrHFOFadc0A_37_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_2fOE9nTPKkOGFGzkzI-SHQ_38_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">780165000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_jbwN-J4zF0O9y9YxrGz7iA_38_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">773565000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_tE0RsX1Ng0-pu3OLDD99lQ_39_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-5066000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_mn3EPQ9kKkOLAy_Ll6-7bw_39_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-3719000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_irFeHfioW0eGIDI9oeA-OQ_40_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-742003000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_7JLGOyb_aUm_VnAvTPeV-Q_40_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-702022000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_wJNoT0mySkKMG3aosI8_nA_41_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">33099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_gb_1lruOGEWWf4IQ69qP7Q_41_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">67827000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Xs2ZymsVjkuLNgu_KGMTog_42_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">224014000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_AEAjmc42cE2GhE6GPpIUGw_42_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">269751000</us-gaap:LiabilitiesAndStockholdersEquity>
    <mgtx:ServiceRevenueFromRelatedParties
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_9fu8n-E5YkyUMPIwSszHuQ_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1926000</mgtx:ServiceRevenueFromRelatedParties>
    <mgtx:ServiceRevenueFromRelatedParties
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_2c3siRUyxkaoKlgbLpTxzQ_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">697000</mgtx:ServiceRevenueFromRelatedParties>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_mBylX5t24kGMLRnWynDt5g_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1378000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_56BBYQibi0-cxSK4nLWA8A_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">9364000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_-NhVF1sR3EeVKy1Rg31PDg_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">13147000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_zbNAS4BCmU6esr7W3vQOGw_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">32780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_d8JDgV7-0EK5r8hYGPCEpQ_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">34322000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_XUPCZucs7kGi1uLbyoCasA_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">43522000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_4lQbP0tTMUS_3P6Io1bRxw_9_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">47469000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_sFuY5i9Faki7t9JxU7adsw_10_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-41596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_EbrNs1pgHUm81YZVChYc-A_10_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-46772000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_vLC2yoFhQUeLwg3JQYdlZg_12_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3687000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_akR1VwKXJ0aQ57izASQH4A_12_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-535000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_UQz4obyqtUizSHTwJr6jYw_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">971000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_zbUS_qfL6kO6DVvMnOhG4g_13_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1097000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_3w3-rkVN-EmXjypJaYv8dg_14_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3043000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_WPqTPt0enkWvaLTk4RDI2Q_14_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3250000</us-gaap:InterestExpense>
    <mgtx:GainLossOnSaleOfNonfinancialAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_auhXERiE_0SL98pL9ru9yw_15_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">29018000</mgtx:GainLossOnSaleOfNonfinancialAssets>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_82LzLfuehUyZ_hOtfCc07Q_16_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_288Pely5DUGCXaDyLRwOEg_16_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_AQ0_V-gfjk2jPSsYpam8Tw_18_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1347000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_Ffb7v9SPDUC5l2hqXbWFYg_18_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1691000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_R46aa4DMpUeppGDWAtGETw_19_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-41328000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_j4h6wxFIk0CxuHu1o68IKg_19_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-22133000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_EQvqrkqZkEWXeEl4TVSn8w_21_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_SylaL9m1-kunQjeFEGm4lA_21_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="2"
      id="Tc_FWY7i72NX0Szqe7eJY2dRw_22_3"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="2"
      id="Tc_HaCzygv0Gk6kIidTxa8w3w_22_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Tc_2Spm0Sp3ZEqUXWiLMyQRsg_23_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">79032341</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Tc_wvTwvifdvkqAnckJHTCaBQ_23_6"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">64065895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g"
      decimals="0"
      id="Tc_-n1rbm_MIEGVrivyx4FVbA_5_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">78397380</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ptP7_QBXhEmDua4qJOB33g"
      decimals="-3"
      id="Tc_Hv1FT0mvOku2m-K71L3UAg_5_5"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6ol14QM12kWnqbV_R0D-VA"
      decimals="-3"
      id="Tc_jYCsg_bGQ0K8A2wyBrimeg_5_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">773565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1se73GomfkuSyGy7U1wlaA"
      decimals="-3"
      id="Tc_e_4qAZTt3kaZirrVafDKQA_5_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-3719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hEK3ws0ZrEaEwHAN5Wlu5Q"
      decimals="-3"
      id="Tc_FAxZI3B130ahx89ekp57Xw_5_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-702022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_h5DpjM-icEGDge4N0h1FBA_5_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">67827000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ"
      decimals="0"
      id="Tc_3JRWprCCAEqik4aOcnfIyg_6_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">457679</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg"
      decimals="-3"
      id="Tc_RbSq38qn7Uu9dBAnmAmOlA_6_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2130000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_Rn6edlq5k0eXHW1yKfyozQ_6_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2130000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3MiIxKKW2Ea_gMckSSPIkQ"
      decimals="0"
      id="Tc__kRb5igcL0qUmea32vefkQ_7_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">563379</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg"
      decimals="-3"
      id="Tc_p5tivpStpkGP3aErWHitFg_7_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4482000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_7gXhnBf7jkeQ3Tbe8DMRWQ_7_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4482000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zqUeKZMz7U6ag1NMYoEDcg"
      decimals="-3"
      id="Tc_GHZXLw1PGUK7qSyK4SW4Xw_8_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_SmcLueiNSk60J7BIDQC30A_8_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J7FckVRKbkG1Z9ZPt1KhVg"
      decimals="-3"
      id="Tc_ZNYSsal95E6oU4Asz4HJXQ_9_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1347000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_QCvnbwOUKUKJHfMHQjH6SQ_9_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1347000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vu8hoWsZ4UmhtEkvY_FXHA"
      decimals="-3"
      id="Tc_gYnB54Cs-U6cElIi60nBig_10_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_zbreMQmJKEqzrrR2Ts9xlg_10_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA"
      decimals="0"
      id="Tc_sZFvxur7Y0SMix_0o1WCTw_11_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">79418438</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JsmB4A6Bv0ub8K32szRkvA"
      decimals="-3"
      id="Tc_xILHP5bp006Zghar7XKhEQ_11_5"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__pIlUQOGC0SWQ9sbcUlL7Q"
      decimals="-3"
      id="Tc_jU5SyUb0hUKMMLA5Y6SMtQ_11_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">780165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ftpWq1xELEO_xiKl9XZu4Q"
      decimals="-3"
      id="Tc_3drCfpq6wUqo9i0wABmz9A_11_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-5066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7PBWyW10bku3vczbnolVKQ"
      decimals="-3"
      id="Tc_8KzYydg4hEih5ovJfyjxLw_11_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-742003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_muaI9FB5ZU2IMsnp0qJzDg_11_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">33099000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg"
      decimals="-3"
      id="Tc_GQd4w7ZzhkGG0VndQsTSTA_5_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">63601015000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tsqu7qcuEus60_marDlLg"
      decimals="-3"
      id="Tc_3i_0G3c6uE2z-V_0QCA2dA_5_5"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Lkt8NZWQY0euvcA_dbiXxQ"
      decimals="-3"
      id="Tc_muaev53R4USmI0zzjgle3g_5_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">693841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cA5kA7WhY0mOZMiW4kBz8Q"
      decimals="-3"
      id="Tc_IFElO7TxrkehPtqK11uoSA_5_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dWFIJ4f8Mk6kiZm_hwhuVA"
      decimals="-3"
      id="Tc_s-hZe0Ek10WFhzAZDk1C3g_5_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-554231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg"
      decimals="-3"
      id="Tc_VesUA7aPvEOLXX31whFCYg_5_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">138177000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA"
      decimals="-3"
      id="Tc_VSY65r114km08X84JlQKfQ_6_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">441348000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg"
      decimals="-3"
      id="Tc_sn3ezNZnZ0qftpkLDtDd9Q_6_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4739000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_oZAyX7oNZEmw7vjEv8wdGQ_6_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4739000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R5zpKogCe0CnAUSOI2RhiA"
      decimals="-3"
      id="Tc_vIG1tY8UZUCr1ptpYyr21Q_7_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">256328000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg"
      decimals="-3"
      id="Tc_-H5V2nPUGEuXBdKbo0urIA_7_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_FmQugme_5EuqMqpUToQ9jw_7_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KxD66HU9AkSff3psobaLkg"
      decimals="-3"
      id="Tc_tcmze-u5iEii3obSJjvYzg_8_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_rcW7db3JGkSQVySs-JMZMg_8_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_g32i2heQxEy-pHMU_5YOow"
      decimals="-3"
      id="Tc_P_kTCojv4U265NK307I-pw_9_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1691000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_lH4VW9KI4k29FpucYidU5Q_9_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1691000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9UJzipOWs02UMP-44_Jc4Q"
      decimals="-3"
      id="Tc_a2jrfB_rYk2Hx5MijUPs2g_10_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_UeaDhyGOq0S1u1fJ3Yw4Tw_10_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg"
      decimals="-3"
      id="Tc_SkP6CrFWJkONSlh0kGOnCA_11_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">64298691000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aHRSM4CD1kKOKJ59qtkAZg"
      decimals="-3"
      id="Tc_3fl1qAGW50Sz5N1waqgucA_11_5"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ab2cnm6P6UGXoyJRBNe9KQ"
      decimals="-3"
      id="Tc_sn5cczSi-0S9lbezm5hiDA_11_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">699531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dOQiYLrDx0es2KwdD-YnMg"
      decimals="-3"
      id="Tc_KdGHPRn4Zkmw8IjMkCgvBg_11_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-3126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XWbwq0m_K0WELesuemAQ5g"
      decimals="-3"
      id="Tc_OHAfzjdBXEOE7Ai6_nJYuA_11_14"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-574673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg"
      decimals="-3"
      id="Tc_e7qr1ZXE4Uei6AGbgRG2zQ_11_17"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">121734000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_X1tFxC-ZIk2YuxmfmVNRfQ_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_gxnFNQ_jKkS8KLa3qTEu1A_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_7paOPzOZ1Eeit6gn4lBV9Q_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4887000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_k-3WOx_A6k2ZATbXyi1qmg_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6960000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_LxYAPOttb0Orld-Q5W6kCw_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3687000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_Nq3dG_eGMEeOSpjW5rhtEg_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-535000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_VIdyEDsbTkCzy_rDc47RQA_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3081000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_lHFL4gLW_kiKZ4tXZsAcng_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3275000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_ZUd5njEFQ0uMVYOEU_W8Bg_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">71000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_Y9WZMuzy6U6lGurDheauTQ_9_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-36000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_4fps5os970yHPtq0dsn7tQ_10_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1365000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_b-cpzFLgxE25dhvYqZeqWA_11_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">122000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_RtvR7BnnEk-0kfpiuUvrFQ_12_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">63000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_wCXERUHvfkCtykifcc_8oQ_12_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">48000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_tnNRUyn-jEW5vv9hjfp6AA_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">274000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_ZIIOZcKFn0uL5U177nF37A_13_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">273000</us-gaap:AmortizationOfDebtDiscountPremium>
    <mgtx:GainLossOnSaleOfNonfinancialAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_U0G3zZAtKEuVJ_t4lVVxhA_14_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">29018000</mgtx:GainLossOnSaleOfNonfinancialAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_ShT7rLGjukefxLaBIgLH1Q_16_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">49000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_sPEAqoePu0uo37ZGdU4SVQ_16_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1603000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_0MhKhVvaWkOAJ7GzwveKUA_17_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-701000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_-09413bmDk6t8EN1sHQiqw_18_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">203000</us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_xB3iMCJpzUa6RjXbYgG-yw_19_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-7000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_zrRxcxYx8UaOCES4odl8hw_19_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-530000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_eboNgnyjlkCmekMdSMWC2g_20_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-4851000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_26g3FP-Hd0iKj6dg3ywYOg_21_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1638000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_oVgLe_03jUqHzjYkeCRIGg_21_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-626000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_h4zOY0ORXEGOfIjpc3fUJg_22_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-632000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_1LyxLMkw002UDKs0R76Uug_24_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-3061000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_4T7JpL6HnEeCQmp_0ihHuQ_24_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5198000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_FhwEt4jthE-5skiNg7tCBg_25_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-3585000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_iKZP8TRnjk6k0JrVsnZAlg_25_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-24231000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_rJJxNTuxW06oU884O4sGGw_26_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-19000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_bdOz_aaJyEyk6t0Y7mIyWQ_26_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">37000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_CtaYU8ugD0KIwjUMDskURA_27_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-329000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_ak9puPfNC0yRCsu9sQ7nEA_27_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">20475000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_USOCObbf7Eukp-b7SX_12A_28_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-36828000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_-YgAsaV0aEWSrzhIuDvKKA_28_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-36741000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_jRyqNvctcEGV_1dUvJawEw_31_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1710000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_jaEsyYdeXkKSXxE6uo_krA_31_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1678000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <mgtx:ProceedsFromGainOnSaleOfNonfinancialAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_Z5nUHJaqr0K_LYffmsTfUw_32_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">29018000</mgtx:ProceedsFromGainOnSaleOfNonfinancialAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_DMxYNm2lCUK414Iiz4Y7Cw_33_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1710000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_f9ZZz9-WRUm50Gwn0HguhA_33_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">27340000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_SoqV97G8zUqRnPIL8RM33Q_36_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_G04ly4qHKkWG57IT2TfnVQ_37_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2761000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_osqKSdWRekSRPA9zPc_0Pg_37_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2221000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_G65-3yipd0-zX_cX8Yg6bQ_38_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4482000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_GG8hos2LyU-WnO3smMl_dA_38_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1586000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_PYJ4kNFavkmjm-pIdCQgiw_39_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">12000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_J5wG5f78q025EyXxOTuGyw_39_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">635000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_od7-Jq7oqEqSWW1Con2Jzw_40_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1713000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_UNKM6aMjc0yTEVP2kunHPA_40_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1270000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_oo5Ec_vzHUiq2rFJMs8l6w_42_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-36825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_aIQ3bIo9fkGWkuWPuMJt3A_42_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-10671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_TD8W6OPS7UCD3oNC3rgHKw_43_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-233000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_CnKuEmbok0eyw8GaTTA5Aw_43_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">287000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_EWPZbYyCe0Cz9MqXlA2YHg_44_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">105668000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg"
      decimals="-3"
      id="Tc_Fqx_FBVO9EKmApu50AOWXg_44_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">130649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_o_3ivRHeDU6VNOsS6T8dRw_45_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">68610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg"
      decimals="-3"
      id="Tc_fNb0Oq_MOEmX8dMu1TrMHw_45_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">120265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_L4gdjm3IiEODViUJ8mVPbw_48_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">615000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_CWPakGf4PEmMcdYKCH4EqQ_48_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1558000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetRetirementObligationRevisionOfEstimate
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_43v8q7P5_0WquxMoguw0Kg_49_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1576000</us-gaap:AssetRetirementObligationRevisionOfEstimate>
    <mgtx:NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_T-OebM7suUOmvrNcA0kLrA_50_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">125000</mgtx:NonCashTransactionReceivableFromSaleOfFixedAssetsIncludedInOtherCurrentAssets>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_gH7n9qXHlUiISSwWn23aDw_52_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2863000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_VyZffcsMTUarcd_Vz22djQ_52_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2953000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_G4MHzo5OmE-F0TwRlzZzQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organization and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;MeiraGTx Holdings plc and subsidiaries (the &#x201c;Company&#x201d; or &#x201c;Meira Holdings&#x201d;), an exempted company incorporated under the laws of the Cayman Islands, is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. MeiraGTx clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by the Company&#x2019;s internal end-to-end manufacturing capabilities. The Company has two viral vector production facilities for good manufacturing practices (&#x201c;GMP&#x201d;), internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. In addition, the Company has developed a proprietary manufacturing platform with leading yield and quality aspects and commercial readiness. The Company&#x2019;s core capabilities in viral vector and capsid optimization allow increased potency, decreased dose and significantly reduced cost of goods for its genetic medicines. The Company has developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive expression of any transgene under the control of oral small molecules. The Company is focusing the riboswitch platform on &lt;i style="font-style:italic;"&gt;in vivo &lt;/i&gt;delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin via oral small molecules, as well as cell therapy for oncology and autoimmune diseases, and long-term intractable pain. &#160;The Company has developed unique comprehensive technology capabilities to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Hologen Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;On March 9, 2025 (the &#x201c;Signing Date&#x201d;), the Company and its affiliates entered into a strategic collaboration with Hologen Limited, a non-cellular company limited by shares incorporated in Guernsey (&#x201c;Hologen&#x201d;), and its affiliates. &#160;Hologen is a leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. As part of the strategic collaboration, the Company and Hologen have entered into the Framework Agreements (as defined below), pursuant to which the Company and its affiliates will receive from Hologen an upfront cash payment of $200 million (the &#x201c;Upfront Payment&#x201d;) on the Closing Date (as defined below), and Hologen will provide additional funding of up to an additional $230 million as further described below. As part of the strategic collaboration, the Company also received 250,000 Class A shares of Hologen at a nominal price. Furthermore, the Company has the option to receive up to an additional 500,000 Class A shares of Hologen at a nominal price if certain funding obligations as described herein are not met by Hologen.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The closing of the transactions contemplated by the Framework Agreements (the &#x201c;Closing Date&#x201d;) is expected to occur in the second calendar quarter of 2025, subject to customary closing and funding conditions, including the receipt of the clearances and approvals applicable to the proposed transactions under the foreign direct investment laws of the United Kingdom and the satisfaction or waiver of certain other closing conditions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;i style="font-style:italic;"&gt;Neuro Framework Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;On the Signing Date, the Company, MeiraGTx Neuro UK Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#x201c;MeiraGTx Neuro UK&#x201d;), Hologen Neuro AI Limited, a non-cellular company limited by shares incorporated in Guernsey and an affiliate of Hologen (&#x201c;Hologen Neuro&#x201d;), and Hologen, entered into that certain Framework Agreement (the &#x201c;Neuro Framework Agreement&#x201d;), pursuant to which, on the Closing Date, the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (&#x201c;MeiraGTx Neuro US&#x201d;), Hologen, Hologen Neuro and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England and an affiliate of Hologen (&#x201c;Hologen Neuro UK&#x201d;), shall enter into a Collaboration and License Agreement (the &#x201c;Hologen Collaboration Agreement&#x201d;) for the research, development, manufacture and commercialization of the Company&#x2019;s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson&#x2019;s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the &#x201c;Clinical Programs&#x201d;) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the &#x201c;Delivery Device&#x201d;), in each case, in accordance with the terms and conditions of the Hologen Collaboration Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;On the Closing Date, under the Hologen Collaboration Agreement, MeiraGTx Neuro US will receive the applicable portion of the Upfront Payment in consideration for granting to Hologen Neuro and Hologen Neuro UK, as of the Closing Date and subject to the license granted by Hologen Neuro and Hologen Neuro UK back to MeiraGTx Neuro UK, exclusive, worldwide, royalty-free, fully paid-up licenses to certain of the Company&#x2019;s intellectual property rights for the research, development, manufacture and commercialization of the Clinical Programs and the Delivery Device. On the Closing Date, (a) MeiraGTx Neuro UK will receive Class A shares of Hologen Neuro representing a 30% ownership of the issued share capital of Hologen Neuro, in consideration for the provision of services to Hologen Neuro and Hologen Neuro UK as specified in the Hologen Collaboration Agreement, including services relating to the development of the Clinical Programs and the Delivery Device and certain other transition services, and (b) Hologen Guernsey will receive Class B shares of Hologen Neuro representing a 70% ownership of the issued share capital of Hologen Neuro, in consideration for paying the applicable portion of the Upfront Payment to MeiraGTx Neuro US, as well as a commitment to provide additional capital of up to $230 million to fund the development of the Clinical Programs and the Delivery Device. Additionally, Hologen will license to Hologen Neuro its proprietary multi-modal generative foundation models (LMMs), or large medicine models, pursuant to a license agreement mutually agreeable to the parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;As of the Closing Date, Hologen Neuro shall be governed by a board of directors comprised of three representatives designated by Hologen and two representatives designated by MeiraGTx Neuro UK, and certain material business decisions (as further enumerated in the Neuro Framework Agreement) will require the approval of at least 70% of the directors then in office. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Following the Closing Date and in accordance with the terms of the Hologen Collaboration Agreement, the parties shall negotiate in good faith and enter into clinical and commercial supply agreements, pursuant to which MeiraGTx Neuro UK (directly, or through affiliates or subcontractors) shall manufacture and supply AAV-GAD, AAV-BDNF and other potential locally delivered genetic medicines to the central nervous system. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.05pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;i style="font-style:italic;"&gt;Manufacturing Framework Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;On the Signing Date, MeiraGTx Manufacturing Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#x201c;MeiraGTx Manufacturing&#x201d;), MeiraGTx Limited, a private company limited by shares incorporated in England and a wholly-owned subsidiary of the Company (&#x201c;MeiraGTx Limited&#x201d;), and Hologen, entered into that certain Framework Agreement (the &#x201c;Manufacturing Framework Agreement&#x201d; and, together with the Neuro Framework Agreement, the &#x201c;Framework Agreements&#x201d;), pursuant to which, on the Closing Date and in exchange for the applicable portion of the Upfront Payment, Hologen will acquire a minority interest in MeiraGTx Manufacturing, an entity that will comprise the Company&#x2019;s flexible and scalable end-to-end genetic medicines manufacturing business, which is solely run by MeiraGTx Manufacturing and MeiraGTx Limited prior to the Closing Date. Hologen will also contribute a portion of the annual funding to MeiraGTx Manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;As of the Closing Date, MeiraGTx Manufacturing shall be governed by a board of directors comprised of three representatives designated by MeiraGTx Limited and two representatives designated by Hologen, and certain material business decisions (as further enumerated in the Manufacturing Framework Agreement) will require the approval of at least 70% of the directors then in office.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;For a period of twelve months following the Closing Date, Hologen has an exclusive, irrevocable option to purchase additional shares in MeiraGTx Manufacturing at a specified price, such that following exercise of such option, Hologen shall own 40% of the issued share capital of MeiraGTx Manufacturing in the aggregate. &#160;In the event that Hologen does not exercise its option, MeiraGTx has an exclusive, irrevocable option to purchase all of the shares of MeiraGTx Manufacturing held by Hologen for the same price that Hologen paid for such shares. Such option shall be exercisable anytime beginning on the third anniversary of the Closing Date and ending three years thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Asset Purchase and Related Agreements with Johnson &amp;amp; Johnson Innovative Medicine&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;On January&#160;30, 2019, the Company entered into a Collaboration, Option and License Agreement with Johnson &amp;amp; Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.)&lt;span style="color:#ff0000;"&gt; &lt;/span&gt;(the &#x201c;Collaboration Agreement&#x201d;), for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases (&#x201c;IRD&#x201d;). Under the terms of the Collaboration Agreement, the Company received funding for certain research, manufacturing, clinical development and commercialization costs, and had the potential to obtain additional milestone payments upon the achievement of such milestones and royalties on future net sales of products. On December 20, 2023, the Company entered into an Asset Purchase Agreement (&#x201c;Asset Purchase Agreement&#x201d;) with Johnson &amp;amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp;amp; Johnson Innovative Medicine, and Johnson &amp;amp; Johnson Innovative Medicine purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) (&#x201c;UCLB&#x201d;), on the one hand, and MeiraGTx UK II Limited and MeiraGTx Limited, on the other hand (the &#x201c;UCLB RPGR License Agreement&#x201d;), relating to the research, development, manufacture and exploitation of botaretigene sparoparvovec, or bota-vec (formerly referred to as AAV-RPGR), for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene, or XLRP-RPGR (the &#x201c;RPGR Product&#x201d;), and other related assets as described in the Asset Purchase Agreement. In connection with entering into the Asset Purchase Agreement, the Company entered into a Termination Agreement with Johnson &amp;amp; Johnson Innovative Medicine terminating the Collaboration Agreement. The Company and Johnson &amp;amp; Johnson Innovative Medicine also entered into a Supply Agreement on December 20, 2023 (the &#x201c;Supply Agreement&#x201d;) pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp;amp; Johnson Innovative Medicine. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Under the Asset Purchase Agreement, Johnson &amp;amp; Johnson Innovative Medicine paid the Company a non-refundable upfront cash payment of $65.0 million in December 2023. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Johnson &amp;amp; Johnson Innovative Medicine agreed to pay the Company future contingent consideration of up to an aggregate of $350.0 million, as follows: (i) a milestone payment of $50.0 million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $10.0 million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $5.0 million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $175.0 million upon the first commercial sale of an RPGR Product in the United States; (v) $75.0 million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $25.0 million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp;amp; Johnson Innovative Medicine; and (vii) $10.0 million upon regulatory approval of a Johnson &amp;amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. During 2024, the Company received $60.0 million in milestone payments from Johnson &amp;amp; Johnson Innovative Medicine. Johnson &amp;amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Interim Financial Statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to&#160;Form&#160;10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary in order to make the condensed consolidated financial statements not misleading. Operating results for the three-month period ended March 31, 2025&#160;are not necessarily indicative of the results that may be expected for the&#160;year ending December&#160;31, 2025. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the&#160;year ended December 31, 2024 included in the Company&#x2019;s Annual Report on Form&#160;10-K for the fiscal&#160;year ended December 31, 2024 (the &#x201c;Form&#160;10-K&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing. The Company&#x2019;s accumulated deficit at March 31, 2025 totaled $742.0 million, and management expects to incur substantial losses in future periods. The success of the Company is subject to certain risks and uncertainties, including, among others: uncertainty of product development; competition in the Company&#x2019;s field of use; uncertainty of capital availability; uncertainty in the Company&#x2019;s ability to enter into agreements and consummate transactions with collaborative partners; expanding and protecting the Company&#x2019;s intellectual property portfolio; dependence on third parties; and dependence on key personnel. For the three months ended March 31, 2025, the Company used $36.8 million in cash flows from operations and there are no assurances that the Company will generate positive cash flows in the future. Additionally, there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;As of March 31, 2025, the Company had cash, cash equivalents and restricted cash in the amount of $68.6 million, which consisted of depository and money market accounts held at large international banks. The Company estimates that its cash and cash equivalents on-hand, tax incentive receivable and accounts receivable &#x2013; related party at March 31, 2025, together with the proceeds from the anticipated closing of the strategic collaboration with Hologen Limited, will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these condensed consolidated financial statements. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company&#x2019;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;"&gt;The Company&#x2019;s capital resources and operations to date have been funded primarily with the proceeds from the Collaboration Agreement, Asset Purchase Agreement and private and public equity offerings, as well as the proceeds from the debt financing described in Note 10. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <mgtx:MilestoneFundingUpfrontPaymentReceived
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"
      decimals="-5"
      id="Narr_OQCRJETDKk2F1wKEssmRhQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">200000000</mgtx:MilestoneFundingUpfrontPaymentReceived>
    <mgtx:MilestoneFundingToProvideAdditionalCapital
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_tiGUIO0qBk69Z-8zacyddg"
      decimals="-5"
      id="Narr_Txetm6B5wUOilDBDiL7RCA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">230000000</mgtx:MilestoneFundingToProvideAdditionalCapital>
    <mgtx:ClassSharesOfHologenReceivedInTransaction
      contextRef="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw"
      decimals="0"
      id="Narr_3OFYDwb3vkmcePakSmFSYw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">250000</mgtx:ClassSharesOfHologenReceivedInTransaction>
    <mgtx:ContingentClassSharesReceivableOfHologenInTransaction
      contextRef="As_Of_3_9_2024_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_-VagWIdO_Eiqq9xwDcWjYw"
      decimals="0"
      id="Narr_pxsTI6UOOE2S5LbQTFg0tg"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">500000</mgtx:ContingentClassSharesReceivableOfHologenInTransaction>
    <mgtx:ClassShareOwnershipPercentageOfHologenNeuro
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"
      decimals="2"
      id="Narr_b04qpA2ry0Wu6UwOisL9ag"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.30</mgtx:ClassShareOwnershipPercentageOfHologenNeuro>
    <mgtx:ClassBShareOwnershipPercentageOfHologenNeuro
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"
      decimals="2"
      id="Narr_xtcv5D6guE6c1WwXWlxvzg"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.70</mgtx:ClassBShareOwnershipPercentageOfHologenNeuro>
    <mgtx:MilestoneFundingToProvideAdditionalCapital
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"
      decimals="-5"
      id="Narr_1FcZxDFuJUu1dVQeCWT7pg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">230000000</mgtx:MilestoneFundingToProvideAdditionalCapital>
    <mgtx:PercentageApprovalOfDirectors
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_HologenTransactionAgreementMember_ZMCs1PgQPEm16MPVPz4JaQ"
      decimals="2"
      id="Narr_DdJYI8c1Mk63nC3ZXOWCwA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.70</mgtx:PercentageApprovalOfDirectors>
    <mgtx:PercentageApprovalOfDirectors
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww"
      decimals="2"
      id="Narr_69lBMT1m_0yihB646OUlwQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.70</mgtx:PercentageApprovalOfDirectors>
    <mgtx:PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww"
      decimals="2"
      id="Narr_CZ0Ii0J8hEi4jDCY7i8o8A"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.40</mgtx:PurchaseOptionAfterTwelveMonthsPercentageOfCompanySOutstandingCommonShares>
    <mgtx:RepurchaseOptionVestingPeriod
      contextRef="Duration_3_9_2025_To_3_9_2025_srt_CounterpartyNameAxis_mgtx_HologenLimitedMember_us-gaap_TypeOfArrangementAxis_mgtx_ManufacturingFrameworkAgreementMember_d-5Ck5sax0Odp5Hg6pmcww"
      id="Narr_rdjoBw_luU6E0MNbka5h0w">P3Y</mgtx:RepurchaseOptionVestingPeriod>
    <mgtx:AssetPurchaseAgreementFundingReceived
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_N-4mBqm950OdHh1AqknNlA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">65000000</mgtx:AssetPurchaseAgreementFundingReceived>
    <mgtx:ContingentFundingAvailable
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_anYll54pokiQcp14tL7FPQ"
      decimals="-5"
      id="Narr_DY0NXyd1F06WrR6VeJEDXw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">350000000</mgtx:ContingentFundingAvailable>
    <mgtx:MilestoneFundingForExtensionOfClinicalTrials
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_vxfqy9OKIUWACknu_IhoYg"
      decimals="-5"
      id="Narr_ch6bBPNlMkCgvbO3BTLiAg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">50000000</mgtx:MilestoneFundingForExtensionOfClinicalTrials>
    <mgtx:MilestoneFundingForDevelopmentOfDrugSubstances
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_VgvgJB2fokKJvsDtF0zNHw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10000000</mgtx:MilestoneFundingForDevelopmentOfDrugSubstances>
    <mgtx:MilestoneFundingForDevelopmentOfDrugProducts
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_ZeSmv9fJvUy9KXhmBMAMow"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5000000</mgtx:MilestoneFundingForDevelopmentOfDrugProducts>
    <mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_SFnqvSCFQkaDEw4oVtgBQg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">175000000</mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates>
    <mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_kHAaktVoXkGlYyetfLB8Ow"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">75000000</mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly>
    <mgtx:MilestoneFundingForTransferOfManufacturingTechnology
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_ir5Vme10Hkqq9Fl_TW9K5A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">25000000</mgtx:MilestoneFundingForTransferOfManufacturingTechnology>
    <mgtx:MilestoneFundingForRegulatoryApproval
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_e0JP0t2xWEmcxtQ4sHLlGA"
      decimals="-5"
      id="Narr_mkm77yadHUWNdKMeBNJXiQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10000000</mgtx:MilestoneFundingForRegulatoryApproval>
    <mgtx:MilestoneFundingReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_bTo8MlYWIEagDkty02ovVw"
      decimals="-5"
      id="Narr_ls_aP3Yw20OcTvkTlw5meQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">60000000</mgtx:MilestoneFundingReceived>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-5"
      id="Narr_bSudVECu8EyKaUIIChKGEg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-742000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_BqiP2NGvgUy506KJMOFcJw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-36800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-5"
      id="Narr__BrIPQL67UmA3ORvabN6Yw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">68600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_Vw-M7JBipU2FH_yt_EXG0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. &#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies and Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Certain of the Company&#x2019;s significant accounting policies are described below. All of the Company&#x2019;s significant accounting policies are disclosed in the notes to the audited consolidated financial statements as of and for the&#160;year ended December 31, 2024 included in the Company&#x2019;s Form&#160;10-K.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx, LLC, a Delaware limited liability company (&#x201c;Meira LLC&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (&#x201c;Meira UK&#160;II&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (&#x201c;Meira Ireland&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#x201c;Meira Netherlands&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Belgium, a private company with limited liability incorporated under the laws of Belgium (&#x201c;Meira Belgium&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;BRI-Alzan,&#160;Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Bio, Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#x201c;Meira B.V.&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neurosciences,&#160;Inc., a Delaware corporation; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Therapeutics, Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (&#x201c;Meira UK&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro I, LLC, a Delaware limited liability company;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro II, LLC, a Delaware limited liability company;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Manufacturing Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Ocular UK Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Gene Regulation Limited, a limited company incorporated under the laws of England and Wales; and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro UK Limited, a limited company incorporated under the laws of England and Wales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: service revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Restricted cash represents a guarantee put in place as required by the terms of the research and innovation grant from IDA Ireland which offers financial assistance in establishing the Company&#x2019;s operations in Shannon, Ireland. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company&#x2019;s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company&#x2019;s own credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company follows ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;The table below represents the values of the Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&#160;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"&gt;At March 31, 2025, the Company's financial instruments included cash and cash equivalents, restricted cash, accounts receivable &#x2013; related party, and accounts payable. The carrying amounts reported in the Company's condensed consolidated financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments. In addition, at March 31, 2025, the Company believes the carrying value of the Tranche 1 Notes (as defined in Note 10) approximates fair value as the interest rate is reflective of the rate the Company could obtain on debt with similar terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Asset Retirement Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.3pt;"&gt;Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level&#160;3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported on the condensed consolidated balance sheets were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"&gt;The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, for which the Company had an associated asset retirement obligation liability in the amount of $1.7 million and a corresponding leasehold improvement with a net book value of $0.3 million as of March 31, 2025. The landlord no longer requires the Company to make any changes to the premises prior to the lease termination and the Company only expects to incur $0.1 million related to decontamination costs. Therefore, a change in estimate of the asset retirement obligation was recorded resulting in a gain on termination of lease liabilities of $1.3 million which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.5pt;"&gt;The change in asset retirement obligations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in estimate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Effects of exchange rate changes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 24.5pt;"&gt;IDA Ireland Grant&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;"&gt;In August 2021, Meira Ireland entered into an agreement pursuant to which it received a grant from IDA Ireland for financial assistance in establishing its operations in Shannon, Ireland. Under the terms of the grant, Meira Ireland is eligible to receive the lesser of &#x20ac;1.0 million or &#x20ac;10,000 for each job created (the &#x201c;employment grant&#x201d;) and the lesser of &#x20ac;1.2 million or 4% of the actual expenditure on the provision of machinery and equipment (the &#x201c;capital grant&#x201d;). Meira Ireland may apply for a drawdown of the employment grant once a job has been created and the position has been held for a period of at least one month, and may apply for a drawdown of the capital grant once an eligible asset has been purchased and installed, conditioned on the creation of a cumulative number of jobs by the end of the immediately preceding year. An aggregate of 100 jobs must be created to receive the maximum benefit under the capital grant. An application for a drawdown must be accompanied by an audit certification for compliance with the terms of the grant. The Company has a guarantee in place with a bank in favor of IDA Ireland, pursuant to which it restricts cash in the amount of claims made under the grant such that the Company maintains the funds to cover any portion of the grant income that may become repayable in the future. This amount is presented as restricted cash in the accompanying condensed consolidated balance sheet. All grant drawdowns were required to be completed by December 31, 2024, and the agreement terminates on the later of five years from the date of the last payment from the grant or five years from completion of the capital investment, which is expenditure of at least &#x20ac;30.0 million on eligible machinery and equipment. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;"&gt;The Company recognizes grant income when there is reasonable assurance that the Company will comply with the conditions attached to the grant and that it will receive the grant. Grant income from the employment grant is recognized as a deduction from the amount of the related expense, and grant income from the capital grant is deducted from the carrying amount of the related asset and recognized in income over the asset&#x2019;s useful life in the form of a reduced depreciation charge. The Company received its first drawdown under the grant in 2023, which was comprised of $0.6 million for the employment grant and $0.4 million for the capital grant. The Company received its second drawdown under the grant in 2024, which was comprised of $0.5 million for the employment grant and $0.5 million for the capital grant. During the three-months ended March 31, 2025 and 2024, the Company recognized de minimis grant income as a reduction of research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;During the five-year period ending on the termination of the grant agreement, Meira Ireland must maintain compliance with the terms of the grant. If the total number of jobs is less than 100 at the time of IDA Ireland&#x2019;s annual review, the Company may have to repay a portion of the capital grant, and if a job for which the Company received employment grant funding remains vacant for a period in excess of &lt;span style="-sec-ix-hidden:Hidden_eNuWP8gC10unY9sqGjg8MQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six&lt;/span&gt;&lt;/span&gt; calendar months, the Company may have to repay the employment grant received for that job. As of March 31, 2025, the Company is in compliance with the terms of the grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 24.45pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition the Company performs the following five steps:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;i.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;identify the contract(s)&#160;with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;ii.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;iii.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;determine the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;iv.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;allocate the transaction price to the performance obligations within the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;v.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;"&gt;At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;If there are multiple performance obligations, the Company allocates the transaction price to each performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a performance obligation requires significant judgment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;The Company records amounts as contract assets when the right to consideration is deemed unconditional. Contract assets are reclassified as accounts receivable once billed. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s condensed consolidated balance sheet.&#160;Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#x2013; related party, current.&#160;Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#x2013; related party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;The Company&#x2019;s revenue arrangements include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Milestone Payments:&#160;At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and Development Services: Under the Asset Purchase Agreement, research and development services (PPQ services) are recorded as incurred under cost of service revenue &#x2013; related party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Customer Options: Customer options are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company&#x2019;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expenses, as the case may be.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Net Loss per Ordinary Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary share equivalents had been issued at the beginning of the&#160;year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,484,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,389,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,094,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,112,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,464,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable and operating segment, which is the development and manufacturing of genetic medicines, for purposes of reporting financial condition and results of operations. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the chief executive officer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM allocates resources and assesses performance of the Company&#x2019;s single reportable segment by regularly reviewing the segment net loss that also is reported on the condensed consolidated statement of operations and comprehensive loss as net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The following table sets forth information about the Company&#x2019;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cost of service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Botaretigene sparoparvovec&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-hAQP1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-CNGB3 / AAV-CNGA3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,179)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-GAD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Other ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Preclinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Gene regulation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Neurodegenerative diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Preclinical ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other research and development&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (624)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Johnson &amp;amp; Johnson Innovative Medicine reimbursement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments or reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1 &lt;/sup&gt;Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt; Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company&#x2019;s service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;The following table summarizes long-lived assets by geographical area (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;European Union&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 134,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 136,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. This update includes a number of amendments to clarify or improve disclosure and presentation requirements of a variety of topics in order to allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the requirements and to align the requirements in the FASB accounting standard codification with the SEC&#x2019;s regulations. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact of these amendments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement: Reporting Comprehensive Income: Expense Disaggregation Disclosures (Subtopic 220-40), which requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date, which revised the effective date of ASU No. 2024-03 for interim periods. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of ASU 2024-03 and ASU 2025-01 on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_5_VDMn-fDUu-brzsj9jT7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx, LLC, a Delaware limited liability company (&#x201c;Meira LLC&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (&#x201c;Meira UK&#160;II&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (&#x201c;Meira Ireland&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#x201c;Meira Netherlands&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Belgium, a private company with limited liability incorporated under the laws of Belgium (&#x201c;Meira Belgium&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;BRI-Alzan,&#160;Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Bio, Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (&#x201c;Meira B.V.&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neurosciences,&#160;Inc., a Delaware corporation; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Therapeutics, Inc., a Delaware corporation;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (&#x201c;Meira UK&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro I, LLC, a Delaware limited liability company;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro II, LLC, a Delaware limited liability company;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Manufacturing Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Ocular UK Limited, a limited company incorporated under the laws of England and Wales;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Gene Regulation Limited, a limited company incorporated under the laws of England and Wales; and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 54pt;"&gt;MeiraGTx Neuro UK Limited, a limited company incorporated under the laws of England and Wales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_XX_znLPQ1USae9X92BC0Qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: service revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_sLpY97Nld0C8RbAwhVvEcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Restricted cash represents a guarantee put in place as required by the terms of the research and innovation grant from IDA Ireland which offers financial assistance in establishing the Company&#x2019;s operations in Shannon, Ireland. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company&#x2019;s condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_E3F7LzMTA0Sqc9urtEQTgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_y4Uf5pjZjkGXDrRKZtQQjw_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">66523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_K-aXQsJXSUuAmo9oHhiCrw_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">103659000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_j32-YTKOwUKch3H9tDp7XQ_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2087000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_SY2BbjAU8kqEYfApKuTUiw_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2009000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_5Fn74psgrEO_MeGhErSaQQ_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">68610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_lRspxIDA4UWU8h9sz6lxxg_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">105668000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_Ydc-3ERsyE-XNayir99VLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company&#x2019;s own credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company follows ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;The table below represents the values of the Company's financial assets and liabilities that are required to be measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&#160;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"&gt;At March 31, 2025, the Company's financial instruments included cash and cash equivalents, restricted cash, accounts receivable &#x2013; related party, and accounts payable. The carrying amounts reported in the Company's condensed consolidated financial statements for these instruments approximates their respective fair values because of the short-term nature of these instruments. In addition, at March 31, 2025, the Company believes the carrying value of the Tranche 1 Notes (as defined in Note 10) approximates fair value as the interest rate is reflective of the rate the Company could obtain on debt with similar terms and conditions.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_NqR4a2kLv0Kxiu7pE94yLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Fair&#160;Value&#160;Measurement&#160;Using:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&#160;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Significant&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Observable&#160;Inputs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;Unobservable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;(Level&#160;3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vNTUyBj1R0iHgetCERxoKw"
      decimals="-3"
      id="Tc_8gCJ6jfi8EmoKlxQbIQLgw_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">57020000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_psKKUO-LuUiwEGnyG3klfQ"
      decimals="-3"
      id="Tc_CUdVUd2zqEa_lucHl7B_qg_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">57020000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtv4RBfxkuuH4RrzAnNHw"
      decimals="-3"
      id="Tc_4T9gfdYOSEyxNQQko2Smaw_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2087000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PWqb2kP-wEuEFAiVAHEfUw"
      decimals="-3"
      id="Tc_ZJrfegF2h0ehDHWbYqUy4A_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2087000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_w0975VuH_EaNXB4Ka939BA"
      decimals="-3"
      id="Tc_dvvRs7L45Ey9d8bW-MQRJw_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">80930000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yNUlMtvIhEu4s5tbktrKBw"
      decimals="-3"
      id="Tc_ZO2N6CrPD0yqKAZQLTThDQ_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">80930000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RF2S-NSeJU61RDz1CxpR0w"
      decimals="-3"
      id="Tc_NJPVo4qUNkG9EpYcHSfsJQ_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2009000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_mgtx_RestrictedCashMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uKmiWTXiFUui62_GfPyv8A"
      decimals="-3"
      id="Tc_VlSxBZGCy0mPrl2NTTO--Q_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2009000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetRetirementObligationsPolicy
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_1VKP3VestES7UcWXIuJrZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Asset Retirement Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.3pt;"&gt;Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level&#160;3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported on the condensed consolidated balance sheets were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"&gt;The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, for which the Company had an associated asset retirement obligation liability in the amount of $1.7 million and a corresponding leasehold improvement with a net book value of $0.3 million as of March 31, 2025. The landlord no longer requires the Company to make any changes to the premises prior to the lease termination and the Company only expects to incur $0.1 million related to decontamination costs. Therefore, a change in estimate of the asset retirement obligation was recorded resulting in a gain on termination of lease liabilities of $1.3 million which is included in general and administrative expenses in the accompanying condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 22.5pt;"&gt;The change in asset retirement obligations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in estimate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Effects of exchange rate changes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetRetirementObligationsPolicy>
    <us-gaap:AssetRetirementObligationLiabilitiesSettled
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_BLrJcfW8-kqF25j_ogBnkA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1700000</us-gaap:AssetRetirementObligationLiabilitiesSettled>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-5"
      id="Narr_HvhmuDPhPkefa7dPLCTUyQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">300000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:AssetRetirementObligationCashPaidToSettle
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_YL8zChNY5Um4QvXD3esRQA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">100000</us-gaap:AssetRetirementObligationCashPaidToSettle>
    <mgtx:GainOnTerminationOfLeaseLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_jP-Ul5E1wk2p9Xsf64X9iw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1300000</mgtx:GainOnTerminationOfLeaseLiabilities>
    <us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_leZNRZLpkUGvzPV9bIKsNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:84.63%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in estimate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Effects of exchange rate changes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_GnpdCGTSP0edK4yoa6_tOg_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2821000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_12_31_2023_z4xq8pR7m0u0XNeqVcVkTg"
      decimals="-3"
      id="Tc_ITXkbvWHaE2DvEhYpmUwHw_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2401000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligationRevisionOfEstimate
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_w-eZEpStwk2pwxFrUv5d8g_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1576000</us-gaap:AssetRetirementObligationRevisionOfEstimate>
    <mgtx:AssetRetirementObligationsAmortizationOfInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_GiwxWILewE2LcCTvo9LH3A_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">63000</mgtx:AssetRetirementObligationsAmortizationOfInterest>
    <mgtx:AssetRetirementObligationsAmortizationOfInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_3doRYfyDjE2pbLN5K3A6XA_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">48000</mgtx:AssetRetirementObligationsAmortizationOfInterest>
    <us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_w26D56GQIkyr1Dues9y7yw_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">36000</us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss>
    <us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_LkEBpgx2sUSwjshk-gO8kA_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-9000</us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_ZksA9XtAvUGvHOSWUuwXnA_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1344000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation
      contextRef="As_Of_3_31_2024_kkVPjt8ykEqpSMhmyb0ttg"
      decimals="-3"
      id="Tc_JRpkA4k5Qk6b0wxDOtuRpQ_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2440000</us-gaap:AssetRetirementObligation>
    <mgtx:ScheduleOfIrelandGrantsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_7o5yMOnvCUKwUfsprEQhAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 24.5pt;"&gt;IDA Ireland Grant&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;"&gt;In August 2021, Meira Ireland entered into an agreement pursuant to which it received a grant from IDA Ireland for financial assistance in establishing its operations in Shannon, Ireland. Under the terms of the grant, Meira Ireland is eligible to receive the lesser of &#x20ac;1.0 million or &#x20ac;10,000 for each job created (the &#x201c;employment grant&#x201d;) and the lesser of &#x20ac;1.2 million or 4% of the actual expenditure on the provision of machinery and equipment (the &#x201c;capital grant&#x201d;). Meira Ireland may apply for a drawdown of the employment grant once a job has been created and the position has been held for a period of at least one month, and may apply for a drawdown of the capital grant once an eligible asset has been purchased and installed, conditioned on the creation of a cumulative number of jobs by the end of the immediately preceding year. An aggregate of 100 jobs must be created to receive the maximum benefit under the capital grant. An application for a drawdown must be accompanied by an audit certification for compliance with the terms of the grant. The Company has a guarantee in place with a bank in favor of IDA Ireland, pursuant to which it restricts cash in the amount of claims made under the grant such that the Company maintains the funds to cover any portion of the grant income that may become repayable in the future. This amount is presented as restricted cash in the accompanying condensed consolidated balance sheet. All grant drawdowns were required to be completed by December 31, 2024, and the agreement terminates on the later of five years from the date of the last payment from the grant or five years from completion of the capital investment, which is expenditure of at least &#x20ac;30.0 million on eligible machinery and equipment. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 24.5pt;"&gt;The Company recognizes grant income when there is reasonable assurance that the Company will comply with the conditions attached to the grant and that it will receive the grant. Grant income from the employment grant is recognized as a deduction from the amount of the related expense, and grant income from the capital grant is deducted from the carrying amount of the related asset and recognized in income over the asset&#x2019;s useful life in the form of a reduced depreciation charge. The Company received its first drawdown under the grant in 2023, which was comprised of $0.6 million for the employment grant and $0.4 million for the capital grant. The Company received its second drawdown under the grant in 2024, which was comprised of $0.5 million for the employment grant and $0.5 million for the capital grant. During the three-months ended March 31, 2025 and 2024, the Company recognized de minimis grant income as a reduction of research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;During the five-year period ending on the termination of the grant agreement, Meira Ireland must maintain compliance with the terms of the grant. If the total number of jobs is less than 100 at the time of IDA Ireland&#x2019;s annual review, the Company may have to repay a portion of the capital grant, and if a job for which the Company received employment grant funding remains vacant for a period in excess of &lt;span style="-sec-ix-hidden:Hidden_eNuWP8gC10unY9sqGjg8MQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six&lt;/span&gt;&lt;/span&gt; calendar months, the Company may have to repay the employment grant received for that job. As of March 31, 2025, the Company is in compliance with the terms of the grant.&lt;/p&gt;</mgtx:ScheduleOfIrelandGrantsPolicyTextBlock>
    <mgtx:GrantAmountForJobCreation
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_x8bvSHQN80e1DIGnCPEO1g"
      decimals="-5"
      id="Narr_RYI9MT2u-kGj418f1Ufa1Q"
      unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ">1000000</mgtx:GrantAmountForJobCreation>
    <mgtx:GrantAmountForJobCreation
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_MYprx316wkKxKCI4_8ofdg"
      decimals="0"
      id="Narr_FCtwUcH5NUSA8yLeClIq4w"
      unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ">10000</mgtx:GrantAmountForJobCreation>
    <mgtx:GrantAmountForMachineryAndEquipment
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_GkhjCPAPaECcrC8N78W-Ng"
      decimals="-5"
      id="Narr_LENe9TK4WE2s7KLa8Sc88Q"
      unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ">1200000</mgtx:GrantAmountForMachineryAndEquipment>
    <mgtx:GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg"
      decimals="2"
      id="Narr_RgcWAjZ-_0WUt6v1jFZO3A"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.04</mgtx:GrantsForMachineryAndEquipmentAsPercentageOfTotalCostToMake>
    <mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding
      contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_BvXvmLHTZ0qgp_SP__HdmA"
      decimals="0"
      id="Narr_p2Z1-w0T00aSYx-Zg4x-eQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">100</mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding>
    <mgtx:FinancialAssistanceDurationFromLastGrantPayment
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA"
      id="Narr_oRabxM07Nka2p_-6Y3asVg">P5Y</mgtx:FinancialAssistanceDurationFromLastGrantPayment>
    <mgtx:FinancialAssistanceDurationFromCompletionOfCapitalInvestment
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_dpPS2QRqcUKLA2pPnL1WQg"
      id="Narr_pEw1W638GEiZznRhtXko8g">P5Y</mgtx:FinancialAssistanceDurationFromCompletionOfCapitalInvestment>
    <mgtx:ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_bCMFJ2jf9UazMtPAcWTYqg"
      decimals="-5"
      id="Narr_IuRIKwh54kaMm6LStOMKMg"
      unitRef="Unit_Standard_EUR_YdlAIOOHhUeSLvQNWru8ZQ">30000000</mgtx:ExpenditureRequirementForGrantFundingOnEligibleMachineryAndEquipment>
    <mgtx:GrantFundingReceived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_e-G_0F-wWkOXxtBy8N16Xg"
      decimals="-5"
      id="Narr_WaoCgGLskEy9E_UOQjV9yg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">600000</mgtx:GrantFundingReceived>
    <mgtx:GrantFundingReceived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_H2Pm54Ton0yrKe8l8jzgVA"
      decimals="-5"
      id="Narr_St7NyfPQFUi1XJ-5lq0bbQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">400000</mgtx:GrantFundingReceived>
    <mgtx:GrantFundingReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_dEYHtikRfE2XPBZmM5ggNQ"
      decimals="-5"
      id="Narr_JNaMO0GVok2cL65G_lRZQA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">500000</mgtx:GrantFundingReceived>
    <mgtx:GrantFundingReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandCapitalMember_IGvtLNP2dUW4TTCCJvLt-Q"
      decimals="-5"
      id="Narr_qlhDTXak9U-HzusUuOdc9A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">500000</mgtx:GrantFundingReceived>
    <mgtx:FinancialAssistanceDurationFromLastGrantPayment
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandMember_1nARwdqd7Ueltc0x2bh4ZA"
      id="Narr_sTyhfuprA0yYIa_465KGcA">P5Y</mgtx:FinancialAssistanceDurationFromLastGrantPayment>
    <mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding
      contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GovernmentAssistanceTypeAxis_mgtx_GrantsIdaIrelandEmploymentMember_3HrtmboMJUKcXvGtnUlX-g"
      decimals="0"
      id="Narr_lAjo3eswZEC05y78_TVzDA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">100</mgtx:NumberOfNewJobsCreatedToReceiveGrantFunding>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_YU_kpPmmVkWdVuXvfQed8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 24.45pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.45pt;"&gt;At inception, the Company determines whether contracts are within the scope of ASC 606 or other topics. For contracts that are determined to be within the scope of ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition the Company performs the following five steps:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;i.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;identify the contract(s)&#160;with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;ii.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;iii.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;determine the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;iv.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;allocate the transaction price to the performance obligations within the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;v.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 24.5pt;"&gt;At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements typically consist of a license to the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.45pt;"&gt;If there are multiple performance obligations, the Company allocates the transaction price to each performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a performance obligation requires significant judgment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;The Company records amounts as contract assets when the right to consideration is deemed unconditional. Contract assets are reclassified as accounts receivable once billed. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s condensed consolidated balance sheet.&#160;Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#x2013; related party, current.&#160;Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue&#160;&#x2013; related party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;The Company&#x2019;s revenue arrangements include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Milestone Payments:&#160;At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and Development Services: Under the Asset Purchase Agreement, research and development services (PPQ services) are recorded as incurred under cost of service revenue &#x2013; related party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Customer Options: Customer options are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_TKh8Ydm4oUega_iYwgU22g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company&#x2019;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expenses, as the case may be.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_Xe13pORDik25N-OEuCsNCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Net Loss per Ordinary Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary share equivalents had been issued at the beginning of the&#160;year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,484,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,389,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,094,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,112,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,464,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_HH-YxA6Wlk-0POn-s5mMMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,484,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,389,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,094,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred share units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,112,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,464,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b0HC4nScVUuIG_mYjEASwA"
      decimals="0"
      id="Tc_7ErTSkNa5UitakL2HmPacQ_3_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">8022989</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_gOdpVqSBHEGJvzck7tJOZA"
      decimals="0"
      id="Tc_VGFMYAy2akOnIsW1GJGzEg_3_4"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">8484644</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_oyaq6jivUkawB4YLvbDI0A"
      decimals="0"
      id="Tc_LBA_RZ9gCk-CcZikz8ekLQ_4_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">3389750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_EPMBHNhui0SPV5q0DQTs9A"
      decimals="0"
      id="Tc_DxJJfyKWvkCGJxrCAV1s1A_4_4"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">4094750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember_uFjEWSkzu0eHvfAynbX9jQ"
      decimals="0"
      id="Tc_ULy_LtBv2UyGfOWHR1JB2Q_5_4"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">185000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_nPdsKTqjKEeHIAIo7QnFLA"
      decimals="0"
      id="Tc_mfrhqn-w7UKrSUDjjdjPOw_6_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_e_mz02J0OEe3fPVeHHSu4w"
      decimals="0"
      id="Tc_uU5yCWWSD0OgCR_X4BKkAw_6_4"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Tc_Rz4gzG6Ir0GLsnlB6_r9ig_7_2"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">12112739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="0"
      id="Tc_4-vEQK7a9UyURM30SCmktg_7_4"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">13464394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_HBbcCvar70SRR73-bgmXYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable and operating segment, which is the development and manufacturing of genetic medicines, for purposes of reporting financial condition and results of operations. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the chief executive officer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM allocates resources and assesses performance of the Company&#x2019;s single reportable segment by regularly reviewing the segment net loss that also is reported on the condensed consolidated statement of operations and comprehensive loss as net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The following table sets forth information about the Company&#x2019;s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cost of service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Botaretigene sparoparvovec&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-hAQP1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-CNGB3 / AAV-CNGA3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,179)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-GAD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Other ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Preclinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Gene regulation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Neurodegenerative diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Preclinical ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other research and development&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (624)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Johnson &amp;amp; Johnson Innovative Medicine reimbursement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments or reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1 &lt;/sup&gt;Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt; Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company&#x2019;s service revenue and deferred revenue from the Asset Purchase Agreement and related agreements were generated in the United Kingdom.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;The following table summarizes long-lived assets by geographical area (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;European Union&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 134,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 136,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_521JCjE1nkGs5wMswWUdiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cost of service revenue - related party&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Botaretigene sparoparvovec&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-hAQP1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-CNGB3 / AAV-CNGA3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,179)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;AAV-GAD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Other ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Preclinical programs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Gene regulation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Neurodegenerative diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;"&gt;Preclinical ocular diseases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other research and development&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (624)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Johnson &amp;amp; Johnson Innovative Medicine reimbursement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (652)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments or reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1 &lt;/sup&gt;Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;2&lt;/sup&gt; Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <mgtx:ServiceRevenueFromRelatedParties
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_kYTOp3G0f0Kii9qk5H4y8g_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1926000</mgtx:ServiceRevenueFromRelatedParties>
    <mgtx:ServiceRevenueFromRelatedParties
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_EIdUAxciF0-KVXbSXF5JnA_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">697000</mgtx:ServiceRevenueFromRelatedParties>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_pE-mEd9Wi0q7U0VLmbOLjQ_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1378000</us-gaap:SellingAndMarketingExpense>
    <mgtx:SegmentGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_9Ff0hSVYb0m4xjzWQDP7ug_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6348000</mgtx:SegmentGeneralAndAdministrativeExpenses>
    <mgtx:SegmentGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_vEv2edeccUaFd0GIZP_irw_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">8864000</mgtx:SegmentGeneralAndAdministrativeExpenses>
    <mgtx:ClinicalProgramsDrugProduct1
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_Rma0QDPtyEaJzKCOelVsYg_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3957000</mgtx:ClinicalProgramsDrugProduct1>
    <mgtx:ClinicalProgramsDrugProduct2
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_Hb7Sa4cuv02xcgPZR3D0FA_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4852000</mgtx:ClinicalProgramsDrugProduct2>
    <mgtx:ClinicalProgramsDrugProduct2
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_DLwECa4jvEKDkWKXl1sxQw_9_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1663000</mgtx:ClinicalProgramsDrugProduct2>
    <mgtx:ClinicalProgramsDrugProduct3
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_2QDDvhCWHUiGXOhc-ZOK3A_10_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1179000</mgtx:ClinicalProgramsDrugProduct3>
    <mgtx:ClinicalProgramsDrugProduct4
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_WGwt2O6iqEyrbGZ3V7VImA_11_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1459000</mgtx:ClinicalProgramsDrugProduct4>
    <mgtx:ClinicalProgramsDrugProduct4
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_gKK6AvFb6kuMlE0D1Tz3Jg_11_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2170000</mgtx:ClinicalProgramsDrugProduct4>
    <mgtx:ResearchAndDevelopmentClinicalTrials
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_4hvYHlYhr0Km_XzfLAvLRg_12_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1445000</mgtx:ResearchAndDevelopmentClinicalTrials>
    <mgtx:ResearchAndDevelopmentClinicalTrials
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_MbAnGWEJy0OPwELgjgEhfg_12_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">293000</mgtx:ResearchAndDevelopmentClinicalTrials>
    <mgtx:ResearchAndDevelopmentManufacturing
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_YwhupzaQd0-Y3GXr6aoIAw_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">17359000</mgtx:ResearchAndDevelopmentManufacturing>
    <mgtx:ResearchAndDevelopmentManufacturing
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_nheKqqxtqkODnOky5Pn2eg_13_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">18360000</mgtx:ResearchAndDevelopmentManufacturing>
    <mgtx:PreClinicalResearchGeneRegulation
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_lIiNpOkNlUm15Pq9u6Y-dA_15_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2286000</mgtx:PreClinicalResearchGeneRegulation>
    <mgtx:PreClinicalResearchGeneRegulation
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_cthZb3V-OES_NmnU3GbfHw_15_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2499000</mgtx:PreClinicalResearchGeneRegulation>
    <mgtx:PreClinicalResearchNeurodegenerativeDiseases
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_WtIkw29VukammzDmfIxSCg_16_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">426000</mgtx:PreClinicalResearchNeurodegenerativeDiseases>
    <mgtx:PreClinicalResearchNeurodegenerativeDiseases
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_YuG3R6PFZECcDFvbpjNvIg_16_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">391000</mgtx:PreClinicalResearchNeurodegenerativeDiseases>
    <mgtx:PreClinicalResearchPreclinicalOcularDiseases
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_68rxqNVZ2EGQV618ruIVQQ_17_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">625000</mgtx:PreClinicalResearchPreclinicalOcularDiseases>
    <mgtx:PreClinicalResearchPreclinicalOcularDiseases
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_ggUOZuZjgkqTiEPXmdlTjg_17_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">327000</mgtx:PreClinicalResearchPreclinicalOcularDiseases>
    <mgtx:ResearchAndDevelopmentOther
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_5aiS11WMIUS0outivrMEOA_18_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-624000</mgtx:ResearchAndDevelopmentOther>
    <mgtx:ResearchAndDevelopmentOther
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_3JN5x3Gj7UyhfuReZvnWHQ_18_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">541000</mgtx:ResearchAndDevelopmentOther>
    <mgtx:InnovativeMedicineReimbursement
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_2UCEcuGfC0KRFGFnYzJTEA_19_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">652000</mgtx:InnovativeMedicineReimbursement>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_jbG34-ztz0OcNhfIsRtnXw_20_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4887000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_HSn2TLr3vE-cCFAfK3oKfQ_20_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6960000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_prd9t_vTBkyoc4e8NF4Jiw_21_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3081000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_jZuzyye3Mku9kaPE_MQK-A_21_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3275000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_Zcoa2pvKjkKILGQOKs68wA_22_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">43522000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_erSWw4wIR0aNeW0hgJCMKg_22_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">47469000</us-gaap:OperatingExpenses>
    <mgtx:OtherSegmentItemsIncomeStatement
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_0Fxfl1bFLk2xCPP-B_r2hw_23_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1615000</mgtx:OtherSegmentItemsIncomeStatement>
    <mgtx:OtherSegmentItemsIncomeStatement
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_i6gfrwEqk0OAvMD-5-l_Cg_23_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">26330000</mgtx:OtherSegmentItemsIncomeStatement>
    <mgtx:SegmentNetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_ejDAqkC_pEOkgPn4hvk6PQ_24_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</mgtx:SegmentNetIncomeLoss>
    <mgtx:SegmentNetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_Zzx7YIzSnUqWs7GCP3J41Q_24_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</mgtx:SegmentNetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_7XHUTbyg50iEI5XCHOOyLQ_26_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-39981000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      decimals="-3"
      id="Tc_cZXJbspHXkuZu6LbslQOhw_26_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-20442000</us-gaap:NetIncomeLoss>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_tX92qTu830CiGL3JAGrcwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;European Union&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 134,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 136,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_US_isAzfTWGxEaw8ldhWLyHVA"
      decimals="-3"
      id="Tc_Yc4Q88c7K0aMW39Xh856pQ_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2515000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_cfMdJz0u7EKj-RrpFQyMpw"
      decimals="-3"
      id="Tc_Z5k0DT2D0kq1l07NuYG_yg_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">7209000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_country_GB_mLJbdBSl7Euj6MToEtRJ-w"
      decimals="-3"
      id="Tc_4lJgaaCblkeec5HgBkA0Pw_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">28255000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_6w38CaNnUkWyGPBi3mG6OQ"
      decimals="-3"
      id="Tc_kmpQXSrAqkm-UxnOeB3KWQ_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">28419000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_3_31_2025_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember__19Q6cUiYEa7qmq_KO8jNg"
      decimals="-3"
      id="Tc_gjnp0fP550iYaS9kodB3Tg_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">103487000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_EiRkplRRA0e4VFOvaZVcUA"
      decimals="-3"
      id="Tc_bpW8IFxBzE-jNcWQoBFrFA_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">100845000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_02X9cvP3H06wByIf2lsA-Q_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">134257000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_ktebdGeL4EydGwhZ0gDCFA_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">136473000</us-gaap:NoncurrentAssets>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_XA_iDe0yZUGbwtgPiWjLXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. This update includes a number of amendments to clarify or improve disclosure and presentation requirements of a variety of topics in order to allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not previously subject to the requirements and to align the requirements in the FASB accounting standard codification with the SEC&#x2019;s regulations. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the impact of these amendments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement: Reporting Comprehensive Income: Expense Disaggregation Disclosures (Subtopic 220-40), which requires public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, Clarifying the Effective Date, which revised the effective date of ASU No. 2024-03 for interim periods. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of ASU 2024-03 and ASU 2025-01 on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_XPIaGlHVhEqUUCUr69KNBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;3. &#160;&#160;&#160;&#160;&#160;&#160;Equity Method and Other Investments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 22.5pt;"&gt;The Company&#x2019;s investments consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investee&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ownership Percentage&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost Basis&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Visiogene LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity Method Investment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity Investment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity method and other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_kkIIjNnfw0OPmOoWcMaPtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investee&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Investment Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ownership Percentage&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost Basis&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Visiogene LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity Method Investment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity Investment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:25.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total equity method and other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q"
      decimals="2"
      id="Tc_U_f8VEaI7EmqvRhqz9P0Gg_3_4"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q"
      decimals="-3"
      id="Tc_pKLgJlVVykSFt0jvzQAcHg_3_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5133000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_VisiogeneLlcMember_xgl8xaBbYki9ABUtaWL77Q"
      decimals="-3"
      id="Tc_CZn9RcL5gkCe886i1QupYQ_3_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5165000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA"
      decimals="3"
      id="Tc_PdkfazkiZU-AQpu8wPamiw_4_4"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.009</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA"
      decimals="-3"
      id="Tc_VscANXUZPkyD8YlxJ4NpOA_4_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1616000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_OtherEquityMethodInvestmentsMember_SOOicvp1M0WdWw09POSqIA"
      decimals="-3"
      id="Tc_qpOfDQ2WrUGf3Hda7dd0XA_4_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_DexFtk274kyJLfdNj2HSUw_5_8"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6749000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_sGm7unlxtEGtKJV6rw29Bg_5_11"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6665000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_uGPTaBQTmE6L2QB0ygkSGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. &#160;&#160;&#160;&#160;&#160;&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;Accrued expenses for the periods presented are comprised of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on Tranche 1 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Manufacturing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Rent and facilities costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_0nZV98gEwkKiTsVHeYAQPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on Tranche 1 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Manufacturing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Rent and facilities costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Nib3vf5WT0KGTdNsRCUQ5A_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">8129000</mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits>
    <mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_LUb10D2gA0CDHOE2aSQqBw_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">11197000</mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_fMlJSU5-Cky5uZeNFDgjMQ_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4163000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_yw5nHtcC_UieopD7TFbEhQ_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6326000</us-gaap:AccruedProfessionalFeesCurrent>
    <mgtx:AccruedResearchAndDevelopment
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_lsN90yElB0y0Q4H5inS7Gw_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2857000</mgtx:AccruedResearchAndDevelopment>
    <mgtx:AccruedResearchAndDevelopment
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_Y3Jh-cN-4EG-CCsfYQ5Irg_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2234000</mgtx:AccruedResearchAndDevelopment>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_kZESISPkiE2p-B_5vTIIkw_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2620000</us-gaap:DepositLiabilitiesAccruedInterest>
    <mgtx:AccruedClinicalTrialCosts
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_n3g9qXMNE0GoXzWW1Ss5Jg_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2421000</mgtx:AccruedClinicalTrialCosts>
    <mgtx:AccruedClinicalTrialCosts
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_oh7JDozWlEOSl-OP7eIckA_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3864000</mgtx:AccruedClinicalTrialCosts>
    <mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_1_TwVbwO5E-ZPkGhgPLXJA_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2104000</mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense>
    <mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_1sbNYUNDO0C2R7I9JwfBcQ_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1540000</mgtx:AccruedLiabilitiesAccruedManufacturingCostsExpense>
    <mgtx:AccruedConsultingExpenses
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_zLtoG2FKwkKxYKD07lDGVQ_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1326000</mgtx:AccruedConsultingExpenses>
    <mgtx:AccruedConsultingExpenses
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_CHFRBxbkyUS14Y7_h-tRSA_9_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1530000</mgtx:AccruedConsultingExpenses>
    <mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_3hV_IzY1pkCPCiU-MSCCbg_10_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">96000</mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts>
    <mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc__wFXk97qWk2TKHdpVe8hVw_10_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">257000</mgtx:AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts>
    <mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Tx2Xw6w6TkWCEM0voZJtyw_11_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">94000</mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets>
    <mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_TglZXrq0pkGaq4Xmgtb-3Q_11_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">326000</mgtx:AccruedExpensesIncurredInConnectionWithFixedAssets>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_orDQ0eWiVkuRU9azike_Uw_12_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">154000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_cP6SxnezAEOoEy4dP028dg_12_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">140000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_pvqa26R2YUG8pqvkC1KZKQ_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">23964000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_oLyrqRQZpk-7AmqBPhqdqA_13_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">27414000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_0o70HcsBgUqHqVQw3gpFjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. &#160;&#160;&#160;&#160;&#160;&#160;Share-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;"&gt;Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company&#x2019;s 2018 Incentive Award Plan and 2016 Equity Incentive Plan (collectively, the &#x201c;Plans&#x201d;) were adopted by the Company&#x2019;s board of directors and shareholders. Under the Plans, the Company has granted share options and restricted share units (&#x201c;RSUs&#x201d;) to selected officers, employees, non-employee members of the board of directors and non-employee consultants. The Company&#x2019;s board of directors or a committee thereof administers the Plans. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;A summary of the Company&#x2019;s share option activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,232,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (638)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (208,960)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,956,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and expected to vest at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Aggregate intrinsic value of options outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Aggregate intrinsic value of options exercisable as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,079&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.5pt;"&gt;Options granted under the Plans have a maximum contractual term of &lt;span style="-sec-ix-hidden:Hidden_9vrz3CYLdkSqMQ_3AtrhKQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten years&lt;/span&gt;&lt;/span&gt;. Options granted generally vest 25% on the first anniversary of the date of grant and the balance ratably over the next 36 months. Options granted to directors when they join the board generally vest in 36 equal monthly installments following the date of grant, and annual options granted to directors generally vest on the earlier of the first anniversary of the date of grant or the day before the Company&#x2019;s annual meeting of shareholders after the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company recorded the following share-based compensation expense in connection with the options for the three-month periods ended March 31, 2025 and 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The total fair value of options vested during the three-month periods ended March 31, 2025 and 2024 was $2.0 million and $4.3 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;There were no options granted during the three-month period ended March 31, 2025. The weighted-average grant date fair value of options granted during the three-month period ended March 31, 2024 was $3.91 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;The grant date fair values of the share options granted were estimated using the Black-Scholes option valuation model with the following ranges of assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.04 - 4.17%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;67%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.6 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;As of March 31, 2025, the total compensation expense relating to unvested options granted that had not yet been recognized was $6.8 million, which is expected to be realized over a period of 2.9 years. The Company will issue shares upon exercise of options from ordinary shares reserved under the Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Share Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;A summary of the Company&#x2019;s RSU activity related to employees, non-employee members of the board of directors and non-employee consultants as of December 31, 2024 and for the three-month period ended March 31, 2025 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,252,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (862,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,389,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 24.5pt;"&gt;RSUs granted generally vest 50% on the second anniversary of the date of grant and 25% on the &lt;span style="-sec-ix-hidden:Hidden_2cEA7rky_EClnxjTOR8EiQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;third&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_3IRehDe7iE-PuKwN7f8KxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;fourth&lt;/span&gt;&lt;/span&gt; anniversaries of the date of grant. Annual RSUs granted to directors generally vest in a single installment on the earliest to occur of the first anniversary of the grant date or the day immediately prior to the date of the next annual meeting of the Company&#x2019;s shareholders occurring after the date of grant. The RSUs granted to the directors in June 2021 will be paid on or within 30 days after the date a director ceases to serve on the board. For RSUs granted in June 2022 and future years, the directors may annually elect whether to defer the payment of their annual RSU awards under the Deferred Compensation Plan for Non-Employee Directors, which was adopted by the board on December 17, 2021.&#160;As of March 31, 2025, there were 272,500 vested shares that have been deferred. The related share-based compensation expense, which is recognized ratably over the requisite service period, is included in general and administrative and research and development expenses, as applicable, in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company recorded the following share-based compensation expense in connection with the RSUs for the three-month periods ended March 31, 2025 and 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;As of March 31, 2025, the total compensation expense relating to unvested RSUs granted that had not yet been recognized was $18.5 million, which is expected to be realized over a period of 3.1 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;To satisfy employee minimum statutory tax withholding requirements for restricted share units that vest, the Company withholds a portion of the vesting ordinary shares. During the three months ended March 31, 2025 and 2024, the Company withheld 405,459 and 348,652 ordinary shares with a total value of approximately $2.8 million and $2.2 million, respectively. These amounts are presented as a cash outflow from financing activities in the accompanying condensed consolidated statement of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;During the three-month periods ended March 31, 2025 and 2024, the Company recognized total share-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2.15pt;text-align:justify;text-indent:-2.15pt;margin:0pt 0pt 12pt 22.3pt;"&gt;The Company does not expect to realize any tax benefits from its share option activity or the recognition of share-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, no &lt;span style="-sec-ix-hidden:Hidden_MlA4-b9GnE64Lz0dPLcYmQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;amounts&lt;/span&gt;&lt;/span&gt; related to &lt;span style="-sec-ix-hidden:Hidden_rcbwIQOgN0KERK7K18fcyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;excess&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_UfokOTS--kuNnksgF_hYAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tax&lt;/span&gt;&lt;/span&gt; benefits have been reported in cash flows from operations or cash flows from financing activities for the three-month periods ended March 31, 2025 and 2024.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_-BfwkaV8P0C0HVkWCbLniQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,232,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (638)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (208,960)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,956,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and expected to vest at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,022,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Aggregate intrinsic value of options outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Aggregate intrinsic value of options exercisable as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,079&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="0"
      id="Tc_VIKxg8ZCSU23QwJbWtdc-Q_6_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">8232587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="2"
      id="Tc_f9OURpD5xkm25ZMAw1ARxg_6_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_tdNnEZsSLUy3YoV_uHASHQ"
      id="Tc_XGD4QqVIo0CPSoNdkcbUmQ_6_9">P5Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Tc_iclkMx19pEKLbQloUu7bGg_8_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">638</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="2"
      id="Tc_7pglixdkiEmrfxKlGS7BQA_8_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">5.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Tc_fzeeogUVaE6xXWct1Cu2Aw_9_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">208960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="2"
      id="Tc_tQUzssHxL0yr0OugZZBkMA_9_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">16.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Tc_aC_DDxt150SK3keME7awvA_10_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">8022989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="2"
      id="Tc_8hiI88OGn0CwHfVkvgwMtw_10_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">12.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_8NrJhSlC9EelrxZ3G0_rGQ_10_9">P5Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Tc_zbBNpC4vYUOL-3cTE1skcQ_11_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">6956612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="2"
      id="Tc_is2xR0CoZUiVw2t0_a21ow_11_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_UpZEKqnLp0-SPiO14Eq-0g_11_9">P4Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Tc_-wqHwegYokmtZ1eSCJxh_A_12_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">8022989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="2"
      id="Tc_jfqD49-y3kCe6Wm2VAXNhQ_12_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">12.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tc_hQTe_i9UPEW9vCgjpfGdeQ_12_9">P5Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Tc_ltsyvYeINEO9dQ3PAu4QSQ_13_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Tc_Jq1TF9psRUmvIXWW2KA30Q_14_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2079</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow"
      decimals="2"
      id="Narr_8LxrSFIxu0GJpgydg3W3VQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_zfRqSafXL0G_tNteXT06Ow"
      id="Narr_OcNay0HHIkW29F0CCsfiYA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_us-gaap_VestingAxis_mgtx_FirstAnniversaryMember_Nbb73BCKL0iQXbnKJ4G6zQ"
      id="Narr_sguYsaBFyU6BpVy8qRYTOw">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"
      id="Tb_mirp1fjS5ESmgV34SpiW4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_x0anTYpTGEKJId2AT2QSMQ"
      decimals="-3"
      id="Tc_Hztbk7Am6E2_KTk6JjFlCQ_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Yx2Gw2c3R0GT0T-W4aVOLw"
      decimals="-3"
      id="Tc_eabXruRwLEmRgQVgDYUUjA_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_WEvytmm6-0as4ezA8Dxq_w"
      decimals="-3"
      id="Tc_60QfTtMMckWPt99Q04bSow_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_-FBDFJh7Y02IFx7FP5-LHQ"
      decimals="-3"
      id="Tc_bvNcPPn--EaYoAoR8H8ZWg_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"
      decimals="-3"
      id="Tc_iBggVZgkUE6oy4n7hR7u8Q_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="-3"
      id="Tc_4LjK6jhMvUC4mj6_ivFrsQ_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_Rv6mdLH1c02VdI0fzltv4g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"
      decimals="-5"
      id="Narr__W054KAowUaUY3NY8c_p0Q"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-5"
      id="Narr_e6SPVjPil0utO5otAWop0g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-5"
      id="Narr_RU1fzFTFm06gwLSEtTlF1Q"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="-5"
      id="Narr_WIaFmOdmXkilOahJhF8Hjg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"
      decimals="0"
      id="Narr_FfeT9ZoGkkGIrH2GmkXSSQ"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="2"
      id="Narr_VQSAjad4dkuv0eHOVeGoWA"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="2"
      id="Narr_HEHke4FjBkuQnHzXFuVAXw"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_AC7fyhbGJUOU7LIdLfSZUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.04 - 4.17%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;67%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3.6 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="4"
      id="Narr_KBrumKJzqEOfVTGz0hwssQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="4"
      id="Narr_eaXywuTjskCh36TlWGd4fg"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.0417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="2"
      id="Tc_mnM_Z8CRBEmCgP-2TJYaRw_3_4"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eyzhaa_xaEeqgMxwyee95Q"
      decimals="2"
      id="Tc_yUCSWS3kmUKiMqjKMCaTRw_4_4"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_FHMLfDF-0EKO7Asq-e8OTw"
      id="Narr_v5FQwDxM4kev2SZTdyPEkg">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uVSHbG4-lEuN03PZ2bf2fw"
      id="Narr_hCoZVt07DkOKxBz30WFRqA">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A34VtYETjkq5z4-tujaPuw"
      decimals="-5"
      id="Narr_VPxK_yXYjUChiuXiYi-alg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q2MFxFokUkWC3EPh9XBUoA"
      id="Narr_BVL5anStYke9eQQClkMG7A">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_mesChtZHe0ugmZQPMv-Bxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,252,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (862,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,389,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w"
      decimals="0"
      id="Tc_vMMoBS5-k0i03anq6OZDVQ_5_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">4252250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZkrHCzWTWUyDLrULEbGX7w"
      decimals="2"
      id="Tc_mRJ7ibOoTEy5MfOdP9x5lA_5_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">8.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      decimals="0"
      id="Tc__3ZJ8bhkB0iO6HJa651FMA_7_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">862500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      decimals="2"
      id="Tc_gkPzOJbQW0m8JtUZjRbXHQ_7_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">13.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ"
      decimals="0"
      id="Tc_p8KAhXCYB0OsprM7e7zx2A_9_3"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">3389750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ"
      decimals="2"
      id="Tc_RU5m-mazbUWTFE068d7f7A_9_6"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">7.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_SecondAnniversaryMember_4r0tTmCAu0SQFy7DaGc90A"
      decimals="4"
      id="Narr_H_tpjRDgQ0KVYgn6RrfTFQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_mgtx_ThirdAnniversaryMember_ulU2RJ4zk0Oio7F75WwC_A"
      decimals="2"
      id="Narr_nMDyq_90Akayh-1yVu4RFA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mgtx:VestedSharesDeferred
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_srt_DirectorMember_PIX3BS0nTUa5tETrcj8elg"
      decimals="0"
      id="Narr_KvQm0dJUuUKXI5tGprx4Iw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">272500</mgtx:VestedSharesDeferred>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      id="Tb_Ywt901KUj0iFYAqzQSq2Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Z5HMPaYik0ye7_ykI_APgA"
      decimals="-3"
      id="Tc_YqFrze4n40WwUZIiAi-eWQ_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WpG7KMWBlUKStgi4QQoKBg"
      decimals="-3"
      id="Tc_-hqaYG6oJUeln4tjHtkCGw_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1240000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4qcy_d4u7k2Tb5wX8MN_yQ"
      decimals="-3"
      id="Tc_B2BI2GM-tEGh__NqOzcyEg_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_co_X9kDcaUaRbStYIRfBYA"
      decimals="-3"
      id="Tc_-P_Q8JGcbkWDsCypqkmFJg_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      decimals="-3"
      id="Tc_N7a6Sd38Zk6P4XY-XFlZ8Q_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg"
      decimals="-3"
      id="Tc_Fp3EO2WgDEiMO_pnKmaUSA_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OOGyurU19U-07kkWLKidLQ"
      decimals="-5"
      id="Narr_GWIIMCruSkKf457hyPPQcQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">18500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      id="Narr_Exi1spgx00Oj4qf3NepllA">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      decimals="0"
      id="Narr_s-piOxIvsECvsyhYqkTM4g"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">405459</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg"
      decimals="0"
      id="Narr_jmG07Be28kyc9Cy7YtuaMQ"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">348652</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gtGMMZh8ZkSMJwuBE0UabQ"
      decimals="-5"
      id="Narr_hEPZAsbvQUiciYj2HnxSug"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2800000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9JrBTqz9KU2WgO23E_VKAg"
      decimals="-5"
      id="Narr_qCi0JCjYmU61HF44DSPGmw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_OZsMEkWk0UifKyDntDHOvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yqGmJ2-KHka0ENT6fES9GA"
      decimals="-3"
      id="Tc_tFLZW1n5mkS7W2uqirDiZQ_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2046000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SDGzmNr-NEmKPaMrfqtjDA"
      decimals="-3"
      id="Tc_siBb7dBulkmzukua-HQ7gQ_3_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_X4X9AYdDDEK7RWtpLuhYsw"
      decimals="-3"
      id="Tc_3LlZ9eL-zUScoeyll6U2Ig_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_bD1h8zBZy0a-rhyOQJBXYw"
      decimals="-3"
      id="Tc_6fDb8UtELkKuI1bR-Tu4jw_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_zGyCl9tPnEecfY4LwuXQIA_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_IrZealTF20665Z8Iwzx6dQ_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6960000</us-gaap:AllocatedShareBasedCompensationExpense>
    <mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_Mv6eoO5bK0mcpBHLxe6MfQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</mgtx:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_oZNcXbN2xkmp6yt0BGTINw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 7pt 0pt;"&gt;6. &#160;&#160;&#160;&#160;&#160;&#160;Ordinary Shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 5pt 24.5pt;"&gt;&lt;span style="font-style:italic;"&gt;At-the-Market&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="font-weight:normal;"&gt;In December 2023, the Company entered into an &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;at-the-market&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; sales agreement with BofA Securities, Inc., or BofA, pursuant to which the Company may sell from time to time, ordinary shares having an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$100.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million through BofA, acting as the Company&#x2019;s agent. During the three-month period ended March 31, 2025, the Company raised gross proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$4.5&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million through the sale of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;563,379&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; ordinary shares pursuant to an &#x201c;at-the-market&#x201d; equity offering program. Under the &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;at-the-market&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; equity program which is currently effective and may remain available for the Company to use in the future, the Company may sell an additional &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$87.1&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million of ordinary shares. Whether the Company chooses to affect future sales under the &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;at-the-market&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; equity offering program will depend on a number of factors, including, among others, market conditions and the trading price of the Company&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x2019;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;s ordinary shares relative to other sources of capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_qIzB0lDadUGRb33apH8qog"
      decimals="-5"
      id="Narr_iuI4qYIsV0KlTLrCGYJQhw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w"
      decimals="-5"
      id="Narr_ph7L6Wj3zEC5IQiDDjU8Lg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_6v1Gfi_M7k27lffIzXLx-w"
      decimals="0"
      id="Narr_P4qL3SWvKEWIz7MUNdXiFw"
      unitRef="Unit_Standard_shares_hyG7Wk1Al06jOsQxyfXprw">563379</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <mgtx:SaleOfStockConsiderationAvailableInFutureTransactions
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_mgtx_BankOfAmericaSecuritiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgtx_AtMarketOfferingMember_t4aotRLKJECS_tQUX6xOmw"
      decimals="-5"
      id="Narr_vZvRg-4kJUquoOa7EWZngQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">87100000</mgtx:SaleOfStockConsiderationAvailableInFutureTransactions>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_B3DoDpaanUGF05DucaEZTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;7. &#160;&#160;&#160;&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;The Company did not record a provision for income &lt;span style="-sec-ix-hidden:Hidden_N4ipPyW_6EecGrCOlZuzUQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;taxes&lt;/span&gt;&lt;/span&gt; for the three-month periods ended March 31, 2025 and 2024, as the Company has generated losses for all periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:1.95pt;text-align:justify;text-indent:-1.95pt;margin:0pt 0pt 12pt 22.5pt;"&gt;The Company periodically evaluates the realizability of its deferred tax assets based on all available evidence, both positive and negative. The realization of deferred tax assets is dependent on the Company&#x2019;s ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. The Company weighed both positive and negative evidence and determined that there is a continued need for a full valuation allowance on its deferred tax assets (after consideration of the reversal of the deferred tax liabilities for the ROU assets and fixed assets) in the United States, United Kingdom, Ireland and Netherlands as of March 31, 2025. Should the Company determine that it would be able to realize its remaining deferred tax assets in the foreseeable future, an adjustment to its remaining deferred tax assets would cause a material increase to income in the period such determination is made.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Narr__Qb6nGALyEixG64kYCQkog"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_VJeBzon4I02hUJAM71GKeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;8. &#160;&#160;&#160;&#160;&#160;&#160;Related-Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 24.45pt;"&gt;Asset Purchase and Related Agreements with Johnson &amp;amp; Johnson Innovative Medicine&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;"&gt;On December 20, 2023, the Company entered into the Asset Purchase Agreement with Johnson &amp;amp; Johnson Innovative Medicine pursuant to which the Company sold and assigned to Johnson &amp;amp; Johnson Innovative Medicine, and Johnson &amp;amp; Johnson Innovative Medicine purchased and assumed, the UCLB RPGR License Agreement relating to the research, development, manufacture and exploitation of the RPGR Product, and other related assets as described in the Asset Purchase Agreement. Simultaneously, the Company and Johnson &amp;amp; Johnson Innovative Medicine also entered into a Supply Agreement pursuant to which the Company agreed to manufacture and supply the RPGR Product for Johnson &amp;amp; Johnson Innovative Medicine. Under the Supply Agreement, MeiraGTx UK II, together with its affiliates, will manufacture commercial supply of the RPGR Product for Johnson &amp;amp; Johnson Innovative Medicine for an initial term of four years, with Johnson &amp;amp; Johnson Innovative Medicine having an option to extend the Supply Agreement for a fifth year upon written notification. Johnson &amp;amp; Johnson Innovative Medicine may terminate the Supply Agreement for convenience upon 90 days&#x2019; written notice with payment of a termination fee. Under the Asset Purchase Agreement, Johnson &amp;amp; Johnson Innovative Medicine paid the Company a non-refundable upfront fee of $65.0 million in December 2023 and the Company is eligible to receive fees from commercial supply of the RPGR Product and in addition, milestones of up to $350.0 million, as follows: (i) a milestone payment of $50.0 million in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product; (ii) $10.0 million upon completion of certain specified development services for the drug substance for the RPGR Product; (iii) $5.0 million upon completion of certain specified development services for the drug product for the RPGR Product; (iv) $175.0 million upon the first commercial sale of an RPGR Product in the United States; (v) $75.0 million upon the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy; (vi) $25.0 million upon completion of the transfer of certain manufacturing technology for drug substance and drug product from the Company to Johnson &amp;amp; Johnson Innovative Medicine; and (vii) $10.0 million upon regulatory approval of a Johnson &amp;amp; Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product. To date, the Company received $60.0 million in milestone payments from Johnson &amp;amp; Johnson Innovative Medicine. Johnson &amp;amp; Johnson Innovative Medicine is also responsible for any royalty or milestone amounts that become payable on the RPGR Product under the UCLB RPGR License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 24.45pt;"&gt;Revenue Recognition under the Asset Purchase and Related Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;The agreements entered into in December 2023 were executed at the same time and were negotiated with a single commercial objective; therefore, the contracts were combined and accounted for as a single contract. These agreements were accounted for as a termination of the Collaboration Agreement and the creation of a new contract where the transaction price includes the remaining deferred revenue &#x2013; related party from the terminated agreement of $30.6 million, the fixed upfront payment of $65.0 million under the Asset Purchase Agreement, and an aggregate of $1.8 million estimated variable consideration for transition services, offset by a credit of $5.1 million for pre-funded inventory, totaling $92.3 million. The transaction price was allocated to four performance obligations on a relative SSP basis, subject to certain exceptions for discounts and variable consideration. As the SSPs are not directly observable for any of the distinct goods and services, the SSPs were estimated based on a valuation. The total transaction price of $92.3 million was allocated to the performance obligations with respect to SSPs as follows: process performance qualification (&#x201c;PPQ&#x201d;) services in the amount of $2.9 million net of future billings, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $6.9 million, manufacturing technology transfer in the amount of $28.7 million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#x2019;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp;amp; Johnson Innovative Medicine in the amount of $53.8 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;Since the commencement of the Asset Purchase Agreement and related agreements, the Company received a $50.0 million milestone payment in connection with the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product. The milestone payment was allocated to the four performance obligations on the same basis noted above increasing the value of each performance obligation as follows: PPQ services in the amount of $1.6 million, material rights representing the commercial supply of RPGR Product and an in-substance contract renewal option in the amount of $3.8 million, manufacturing technology transfer in the amount of $15.6 million, and the sale of nonfinancial assets representing the sale and transfer of all the Company&#x2019;s right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson &amp;amp; Johnson Innovative Medicine in the amount of $29.0 million. Additionally, the Company received a $10.0 million milestone payment in connection with the completion of certain specified development services for the drug substance for the RPGR Product which was allocated to the PPQ services performance obligation. The Company also entered into additional agreements to provide additional services under the Asset Purchase Agreement and related agreements amounting to an aggregate of $5.8 million which was included in the transaction price and allocated to each of the respective performance obligations. Furthermore, the Company recorded certain changes in estimates related to the valuation of its performance obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;The transaction price allocated to PPQ services will be recognized over time using an inputs method measure of progress. The transaction price allocated to the material right for the commercial supply of RPGR Product will be recorded as deferred revenue until Johnson &amp;amp; Johnson Innovative Medicine exercises its option to purchase supply and the Company transfers control of such supply to Johnson &amp;amp; Johnson Innovative Medicine. The transaction price allocated to the in-substance renewal option (material right) will be recorded as deferred revenue until Johnson &amp;amp; Johnson Innovative Medicine exercises the option and the Company transfers control of the underlying goods or services to Johnson &amp;amp; Johnson Innovative Medicine. The Company will account for the exercise of the in-substance renewal option (material right) as a continuation of the existing contract (i.e., a change in the transaction price). The transaction price allocated to the technology transfer will be recognized over time using an inputs method measure of progress. The Company will recognize a gain for the difference between the carrying amount of the nonfinancial assets and the consideration allocated to that unit of account when control of the nonfinancial assets transfers in accordance with ASC 610-20, &lt;i style="font-style:italic;"&gt;Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;During the three-month period ended March 31, 2024, the Company recognized a gain of $29.0 million related to the sale of nonfinancial assets which is included in other income in the condensed consolidated statements of operations and comprehensive loss. There was no gain on sale of nonfinancial assets recognized during the three-month period ended March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;As of March 31, 2025, the aggregate transaction price allocated to unsatisfied performance obligations was $63.9 million which the Company expects to recognize over an estimated period of approximately 2.8 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"&gt;A summary of the deferred revenue is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other amounts collected or invoiced&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue recognized as service revenue during the three-month period ended March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (741)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effects of exchange rate changes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,859&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;During each of the three-month periods ended March 31, 2025 and 2024, the Company recognized $0.7 million of deferred revenue &#x2013; related party as service revenue in connection with PPQ services under the Asset Purchase Agreement and related agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 24.5pt;"&gt;During the three-month period ended March 31, 2025, the Company recognized $1.9 million of service revenue, inclusive of the $0.7 million of deferred revenue &#x2013; related party recognized as service revenue, based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements. There was no service revenue based on cumulative progress of PPQ services under the Asset Purchase Agreement and related agreements recognized during the three-month period ended March 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"&gt;Debt Financing&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 22.3pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;On August 2, 2022 the Company, as borrower, and Meira UK II and Meira Ireland, as guarantors (the &#x201c;Subsidiary Guarantors&#x201d;), entered into a senior secured financing arrangement (the &#x201c;Financing Agreement&#x201d;) by and among the Company, the Subsidiary Guarantors, the lenders and other parties from time to time party thereto and Perceptive Credit Holdings III, LP, as administrative agent and lender (&#x201c;Perceptive&#x201d;). On December 19, 2022, the Financing Agreement was converted to a notes purchase agreement and guaranty (the &#x201c;Notes Purchase Agreement&#x201d;) between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. Perceptive Advisors, LLC, an affiliate of Perceptive, is a greater than &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;10%&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; holder of the ordinary shares of the Company. Additionally, Ellen Hukkelhoven, Ph.D., a director of the Company, is an employee of Perceptive Advisors, LLC. Refer to the discussion in Note 10 for further information related to the accounting for the debt financing.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <mgtx:InitialAgreementPeriodDuration
      contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ"
      id="Narr_uKsrH7GK6Ue_Nzy1r8dZwg">P4Y</mgtx:InitialAgreementPeriodDuration>
    <mgtx:AgreementTerminationPeriodDaysWrittenNotice
      contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_BsmhexbMwE675IeOnlP8HQ"
      id="Narr_L5NkWMJ7kk-jvZuraQafzA">P90D</mgtx:AgreementTerminationPeriodDaysWrittenNotice>
    <mgtx:AssetPurchaseAgreementFundingReceived
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_MnXS91dZ_k2umuSXbVOt1A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">65000000</mgtx:AssetPurchaseAgreementFundingReceived>
    <mgtx:ContingentFundingAvailable
      contextRef="Duration_12_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_zgUUktVOakyME70F8CQ1DQ"
      decimals="-5"
      id="Narr_i_UGg6_A5EGuVX4uUDWC1A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">350000000</mgtx:ContingentFundingAvailable>
    <mgtx:MilestoneFundingForExtensionOfClinicalTrials
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-5"
      id="Narr_-WmQmm90jEWltg1T1Qzaow"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">50000000</mgtx:MilestoneFundingForExtensionOfClinicalTrials>
    <mgtx:MilestoneFundingForDevelopmentOfDrugSubstances
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_EoRQMsxZl0yrjoy6z-NgOQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10000000</mgtx:MilestoneFundingForDevelopmentOfDrugSubstances>
    <mgtx:MilestoneFundingForDevelopmentOfDrugProducts
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_Wvj56FX0502sqOy3ck1D5Q"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5000000</mgtx:MilestoneFundingForDevelopmentOfDrugProducts>
    <mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_Jss4r0_0CE2zciJWgFRurw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">175000000</mgtx:MilestoneFundingForSaleOfDrugProductsInUnitedStates>
    <mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_vruLVQNgcUK_qno6DSnisA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">75000000</mgtx:MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly>
    <mgtx:MilestoneFundingForTransferOfManufacturingTechnology
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_NUDES4TwQUehwOIuz3jb_A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">25000000</mgtx:MilestoneFundingForTransferOfManufacturingTechnology>
    <mgtx:MilestoneFundingForRegulatoryApproval
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_OaEepgRAG0yfq26DrGU7QA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10000000</mgtx:MilestoneFundingForRegulatoryApproval>
    <mgtx:MilestoneFundingReceived
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-5"
      id="Narr_C785JQJh20KkQp1hdkG4ag"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">60000000</mgtx:MilestoneFundingReceived>
    <mgtx:RelatedPartyDeferredRevenueReclassified
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_hkWr_ueXvkKFc1SiW4nYeQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">30600000</mgtx:RelatedPartyDeferredRevenueReclassified>
    <mgtx:AssetPurchaseAgreementFundingReceived
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_2Ss00WLW0kKME1iUcBT41A"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">65000000</mgtx:AssetPurchaseAgreementFundingReceived>
    <mgtx:VariableConsiderationForServices
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_ZsCbUFWNG0q495UppsAWkg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1800000</mgtx:VariableConsiderationForServices>
    <mgtx:OffsettingCreditForTransitionServices
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_jzNtFeu4XkyRXuI_l0GAtw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5100000</mgtx:OffsettingCreditForTransitionServices>
    <mgtx:ContractPriceOfLicenseAgreement
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_6Rq4AXaiqUiidzFGyONHiQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">92300000</mgtx:ContractPriceOfLicenseAgreement>
    <mgtx:ContractPriceOfLicenseAgreement
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_DoDewNq6XUmVCgzR4JPNrw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">92300000</mgtx:ContractPriceOfLicenseAgreement>
    <mgtx:PerformanceObligationForProcessPerformanceQualificationServices
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_jZYiumoSUEGoI8Jx-Fb-hQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2900000</mgtx:PerformanceObligationForProcessPerformanceQualificationServices>
    <mgtx:PerformanceObligationForCommercialSupplyOfRpgrProduct
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_jQV4PZg1VEKVdEgLYFe1rQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6900000</mgtx:PerformanceObligationForCommercialSupplyOfRpgrProduct>
    <mgtx:PerformanceObligationForManufacturingTechnologyTransfer
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_-ApUfhII3EavoB0qqS-0CA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">28700000</mgtx:PerformanceObligationForManufacturingTechnologyTransfer>
    <mgtx:PerformanceObligationForSaleOfNonfinancialAssets
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_kM3VIL7M3UWNoEFOVnm1kg"
      decimals="-5"
      id="Narr_ISiJYv6uD0yjvbhjM_nCEw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">53800000</mgtx:PerformanceObligationForSaleOfNonfinancialAssets>
    <mgtx:MilestoneFundingForExtensionOfClinicalTrials
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_xsdZJIE8JU6DCLoZAlHWJA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">50000000</mgtx:MilestoneFundingForExtensionOfClinicalTrials>
    <mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_reZWHxXofkujABfngzGNbQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1600000</mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices>
    <mgtx:MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_BA_TSN2Bz0Ce7sa5zDvTYA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3800000</mgtx:MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct>
    <mgtx:MilestoneFundingAllocatedToManufacturingTechnologyTransfer
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_Hx80GjhXDU-EkCgf5s23pw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">15600000</mgtx:MilestoneFundingAllocatedToManufacturingTechnologyTransfer>
    <mgtx:MilestoneFundingAllocatedToSaleOfNonfinancialAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_c8HRW5HOI0ujnuvtyQcZSw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">29000000</mgtx:MilestoneFundingAllocatedToSaleOfNonfinancialAssets>
    <mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-5"
      id="Narr_zPnI0PiXSESsqpu5Kp_lqg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10000000</mgtx:MilestoneFundingAllocatedToProcessPerformanceQualificationServices>
    <mgtx:AssetPurchaseAgreementFundingReclassified
      contextRef="Duration_12_1_2023_To_12_31_2023_Di1tUbrdG0CEvFGNkpUsfQ"
      decimals="-5"
      id="Narr_Cir7Qst1ZEe92Kn6bypocQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">5800000</mgtx:AssetPurchaseAgreementFundingReclassified>
    <mgtx:GainLossOnSaleOfNonfinancialAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-5"
      id="Narr_hOs22tsQP0yyVWNMh-z3rw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">29000000</mgtx:GainLossOnSaleOfNonfinancialAssets>
    <mgtx:RevenueUnsatisfiedPerformanceObligationAmount
      contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw"
      decimals="-5"
      id="Narr_aZSxOIkReUmxTEXTj-ngjw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">63900000</mgtx:RevenueUnsatisfiedPerformanceObligationAmount>
    <mgtx:RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod
      contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw"
      id="Narr_tfmR2elC2UyABcOpKxpa6Q">P2Y9M18D</mgtx:RevenueUnsatisfiedPerformanceObligationExpectedRecognitionPeriod>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_A7-wn_hMoUCx-SPe_xNc8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other amounts collected or invoiced&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue recognized as service revenue during the three-month period ended March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (741)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effects of exchange rate changes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,859&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_O1KWw4ArDkiJPoDlyECyng"
      decimals="-3"
      id="Tc_pVNqVVJBM0mM2LHga3yO_g_1_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">62403000</us-gaap:ContractWithCustomerLiability>
    <mgtx:ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-3"
      id="Tc_Pssu7lCjJE6FjH_s6VZYBQ_2_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">323000</mgtx:ContractWithCustomerLiabilityOtherAmountsCollectedOrInvoiced>
    <mgtx:DeferredRevenueRecognizedDuringPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-3"
      id="Tc_0l21nKw-nUK7JfNCU7rTDg_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">741000</mgtx:DeferredRevenueRecognizedDuringPeriod>
    <mgtx:ContractWithCustomerLiabilityEffectOfExchangeRate
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-3"
      id="Tc_8zKXdk7JZUabNUL-vboc8A_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">-1874000</mgtx:ContractWithCustomerLiabilityEffectOfExchangeRate>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_XHijMDNuIUq0irIytC-yWw"
      decimals="-3"
      id="Tc_GVV6C-bI2UiH-uBNFaQbPA_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">63859000</us-gaap:ContractWithCustomerLiability>
    <mgtx:DeferredRevenueRecognizedDuringPeriod
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_tKEM0zXFv06nV8HqEfycfw"
      decimals="-5"
      id="Narr_nb2etssbOUSLrdAnrdUISA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">700000</mgtx:DeferredRevenueRecognizedDuringPeriod>
    <mgtx:ServiceRevenueFromRelatedParties
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-5"
      id="Narr_gxl5V4tHb0GOXLhq0yWLmw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1900000</mgtx:ServiceRevenueFromRelatedParties>
    <mgtx:DeferredRevenueRecognizedDuringPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_JanssenPharmaceuticalsIncMember_us-gaap_TypeOfArrangementAxis_mgtx_AssetPurchaseAgreementMember_241smNaWB02UI3Rf4H4LwQ"
      decimals="-5"
      id="Narr_RROzXx3xg0ep0eVO5b148g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">700000</mgtx:DeferredRevenueRecognizedDuringPeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_19_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_mgtx_FinancingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mgtx_PerceptiveAdvisorsLlcMember_oAxyTHASgU6LiyqF1ZUF5g"
      decimals="2"
      id="Narr_uj53NcaznESDT8Bf7SjnLA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_HnSuyt-TPE2aCHKmPtB_VA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;9. &#160;&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;The Company has commitments under operating leases for laboratory, warehouse, clinical trial sites and office space. The Company also has finance leases for manufacturing space and office equipment. The Company&#x2019;s leases have initial lease terms ranging from 3 years to 191 years. Certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include fixed payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;Total rent expense under these leases was $1.3 million and $1.4 million for the three-month periods ended March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;There were no &lt;span style="-sec-ix-hidden:Hidden_50G5iuwwS0COib-U_gl6RQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;leases&lt;/span&gt;&lt;/span&gt; recognized during the three-month periods ended March 31, 2025 and 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;During the three months ended March 31, 2025, the Company determined that it was reasonably certain to exercise its early termination option on an operating lease for laboratory and office space, resulting in a remeasurement of the ROU asset and lease liability reflected in the accompanying condensed consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;The components of lease cost for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total finance lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;Amounts reported in the condensed consolidated balance sheets for leases where the Company is the lessee as of March 31, 2025 and December 31, 2024 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;Other information related to leases for the three-month periods ended March 31, 2025 and 2024 are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;Future minimum lease payments under non-cancellable leases as of March 31, 2025 are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total undiscounted lease payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,233)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mgtx:LeaseMaturityTerm
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MinimumMember_2b1HMRkaD06hhuC2_CUTZw"
      id="Narr_a10bwcZAckm5H-2zjLzDTg">P3Y</mgtx:LeaseMaturityTerm>
    <mgtx:LeaseMaturityTerm
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_BgkV0HRRGEO9W9pctp9CrQ"
      id="Narr_WJM8Ig-teUGxfRAwbwvKkA">P191Y</mgtx:LeaseMaturityTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-5"
      id="Narr_ROVQ7t55rUWVgxnkB3DDQQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-5"
      id="Narr_qdrWxX3Ys0GLx93_fs4w1g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1400000</us-gaap:OperatingLeaseExpense>
    <mgtx:OperatingLeaseNumberNewLeasesRecognized
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="0"
      id="Narr_ipF-PYhzHka3yo7sqJnHeQ"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0</mgtx:OperatingLeaseNumberNewLeasesRecognized>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_SmgeTDpX7EC_iLFW8EKEdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total finance lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_2MaokFYeXEmnpLTFbAEzCQ_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">138000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_Ugi2TDH7ykWNH9Q6jZxh7A_4_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">281000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_qqG9VpaLuUuUrqefgNWzkA_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">138000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_cUe_IWphCE2PepwKRxNcPg_5_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">281000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_g1w0xKZLnUqCbnMnYtuQFA_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1284000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_EeyRbTVSb02IsIcvc0aNbA_6_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1437000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_3xNwkMKkMUuU5ZItnQA4sw_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">95000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_1rI6UswtVUmln-l4Ad7eeA_7_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">41000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_r52-YiVQGUGRsd1o8ep7eA_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1517000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_kUGAltui3U63hjDspDm_Ng_8_6"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1759000</us-gaap:LeaseCost>
    <mgtx:ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_wfCdy4qqjkuGGkyk_A7r8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgtx:ScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_zTu3nQyxP0Kh4qU5aipBXw_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">6348000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_TZoVDxjGDUyksz25HAXtFg_4_7"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">10576000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_LUPkbcs1g0SmYGBkTVWPCw_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">7383000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_ziyT7bgUz0eu1HzRkyaozQ_5_7"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">11576000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_I4_5TJHj-Uy8KUnPVlwROg_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">22728000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="-3"
      id="Tc_M2tyEG-MHUGWmUv1Hn23eQ_7_7"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">22198000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      id="Tc_6X2oMZhhxkycAWikbrG9Xw_9_3">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      id="Tc_kLxqOEE3Q0KyUv9Aa_aREQ_9_7">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      id="Tc_jshRJ2gW80esx4GU5KtRkg_10_3">P173Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      id="Tc_ghuMtxSwPUmEybUWC_svRg_10_7">P173Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="3"
      id="Tc_XNHnjvilVE-wSva-RDpplA_12_3"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="3"
      id="Tc_G_db2jmwwEyWN48-NPlRmQ_12_7"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.088</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="3"
      id="Tc_D70NOYvHDE6d-4fJXgUKew_13_3"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_DYWNAhRU6ky9OccnkZN8YQ"
      decimals="3"
      id="Tc_WpxHjPmdKU-LBYqSk410gA_13_7"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_Nrwzi9GMw0ueq7rpeKFh0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three-Month Periods Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      decimals="-3"
      id="Tc_YZuZnbYvV0-HjIn0wcrjnQ_4_2"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1201000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_3_31_2024_HvcrAq-yvkOzE_ZgON7rog"
      decimals="-3"
      id="Tc_fmUySMKoOEi3XGrpk5qvzA_4_5"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1419000</us-gaap:OperatingLeasePayments>
    <mgtx:ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_HWQXmoWrj0m-qai260nsEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 24.5pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total undiscounted lease payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,233)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mgtx:ScheduleOfFutureMinimumPaymentsUnderNonCancellableLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_Ii-fG2z4kUusx_vwudBP6Q_2_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2690000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_YInWUH4VMUKCv6uTOcrkGA_3_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2451000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_JUIpnDMCpUCLJNJ7JKqVNw_4_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1547000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_fFvbjR5VAU67teGyrzc6Kg_5_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1352000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_trQqpOWJIkCpLnnZ8iHZ3w_6_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">576000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_xS7dNE-T4UuyMb88OXnbLA_7_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">8616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_79hccJAURkKPSc9iFmpgaQ_8_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">1233000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="-3"
      id="Tc_dd8xzT7jHEK6VczIiJyzug_9_3"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">7383000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_Z31UGyDw5k2l1dBPg3eIOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. &#160;&#160;&#160;Debt Financing&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;On August 2, 2022 the Company, and the Subsidiary Guarantors, entered into the Financing Agreement with Perceptive. On December 19, 2022, the Financing Agreement was converted to a Notes Purchase Agreement between the same parties and under substantially the same terms and conditions as the Financing Agreement, subject to certain customary note constitution terms. The Company and the Subsidiary Guarantors entered into a Consent and Amendment with Perceptive on August 10, 2023 (the &#x201c;First Consent and Amendment), and the Company and the Subsidiary Guarantors entered into a second Consent and Amendment with Perceptive on December 20, 2023 (the &#x201c;Second Consent and Amendment&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;The Notes Purchase Agreement provides for an initial $75.0 million notes issuance (the &#x201c;Tranche 1 Notes&#x201d;). &#160;Pursuant to the First Consent and Amendment, &lt;span style="background:#ffffff;"&gt;the Company was able to request in its sole discretion, and Perceptive agreed to subscribe to purchase upon such request, an additional &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million notes issuance (the &#x201c;Tranche 2 Notes&#x201d;) at any time before August 2, 2024 subject to the terms of the Notes Purchase Agreement.&lt;/span&gt; Previously, the Company&#x2019;s request for issuance of the Tranche 2 Notes was to be determined at Perceptive&#x2019;s sole discretion. The Notes Purchase Agreement matures on August 2, 2026 and is interest-only during the term. The Company has the option to redeem outstanding principal notes at any time along with an applicable early redemption fee. Under each of the First Consent and Amendment and the Second Consent and Amendment, the Notes Purchase Agreement was amended to increase the applicable early redemption fee. Outstanding amounts under the Notes Purchase Agreement bear interest at a fluctuating rate per annum equal to 10.00% plus the secured overnight financing rate administered by the Federal Reserve Bank of New York for a one-month tenor, subject to a 1.00% floor. The annual interest rate was 14.34% at March 31, 2025. As of March 31, 2025, the outstanding balance of the Tranche 1 Notes was $75.0 million plus accrued interest of $2.6 million. During the three-month periods ended March 31, 2025 and 2024, the Company recorded interest expense of $2.7 million and $2.9 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;The Company&#x2019;s obligations under the Notes Purchase Agreement are secured by the Company&#x2019;s London, UK and Shannon, Ireland manufacturing facilities, $3.0 million of the Company&#x2019;s cash and the bank accounts of the Subsidiary Guarantors, and the issued and outstanding equity interests of the Subsidiary Guarantors. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;The Notes Purchase Agreement imposes certain covenants and restrictions on the Company and the Subsidiary Guarantors, including restrictions pertaining to: (i) the incurrence of additional indebtedness, (ii) limitations on liens, (iii) limitations on certain investments, (iv) making distributions, dividends and other payments, (v) mergers, consolidations and acquisitions, (vi) dispositions of assets, (vii) the Company&#x2019;s maintenance of at least $3.0 million in a U.S. bank account, (viii) transactions with affiliates, (ix) changes to governing documents, (x) changes to certain agreements and leases and (xi) changes in control; however, certain of these restrictions contain exceptions which allow the Company to license, sell and monetize assets in its AAV-hAQP1 program in development to treat radiation-induced xerostomia, its AAV-GAD program in development to treat Parkinson&#x2019;s disease and its gene regulation platform technologies. As of March 31, 2025, the Company is in compliance with all covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 22.3pt;"&gt;In connection with entering into the Financing Agreement, the Company granted warrants to Perceptive to purchase up to (i) 400,000 ordinary shares of the Company at an exercise price of $15.00 per share and (ii) 300,000 ordinary shares of the Company at an exercise price of $20.00 per share. The warrants are exercisable immediately and expire on August 2, 2027. The Company recorded a debt discount of $2.3 million for the allocated fair value of the warrants. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"&gt;The Company also capitalized certain lender and legal costs associated with the Notes Purchase Agreement totaling $2.1 million, which were recorded as a discount to the loan. The aggregate discount of $4.4 million is being amortized to interest expense over the term of the Notes Purchase Agreement. The Company amortized $0.3 million of the discount to interest expense during each of the three-month periods ended March 31, 2025 and 2024.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg"
      decimals="-5"
      id="Narr_J1U8kk-mzUWPupZA_s7Apw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_X8W9CoWVLEG_tr6FSVDMEg"
      decimals="-5"
      id="Narr_MZD5PIyNP0WzmiXGtMXqqg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">25000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_42lCiz8CVUyY3EVhVz0_cQ"
      decimals="4"
      id="Narr_dI0wO1rLw0i14xrLBRMeWg"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <mgtx:SecuredOvernightFinancingRateAdjustmentTerm
      contextRef="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw"
      id="Narr_6Lmm1RyVwk6xqZoWxLq4CA">P1M</mgtx:SecuredOvernightFinancingRateAdjustmentTerm>
    <mgtx:BasisSpreadOnVariableRateFloor
      contextRef="Duration_8_2_2022_To_8_2_2022_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_O_enCN20rk2yg68Q3DJtJw"
      decimals="4"
      id="Narr_HiQoTHxlNEab0DRWRwKVoA"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.01</mgtx:BasisSpreadOnVariableRateFloor>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA"
      decimals="4"
      id="Narr_SOsfLvSesUGshbNz1uPr2Q"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0.1434</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:SecuredDebtCurrent
      contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA"
      decimals="-5"
      id="Narr_0SjaYKWwoEqraWK-ADKyTQ"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">75000000</us-gaap:SecuredDebtCurrent>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ"
      decimals="-5"
      id="Narr_EghgzLLwSE-DqbsOA-M2pg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2600000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_bF_4ntIBxEqPXld6dMVSEQ"
      decimals="-5"
      id="Narr_PgO4Y5NXYkGPZowyURAqFA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_E01NWWscaku_l4LSWzU0oQ"
      decimals="-5"
      id="Narr_Vrwpld5kJ0iODVz6Y4YjBg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2900000</us-gaap:InterestExpenseDebt>
    <us-gaap:GuaranteedBenefitLiabilityNet
      contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA"
      decimals="-5"
      id="Narr_3iqKpwwXvEKWuyxjW0eN5g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000000</us-gaap:GuaranteedBenefitLiabilityNet>
    <mgtx:SecuredCashAndBankAccounts
      contextRef="As_Of_3_31_2025_us-gaap_CreditFacilityAxis_mgtx_TermLoanMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_OXECZcgfU06VbDAzFmPOpA"
      decimals="-5"
      id="Narr_q2THR8Ad_kiOl-BHqQyZsw"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">3000000</mgtx:SecuredCashAndBankAccounts>
    <mgtx:SharesIssuedInConnectionWithFinancingAgreement
      contextRef="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_iZlT0i7a9E65CzOL8E1S9w"
      decimals="0"
      id="Narr_Hyr4ApHIXkGRayDR44AfhA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">400000</mgtx:SharesIssuedInConnectionWithFinancingAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_9Zn4kfnKBEST_irxiQRuhw"
      decimals="2"
      id="Narr_rOk7x0wJ_ke_bNFmhl4-bA"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mgtx:SharesIssuedInConnectionWithFinancingAgreement
      contextRef="Duration_8_2_2022_To_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_vpSCkZsxXEKNmuae513iJA"
      decimals="0"
      id="Narr_Ij48q3sZ20SA_K6YkbbojA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">300000</mgtx:SharesIssuedInConnectionWithFinancingAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_2_2022_srt_StatementScenarioAxis_mgtx_ExercisePriceScenarioBMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_1LCuyPsVy0exXA5eGmOHbQ"
      decimals="2"
      id="Narr_CFYhuGBlLkCXLKGM0IOBVA"
      unitRef="Unit_Divide_USD_shares_o-9RNFGKgUuaZGs6-PjKqg">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q"
      decimals="-5"
      id="Narr_Oa7DWHttZkOjPzDFH1wFyg"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2300000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q"
      decimals="-5"
      id="Narr_NQc4Urslpk6AmICEr-3fSA"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">2100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_8_2_2022_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_Qy-_6iD4jE-3NrH2YURm1Q"
      decimals="-5"
      id="Narr_-wKMV-_cxEaPlabeYS0Kew"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">4400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2024_To_3_31_2025_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_mgtx_PerceptiveCreditHoldingsMember_KaXdu7E4UU23VU_CUmILww"
      decimals="-5"
      id="Narr_b_KBjwubmkqFjsqm5kZj-g"
      unitRef="Unit_Standard_USD_SdrqO41Khkit2nWTGkSxNg">300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Tb_PZfDWn1Z30yrkXYUuQt7Pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;11.    Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 22.3pt;"&gt;There were no new material commitments or contingencies entered into during the three-month period ended March 31, 2025.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <mgtx:NumberOfNewMaterialCommitments
      contextRef="As_Of_3_31_2025_re18fj2K60CYRwYYEAMLxg"
      decimals="0"
      id="Narr_qOoPa7FtLE-7j_Ek6a3FUw"
      unitRef="Unit_Standard_pure_QJEaf5iGuk2hI53tAp8hQw">0</mgtx:NumberOfNewMaterialCommitments>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_iNHiZvSbukW_9mu5iWfpBw">false</ecd:Rule10b51ArrAdoptedFlag>
    <mgtx:Rule10b51ArrangementModifiedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_d8dOKR02gU-fSeNP4CKVnQ">false</mgtx:Rule10b51ArrangementModifiedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_6G_CVr8RdE-jC91-_9KU5w">false</ecd:NonRule10b51ArrAdoptedFlag>
    <mgtx:NonRule10b51ArrangementModifiedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_g2QRJaX_8EqM5qJYhK1l9A">false</mgtx:NonRule10b51ArrangementModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_RsJiBHrls0mQNEMWPTTZlw">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_QL4mmG_l-kGDdfK4v0BSVA"
      id="Narr_UHGwOc1iDUObWH1bnrKFfA">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
